
<html lang="en"     class="pb-page"  data-request-id="7516e9b7-4101-4582-aa70-7fb506c09854"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.0c01473;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2021.64.issue-1;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Spirocyclic Scaffolds in Medicinal Chemistry" /></meta><meta name="dc.Creator" content="Kerstin  Hiesinger" /></meta><meta name="dc.Creator" content="Dmitry  Dar’in" /></meta><meta name="dc.Creator" content="Ewgenij  Proschak" /></meta><meta name="dc.Creator" content="Mikhail  Krasavin" /></meta><meta name="dc.Description" content="Spirocyclic scaffolds are incorporated in various approved drugs and drug candidates. The increasing interest in less planar bioactive compounds has given rise to the development of synthetic metho..." /></meta><meta name="Description" content="Spirocyclic scaffolds are incorporated in various approved drugs and drug candidates. The increasing interest in less planar bioactive compounds has given rise to the development of synthetic metho..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 31, 2020" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01473" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01473" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01473" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01473" /></link>
        
    
    

<title>Spirocyclic Scaffolds in Medicinal Chemistry | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01473" /></meta><meta property="og:title" content="Spirocyclic Scaffolds in Medicinal Chemistry" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0067.jpeg" /></meta><meta property="og:description" content="Spirocyclic scaffolds are incorporated in various approved drugs and drug candidates. The increasing interest in less planar bioactive compounds has given rise to the development of synthetic methodologies for the preparation of spirocyclic scaffolds. In this Perspective, we summarize the diverse synthetic routes to obtain spirocyclic systems. The impact of spirocycles on potency and selectivity, including the aspect of stereochemistry, is discussed. Furthermore, we examine the changes in physicochemical properties as well as in in vitro and in vivo ADME using selected studies that compare spirocyclic compounds to their nonspirocyclic counterparts. In conclusion, the value of spirocyclic scaffolds in medicinal chemistry is discussed." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01473"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01473">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01473&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01473&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01473&amp;href=/doi/10.1021/acs.jmedchem.0c01473" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 1</span><span class="cit-fg-pageRange">, 150-183</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/1" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01459" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.0c01507" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Spirocyclic Scaffolds in Medicinal Chemistry</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Kerstin Hiesinger</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kerstin Hiesinger</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Pharmaceutical Chemistry, Goethe University, Max-von-Laue Straße 9, D-60348 Frankfurt am Main, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kerstin++Hiesinger">Kerstin Hiesinger</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dmitry Dar’in</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dmitry Dar’in</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Chemistry, Saint Petersburg State University, 199034 Saint Petersburg, Russia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dmitry++Dar%E2%80%99in">Dmitry Dar’in</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ewgenij Proschak</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ewgenij Proschak</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Pharmaceutical Chemistry, Goethe University, Max-von-Laue Straße 9, D-60348 Frankfurt am Main, Germany</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#19696b766a7a717872596971786b747a717c74376c7770347f6b7877727f6c6b6d377d7c"><span class="__cf_email__" data-cfemail="6212100d11010a030922120a03100f010a070f4c170c0b4f0410030c09041710164c0607">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ewgenij++Proschak">Ewgenij Proschak</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1961-1859" title="Orcid link">http://orcid.org/0000-0003-1961-1859</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Mikhail Krasavin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mikhail Krasavin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Chemistry, Saint Petersburg State University, 199034 Saint Petersburg, Russia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mikhail++Krasavin">Mikhail Krasavin</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01473&amp;href=/doi/10.1021%2Facs.jmedchem.0c01473" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 1</span><span class="cit-pageRange">, 150–183</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">December 31, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>24 August 2020</li><li><span class="item_label"><b>Published</b> online</span>31 December 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 January 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01473" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01473</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D150%26pageCount%3D34%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DKerstin%2BHiesinger%252C%2BDmitry%2BDar%25E2%2580%2599in%252C%2BEwgenij%2BProschak%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D1%26contentID%3Dacs.jmedchem.0c01473%26title%3DSpirocyclic%2BScaffolds%2Bin%2BMedicinal%2BChemistry%26numPages%3D34%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D183%26publicationDate%3DJanuary%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01473"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">6680</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">8</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01473" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Spirocyclic Scaffolds in Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Kerstin&quot;,&quot;last_name&quot;:&quot;Hiesinger&quot;},{&quot;first_name&quot;:&quot;Dmitry&quot;,&quot;last_name&quot;:&quot;Dar’in&quot;},{&quot;first_name&quot;:&quot;Ewgenij&quot;,&quot;last_name&quot;:&quot;Proschak&quot;},{&quot;first_name&quot;:&quot;Mikhail&quot;,&quot;last_name&quot;:&quot;Krasavin&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;31&quot;,&quot;issue&quot;:&quot;1&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;150-183&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01473&quot;},&quot;abstract&quot;:&quot;Spirocyclic scaffolds are incorporated in various approved drugs and drug candidates. The increasing interest in less planar bioactive compounds has given rise to the development of synthetic methodologies for the preparation of spirocyclic scaffolds. In this Perspective, we summarize the diverse synthetic routes to obtain spirocyclic systems. The impact of spirocycles on potency and selectivity, including the aspect of stereochemistry, is discussed. Furthermore, we examine the changes in physicochemical properties as well as in in vitro and in vivo ADME using selected studies that compare spirocyclic compounds to their nonspirocyclic counterparts. In conclusion, the value of spirocyclic scaffolds in medicinal chemistry is discussed.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01473&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01473" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01473&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01473" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01473&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01473" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01473&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01473&amp;href=/doi/10.1021/acs.jmedchem.0c01473" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01473" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01473" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (10 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01473%26sid%3Dliteratum%253Aachs%26pmid%3D33381970%26genre%3Darticle%26aulast%3DHiesinger%26date%3D2021%26atitle%3DSpirocyclic%2BScaffolds%2Bin%2BMedicinal%2BChemistry%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D1%26spage%3D150%26epage%3D183%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292201" title="Scaffolds">Scaffolds</a>,</li><li><a href="/action/doSearch?ConceptID=292181" title="Condensation">Condensation</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292444" title="Molecular structure">Molecular structure</a>,</li><li><a href="/action/doSearch?ConceptID=291070" title="Pharmaceuticals">Pharmaceuticals</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/1" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/jmcmar.2021.64.issue-1/20210114/jmcmar.2021.64.issue-1.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0067.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0067.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Spirocyclic scaffolds are incorporated in various approved drugs and drug candidates. The increasing interest in less planar bioactive compounds has given rise to the development of synthetic methodologies for the preparation of spirocyclic scaffolds. In this Perspective, we summarize the diverse synthetic routes to obtain spirocyclic systems. The impact of spirocycles on potency and selectivity, including the aspect of stereochemistry, is discussed. Furthermore, we examine the changes in physicochemical properties as well as in in vitro and in vivo ADME using selected studies that compare spirocyclic compounds to their nonspirocyclic counterparts. In conclusion, the value of spirocyclic scaffolds in medicinal chemistry is discussed.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43842" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43842" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">According to IUPAC, “spiro ring systems have two or more rings linked by one common atom”.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Spirocyclic compounds are the focus of modern drug discovery, as can be observed by the number of publications in medicinal chemistry journals over time (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). However, after a peak in 2008, the number has slowly decreased. The peak coincides with the landmark publication by Lovering et al., who propose an “escape from flatland” and suggest that compounds with a higher fraction of sp<sup>3</sup> (Fsp<sup>3</sup> = number of sp<sup>3</sup> hybridized carbons/total carbon count) have an increased probability to succeed in compound translation to the clinic.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Very recently, the advantages of quarternary carbon structures leading to higher Fsp<sup>3</sup> and enhanced three-dimensionality have been comprehensively reviewed.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> Following these observations, the introduction of spirocycles into lead structures seems highly attractive; however, it is often associated with increased synthetic effort, resulting from an increased number of synthetic steps and stereocenters or unusual reaction procedures. Nevertheless, medicinal chemists accept the increased expenditure due to the expected favorable effects on potency, selectivity, physicochemical properties, and pharmacokinetic (PK) profile. Some of the expectations of spirocyclic compounds are fully justified. Successful replacement of a central scaffold by a spirocycle will in most cases result in new intellectual property, thereby enabling the development of novel lead structures. In contrast, an improvement of solubility or metabolic stability cannot be expected in every case. Therefore, one of the aims of this Perspective is to summarize a range of exemplary studies that in turn influence the decision for and against the introduction of a spirocycle.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Number of publications with the key word “spiro” in medicinal chemistry journals (<i>J. Med. Chem.</i>, <i>Eur. J. Med. Chem.</i>, <i>ACS Med. Chem. Lett.</i>, <i>ChemMedChem</i>, <i>Bioorg. Med. Chem.</i>, <i>Bioorg. Med. Chem. Lett.</i>, <i>Bioorg. Chem.</i>, and <i>MedChemComm</i>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The use of spirocyclic scaffolds is not by any means new in the history of medicinal chemistry. A breakthrough in the development of mineralocorticoid receptor (MR) antagonists was achieved in 1957 by the discovery of <b>1</b> (spironolactone, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). In fact, the introduction of the spirolactone moiety into the progesterone structure was motivated by the combination of antimetallocorticoid activity with the cardiotonic effects of digitoxin, which carries a lactone ring.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Serendipitously, the spirolactone series blocked aldosterone activity and exhibited oral bioavailability,<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6,7)</a> which ultimately led to the approval of <b>1</b> in 1959. The development of spirolactone antiandrogens went on over the decades,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> leading back to the development of progestogens. <b>2</b> (drospirenone), a progesterone analogue with antiandrogenic and antiminerallocorticoid activity was invented in 1976 and approved in 2000 as a contraceptive.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Approved Drugs Containing a Spirocycle<a class="ref internalNav" href="#tbl1-fn1" aria-label="a">a</a><a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">()</a><a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">()</a><a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">()</a><a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">()</a><a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">()</a><a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">()</a><a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">()</a><a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">()</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0061.gif" alt="" id="gr2" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0062.gif" alt="" id="GRAPHIC-d7e259-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl1-fn1"><div class="footnote" id="tbl1-fn1"><sup><sup>a</sup></sup><p class="last">The information on indication and molecular targets is extracted from DrugBank unless otherwise annotated.</p></div></div><div></div></div><div class="NLM_p last">A wide range of spirocyclic motifs can be recognized in natural products, and sometimes more than one such system can be featured in a single naturally occurring compound.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Several short reviews highlighted the use of spirocyclic scaffolds in drug discovery.<a onclick="showRef(event, 'ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13">(11−13)</a> The aim of this review is to give a broad perspective on recent advances of these interesting chemotypes in medicinal chemistry. Therefore, we give an exemplary overview of synthetic approaches to the very recent spirocyclic drugs and drug candidates to provide insights into the synthetical method advances related to drug discovery. We then discuss the strategic reasons to introduce spirocyclic motifs. We intend to compare spirocyclic compounds to their nonspirocyclic counterparts and, when possible, investigate whether the expectations of medicinal chemists are justified.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Synthetic Approaches to Spirocycle Construction in Approved Drugs and Advanced Drug Candidates</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86061" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86061" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In this section, we aim to highlight various approaches to construct a spirocyclic moiety employed in the published syntheses of either marketed drugs or drug candidates that have completed various phases of clinical investigation. The syntheses are grouped according to the key step leading to the formation of the spirocycle.</div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Condensation of a β-Aminoethanol or Mercaptoethanol (Generated from a Cyclic Ketone) with a Dielectrophile</h3><div class="NLM_p">The bifunctional muscarinic antagonist <b>26</b> (AZD-2115), a β<sub>2</sub>-agonist originated at Pulmagen Therapeutics, was developed by AstraZeneca as an inhaled bronchodilator for the treatment of chronic obstructive pulmonary disease (discontinued after phase II clinical trials).<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> The key Boc-protected 1-oxa-4,9-diazaspiro[5.5]undecane intermediate <b>25</b> was elaborated from <i>N</i>-Boc-4-piperidone <b>21</b> in four steps including a Corey–Chaykovsky reaction,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> aminolysis of the resulting epoxide <b>22</b>, base-promoted condensation of vicinal amino alcohol <b>23</b> with chloroacetyl chloride, and reduction of spirocyclic lactam <b>24</b> with borane (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0032.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthetic Route of <b>26</b> (AZD-2115)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The anti-inflammatory, antiallergic, and antioxidant drug fenspiride is used to treat bronchial asthma, allergic rhinitis, and other allergy symptoms within the otolaryngological system and respiratory tracts as well as respiratory manifestations of measles and the flu.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> It is also used in symptomatic therapy for whooping cough. Numerous synthetic routes, mostly differing in the approach to the key vicinal amino alcohol <b>29</b>, were featured in the literature.<a onclick="showRef(event, 'ref26 ref27 ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref26 ref27 ref28 ref29">(26−29)</a> However, the competitive characteristics of generic API markets demand that new and more cost-efficient routes are invented. In 2019, a new nitroaldol approach to the synthesis of <b>29</b> was reported by Emcure Pharmaceuticals, Ltd.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> It involved condensation of 4-piperidone <b>27</b> with nitromethane, reduction of resulting nitro compound <b>28</b> with Zn in HCl, and elaboration of the oxazolidinone spirocycle from <b>29</b> through successive treatment with Boc<sub>2</sub>O and HCl. Thereafter, fenspiride was obtained as a hydrochloride salt (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0033.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Commercial Synthesis of <b>8</b> (Fenspiride)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Cevimeline (<b>6</b>) is a muscarinic receptor agonist used for the symptomatic treatment of ocular and oral dryness associated with Sjögren’s syndrome.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> The commercial synthesis route<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> to this drug began with a Corey–Chaykovsky epoxide synthesis<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> from prochiral quinuclidone <b>30</b>. Treatment of epoxide <b>31</b> (obtained as a diastereomeric mixture) with hydrogen sulfide followed by cyclization of the resulting thiol <b>32</b> with acetaldehyde in the presence of BF<sub>3</sub>·Et<sub>2</sub>O produced a 1:1 <i>cis</i>:<i>trans</i> mixture of spirocyclic product <b>33</b> (obtained as a hydrochloride salt on treatment with HCl). <b>6</b> (<i>cis</i> isomer) was resolved from the mixture by successive chromatographic purifications (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).</div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0034.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Commercial Synthesis of <b>6</b> (Cevimeline Hydrochloride)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Pictet–Spengler Spirocyclization</h3><div class="NLM_p">The dual nociception receptor and opioid μ receptor agonist cebranopadol (<b>36</b>) was developed by Grünenthal for the treatment of severe chronic nociceptive and neuropathic pain.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> The synthesis of <b>36</b> is based on trimethylsilyl triflate-promoted spirocyclization of 4,4-disubstituted cyclohexanone <b>34</b> and 5-fluoro-3-(2-hydroxyethyl)indole (<b>35</b>). This process essentially represented an oxa-Pictet–Spengler reaction<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> and proceeded with no particular diastereoselectivity, which mandates that the correct diastereomer was separated by high performance liquid chromatography (HPLC) (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). More scalable routes toward <b>36</b> have been described in a 2013 Grünenthal patent application.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></div><figure id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0035.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0035.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of <b>36</b> (Cebranopadol)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The antimalarial indole alkaloid cipargamin (<b>37</b>) from the Novartis Institute of Tropic Disease under NITD609 is currently codeveloped by Novartis and Medicines for Malaria Venture.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> The compound has completed phase II clinical studies in several African countries. The synthesis of this compound entailed a <i>p</i>-toluenesulfonic acid-catalyzed, highly diastereoselective<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Pictet–Spengler spirocyclization of a chiral enantiopure tryptamine <b>38</b> (synthesized in six steps from the respective indole) and 5-chloroisatin (<b>39</b>), which furnished <b>37</b> (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>).<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a></div><figure id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0036.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0036.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Antimalarial <b>37</b> (Cipargamin)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0036.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">An oxa-Pictet–Spengler spirocondensation of <i>N</i>-Boc-protected 4-piperidone (<b>40</b>) with 3-(2-hydroxyethyl)thiophene (<b>41</b>) was the key step in the construction of the spirocyclic building block <b>42</b>, which was elaborated into <b>43</b> (NOP-1A), a ligand for the nociceptin/orphanin FQ peptide (NOP) receptor (<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>). The NOP receptor is thought to be involved in several central nervous system disorders such as anxiety, depression, drug abuse, and seizures.<a onclick="showRef(event, 'ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref39 ref40">(39,40)</a> [<sup>11</sup>C]NOP-1A recently underwent a phase I clinical study for brain and whole body PET imaging.</div><figure id="sch6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0037.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0037.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of <b>43</b> (NOP-1A)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0037.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Prins Spirocyclization</h3><div class="NLM_p">The potent, selective, and G-protein-based μ opioid receptor agonist oliceridine (<b>44</b>) was developed by Trevena, Inc. as TRV130 for the treatment of acute severe pain<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> and was approved by the FDA in August 2020.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Its synthesis involves the Prins spirocondensation of cyclopentanone <b>45</b> and homoallyl alcohol <b>46</b> promoted by sulfuric acid. The resulting 6-oxaspiro[4.5]decan-9-ol (<b>47</b>) was then oxidized to the respective ketone <b>48</b>. The carbonyl carbon of <b>48</b> was further elaborated into the stereogenic center in <b>44</b> through six steps including chiral HPLC separation (<a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>).<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a></div><figure id="sch7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0038.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0038.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Oliceridine</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0038.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Intramolecular Reductive Amination</h3><div class="NLM_p">The myeloid cell leukemia 1 (MCL-1) inhibitor <b>49</b> (AMG-176) developed by Amgen for the treatment of hematological cancers was advanced into a phase I clinical study (currently on hold).<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Its synthesis is quite lengthy and entailed the initial elaboration of a spirocyclic benzo[<i>b</i>][1,4]oxazepine core followed by the installation of the cyclobutane-including macrocycle.<a onclick="showRef(event, 'ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref45 ref46">(45,46)</a> In the initial part of the synthetic route, 6-chloro-α-tetralone (<b>50</b>) was transformed into a highly functionalized aldehyde <b>51</b>. The nitro group of the latter was reduced by iron powder in acetic acid and the intermediate aniline, without isolation, was treated with NaBH(OAc)<sub>3</sub> to give the core spirocyclic building block <b>52</b> in nearly quantitative yield (<a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>).</div><figure id="sch8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0039.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0039.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of the MCL-1 Inhibitor <b>49</b> (AMG-176)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0039.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The ghrelin inverse agonist <b>53</b> (PF-5190457) was developed by Pfizer for the treatment of type 2 diabetes mellitus<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> and was discontinued in phase I with no progress reported since. The intriguing spirocyclic azetidine core of this compound was described using bis-electrophilic piperidine <b>54</b> and enantiopure 5-bromo-1-amino indane <b>55</b>. The two-step reductive amination intramolecular nucleophilic substitution delivered core building block <b>56</b> in nearly quantitative yield (<a class="ref internalNav" href="#sch9" aria-label="Scheme 9">Scheme 9</a>).<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a></div><figure id="sch9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0040.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0040.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthesis of the Ghrelin Reverse Agonist <b>53</b> (PF-5190457)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0040.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Spirocyclizations Involving Cyclic Strecker-Type α-Aminonitriles and Carboxamides</h3><div class="NLM_p">Antiandrogenic <b>4</b> (apalutamide) for the treatment of prostate cancer was discovered in the laboratories of Jung and Sawyers at University of California, Los Angeles (UCLA) and subsequently licensed to Aragon Pharmaceuticals.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Following acquisition of Aragon by Johnson & Johnson, the drug is now marketed by the latter company.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> The original synthetic route to apalutamide developed at UCLA involved a Strecker reaction of cyclobutanone <b>57</b> and substituted aniline <b>58</b>. The resulting α-aminonitrile <b>59</b> was further condensed with isothiocyanate <b>60</b> under microwave irradiation followed by acidic hydration of the nitrile.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> This approach was subsequently improved by excluding the need for a microwave reactor. The three-component reaction of <b>59</b> with 3-aminopyridine <b>61</b> and thiophosgene (which proceeded, presumably, via the <i>in situ</i> formation of <b>60</b>) gave <b>4</b> (<a class="ref internalNav" href="#sch10" aria-label="Scheme 10">Scheme 10</a>).</div><figure id="sch10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0041.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0041.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Syntheses of <b>4</b> (Apalutamide)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0041.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The antihypertensive drug <b>13</b> (irbesartan) acts by blocking the angiotensin receptor. In addition to the biphenyl <i>NH</i>-tetrazole moiety characteristic of this class of therapeutic agents, <b>13</b> features the spirocyclic imidazolin-4-one moiety. Various strategies to construct this peripheral motif have been described,<a onclick="showRef(event, 'ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref52 ref53">(52,53)</a> and the dedicated report by ArQule presented the following optimized route.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> Microwave-promoted three-component condensation of methyl 1-amino-1-cyclopentane carboxylate <b>62</b> with benzylic amine <b>63</b> and valeric acid <b>64</b> afforded nitrile <b>65</b> in 71% isolated yield. Cycloaddition of the latter with tributyltin azide produced <b>13</b> (<a class="ref internalNav" href="#sch11" aria-label="Scheme 11">Scheme 11</a>).<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a></div><figure id="sch11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0042.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0042.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. ArQule Synthesis of <b>13</b> (Irbesartan)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0042.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A similar spirocyclic imidazolin-4-one moiety is featured in the parathyroid hormone receptor 1 (PTHR1) agonist <b>66</b> (PCO-371) developed by Chugai Pharmaceutical Co. for the treatment of hypoparathyroidism.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> Its synthesis commenced with Strecker-type piperidine building block <b>67</b>, which was then acylated. The resulting nitrile <b>68</b> was hydrolyzed to give the respective primary amide which underwent <i>in situ</i> spirocyclization at 50 °C to deliver the core spirocycle <b>69</b>. The latter was elaborated into the final investigational drug molecule <b>66</b> over several steps including synthesis of the peripheral hydantoin motif (<a class="ref internalNav" href="#sch12" aria-label="Scheme 12">Scheme 12</a>).</div><figure id="sch12" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0043.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0043.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 12. Synthesis of PTHR1 Agonist <b>66</b> (PCO-371)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0043.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Spiperone<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> (<b>17</b>) and fluspirilene<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> (<b>9</b>) are typical antipsychotics used to treat schizophrenia. Both drugs can be synthesized from the common spirocyclic imidazolidin-4-one precursor <b>73</b>. Today, the synthetic route to <b>73</b> is quite established.<a onclick="showRef(event, 'ref59 ref60'); return false;" href="javascript:void(0);" class="ref ref59 ref60">(59,60)</a> It commenced with the Strecker reaction of <i>N</i>-benzyl-4-piperidone <b>70</b> followed by nitrile hydrolysis and imidazolin-4-one ring closure to give intermediate <b>73</b>. Reduction of the latter with sodium borohydride followed by debenzylation produced the spirocyclic core building block <b>75</b> (<a class="ref internalNav" href="#sch13" aria-label="Scheme 13">Scheme 13</a>).</div><figure id="sch13" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0044.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0044.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 13. Syntheses of <b>17</b> (Spiperone) and <b>9</b> (Fluspirilene)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0044.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch13"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Intramolecular <i>N</i>-Acylation</h3><div class="NLM_p">The antihyperglycemic aldose reductase inhibitor <b>76</b> (ranirestat) originating from Dainippon Sumitomo Pharma was codeveloped jointly by this company and Eisai for the treatment of diabetic neuropathies but was discontinued after phase III clinical trials. This compound appears to be related to another older spirocyclic drug, sorbinil, with the same mechanism of action,<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> as it contains an <i>N</i>H-acidic five-membered cyclic imide in lieu of sorbinil’s hydantoin.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Two synthetic approaches to the spirocyclic framework of ranirestat were described by Dainippon, both of which include an intramolecular acylation step as the key event. In the first approach, the pyrrolopiperazine-2,6-dione core <b>77</b> was installed followed by the introduction of the acetamide side chain <b>78</b> and the final imide formation. Alternatively, the succinimide ring <b>80</b> was constructed first followed by piperazine-2,6-dione ring closure upon treatment of monoactivated dicarboxylate <b>81</b> with 4-bromo-2-fluorobenzylamine (<a class="ref internalNav" href="#sch14" aria-label="Scheme 14">Scheme 14</a>).</div><figure id="sch14" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0045.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0045.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 14. Synthesis of <b>76</b> (Ranirestat) Reported by Dainippon Sumitomo</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0045.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Rolapitant (<b>82</b>) is a neurokinin 1 inhibitor originally developed by Schering-Plough. It was approved in the U.S. in September 2015 (trade name Varubi) and the EU in April 2017 (trade name Varuby) to prevent delayed phase chemotherapy-induced nausea and vomiting (emesis).<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> The original Schering-Plough synthetic route was reliant on the chiral enantiopure building block <b>83</b>, which was obtained from chiral pool material.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> This intermediate underwent nitration at the enamine double bond which was reduced with lithium borohydride. Following removal of the Cbz protecting group from intermediate <b>84</b>, the nitro compound <b>85</b> underwent Michael addition to an acrylate ester and the resulting diastereomeric mixture was separated to obtain the desired diastereomer (<b>86</b>). Reduction of the nitro group with zinc in acetic acid gave <b>82</b> (<a class="ref internalNav" href="#sch15" aria-label="Scheme 15">Scheme 15</a>).<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> It should be mentioned that in addition to this original synthetic route, several alternative routes have been developed to obtain <b>82</b> which exploit olefin metathesis as a means to construct the spirocyclic piperidine (<i>vide infra</i>, <a class="ref internalNav" href="#sch28" aria-label="Scheme 28">Scheme 28</a>).<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a></div><figure id="sch15" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0046.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0046.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 15. Synthesis of <b>82</b> (Rolapitant) by Schering-Plough</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0046.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The cyclin-dependent kinase 4 inhibitor trilaciclib (<b>87</b>) developed by G1 Therapeutics for the treatment of various cancers and for the reduction of chemotherapy side effects is being prepared for marketing authorization in late-2020. Two alternative synthetic routes developed by the compound’s originator include intramolecular <i>N</i>-acylation as the key step in the construction of the spirocyclic moiety. An earlier route started with pyrimidine <b>88</b> that was decorated via nucleophilic substitution and Sonogashira coupling to give intermediate <b>91</b>. The latter was cyclized into 5,7-diazaindole <b>92</b> which underwent lactamization to deliver key spirocycle <b>93</b>.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> Alternatively, spirocyclic motif <b>95</b> could be synthesized early in the sequence whereupon it was condensed with pyrimidine-5-carboxaldehyde <b>96</b> to give spirocyclic 5,7-diazaindole <b>97</b>.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> Either <b>93</b> or <b>97</b> could be elaborated into <b>87</b> via direct displacement or Pd-catalyzed coupling with the side-chain 2-aminopyridine building block (<a class="ref internalNav" href="#sch16" aria-label="Scheme 16">Scheme 16</a>).</div><figure id="sch16" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0047.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0047.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 16. Alternative Approaches to <b>87</b> (Trilaciclib) Synthesis</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0047.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch16"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Condensation of a 1,4-Dinucleophile with a Cyclic Carbonyl Compound</h3><div class="NLM_p">The spirocyclic vasopressin receptor 1 antagonist RO-5028442 (<b>98</b>) developed by Roche for the treatment of pervasive child development disorders<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> has recently completed phase I clinical study. The spirocyclic isobenzofuran moiety of this drug was constructed by condensation of dianion species <b>100</b>, which was generated by lithiation of 2-bromobenzoic acid <b>99</b>, with <i>N</i>-methyl-4-piperidone <b>101</b>. Reduction and demethylation of resulting spirolactone <b>102</b> gave the core spirocyclic building block <b>103</b>, which was elaborated into the drug molecule via a few straightforward transformations (<a class="ref internalNav" href="#sch17" aria-label="Scheme 17">Scheme 17</a>).<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a></div><figure id="sch17" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0048.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0048.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 17. Synthesis of <b>98</b> (RO-5028442)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0048.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The sodium-glucose transporter 2 inhibitor <b>19</b> was developed by Chugai Pharmaceutical Co. for the treatment of type 2 diabetes mellitus and received its first global approval in Japan in 2014.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> The unique spirocyclic carbohydrate moiety of the drug was constructed from globally protected sugar building block <b>106</b> upon reaction with lithiated aromatic species generated from bis-acetonide bromoarene <b>105</b>. The initial adduct was treated with <i>p</i>-toluenesulfonic acid which led to the deprotection of the hydroxymethyl moieties, one of which cyclized onto the anomeric position of the sugar core giving rise to spirocycle <b>107</b>. The latter was globally methoxycarbonylated, which set the scene for Suzuki coupling at the benzylic position and led, after deprotection, to <b>19</b> (<a class="ref internalNav" href="#sch18" aria-label="Scheme 18">Scheme 18</a>).<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a></div><figure id="sch18" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0049.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0049.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 18. Original Synthesis of <b>19</b> by Chugai Pharmaceutical Co.</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0049.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The antineoplastic drug <b>110</b> (tomivosertib) was developed by Effector Therapeutics<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> as an inhibitor of mitogen-activated protein kinase interacting kinases 1 and 2 (MNK1/2) and is currently in phase II clinical study in combination with approved checkpoint inhibitors or paclitaxel. Its synthesis involved an acid-promoted cyclocondensation of 2-pyridone-6-carboxamide <b>111</b> with cyclohexanone giving spiro intermediate <b>112</b> (<a class="ref internalNav" href="#sch19" aria-label="Scheme 19">Scheme 19</a>).<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a></div><figure id="sch19" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Scheme 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0050.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0050.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 19. Synthesis of <b>110</b> (Tomivosertib) by Effector Therapeutics</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0050.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch19"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Mono- and Bis-alkylation</h3><div class="NLM_p">The β-secretase 1 inhibitor <b>113</b> (lanabecestat) was codeveloped by AstraZeneca and Eli Lilly for the treatment of Alzheimer’s disease progression by slowing the buildup of β-amyloid.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> Despite its progression to phase III clinical trials and receiving a fast track designation from the FDA, drug candidate <b>113</b> failed to meet the investigation end point, and the study was discontinued.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> This doubly spirocyclic compound was constructed from spirocyclic indan-1-one building block <b>115</b>, which was obtained by bis-alkylation of 6-bromo-1-indanone (<b>114</b>) with methyl acrylate. Double Michael addition followed by intramolecular Claisen condensation and decarboxylation gave ketone <b>115</b>. The latter was reduced with a borane-<i>tert</i>-butylamine complex and the resulting alcohol was O-methylated with methyl mesylate under phase transfer conditions to give compound <b>116</b> with a 38% overall yield from <b>114</b>.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> After construction of bis-spirocyclic amidine and obtaining its enantiopure form <b>117</b> by diastereomeric racemate resolution with (+)-camphorsulfonic acid, Suzuki coupling with pyridine-3-boronic acid <b>118</b> gave lanabecestat (<a class="ref internalNav" href="#sch20" aria-label="Scheme 20">Scheme 20</a>).<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a></div><figure id="sch20" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Scheme 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0051.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0051.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 20. Synthesis of <b>113</b> (Lanabecestat) by AstraZeneca</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0051.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The free fatty acid receptor 1 agonist <b>119</b> (LY-2881835) was developed by Eli Lilly for the treatment of type 2 diabetes mellitus and was discontinued after phase I clinical study.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> The spiropiperidine peripheral motif (<b>123</b>) of this free fatty acid mimic molecule (originally developed as a selective σ-ligand by Merck Sharp and Dohme) was assembled via bis-alkylation of indene <b>120</b> and removal of the protecting group.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> Subsequent installation of a <i>p</i>-(hydroxymethyl)benzyl moiety, Mitsunobu coupling with 4-hydroxyphenylpropionic acid building block <b>126</b>, and ester hydrolysis furnished <b>119</b> (<a class="ref internalNav" href="#sch21" aria-label="Scheme 21">Scheme 21</a>).<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a></div><figure id="sch21" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Scheme 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0052.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0052.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 21. Synthesis of <b>119</b> (LY-2881835)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0052.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The first-in-class antagonist of calcitonin gene-related receptor, <b>20</b> (ubrogepant), was approved for the treatment of migraine in December 2019 and is currently marketed by its developer Allergan USA, Inc.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> Compound <b>20</b> contains four chiral centers, one of which is in the spirocyclic carboxylic acid building block <b>134</b> that is coupled to tetrasubstituted 2-piperidone <b>135</b> in the final step of the synthesis.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> The synthesis starts with the condensation of 7-azaindolinone <b>128</b> with aldehyde <b>129</b>. Reduction of the double bond and installation of the leaving group chloride in the latter produced <b>131</b>. Asymmetric spirocyclization involving phase-transfer catalysis with <i>Cinchona</i> alkaloid-derived bis-ammonium salt <b>132</b> gave spirocycle <b>133</b> with high chemical yield and enantiomeric purity. Pd-catalyzed carbonylation of the latter and protecting group removal led to spirocyclic carboxylic acid <b>134</b>, which, following amide coupling with <b>135</b>, gave <b>20</b> (<a class="ref internalNav" href="#sch22" aria-label="Scheme 22">Scheme 22</a>).</div><figure id="sch22" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Scheme 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0053.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0053.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 22. Synthesis of <b>20</b> (Ubrogepant)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0053.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch22"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Williamson Ether Synthesis</h3><div class="NLM_p">The novel analgesic drug <b>136</b> (funapide) that acts as a Nav1.7 voltage-gated sodium channel inhibitor is under development (phase II) by Xenon Pharmaceuticals as a treatment for various chronic pain conditions.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> The chiral center in the funapide molecule is installed in enantioselective fashion before the formation of the spirocyclic system. In the pilot plant scale synthesis developed by Teva Pharmaceuticals, isatin <b>137</b> was initially fitted with the furyl and benzodioxole appendage whereupon adduct <b>140</b> was reduced and protected at the phenolic hydroxyl. The resulting indolinone <b>141</b> was set for an asymmetric aldol reaction with formaldehyde catalyzed by the <i>Cinchona</i> alkaloid-derived thiourea <b>143</b>. Enantiopure adduct <b>142</b> was deprotected and underwent cyclic ether synthesis to give <b>136</b> (<a class="ref internalNav" href="#sch23" aria-label="Scheme 23">Scheme 23</a>).<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a></div><figure id="sch23" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Scheme 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0054.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0054.jpeg" id="gr25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 23. Pilot-Scale Synthesis of <b>136</b> (Funapide)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0054.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch23"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> Intramolecular Claisen Condensation</h3><div class="NLM_p">The antifungal drug <b>11</b> (griseofulvin) was isolated in 1939 from a <i>Penicillium</i> mold.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> The intriguing molecule has attracted much attention from the standpoint of total synthesis.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> In one enantioselective total synthesis published by Pirrung and co-workers, the future spirocyclic center is installed in diastereoselective fashion using enantiopure diazo precursor <b>144</b>.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> Generation of a rhodium carbene species led to a sigmatropic rearrangement reaction, producing key intermediate <b>145</b>. Manipulation of the olefinic side chain gave ketoester intermediate <b>146</b>, which underwent intramolecular Claisen condensation and <i>O</i>-methylation with diazomethane to produce <b>11</b> in modest yield (<a class="ref internalNav" href="#sch24" aria-label="Scheme 24">Scheme 24</a>).</div><figure id="sch24" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Scheme 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0055.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0055.jpeg" id="gr26" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 24. Synthesis of <b>11</b> (Griseofulvin) Developed by Pirrung and Co-Workers</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0055.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch24"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> Robinson-Type Spiroannulation</h3><div class="NLM_p">The acetyl-CoA carboxylase inhibitor <b>147</b> (PF-05175157) was developed by Pfizer for the treatment of type 2 diabetes mellitus and was terminated in the course of a phase II study due to safety concerns.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> The pyrazolo-fused spirocycle was assembled through condensation of Boc-protected piperidine-4-carboxaldehyde <b>148</b> with methyl vinyl ketone <b>149</b> in a Robinson-type fashion involving a Michael addition followed by intramolecular Knoevenagel condensation. Resulting spirocyclic ketone <b>150</b> was elaborated into the final molecule in a few straightforward steps including ketone α-aminomethylenation, pyrazole synthesis, double bond oxygenation, deprotection, and piperidine <i>N</i>-acylation (<a class="ref internalNav" href="#sch25" aria-label="Scheme 25">Scheme 25</a>).<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a></div><figure id="sch25" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Scheme 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0056.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0056.jpeg" id="gr27" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 25. Synthesis of Pfizer’s Acetyl-CoA Carboxylase Inhibitor <b>147</b> (PF-05175157)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0056.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch25"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> Brunner-Type Fischer Indolization</h3><div class="NLM_p">The vasopressin V2 receptor antagonist <b>154</b> (satavaptan) was developed by Sanofi Aventis for the treatment of low sodium concentration in the blood (hyponatremia) as well as cirrhosis-related ascites.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> The development of this drug candidate discontinued in 2009 after phase III clinical study. Several alternative routes to the spirocyclic 2-oxindole core of this drug candidate were developed, which were primarily based on bis-alkylation followed by intramolecular Claisen condensation.<a onclick="showRef(event, 'ref91 ref92'); return false;" href="javascript:void(0);" class="ref ref91 ref92">(91,92)</a> However, we consider the so-called discovery route to this molecule rather intriguing from the synthetic standpoint. According to this approach, acyl hydrazine <b>155</b> underwent a Brunner-type Fischer indole synthesis upon treatment with <i>n</i>-butyllithium and subsequent heating at 180 °C. The protected keto group in the resulting 2-oxindole product <b>157</b> was elaborated into the morpholine-substituted side chain, and the lactam nitrogen atom was sulfonylated to give <b>154</b> (<a class="ref internalNav" href="#sch26" aria-label="Scheme 26">Scheme 26</a>).<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a></div><figure id="sch26" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Scheme 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0057.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0057.jpeg" id="gr28" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 26. Synthesis of <b>154</b> (Satavaptan)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0057.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch26"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> Intramolecular Friedel–Crafts Alkylation</h3><div class="NLM_p">Vapitadine hydrochloride <b>158</b> was developed as a nonsedating antihistamine by Barrier Therapeutics and Johnson & Johnson.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> It had been in phase II clinical trials for the treatment of patients with atopic dermatitis. However, no development has been reported in the past decade. Its unique spirocyclic benzo[<i>d</i>]imidazo[1,2-<i>a</i>]azepine-11,4′-piperidine core was assembled in a very elegant and atom-economical fashion via lithiation of <i>N</i>-phenethylimidazole (<b>159</b>) and addition of the resulting anion to the <i>N</i>-benzylpiperidone carbonyl group. Generation of a benzyl-type cation from the resulting tertiary alcohol <b>161</b> led to a rather slow intramolecular Friedel–Crafts alkylation of the benzyl ring and the construction of tetracycle <b>162</b>. The synthesis of <b>158</b> was completed by bromination, Pd-catalyzed aminocarbonylation, and debenzylation (<a class="ref internalNav" href="#sch27" aria-label="Scheme 27">Scheme 27</a>).<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a></div><figure id="sch27" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Scheme 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0058.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0058.jpeg" id="gr29" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 27. Synthesis of <b>158</b> (Vapitadine)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0058.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch27"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> Ring-Closing Metathesis</h3><div class="NLM_p">The synthesis of the approved antiemetic drug <b>82</b> was discussed above; its patented synthesis included an intramolecular <i>N</i>-acylation step (<a class="ref internalNav" href="#sch15" aria-label="Scheme 15">Scheme 15</a>). However, in addition to this original Schering-Plough synthetic route, alternative approaches to the construction of the spirocyclic piperidine moiety have been developed that are based on a ring-closing metathesis (RCM) step. Exploring metathesis-based disconnections of <b>82</b> provided better stereoselectivity compared to the lactamization approach, as it allowed drawing the chiral spiro center from a chiral pool material or introducing it via a chiral auxiliary.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a></div><div class="NLM_p">One of the RCM-based routes relied on chiral building blocks <b>163</b> and <b>164</b>, which were coupled via reductive amination. RCM of resulting intermediate <b>165</b> using the type II Hoveyda–Grubbs catalyst followed by hydrogenation afforded <b>82</b> (<a class="ref internalNav" href="#sch28" aria-label="Scheme 28">Scheme 28</a>).<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a></div><figure id="sch28" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Scheme 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0059.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0059.jpeg" id="gr30" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 28. RCM-Based Synthesis of <b>82</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0059.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch28"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i47">Diversity of Spirocycles in Bioactive Compounds</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08861" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08861" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> Introducing Spirocycle Diversity in Medicinal Chemistry</h3><div class="NLM_p">Recent developments of synthetic methods aimed at the preparation of novel heterocycles have enabled the generation of highly diverse scaffolds. Therefore, methods for systematic assessment of spirocyclic scaffolds are needed to enable the efficient use of this resource in medicinal chemistry. Müller et al. introduced a cheminformatics methodology to explore the chemical space of spirocycles.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> The authors suggest a hierarchical classification scheme, which considers the topology of the spirocycle (isolated, condensed, and bridged), number of spiro atoms, ring combination in the spirocyclic system, and scaffold of the spirocyclic system. The authors used their approach to generate novel spirocyclic scaffolds for diverse screening libraries.</div><div class="NLM_p last">Synthesis of spirocycle-based diversity libraries has been explored by several groups. King et al. developed cycloaddition strategies for the generation of diverse spirocyclic scaffolds for fragment-based screening.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> Hereby, the authors proposed that a [3 + 2] cycloaddition would deliver a variety of different spirocyclic scaffolds. In a different publication, the authors suggest heterocycle formation and subsequent ring-closing metathesis for carbocycle synthesis as sources of diverse spirocyclic fragments.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> The fragment libraries generated by this strategy exhibited high Fsp<sup>3</sup> and molecular complexity, making them valuable resources for hit retrieval. Notably, the applicability of fragment libraries exhibiting these characteristics was recently demonstrated.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> Beyond C, O, N, and S</h3><div class="NLM_p">Common spirocyclic scaffolds consist of carbon, nitrogen, oxygen, and sometimes sulfur. The incorporation of other elements is rare, but a few selected examples demonstrate the feasibility of this approach. In 2011, Wang et al. explored organosilane amines as potent inhibitors of the membrane protein M2 proton channel (A/M2) from influenza A viruses.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> The silane analogues were generally as potent as their carbon counterparts and even more potent against the drug-resistant mutant A/M2-V27A. The unusual spirocyclic inhibitor <b>168</b> showed a 3.3-fold potency increase against the V27A mutant (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). The substitution with silicon means a larger size and higher lipophilicity compared to its carbon analogue, potentially providing a better hydrophobic interaction between the inhibitor and the channel.</div><figure id="fig2" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0002.jpeg" id="gr31" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Organosilane antiviral spirocycles.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Another study by Tacke et al. reported silicon-containing spirocyclic scaffolds as potent and selective σ<sub>1</sub> ligands.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> They synthesized 1,2,3,4-tetrahydro-1,4′-silaspiro[naphthalene-1,4′-piperidine] derivatives and compared them with carbon analogues. Using single-crystal X-ray diffraction studies, they could observe structural differences, which are attributed to the different covalent radii of carbon (0.77 Å) and silicon (1.17 Å). The silane derivatives exhibited higher σ<sub>1</sub> and lower σ<sub>2</sub> affinity. <b>170</b> showed a 6-fold lower σ<sub>2</sub> affinity and a slightly higher σ<sub>1</sub> affinity, resulting in an increased selectivity profile (10-fold higher). These observations might be due to the structural differences of shape and conformational behavior caused by the C/Si exchange.</div><div class="NLM_p">Similar beneficial effects of an exotic spirocycle were demonstrated by Zhao et al.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> They developed a series of novel spirocyclic sulfone inhibitors of γ-secretase (GS). The inhibitors decreased the production of Aβ peptides (Aβ<sub>40</sub> and Aβ<sub>44</sub>) indicating inhibitory activity instead of modulator activity. Incorporation of a spiro thiopyrane or spiro sulfone moiety (<b>171</b>) could not restore potency compared to potent GS inhibitor MRK-560, though the pharmacokinetics effects (area under the curve, AUC) were improved. The modification of cyclic phosphonates led to a potent inhibitor <b>172</b> with an excellent pharmacokinetic profile in rats (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Furthermore, the spirocyclic phosphonate derivative showed superior selectivity for cytochrome P2C9 (CYP2C9) inhibition and inhibition of the presenilin 1 (PS-1) isoform of GS (33-fold vs PS-2), indicating it was a safer drug candidate.</div><figure id="fig3" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0003.jpeg" id="gr32" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Bioisosteric replacement of phosphonate-containing spirocycle.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Spirocyclic compounds containing boron with a potential medical use similar to tatrolon E are known from natural derived products.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> The synthesis of spiro-fused benzoxaborins is quite challenging, as Murugan et al. demonstrated.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> They tried to obtain spirocyclic boron compounds through the condensation of isatin with acetylphenylboronic acid but yielded exclusively benzoxaborinin-4-ones. Natsutani et al. could synthesize spiro-fused benzoxaborins <b>173</b> in a four/five step protocol (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> One superior effect of boron is its vacant p-orbital, which can covalently bind to target proteins, for instance with a serine or threonine residue of the target protein. The synthesized spirocycles were evaluated regarding their lipophilicity and metabolic stability in human liver microsomes (HLMs). The compounds showed log <i>P</i> values below 4 and possess good stability (>80% remaining). Because they show satisfying physiochemical properties for oral drugs, boron-containing spirocycles might be a promising scaffold for medicinal chemists.</div><figure id="fig4" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0004.jpeg" id="gr33" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Boron-containing spirocyclic compound series.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i50">Stereochemistry of Spirocycles: Influence on Biological Activity</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07215" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07215" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Recent developments in the enantioselective synthesis of spiro compounds allow for access to pure enantiomers.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> In some cases, the configuration of the spirocycle can tremendously affect the affinity, and a closer look at both enantiomers can be worthwhile. In this section, we summarize a selection of examples in which the stereochemistry of the spirocyclic compounds was examined. Zou et al. developed a novel dengue virus (DENV) inhibitor.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> The racemate <b>174</b> was identified and active against DENV in a dengue virus high-throughput phenotypic screen (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). The authors assumed that this type of inhibitor containing a spiropyrazolopyridone motif inhibited DENV replication via the nonstructural protein 4B (NS4B) protein. The enantiomers were separated via chiral HPLC, and the (<i>R</i>)-configurated inhibitor (<i>R</i>)-<b>174</b> was 225-fold more potent in vitro than the (<i>S</i>)-enantiomer. Another spirocyclic scaffold targeting NS4B was published by Tai et al.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> They developed a series of piperidine oxazolidinones that inhibited the hepatitis C virus (HCV) replication. The influence of stereochemistry toward anti-HCV activity (1a and 1b replicons) was examined with inhibitor <b>175</b>. In this case, three of the four diastereomers were potent and only one diastereomer lost potency.</div><figure id="fig5" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0005.jpeg" id="gr34" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Spirocyclic chiral NS4B inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">An affinity gap between enantiomers was reported by Ito et al. targeting with a selective molecular probe the bad response to refrigeration 2 (Brr2), a member of the Ski2-like RNA helicases, which is important to unwind the U4/U6 RNA duplex in spliceosomal activation during splicing.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> High-throughput screening revealed the racemic spiro[indole-3,20-pyrrolidin]-2(1<i>H</i>)-one scaffold as hit. Four diastereomers were separated by chiral HPLC, and only one isomer (<b>176</b>, 2′<i>S</i>,3′<i>R</i>,5′<i>S</i>) inhibited Brr2. In this case, not only the stereochemistry of the spiro center influenced the potency, but also the configuration of the ester is essential (<i>R</i>-configuration favored). This trend was observed through the whole SAR study. An example showing a similar effect with a stereochemically less challenging structure was published by Imaeda et al.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> Screening of their in-house library identified a 1,3-dihydro-5<i>H</i>-spiro(benzo[<i>c</i>,<i>d</i>]indole-4,20-piperidin)-5-one <b>177</b> derivative as a reversible H<sup>+</sup>,K<sup>+</sup>-ATPase inhibitor (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). Modification of the scaffold led to the spirocyclic inhibitor <b>178</b>. Separation of the enantiomers showed a dramatic difference between both configurations. (<i>S</i>)<i>-</i><b>178</b> showed approximately twice the inhibitory potency compared with the racemate, and the activity of (<i>R</i>)<i>-</i><b>178</b> dropped intensely.</div><figure id="fig6" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0006.jpeg" id="gr35" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Spirocyclic chiral ATPase inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In 2018, Michaelides et al. published a spiroindane scaffold for the inhibition of histone acetyltransferase p300 (HAT) (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> Additionally, they determined the influence of the diastereomers toward their inhibitory activity. The spiroindane inhibitor <b>179</b> contained two chiral centers, and the stereochemistry of the side chain had a modest effect on potency (2- to 3-fold). The spirocyclic center had a great impact on the potency, and (<i>S</i>,<i>S</i>)-<b>179</b> exhibited an IC<sub>50</sub> value of 0.51 μM. The compounds with the (<i>R</i>)-configured spirocycle, (<i>S</i>,<i>R</i>)-<b>179</b> and (<i>R</i>,<i>R</i>)-<b>179</b>, were considerably less potent. To improve the physicochemical properties, an oxazolidinedione scaffold was introduced. Surprisingly, scaffold hopping resulted in the opposite affinity ranking of the diastereomers, with (<i>R,S</i>)<i>-</i><b>180</b> being 5-fold more potent than the (<i>S,S</i>)<i>-</i><b>180</b> diastereomer.</div><figure id="fig7" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0007.jpeg" id="gr36" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Spiroindane based HAT inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A dramatic discrepancy in the selectivity profile of spirocyclic protease β-site APP cleaving enzyme 1 (BACE1) inhibitors based on pyranochromene scaffolds with three chiral centers was observed by Volgraf et al.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> They observed that the chiral spiro center also greatly impacted CYP2D6 inhibition. While (4<i>R</i>,4a′<i>S</i>,10a′<i>S</i>)-<b>181</b> exhibited an IC<sub>50</sub> of 0.11 μM against BACE1, the inhibition of CYP2D6 was reduced (IC<sub>50</sub> > 10 μM). The epimer showed less BACE1 inhibition (IC<sub>50</sub> = 17 μM) and a higher inhibitory potency toward CYP2D6 with an IC<sub>50</sub> of 0.42 μM. Interestingly, the chirality of the tetrahydropyran moiety also strongly influenced the potency but not as strongly as the spirocyclic scaffold (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). The authors did not investigate the influence of the third stereogenic center (C10a′).</div><figure id="fig8" data-index="36" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0008.jpeg" id="gr37" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Spirocyclic BACE1 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Targeting protein–protein interactions (PPIs) with small molecules is still a challenge in medicinal chemistry. Nevertheless, spirocyclic compounds have been applied in this area as well. One example targeting PPIs is the formation of the IκB kinase (IKK) complex, which consists of two homologous catalytic subunits IKKα and IKKβ and a regulatory subunit IKKγ (also named NEMO). Chao et al. screened an azatryptophan-based fluorescent platform with spirocyclic oxindole derivatives. <b>182</b> and <b>183</b> contained six chiral centers, and the authors determined the impact of several chiral centers on their ability to inhibit PPIs.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> By maintaining the configurations, except the spirocyclic configuration, they only observed a 2-fold change in the <i>K</i><sub>d</sub> values (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>A).</div><figure id="fig9" data-index="37" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0009.jpeg" id="gr38" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Various spirocyclic structures: (A) inhibitor targeting PPI; (B) partial agonist of nAChR; (C) spiroketal partial RXR agonist.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Hill et al. developed a series of quinuclidine-containing spiroimidates as partial agonists for the α7 nicotinic acetylcholine receptor (nAChR). nAChR agonists may be helpful to treat cognitive and negative symptoms in schizophrenia patients.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> In their previous work, the authors developed a spirocyclic partial agonist that showed a disfavored off-target profile as well as low micromolar inhibition of the human ether-a-go-go-related gene (hERG) potassium channel. By changing the heteroaryl moieties, they could improve the selectivity over 5-HT<sub>3A</sub> antagonism and reduce the affinity toward the hERG channel. Within their work, the authors isolated an (<i>S</i>)-configured spirocycle (<i>S</i>)-<b>184</b> that exhibited a drop in potency and selectivity (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>B).</div><div class="NLM_p">Scheepstra et al. synthesized a bisbenzannulated spiroketal partial agonist targeting the retinoid X receptor (RXR), a member of the gene transcription factor superfamily.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> The spirocyclic modulator <b>185</b> bound to RXR and induced partial coactivator recruitment. The effect of spiroketal stereochemistry was evaluated in a fluorescence polarization assay with fluorescently labeled peptides as D22. One enantiomer (<b>185</b>-<i>ent</i>1) exhibited a 7-fold higher potency and a 2-fold higher efficacy (%<sub>eff</sub>) than enantiomer <b>185</b>-<i>ent</i>2 (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>C). For further investigation, the racemate was cocrystallized with the human RXRα ligand binding domain-TIF2 peptide complex (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5LYQ">5LYQ</a>). The electronic density indicated that the <i>R</i> enantiomer had a bis-anomeric diaxial conformation. Docking studies with the <i>S</i> enantiomer suggested an axial–equatorial conformation proposed to be a protein-induced fit, which is a thermodynamically less favorable conformation and would explain the difference in potency.</div><div class="NLM_p last">The selected examples highlight how worthwhile it may be to take a closer look at separated enantiomers.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i51">Use of Spirocycles in Structure-Based Design</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07702" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07702" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Advancement of structure-based drug design, which heavily relies on the knowledge of the bioactive conformation of ligand–protein complexes determined by X-ray crystallography, NMR, or electron microscopy, enables the rational application of spirocyclic scaffolds. The bioactive information incorporates the knowledge of the dihedral angles as well as intramolecular interactions. Using this information, it is possible to introduce a rigid spirocyclic scaffold, which replaces rotatable bonds and maintains the favored orientation of functional groups. Application of spirocycles in the design of analogues of flexible ligands such as peptides<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> appears very attractive in this context. The following section summarizes the successful application of spirocyclic scaffolds in structure-based drug design.</div><div class="NLM_p">Impressive efforts in structure-based design have been made by Caenepeel et al. during optimization of the MCL-1 inhibitor <b>49</b>, which was previously mentioned in the synthesis section (<a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>).<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Inhibitors of MCL-1 rely on an interaction with the shallow BH3 domain binding pocket. Development of PPI interfaces with favorable potency, selectivity, and ADME properties is especially challenging due to the size and shape of the pockets and competing tight interactions between protein partners.<a onclick="showRef(event, 'ref118 ref119'); return false;" href="javascript:void(0);" class="ref ref118 ref119">(118,119)</a> Starting with a micromolar high throughput screening hit, ring expansion rapidly led to inhibitor <b>186</b> with an IC<sub>50</sub> of 0.3 μM. Crystallization of <b>186</b> in complex with MCL-1 succeeded and provided information about the bioactive conformation (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>). The 2,4-dichlorophenyl substituent occupies a tight hydrophobic pocket at a privileged dihedral angle of 112°. Introduction of the spirocycle led to inhibitor <b>187</b>, which constrains the rotation of the phenyl moiety to a dihedral angle of 107°, which improves the potency by 10-fold. Macrocyclization and optimization steps then led to the discovery of <b>49</b>, which exhibits picomolar potency and entered clinical trials.</div><figure id="fig10" data-index="38" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0010.jpeg" id="gr39" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Structure-based introduction of spiroindane leads to discovery of MCL-1 inhibitor <b>49</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Rigidization of the primary amine by a spirocycle has been performed by researchers at Novartis during optimization of protein tyrosine phosphatase 2 (SHP2) inhibitors for cancer treatment. Sarver et al.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> and Bagdanoff et al.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> reported on two lead series <b>188</b> and <b>189</b> making use of the same spirocyclic rigidization. Both lead series started with compounds bearing a (4-methylpiperidin-4-yl)methanamine moiety, which exhibited very good in vitro potency. However, cellular potency and antiproliferative effects were significantly diminished. X-ray structure analysis revealed that the primary amine group is engaged in three directed H-bond interactions (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, upper left). Rigidization of the aminomethyl moiety could be achieved by introduction of spirocyclic systems carrying the exocyclic amine. All spirocyclic variants exhibited comparable in vitro potency; however, the cellular efficacy was improved by increased lipophilicity.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Effects of Structure-Based Introduction of a Spirocycle into Two Series of SHP2 Inhibitors</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0063.gif" alt="" id="gr40" /></img><div></div></div><div class="NLM_p">Goldberg et al. reported the optimization of tryptophan hydroxylase-1 (TPH1) inhibitors.<a onclick="showRef(event, 'ref122 ref123'); return false;" href="javascript:void(0);" class="ref ref122 ref123">(122,123)</a> In this case, the goal of optimization was the prevention of central nervous system (CNS) exposure. Tyrosine-derived inhibitors such as <b>190</b> are able to cross the blood–brain barrier and thereby exhibit adverse effects related to alterations in serotonin levels in the CNS. Goldberg et al. examined the bioactive conformation of <b>190</b> in complex with TPH1<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> and modeled a variety of diverse saturated heterocyclic scaffolds, which were successfully synthesized and evaluated in vitro. The spirocyclic proline-based scaffold, as shown in <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>, exhibited the best profile and led to optimized lead <b>191</b> without CNS exposure.</div><figure id="fig11" data-index="39" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0011.jpeg" id="gr41" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Structure-based introduction of a spirocyclic moiety into TPH1 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The structure-based introduction of the spirocyclic scaffold was performed by Schwertz et al.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> In their study, they evaluated spirocyclic 2-indolinone or dihydroindene scaffolds and their ability to inhibit serine hydroxymethyltransferase (SHMT), a druggable target for antimalarials. The inhibitors contained a spirocyclic chiral center, and a selection of enantiomers were separated by chiral HPLC. The determination of their inhibitory potency against <i>Plasmodium falciparum</i> (<i>Pf</i>) SHMT revealed a favored <i>S</i>-conformation of the nonspirocyclic compound <i>S</i>-<b>192</b> and suggested that cyclization of the isopropyl moiety with the phenyl ring is possible. The resulting compound <b>193</b> was indeed more potent than the nonspirocyclic analogue <b>192</b>. However, the X-ray structure of <i>Plasmodium vivax</i> (<i>Pv</i>) SHMT with <i>S</i>-<b>193</b> revealed several differences in the binding mode induced by the constrained ring system. Most interestingly, the gem-dimethyl moiety prevents the tyrosine side chain from forming H-bond interactions with the glutamate carboxylate group. As a consequence, the fused pyrazole in <i>S</i>-<b>193</b> is involved in a water-mediated H-bond interaction with the glutamate (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>).</div><figure id="fig12" data-index="40" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0012.jpeg" id="gr42" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Structure-based introduction of a spirocyclic moiety into SHMT inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Taken together, spirocyclic replacement can be considered a useful tool in structure-based drug design. Given the knowledge of the bioactive conformation, rigidization of a spirocycle can be used not only to optimize potency but also for rational improvements of efficacy and ADME properties. Considering the advances due to X-ray crystallography and electron microscopy in the past decade, opportunities for the structure-guided introduction of spirocyclic scaffolds will increase in importance and require the development of specialized computer-aided methodologies, some of which we will discuss later.</div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i53">Influence on Selectivity</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74324" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74324" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Previous examples of applications of spirocyclic compounds in structure-based drug design showed that a potency increase, though moderate, can be observed upon spirocyclization. In this section, we examine how spirocyclic scaffolds can influence the selectivity profile against related and general off-targets.</div><div class="NLM_p">Reilly et al. examined the replacement of the piperazine core with diverse spirocyclic systems in dopamine D3 receptor antagonists.<a onclick="showRef(event, 'ref126 ref127'); return false;" href="javascript:void(0);" class="ref ref126 ref127">(126,127)</a> Although the fragment <b>195a</b>, which binds to the orthosteric site of dopamine receptors and exhibits a spirocyclic core, is more than 100-fold less potent than the piperazine analog <b>194a</b>, it already shows 10-fold selectivity compared to the related dopamine D2 receptor (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). When extended, lead compound <b>195b</b>, with exclusive selectivity ratio of 905-fold, was obtained. Furthermore, measurement of binding affinities against a panel of selected aminergic receptors revealed a much better selectivity profile of spirocyclic compound <b>195b</b>.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Selective Dopamine D3 Receptor Antagonists</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0064.gif" alt="" id="gr43" /></img><div></div></div><div class="NLM_p">Similar observations were made by Reilly in the context of poly (ADP-ribose) polymerase (PARP) inhibitors, where the piperazine moiety of <b>196</b> (olaparib) was replaced by diverse spirocyclic analogues (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>).<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> The best compound, the diazaspiro[3.3]heptane analogue <b>197</b>, showed a 2-fold reduction in potency toward PARP-1. However, the selectivity against other members of the PARP family increased significantly, which came along with reduced DNA damage and cytotoxicity.</div><figure id="fig13" data-index="41" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0013.jpeg" id="gr44" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Replacement of piperazine by diazaspiro[3.3]heptane in <b>196</b> (olaparib).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The usage of spirocyclic derivatives to improve the selectivity profile was also evaluated by Ren et al. for the discovery of 5-hydroxytryptamine receptor (5-HT<sub>2C</sub>R) agonists.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> On the basis of the vabicaserin scaffold, they synthesized derivatives and evaluated the substitution pattern of the five-membered ring (compounds <b>198</b> and <b>199</b>, <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>). Introduction of a dimethyl group gave a modest improvement in 5-HT<sub>2C</sub>R activity but increased the selectivity. Introducing a spirocyclobutyl group resulted in an approximately 10-fold more potent agonist with similar selectivity. Both compounds showed no significant inhibition of the hERG channel (dimethyl derivative <12% inhibition at 10 μM; spirocyclobutyl <30% inhibition at 3 μM) or toward major CYP enzymes (both compounds showed an IC<sub>50</sub> of >50 μM for CYP3A4, 2C8, 2C9, 2C19, 1A2, and 2D6). Despite these promising properties, the spirocyclic inhibitor was not convincing in a full PK study. In fact, both compounds had a similar half-life (dimethyl 1.9 h, spiro 1.4 h) and oral bioavailability (nearly 100%), but the clearance of the spirocyclic agonist was 2-fold higher than the dimethyl derivative and hepatic blood flow in rat was even higher.</div><figure id="fig14" data-index="42" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0014.jpeg" id="gr45" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Spirocyclic 5-HT<sub>2C</sub>R agonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Comparison of a dimethyl and spiro cyclopropyl derivative was performed by García et al.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> They designed and synthesized a dual μ-opioid receptor (MOR) agonist and σ<sub>1</sub> receptor (σ<sub>1</sub>R) antagonist. By the merging approach, they combined two target pharmacophores in the same central core, leading to a diazaspiro[5.5]undecane scaffold. The scaffold residue was optimized with regard to balanced potency, as well as selectivity profile (hERG and α1 adrenoreceptor (α1AR) affinity) and lipophilicity. The rigidization from the dimethyl spirocyclic compound (compound <b>200</b>) to the bis-spirocyclic derivative (compound <b>201</b>) reduced the hERG affinity, produced a slight decrease in adrenoreceptor inhibition, and decreased the cLogP value (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>). Interestingly, the affinity against the targeted receptors was reversed and the spirocyclic compound showed a marginal drop in affinity.</div><figure id="fig15" data-index="43" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0015.jpeg" id="gr46" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Dual μ-opioid receptor agonists/σ<sub>1</sub> receptor antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Taken together, even if the introduction of a spirocyclic framework has little effect or even promotes a loss of potency, it can lead to significantly increased selectivity. Thus, in campaigns where selectivity toward closely related off-targets is an issue, the use of spirocycles might be highly recommendable.</div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i55">Physicochemical and in Vitro Pharmacological Properties of Spirocyclic Compounds</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64202" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64202" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Good physicochemical properties are key prerequisites of a successful drug candidate. Incorporation of spirocycles and associated high Fsp<sup>3</sup> raises the expectations of improved solubility and lipophilicity. This section will highlight several examples in which spirocyclic inhibitors were evaluated regarding their physicochemical properties compared with similar nonspirocyclic compounds. Studies such as the one published by Degorce et al. clearly demonstrate that the replacement of morpholines and piperazines with their spirocyclic azaspiro[3.3]heptane counterparts reduced the log <i>D</i><sub>7.4</sub> value in almost all cases.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> Similar observations were made for spirooxetanes compared with morpholines.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> Metabolic stability was significantly improved by the introduction of azaspirocycles instead of morpholine, piperidine, and piperazine counterparts.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> In the following section, we examine select examples of spirocyclic replacement and the observed effects on physicochemical and in vitro pharmacological properties.</div><div class="NLM_p">The development of polo-like kinase 4 (PLK4) inhibitors by Sampson et al. showed the superior effects of introducing a spiro cyclopropane to an already promising scaffold.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> The rigid double bond of compound <b>202</b> next to the indolin-2-one was replaced (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>). Although compound <b>203</b> lost potency, it gained quality through physicochemical properties. For instance, the solubility at pH 7.4 was raised more than 11-fold. The authors explained this as due to different crystal packing because the spirocyclic moiety is orthogonal to the plane of the indolinone, whereas the alkene is in plane and in conjugation with the heterocycle. Furthermore, the spirocyclic derivative exhibited an equal selectivity profile regarding other kinases (Flt3, KDR) and an improved selectivity profile by showing less inhibition of five CYP450 isoforms. Plasma protein binding was reduced (83% vs 99.9%), and the microsomal stability in mice and human was increased (4 min vs 49 min). In an ip dosage of 50 mg/kg, the spirocyclic scaffold yielded a 100-fold higher exposure in mouse plasma compared to the alkene derivative.</div><figure id="fig16" data-index="44" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0016.jpeg" id="gr47" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Replacement of an alkene with a spirocyclic moiety leads to PLK4 inhibitors with improved physicochemical properties.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In a high-throughput cell-based reporter assay focused on WNT pathway activity with 7dF3 clones, Mallinger et al. found a hit that was subsequently modified using a classical ligand-based design approach.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> To explore the optimal geometry for hydrogen bonding and avoid amidase-mediated cleavage of the exocyclic amide in compound <b>204</b>, a geminal methyl group was introduced. Compound <b>205</b> marginally dropped in potency though its microsomal stability remained. The next step was a ring closure resulting in spirocyclic compound <b>206</b> with better potency than the nonspiro inhibitor and a slightly higher microsomal stability (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>).</div><figure id="fig17" data-index="45" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0017.jpeg" id="gr48" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Introduction of a spirocycle into WNT inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Johansson et al. developed melanin concentrating hormone receptor 1 (MCHr1) antagonists and started with a pyrrolidine derivative as the lead structure.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> During the optimization process, they tried to increase the margin between MCHr1 and hERG activity by lowering the p<i>K</i><sub>a</sub> and lipophilicity of their agonists. Introduction of a morpholine lowered the p<i>K</i><sub>a</sub> and the metabolic stability. A homomorpholine-bearing compound <b>207</b> was superior compared to the morpholine derivative, but the metabolic turnover rate was still high. Exchange to diverse azaspiro cycles (compounds <b>208</b> and <b>209</b>) improved the metabolic stability and lowered log <i>D</i> values, and the affinity gap between MCHr1 and hERG was wider (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>).</div><figure id="fig18" data-index="46" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0018.jpeg" id="gr49" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Spirocyclic MCHr1 antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Degorce et al. reviewed the influence of exchanging morpholines with azaspiroheptanes to lower the lipophilicity.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> They also showed their results of the discovery of interleukin-1 receptor-associated kinase-4 (IRAK4) inhibitors. The spiro compound <b>211</b> exhibited higher basicity and lower lipophilicity (Δp<i>K</i><sub>a</sub> = +0.6, Δlog <i>D</i><sub>7.4</sub> = −0.7) compared to the morpholine analogue <b>210</b>. Although <b>211</b> lost its cell potency (ΔpIC<sub>50</sub> = −0.4), the cellular ligand-lipophilicity efficiency (LLE) was improved (ΔLLE = +0.3). Due to its higher basicity and lower lipophilicity, the permeability was approximately 3-fold lower (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>).</div><figure id="fig19" data-index="47" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0019.jpeg" id="gr50" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. IRAK4 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The use of spirocyclic inhibitors against IRAK4 was demonstrated by Bryan et al. from a high-throughput screen that identified quinoline-based hits, which were modified using a classical structure-based design approach.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> To disrupt the planarity of the inhibitors, they introduced either an alcohol <b>212</b> or azaspiro[4.5]decane <b>213</b>. The spirocyclic compound <b>213</b> dramatically improved the solubility and maintained the permeability (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>).</div><div class="NLM_p">A spirocyclic agonist of G-protein-coupled receptor 119 (GPR119) was reported by Harada et al.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> By using traditional pharmacophores of GPR119 agonists and replacement of the carbamate moiety in compound <b>214</b> with a spirocycle, they obtained novel potent derivatives. The 3,3-dimethyl-2-oxaspiro[4.5]decane <b>215</b> yielded the best results, showing lower CYP inhibitory activities (IC<sub>50</sub> < 10 μM against CYP1A2, 3A4, 2C8, 2C9, 2C19, and 2D6) compared with the best nonspirocyclic agonist <b>214</b> (IC<sub>50</sub> > 10 μM against CYP2C8, 2C9, and 2C19) (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>). The solubility in the fed state simulated intestinal fluid (FeSSIF) was also improved and twice that of the nonspirocyclic agonist <b>214</b>.</div><figure id="fig20" data-index="48" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0020.jpeg" id="gr51" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. GPR119 agonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Alen et al. discovered sepiapterin reductase (SPR) inhibitors via a fragment-based approach.<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> By exploring the initial fragment screening hit, they found potent inhibitors containing a spirocyclic moiety. During their SAR studies, they synthesized and tested diverse spirocyclic scaffolds. Moreover, they compared a nonspiro inhibitor <b>216</b> with a spirocyclic inhibitor <b>217</b>, and the spirocycle showed a higher potency and slightly improved solubility and log <i>D</i> (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>).</div><figure id="fig21" data-index="49" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0021.jpeg" id="gr52" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. SPR inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The great impact of spirocyclic inhibitors on in vitro stability and efflux properties was demonstrated by Mould et al. in a high throughput screen, in which they identified hit <b>218</b> for the inhibition of lysine specific demethylase 1 (LSD1).<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> Subsequent modifications and SAR analysis led to a potent diazaspiro[3.5]nonane-based reversible inhibitor <b>219</b>, which inhibited LSD with two-digit nanomolar activity. The selectivity was improved, and hERG inhibition was lower compared with the nonspirocyclic analogue. Additionally, determination of clearance in mouse microsomes showed the enhanced stability of the spirocyclic scaffolds. Nevertheless, the poor membrane permeability and high levels of efflux of <b>219</b> could complicate its oral bioavailability (<a data-tab="pane-pcw-Figures" href="#fig21a" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21a" id="" class=" internalNav">22</a></a>).</div><figure id="fig21a" data-index="50" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0022.jpeg" id="gr53" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. LSD1 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig21a"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The improved selectivity profile of spirocyclic inhibitors is well-demonstrated in the following example. To reduce the side-effects of <b>220</b> (linezolid), morpholine heterocycle-containing oxazolidinone antibiotic geminal-substituted derivatives were synthesized and evaluated.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a><b>220</b> inhibited the mitochondrial protein synthesis (MPS) activity of human ribosomes due to their high homology to bacterial ribosomes. Diverse modifications were tested, and a spirotetrahydropyran analogue <b>221</b> displayed the greatest minimum inhibitory concentration (MIC) values in a broth microdilution assay against <i>S. aureus</i>. Further ADME analyses revealed that the spirocyclic inhibitor showed slightly reduced aqueous solubility, stability at low pH (Δstability 4%), and microsomal stability compared to linezolid (<a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">23</a></a>). The MPS inhibition could be reduced, which correlated with decreased relative MIC values for the spirocyclic derivative. The newly designed compound exhibited moderate binding affinity toward bacterial ribosomes and decreased inhibition of mitochondrial ribosomes.</div><figure id="fig22" data-index="51" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0023.jpeg" id="gr54" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Linezolid and its spirocyclic analogue.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i56">Spirocycles as Covalent Warheads</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71512" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71512" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Covalent targeting with binding drugs is an underestimated field in drug discovery. This kind of modifier, also termed as a warhead, preferably binds to poorly conserved nucleophilic amino acid residues within a protein. An excellent Perspective was published by Gehringer et al. and highlighted the common types of those modifiers.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> Herein, we will concentrate on spirocyclic warheads with strained tricyclic moieties, such as epoxides and diaziridines. Certainly, thiiranes and aziridines could also serve as warheads, and nonspiro examples have been published;<a onclick="showRef(event, 'ref143 ref144 ref145'); return false;" href="javascript:void(0);" class="ref ref143 ref144 ref145">(143−145)</a> however, spirocyclic scaffolds incorporating these heterocyclic warheads have not been published to our knowledge.</div><div class="NLM_p">Evans et al. showed a subtle strategy to identify targets in a cell-based assay wherein the enzymes were covalently labeled.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> The generated small molecules were inspired by natural products and contained an electrophilic spirocyclic epoxide, a variable binding group and an alkyne for click chemistry to fluorophores. In the cell-based screen, the authors identified <b>222</b> as inhibiting breast cancer cell proliferation by covalently binding the glycolytic enzyme phosphoglycerate mutase 1 (PGAM1) (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">24</a></a>). The inhibition and labeling only occurred in intact cells, showing the advantage of discovering targets in a living system to enable downstream mechanistic studies.</div><figure id="fig23" data-index="52" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0024.jpeg" id="gr55" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Compounds bearing an electrophilic spirocyclic epoxide.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">An approach for chemically covalent binding probes was published by Schröder et al.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> Glycosidases cleave <i>N</i>-glycans, which are complex oligosaccharides linked to asparagine residues in proteins. Glycoside hydrolase (GH) family 99 endomannodidase/endomannanase cleaves within complex <i>N</i>-glycans. An unconventional mechanism was postulated for bacterial endo-1,2-α-mannanase in the human gut. To examine the catalytic steps, spiro-epoxyglycoside probes were developed. The probe <b>223</b> equipped with a fluorescent tag bound covalently to the catalytic residues in the protein via the epoxide (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">24</a></a>). However, the labeling was not exclusively at a single residue, and more investigation has to be performed to deliver chemical tools for functional investigation of GH99 endo-1,2-α-mannosidase/mannanases.</div><div class="NLM_p">Improved irreversible inhibitors of methionine aminopeptidase (MetAP) were developed by Morgen et al. They synthesized derivatives of <b>10</b> with a better pharmacokinetic profile than the earlier reported and former clinical candidate beloranib.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> The potent inhibitor <b>224</b> was selective, and the potency could be confirmed in cell-based assays. The stereochemistry strongly influenced the activity, and the derivatives with the same configuration as <b>10</b> were more potent. The improved pharmacokinetic properties could be fulfilled, and the derivatives were more stable in mouse plasma and microsomes (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">24</a></a>). Interestingly, the enantiomers of <b>224</b> reacted in a different manner. While (+)-<b>224</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CLS">5CLS</a>) was found to bind to His231, the other configuration led to a covalent bond with Glu364 at the spirocyclic moiety (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5D6E">5D6E</a>).</div><div class="NLM_p">Photoaffinity labeling has become attractive for detailed structural analysis of ligand binding domains in the past decades. Photolabile groups such as diazirines are irradiated with UV light and convert into carbenes and elementary nitrogen. The carbene can bind to a protein through insertion into C–H or heteroatom-H bonds.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> For example, Cruz et al. synthesized a cholesterol analogue with a spirocyclic diazirine <b>225</b> and demonstrated the applicability of photoaffinity labeling to investigate cholesterol–protein interactions that are involved in intracellular cholesterol trafficking (<a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">25</a></a>).<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> Although the application is widely used, methods to synthesize spirocyclic compounds have been reported less. Martyloga et al. dedicated themselves to the multigram synthesis of functionalized spirocyclic diazirines. They generated building blocks with a carboxylic acid or amine with a photoaffinity labeling group through a two-step procedure (<a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">25</a></a>).<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a></div><figure id="fig24" data-index="53" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0025.jpeg" id="gr56" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. Spirocyclic diazirines: example and general reaction procedure.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec9" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i57">Spirocycles Back and Forth: Bioisosteric Replacement of Spirocyclic Scaffolds</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22220" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22220" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Although various studies described in previous sections suggest that spirocycles display benefits in the drug discovery process, there are several examples where nonspirocyclic scaffolds have displayed superior profiles. One of these examples is the discovery of potent HCV NS5A inhibitors. In the introductory section, we mentioned <b>14</b>, an NS5A inhibitor that exhibits a spirocyclic proline analogue. However, a study performed by Ramdas et al. aimed at introducing a lipophilic spirocyclic scaffold in the linker region between the peptidoid parts showed that the spirocyclic linker <b>226</b> displayed subnanomolar activity, though only toward the hepatitis C virus genotype 1b (GT1b) replicon.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> The fully planar tricyclic linker was obviously more suitable, leading to lead compound <b>227</b>, which exhibited picomolar activity toward both replicons GT1a and GT1b (<a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">26</a></a>).</div><figure id="fig25" data-index="54" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0026.jpeg" id="gr57" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. NS5A inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The work of Yang et al. demonstrated that starting with a promising spirocyclic scaffold may not guarantee ending with a spirocyclic inhibitor.<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> They developed a new series of aldehyde dehydrogenase (ALDH) inhibitors by merging one of their published structures with a hit from a high throughput screen that exhibited a similar core. This hybrid <b>228a</b>, containing a spirocyclic ketal, was extensively optimized to avoid the acid-labile ketal moiety. Modifications in ring sizes and substitution of the oxygen in the spirocyclic entity <b>228b</b> led to reduced potency (ΔpIC<sub>50</sub> = 0.3) and decreased rat liver microsomes (RLM) stability (<i>t</i><sub>1/2</sub> > 30 min vs <i>t</i><sub>1/2</sub> = 2 min). In contrast, the dimethyl inhibitor <b>228c</b> retained almost all of the potency and substitution of a methyl group by a nitrile (compound <b>228d</b>) retained the RLM stability (<i>t</i><sub>1/2</sub> = 22 min) (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Substitution of the spirocyclic/spiro residue with fluorine (<b>228e</b>) led to less potent inhibitors; however the RLM stability was retained. During the optimization process, the spiro compounds showed superior activities and RLM stabilities compared with diverse spirocyclic derivatives, which did not contain a ketal moiety.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. ALDH Inhibitors</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0065.gif" alt="" id="gr58" /></img><div></div></div></div><div id="sec10" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i59">Pharmacokinetic Properties of Spirocyclic Compounds</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53223" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53223" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In the previous section, the potential beneficial effects of the incorporation of a spirocycle on the physicochemical properties were highlighted. A spirocycle does not guarantee improved physicochemical attributes, but the likelihood is high as the selected examples of the aforementioned section showed. The physicochemical properties are tightly interconnected with the pharmacokinetic profile. In the following section, we summarize selected examples of spirocycles and nonspiro counterparts in light of ADME.</div><div class="NLM_p">Naidu et al. reported a potent HIV-1 integrase strand transfer inhibitor that was discovered in a systematic SAR series supported by a single X-ray crystal structure.<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> X-ray structure analysis revealed that a spirocyclic compound may lock the ideal geometry for improved antiviral potency. Further optimization of the physicochemical properties led to <b>229</b>, whose ADME was evaluated in vivo. The nonspirocyclic derivative showed intravenous (iv) low clearance (CL), a short half-life, and low steady state volumes of distribution (<i>V</i><sub>ss</sub>). The oral dosage demonstrated high exposure and bioavailability (<i>F</i>) in male Sprague-Dawley rats. The spirocyclic derivative <b>230</b> had a higher clearance, but the aqueous solubility was poor (≤5 μg/mL). To increase the solubility, a fused heterocycle was incorporated and the cyclopentyl was substituted by a gem-dimethyl group. Compound <b>231</b> showed better bioavailability, and the exposure was high. According to the authors, the <i>t</i><sub>max</sub> value of 0.25 suggested rapid absorption of the compound. Following iv application, the clearance of <b>231</b> was higher than the nonspiro compound <b>229</b>; however, the half-life was prolonged, and the volumes of distribution were increased (<a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">27</a></a>).</div><figure id="fig26" data-index="55" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0027.jpeg" id="gr59" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. Spirocyclic HIV-1 integrase strand transfer inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A new class of hepatitis C NS3/4A protease inhibitors were identified by Velázquez et al.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> In a previous publication, they reported the protease inhibitor MK-6325 <b>232</b>, which showed an excellent potency profile for several genotypes and mutant strains of HCV.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> The quinoxaline-based inhibitor contained a spirocyclic scaffold in the macrocyclic entity. The introduction of a second spirocycle linking the quinoxaline and the proline moiety yielded a potent inhibitor <b>233</b> with nanomolar to subnanomolar activity. ADME was evaluated in rats and did not fulfill the expectations of the authors. It had a high clearance, very low exposure after oral exposure (po applicated), and a low concentration in the liver after 24 h (<a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">28</a></a>) Nevertheless, the clearance of <b>232</b> was higher and the volume of distribution (Vd) lower compared to <b>233</b>. In contrast, po application of <b>232</b> resulted in higher AUC values (dosage of <b>233</b> was 2-fold higher). However, the authors did not define the time frame for the AUC values of the spirocyclic inhibitor <b>233</b>. Because of the different vehicles and dosages, comparison of the data is difficult.</div><figure id="fig27" data-index="56" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0028.jpeg" id="gr60" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. NS3/4A protease inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A series of spirocyclic renal outer medullary potassium channel (ROMK) inhibitors were developed by Chobanian et al.<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a> A previously reported inhibitor <b>234</b> was further modified to optimize its potency, selectivity, and ADME. Substitution of the central piperazine ring by several spirocyclic moieties led to conformationally more constrained inhibitor <b>235</b>. The spirocyclic derivative showed improved potency (140 nM vs 10 nM) and selectivity (hERG/ROMK selectivity: 128 vs 240). The pharmacokinetic properties determined in rats demonstrated that the spirocycle improved the half-life and volume of distribution. The clearance was lower, but the bioavailability was excellent. Moreover, the free fraction (Fu) was reduced compared with the nonspirocyclic inhibitor <b>234</b> (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Pharmacokinetic Properties of ROMK Inhibitors</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0066.gif" alt="" id="gr61" /></img><div></div></div><div class="NLM_p">Pettus et al. reported inhibitors of the proviral integration site of moloney murine leukemia virus proteins 1, 2, and 3 (Pim-1, Pim-2, and Pim-3, respectively).<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a> In their earlier work, they identified pan-Pim kinase 2-aryl-6,7-dihydro-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-4(5<i>H</i>)-ones inhibitors such as <b>236</b>. Although the potency and efficacy were satisfying, the compounds possessed rapid clearance and a short half-life. A quinazolinone-pyrrolopyrrolone series yielded potent and selective pan-Pim inhibitors. In this series, spirocyclic compound <b>237</b> showed a similar iv clearance (vehicle 100% DMSO) as the nonspirocyclic derivative. However, the half-life and bioavailability (% <i>F</i>, vehicle, 40% PEG 400 in water, pH 2.2 water/maleic anhydride) of the spirocycle were significantly increased (<a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">29</a></a>).</div><figure id="fig28" data-index="57" class="article__inlineFigure"><h2 class="fig-label">Figure 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0029.jpeg" id="gr62" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 29. Spirocyclic Pim kinase inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Fused and spirocyclic derivatives of the GPR40 agonist <b>238</b> were developed to improve its off-target selectivity.<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a> GPR40, a G-protein-coupled receptor, takes part in insulin secretion and may be a target for the treatment of type 2 diabetes. The further optimization of <b>238</b> was performed by Wang et al., and conformational constraints, realized by spirocyclic moieties, led to <b>239</b>. A pharmacokinetic study in rats and cynomolgus monkeys was performed (vehicle po 1% Tween 80, 1% methyl cellulose, 98% water.). In rats, the clearance was reduced but the volume of distribution was also decreased. The half-life was 2-fold higher compared to <b>238</b>. In contrast, the PK profile of the spirocyclic agonist was slightly worse in monkeys, especially the volume of distribution, which was lower and coincided with the PK data in rats (<a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">30</a></a>).</div><figure id="fig29" data-index="58" class="article__inlineFigure"><h2 class="fig-label">Figure 30</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0030.jpeg" id="gr63" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 30. GPR40 agonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig29"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A new κ-opioid receptor agonist was developed by rigidizing salvinorin A.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> Salvinorin A (<b>240</b>) is a substrate of CYP450 enzymes and esterases and exhibited a short half-life. The formed spirobutyrolactone modulator <b>241</b> showed similar potency and selectivity. <b>241</b> was evaluated in rat liver microsomes with and without cofactor NADPH. Metabolism in the presence of NADPH indicated CYP450-mediated reactions, while non-CYP450-mediated metabolism occurs without the cofactor. The spirocycle is significantly more stable than salvinorin A at reducing both described metabolism scenarios. The in vivo antinociceptive effects were evaluated in a warm-water tail-withdrawal assay in mice. Both modulators showed similar abilities to attenuate thermal spinal cord reflexes and analgesic effects. The effective dose (ED<sub>50</sub>) was determined and was similar (<b>241</b>, ED<sub>50</sub> = 0.7592 mg/kg [95% CI, 0.1508–3.822]; <b>240</b>, 1.28 mg/kg [95% CI, 0.58–2.82]). The efficacy in the dose–response tail withdrawal assay was lower, as was observed in the thermally induced assay. The authors explained this as potentially reduced CNS penetration or as possible partial agonist activity of <b>241</b> in vivo. However, the spirocyclic compound displayed improved in vitro metabolic stability (<a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">31</a></a>).</div><figure id="fig30" data-index="59" class="article__inlineFigure"><h2 class="fig-label">Figure 31</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0031.jpeg" id="gr64" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 31. κ-Opioid receptor agonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig30"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Incorporation of a spirocyclic scaffold may improve the physicochemical parameters and metabolic stability of a protein modulator. However, when using new moieties, new metabolic pathways may be observed beyond cytochrome P450 transformation. Toselli et al. reported a ring-opening reaction of oxetanes by microsomal epoxide hydrolase (mEH) (<a class="ref internalNav" href="#sch29" aria-label="Scheme 29">Scheme 29</a>A).<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> Participation of the soluble epoxide hydrolase or cytochrome P450 oxidation in human liver fractions and hepatocytes was not observed. This opening of a four-membered ring is the first nonepoxide class of substrates reported and was observed in the metabolism of the clinical candidate <b>209</b> (AZD1979).<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> A clear correlation between the degree of oxetane cleavage and physicochemical features (p<i>K</i><sub>a</sub> or log <i>D</i>) could not be observed using a series of derivatives (<b>242</b>). These results demonstrated that mEH-mediated metabolism should be evaluated using oxetane-containing structures.</div><figure id="sch29" data-index="60" class="article__inlineFigure"><h2 class="fig-label">Scheme 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0060.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0060.jpeg" id="gr65" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 29. Metabolization of Oxetane-Containing Spirocycles</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0060.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch29"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">A further metabolic pathway of the strained spiro-azetidinyl moiety in <b>209</b> was detected by Li et al.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> A series of glutathione-related metabolites were found in human hepatocytes that were not derived from the CYP P450 pathway. Through closer examination of human liver subcellular fractions in combination with different metabolic enzyme inhibitors, the authors identified glutathione <i>S</i>-transferase (GST) as an executive enzyme. The glutathione-conjugated spiro-azetidines <b>244</b> were formed without prior bioactivation (<a class="ref internalNav" href="#sch29" aria-label="Scheme 29">Scheme 29</a>B).</div></div><div id="sec11" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i62">Future Perspectives and Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54827" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54827" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Spirocyclic scaffolds are popular in medicinal chemistry and contribute to a variety of approved drugs and drug candidates. Recent advances in the development of synthetic methods have allowed the introduction and increase in spirocycles in medicinal chemistry in the past decade. Today, a great variety of reaction pathways are available to prepare desired spirocyclic scaffolds and promote the diversity of spirocyclic systems. However, their full potential has not yet been exploited. Methodologies for the systematic exploration of the spirocyclic chemical space are still in their infancy, although several successful in silico and in vitro studies on this topic have been published. Studies that endorse the use of scaffolds with high Fsp<sup>3</sup> further enhance the interest in novel and established spirocycles. The increase in rigidity resulting from spirocyclization can influence important factors, such as potency and selectivity, but further work in the field is required to fully understand the broad impact of such approaches. Furthermore, significant improvements in physicochemical properties, such as the log <i>D</i>, lipophilicity, and solubility, as well as ADME properties, are achievable, ultimately leading to improved pharmacokinetic profiles. Taken together, spirocycles are a powerful tool for medicinal chemists with further potential to advance in the near future.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01473" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61107" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61107" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ewgenij Proschak</span> - <span class="hlFld-Affiliation affiliation">Institute
of Pharmaceutical Chemistry, Goethe University, Max-von-Laue Straße 9, D-60348 Frankfurt am Main, Germany</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1961-1859" title="Orcid link">http://orcid.org/0000-0003-1961-1859</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#3f4f4d504c5c575e547f4f575e4d525c575a52114a515612594d5e5154594a4d4b115b5a"><span class="__cf_email__" data-cfemail="3a4a48554959525b517a4a525b485759525f57144f5453175c485b54515c4f484e145e5f">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kerstin Hiesinger</span> - <span class="hlFld-Affiliation affiliation">Institute
of Pharmaceutical Chemistry, Goethe University, Max-von-Laue Straße 9, D-60348 Frankfurt am Main, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dmitry Dar’in</span> - <span class="hlFld-Affiliation affiliation">Institute
of Chemistry, Saint Petersburg State University, 199034 Saint Petersburg, Russia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mikhail Krasavin</span> - <span class="hlFld-Affiliation affiliation">Institute
of Chemistry, Saint Petersburg State University, 199034 Saint Petersburg, Russia</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li><span class="author-information-subsection-header">Funding</span><p>This work has been supported by the Deutsche Forschungsgemeinschaft (DFG; Heisenberg-Professur PR1405/7-1; Sachbeihilfe PR1405/8-1; SFB1039 TPA07). M.K. acknowledges funding from the Russian Science Foundation (grant no. 19-75-30008).</p></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41351" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41351" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="61" class="article__inlineFigure"><h2 class="fig-label">Kerstin Hiesinger</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=BIO-d7e3477-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Kerstin Hiesinger</b> studied chemistry at the Goethe University and graduated from the Institute of Pharmaceutical Chemistry at the Goethe University in Frankfurt in 2020 under the supervision of Prof. E. Proschak. She discussed in her doctoral thesis the synthesis and evaluation of dual inhibitors of the arachidonic acid cascade. Currently, she is conducting her postdoctoral research on the synthesis of spirocyclic and fluorescent bioactive compounds.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="62" class="article__inlineFigure"><h2 class="fig-label">Dmitry Dar’in</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=BIO-d7e3482-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Dmitry Dar’in</b> obtained his Diploma in Chemistry from Saint Petersburg State University in 2002 and stayed at the same university until the present, obtaining his Candidate of Science (CSc, Ph.D. equivalent) degree in 2005 and a Doctor of Science (DSc, Habilitation equivalent) in 2017. During this time, Dr. Dar’in was a frequent visitor to University of Göttingen (Prof. De Meijere’s group) and rose through the ranks of Research Assistant, Senior Lecturer, and Docent. In 2015, he joined the Krasavin group. In 2019, he was promoted to the rank of Full Professor. Prof. Dar’in’s interests are in diazo compound chemistry, multicomponent reactions, chemistry of heterocyclic compounds, and medicinal chemistry.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="63" class="article__inlineFigure"><h2 class="fig-label">Ewgenij Proschak</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=BIO-d7e3487-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Ewgenij Proschak</b> is Professor of Drug Design at the Institute of Pharmaceutical Chemistry at the Goethe University of Frankfurt. After his doctoral and postdoctoral studies at Goethe University, he became Independent Group Leader at the Lipid Signaling Research Center (LIFF) in Frankfurt. Currently, the German Research Council (DFG) awarded him with a Heisenberg professorship. He has worked on hit identification and hit-to-lead optimization for fatty acid mimetics including inhibitors of 5-LO, mPGES-1, sEH, and LTA4H and modulators of PPARs and FXR. His current research interests are the design and synthesis of multitarget drugs for the treatment of inflammatory conditions and metabolic syndrome.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="64" class="article__inlineFigure"><h2 class="fig-label">Mikhail Krasavin</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=BIO-d7e3492-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Mikhail Krasavin</b> studied chemistry at Saint Petersburg State University and obtained his Master of Arts degree from the John Hopkins University. After working as a medicinal chemistry research associate at Millennium Pharmaceuticals and Abbott in the U.S., Mikhail returned to Russia to join ChemDiv, Inc. in Moscow. While at ChemDiv, Mikhail obtained his CSc degree in 2006 and his DSc degree in 2011. In 2011–2013 Dr. Krasavin served as a group leader at the Griffith University Institute for Drug Discovery in Brisbane, Australia. From 2014, he has been a Full Professor at Saint Petersburg State University and was elected professor of the Russian Academy of Science in 2016. Prof. Krasavin’s interests are in synthetic methodology, medicinal chemistry, and chemical biology</p></figure></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">5-HTR</td><td class="NLM_def"><p class="first last">5-hydroxytryptamine receptor</p></td></tr><tr><td class="NLM_term">A/M2</td><td class="NLM_def"><p class="first last">influenza A membrane protein M2 proton channel</p></td></tr><tr><td class="NLM_term">α1AR</td><td class="NLM_def"><p class="first last">α1 adrenoreceptor</p></td></tr><tr><td class="NLM_term">AR</td><td class="NLM_def"><p class="first last">androgen receptor</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the curve</p></td></tr><tr><td class="NLM_term">ALDH</td><td class="NLM_def"><p class="first last">aldehyde dehydrogenase</p></td></tr><tr><td class="NLM_term">BACE1</td><td class="NLM_def"><p class="first last">β-site APP cleaving enzyme 1</p></td></tr><tr><td class="NLM_term">Brr2</td><td class="NLM_def"><p class="first last">bad response to refrigeration 2</p></td></tr><tr><td class="NLM_term">CL</td><td class="NLM_def"><p class="first last">clearance</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P</p></td></tr><tr><td class="NLM_term">DENV</td><td class="NLM_def"><p class="first last">dengue virus</p></td></tr><tr><td class="NLM_term">ED<sub>50</sub></td><td class="NLM_def"><p class="first last">effective dose</p></td></tr><tr><td class="NLM_term"><i>F</i></td><td class="NLM_def"><p class="first last">bioavailability</p></td></tr><tr><td class="NLM_term">FeSSIF</td><td class="NLM_def"><p class="first last">fed state simulated intestinal fluid</p></td></tr><tr><td class="NLM_term">Fsp3</td><td class="NLM_def"><p class="first last">number of sp<sup>3</sup> hybridized carbons</p></td></tr><tr><td class="NLM_term">Fu</td><td class="NLM_def"><p class="first last">free fraction</p></td></tr><tr><td class="NLM_term">GPR119</td><td class="NLM_def"><p class="first last">G-protein-coupled receptor 119</p></td></tr><tr><td class="NLM_term">GH</td><td class="NLM_def"><p class="first last">glycoside hydrolase</p></td></tr><tr><td class="NLM_term">GR</td><td class="NLM_def"><p class="first last">glucocorticoid receptor</p></td></tr><tr><td class="NLM_term">GS</td><td class="NLM_def"><p class="first last">γ-secretase</p></td></tr><tr><td class="NLM_term">GST</td><td class="NLM_def"><p class="first last">glutathione <i>S</i>-transferase</p></td></tr><tr><td class="NLM_term">GT1b</td><td class="NLM_def"><p class="first last">hepatitis C virus genotype 1b</p></td></tr><tr><td class="NLM_term">HAT</td><td class="NLM_def"><p class="first last">histone acetyltransferase p300</p></td></tr><tr><td class="NLM_term">HCV</td><td class="NLM_def"><p class="first last">hepatitis C virus</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">ether-a-go-go-related gene</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsome</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high performance liquid chromatography</p></td></tr><tr><td class="NLM_term">IKK</td><td class="NLM_def"><p class="first last">IκB kinase</p></td></tr><tr><td class="NLM_term">IRAK4</td><td class="NLM_def"><p class="first last">interleukin-1 receptor-associated kinase-4</p></td></tr><tr><td class="NLM_term">iv</td><td class="NLM_def"><p class="first last">intravenous</p></td></tr><tr><td class="NLM_term">LLE</td><td class="NLM_def"><p class="first last">ligand-lipophilicity efficiency</p></td></tr><tr><td class="NLM_term">LSD1</td><td class="NLM_def"><p class="first last">lysine specific demethylase 1</p></td></tr><tr><td class="NLM_term">MCL-1</td><td class="NLM_def"><p class="first last">induced myeloid leukemia cell differentiation protein</p></td></tr><tr><td class="NLM_term">MCHr1</td><td class="NLM_def"><p class="first last">melanin concentrating hormone receptor 1</p></td></tr><tr><td class="NLM_term">MetAP</td><td class="NLM_def"><p class="first last">methionine aminopeptidase</p></td></tr><tr><td class="NLM_term">mEH</td><td class="NLM_def"><p class="first last">microsomal epoxide hydrolase</p></td></tr><tr><td class="NLM_term">MIC</td><td class="NLM_def"><p class="first last">minimum inhibitory concentration</p></td></tr><tr><td class="NLM_term">MNK1/2</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase interacting kinases 1/2</p></td></tr><tr><td class="NLM_term">MOR</td><td class="NLM_def"><p class="first last">μ-opioid receptor</p></td></tr><tr><td class="NLM_term">MPS</td><td class="NLM_def"><p class="first last">mitochondrial protein synthesis</p></td></tr><tr><td class="NLM_term">MR</td><td class="NLM_def"><p class="first last">mineralocorticoid receptor</p></td></tr><tr><td class="NLM_term">nAChR</td><td class="NLM_def"><p class="first last">α7 nicotinic acetylcholine receptor</p></td></tr><tr><td class="NLM_term">NOP</td><td class="NLM_def"><p class="first last">nociceptin/orphanin FQ peptide</p></td></tr><tr><td class="NLM_term">NS4B</td><td class="NLM_def"><p class="first last">nonstructural protein 4B</p></td></tr><tr><td class="NLM_term">NS5A</td><td class="NLM_def"><p class="first last">nonstructural protein 5A</p></td></tr><tr><td class="NLM_term">PARP</td><td class="NLM_def"><p class="first last">poly (ADP-ribose) polymerase</p></td></tr><tr><td class="NLM_term">p-ERK</td><td class="NLM_def"><p class="first last">phosphoextracellular signal-regulated kinase</p></td></tr><tr><td class="NLM_term">PGAM</td><td class="NLM_def"><p class="first last">phosphoglycerate mutase</p></td></tr><tr><td class="NLM_term">PIM</td><td class="NLM_def"><p class="first last">proviral integration site of Moloney murine leukemia virus protein</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">PLK4</td><td class="NLM_def"><p class="first last">polo-like kinase 4</p></td></tr><tr><td class="NLM_term">PPI</td><td class="NLM_def"><p class="first last">protein–protein interaction</p></td></tr><tr><td class="NLM_term">po</td><td class="NLM_def"><p class="first last">oral exposure</p></td></tr><tr><td class="NLM_term">PR</td><td class="NLM_def"><p class="first last">progesterone receptor</p></td></tr><tr><td class="NLM_term">PTHR1</td><td class="NLM_def"><p class="first last">parathyroid hormone receptor 1</p></td></tr><tr><td class="NLM_term">PS-1</td><td class="NLM_def"><p class="first last">presenilin 1</p></td></tr><tr><td class="NLM_term">RCM</td><td class="NLM_def"><p class="first last">ring-closing metathesis</p></td></tr><tr><td class="NLM_term">RLM</td><td class="NLM_def"><p class="first last">rat liver microsome</p></td></tr><tr><td class="NLM_term">ROMK</td><td class="NLM_def"><p class="first last">renal outer medullary potassium channel</p></td></tr><tr><td class="NLM_term">RXR</td><td class="NLM_def"><p class="first last">retinoid X receptor</p></td></tr><tr><td class="NLM_term">σ<sub>1</sub>R</td><td class="NLM_def"><p class="first last">σ<sub>1</sub> receptor</p></td></tr><tr><td class="NLM_term">SGLT2</td><td class="NLM_def"><p class="first last">sodium-glucose cotransporter 2</p></td></tr><tr><td class="NLM_term">SHMT</td><td class="NLM_def"><p class="first last">serine hydroxymethyltransferase</p></td></tr><tr><td class="NLM_term">SHP2</td><td class="NLM_def"><p class="first last">protein tyrosine phosphatase 2</p></td></tr><tr><td class="NLM_term">SPR</td><td class="NLM_def"><p class="first last">sepiapterin reductase</p></td></tr><tr><td class="NLM_term">TPH1</td><td class="NLM_def"><p class="first last">tryptophan hydroxylase-1</p></td></tr><tr><td class="NLM_term">UCLA</td><td class="NLM_def"><p class="first last">University of California, Los Angeles</p></td></tr><tr><td class="NLM_term">Vd</td><td class="NLM_def"><p class="first last">volume of distribution</p></td></tr><tr><td class="NLM_term"><i>V</i><sub>ss</sub></td><td class="NLM_def"><p class="first last">steady state volume of distribution</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i69">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28651" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28651" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 162 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moss, G. P.</span></span> <span> </span><span class="NLM_article-title">Extension and Revision of the Nomenclature for Spiro Compounds</span>. <i>Pure Appl. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>71</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">531</span>– <span class="NLM_lpage">558</span>, <span class="refDoi"> DOI: 10.1351/pac199971030531</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1351%2Fpac199971030531" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADyaK1MXlt1Cksbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=1999&pages=531-558&issue=3&author=G.+P.+Moss&title=Extension+and+Revision+of+the+Nomenclature+for+Spiro+Compounds&doi=10.1351%2Fpac199971030531"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Extension and revision of the nomenclature for spiro compounds</span></div><div class="casAuthors">Moss, G. P.</div><div class="citationInfo"><span class="NLM_cas:title">Pure and Applied Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">531-558</span>CODEN:
                <span class="NLM_cas:coden">PACHAS</span>;
        ISSN:<span class="NLM_cas:issn">0033-4545</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">The nomenclature of spiro compds. is described in detail and is extended to cover branched polyspiro systems and compds. where 3 rings have 1 common spiro atom.  A new notation, based on the von Baeyer method of naming spiro systems where all components are monocyclic, allows both unbranched and branched polyspiro systems to be named without ambiguity.  It also enables the names to be readily interpreted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdeugzlS3FDrVg90H21EOLACvtfcHk0li-HTk0eK_JLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlt1Cksbg%253D&md5=b6f6f0e0a3a0c832bffb6fef9c35fbc0</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1351%2Fpac199971030531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1351%252Fpac199971030531%26sid%3Dliteratum%253Aachs%26aulast%3DMoss%26aufirst%3DG.%2BP.%26atitle%3DExtension%2520and%2520Revision%2520of%2520the%2520Nomenclature%2520for%2520Spiro%2520Compounds%26jtitle%3DPure%2520Appl.%2520Chem.%26date%3D1999%26volume%3D71%26issue%3D3%26spage%3D531%26epage%3D558%26doi%3D10.1351%2Fpac199971030531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bikker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humblet, C.</span></span> <span> </span><span class="NLM_article-title">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">6752</span>– <span class="NLM_lpage">6756</span>, <span class="refDoi"> DOI: 10.1021/jm901241e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901241e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6752-6756&issue=21&author=F.+Loveringauthor=J.+Bikkerauthor=C.+Humblet&title=Escape+from+Flatland%3A+Increasing+Saturation+as+an+Approach+to+Improving+Clinical+Success&doi=10.1021%2Fjm901241e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span></div><div class="casAuthors">Lovering, Frank; Bikker, Jack; Humblet, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6752-6756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has become increasingly aware of the value of tracking calcd. phys. properties such as mol. wt., topol. polar surface area, rotatable bonds, and hydrogen bond donors and acceptors.  The authors hypothesized that the shift to high-throughput synthetic practices over the past decade may be another factor that may predispose mols. to fail by steering discovery efforts toward achiral, arom. compds.  The authors have proposed two simple and interpretable measures of the complexity of mols. prepd. as potential drug candidates.  The first is carbon bond satn. as defined by fraction Sp3 (Fsp3) where Fsp3 = (no. of Sp3 hybridized carbons/total carbon count).  The second is simply whether a chiral carbon exists in the mol.  The authors demonstrate that both complexity (as measured by Fsp3) and the presence of chiral centers correlate with success as compds. transition from discovery, through clin. testing, to drugs.  To explain these observations, the authors further demonstrate that satn. correlates with soly., an exptl. phys. property important to success in the drug discovery setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC1f3Ed7nUBbVg90H21EOLACvtfcHk0lhSorBZJNHgbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN&md5=4ca92c30c17c53d77ad376719bad951e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Fjm901241e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901241e%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26aulast%3DBikker%26aufirst%3DJ.%26aulast%3DHumblet%26aufirst%3DC.%26atitle%3DEscape%2520from%2520Flatland%253A%2520Increasing%2520Saturation%2520as%2520an%2520Approach%2520to%2520Improving%2520Clinical%2520Success%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26issue%3D21%26spage%3D6752%26epage%3D6756%26doi%3D10.1021%2Fjm901241e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Talele, T. T.</span></span> <span> </span><span class="NLM_article-title">Opportunities for Tapping into Three-Dimensional Chemical Space Through a Quaternary Carbon</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">13291</span>– <span class="NLM_lpage">13315</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00829</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00829" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1WktLbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=13291-13315&issue=22&author=T.+T.+Talele&title=Opportunities+for+Tapping+into+Three-Dimensional+Chemical+Space+Through+a+Quaternary+Carbon&doi=10.1021%2Facs.jmedchem.0c00829"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Opportunities for Tapping into Three-Dimensional Chemical Space through a Quaternary Carbon</span></div><div class="casAuthors">Talele, Tanaji T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">13291-13315</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A quaternary carbon bears four other carbon substituents or combination of four non-hydrogen substituents at four vertices of a tetrahedron.  The spirocyclic quaternary carbon positioned at the center of a bioactive mol. offers conformational rigidity, which in turn reduces the penalty for conformational entropy.  The quaternary carbon is a predominant feature of natural product structures and has been assocd. with more effective and selective binding to target proteins compared to planar compds. with a high sp2 count.  The presence of a quaternary carbon stereocenter allows the exploration of novel chem. space to obtain new mols. with enhanced three-dimensionality.  These characteristics, coupled to an increasing awareness to develop sp3-rich mols., boosted utility of quaternary carbon stereocenters in bioactive compds.  It is hoped that this Perspective will inspire the chemist to utilize quaternary carbon stereocenters to enhance potency, selectivity, and other drug-like properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMfj5wUL80Z7Vg90H21EOLACvtfcHk0ljLJDKdJxkYkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1WktLbL&md5=4aebceb05cdc84702ea15908488a4e58</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00829%26sid%3Dliteratum%253Aachs%26aulast%3DTalele%26aufirst%3DT.%2BT.%26atitle%3DOpportunities%2520for%2520Tapping%2520into%2520Three-Dimensional%2520Chemical%2520Space%2520Through%2520a%2520Quaternary%2520Carbon%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26issue%3D22%26spage%3D13291%26epage%3D13315%26doi%3D10.1021%2Facs.jmedchem.0c00829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wei, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherukupalli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, P.</span></span> <span> </span><span class="NLM_article-title">Fsp3: A New Parameter for Drug-Likeness</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1839</span>– <span class="NLM_lpage">1845</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2020.07.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2Fj.drudis.2020.07.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFSmtbvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2020&pages=1839-1845&author=W.+Weiauthor=S.+Cherukupalliauthor=L.+Jingauthor=X.+Liuauthor=P.+Zhan&title=Fsp3%3A+A+New+Parameter+for+Drug-Likeness&doi=10.1016%2Fj.drudis.2020.07.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Fsp3: A new parameter for drug-likeness</span></div><div class="casAuthors">Wei, Wenxiu; Cherukupalli, Srinivasulu; Jing, Lanlan; Liu, Xinyong; Zhan, Peng</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1839-1845</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The drug-likeness of a compd. is a key factor during the initial phases of drug discovery.  It can be defined as the similarity between compds. and drugs.  Here, we collate research related to the fraction of sp3 carbon atoms (Fsp3), including related high-throughput screening (HTS) cases, structural modifications based on Fsp3, and strategies to improve it.  We also introduce new synthetic methods for spirocyclic scaffolds.  It is likely that the reasonable rigidity of spirocyclic scaffolds will provide a new generation of drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF35W9sn4g07Vg90H21EOLACvtfcHk0ljLJDKdJxkYkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFSmtbvO&md5=a39174fbd58b911b911587bdea949d1d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2020.07.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2020.07.017%26sid%3Dliteratum%253Aachs%26aulast%3DWei%26aufirst%3DW.%26aulast%3DCherukupalli%26aufirst%3DS.%26aulast%3DJing%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DZhan%26aufirst%3DP.%26atitle%3DFsp3%253A%2520A%2520New%2520Parameter%2520for%2520Drug-Likeness%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2020%26volume%3D25%26spage%3D1839%26epage%3D1845%26doi%3D10.1016%2Fj.drudis.2020.07.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garthwaite, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMahon, E. G.</span></span> <span> </span><span class="NLM_article-title">The Evolution of Aldosterone Antagonists</span>. <i>Mol. Cell. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>217</i></span> (<span class="NLM_issue">1–2</span>),  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.1016/j.mce.2003.10.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2Fj.mce.2003.10.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=15134797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjvVeqtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=217&publication_year=2004&pages=27-31&issue=1%E2%80%932&author=S.+M.+Garthwaiteauthor=E.+G.+McMahon&title=The+Evolution+of+Aldosterone+Antagonists&doi=10.1016%2Fj.mce.2003.10.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The evolution of aldosterone antagonists</span></div><div class="casAuthors">Garthwaite, Susan M.; McMahon, Ellen G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">217</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">27-31</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Since the isolation and purifn. of aldosterone from adrenal exts. 50 yr ago (Experientia 9 (1953) 33), scientists have learned a great deal about how and where aldosterone acts, the factors that control its release, what is its role in the pathophysiol. of cardiovascular disease, how to make and study aldosterone antagonists, and for what medical purposes these agents are useful.  In this paper, the authors will discuss the evolution of aldosterone antagonists from the relatively nonselective spironolactone (Aldactone), to the highly selective eplerenone (Inspra).  Eplerenone represents a mol. with improved steroid receptor selectivity and pharmacokinetic properties in man compared to spironolactone.  Recent clin. results have demonstrated that these improvements translate into tolerability and efficacy in patients with cardiovascular disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBhCstj43wZLVg90H21EOLACvtfcHk0lgG6DTXz1SQ2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjvVeqtbw%253D&md5=57c4a98a199541b20662d05e7253b642</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.mce.2003.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mce.2003.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DGarthwaite%26aufirst%3DS.%2BM.%26aulast%3DMcMahon%26aufirst%3DE.%2BG.%26atitle%3DThe%2520Evolution%2520of%2520Aldosterone%2520Antagonists%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2004%26volume%3D217%26issue%3D1%25E2%2580%25932%26spage%3D27%26epage%3D31%26doi%3D10.1016%2Fj.mce.2003.10.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cella, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burtner, R. R.</span></span> <span> </span><span class="NLM_article-title">Steroidal Aldosterone Blockers. I.</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1959</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">743</span>– <span class="NLM_lpage">748</span>, <span class="refDoi"> DOI: 10.1021/jo01088a004</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo01088a004" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADyaF3cXisVCm" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1959&pages=743-748&issue=6&author=J.+A.+Cellaauthor=E.+A.+Brownauthor=R.+R.+Burtner&title=Steroidal+Aldosterone+Blockers.+I.&doi=10.1021%2Fjo01088a004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Steroidal aldosterone blockers. I</span></div><div class="casAuthors">Cella, John A.; Brown, Edward A.; Burtner, Robert R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1959</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">743-8</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    </div><div class="casAbstract">The synthetic and specific biol. activities of a variety of steroidal 5- and 6-membered spirolactones are presented.  The 19-nor compd. with a 5-membered lactone is the most potent aldosterone blocker.  Procedure A.  The ethynylated steroid (1 g.) in 5 ml. tetrahydrofuran was refluxed 24 hrs. with 6 ml. 3M MeMgBr in 15 ml. tetrahydrofuran, a slight pos. pressure maintained over the soln. for 24 hrs., poured into ice cold 0.2M H2SO4, most of the solvent removed in vacuo, the crude granular product collected, washed, and dried.  Procedure B.  The 17α-steroidylalkynoic acid (1 g.) in 10 ml. dioxane contg. 1 ml. C5H5N was stirred under H at atm. pressure over 0.3 g. 5% Pd-CaCO3, the catalyst removed, the solvent evapd., the residue dissolved in 10 ml. cold alc. and 1.4 ml. concd. HCl, left 5 min., dild. with 175 ml. cold H2O, and the crude unsatd. lactone collected and dried.  Procedure C.  The 3β-hydroxy-5-ene lactone (1 g.) in 25 ml. PhMe and 8 ml. cyclohexanone refluxed 20 min. with 0.5 g. Al(iso-PrO)3 in 5 ml. PhMe, cooled to 95°, 5 ml. H2O added, the mixt. cooled to room temp., and made strongly acid, the layers sepd., washed, and each back-extd., the combined org. layers steam distd., the cooled distn. residue extd. with CHCl3, this ext. dried, and evapd. to dryness gave the crude 3-oxo-4-ene lactone.  Procedure D.  The aromatic acid or salt (10 g.) in 150 ml. tert-BuOH and 150 ml. tetrahydrofuran was treated with 650 ml. anhyd. NH3, 5.5 g. Li wire added during 0.5 hr., after 3 hrs. 25 ml. alc. added, an addnl. 25 ml. alc. added, the condenser removed, the NH3 allowed to evap. under N, 200 ml. H2O added, the mixt. distd., and the residue worked up in a suitable way described for each compd. CH≡CCH2Br (64.2 g.) was added during 20 min. to a refluxing suspension of 35.2 g. 20 mesh Zn and 36 g. dehydroisoandrosterone acetate in 1 l. tetrahydrofuran and about half the bromide added before vigorous reaction began; after 5 min. the reaction subsided, and the remaining bromide was added, the mixt. refluxed 15 min., cooled, poured into 2 l. H2O contg. 100 ml. 12M HCl, extd. with C6H6, and the solvent removed to give the crude acetate, which was refluxed 0.5 hr. under N with 25 g. KOH in 1 l. MeOH, dild. with 8 l. H2O, the ppt. collected, rinsed free of base, and dried.  The crude product refluxed with 15 g. Girard T reagent and 15 ml. AcOH in 380 ml. alc. for 0.5 hr. gave 20 g. 17α-propargyl-5-androstene-3β,17β-diol (I), m. 152-4°.  The prepn. of 3-methoxy-17α-propargyl-1,3,5-(10)-estratrien-17β-ol (II) was the same as for I, but the reaction was more sluggish and was refluxed 2 hrs.  The crude II sepd. and treated with Girard T gave 6 g. II (from 10 g. starting material), m. 59-60° (MeOH)) λ 2.82, 3.05 μ.  Procedure A was used on 25 g. 17α-ethynyl-5-androstene-3β,17β-diol, and the crude product was dissolved in 250 ml. tetrahydrofuran, 12.1 g. NEt3 added, the 28.8 g. of salt dissolved in 300 ml. 50% aq. dioxane and the refluxing soln. acidified to give 20 g. 3-(3β,17β-dihydroxy-5-androsten-17α-yl)propynoic acid-H2O (III), m. 234-5° (decompn.), [α]D -132.5° (dioxane).  I (4.58 g.) gave by procedure A 3.5 g. 4-(3β17β-dihydroxy-5-androsten-17α-yl)-2-butynoic acid (IV), m. 203-6° (MeCN).  Procedure A with 132 g. 17α-ethynyl-3-methoxy-1,3,5(10)-estratrien-17β-ol gave 108 g. crude 3-(3-methoxy-17β-hydroxy-1,3,5(10)-estratrien-17α-yl)propynoic acid (V), m. 204-7° (decompn.), [α]D -17.7° (dioxane).  Procedure A with 6.5 g. II gave 7 g. crude 4-(3-methoxy-17β-hydroxy-1,3,5(10)-estratrien-17α-yl)-2-butynoic acid (VI), m. 187.5-91.5° (decompn.) (50% aq. alc.).  Procedure B with 0.2 g. III gave 0.07 g. 3-(3β,17β-dihydroxy-5-androsten-17α-yl)propenoic acid lactone (VII), m. 201-3° (aq. MeOH), [α]D 2° (CHCl3), λ 220 mμ, ε 9550.  Procedure B used on 3 g. IV gave crude 4-(3β,17β-dihydroxy-5-androsten-17α-yl)-2-butenoic acid (VIII), not characterized.  Procedure B used on 5 g. V gave 2.55 g. 3-(3-methoxy-17β-hydroxy-1,3,5(10)-estratrien-17α-yl)propenoic acid (IX), m. 170-3° (EtOAc), [α]D 94° (dioxane).  Procedure C with 0.81 g. VII gave 0.30 g. 3-(3-oxo-17β-hydroxy-4-androsten-17α-yl)propenoic acid lactone, m. 153.5-4.5° (EtOAc-cyclohexane), [α]D 203.5° (CHCl3), λ 237 mμ (ε 20,200), λ 5.78 μ.  VII (20 g.) in 225 ml. alc. hydrogenated at atm. pressure and room temp. over 4 g. 5% Pd-C gave 14 g. 3-(3β,17β-dihydroxy-5-androsten-17α-yl)propanoic acid lactone (X), m. 190-1° (EtOAc), [α]D -91.5° (CHCl3).  Crude VIII in 50 ml. alc. contg. 0.1 ml. HCl hydrogenated at atm. pressure over 0.5 5% Pd-C gave 3 g. 4-(3β,17β-dihydroxy-5-androsten-17α-yl)butanoic acid lactone (XI), viscous oil, λ 5.80 μ.  IX (2.55 g.) in 150 ml. EtOAc hydrogenated at 21° over 0.5 g. 5% Pd-C gave 1.8 g. 3-(3-methoxy-17β-hydroxy-1,3,5(10)-estratrien-17-α-yl)propanoic acid lactone, m. 150-2° (EtOAc-iso-Pr2O), [α]D 12.5° (dioxane).  VI (6.5 g.) in 130 ml. alc. hydrogenated over 1 g. 5% Pd-C at room temp. and 24 lb./sq. in. in the presence of 2 ml. NEt3 gave 4.05 g. 4-(3-methoxy-17β-hydroxy-1,3,5(10)-estratrien-17α-yl)butanoic acid (XII), m. 164-8.5° (decompn.) (EtOAc).  XII (3.1 g.) with 100 ml. p-MeC6H4SO3H in 500 ml. C6H6 slowly distd. to 100 ml., the soln. washed, dried, and distd. gave 1.5 g. lactone, m. 161-6° (EtOAc).  Procedure C was used on 10 g. X to give 4.8 g. 3-(3-oxo-17β-hydroxy-4-androsten-17α-yl)propanoic acid lactone (XIII), m. 148-50° (EtOAc), [α]D 76.5° (CHCl3), λ 241 mμ, ε 17,000.  Crude XI oxidized according to procedure C and the product chromatographed over silica gave 0.7 g. 4-(3-oxo-17β-hydroxy-4-androsten-17α-yl)butanoic acid lactone (XIV), m. 192-3° (EtOAc-iso-Pr2O), λ 240 mμ, ε 17,000, λ 5.77 μ.  V (7.8 g.) in 500 ml. tert-BuOH and 1 l. NH3 treated during 0.5 hr. with 8 g. Li, after 2 hrs. the Li had reacted, the NH3 evapd., the soln. quenched with 250 ml. H2O, alc. removed, soln. made acid, extd. with Et2O, the product in 50 ml. MeOH treated 1 hr. with 2 ml. HCl, and the crude product chromatographed on silica gave 0.14 g. 3-(3-oxo-17β-hydroxy-19-nor-4-androsten-17α-yl)propenoic acid lactone, m. 117-18° (EtOAc-iso-Pr2O), [α]D 55.2° (dioxane), λ 239.5 mμ, ε 18,700, λ 5.78 μ.  Elution with 15% EtOAc gave 1 g. 3-(3-oxo-17β-hydroxy-19-nor-4-androsten-17α-yl)propanoic acid lactone (XV), m. 135.5-7.10° (EtOAc), [α]D 22.7° (CHCl3), λ 240 mμ, ε 17,500.  V (124 g.) and 40.4 g. NEt3 in 1 l. alc. hydrogenated over 12.4 g. 5% Pd-C at 500 lb./sq. in. in 25 min., mixt. left 5 hrs. with 28 g. NaOH in 200 ml. MeOH, salt collected, rinsed with 100 ml. alc., and dried 12 hrs. at 75° in vacuo gave 116 g. Na 3-(3-methoxy-17β-hydroxy-1,3,5(10)-estratrien-17α-yl)propanoate (XVI).  The mother liquor from XVI evapd. and poured into dil. HCl gave 10 g. 3-methoxy-17β-hydroxy-1,3,5(10)-estratrien-17α-ylpropanoic acid, m. 150-2° (decompn.).  Heating this acid a few min. at 160° led to loss of H2O and conversion to X.  Lactonization may be achieved by treatment of a concd. soln. of the acid in alc. with small amt. of 3N HCl.  Procedure D was applied to 114 g. XVI in 3 l. H2O and the reaction mixt. acidified by addn. of 600 ml. AcOH; after 2 hrs. the solid was collected and this enol ether hydrolyzed 2 hrs. in 200 ml. HCl and 360 ml. H2O in 2 l. MeOH to give 79.1 g. crude XV.  Procedure D was followed on 3.7 g. XVI to the point where excess NH3 was evapd.; addn. of 250 ml. H2O produced a 2-phase soln., and the upper solvent layer was sepd., acidified, and dild. with H2O to give 0.470 g. 3-(3-oxo-17β-hydroxy-19-nor-5(10)-androsten-17α-yl)propanoic acid lactone, m. 173-7° (EtOAc).  Procedure D used on 6.9 g. XII, with the dil. aq. soln. contg. crude Li salt acidified with dil. HCl gave 1.45 g. 4-(3-oxo-17β-hydroxy-19-nor-5(10)-androsten-17α-yl)butanoic acid, m. 108-11° (EtOAc).  The EtOAc mother liquors evapd. to dryness, dissolved in 500 ml. C6H6, treated with 150 mg. p-MeC6H4SO3H, the soln. distd. to 100 ml. vol., washed, dried, and chromatographed on silica gel gave 84 mg. 4-(3-oxo-17β-hydroxy-19-nor-4-androsten-17α-yl)butanoic acid lactone, m. 143-5°, λ 240 mμ, ε 17,700.  XIII (1 g.) in 25 ml. EtOAc treated with H at atm. pressure at 30° in the presence of 0.2 g. 5% Pd-C and the crude product chromatographed over silica gave 0.50 g. 3-(3-oxo-17β-hydroxy-5α-androstan-17α-yl)propanoic acid lactone (XVII), m. 178-9° (EtOAc), [α]D 5.2° (CHCl3).  The later eluates gave 0.14 g. 3-(3-oxo-17β-hydroxy-5β-androstan-17α-yl)propanoic acid lactone, m. 183-5° (EtOAc), [α]D 6.8° (CHCl3).  XIV (7.5 g.) similarly hydrogenated over 1.5 g. 5% Pd-C in alc. and the crude product chromatographed on silica gave 260 mg. 4-(3-oxo-17β-hydroxy-5α-androstan-17α-yl)butanoic acid lactone, white needles, m. 191-3° (EtOAc-iso-Pr2O), [α]D 30° (CHCl3).  Late in the 10% EtOAc eluate 1.7 g. crude 4-(3-oxo-17β-hydroxy-5β-androstan-17α-yl)butanoic acid lactone was collected, m. 196-7°, [α]D 28.6° (CHCl3).  XV (6 g.) in 100 ml. EtOAc at 30° treated with H at atm. pressure in the presence of 1 g. 5% Pd-C, soln. filtered, evapd. to dryness, and the residue chromatographed over silica gave 0.45 g. 3-(3-oxo17β-hydroxy-19-nor-5α-androstan-17α-yl)propanoic acid lactone (XVIII), m. 198-201° (EtOAc), [α]D 9.7° (dioxane).  The middle fractions of this eluate contd. a mixt. of XVIII and 3-(3-oxo-17β-hydroxy-19-nor-5β-androstan- 17α-yl)propanoic acid lactone (XIX).  Pure XIX was obtained by crystn., m. 218-22° (EtOAc), [α]D 0.0° (dioxane).  X (0.6 g.) in 20 ml. alc. treated with H at 24° over 0.1 g. 5% Pd-C for 7 hrs. gave 0.40 g. 3-(3-β,17β-dihydroxy-5α-androstan-17α-yl)propanoic acid lactone (XX), m. 199-201° (EtOAc), [α]D -20.0° (CHCl3).  Procedure C used on 10 g. XX gave 7.1 g. XVII.  XV (1.5 g.) in 50 ml. tert-BuOH, 50 ml. tetrahydrofuran, and 150 ml. NH3 treated with Li, the solvents removed, the residue treated with H2O, and made strongly acid, and the ppt. suspended in 150 ml. Me2CO and treated with 3.5 ml. 6N CrO3-H2SO4 gave 0.65 g. XVIII.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgALduxRvOZLVg90H21EOLACvtfcHk0lgG6DTXz1SQ2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF3cXisVCm&md5=a3a2c2b196c3331bafdcfd087035aa1d</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fjo01088a004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo01088a004%26sid%3Dliteratum%253Aachs%26aulast%3DCella%26aufirst%3DJ.%2BA.%26aulast%3DBrown%26aufirst%3DE.%2BA.%26aulast%3DBurtner%26aufirst%3DR.%2BR.%26atitle%3DSteroidal%2520Aldosterone%2520Blockers.%2520I.%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1959%26volume%3D24%26issue%3D6%26spage%3D743%26epage%3D748%26doi%3D10.1021%2Fjo01088a004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cella, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tweit, R. C.</span></span> <span> </span><span class="NLM_article-title">Steroidal Aldosterone Blockers. II1</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1959</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1109</span>– <span class="NLM_lpage">1110</span>, <span class="refDoi"> DOI: 10.1021/jo01090a019</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo01090a019" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADyaF3cXivV2mtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1959&pages=1109-1110&issue=8&author=J.+A.+Cellaauthor=R.+C.+Tweit&title=Steroidal+Aldosterone+Blockers.+II1&doi=10.1021%2Fjo01090a019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Steroidal aldosterone blockers. II</span></div><div class="casAuthors">Cella, John A.; Tweit, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1959</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1109-10</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    </div><div class="casAbstract">The synthesis and biol. activities of several new steroidal 17-spirolactones were presented.  Introduction of unsatn. and the acylthio grouping enhanced oral aldosterone blocking activity in this series of compds. 3-(3-Oxo-17β-hydroxy-4-androsten-17α-yl)propionic acid lactone (I) (50 g.) and 1 g. HgCl2 in 3 l. tert-BuOH and 30 ml. AcOH refluxed 8 hrs. under N with 17.8 g. selenious acid, a further portion of 17.8 g. selenious acid added, and refluxed an addnl. 13 hrs. gave 16.3 g. 3-(3-oxo-17β-hydroxy-1,4-androstadien-17α-yl)propionic acid (II), m. 179-80° (EtOAc), [α]D 22° (dioxane), λ 245 mμ, ε 14,900.  I (2.5 g.), 2.5 g. chloranil, and 0.025 g. p-MeC6H4SO3H.H2O in 250 ml. xylene refluxed 20 hrs., the residue taken up in C6H6, and chromatographed on silica gave 0.44 g. 3-(3-oxo-17β-hydroxy-4,6-androstadien-16α-yl)propionic acid lactone (III), m. 149-51° (EtOAc), [α]D 24.5°, λ 283 mμ, ε 26,700.  3-(3-Oxo-17β-hydroxy-19-nor-4-androsten-17α-yl)propionic acid lactone (4.05 g.), 3.34 g. chloranil, and 0.01 g. p-MeC6H4SO3H.H2O in 400 ml. xylene refluxed 1 hr. and the crude product chromatographed on silica gel gave 0.26 g. 3-(3-oxo-17β-hydroxy-19-nor-4,6-androstadien-17α-yl)propionic acid lactone (IV), m. 235-9° (EtOAc), [α]D -44°, λ 283 mμ, ε 27,000.  III (0.34 g.) treated with a total of 0.155 g. selenious acid in 50 ml. tert-BuOH contg. 0.5 ml. AcOH and the product chromatographed over silica gave 0.05 g. 3-(3-oxo-17β-hydroxy-1,4,6-androstatrien-17α-yl)propionic acid lactone, m. 97-100° (decompn.), rem. 136-8°, [α]D 0°, λ 222 mμ, ε 11,100, λ 266 mμ, ε 10,700, λ 296 mμ, ε 13,700.  II (1 g.) in 1 ml. ethanethiolic acid heated 0.5 hr., part of the excess thiolic acid evapd. under N, the residue dissolved in EtOAc-Et2O, and cooled gave 0.40 g. 3-(3-oxo-1α-acetylthio-17β-hydroxy-4-androsten-17α-yl)propionic acid lactone, m. 199-200° (decompn.), [α]D 56°, λ 240.5 mμ, ε 16,200.  II (0.35 g.) in 0.5 ml. propanethiolic acid heated 1.25 hrs. on the steam bath and left overnight gave 0.08 g. 3-(3-oxo-1α-propionylthio-17β-hydroxy-4-androsten-17α-yl)propionic acid lactone, m. 176-8° (decompn.), λ 240.5 mμ, ε 16,500.  III (0.75 g.) in 0.75 ml. ethanethiolic acid heated 1 hr. gave 0.45 g. 3-(3-oxo-7α-acetylthio-17β-hydroxy-4-androsten-17α-yl)propionic acid, m. 134-5°, resolidified and m. 201-2° (decompn.), [α]D -33.5°, λ 238 mμ, ε 20,200.  III (0.65 g.) in 0.5 ml. propanethiolic acid similarly heated 0.5 hr. gave 0.34 g. 3-(3oxo-7α-propionylthio-17β-hydroxy-4-androsten-17α-yl)propionic acid lactone, m. 192-4° (decompn.), [α]D -37°, λ 238 mμ, ε 19,800.  IV (170 mg.) in 0.5 ml. ethanethiolic acid heated 1.5 hrs. gave 87 mg. 3-(3-oxo-7α-acetylthio-17β-hydroxy-19-nor-4-androsten-17α-yl)propionic acid lactone, m. 111-13°, λ 237 mμ, ε 21,000.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSYmaV8LxsBbVg90H21EOLACvtfcHk0ljw3y7HTVITXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF3cXivV2mtA%253D%253D&md5=de8871136b0ddde6ec0af6a7c5383480</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fjo01090a019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo01090a019%26sid%3Dliteratum%253Aachs%26aulast%3DCella%26aufirst%3DJ.%2BA.%26aulast%3DTweit%26aufirst%3DR.%2BC.%26atitle%3DSteroidal%2520Aldosterone%2520Blockers.%2520II1%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1959%26volume%3D24%26issue%3D8%26spage%3D1109%26epage%3D1110%26doi%3D10.1021%2Fjo01090a019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quintavalla, A.</span></span> <span> </span><span class="NLM_article-title">Spirolactones: Recent Advances in Natural Products, Bioactive Compounds and Synthetic Strategies</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">917</span>– <span class="NLM_lpage">962</span>, <span class="refDoi"> DOI: 10.2174/0929867324666171106162259</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.2174%2F0929867324666171106162259" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=29110593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntVCku74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=917-962&issue=8&author=A.+Quintavalla&title=Spirolactones%3A+Recent+Advances+in+Natural+Products%2C+Bioactive+Compounds+and+Synthetic+Strategies&doi=10.2174%2F0929867324666171106162259"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Spirolactones: Recent Advances in Natural Products, Bioactive Compounds and Synthetic Strategies</span></div><div class="casAuthors">Quintavalla, Arianna</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">917-962</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Background: The spirocyclic compds. have always aroused a great interest because this motif is present as structural core in a no. of natural products and bioactive compds.  In particular, the spirolactone moiety has been recognized in a wide array of natural and non-natural scaffolds showing a variety of useful pharmacol. properties.  Methods: Extensive literature search using SciFinder (Databases: CA Plus, CAS Registry, CAS React, Chemlist, Chemcat and Medline) and Web of Science (Database: Web of Science Core Collection) was conducted.  Results: Nowadays, many efforts are being devoted to the discovery of new natural products contg. the promising spirolactone framework and to the disclosure of the potential bioactivities of these chem. entities.  Moreover, the medicinal relevance of many spirolactones makes these scaffolds attractive targets for the design and development of innovative and efficient synthetic strategies, enabling the construction of complex and variably substituted products.  Conclusion: This review gives an overview on the recent advances in the spirolactones field, in terms of new compds. isolated from natural sources, recently detd. bioactivity profiles and innovative synthetic approaches.  The collected data demonstrate the key role played by spirolactones in medicinal chem. and the great attention still devoted by the scientific community to these compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKLtKKJM1H-bVg90H21EOLACvtfcHk0ljw3y7HTVITXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntVCku74%253D&md5=a58880c41c26fb3a9c3356bb5d68b1b0</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.2174%2F0929867324666171106162259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867324666171106162259%26sid%3Dliteratum%253Aachs%26aulast%3DQuintavalla%26aufirst%3DA.%26atitle%3DSpirolactones%253A%2520Recent%2520Advances%2520in%2520Natural%2520Products%252C%2520Bioactive%2520Compounds%2520and%2520Synthetic%2520Strategies%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2018%26volume%3D25%26issue%3D8%26spage%3D917%26epage%3D962%26doi%3D10.2174%2F0929867324666171106162259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollow, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garfield, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, S. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillisch, A.</span></span> <span> </span><span class="NLM_article-title">Conception and Pharmacodynamic Profile of Drospirenone</span>. <i>Steroids</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>68</i></span> (<span class="NLM_issue">10–13</span>),  <span class="NLM_fpage">891</span>– <span class="NLM_lpage">905</span>, <span class="refDoi"> DOI: 10.1016/j.steroids.2003.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2Fj.steroids.2003.08.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=14667981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BD3sXps1Olurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2003&pages=891-905&issue=10%E2%80%9313&author=W.+Elgerauthor=S.+Beierauthor=K.+Pollowauthor=R.+Garfieldauthor=S.+Q.+Shiauthor=A.+Hillisch&title=Conception+and+Pharmacodynamic+Profile+of+Drospirenone&doi=10.1016%2Fj.steroids.2003.08.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Conception and pharmacodynamic profile of drospirenone</span></div><div class="casAuthors">Elger, Walter; Beier, Sybille; Pollow, Kunhard; Garfield, Robert; Shi, Shao Qing; Hillisch, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Steroids</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">10-13</span>),
    <span class="NLM_cas:pages">891-905</span>CODEN:
                <span class="NLM_cas:coden">STEDAM</span>;
        ISSN:<span class="NLM_cas:issn">0039-128X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Progesterone is more than a progestin.  Beyond functions in cycle and pregnancy, progesterone binds with high affinity to the mineralocorticoid receptor (MR) acting as an antagonist, with obvious significance for electrolyte homeostasis, an array of MR-related functions in the circulation as well as in the CNS.  Progesterone induces natriuresis at physiol. concns.  Lack of anti-mineralocorticoid activity with conventional progestins may account for sodium and water retention, minor elevation of blood pressure and "pill hypertension" in susceptible women on oral contraceptives.  Ethinylestradiol (EE) contributes to this problem by distinct activation of the renin-angiotensin-aldosterone (RAAS) system.  Drospirenone (DRSP: 6β,7β,15β,16β-dimethylene-3-oxo 17α-pregn-4-ene-21,17 carbolactone) is the first synthetic progestin with anti-aldosterone activity.  DRSP and progesterone bind to PR in uterine (affinity of both is about 30% of R5020) and MR in kidney cytosol (affinity about 230 and 100% of aldosterone, resp.).  Intrauterine administration of DRSP in silastic tubes induced max. local progestational effects in rabbits.  At systemic s.c. administration (McPhail-assay) full endometrial transformation was obtained at 1 mg per animal per day.  At 1-3 mg DRSP per animal per day s.c., pregnancy maintenance after ovariectomy, antiovulatory activity, and anti-mineralocorticoid activity were seen in the resp. assays in rats.  The latter activity indicates about eight-fold higher potency than spironolactone.  DRSP decreased blood pressure in male hypertensive rats, whereas an increase was noted under conventional progestins.  DRSP also prevented hypertension and fetal growth retardation in pregnant rats after l-NAME, an inhibitor of nitric oxide synthase.  DRSP has antiandrogenic activity.  Feminizing effects were recorded during sexual differentiation in male fetuses at high doses.  Powerful antiandrogenic effects were also seen in gonad intact and testosterone substituted castrated male rats.  The antiandrogenic potency of DRSP is superior to that of spironolactone but below that of cyproterone acetate.  Endometrial transformation, inhibition of ovulation, and anti-mineralocorticoid, i.e. natriuretic effects and mild antiandrogenic effects were recorded at the same range of oral doses (0.5-4 mg per day) in humans.  Combined with EE (3 mg DRSP + 30 μg EE), DRSP provides effective inhibition of ovulation and cycle control.  Body wt. compared to conventional oral contraceptives was reduced.  DRSP (3 mg per day + 15, 20, or 30 μg ethinyl estradiol per day) prevented the mild increase of blood pressure seen under a conventional levonorgestrel-contg. contraceptive and even tended to reduce pretreatment blood pressure.  Studies on modulation (i.e. inhibition) of glucocorticoid effects at the MR in the CNS remain an unexplored and interesting area for research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoW2WqlqLlZP7Vg90H21EOLACvtfcHk0lgbSpZ47m5OWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXps1Olurs%253D&md5=8e50f46e00c8e5eb819af6f0f10156b8</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.steroids.2003.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.steroids.2003.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DElger%26aufirst%3DW.%26aulast%3DBeier%26aufirst%3DS.%26aulast%3DPollow%26aufirst%3DK.%26aulast%3DGarfield%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DS.%2BQ.%26aulast%3DHillisch%26aufirst%3DA.%26atitle%3DConception%2520and%2520Pharmacodynamic%2520Profile%2520of%2520Drospirenone%26jtitle%3DSteroids%26date%3D2003%26volume%3D68%26issue%3D10%25E2%2580%259313%26spage%3D891%26epage%3D905%26doi%3D10.1016%2Fj.steroids.2003.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chupakhin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babich, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prosekov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asyakina, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krasavin, M.</span></span> <span> </span><span class="NLM_article-title">Spirocyclic Motifs in Natural Products</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">4165</span>, <span class="refDoi"> DOI: 10.3390/molecules24224165</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.3390%2Fmolecules24224165" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlyrsb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=4165&issue=22&author=E.+Chupakhinauthor=O.+Babichauthor=A.+Prosekovauthor=L.+Asyakinaauthor=M.+Krasavin&title=Spirocyclic+Motifs+in+Natural+Products&doi=10.3390%2Fmolecules24224165"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Spirocyclic motifs in natural products</span></div><div class="casAuthors">Chupakhin, Evgeny; Babich, Olga; Prosekov, Alexander; Asyakina, Lyudmila; Krasavin, Mikhail</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">4165</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Spirocyclic motifs are emerging privileged structures for drug discovery.  They are also omnipresent in the natural products domain.  However, until today, no attempt to analyze the structural diversity of various spirocyclic motifs occurring in natural products and their relative populations with unique compds. reported in the literature has been undertaken.  This review aims to fill that void and analyze the diversity of structurally unique natural products contg. spirocyclic moieties of various sizes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGri8MkVeKg0lrVg90H21EOLACvtfcHk0lgbSpZ47m5OWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlyrsb3N&md5=45ccad33af7d4da522b9118263fefb5b</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.3390%2Fmolecules24224165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules24224165%26sid%3Dliteratum%253Aachs%26aulast%3DChupakhin%26aufirst%3DE.%26aulast%3DBabich%26aufirst%3DO.%26aulast%3DProsekov%26aufirst%3DA.%26aulast%3DAsyakina%26aufirst%3DL.%26aulast%3DKrasavin%26aufirst%3DM.%26atitle%3DSpirocyclic%2520Motifs%2520in%2520Natural%2520Products%26jtitle%3DMolecules%26date%3D2019%26volume%3D24%26issue%3D22%26spage%3D4165%26doi%3D10.3390%2Fmolecules24224165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tice, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, S. B.</span></span> <span> </span><span class="NLM_article-title">The Use of Spirocyclic Scaffolds in Drug Discovery</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">3673</span>– <span class="NLM_lpage">3682</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.06.081</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2Fj.bmcl.2014.06.081" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=25052427" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFykt7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=3673-3682&issue=16&author=Y.+Zhengauthor=C.+M.+Ticeauthor=S.+B.+Singh&title=The+Use+of+Spirocyclic+Scaffolds+in+Drug+Discovery&doi=10.1016%2Fj.bmcl.2014.06.081"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The use of spirocyclic scaffolds in drug discovery</span></div><div class="casAuthors">Zheng, Yajun; Tice, Colin M.; Singh, Suresh B.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3673-3682</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Owing to their inherent three-dimensionality and structural novelty, spiro scaffolds have been increasingly utilized in drug discovery.  In this brief review, we highlight selected examples from the primary medicinal chem. literature during the last three years to demonstrate the versatility of spiro scaffolds.  With recent progress in synthetic methods providing access to spiro building blocks, spiro scaffolds are likely to be used more frequently in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqzTjJrsRkyLVg90H21EOLACvtfcHk0lghucaFjQA6qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFykt7bM&md5=9a2a644cf2b97edf7876b43b6457f6d5</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.06.081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.06.081%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DTice%26aufirst%3DC.%2BM.%26aulast%3DSingh%26aufirst%3DS.%2BB.%26atitle%3DThe%2520Use%2520of%2520Spirocyclic%2520Scaffolds%2520in%2520Drug%2520Discovery%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26issue%3D16%26spage%3D3673%26epage%3D3682%26doi%3D10.1016%2Fj.bmcl.2014.06.081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tice, C. M.</span></span> <span> </span><span class="NLM_article-title">The Utilization of Spirocyclic Scaffolds in Novel Drug Discovery</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">831</span>– <span class="NLM_lpage">834</span>, <span class="refDoi"> DOI: 10.1080/17460441.2016.1195367</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1080%2F17460441.2016.1195367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=27233084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252FktVGkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=831-834&issue=9&author=Y.-J.+Zhengauthor=C.+M.+Tice&title=The+Utilization+of+Spirocyclic+Scaffolds+in+Novel+Drug+Discovery&doi=10.1080%2F17460441.2016.1195367"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The utilization of spirocyclic scaffolds in novel drug discovery</span></div><div class="casAuthors">Zheng Ya-Jun; Tice Colin M</div><div class="citationInfo"><span class="NLM_cas:title">Expert opinion on drug discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">831-4</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTYAtKgZnFeprYtC3U5jeOifW6udTcc2eZmyqkNqL6JJLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252FktVGkug%253D%253D&md5=a736a7ecb934f323069bef58eaed9bbe</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1080%2F17460441.2016.1195367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17460441.2016.1195367%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DY.-J.%26aulast%3DTice%26aufirst%3DC.%2BM.%26atitle%3DThe%2520Utilization%2520of%2520Spirocyclic%2520Scaffolds%2520in%2520Novel%2520Drug%2520Discovery%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2016%26volume%3D11%26issue%3D9%26spage%3D831%26epage%3D834%26doi%3D10.1080%2F17460441.2016.1195367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benabdallah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talhi, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nouali, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choukchou-Braham, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachari, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, A. M. S.</span></span> <span> </span><span class="NLM_article-title">Advances in Spirocyclic Hybrids: Chemistry and Medicinal Actions</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">31</span>),  <span class="NLM_fpage">3748</span>– <span class="NLM_lpage">3767</span>, <span class="refDoi"> DOI: 10.2174/0929867325666180309124821</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.2174%2F0929867325666180309124821" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=29521213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFWjsrbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=3748-3767&issue=31&author=M.+Benabdallahauthor=O.+Talhiauthor=F.+Noualiauthor=N.+Choukchou-Brahamauthor=K.+Bachariauthor=A.+M.+S.+Silva&title=Advances+in+Spirocyclic+Hybrids%3A+Chemistry+and+Medicinal+Actions&doi=10.2174%2F0929867325666180309124821"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in Spirocyclic Hybrids: Chemistry and Medicinal Actions</span></div><div class="casAuthors">Benabdallah, Mohammed; Talhi, Oualid; Nouali, Fatiha; Choukchou-Braham, Nouredine; Bachari, Khaldoun; Silva, Artur M. S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">3748-3767</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">The present review deals with the progress in medicinal chem. of spirocyclic compds., a wider class of natural and synthetic org. mols., defined as a hybrid of two mol. entities covalently linked via a unique tetrahedral carbon.  This spiro central carbon confers to the mols. a tridimensional structurally oriented framework, which is found in many medicinally relevant compds., a well-known example is the antihypertensive spironolactone.  Various bioactive natural products possess the privileged spiro linkage and different chemo-types thereof become synthetically accessible since the 20th century.  Actually, there has been a growing interest in the synthesis of heterocyclic hybrids gathered via a spiro carbon.  Most of these combinations are two moieties in one scaffold being able to interfere with biol. systems through sequential mechanisms.  Spirocyclic hybrids contg. indole or oxindole units are compds. exhibiting higher interaction with biol. receptors by protein inhibition or enzymic pathways and their recognition as promising anticancer agents in targeted chemotherapy is foreseen.  These specific, low-wt. and noncomplex spirocyclic hybrids are potent inhibitors of SIRT1, Mdm2-p53 and PLK4, showing affinity for anaplastic lymphoma kinase (ALK) receptor.  They are also known as excellent DNA binders, acting on cellular division by arresting the cell cycle at different phases and inducing apoptotic cell death.  A structural diversity of spirocyclic hybrids has proved neuroprotective effects, anti-HIV, antiviral and antibacterial activities.  Hundred of papers are mentioned in this review underlying chem. issues and pharmacol. potencies of spiro compds., which render them impressive synthetic hits for innovative drug conception.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1fwEbDhLz47Vg90H21EOLACvtfcHk0lgFakAEwY2v4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFWjsrbJ&md5=ac62940ca3a589d38314883855772c66</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.2174%2F0929867325666180309124821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867325666180309124821%26sid%3Dliteratum%253Aachs%26aulast%3DBenabdallah%26aufirst%3DM.%26aulast%3DTalhi%26aufirst%3DO.%26aulast%3DNouali%26aufirst%3DF.%26aulast%3DChoukchou-Braham%26aufirst%3DN.%26aulast%3DBachari%26aufirst%3DK.%26aulast%3DSilva%26aufirst%3DA.%2BM.%2BS.%26atitle%3DAdvances%2520in%2520Spirocyclic%2520Hybrids%253A%2520Chemistry%2520and%2520Medicinal%2520Actions%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2018%26volume%3D25%26issue%3D31%26spage%3D3748%26epage%3D3767%26doi%3D10.2174%2F0929867325666180309124821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cortijo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naline, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berto, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girard, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malbezin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Advenier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morcillo, E. J.</span></span> <span> </span><span class="NLM_article-title">Effects of Fenspiride on Human Bronchial Cyclic Nucleotide Phosphodiesterase Isoenzymes: Functional and Biochemical Study</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>341</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">79</span>– <span class="NLM_lpage">86</span>, <span class="refDoi"> DOI: 10.1016/S0014-2999(97)01439-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2FS0014-2999%2897%2901439-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=9489859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADyaK1cXjslelug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=1998&pages=79-86&issue=1&author=J.+Cortijoauthor=E.+Nalineauthor=J.+L.+Ortizauthor=L.+Bertoauthor=V.+Girardauthor=M.+Malbezinauthor=C.+Advenierauthor=E.+J.+Morcillo&title=Effects+of+Fenspiride+on+Human+Bronchial+Cyclic+Nucleotide+Phosphodiesterase+Isoenzymes%3A+Functional+and+Biochemical+Study&doi=10.1016%2FS0014-2999%2897%2901439-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of fenspiride on human bronchial cyclic nucleotide phosphodiesterase isoenzymes: Functional and biochemical study</span></div><div class="casAuthors">Cortijo, Julio; Naline, Enmanuel; Ortiz, Jose L.; Berto, Luisa; Girard, Valerie; Malbezin, Muriel; Advenier, Charles; Morcillo, Esteban J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">79-86</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">We have investigated the role of human bronchial cyclic nucleotide phosphodiesterases in the effects of fenspiride, a drug endowed with bronchodilator and anti-inflammatory properties.  Functional studies on human isolated bronchi showed that fenspiride (10-6-3×10-3 M, 30 min) induced a shift to the left of the concn.-response curves for isoprenaline and sodium nitroprusside with -log EC50 values of 4.1±0.1 (n=7) and 3.5±0.2 (n=8), resp.  Biochem. studies were carried out on three human bronchi in which sepn. of cyclic nucleotide phosphodiesterase isoenzymes was performed by ion exchange chromatog. followed by detn. of phosphodiesterase activity with a radioisotopic method.  Phosphodiesterase 4 (cAMP-specific) and phosphodiesterase 5 (cyclic GMP-specific) were the major phosphodiesterase isoforms present in the human bronchial tissue.  The presence of phosphodiesterase 1 (Ca2+/calmodulin-stimulated), phosphodiesterase 2 (cyclic GMP-stimulated) and, in two cases, phosphodiesterase 3 (cyclic GMP-inhibited) was also identified.  Fenspiride inhibited phosphodiesterase 4 and phosphodiesterase 3 activities with -log IC50 values of 4.16±0.09 and 3.44±0.12, resp.  Phosphodiesterase 5 activity was also inhibited with a -log IC50 value of ∼3.8.  Fenspiride (≤10-3 M) produced less than 25% inhibition of phosphodiesterase 1 and phosphodiesterase 2 activities.  In conclusion, fenspiride is an effective inhibitor of both cAMP and cyclic GMP hydrolytic activity in human bronchial tissues and this action may contribute to its airway effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdsNvRk7RVU7Vg90H21EOLACvtfcHk0lgFakAEwY2v4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjslelug%253D%253D&md5=2c6e6d3363dc37b1ed08ae3594a15629</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2897%2901439-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252897%252901439-8%26sid%3Dliteratum%253Aachs%26aulast%3DCortijo%26aufirst%3DJ.%26aulast%3DNaline%26aufirst%3DE.%26aulast%3DOrtiz%26aufirst%3DJ.%2BL.%26aulast%3DBerto%26aufirst%3DL.%26aulast%3DGirard%26aufirst%3DV.%26aulast%3DMalbezin%26aufirst%3DM.%26aulast%3DAdvenier%26aufirst%3DC.%26aulast%3DMorcillo%26aufirst%3DE.%2BJ.%26atitle%3DEffects%2520of%2520Fenspiride%2520on%2520Human%2520Bronchial%2520Cyclic%2520Nucleotide%2520Phosphodiesterase%2520Isoenzymes%253A%2520Functional%2520and%2520Biochemical%2520Study%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1998%26volume%3D341%26issue%3D1%26spage%3D79%26epage%3D86%26doi%3D10.1016%2FS0014-2999%2897%2901439-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jankowski, R.</span></span> <span> </span><span class="NLM_article-title">[ENT Inflammation and Importance of Fenspiride]</span>. <i>Presse Med.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">Spec No 1</span>),  <span class="NLM_fpage">HS7-10</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=12378970" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2002&pages=HS7-10&issue=Spec+No+1&author=R.+Jankowski&title=%5BENT+Inflammation+and+Importance+of+Fenspiride%5D"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJankowski%26aufirst%3DR.%26atitle%3D%255BENT%2520Inflammation%2520and%2520Importance%2520of%2520Fenspiride%255D%26jtitle%3DPresse%2520Med.%26date%3D2002%26volume%3D31%26issue%3DSpec%2520No%25201%26spage%3DHS7-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kulakova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galkin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Southall, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marugan, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herzberg, O.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel Antigiardiasis Drug Candidates</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">7303</span>– <span class="NLM_lpage">7311</span>, <span class="refDoi"> DOI: 10.1128/AAC.03834-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1128%2FAAC.03834-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=25267663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVymsb3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=7303-7311&issue=12&author=L.+Kulakovaauthor=A.+Galkinauthor=C.+Z.+Chenauthor=N.+Southallauthor=J.+J.+Maruganauthor=W.+Zhengauthor=O.+Herzberg&title=Discovery+of+Novel+Antigiardiasis+Drug+Candidates&doi=10.1128%2FAAC.03834-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel antigiardiasis drug candidates</span></div><div class="casAuthors">Kulakova, Liudmila; Galkin, Andrey; Chen, Catherine Z.; Southall, Noel; Marugan, Juan J.; Zheng, Wei; Herzberg, Osnat</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">7303-7311, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Giardiasis is a severe intestinal parasitic disease caused by Giardia lamblia, which inflicts many people in poor regions and is the most common parasitic infection in the United States.  Current std. care drugs are assocd. with undesirable side effects, treatment failures, and an increasing incidence of drug resistance.  As follow-up to a high-throughput screening of an approved drug library, which identified compds. lethal to G. lamblia trophozoites, we have detd. the min. lethal concns. of 28 drugs and advanced 10 of them to in vivo studies in mice.  The results were compared to treatment with the std. care drug, metronidazole, in order to identify drugs with equal or better anti-Giardia activities.  Three drugs, fumagillin, carbadox, and tioxidazole, were identified.  These compds. were also potent against metronidazole-resistant human G. lamblia isolates (assemblages A and B), as detd. in in vitro assays.  Of these three compds., fumagillin is currently an orphan drug used within the European Union to treat microsporidiosis in immunocompromised individuals, whereas carbadox and tioxidazole are used in veterinary medicine.  A dose-dependent study of fumagillin in a giardiasis mouse model revealed that the ED of fumagillin was ∼100-fold lower than the metronidazole dose.  Therefore, fumagillin may be advanced to further studies as an alternative treatment for giardiasis when metronidazole fails.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobXV8bNxbN8rVg90H21EOLACvtfcHk0lj97rZpf_olOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVymsb3E&md5=e7425b8ad898544b6e18f45293997f8b</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1128%2FAAC.03834-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.03834-14%26sid%3Dliteratum%253Aachs%26aulast%3DKulakova%26aufirst%3DL.%26aulast%3DGalkin%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DC.%2BZ.%26aulast%3DSouthall%26aufirst%3DN.%26aulast%3DMarugan%26aufirst%3DJ.%2BJ.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DHerzberg%26aufirst%3DO.%26atitle%3DDiscovery%2520of%2520Novel%2520Antigiardiasis%2520Drug%2520Candidates%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26issue%3D12%26spage%3D7303%26epage%3D7311%26doi%3D10.1128%2FAAC.03834-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henkin, J.</span></span> <span> </span><span class="NLM_article-title">Selective Inhibition of Endothelial Cell Proliferation by Fumagillin Is Not Due to Differential Expression of Methionine Aminopeptidases</span>. <i>J. Cell. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">465</span>– <span class="NLM_lpage">473</span>, <span class="refDoi"> DOI: 10.1002/(SICI)1097-4644(20000601)77:3<465::AID-JCB11>3.0.CO;2-M</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1002%2F%28SICI%291097-4644%2820000601%2977%3A3%3C465%3A%3AAID-JCB11%3E3.0.CO%3B2-M" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10760954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BD3cXivFWju7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2000&pages=465-473&issue=3&author=J.+Wangauthor=P.+Louauthor=J.+Henkin&title=Selective+Inhibition+of+Endothelial+Cell+Proliferation+by+Fumagillin+Is+Not+Due+to+Differential+Expression+of+Methionine+Aminopeptidases&doi=10.1002%2F%28SICI%291097-4644%2820000601%2977%3A3%3C465%3A%3AAID-JCB11%3E3.0.CO%3B2-M"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Selective inhibition of endothelial cell proliferation by fumagillin is not due to differential expression of methionine aminopeptidases</span></div><div class="casAuthors">Wang, Jieyi; Lou, Pingping; Henkin, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Biochemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">465-473</span>CODEN:
                <span class="NLM_cas:coden">JCEBD5</span>;
        ISSN:<span class="NLM_cas:issn">0730-2312</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The angiogenesis inhibitors fumagillin and TNP-470 selectively inhibit the proliferation of endothelial cells, as compared with most other cell types.  The mechanism of this selective inhibition remains uncertain, although methionine aminopeptidase-2 (MetAP2) has recently been found to be a target for fumagillin or TNP-470, which inactivates MetAP2 enzyme activity through covalent modification.  Primary cultures of human endothelial cells and six other non-endothelial cell types were treated with fumagillin to det. its effect on cell proliferation.  Only the growth of endothelial cells was completely inhibited at low concns. of fumagillin.  MetAP1 and MetAP2 levels in these cells were investigated to det. whether differential enzyme expression plays a role in the selective action of fumagillin.  Western blot anal. and RT-PCR data showed that MetAP1 and MetAP2 were both expressed in these different types of cells, thus, ruling out differential expression of MetAP1 and MetAP2 as an explanation for the cell specificity of fumagillin.  Expression of MetAP2, but not of MetAP1, is regulated.  Treatment of human microvascular endothelial cells (HMVEC) with fumagillin resulted in threefold increases of MetAP2 protein in the cells, while MetAP1 remained const.  Similar upregulation of MetAP2 by exposure to fumagillin was also obsd. in non-endothelial cells, eliminating this response as an explanation for cell specificity.  Taken together, these results indicate that while MetAP2 plays a crit. role in the effect of fumagillin on endothelial cell proliferation, differential endogenous expression or fumagillin-induced upregulation of methionine aminopeptidases is not responsible for this obsd. selective inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnEHBXHmConLVg90H21EOLACvtfcHk0lj97rZpf_olOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXivFWju7k%253D&md5=f05de66bc107cb486c48ee6a81991234</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291097-4644%2820000601%2977%3A3%3C465%3A%3AAID-JCB11%3E3.0.CO%3B2-M&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291097-4644%252820000601%252977%253A3%253C465%253A%253AAID-JCB11%253E3.0.CO%253B2-M%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLou%26aufirst%3DP.%26aulast%3DHenkin%26aufirst%3DJ.%26atitle%3DSelective%2520Inhibition%2520of%2520Endothelial%2520Cell%2520Proliferation%2520by%2520Fumagillin%2520Is%2520Not%2520Due%2520to%2520Differential%2520Expression%2520of%2520Methionine%2520Aminopeptidases%26jtitle%3DJ.%2520Cell.%2520Biochem.%26date%3D2000%26volume%3D77%26issue%3D3%26spage%3D465%26epage%3D473%26doi%3D10.1002%2F%28SICI%291097-4644%2820000601%2977%3A3%3C465%3A%3AAID-JCB11%3E3.0.CO%3B2-M" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. L.</span></span> <span> </span><span class="NLM_article-title">Sitafloxacin Hydrate for Bacterial Infections</span>. <i>Drugs Today</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>44</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">489</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1358/dot.2008.44.7.1219561</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1358%2Fdot.2008.44.7.1219561" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1ShtrfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2008&pages=489-501&issue=7&author=D.+L.+Anderson&title=Sitafloxacin+Hydrate+for+Bacterial+Infections&doi=10.1358%2Fdot.2008.44.7.1219561"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Sitafloxacin hydrate for bacterial infections</span></div><div class="casAuthors">Anderson, David Leif</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of Today</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">489-501</span>CODEN:
                <span class="NLM_cas:coden">MDACAP</span>;
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Sitafloxacin hydrate (DU-6859a, Gracevit), a new-generation, broad-spectrum oral fluoroquinolone that is very active against many Gram-pos., Gram-neg. and anaerobic clin. isolates, including strains resistant to other fluoroquinolones, was recently approved in Japan for the treatment of respiratory and urinary tract infections.  Sitafloxacin is active against methicillin-resistant staphylococci, Streptococcus pneumoniae and other streptococci with reduced susceptibility to levofloxacin and other quinolones and enterococci.  Sitafloxacin has also demonstrated activity against clin. isolates of Klebsiella pneumoniae (including about 67% of strains producing extended-spectrum, β-lactamases and resistant to ciprofloxacin), Enterobacter cloacae, Pseudomonas aeruginosa with some activity against quinolone-resistant strains and Acinetobacter baumannii.  The in vitro activity against anaerobes is comparable to imipenem or metronidazole.  In a published phase II randomized, open-label, multicenter study of patients hospitalized with pneumonia, sitafloxacin (400 mg once daily) was comparable to imipenem/cilastatin (500 mg three times a day).  Results of the phase III trials of sitafloxacin are not available in English.  The clin. safety profile of sitafloxacin has been characterized from 1,059 patients who participated in 10 clin. trials.  The most common events with 50 or 100 mg twice daily were gastrointestinal disorders (17.2%),mostly diarrhea, and abnormal lab. test results (16.2%), mostly liver enzyme elevations.  For Japanese patients, sitafloxacin provides the broad-spectrum coverage promised by clinafloxacin and trovafloxacin and comparable to carbapenems.  While it is currently limited by its potential for phototoxicity in Caucasians, phototoxicity is essentially irrelevant if sitafloxacin is used in hospitals and esp. in intensive care units.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIM0gx8FYiJ7Vg90H21EOLACvtfcHk0lgnD5AhfmQZVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1ShtrfL&md5=87f8f6395c6e311bd8e634ef57d1cc44</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1358%2Fdot.2008.44.7.1219561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2008.44.7.1219561%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DD.%2BL.%26atitle%3DSitafloxacin%2520Hydrate%2520for%2520Bacterial%2520Infections%26jtitle%3DDrugs%2520Today%26date%3D2008%26volume%3D44%26issue%3D7%26spage%3D489%26epage%3D501%26doi%3D10.1358%2Fdot.2008.44.7.1219561" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okumura, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onodera, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoshino, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, T.</span></span> <span> </span><span class="NLM_article-title">Dual-Targeting Properties of the 3-Aminopyrrolidyl Quinolones, DC-159a and Sitafloxacin, against DNA Gyrase and Topoisomerase IV: Contribution to Reducing in Vitro Emergence of Quinolone-Resistant Streptococcus Pneumoniae</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">98</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.1093/jac/dkn136</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1093%2Fjac%2Fdkn136" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=18390884" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnt1Sms7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2008&pages=98-104&issue=1&author=R.+Okumuraauthor=T.+Hirataauthor=Y.+Onoderaauthor=K.+Hoshinoauthor=T.+Otaniauthor=T.+Yamamoto&title=Dual-Targeting+Properties+of+the+3-Aminopyrrolidyl+Quinolones%2C+DC-159a+and+Sitafloxacin%2C+against+DNA+Gyrase+and+Topoisomerase+IV%3A+Contribution+to+Reducing+in+Vitro+Emergence+of+Quinolone-Resistant+Streptococcus+Pneumoniae&doi=10.1093%2Fjac%2Fdkn136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae</span></div><div class="casAuthors">Okumura, Ryo; Hirata, Tsuyoshi; Onodera, Yoshikuni; Hoshino, Kazuki; Otani, Tsuyoshi; Yamamoto, Tomoko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">98-104</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">DC-159a (a novel quinolone) and sitafloxacin (DU-6859a) are structurally related quinolones, bearing a 3-aminopyrrolidyl substitution.  We investigated the relationship between the target preferences of these 3-aminopyrrolidyl quinolones, in vitro potencies and emergence of quinolone-resistant mutants in Streptococcus pneumoniae, compared with other quinolones.  MICs, resistance frequencies and mutant prevention concns. (MPCs) were detd. using quinolone-susceptible strains and first-step parC mutant strains of S. pneumoniae.  Target preferences were tested by the following two methods: antibacterial activities against gyrA or parC mutants and in vitro enzyme assays for the detn. of 50% inhibition (IC50) values.  DC-159a and sitafloxacin exhibited potent antibacterial activities, low frequencies of mutant selection, low MPCs and narrow mutant selection windows against both quinolone-susceptible strains and first-step parC mutants of S. pneumoniae, compared with gatifloxacin, moxifloxacin and other quinolones tested.  DC-159a and sitafloxacin showed relatively low MIC ratios against single gyrA or parC mutants relative to the wild-type strain and low IC50 ratios against DNA gyrase and topoisomerase IV.  Conclusions: DC-159a and sitafloxacin demonstrated a more balanced dual-targeting activity than gatifloxacin, moxifloxacin and other quinolones tested.  In addn., DC-159a and sitafloxacin have a lower propensity for selecting first- and second-step resistant mutants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWChG-7CogrbVg90H21EOLACvtfcHk0lgnD5AhfmQZVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnt1Sms7Y%253D&md5=efd7a23d1718e54884b906bbc5fa464f</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkn136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkn136%26sid%3Dliteratum%253Aachs%26aulast%3DOkumura%26aufirst%3DR.%26aulast%3DHirata%26aufirst%3DT.%26aulast%3DOnodera%26aufirst%3DY.%26aulast%3DHoshino%26aufirst%3DK.%26aulast%3DOtani%26aufirst%3DT.%26aulast%3DYamamoto%26aufirst%3DT.%26atitle%3DDual-Targeting%2520Properties%2520of%2520the%25203-Aminopyrrolidyl%2520Quinolones%252C%2520DC-159a%2520and%2520Sitafloxacin%252C%2520against%2520DNA%2520Gyrase%2520and%2520Topoisomerase%2520IV%253A%2520Contribution%2520to%2520Reducing%2520in%2520Vitro%2520Emergence%2520of%2520Quinolone-Resistant%2520Streptococcus%2520Pneumoniae%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2008%26volume%3D62%26issue%3D1%26spage%3D98%26epage%3D104%26doi%3D10.1093%2Fjac%2Fdkn136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hess, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creese, I.</span></span> <span> </span><span class="NLM_article-title">Chronic Treatment with Dopamine Receptor Antagonists: Behavioral and Pharmacologic Effects on D1 and D2 Dopamine Receptors</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2361</span>– <span class="NLM_lpage">2370</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.08-07-02361.1988</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1523%2FJNEUROSCI.08-07-02361.1988" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=2907912" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADyaL1cXlt1agt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1988&pages=2361-2370&issue=7&author=E.+J.+Hessauthor=A.+B.+Normanauthor=I.+Creese&title=Chronic+Treatment+with+Dopamine+Receptor+Antagonists%3A+Behavioral+and+Pharmacologic+Effects+on+D1+and+D2+Dopamine+Receptors&doi=10.1523%2FJNEUROSCI.08-07-02361.1988"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic treatment with dopamine receptor antagonists:  behavioral and pharmacologic effects on D1 and D2 dopamine receptors</span></div><div class="casAuthors">Hess, Ellen J.; Norman, Andrew B.; Creese, Ian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2361-70</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    </div><div class="casAbstract">Chronic treatment with the D1 receptor-selective antagonist SCH23390 resulted in a significant and selective increase in the D1 dopamine receptor d. in brain tissue.  Likewise chronic treatment with the D2 dopamine receptor-selective antagonist spiperone selectively increased the D2 dopamine receptor d.  However, chronic treatment with the mixed D1/D2 receptor antagonist cis-flupentixol resulted in the up-regulation of D2 dopamine receptors only while the D1 dopamine receptor d. was unchanged.  In in vivo studies using N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline, which irreversibly inactivates D1 and D2 dopamine receptors, it was demonstrated that cis-flupentixol preferentially interacts with D2 dopamine receptors.  Rats were tested for their cataleptic response to the administered drug over the course of the chronic drug treatment.  Catalepsy scores of rats receiving spiperone decreased over the course of treatment, with a significant redn. in catalepsy occurring by treatment day 5.  The profound catalepsy obsd. in rats receiving SCH23390 did not change over the 21 days of treatment.  Rats receiving cis-flupentixol demonstrated tolerance to its cataleptogenic effects, with a significant redn. in catalepsy obsd. by treatment day 7.  During the 3 wk treatment, the time between drug injection and a full cataleptic response to cis-flupentixol increased from 20 to 60 min, suggesting a tolerance to the D2, but not D1, dopamine receptor antagonism by cis-flupentixol.  A group of rats treated with SCH23390 for 21 days received a final acute injection of spiperone on day 22.  These rats were as tolerant to the cataleptogenic effects of spiperone as were those rats tested on day 21 of chronic spiperone treatment.  Conversely, rats challenged with an acute dose of SCH23390 after 21 days spiperone treatment were profoundly cataleptic.  Thus, D2 dopamine receptor up-regulation is not necessary for the development of behavioral tolerance to D2 dopamine receptor antagonism, whereas behavioral tolerance to D1 dopamine receptor antagonism was not obsd. in these studies in spite of a D1 dopamine receptor up-regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsYyVHlEovXLVg90H21EOLACvtfcHk0lgnD5AhfmQZVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXlt1agt7o%253D&md5=5ea16645d476d29989832775cbcd0bca</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.08-07-02361.1988&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.08-07-02361.1988%26sid%3Dliteratum%253Aachs%26aulast%3DHess%26aufirst%3DE.%2BJ.%26aulast%3DNorman%26aufirst%3DA.%2BB.%26aulast%3DCreese%26aufirst%3DI.%26atitle%3DChronic%2520Treatment%2520with%2520Dopamine%2520Receptor%2520Antagonists%253A%2520Behavioral%2520and%2520Pharmacologic%2520Effects%2520on%2520D1%2520and%2520D2%2520Dopamine%2520Receptors%26jtitle%3DJ.%2520Neurosci.%26date%3D1988%26volume%3D8%26issue%3D7%26spage%3D2361%26epage%3D2370%26doi%3D10.1523%2FJNEUROSCI.08-07-02361.1988" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poole, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prossler, J. E.</span></span> <span> </span><span class="NLM_article-title">Tofogliflozin: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">939</span>– <span class="NLM_lpage">944</span>, <span class="refDoi"> DOI: 10.1007/s40265-014-0229-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1007%2Fs40265-014-0229-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=24848755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2cXoslCgsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=939-944&issue=8&author=R.+M.+Pooleauthor=J.+E.+Prossler&title=Tofogliflozin%3A+First+Global+Approval&doi=10.1007%2Fs40265-014-0229-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Tofogliflozin: First Global Approval</span></div><div class="casAuthors">Poole, Raewyn M.; Prossler, Jennifer E.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">939-944</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Tofogliflozin (Apleway, Deberza [Japan]), an orally active small mol. sodium-glucose co-transporter type 2 (SGLT2) inhibitor, has been developed by Chugai Pharmaceutical for the treatment of type 2 diabetes mellitus (T2DM), and a marketing authorization application was filed in Japan in 2013 by licensees Sanofi K.  K. and Kowa.  Tofogliflozin has received its first global approval for this indication in Japan as either monotherapy or in combination with other antihyperglycemic agents.  This article summarizes the milestones in the development of tofogliflozin leading to this first approval for the treatment of T2DM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoP5PjlYV_ierVg90H21EOLACvtfcHk0lj2tYc3HnoEWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXoslCgsrY%253D&md5=68c66f591167857548fb3b3fd6685f34</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1007%2Fs40265-014-0229-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-014-0229-1%26sid%3Dliteratum%253Aachs%26aulast%3DPoole%26aufirst%3DR.%2BM.%26aulast%3DProssler%26aufirst%3DJ.%2BE.%26atitle%3DTofogliflozin%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2014%26volume%3D74%26issue%3D8%26spage%3D939%26epage%3D944%26doi%3D10.1007%2Fs40265-014-0229-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alcaraz, L.</span>; <span class="NLM_string-name">Bailey, A.</span>; <span class="NLM_string-name">Kindon, N.</span></span> <span> </span><span class="NLM_article-title">Compounds - 801</span>. <span class="NLM_patent">WO2011012896A2</span>, February 3, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=L.+Alcaraz&author=A.+Bailey&author=N.+Kindon&title=Compounds+-+801"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAlcaraz%26aufirst%3DL.%26atitle%3DCompounds%2520-%2520801%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corey, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaykovsky, M.</span></span> <span> </span><span class="NLM_article-title">Dimethyloxosulfonium Methylide ((CH3)2SOCH2) and Dimethylsulfonium Methylide ((CH3)2SCH2). Formation and Application to Organic Synthesis</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1965</span>,  <span class="NLM_volume"><i>87</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1353</span>– <span class="NLM_lpage">1364</span>, <span class="refDoi"> DOI: 10.1021/ja01084a034</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja01084a034" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADyaF2MXntlGrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=1965&pages=1353-1364&issue=6&author=E.+J.+Coreyauthor=M.+Chaykovsky&title=Dimethyloxosulfonium+Methylide+%28%28CH3%292SOCH2%29+and+Dimethylsulfonium+Methylide+%28%28CH3%292SCH2%29.+Formation+and+Application+to+Organic+Synthesis&doi=10.1021%2Fja01084a034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Dimethyloxosulfonium methylide and dimethylsulfonium methylide. Formation and application to organic synthesis</span></div><div class="casAuthors">Corey, E. J.; Chaykovsky, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1965</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1353-64</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">The generation of dimethyloxosulfonium methylide (Me2SOCH2) and dimethylsulfonium methylide (Me2SCH2) as reactive intermediates is described.  Both ylides are nucleophiles and both function to transfer methylene to certain electrophilic unsatd. linkages, including C:O, C:N, C:S, and in certain cases, C:C.  The less reactive oxosulfonium ylide interacts with the carbonyl function of aromatic and nonconjugated aldehydes and ketones to form oxiranes and with α,β-unsatd. ketones which are Michael receptors to form cyclopropyl ketones.  The sulfonium ylide reacts with the same substrates to give oxiranes exclusively even with the α,β-unsatd. carbonyl systems.  These reactions are quite general and, therefore, of considerable practical value.  The stereochemistry of carbonyl addn. to cyclohexanones varies depending on the ylide; the oxosulfonium ylide reacts by equatorial addn. (i.e., of methylene) and the sulfonium ylide shows a preference for axial addn.  A no. of other reactions of these ylides are described including "over-all methylene insertion," and a differential comparison of their chem. properties is made.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqt0xfN-tNfFLVg90H21EOLACvtfcHk0lj2tYc3HnoEWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2MXntlGrtw%253D%253D&md5=ae22573e36db50409c7832e5950df7f1</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fja01084a034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja01084a034%26sid%3Dliteratum%253Aachs%26aulast%3DCorey%26aufirst%3DE.%2BJ.%26aulast%3DChaykovsky%26aufirst%3DM.%26atitle%3DDimethyloxosulfonium%2520Methylide%2520%2528%2528CH3%25292SOCH2%2529%2520and%2520Dimethylsulfonium%2520Methylide%2520%2528%2528CH3%25292SCH2%2529.%2520Formation%2520and%2520Application%2520to%2520Organic%2520Synthesis%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1965%26volume%3D87%26issue%3D6%26spage%3D1353%26epage%3D1364%26doi%3D10.1021%2Fja01084a034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stocks, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcaraz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowers, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donald, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kindon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pairaudeau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theaker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, D. J.</span></span> <span> </span><span class="NLM_article-title">The Discovery of New Spirocyclic Muscarinic M3 Antagonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">7458</span>– <span class="NLM_lpage">7461</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.10.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2Fj.bmcl.2010.10.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=21036043" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVKjtbrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=7458-7461&issue=24&author=M.+J.+Stocksauthor=L.+Alcarazauthor=A.+Baileyauthor=K.+Bowersauthor=D.+Donaldauthor=H.+Edwardsauthor=F.+Huntauthor=N.+Kindonauthor=G.+Pairaudeauauthor=J.+Theakerauthor=D.+J.+Warner&title=The+Discovery+of+New+Spirocyclic+Muscarinic+M3+Antagonists&doi=10.1016%2Fj.bmcl.2010.10.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery of new spirocyclic muscarinic M3 antagonists</span></div><div class="casAuthors">Stocks, Michael J.; Alcaraz, Lilian; Bailey, Andrew; Bowers, Keith; Donald, David; Edwards, Helen; Hunt, Fraser; Kindon, Nicholas; Pairaudeau, Garry; Theaker, Jill; Warner, Daniel J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7458-7461</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The optimization of a new series of spirocyclic high potency muscarinic M3 antagonists, e.g., I, derived from high throughput screening library hits, is described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKoe2HBqvb_7Vg90H21EOLACvtfcHk0lj2tYc3HnoEWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVKjtbrP&md5=4c90afe6e914d1becb38a9441b69d4d1</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.10.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.10.016%26sid%3Dliteratum%253Aachs%26aulast%3DStocks%26aufirst%3DM.%2BJ.%26aulast%3DAlcaraz%26aufirst%3DL.%26aulast%3DBailey%26aufirst%3DA.%26aulast%3DBowers%26aufirst%3DK.%26aulast%3DDonald%26aufirst%3DD.%26aulast%3DEdwards%26aufirst%3DH.%26aulast%3DHunt%26aufirst%3DF.%26aulast%3DKindon%26aufirst%3DN.%26aulast%3DPairaudeau%26aufirst%3DG.%26aulast%3DTheaker%26aufirst%3DJ.%26aulast%3DWarner%26aufirst%3DD.%2BJ.%26atitle%3DThe%2520Discovery%2520of%2520New%2520Spirocyclic%2520Muscarinic%2520M3%2520Antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26issue%3D24%26spage%3D7458%26epage%3D7461%26doi%3D10.1016%2Fj.bmcl.2010.10.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Volkova, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budkova, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filonova, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khristolyubova, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutuzova, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koroleva, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radzivil, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aminova, Z. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuchalin, A. G.</span></span> <span> </span><span class="NLM_article-title">Efficacy of Supplemental Anti-Inflammatory Therapy with Fenspiride in Chronic Obstructive and Nonobstructive Bronchitis</span>. <i>Clin. Drug Invest.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">257</span>– <span class="NLM_lpage">264</span>, <span class="refDoi"> DOI: 10.2165/00044011-200525040-00005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.2165%2F00044011-200525040-00005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=17523776" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1aiu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2005&pages=257-264&issue=4&author=L.+I.+Volkovaauthor=A.+A.+Budkovaauthor=N.+N.+Filonovaauthor=E.+I.+Khristolyubovaauthor=E.+B.+Kutuzovaauthor=N.+V.+Korolevaauthor=T.+T.+Radzivilauthor=Z.+R.+Aminovaauthor=A.+G.+Chuchalin&title=Efficacy+of+Supplemental+Anti-Inflammatory+Therapy+with+Fenspiride+in+Chronic+Obstructive+and+Nonobstructive+Bronchitis&doi=10.2165%2F00044011-200525040-00005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of supplemental anti-inflammatory therapy with fenspiride in chronic obstructive and nonobstructive bronchitis</span></div><div class="casAuthors">Volkova, L. I.; Budkova, A. A.; Filonova, N. N.; Khristolyubova, E. I.; Kutuzova, E. B.; Koroleva, N. V.; Radzivil, T. T.; Aminova, Z. R.; Chuchalin, A. G.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Drug Investigation</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">257-264</span>CODEN:
                <span class="NLM_cas:coden">CDINFR</span>;
        ISSN:<span class="NLM_cas:issn">1173-2563</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">Objective: The objective of this randomized, nonblind study was to assess the efficacy of fenspiride as complementary anti-inflammatory therapy in combination with ipratropium bromide in patients with chronic bronchitis (CB).  A comparison was made with ipratropium bromide alone, the generally accepted std. therapy for CB.  Methods and subjects: The study population comprised 20 patients with chronic obstructive bronchitis (COB) and 60 patients without signs of obstruction.  Fifty-one males (64%) and 29 females (36%) aged from 25 to 65 years were studied over a 6-mo treatment period.  Combined therapy with fenspiride (160 mg/day) and ipratropium bromide (160 μg/day) was prescribed to 39 patients (28 with CB and 11 with COB) for 6 mo, and monotherapy with ipratropium bromide (160 μg/day) was prescribed for 41 patients (32 with CB and nine with COB).  Results: The combined therapy group had a reduced intensity of dyspnoea, improvements in sputum nature and quantity of exudation, and a reduced intensity of coughing.  The monotherapy group showed redns. in sputum exudation and cough intensity.  Improvements in lung respiratory function were obsd. in both groups, but were greater in the combined therapy group of patients.  Reduced cytosis, percentage and abs. content of neutrophils, and abs. content of lymphocytes and eosinophils in induced sputum were obsd. with CB patients in the combined therapy group.  A reduced content of lymphocytes and an increase in macrophages were obsd. with CB patients in the monotherapy group.  A significant decline in tumor necrosis factor (TNF)-α content in sputum was obsd. with both therapeutic regimens, although a statistically significant decline in serum TNFα (10.85 ng/L to 5.58 ng/L; p = 0.03) and reduced interleukin-8 in sputum (311.94 ng/L to 122.02 ng/L; p = 0.027) were obsd. with patients given combined therapy.  Conclusion: The study showed greater efficacy of long-term treatment with fenspiride and ipratropium bromide compared with ipratropium bromide alone in patients with CB.  This combination regimen can be recommended for the redn. of inflammation and prevention of disease progression in patients with CB and may also be useful in patients with COB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGMt6oKsKK8bVg90H21EOLACvtfcHk0lgokRWlU7fBLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1aiu7Y%253D&md5=99b4a9164bd287f0cfaf1a64badf9c15</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.2165%2F00044011-200525040-00005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00044011-200525040-00005%26sid%3Dliteratum%253Aachs%26aulast%3DVolkova%26aufirst%3DL.%2BI.%26aulast%3DBudkova%26aufirst%3DA.%2BA.%26aulast%3DFilonova%26aufirst%3DN.%2BN.%26aulast%3DKhristolyubova%26aufirst%3DE.%2BI.%26aulast%3DKutuzova%26aufirst%3DE.%2BB.%26aulast%3DKoroleva%26aufirst%3DN.%2BV.%26aulast%3DRadzivil%26aufirst%3DT.%2BT.%26aulast%3DAminova%26aufirst%3DZ.%2BR.%26aulast%3DChuchalin%26aufirst%3DA.%2BG.%26atitle%3DEfficacy%2520of%2520Supplemental%2520Anti-Inflammatory%2520Therapy%2520with%2520Fenspiride%2520in%2520Chronic%2520Obstructive%2520and%2520Nonobstructive%2520Bronchitis%26jtitle%3DClin.%2520Drug%2520Invest.%26date%3D2005%26volume%3D25%26issue%3D4%26spage%3D257%26epage%3D264%26doi%3D10.2165%2F00044011-200525040-00005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Somanathan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivero, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuñez, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellberg, L. H.</span></span> <span> </span><span class="NLM_article-title">Convenient Synthesis of 1-Oxa-3,8-Diazaspiro [4,5] Decan-2-Ones</span>. <i>Synth. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1483</span>– <span class="NLM_lpage">1487</span>, <span class="refDoi"> DOI: 10.1080/00397919408011753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1080%2F00397919408011753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADyaK2cXkvVeisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1994&pages=1483-1487&issue=10&author=R.+Somanathanauthor=I.+A.+Riveroauthor=G.+I.+Nu%C3%B1ezauthor=L.+H.+Hellberg&title=Convenient+Synthesis+of+1-Oxa-3%2C8-Diazaspiro+%5B4%2C5%5D+Decan-2-Ones&doi=10.1080%2F00397919408011753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Convenient synthesis of 1-oxa-3,8-diazaspiro[4,5]decan-2-ones</span></div><div class="casAuthors">Somanathan R.; Rivero, I. A.; Nunez, G. I.; Hellberg, L. H.</div><div class="citationInfo"><span class="NLM_cas:title">Synthetic Communications</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1483-7</span>CODEN:
                <span class="NLM_cas:coden">SYNCAV</span>;
        ISSN:<span class="NLM_cas:issn">0039-7911</span>.
    </div><div class="casAbstract">Addn. reaction of Me3SiCN to 4-pyridones in the presence of ZnI2 gave cyanosilylppiperidones I (n = 1, 2) which on LiAlH4 desilylation followed by cyclization with triphosgene gave title compds. II.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_qlswvUTT4rVg90H21EOLACvtfcHk0lgokRWlU7fBLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXkvVeisb4%253D&md5=eacb59014595a46a1041666b17e19900</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1080%2F00397919408011753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00397919408011753%26sid%3Dliteratum%253Aachs%26aulast%3DSomanathan%26aufirst%3DR.%26aulast%3DRivero%26aufirst%3DI.%2BA.%26aulast%3DNu%25C3%25B1ez%26aufirst%3DG.%2BI.%26aulast%3DHellberg%26aufirst%3DL.%2BH.%26atitle%3DConvenient%2520Synthesis%2520of%25201-Oxa-3%252C8-Diazaspiro%2520%255B4%252C5%255D%2520Decan-2-Ones%26jtitle%3DSynth.%2520Commun.%26date%3D1994%26volume%3D24%26issue%3D10%26spage%3D1483%26epage%3D1487%26doi%3D10.1080%2F00397919408011753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taccone, I.</span></span> <span> </span><span class="NLM_article-title">Method for the Preparation of Derivatives of Spiro (4,5)-Decane and Derivatives Thus Obtained</span>. <span class="NLM_patent">US4028351A</span>, <span class="NLM_year">1977</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1977&author=I.+Taccone&title=Method+for+the+Preparation+of+Derivatives+of+Spiro+%284%2C5%29-Decane+and+Derivatives+Thus+Obtained"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTaccone%26aufirst%3DI.%26atitle%3DMethod%2520for%2520the%2520Preparation%2520of%2520Derivatives%2520of%2520Spiro%2520%25284%252C5%2529-Decane%2520and%2520Derivatives%2520Thus%2520Obtained%26date%3D1977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, R.</span>; <span class="NLM_string-name">Roger, C.</span>; <span class="NLM_string-name">Le, D. J.-C.</span></span> <span> </span><span class="NLM_article-title">1-Oxa-2-Oxo 3, 8-Diaza Spiro (4, 5) Decanes</span>. <span class="NLM_patent">US3399192A</span>, <span class="NLM_year">1968</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1968&author=R.+Gilbert&author=C.+Roger&author=D.+J.-C.+Le&title=1-Oxa-2-Oxo+3%2C+8-Diaza+Spiro+%284%2C+5%29+Decanes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGilbert%26aufirst%3DR.%26atitle%3D1-Oxa-2-Oxo%25203%252C%25208-Diaza%2520Spiro%2520%25284%252C%25205%2529%2520Decanes%26date%3D1968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Regnier, G.</span>; <span class="NLM_string-name">Guillonneau, C.</span>; <span class="NLM_string-name">Duhault, J.</span>; <span class="NLM_string-name">Lonchampt, M.</span></span> <span> </span><span class="NLM_article-title">Spiro (4,5) Decone Compounds</span>. <span class="NLM_patent">US4824836A</span>, <span class="NLM_year">1989</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1989&author=G.+Regnier&author=C.+Guillonneau&author=J.+Duhault&author=M.+Lonchampt&title=Spiro+%284%2C5%29+Decone+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRegnier%26aufirst%3DG.%26atitle%3DSpiro%2520%25284%252C5%2529%2520Decone%2520Compounds%26date%3D1989" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pramanik, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bapat, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotharkar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">More, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotrane, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaskar, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripathy, N. K.</span></span> <span> </span><span class="NLM_article-title">Nitro-Aldol Approach for Commercial Manufacturing of Fenspiride Hydrochloride</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1252</span>– <span class="NLM_lpage">1256</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.9b00022</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.9b00022" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1MXptFymt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2019&pages=1252-1256&issue=6&author=C.+Pramanikauthor=K.+Bapatauthor=P.+Patilauthor=S.+Kotharkarauthor=Y.+Moreauthor=D.+Gotraneauthor=S.+P.+Chaskarauthor=U.+Mahajanauthor=N.+K.+Tripathy&title=Nitro-Aldol+Approach+for+Commercial+Manufacturing+of+Fenspiride+Hydrochloride&doi=10.1021%2Facs.oprd.9b00022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Nitro-Aldol Approach for Commercial Manufacturing of Fenspiride Hydrochloride</span></div><div class="casAuthors">Pramanik, Chinmoy; Bapat, Kiran; Patil, Pradip; Kotharkar, Sandeep; More, Yogesh; Gotrane, Dinkar; Chaskar, Sudhir P.; Mahajan, Ulhas; Tripathy, Narendra K.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1252-1256</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An efficient, short manufg. process for fenspiride hydrochloride is reported.  Nitro-aldol condensation is the key reaction in the developed process.  Improved routes to key building blocks are demonstrated by expedient multikilogram prodn.  Hazardous reactions are avoided.  API produced following this new route meets the quality requirement NLT 99.70% purity by HPLC with any individual impurity NMT 0.10% with very good yield.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomLVnQCgqx4LVg90H21EOLACvtfcHk0lhAX-6jIfzBsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXptFymt7c%253D&md5=7bddbcba67ae65d44b1dec9fcf29825f</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.9b00022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.9b00022%26sid%3Dliteratum%253Aachs%26aulast%3DPramanik%26aufirst%3DC.%26aulast%3DBapat%26aufirst%3DK.%26aulast%3DPatil%26aufirst%3DP.%26aulast%3DKotharkar%26aufirst%3DS.%26aulast%3DMore%26aufirst%3DY.%26aulast%3DGotrane%26aufirst%3DD.%26aulast%3DChaskar%26aufirst%3DS.%2BP.%26aulast%3DMahajan%26aufirst%3DU.%26aulast%3DTripathy%26aufirst%3DN.%2BK.%26atitle%3DNitro-Aldol%2520Approach%2520for%2520Commercial%2520Manufacturing%2520of%2520Fenspiride%2520Hydrochloride%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2019%26volume%3D23%26issue%3D6%26spage%3D1252%26epage%3D1256%26doi%3D10.1021%2Facs.oprd.9b00022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cornec, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pers, J.-O.</span></span> <span> </span><span class="NLM_article-title">Sjögren’s Syndrome: Where Do We Stand, and Where Shall We Go?</span>. <i>J. Autoimmun.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">109</span>– <span class="NLM_lpage">114</span>, <span class="refDoi"> DOI: 10.1016/j.jaut.2014.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2Fj.jaut.2014.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=24612946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A280%3ADC%252BC2crisVSgsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2014&pages=109-114&author=D.+Cornecauthor=C.+Jaminauthor=J.-O.+Pers&title=Sj%C3%B6gren%E2%80%99s+Syndrome%3A+Where+Do+We+Stand%2C+and+Where+Shall+We+Go%3F&doi=10.1016%2Fj.jaut.2014.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Sjogren's syndrome: where do we stand, and where shall we go?</span></div><div class="casAuthors">Cornec Divi; Jamin Christophe; Pers Jacques-Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of autoimmunity</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">109-14</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Primary Sjogren's syndrome (pSS) is one of the most frequent autoimmune systemic diseases, mainly characterized by ocular and oral dryness due to the progressive destruction of lachrymal and salivary glands by an inflammatory process.  A noteworthy proportion of patients also features extraglandular manifestations, sometimes severe and life-threatening.  Until now, its management relies mostly on symptomatic interventions, long-term monitoring, and, in patients with severe systemic complications, immunosuppressive drugs can be provided.  However, recent years have seen great progresses in the understanding of the pathological processes of the disease.  The central role of regulatory lymphocytes, the implication of the type 1 interferon pathway in some patients or the importance of epigenetics have been highlighted.  New classification criteria have been recently published and have shed in light an international attempt for a better recognition of the patients, probably thanks to the development of new diagnostic procedures such as salivary gland ultrasonography.  To facilitate the detection of treatment efficacy in clinical trials and to help in determining which subgroups of patients would have benefits from intensive therapies, a better definition of activity scores and the availability of new prognostic markers are urgent.  Thereby, the development of future therapies should be based on specific molecular signatures that will enable a personalized management of each patient.  This review focuses on the most striking advances in the fields of pathophysiology, diagnosis and treatment of pSS, which generate a great hope for pSS patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSU4Ml3861NqBLDWw4HIq2sfW6udTcc2eZc1vPM3JpElrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2crisVSgsw%253D%253D&md5=fdba0d4200603f38bd917f7763590a8e</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.jaut.2014.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaut.2014.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DCornec%26aufirst%3DD.%26aulast%3DJamin%26aufirst%3DC.%26aulast%3DPers%26aufirst%3DJ.-O.%26atitle%3DSj%25C3%25B6gren%25E2%2580%2599s%2520Syndrome%253A%2520Where%2520Do%2520We%2520Stand%252C%2520and%2520Where%2520Shall%2520We%2520Go%253F%26jtitle%3DJ.%2520Autoimmun.%26date%3D2014%26volume%3D51%26spage%3D109%26epage%3D114%26doi%3D10.1016%2Fj.jaut.2014.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, A.</span>; <span class="NLM_string-name">Karton, I.</span>; <span class="NLM_string-name">Heldman, E.</span>; <span class="NLM_string-name">Levy, A.</span>; <span class="NLM_string-name">Grunfeld, Y.</span></span> <span> </span><span class="NLM_article-title">Derivatives of Quinuclidine</span>. <span class="NLM_patent">US4855290A</span>, <span class="NLM_year">1989</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1989&author=A.+Fisher&author=I.+Karton&author=E.+Heldman&author=A.+Levy&author=Y.+Grunfeld&title=Derivatives+of+Quinuclidine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFisher%26aufirst%3DA.%26atitle%3DDerivatives%2520of%2520Quinuclidine%26date%3D1989" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schunk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinze, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frormann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oberbörsch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundermann, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zemolka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Englberger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Germann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christoph, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kögel, B.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schröder, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harlfinger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kless, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schick, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonnenschein, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Potent Analgesic NOP and Opioid Receptor Agonist: Cebranopadol</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">857</span>– <span class="NLM_lpage">862</span>, <span class="refDoi"> DOI: 10.1021/ml500117c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500117c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVentLfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=857-862&issue=8&author=S.+Schunkauthor=K.+Linzauthor=C.+Hinzeauthor=S.+Frormannauthor=S.+Oberb%C3%B6rschauthor=B.+Sundermannauthor=S.+Zemolkaauthor=W.+Englbergerauthor=T.+Germannauthor=T.+Christophauthor=B.-Y.+K%C3%B6gelauthor=W.+Schr%C3%B6derauthor=S.+Harlfingerauthor=D.+Saundersauthor=A.+Klessauthor=H.+Schickauthor=H.+Sonnenschein&title=Discovery+of+a+Potent+Analgesic+NOP+and+Opioid+Receptor+Agonist%3A+Cebranopadol&doi=10.1021%2Fml500117c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent Analgesic NOP and Opioid Receptor Agonist: Cebranopadol</span></div><div class="casAuthors">Schunk, Stefan; Linz, Klaus; Hinze, Claudia; Frormann, Sven; Oberboersch, Stefan; Sundermann, Bernd; Zemolka, Saskia; Englberger, Werner; Germann, Tieno; Christoph, Thomas; Koegel, Babette-Y.; Schroeder, Wolfgang; Harlfinger, Stephanie; Saunders, Derek; Kless, Achim; Schick, Hans; Sonnenschein, Helmut</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">857-862</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In a previous communication, our efforts leading from 1 to the identification of spiro[cyclohexane-dihydropyrano[3,4-b]indole]-amine 2a as analgesic NOP and opioid receptor agonist were disclosed and their favorable in vitro and in vivo pharmacol. properties revealed.  We herein report our efforts to further optimize lead 2a, toward trans-6'-fluoro-4',9'-dihydro-N,N-dimethyl-4-phenyl-spiro[cyclohexane-1,1'(3'H)-pyrano[3,4-b]indol]-4-amine (cebranopadol, 3a), which is currently in clin. development for the treatment of severe chronic nociceptive and neuropathic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_oo_6lpPHoLVg90H21EOLACvtfcHk0lhAX-6jIfzBsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVentLfL&md5=270b1eef8252dcae7ce2e84c17d78b81</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fml500117c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500117c%26sid%3Dliteratum%253Aachs%26aulast%3DSchunk%26aufirst%3DS.%26aulast%3DLinz%26aufirst%3DK.%26aulast%3DHinze%26aufirst%3DC.%26aulast%3DFrormann%26aufirst%3DS.%26aulast%3DOberb%25C3%25B6rsch%26aufirst%3DS.%26aulast%3DSundermann%26aufirst%3DB.%26aulast%3DZemolka%26aufirst%3DS.%26aulast%3DEnglberger%26aufirst%3DW.%26aulast%3DGermann%26aufirst%3DT.%26aulast%3DChristoph%26aufirst%3DT.%26aulast%3DK%25C3%25B6gel%26aufirst%3DB.-Y.%26aulast%3DSchr%25C3%25B6der%26aufirst%3DW.%26aulast%3DHarlfinger%26aufirst%3DS.%26aulast%3DSaunders%26aufirst%3DD.%26aulast%3DKless%26aufirst%3DA.%26aulast%3DSchick%26aufirst%3DH.%26aulast%3DSonnenschein%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520a%2520Potent%2520Analgesic%2520NOP%2520and%2520Opioid%2520Receptor%2520Agonist%253A%2520Cebranopadol%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26issue%3D8%26spage%3D857%26epage%3D862%26doi%3D10.1021%2Fml500117c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanter, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sui, Z.</span></span> <span> </span><span class="NLM_article-title">Silicon-Directed Oxa-Pictet-Spengler Cyclization and an Unusual Dimerization of 2-Trimethylsilanyl Tryptophols</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2043</span>– <span class="NLM_lpage">2046</span>, <span class="refDoi"> DOI: 10.1021/ol050623n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol050623n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtVOitrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=2043-2046&issue=10&author=X.+Zhangauthor=X.+Liauthor=J.+C.+Lanterauthor=Z.+Sui&title=Silicon-Directed+Oxa-Pictet-Spengler+Cyclization+and+an+Unusual+Dimerization+of+2-Trimethylsilanyl+Tryptophols&doi=10.1021%2Fol050623n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Silicon-Directed Oxa-Pictet-Spengler Cyclization and an Unusual Dimerization of 2-Trimethylsilanyl Tryptophols</span></div><div class="casAuthors">Zhang, Xuqing; Li, Xiaojie; Lanter, James C.; Sui, Zhihua</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2043-2046</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The tetrahydropyrano[3,4-b]indoles I (n = 1, 2; R1 = H, CN, Cl, NO2, F, CF3, CO2Me; R2 = H, CF3, Cl; R3 = Me; R4 = Me, MeS, EtS, BnS) were synthesized from 2-(2-trimethylsilanyl-1H-indol-3-yl)alkanols II and various ketones or aldehydes through silicon-directed oxa-Pictet-Spengler cyclizations.  An unusual reaction led to the dimeric products III when some of II was treated with acetone using BF3 as the catalyst.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN6Rri3huVu7Vg90H21EOLACvtfcHk0lhLxV7YvfvlqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtVOitrs%253D&md5=75259d3e604c1568449e42ac8def0c47</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fol050623n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol050623n%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLanter%26aufirst%3DJ.%2BC.%26aulast%3DSui%26aufirst%3DZ.%26atitle%3DSilicon-Directed%2520Oxa-Pictet-Spengler%2520Cyclization%2520and%2520an%2520Unusual%2520Dimerization%2520of%25202-Trimethylsilanyl%2520Tryptophols%26jtitle%3DOrg.%2520Lett.%26date%3D2005%26volume%3D7%26issue%3D10%26spage%3D2043%26epage%3D2046%26doi%3D10.1021%2Fol050623n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pruehs, S.</span>; <span class="NLM_string-name">Griebel, C.</span>; <span class="NLM_string-name">Hell, W.</span></span> <span> </span><span class="NLM_article-title">Process for the Preparation of (1r,4r)-6’-Fluoro-(N,N-Dimethyl- and N-Methyl)-4-Phenyl-4’,9’-Dihydro-3’H-Spiro[Cyclohexane-1,1’-Pyrano-[3,4,b]Indol]-4-Amine</span>. <span class="NLM_patent">US20130150590A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=S.+Pruehs&author=C.+Griebel&author=W.+Hell&title=Process+for+the+Preparation+of+%281r%2C4r%29-6%E2%80%99-Fluoro-%28N%2CN-Dimethyl-+and+N-Methyl%29-4-Phenyl-4%E2%80%99%2C9%E2%80%99-Dihydro-3%E2%80%99H-Spiro%5BCyclohexane-1%2C1%E2%80%99-Pyrano-%5B3%2C4%2Cb%5DIndol%5D-4-Amine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPruehs%26aufirst%3DS.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520%25281r%252C4r%2529-6%25E2%2580%2599-Fluoro-%2528N%252CN-Dimethyl-%2520and%2520N-Methyl%2529-4-Phenyl-4%25E2%2580%2599%252C9%25E2%2580%2599-Dihydro-3%25E2%2580%2599H-Spiro%255BCyclohexane-1%252C1%25E2%2580%2599-Pyrano-%255B3%252C4%252Cb%255DIndol%255D-4-Amine%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rottmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, B. K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seitz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plouffe, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dharia, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González-Páez, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakshminarayana, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suwanarusk, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jegla, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, H.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosten, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dartois, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diagana, T. T.</span></span> <span> </span><span class="NLM_article-title">Spiroindolones, a Potent Compound Class for the Treatment of Malaria</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>329</i></span> (<span class="NLM_issue">5996</span>),  <span class="NLM_fpage">1175</span>– <span class="NLM_lpage">1180</span>, <span class="refDoi"> DOI: 10.1126/science.1193225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1126%2Fscience.1193225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=20813948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtV2hsr%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=329&publication_year=2010&pages=1175-1180&issue=5996&author=M.+Rottmannauthor=C.+McNamaraauthor=B.+K.+S.+Yeungauthor=M.+C.+S.+Leeauthor=B.+Zouauthor=B.+Russellauthor=P.+Seitzauthor=D.+M.+Plouffeauthor=N.+V.+Dhariaauthor=J.+Tanauthor=S.+B.+Cohenauthor=K.+R.+Spencerauthor=G.+E.+Gonz%C3%A1lez-P%C3%A1ezauthor=S.+B.+Lakshminarayanaauthor=A.+Gohauthor=R.+Suwanaruskauthor=T.+Jeglaauthor=E.+K.+Schmittauthor=H.-P.+Beckauthor=R.+Brunauthor=F.+Nostenauthor=L.+Reniaauthor=V.+Dartoisauthor=T.+H.+Kellerauthor=D.+A.+Fidockauthor=E.+A.+Winzelerauthor=T.+T.+Diagana&title=Spiroindolones%2C+a+Potent+Compound+Class+for+the+Treatment+of+Malaria&doi=10.1126%2Fscience.1193225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Spiroindolones, a Potent Compound Class for the Treatment of Malaria</span></div><div class="casAuthors">Rottmann, Matthias; McNamara, Case; Yeung, Bryan K. S.; Lee, Marcus C. S.; Zou, Bin; Russell, Bruce; Seitz, Patrick; Plouffe, David M.; Dharia, Neekesh V.; Tan, Jocelyn; Cohen, Steven B.; Spencer, Kathryn R.; Gonzalez-Paez, Gonzalo E.; Lakshminarayana, Suresh B.; Goh, Anne; Suwanarusk, Rossarin; Jegla, Timothy; Schmitt, Esther K.; Beck, Hans-Peter; Brun, Reto; Nosten, Francois; Renia, Laurent; Dartois, Veronique; Keller, Thomas H.; Fidock, David A.; Winzeler, Elizabeth A.; Diagana, Thierry T.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">329</span>
        (<span class="NLM_cas:issue">5996</span>),
    <span class="NLM_cas:pages">1175-1180</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Recent reports of increased tolerance to artemisinin derivs.-the most recently adopted class of antimalarials-have prompted a need for new treatments.  The spirotetrahydro-β-carbolines, or spiroindolones, are potent drugs that kill the blood stages of Plasmodium falciparum and Plasmodium vivax clin. isolates at low nanomolar concn.  Spiroindolones rapidly inhibit protein synthesis in P. falciparum, an effect that is ablated in parasites bearing nonsynonymous mutations in the gene encoding the P-type cation-transporter ATPase4 (PfATP4).  The optimized spiroindolone NITD609 shows pharmacokinetic properties compatible with once-daily oral dosing and has single-dose efficacy in a rodent malaria model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqI6O1WaX-1b7Vg90H21EOLACvtfcHk0lhLxV7YvfvlqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtV2hsr%252FJ&md5=239bc9babd5cb5f07e2be38741038e2c</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1126%2Fscience.1193225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1193225%26sid%3Dliteratum%253Aachs%26aulast%3DRottmann%26aufirst%3DM.%26aulast%3DMcNamara%26aufirst%3DC.%26aulast%3DYeung%26aufirst%3DB.%2BK.%2BS.%26aulast%3DLee%26aufirst%3DM.%2BC.%2BS.%26aulast%3DZou%26aufirst%3DB.%26aulast%3DRussell%26aufirst%3DB.%26aulast%3DSeitz%26aufirst%3DP.%26aulast%3DPlouffe%26aufirst%3DD.%2BM.%26aulast%3DDharia%26aufirst%3DN.%2BV.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DCohen%26aufirst%3DS.%2BB.%26aulast%3DSpencer%26aufirst%3DK.%2BR.%26aulast%3DGonz%25C3%25A1lez-P%25C3%25A1ez%26aufirst%3DG.%2BE.%26aulast%3DLakshminarayana%26aufirst%3DS.%2BB.%26aulast%3DGoh%26aufirst%3DA.%26aulast%3DSuwanarusk%26aufirst%3DR.%26aulast%3DJegla%26aufirst%3DT.%26aulast%3DSchmitt%26aufirst%3DE.%2BK.%26aulast%3DBeck%26aufirst%3DH.-P.%26aulast%3DBrun%26aufirst%3DR.%26aulast%3DNosten%26aufirst%3DF.%26aulast%3DRenia%26aufirst%3DL.%26aulast%3DDartois%26aufirst%3DV.%26aulast%3DKeller%26aufirst%3DT.%2BH.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26aulast%3DDiagana%26aufirst%3DT.%2BT.%26atitle%3DSpiroindolones%252C%2520a%2520Potent%2520Compound%2520Class%2520for%2520the%2520Treatment%2520of%2520Malaria%26jtitle%3DScience%26date%3D2010%26volume%3D329%26issue%3D5996%26spage%3D1175%26epage%3D1180%26doi%3D10.1126%2Fscience.1193225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonntag, L.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leong, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, B. K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, T. H.</span></span> <span> </span><span class="NLM_article-title">Mechanistic Study of the Spiroindolones: A New Class of Antimalarials</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">10131</span>– <span class="NLM_lpage">10141</span>, <span class="refDoi"> DOI: 10.3390/molecules170910131</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.3390%2Fmolecules170910131" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=22922283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht12htLbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=10131-10141&issue=9&author=B.+Zouauthor=P.+Yapauthor=L.-S.+Sonntagauthor=S.+Y.+Leongauthor=B.+K.+S.+Yeungauthor=T.+H.+Keller&title=Mechanistic+Study+of+the+Spiroindolones%3A+A+New+Class+of+Antimalarials&doi=10.3390%2Fmolecules170910131"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic study of the spiroindolones: a new class of antimalarials</span></div><div class="casAuthors">Zou, Bin; Yap, Peiling; Sonntag, Louis-Sebastian; Leong, Seh Yong; Yeung, Bryan K. S.; Keller, Thomas H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10131-10141</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">During the synthesis of the new antimalarial drug candidate NITD609, a high degree of diastereoselectivity was obsd. in the Pictet-Spengler reaction.  By isolating both the 4E and 4Z imine intermediates, a systematic mechanistic study of the reaction under both kinetic and thermodn. conditions was conducted.  This study provides insight into the source of the diastereoselectivity for this important class of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruzD1qORJEkrVg90H21EOLACvtfcHk0lgragK8XmxKqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht12htLbL&md5=5d8c1df74fd2ed4801a220da4b7d0fb1</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.3390%2Fmolecules170910131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules170910131%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DB.%26aulast%3DYap%26aufirst%3DP.%26aulast%3DSonntag%26aufirst%3DL.-S.%26aulast%3DLeong%26aufirst%3DS.%2BY.%26aulast%3DYeung%26aufirst%3DB.%2BK.%2BS.%26aulast%3DKeller%26aufirst%3DT.%2BH.%26atitle%3DMechanistic%2520Study%2520of%2520the%2520Spiroindolones%253A%2520A%2520New%2520Class%2520of%2520Antimalarials%26jtitle%3DMolecules%26date%3D2012%26volume%3D17%26issue%3D9%26spage%3D10131%26epage%3D10141%26doi%3D10.3390%2Fmolecules170910131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ang, S. H.</span>; <span class="NLM_string-name">Krastel, P.</span>; <span class="NLM_string-name">Leong, S. Y.</span>; <span class="NLM_string-name">Tan, L. J.</span>; <span class="NLM_string-name">Wong, W. L. J.</span>; <span class="NLM_string-name">Yeung, B. K.</span>; <span class="NLM_string-name">Zou, B.</span></span> <span> </span><span class="NLM_article-title">Spiro-Indole Derivatives for the Treatment of Parasitic Diseases</span>. <span class="NLM_patent">WO2009132921A1</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=S.+H.+Ang&author=P.+Krastel&author=S.+Y.+Leong&author=L.+J.+Tan&author=W.+L.+J.+Wong&author=B.+K.+Yeung&author=B.+Zou&title=Spiro-Indole+Derivatives+for+the+Treatment+of+Parasitic+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAng%26aufirst%3DS.%2BH.%26atitle%3DSpiro-Indole%2520Derivatives%2520for%2520the%2520Treatment%2520of%2520Parasitic%2520Diseases%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pike, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rash, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedregal, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Statnick, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoghbi, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toledo, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gackenheimer, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tauscher, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Innis, R. B.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Evaluation of Radioligands for Imaging Brain Nociceptin/Orphanin FQ Peptide (NOP) Receptors with Positron Emission Tomography</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2687</span>– <span class="NLM_lpage">2700</span>, <span class="refDoi"> DOI: 10.1021/jm101487v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101487v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvVSisLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2687-2700&issue=8&author=V.+W.+Pikeauthor=K.+S.+Rashauthor=Z.+Chenauthor=C.+Pedregalauthor=M.+A.+Statnickauthor=Y.+Kimuraauthor=J.+Hongauthor=S.+S.+Zoghbiauthor=M.+Fujitaauthor=M.+A.+Toledoauthor=N.+Diazauthor=S.+L.+Gackenheimerauthor=J.+T.+Tauscherauthor=V.+N.+Barthauthor=R.+B.+Innis&title=Synthesis+and+Evaluation+of+Radioligands+for+Imaging+Brain+Nociceptin%2FOrphanin+FQ+Peptide+%28NOP%29+Receptors+with+Positron+Emission+Tomography&doi=10.1021%2Fjm101487v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of radioligands for imaging brain nociceptin/orphanin FQ peptide (NOP) receptors with positron emission tomography</span></div><div class="casAuthors">Pike, Victor W.; Rash, Karen S.; Chen, Zhaogen; Pedregal, Concepcion; Statnick, Michael A.; Kimura, Yasuyuki; Hong, Jinsoo; Zoghbi, Sami S.; Fujita, Masahiro; Toledo, Miguel A.; Diaz, Nuria; Gackenheimer, Susan L.; Tauscher, Johannes T.; Barth, Vanessa N.; Innis, Robert B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2687-2700</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Positron emission tomog. (PET) coupled to an effective radioligand could provide an important tool for understanding possible links between neuropsychiatric disorders and brain NOP (nociceptin/orphanin FQ peptide) receptors.  We sought to develop such a PET radioligand.  High-affinity NOP ligands were synthesized based on a 3-(2'-fluoro-4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran]-1-yl)-2(2-halobenzyl)-N-alkylpropanamide scaffold and from exptl. screens in rats, with ex vivo LC-MS/MS measures, three ligands were identified for labeling with carbon-11 and evaluation with PET in monkey.  Each ligand was labeled by 11C-methylation of an N-demethyl precursor and studied in monkey under baseline and NOP receptor-preblock conditions.  The three radioligands, [11C](S)-I (X = F, Cl, R = H; X = F, R = iPr) gave similar results.  Baseline scans showed high entry of radioactivity into the brain to give a distribution reflecting that expected for NOP receptors.  Preblock expts. showed high early peak levels of brain radioactivity, which rapidly declined to a much lower level than seen in baseline scans, thereby indicating a high level of receptor-specific binding in baseline expts.  Overall, [11C](S)-I (X = F, R = iPr) showed the most favorable receptor-specific signal and kinetics and is now selected for evaluation in human subjects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLbdZG2H-gRLVg90H21EOLACvtfcHk0lgragK8XmxKqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvVSisLk%253D&md5=7519fa250770248d3c73c58e20eca3f1</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm101487v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101487v%26sid%3Dliteratum%253Aachs%26aulast%3DPike%26aufirst%3DV.%2BW.%26aulast%3DRash%26aufirst%3DK.%2BS.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DPedregal%26aufirst%3DC.%26aulast%3DStatnick%26aufirst%3DM.%2BA.%26aulast%3DKimura%26aufirst%3DY.%26aulast%3DHong%26aufirst%3DJ.%26aulast%3DZoghbi%26aufirst%3DS.%2BS.%26aulast%3DFujita%26aufirst%3DM.%26aulast%3DToledo%26aufirst%3DM.%2BA.%26aulast%3DDiaz%26aufirst%3DN.%26aulast%3DGackenheimer%26aufirst%3DS.%2BL.%26aulast%3DTauscher%26aufirst%3DJ.%2BT.%26aulast%3DBarth%26aufirst%3DV.%2BN.%26aulast%3DInnis%26aufirst%3DR.%2BB.%26atitle%3DSynthesis%2520and%2520Evaluation%2520of%2520Radioligands%2520for%2520Imaging%2520Brain%2520Nociceptin%252FOrphanin%2520FQ%2520Peptide%2520%2528NOP%2529%2520Receptors%2520with%2520Positron%2520Emission%2520Tomography%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D8%26spage%3D2687%26epage%3D2700%26doi%3D10.1021%2Fjm101487v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pedregal, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toledo, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafuente, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Grau, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiménez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benito, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mudra, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahl, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rash, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Statnick, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, V. N.</span></span> <span> </span><span class="NLM_article-title">Development of LC-MS/MS-Based Receptor Occupancy Tracers and Positron Emission Tomography Radioligands for the Nociceptin/Orphanin FQ (NOP) Receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">4955</span>– <span class="NLM_lpage">4967</span>, <span class="refDoi"> DOI: 10.1021/jm201629q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201629q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmt1Oqu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4955-4967&issue=11&author=C.+Pedregalauthor=E.+M.+Joshiauthor=M.+A.+Toledoauthor=C.+Lafuenteauthor=N.+Diazauthor=M.+A.+Martinez-Grauauthor=A.+Jim%C3%A9nezauthor=A.+Benitoauthor=A.+Navarroauthor=Z.+Chenauthor=D.+R.+Mudraauthor=S.+D.+Kahlauthor=K.+S.+Rashauthor=M.+A.+Statnickauthor=V.+N.+Barth&title=Development+of+LC-MS%2FMS-Based+Receptor+Occupancy+Tracers+and+Positron+Emission+Tomography+Radioligands+for+the+Nociceptin%2FOrphanin+FQ+%28NOP%29+Receptor&doi=10.1021%2Fjm201629q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Development of LC-MS/MS-Based Receptor Occupancy Tracers and Positron Emission Tomography Radioligands for the Nociceptin/Orphanin FQ (NOP) Receptor</span></div><div class="casAuthors">Pedregal, Concepcion; Joshi, Elizabeth M.; Toledo, Miguel A.; Lafuente, Celia; Diaz, Nuria; Martinez-Grau, Maria A.; Jimenez, Alma; Benito, Ana; Navarro, Antonio; Chen, Zhaogen; Mudra, Daniel R.; Kahl, Steven D.; Rash, Karen S.; Statnick, Michael A.; Barth, Vanessa N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4955-4967</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Currently, a lack of sufficient tools has limited the understanding of the relation between neuropsychiatric disorders and the nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptor.  Herein, we describe the discovery and development of an antagonist NOP receptor occupancy (RO) tracer and a novel positron emission tomog. (PET) radioligand suitable to probe the NOP receptor in human clin. studies.  A thorough structure-activity relation (SAR) around the high-affinity 3-(2'-fluoro-4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran]-1-yl)-2-(2-halobenzyl)-N-alkylpropanamide scaffold identified a series of subnanomolar, highly selective NOP antagonists.  Subsequently, these unlabeled NOP ligands were evaluated in vivo by liq. chromatog.-tandem mass spectrometry (LC-MS/MS) in rat to det. brain uptake, kinetics and specific binding.  Three compds. were selected for evaluation in nonhuman primates as PET tracers.  Carbon-11 labeling yielded [11C]I, which exhibited minimal generation of central nervous system (CNS) penetrant radiometabolites, improved brain uptake, and was an excellent PET radioligand in both rat and monkey.  Currently [11C]I is being evaluated as a PET radiotracer for the NOP receptor in human subjects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9BUDm4qd1VrVg90H21EOLACvtfcHk0lht6JgDCyvv1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmt1Oqu7c%253D&md5=37ba5b3497d5300a487c179a668a9055</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm201629q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201629q%26sid%3Dliteratum%253Aachs%26aulast%3DPedregal%26aufirst%3DC.%26aulast%3DJoshi%26aufirst%3DE.%2BM.%26aulast%3DToledo%26aufirst%3DM.%2BA.%26aulast%3DLafuente%26aufirst%3DC.%26aulast%3DDiaz%26aufirst%3DN.%26aulast%3DMartinez-Grau%26aufirst%3DM.%2BA.%26aulast%3DJim%25C3%25A9nez%26aufirst%3DA.%26aulast%3DBenito%26aufirst%3DA.%26aulast%3DNavarro%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DMudra%26aufirst%3DD.%2BR.%26aulast%3DKahl%26aufirst%3DS.%2BD.%26aulast%3DRash%26aufirst%3DK.%2BS.%26aulast%3DStatnick%26aufirst%3DM.%2BA.%26aulast%3DBarth%26aufirst%3DV.%2BN.%26atitle%3DDevelopment%2520of%2520LC-MS%252FMS-Based%2520Receptor%2520Occupancy%2520Tracers%2520and%2520Positron%2520Emission%2520Tomography%2520Radioligands%2520for%2520the%2520Nociceptin%252FOrphanin%2520FQ%2520%2528NOP%2529%2520Receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D11%26spage%3D4955%26epage%3D4967%26doi%3D10.1021%2Fjm201629q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, D.</span>; <span class="NLM_string-name">Gotchev, D.</span>; <span class="NLM_string-name">Pitis, P.</span>; <span class="NLM_string-name">Chen, X.-T.</span>; <span class="NLM_string-name">Liu, G.</span>; <span class="NLM_string-name">Yuan, C. C. K.</span></span> <span> </span><span class="NLM_article-title">Opioid Receptor Ligands and Methods of Using and Making Same</span>. <span class="NLM_patent">WO2012129495A1</span>, September 27, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=D.+Yamashita&author=D.+Gotchev&author=P.+Pitis&author=X.-T.+Chen&author=G.+Liu&author=C.+C.+K.+Yuan&title=Opioid+Receptor+Ligands+and+Methods+of+Using+and+Making+Same"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYamashita%26aufirst%3DD.%26atitle%3DOpioid%2520Receptor%2520Ligands%2520and%2520Methods%2520of%2520Using%2520and%2520Making%2520Same%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span> <span> </span><span class="NLM_article-title">Oliceridine: First Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>80</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">1739</span>– <span class="NLM_lpage">1744</span>, <span class="refDoi"> DOI: 10.1007/s40265-020-01414-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1007%2Fs40265-020-01414-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=33025536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVKhu7%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2020&pages=1739-1744&issue=16&author=A.+Markham&title=Oliceridine%3A+First+Approval&doi=10.1007%2Fs40265-020-01414-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Oliceridine: First Approval</span></div><div class="casAuthors">Markham, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1739-1744</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Oliceridine (Olinvyk, Trevena, Inc.) is a novel μ opioid agonist that was recently approved in the USA for use in adults for the management of acute pain severe enough to require an i.v. opioid analgesic and for whom alternative treatments are inadequate.  Unlike opioid agonists currently in use, the interaction of oliceridine with the opioid receptor is selective to the G protein pathway, with low potency for β-arrestin recruitment, which may lead to fewer opioid-related adverse events.  This article summarizes the milestones in the development of oliceridine leading to this first approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1fHqCB19-nLVg90H21EOLACvtfcHk0lht6JgDCyvv1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVKhu7%252FF&md5=a5c8fe4dd05f7991a98686077eec4a80</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1007%2Fs40265-020-01414-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-020-01414-9%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26atitle%3DOliceridine%253A%2520First%2520Approval%26jtitle%3DDrugs%26date%3D2020%26volume%3D80%26issue%3D16%26spage%3D1739%26epage%3D1744%26doi%3D10.1007%2Fs40265-020-01414-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotchev, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rominger, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koblish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewire, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crombie, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Violin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, D. S.</span></span> <span> </span><span class="NLM_article-title">Structure-Activity Relationships and Discovery of a G Protein Biased μ Opioid Receptor Ligand, [(3-Methoxythiophen-2-Yl)Methyl]({2-[(9R)-9-(Pyridin-2-Yl)-6-Oxaspiro-[4.5]Decan-9-Yl]Ethyl})Amine (TRV130), for the Treatment of Acute Severe Pain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">8019</span>– <span class="NLM_lpage">8031</span>, <span class="refDoi"> DOI: 10.1021/jm4010829</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4010829" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFSmsrjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8019-8031&issue=20&author=X.-T.+Chenauthor=P.+Pitisauthor=G.+Liuauthor=C.+Yuanauthor=D.+Gotchevauthor=C.+L.+Cowanauthor=D.+H.+Romingerauthor=M.+Koblishauthor=S.+M.+Dewireauthor=A.+L.+Crombieauthor=J.+D.+Violinauthor=D.+S.+Yamashita&title=Structure-Activity+Relationships+and+Discovery+of+a+G+Protein+Biased+%CE%BC+Opioid+Receptor+Ligand%2C+%5B%283-Methoxythiophen-2-Yl%29Methyl%5D%28%7B2-%5B%289R%29-9-%28Pyridin-2-Yl%29-6-Oxaspiro-%5B4.5%5DDecan-9-Yl%5DEthyl%7D%29Amine+%28TRV130%29%2C+for+the+Treatment+of+Acute+Severe+Pain&doi=10.1021%2Fjm4010829"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationships and Discovery of a G Protein Biased μ Opioid Receptor Ligand, [(3-Methoxythiophen-2-yl)methyl]({2-[(9R)9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the Treatment of Acute Severe Pain</span></div><div class="casAuthors">Chen, Xiao-Tao; Pitis, Philip; Liu, Guodong; Yuan, Catherine; Gotchev, Dimitar; Cowan, Conrad L.; Rominger, David H.; Koblish, Michael; DeWire, Scott M.; Crombie, Aimee L.; Violin, Jonathan D.; Yamashita, Dennis S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8019-8031</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The concept of ligand bias at G protein coupled receptors has been introduced to describe ligands which preferentially stimulate one intracellular signaling pathway over another.  There is growing interest in developing biased G protein coupled receptor ligands to yield safer, better tolerated, and more efficacious drugs.  The classical μ opioid morphine elicited increased efficacy and duration of analgesic response with reduced side effects in β-arrestin-2 knockout mice compared to wild-type mice, suggesting that G protein biased μ opioid receptor agonists would be more efficacious with reduced adverse events.  Here we describe our efforts to identify a potent, selective, and G protein biased μ opioid receptor agonist, TRV130 (I).  This novel mol. demonstrated an improved therapeutic index (analgesia vs adverse effects) in rodent models and characteristics appropriate for clin. development.  It is currently being evaluated in human clin. trials for the treatment of acute severe pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-rI0Et_vFqrVg90H21EOLACvtfcHk0lht6JgDCyvv1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFSmsrjK&md5=c80bd62062f31418f18392f97c880bea</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjm4010829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4010829%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.-T.%26aulast%3DPitis%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DYuan%26aufirst%3DC.%26aulast%3DGotchev%26aufirst%3DD.%26aulast%3DCowan%26aufirst%3DC.%2BL.%26aulast%3DRominger%26aufirst%3DD.%2BH.%26aulast%3DKoblish%26aufirst%3DM.%26aulast%3DDewire%26aufirst%3DS.%2BM.%26aulast%3DCrombie%26aufirst%3DA.%2BL.%26aulast%3DViolin%26aufirst%3DJ.%2BD.%26aulast%3DYamashita%26aufirst%3DD.%2BS.%26atitle%3DStructure-Activity%2520Relationships%2520and%2520Discovery%2520of%2520a%2520G%2520Protein%2520Biased%2520%25CE%25BC%2520Opioid%2520Receptor%2520Ligand%252C%2520%255B%25283-Methoxythiophen-2-Yl%2529Methyl%255D%2528%257B2-%255B%25289R%2529-9-%2528Pyridin-2-Yl%2529-6-Oxaspiro-%255B4.5%255DDecan-9-Yl%255DEthyl%257D%2529Amine%2520%2528TRV130%2529%252C%2520for%2520the%2520Treatment%2520of%2520Acute%2520Severe%2520Pain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D20%26spage%3D8019%26epage%3D8031%26doi%3D10.1021%2Fjm4010829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caenepeel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belmontes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moody, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chui, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poppe, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardozo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houze, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paras, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taygerly, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vimolratana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zancanella, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cajulis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osgood, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egan, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greninger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClanaghan, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moujalled, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pomilio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beltran, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benes, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coxon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, P. E.</span></span> <span> </span><span class="NLM_article-title">AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1582</span>– <span class="NLM_lpage">1597</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-18-0387</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1158%2F2159-8290.CD-18-0387" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=30254093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFOmsb7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=1582-1597&issue=12&author=S.+Caenepeelauthor=S.+P.+Brownauthor=B.+Belmontesauthor=G.+Moodyauthor=K.+S.+Keeganauthor=D.+Chuiauthor=D.+A.+Whittingtonauthor=X.+Huangauthor=L.+Poppeauthor=A.+C.+Chengauthor=M.+Cardozoauthor=J.+Houzeauthor=Y.+Liauthor=B.+Lucasauthor=N.+A.+Parasauthor=X.+Wangauthor=J.+P.+Taygerlyauthor=M.+Vimolratanaauthor=M.+Zancanellaauthor=L.+Zhuauthor=E.+Cajulisauthor=T.+Osgoodauthor=J.+Sunauthor=L.+Damonauthor=R.+K.+Eganauthor=P.+Greningerauthor=J.+D.+McClanaghanauthor=J.+Gongauthor=D.+Moujalledauthor=G.+Pomilioauthor=P.+Beltranauthor=C.+H.+Benesauthor=A.+W.+Robertsauthor=D.+C.+Huangauthor=A.+Weiauthor=J.+Canonauthor=A.+Coxonauthor=P.+E.+Hughes&title=AMG+176%2C+a+Selective+MCL1+Inhibitor%2C+Is+Effective+in+Hematologic+Cancer+Models+Alone+and+in+Combination+with+Established+Therapies&doi=10.1158%2F2159-8290.CD-18-0387"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies</span></div><div class="casAuthors">Caenepeel, Sean; Brown, Sean P.; Belmontes, Brian; Moody, Gordon; Keegan, Kathleen S.; Chui, Danny; Whittington, Douglas A.; Huang, Xin; Poppe, Leszek; Cheng, Alan C.; Cardozo, Mario; Houze, Jonathan; Li, Yunxiao; Lucas, Brian; Paras, Nick A.; Wang, Xianghong; Taygerly, Joshua P.; Vimolratana, Marc; Zancanella, Manuel; Zhu, Liusheng; Cajulis, Elaina; Osgood, Tao; Sun, Jan; Damon, Leah; Egan, Regina K.; Greninger, Patricia; McClanaghan, Joseph D.; Gong, Jianan; Moujalled, Donia; Pomilio, Giovanna; Beltran, Pedro; Benes, Cyril H.; Roberts, Andrew W.; Huang, David C.; Wei, Andrew; Canon, Jude; Coxon, Angela; Hughes, Paul E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1582-1597</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The prosurvival BCL2 family member MCL1 is frequently dysregulated in cancer.  To overcome the significant challenges assocd. with inhibition of MCL1 protein-protein interactions, we rigorously applied small-mol. conformational restriction, which culminated in the discovery of AMG 176, the first selective MCL1 inhibitor to be studied in humans.  We demonstrate that MCL1 inhibition induces a rapid and committed step toward apoptosis in subsets of hematol. cancer cell lines, tumor xenograft models, and primary patient samples.  With the use of a human MCL1 knock-in mouse, we demonstrate that MCL1 inhibition at active doses of AMG 176 is tolerated and correlates with clear pharmacodynamic effects, demonstrated by redns. in B cells, monocytes, and neutrophils.  Furthermore, the combination of AMG 176 and venetoclax is synergistic in acute myeloid leukemia (AML) tumor models and in primary patient samples at tolerated doses.  These results highlight the therapeutic promise of AMG 176 and the potential for combinations with other BH3 mimetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUtMExVVtn5rVg90H21EOLACvtfcHk0ljO0sGBUGTlhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFOmsb7E&md5=795a713908c3635bbd5e9fc3d95f3ae0</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-18-0387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-18-0387%26sid%3Dliteratum%253Aachs%26aulast%3DCaenepeel%26aufirst%3DS.%26aulast%3DBrown%26aufirst%3DS.%2BP.%26aulast%3DBelmontes%26aufirst%3DB.%26aulast%3DMoody%26aufirst%3DG.%26aulast%3DKeegan%26aufirst%3DK.%2BS.%26aulast%3DChui%26aufirst%3DD.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DPoppe%26aufirst%3DL.%26aulast%3DCheng%26aufirst%3DA.%2BC.%26aulast%3DCardozo%26aufirst%3DM.%26aulast%3DHouze%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLucas%26aufirst%3DB.%26aulast%3DParas%26aufirst%3DN.%2BA.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DTaygerly%26aufirst%3DJ.%2BP.%26aulast%3DVimolratana%26aufirst%3DM.%26aulast%3DZancanella%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DCajulis%26aufirst%3DE.%26aulast%3DOsgood%26aufirst%3DT.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DDamon%26aufirst%3DL.%26aulast%3DEgan%26aufirst%3DR.%2BK.%26aulast%3DGreninger%26aufirst%3DP.%26aulast%3DMcClanaghan%26aufirst%3DJ.%2BD.%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DMoujalled%26aufirst%3DD.%26aulast%3DPomilio%26aufirst%3DG.%26aulast%3DBeltran%26aufirst%3DP.%26aulast%3DBenes%26aufirst%3DC.%2BH.%26aulast%3DRoberts%26aufirst%3DA.%2BW.%26aulast%3DHuang%26aufirst%3DD.%2BC.%26aulast%3DWei%26aufirst%3DA.%26aulast%3DCanon%26aufirst%3DJ.%26aulast%3DCoxon%26aufirst%3DA.%26aulast%3DHughes%26aufirst%3DP.%2BE.%26atitle%3DAMG%2520176%252C%2520a%2520Selective%2520MCL1%2520Inhibitor%252C%2520Is%2520Effective%2520in%2520Hematologic%2520Cancer%2520Models%2520Alone%2520and%2520in%2520Combination%2520with%2520Established%2520Therapies%26jtitle%3DCancer%2520Discovery%26date%3D2018%26volume%3D8%26issue%3D12%26spage%3D1582%26epage%3D1597%26doi%3D10.1158%2F2159-8290.CD-18-0387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, S. P.</span>; <span class="NLM_string-name">Li, Y.</span>; <span class="NLM_string-name">Lizarzaburu, M. E.</span>; <span class="NLM_string-name">Lucas, B. S.</span>; <span class="NLM_string-name">Paras, N. A.</span>; <span class="NLM_string-name">Taygerly, J.</span>; <span class="NLM_string-name">Vimolratana, M.</span>; <span class="NLM_string-name">Wang, X.</span>; <span class="NLM_string-name">Yu, M.</span>; <span class="NLM_string-name">Zancanella, M.</span>; <span class="NLM_string-name">Zhu, L.</span>; <span class="NLM_string-name">Buenrostro, A. G.</span>; <span class="NLM_string-name">Li, Z.</span></span> <span> </span><span class="NLM_article-title">Tetrahydronaphthalene Derivatives That Inhibit Mcl-1 Protein</span>. <span class="NLM_patent">WO2016033486A1</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=S.+P.+Brown&author=Y.+Li&author=M.+E.+Lizarzaburu&author=B.+S.+Lucas&author=N.+A.+Paras&author=J.+Taygerly&author=M.+Vimolratana&author=X.+Wang&author=M.+Yu&author=M.+Zancanella&author=L.+Zhu&author=A.+G.+Buenrostro&author=Z.+Li&title=Tetrahydronaphthalene+Derivatives+That+Inhibit+Mcl-1+Protein"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DS.%2BP.%26atitle%3DTetrahydronaphthalene%2520Derivatives%2520That%2520Inhibit%2520Mcl-1%2520Protein%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rescourio, G.</span>; <span class="NLM_string-name">Buenrostro, A. G.</span>; <span class="NLM_string-name">Brown, S. P.</span>; <span class="NLM_string-name">Lizarzaburu, M.</span>; <span class="NLM_string-name">Medina, J. C.</span>; <span class="NLM_string-name">Jabri, S. Y.</span>; <span class="NLM_string-name">Sun, D.</span>; <span class="NLM_string-name">Simonovich, S. P.</span>; <span class="NLM_string-name">Yan, X.</span>; <span class="NLM_string-name">Li, Y.</span>; <span class="NLM_string-name">Rew, Y.</span></span> <span> </span><span class="NLM_article-title">Alpha-Hydroxy Phenylacetic Acid Pharmacophore or Bioisostere Mcl-1 Protein Antagonists</span>. <span class="NLM_patent">WO2019173181A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=G.+Rescourio&author=A.+G.+Buenrostro&author=S.+P.+Brown&author=M.+Lizarzaburu&author=J.+C.+Medina&author=S.+Y.+Jabri&author=D.+Sun&author=S.+P.+Simonovich&author=X.+Yan&author=Y.+Li&author=Y.+Rew&title=Alpha-Hydroxy+Phenylacetic+Acid+Pharmacophore+or+Bioisostere+Mcl-1+Protein+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRescourio%26aufirst%3DG.%26atitle%3DAlpha-Hydroxy%2520Phenylacetic%2520Acid%2520Pharmacophore%2520or%2520Bioisostere%2520Mcl-1%2520Protein%2520Antagonists%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, S. K.</span>; <span class="NLM_string-name">Cameron, K. O.</span>; <span class="NLM_string-name">Fernando, D. P.</span>; <span class="NLM_string-name">Kung, D. W.-S.</span>; <span class="NLM_string-name">Londregan, A. T.</span>; <span class="NLM_string-name">Mcclure, K. F.</span>; <span class="NLM_string-name">Simila, S. T. M.</span></span> <span> </span><span class="NLM_article-title">2,3 Dihydro-1h-Inden-1-Yl- 2,7-Diazaspiro [3.6] Nonane Derivatives and Their Use as Antagonists or Inverse Agonists of the Ghrelin Receptor</span>. <span class="NLM_patent">WO2011114271A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=S.+K.+Bhattacharya&author=K.+O.+Cameron&author=D.+P.+Fernando&author=D.+W.-S.+Kung&author=A.+T.+Londregan&author=K.+F.+Mcclure&author=S.+T.+M.+Simila&title=2%2C3+Dihydro-1h-Inden-1-Yl-+2%2C7-Diazaspiro+%5B3.6%5D+Nonane+Derivatives+and+Their+Use+as+Antagonists+or+Inverse+Agonists+of+the+Ghrelin+Receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBhattacharya%26aufirst%3DS.%2BK.%26atitle%3D2%252C3%2520Dihydro-1h-Inden-1-Yl-%25202%252C7-Diazaspiro%2520%255B3.6%255D%2520Nonane%2520Derivatives%2520and%2520Their%2520Use%2520as%2520Antagonists%2520or%2520Inverse%2520Agonists%2520of%2520the%2520Ghrelin%2520Receptor%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beveridge, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, K. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernando, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hepworth, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khot, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosa, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapham, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loria, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Londregan, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClure, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orr, S. T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saenz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stock, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VanVolkenburg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vrieze, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of PF-5190457, a Potent, Selective, and Orally Bioavailable Ghrelin Receptor Inverse Agonist Clinical Candidate</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">474</span>– <span class="NLM_lpage">479</span>, <span class="refDoi"> DOI: 10.1021/ml400473x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml400473x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtVeqsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=474-479&issue=5&author=S.+K.+Bhattacharyaauthor=K.+Andrewsauthor=R.+Beveridgeauthor=K.+O.+Cameronauthor=C.+Chenauthor=M.+Dunnauthor=D.+Fernandoauthor=H.+Gaoauthor=D.+Hepworthauthor=V.+M.+Jacksonauthor=V.+Khotauthor=J.+Kongauthor=R.+E.+Kosaauthor=K.+Laphamauthor=P.+M.+Loriaauthor=A.+T.+Londreganauthor=K.+F.+McClureauthor=S.+T.+M.+Orrauthor=J.+Patelauthor=C.+Roseauthor=J.+Saenzauthor=I.+A.+Stockauthor=G.+Storerauthor=M.+VanVolkenburgauthor=D.+Vriezeauthor=G.+Wangauthor=J.+Xiaoauthor=Y.+Zhang&title=Discovery+of+PF-5190457%2C+a+Potent%2C+Selective%2C+and+Orally+Bioavailable+Ghrelin+Receptor+Inverse+Agonist+Clinical+Candidate&doi=10.1021%2Fml400473x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of PF-5190457, a Potent, Selective, and Orally Bioavailable Ghrelin Receptor Inverse Agonist Clinical Candidate</span></div><div class="casAuthors">Bhattacharya, Samit K.; Andrews, Kim; Beveridge, Ramsay; Cameron, Kimberly O.; Chen, Chiliu; Dunn, Matthew; Fernando, Dilinie; Gao, Hua; Hepworth, David; Jackson, V. Margaret; Khot, Vishal; Kong, Jimmy; Kosa, Rachel E.; Lapham, Kimberly; Loria, Paula M.; Londregan, Allyn T.; McClure, Kim F.; Orr, Suvi T. M.; Patel, Jigna; Rose, Colin; Saenz, James; Stock, Ingrid A.; Storer, Gregory; Van Volkenburg, Maria; Vrieze, Derek; Wang, Guoqiang; Xiao, Jun; Zhang, Yingxin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">474-479</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The identification of potent, highly selective orally bioavailable ghrelin receptor inverse agonists from a spiro-azetidino-piperidine series is described.  Examples from this series have promising in vivo pharmacokinetics and increase glucose-stimulated insulin secretion in human whole and dispersed islets.  A physicochem.-based strategy to increase lipophilic efficiency for ghrelin receptor potency and retain low clearance and satisfactory permeability while reducing off-target pharmacol. led to the discovery of I.  Compd. I has a superior balance of ghrelin receptor pharmacol. and off-target selectivity.  On the basis of its promising pharmacol. and safety profile, I was advanced to human clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohmbqWISrADbVg90H21EOLACvtfcHk0lhfoMZ1VAhOmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtVeqsbc%253D&md5=32382b6183ae39e9aa34e17729e314b3</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fml400473x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400473x%26sid%3Dliteratum%253Aachs%26aulast%3DBhattacharya%26aufirst%3DS.%2BK.%26aulast%3DAndrews%26aufirst%3DK.%26aulast%3DBeveridge%26aufirst%3DR.%26aulast%3DCameron%26aufirst%3DK.%2BO.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DDunn%26aufirst%3DM.%26aulast%3DFernando%26aufirst%3DD.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DHepworth%26aufirst%3DD.%26aulast%3DJackson%26aufirst%3DV.%2BM.%26aulast%3DKhot%26aufirst%3DV.%26aulast%3DKong%26aufirst%3DJ.%26aulast%3DKosa%26aufirst%3DR.%2BE.%26aulast%3DLapham%26aufirst%3DK.%26aulast%3DLoria%26aufirst%3DP.%2BM.%26aulast%3DLondregan%26aufirst%3DA.%2BT.%26aulast%3DMcClure%26aufirst%3DK.%2BF.%26aulast%3DOrr%26aufirst%3DS.%2BT.%2BM.%26aulast%3DPatel%26aufirst%3DJ.%26aulast%3DRose%26aufirst%3DC.%26aulast%3DSaenz%26aufirst%3DJ.%26aulast%3DStock%26aufirst%3DI.%2BA.%26aulast%3DStorer%26aufirst%3DG.%26aulast%3DVanVolkenburg%26aufirst%3DM.%26aulast%3DVrieze%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DXiao%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520PF-5190457%252C%2520a%2520Potent%252C%2520Selective%252C%2520and%2520Orally%2520Bioavailable%2520Ghrelin%2520Receptor%2520Inverse%2520Agonist%2520Clinical%2520Candidate%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26issue%3D5%26spage%3D474%26epage%3D479%26doi%3D10.1021%2Fml400473x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, D. L.</span></span> <span> </span><span class="NLM_article-title">Review of Synthetic Routes and Crystalline Forms of the Antiandrogen Oncology Drugs Enzalutamide, Apalutamide, and Darolutamide</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">347</span>– <span class="NLM_lpage">362</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.0c00005</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.0c00005" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjtl2ku7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2020&pages=347-362&issue=3&author=D.+L.+Hughes&title=Review+of+Synthetic+Routes+and+Crystalline+Forms+of+the+Antiandrogen+Oncology+Drugs+Enzalutamide%2C+Apalutamide%2C+and+Darolutamide&doi=10.1021%2Facs.oprd.0c00005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Review of Synthetic Routes and Crystalline Forms of the Anti-Androgen Oncology Drugs Enzalutamide, Apalutamide, and Darolutamide</span></div><div class="casAuthors">Hughes, David L.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">347-362</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This article reviewed the synthetic routes and final cryst. forms of recently approved anti-androgen drugs enzalutamide, apalutamide, and darolutamide, used for treatment of prostate cancer.  The patent literature was the primary source of information.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJxg3gDFfY3bVg90H21EOLACvtfcHk0lgaE_ehcz9TVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjtl2ku7k%253D&md5=4e5ef1b009701200500f5ea16744b1fa</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.0c00005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.0c00005%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DD.%2BL.%26atitle%3DReview%2520of%2520Synthetic%2520Routes%2520and%2520Crystalline%2520Forms%2520of%2520the%2520Antiandrogen%2520Oncology%2520Drugs%2520Enzalutamide%252C%2520Apalutamide%252C%2520and%2520Darolutamide%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2020%26volume%3D24%26issue%3D3%26spage%3D347%26epage%3D362%26doi%3D10.1021%2Facs.oprd.0c00005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Al-Salama, Z. T.</span></span> <span> </span><span class="NLM_article-title">Apalutamide: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">699</span>– <span class="NLM_lpage">705</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0900-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1007%2Fs40265-018-0900-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=29626324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnsVaqtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=699-705&issue=6&author=Z.+T.+Al-Salama&title=Apalutamide%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-0900-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Apalutamide: First Global Approval</span></div><div class="casAuthors">Al-Salama, Zaina T.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">699-705</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Apalutamide (ErleadaTM) is a next-generation oral androgen receptor (AR) inhibitor that is being developed by Janssen for the treatment of prostate cancer (PC).  It binds directly to the ligand-binding domain of the AR and blocks the effects of androgens.  In Feb. 2018, apalutamide received its first global approval in the USA for the treatment of non-metastatic castration-resistant PC (nmCRPC).  Apalutamide is undergoing phase III investigation in chemotherapy-naive patients with metastatic CRPC (in combination with abiraterone acetate plus prednisone), patients with high-risk localized or locally advanced PC receiving primary radiation therapy, and in patients with metastatic hormone-sensitive PC and biochem.-relapsed PC.  This article summarizes the milestones in the development of apalutamide leading to this first approval in nmCRPC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfajxysBf-c7Vg90H21EOLACvtfcHk0lgaE_ehcz9TVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnsVaqtr8%253D&md5=b6a8295485956422287476b4192ee789</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0900-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0900-z%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Salama%26aufirst%3DZ.%2BT.%26atitle%3DApalutamide%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26issue%3D6%26spage%3D699%26epage%3D705%26doi%3D10.1007%2Fs40265-018-0900-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M. E.</span>; <span class="NLM_string-name">Sawyers, C. L.</span>; <span class="NLM_string-name">Ouk, S.</span>; <span class="NLM_string-name">Tran, C.</span>; <span class="NLM_string-name">Wongvipat, J.</span></span> <span> </span><span class="NLM_article-title">Androgen Receptor Modulator for the Treatment of Prostate Cancer and Androgen Receptor-Associated Diseases</span>. <span class="NLM_patent">WO2007126765A2</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=M.+E.+Jung&author=C.+L.+Sawyers&author=S.+Ouk&author=C.+Tran&author=J.+Wongvipat&title=Androgen+Receptor+Modulator+for+the+Treatment+of+Prostate+Cancer+and+Androgen+Receptor-Associated+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJung%26aufirst%3DM.%2BE.%26atitle%3DAndrogen%2520Receptor%2520Modulator%2520for%2520the%2520Treatment%2520of%2520Prostate%2520Cancer%2520and%2520Androgen%2520Receptor-Associated%2520Diseases%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DiPoto, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span> <span> </span><span class="NLM_article-title">Synthesis of 2-Aminoimidazolones and Imidazolones by (3 + 2) Annulation of Azaoxyallyl Cations</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">499</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1021/acs.orglett.7b03719</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.orglett.7b03719" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A280%3ADC%252BC1MzptlGmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2018&pages=499-501&issue=3&author=M.+C.+DiPotoauthor=J.+Wu&title=Synthesis+of+2-Aminoimidazolones+and+Imidazolones+by+%283+%2B+2%29+Annulation+of+Azaoxyallyl+Cations&doi=10.1021%2Facs.orglett.7b03719"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of 2-Aminoimidazolones and Imidazolones by (3 + 2) Annulation of Azaoxyallyl Cations</span></div><div class="casAuthors">DiPoto Maria C; Wu Jimmy</div><div class="citationInfo"><span class="NLM_cas:title">Organic letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">499-501</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The first examples of (3 + 2) annulations between azaoxyallyl cations and cyanamides and nitriles to give the corresponding 2-aminoimidazolones and imidazolones are reported.  On the basis of the isolation of unexpected imidate products with certain substrates, it is proposed that the reaction proceeds via fast kinetic O-alkylation followed by rearrangement to the thermodynamically favored 2-aminoimidazolones and imidazolones.  The method was applied to the formal synthesis of the antihypertensive drug irbesartan.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSP0nNOO6781GGmni0r9GoKfW6udTcc2eYz34atycwaX7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MzptlGmtg%253D%253D&md5=c28e260c72ad6637a437feedd17cff55</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Facs.orglett.7b03719&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.orglett.7b03719%26sid%3Dliteratum%253Aachs%26aulast%3DDiPoto%26aufirst%3DM.%2BC.%26aulast%3DWu%26aufirst%3DJ.%26atitle%3DSynthesis%2520of%25202-Aminoimidazolones%2520and%2520Imidazolones%2520by%2520%25283%2520%252B%25202%2529%2520Annulation%2520of%2520Azaoxyallyl%2520Cations%26jtitle%3DOrg.%2520Lett.%26date%3D2018%26volume%3D20%26issue%3D3%26spage%3D499%26epage%3D501%26doi%3D10.1021%2Facs.orglett.7b03719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Satyanarayana, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sumalatha, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhar, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatraman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, P. P.</span></span> <span> </span><span class="NLM_article-title">A New Entry to Antihypertensive Active Pharmaceutical Ingredient, Irbesartan and Its Analogues</span>. <i>Heterocycl. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">328</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1515%2FHC.2006.12.5.323" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1GksLvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=323-328&issue=5&author=B.+Satyanarayanaauthor=Y.+Sumalathaauthor=C.+Sridharauthor=S.+Venkatramanauthor=P.+P.+Reddy&title=A+New+Entry+to+Antihypertensive+Active+Pharmaceutical+Ingredient%2C+Irbesartan+and+Its+Analogues"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">A new entry to antihypertensive active pharmaceutical ingredient, irbesartan and its analogues</span></div><div class="casAuthors">Satyanarayana, Bollikonda; Sumalatha, Yasareni; Sridhar, Chaganti; Venkatraman, Sundaram; Reddy, Padi Pratap</div><div class="citationInfo"><span class="NLM_cas:title">Heterocyclic Communications</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">323-328</span>CODEN:
                <span class="NLM_cas:coden">HCOMEX</span>;
        ISSN:<span class="NLM_cas:issn">0793-0283</span>.
    
            (<span class="NLM_cas:orgname">Freund Publishing House Ltd.</span>)
        </div><div class="casAbstract">A new synthesis of Irbesartan, an antihypertensive active pharmaceutical ingredient and its analogs is reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFvSRsitADuLVg90H21EOLACvtfcHk0lhzWIxBxUXJCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1GksLvE&md5=af6fcf44941bc711f64701859716efb0</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1515%2FHC.2006.12.5.323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1515%252FHC.2006.12.5.323%26sid%3Dliteratum%253Aachs%26aulast%3DSatyanarayana%26aufirst%3DB.%26aulast%3DSumalatha%26aufirst%3DY.%26aulast%3DSridhar%26aufirst%3DC.%26aulast%3DVenkatraman%26aufirst%3DS.%26aulast%3DReddy%26aufirst%3DP.%2BP.%26atitle%3DA%2520New%2520Entry%2520to%2520Antihypertensive%2520Active%2520Pharmaceutical%2520Ingredient%252C%2520Irbesartan%2520and%2520Its%2520Analogues%26jtitle%3DHeterocycl.%2520Commun.%26date%3D2006%26volume%3D12%26issue%3D5%26spage%3D323%26epage%3D328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ye, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sargent, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yohannes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span> <span> </span><span class="NLM_article-title">Novel and Expeditious Microwave-Assisted Three-Component Reactions for the Synthesis of Spiroimidazolin-4-Ones</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>71</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">3137</span>– <span class="NLM_lpage">3140</span>, <span class="refDoi"> DOI: 10.1021/jo060228q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo060228q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BD28Xis1Ogu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2006&pages=3137-3140&issue=8&author=P.+Yeauthor=K.+Sargentauthor=E.+Stewartauthor=J.-F.+Liuauthor=D.+Yohannesauthor=L.+Yu&title=Novel+and+Expeditious+Microwave-Assisted+Three-Component+Reactions+for+the+Synthesis+of+Spiroimidazolin-4-Ones&doi=10.1021%2Fjo060228q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Novel and Expeditious Microwave-Assisted Three-Component Reactions for the Synthesis of Spiroimidazolin-4-ones</span></div><div class="casAuthors">Ye, Ping; Sargent, Katie; Stewart, Ethan; Liu, Ji-Feng; Yohannes, Daniel; Yu, Libing</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3137-3140</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Highly efficient methods for the syntheses of spiroimidazolinones via microwave-assisted three-component one-pot sequential reactions or one-pot domino reactions are described.  E.g., microwave-assisted three-component one-pot sequential reaction of Me 1-amino-1-cyclopentanecarboxylic acid hydrochloride, BuCO2H, and BnNH2 gave 75% spiroimidazolinone I.  The efficiency and utility of the methods have been demonstrated by quickly accessing the antihypertensive drug irbesartan.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-vO4uk69_vLVg90H21EOLACvtfcHk0lhzWIxBxUXJCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xis1Ogu7k%253D&md5=260a8be73322585a0e7f678fdc0d90d1</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fjo060228q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo060228q%26sid%3Dliteratum%253Aachs%26aulast%3DYe%26aufirst%3DP.%26aulast%3DSargent%26aufirst%3DK.%26aulast%3DStewart%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DJ.-F.%26aulast%3DYohannes%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DL.%26atitle%3DNovel%2520and%2520Expeditious%2520Microwave-Assisted%2520Three-Component%2520Reactions%2520for%2520the%2520Synthesis%2520of%2520Spiroimidazolin-4-Ones%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2006%26volume%3D71%26issue%3D8%26spage%3D3137%26epage%3D3140%26doi%3D10.1021%2Fjo060228q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deshpande, P. B.</span>; <span class="NLM_string-name">Luthra, P. K.</span>; <span class="NLM_string-name">Rathod, D. M.</span>; <span class="NLM_string-name">Patel, H. K.</span>; <span class="NLM_string-name">Parikh, P. T.</span></span> <span> </span><span class="NLM_article-title">An Improved Process for Preparation of Irbesartan</span>. <span class="NLM_patent">WO2007049293A1</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=P.+B.+Deshpande&author=P.+K.+Luthra&author=D.+M.+Rathod&author=H.+K.+Patel&author=P.+T.+Parikh&title=An+Improved+Process+for+Preparation+of+Irbesartan"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDeshpande%26aufirst%3DP.%2BB.%26atitle%3DAn%2520Improved%2520Process%2520for%2520Preparation%2520of%2520Irbesartan%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joyashiki, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoshino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinosaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyake, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitamura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawabe, Y.</span></span> <span> </span><span class="NLM_article-title">Identification of an Orally Active Small-Molecule PTHR1 Agonist for the Treatment of Hypoparathyroidism</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">13384</span>, <span class="refDoi"> DOI: 10.1038/ncomms13384</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1038%2Fncomms13384" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=27857062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjtVCmsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=13384&author=T.+Tamuraauthor=H.+Nodaauthor=E.+Joyashikiauthor=M.+Hoshinoauthor=T.+Watanabeauthor=M.+Kinosakiauthor=Y.+Nishimuraauthor=T.+Esakiauthor=K.+Ogawaauthor=T.+Miyakeauthor=S.+Araiauthor=M.+Shimizuauthor=H.+Kitamuraauthor=H.+Satoauthor=Y.+Kawabe&title=Identification+of+an+Orally+Active+Small-Molecule+PTHR1+Agonist+for+the+Treatment+of+Hypoparathyroidism&doi=10.1038%2Fncomms13384"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of an orally active small-molecule PTHR1 agonist for the treatment of hypoparathyroidism</span></div><div class="casAuthors">Tamura, Tatsuya; Noda, Hiroshi; Joyashiki, Eri; Hoshino, Maiko; Watanabe, Tomoyuki; Kinosaki, Masahiko; Nishimura, Yoshikazu; Esaki, Tohru; Ogawa, Kotaro; Miyake, Taiji; Arai, Shinichi; Shimizu, Masaru; Kitamura, Hidetomo; Sato, Haruhiko; Kawabe, Yoshiki</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">13384</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Parathyroid hormone (PTH) is essential for calcium homeostasis and its action is mediated by the PTH type 1 receptor (PTHR1), a class B G-protein-coupled receptor.  Hypoparathyroidism and osteoporosis can be treated with PTH injections; however, no orally effective PTH analog is available.  Here we show that PCO371 is a novel, orally active small mol. that acts as a full agonist of PTHR1.  PCO371 does not affect the PTH type 2 receptor (PTHR2), and anal. using PTHR1-PTHR2 chimeric receptors indicated that Proline 415 of PTHR1 is crit. for PCO371-mediated PTHR1 activation.  Oral administration of PCO371 to osteopenic rats provokes a significant increase in bone turnover with limited increase in bone mass.  In hypocalcemic rats, PCO371 restores serum calcium levels without increasing urinary calcium, and with stronger and longer-lasting effects than PTH injections.  These results strongly suggest that PCO371 can provide a new treatment option for PTH-related disorders, including hypoparathyroidism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnV-D_JlrJgLVg90H21EOLACvtfcHk0lj1jpFMgSvvfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjtVCmsrs%253D&md5=99fb78e7bbc692aafb60e3d4718a5f0c</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fncomms13384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms13384%26sid%3Dliteratum%253Aachs%26aulast%3DTamura%26aufirst%3DT.%26aulast%3DNoda%26aufirst%3DH.%26aulast%3DJoyashiki%26aufirst%3DE.%26aulast%3DHoshino%26aufirst%3DM.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DKinosaki%26aufirst%3DM.%26aulast%3DNishimura%26aufirst%3DY.%26aulast%3DEsaki%26aufirst%3DT.%26aulast%3DOgawa%26aufirst%3DK.%26aulast%3DMiyake%26aufirst%3DT.%26aulast%3DArai%26aufirst%3DS.%26aulast%3DShimizu%26aufirst%3DM.%26aulast%3DKitamura%26aufirst%3DH.%26aulast%3DSato%26aufirst%3DH.%26aulast%3DKawabe%26aufirst%3DY.%26atitle%3DIdentification%2520of%2520an%2520Orally%2520Active%2520Small-Molecule%2520PTHR1%2520Agonist%2520for%2520the%2520Treatment%2520of%2520Hypoparathyroidism%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D13384%26doi%3D10.1038%2Fncomms13384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gundlach, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Largent, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, S. H.</span></span> <span> </span><span class="NLM_article-title">125I-Spiperone: A Novel Ligand for D2 Dopamine Receptors</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">1981</span>– <span class="NLM_lpage">1988</span>, <span class="refDoi"> DOI: 10.1016/0024-3205(84)90479-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2F0024-3205%2884%2990479-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=6149442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADyaL2cXmt1ehurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1984&pages=1981-1988&issue=19&author=A.+L.+Gundlachauthor=B.+L.+Largentauthor=S.+H.+Snyder&title=125I-Spiperone%3A+A+Novel+Ligand+for+D2+Dopamine+Receptors&doi=10.1016%2F0024-3205%2884%2990479-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">125I-Spiperone:  a novel ligand for D2 dopamine receptors</span></div><div class="casAuthors">Gundlach, Andrew L.; Largent, Brian L.; Snyder, Solomon H.</div><div class="citationInfo"><span class="NLM_cas:title">Life Sciences</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1981-8</span>CODEN:
                <span class="NLM_cas:coden">LIFSAK</span>;
        ISSN:<span class="NLM_cas:issn">0024-3205</span>.
    </div><div class="casAbstract">125I-labeled 4-iodospiperone (I)  [85562-22-7] binds with high affinity (equil. dissocn. const. = 0.3 nM) to a single specific site (binding site capacity = 34 pmol/g wet wt.) in homogenates of rat corpus striatum.  Specific binding is ∼40-60% of total binding and is displaced stereospecifically by butaclamol and clopenthixol.  Neuroleptic drugs of various classes are potent inhibitors of [125I]I binding (inhibitory const. (Ki) = 1-10 nM).  Selective dopamine antagonists such as sulpiride (Ki 50 nM) and dopamine agonists such as apomorphine (Ki 200 nM) are also potent inhibitors.  The drug specificity of [125I]I binding correlates well with that of [3H]spiperone binding, indicating that [125I]I labels D2 dopamine receptors in striatal membranes.  [125I]I, with its high specific activity (2200 Ci/mmol), may be a useful ligand in studies examg. D2 dopamine receptors in sol. prepns. and by autoradiog.  Iodinated spiperone may also be useful in radioreceptor assays of neuroleptic drug levels and, in a 123I-labeled form, for imaging of dopamine receptors in vivo using single photon tomog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpymr04vuJKyLVg90H21EOLACvtfcHk0lj1jpFMgSvvfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXmt1ehurs%253D&md5=d680d3c43111a697c3fec5c02c45709a</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2F0024-3205%2884%2990479-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0024-3205%252884%252990479-X%26sid%3Dliteratum%253Aachs%26aulast%3DGundlach%26aufirst%3DA.%2BL.%26aulast%3DLargent%26aufirst%3DB.%2BL.%26aulast%3DSnyder%26aufirst%3DS.%2BH.%26atitle%3D125I-Spiperone%253A%2520A%2520Novel%2520Ligand%2520for%2520D2%2520Dopamine%2520Receptors%26jtitle%3DLife%2520Sci.%26date%3D1984%26volume%3D35%26issue%3D19%26spage%3D1981%26epage%3D1988%26doi%3D10.1016%2F0024-3205%2884%2990479-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niemegeers, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schellekens, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenaerts, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verbruggen, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Nueten, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsboom, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hérin, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaper, W. K.</span></span> <span> </span><span class="NLM_article-title">The Pharmacology of Fluspirilene (R 6218), a Potent, Long-Acting and Injectable Neuroleptic Drug</span>. <i>Arzneimittelforschung</i> <span class="NLM_year" style="font-weight: bold;">1970</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1689</span>– <span class="NLM_lpage">1698</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=4992598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A280%3ADyaE3M%252Fns1yrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1970&pages=1689-1698&issue=11&author=P.+A.+Janssenauthor=C.+J.+Niemegeersauthor=K.+H.+Schellekensauthor=F.+M.+Lenaertsauthor=F.+J.+Verbruggenauthor=J.+M.+van+Nuetenauthor=R.+H.+Marsboomauthor=V.+V.+H%C3%A9rinauthor=W.+K.+Schaper&title=The+Pharmacology+of+Fluspirilene+%28R+6218%29%2C+a+Potent%2C+Long-Acting+and+Injectable+Neuroleptic+Drug"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">The pharmacology of fluspirilene (R 6218), a potent, long-acting and injectable neuroleptic drug</span></div><div class="casAuthors">Janssen P A; Niemegeers C J; Schellekens K H; Lenaerts F M; Verbruggen F J; van Nueten J M; Marsboom R H; Herin V V; Schaper W K</div><div class="citationInfo"><span class="NLM_cas:title">Arzneimittel-Forschung</span>
        (<span class="NLM_cas:date">1970</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1689-98</span>
        ISSN:<span class="NLM_cas:issn">0004-4172</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQkNaa24B2a8hjv2lLSLOxFfW6udTcc2eYQ9qxI5xGU9bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE3M%252Fns1yrtg%253D%253D&md5=3c0013ffb85571124c2e2e15d2bf1934</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJanssen%26aufirst%3DP.%2BA.%26aulast%3DNiemegeers%26aufirst%3DC.%2BJ.%26aulast%3DSchellekens%26aufirst%3DK.%2BH.%26aulast%3DLenaerts%26aufirst%3DF.%2BM.%26aulast%3DVerbruggen%26aufirst%3DF.%2BJ.%26aulast%3Dvan%2BNueten%26aufirst%3DJ.%2BM.%26aulast%3DMarsboom%26aufirst%3DR.%2BH.%26aulast%3DH%25C3%25A9rin%26aufirst%3DV.%2BV.%26aulast%3DSchaper%26aufirst%3DW.%2BK.%26atitle%3DThe%2520Pharmacology%2520of%2520Fluspirilene%2520%2528R%25206218%2529%252C%2520a%2520Potent%252C%2520Long-Acting%2520and%2520Injectable%2520Neuroleptic%2520Drug%26jtitle%3DArzneimittelforschung%26date%3D1970%26volume%3D20%26issue%3D11%26spage%3D1689%26epage%3D1698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morciano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedriali, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aquila, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Missiroli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fantinati, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caroccia, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacifico, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonora, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talarico, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morganti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieckowski, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giorgi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trapella, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinton, P.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel 1,3,8-Triazaspiro[4.5]Decane Derivatives That Target the c Subunit of F1/FO-Adenosine Triphosphate (ATP) Synthase for the Treatment of Reperfusion Damage in Myocardial Infarction</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">7131</span>– <span class="NLM_lpage">7143</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00278</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00278" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVSrsbzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7131-7143&issue=16&author=G.+Morcianoauthor=D.+Pretiauthor=G.+Pedrialiauthor=G.+Aquilaauthor=S.+Missiroliauthor=A.+Fantinatiauthor=N.+Carocciaauthor=S.+Pacificoauthor=M.+Bonoraauthor=A.+Talaricoauthor=C.+Morgantiauthor=P.+Rizzoauthor=R.+Ferrariauthor=M.+R.+Wieckowskiauthor=G.+Campoauthor=C.+Giorgiauthor=C.+Trapellaauthor=P.+Pinton&title=Discovery+of+Novel+1%2C3%2C8-Triazaspiro%5B4.5%5DDecane+Derivatives+That+Target+the+c+Subunit+of+F1%2FFO-Adenosine+Triphosphate+%28ATP%29+Synthase+for+the+Treatment+of+Reperfusion+Damage+in+Myocardial+Infarction&doi=10.1021%2Facs.jmedchem.8b00278"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel 1,3,8-Triazaspiro[4.5]decane Derivatives That Target the c Subunit of F1/FO-Adenosine Triphosphate (ATP) Synthase for the Treatment of Reperfusion Damage in Myocardial Infarction</span></div><div class="casAuthors">Morciano, Giampaolo; Preti, Delia; Pedriali, Gaia; Aquila, Giorgio; Missiroli, Sonia; Fantinati, Anna; Caroccia, Natascia; Pacifico, Salvatore; Bonora, Massimo; Talarico, Anna; Morganti, Claudia; Rizzo, Paola; Ferrari, Roberto; Wieckowski, Mariusz R.; Campo, Gianluca; Giorgi, Carlotta; Trapella, Claudio; Pinton, Paolo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7131-7143</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Recent cardiol. research studies have reported the role, function, and structure of the mitochondrial permeability transition pore (mPTP) and have shown that its opening plays a key role in the progression of myocardial cell death secondary to reperfusion.  In this manuscript, we validated a new pharmacol. approach as an adjunct to reperfusion in myocardial infarction (MI) treatment and describe the discovery, optimization, and structure-activity relationship (SAR) studies of the first small-mol. mPTP opening inhibitors based on a 1,3,8-triazaspiro[4.5]decane scaffold that targets the c subunit of the F1/FO-ATP synthase complex.  We identified three potential compds. with good mPTP inhibitory activity and beneficial effects in a model of MI, including a decreased apoptotic rate in the whole heart and overall improvement of cardiac function upon administration during reperfusion.  The selected compds. did not show off-target effects at the cellular and mitochondrial levels.  Moreover, the compds. preserved the mitochondrial ATP content despite interacting with the ATP synthase complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3Sy5k_30UJbVg90H21EOLACvtfcHk0lh58uV2zIcOcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVSrsbzJ&md5=03c973541392b13f41a2c0d65ac6c61a</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00278&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00278%26sid%3Dliteratum%253Aachs%26aulast%3DMorciano%26aufirst%3DG.%26aulast%3DPreti%26aufirst%3DD.%26aulast%3DPedriali%26aufirst%3DG.%26aulast%3DAquila%26aufirst%3DG.%26aulast%3DMissiroli%26aufirst%3DS.%26aulast%3DFantinati%26aufirst%3DA.%26aulast%3DCaroccia%26aufirst%3DN.%26aulast%3DPacifico%26aufirst%3DS.%26aulast%3DBonora%26aufirst%3DM.%26aulast%3DTalarico%26aufirst%3DA.%26aulast%3DMorganti%26aufirst%3DC.%26aulast%3DRizzo%26aufirst%3DP.%26aulast%3DFerrari%26aufirst%3DR.%26aulast%3DWieckowski%26aufirst%3DM.%2BR.%26aulast%3DCampo%26aufirst%3DG.%26aulast%3DGiorgi%26aufirst%3DC.%26aulast%3DTrapella%26aufirst%3DC.%26aulast%3DPinton%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520Novel%25201%252C3%252C8-Triazaspiro%255B4.5%255DDecane%2520Derivatives%2520That%2520Target%2520the%2520c%2520Subunit%2520of%2520F1%252FFO-Adenosine%2520Triphosphate%2520%2528ATP%2529%2520Synthase%2520for%2520the%2520Treatment%2520of%2520Reperfusion%2520Damage%2520in%2520Myocardial%2520Infarction%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D16%26spage%3D7131%26epage%3D7143%26doi%3D10.1021%2Facs.jmedchem.8b00278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, X.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Biological Evaluation of 2-Arylaminopyrimidine Derivatives Bearing 1,3,8-Triazaspiro[4,5]Decan-4-One or Piperidine-3-Carboxamide Moiety as Novel Type-I1/2 ALK Inhibitors</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">103456</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2019.103456</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2Fj.bioorg.2019.103456" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=31787343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit12ktr3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2020&pages=103456&author=X.+Miaoauthor=L.+Xingauthor=M.+Guoauthor=H.+Zhangauthor=S.+Liuauthor=S.+Yinauthor=P.+Gongauthor=D.+Zhangauthor=X.+Zhai&title=Design%2C+Synthesis+and+Biological+Evaluation+of+2-Arylaminopyrimidine+Derivatives+Bearing+1%2C3%2C8-Triazaspiro%5B4%2C5%5DDecan-4-One+or+Piperidine-3-Carboxamide+Moiety+as+Novel+Type-I1%2F2+ALK+Inhibitors&doi=10.1016%2Fj.bioorg.2019.103456"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of 2-arylaminopyrimidine derivatives bearing 1,3,8-triazaspiro[4,5]decan-4-one or piperidine-3-carboxamide moiety as novel Type-I1/2 ALK inhibitors</span></div><div class="casAuthors">Miao, Xiuqi; Xing, Lingyun; Guo, Ming; Zhang, Hong; Liu, Sicong; Yin, Shiliang; Gong, Ping; Zhang, Dajun; Zhai, Xin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">103456</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Aiming to develop novel Type-I1/2 inhibitors of ALK to overcome extensive resistance mutations, esp. the L1196M mutation surrounding the ATP pocket, two series of 2-arylaminopyrimidine derivs. (I (R1 = pyrrolidin-1-yl, piperidin-1-yl, 4-methylpiperazin-1-yl, 4-(2-hydroxyethyl)piperazin-1-yl), II (R2 = 4-methylpiperazin-1-yl, 4-(2-hydroxyethyl)piperazin-1-yl) and III (R3 = ethoxycarbonylmethylamino, 2-(piperidin-1-yl)acetamido, 2-(4-methylpiperazin-1-yl)acetamido, etc.), IV (R4 = allyl, cyclopropanecarbonyl, 2-carboxyethyl, etc.)) were designed based on scaffold hopping.  The extensive structural elaboration discovered compd. IV ((A), R4 = 3-ethoxy-3-oxopropyl) which possessed excellent IC50 values of 0.06 and 0.23μM against ALK-pos. Karpas299 and H2228 cell lines, resp.  Meanwhile, (A) displayed encouraging inhibitory potency in the ALKWT (2.5 nM) and ALKL1196M (6.5 nM) enzymic assays.  Furthermore, the AO/EB and Hoechst 33258 assays illustrated that (A) could induce cell apoptosis in a dose-dependent manner.  Eventually, the mol. docking of (A) with ALK clearly presented the vital interactions within the active site, which was in accordance with Type-I1/2 inhibitor binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7Mhke0Lt_N7Vg90H21EOLACvtfcHk0lgAaH-EQb55WA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit12ktr3M&md5=07590ede380018be938f43168c281e7a</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2019.103456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2019.103456%26sid%3Dliteratum%253Aachs%26aulast%3DMiao%26aufirst%3DX.%26aulast%3DXing%26aufirst%3DL.%26aulast%3DGuo%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DYin%26aufirst%3DS.%26aulast%3DGong%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DZhai%26aufirst%3DX.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Biological%2520Evaluation%2520of%25202-Arylaminopyrimidine%2520Derivatives%2520Bearing%25201%252C3%252C8-Triazaspiro%255B4%252C5%255DDecan-4-One%2520or%2520Piperidine-3-Carboxamide%2520Moiety%2520as%2520Novel%2520Type-I1%252F2%2520ALK%2520Inhibitors%26jtitle%3DBioorg.%2520Chem.%26date%3D2020%26volume%3D94%26spage%3D103456%26doi%3D10.1016%2Fj.bioorg.2019.103456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kador, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinoshita, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpless, N. E.</span></span> <span> </span><span class="NLM_article-title">Aldose Reductase Inhibitors: A Potential New Class of Agents for the Pharmacological Control of Certain Diabetic Complications</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">841</span>– <span class="NLM_lpage">849</span>, <span class="refDoi"> DOI: 10.1021/jm00145a001</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00145a001" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADyaL2MXktVSjsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=1985&pages=841-849&issue=7&author=P.+F.+Kadorauthor=J.+H.+Kinoshitaauthor=N.+E.+Sharpless&title=Aldose+Reductase+Inhibitors%3A+A+Potential+New+Class+of+Agents+for+the+Pharmacological+Control+of+Certain+Diabetic+Complications&doi=10.1021%2Fjm00145a001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Aldose reductase inhibitors:  a potential new class of agents for the pharmacological control of certain diabetic complications</span></div><div class="casAuthors">Kador, Peter F.; Kinoshita, Jin H.; Sharpless, Norman E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">841-9</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">A review with 94 refs.  The polyol concept and the role of aldose reductase (I)  [9028-31-3] in the pathogenesis of diabetic complications such as cataract, keropathy, microangiopathy, neuropathy and nephropathy, the biol. evaluation of I inhibitors, their common mol. features, and a proposed inhibitor site model is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNtvBgXC-_KbVg90H21EOLACvtfcHk0lgAaH-EQb55WA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXktVSjsrs%253D&md5=bc09417a4dda641e144b290bb845cfe5</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fjm00145a001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00145a001%26sid%3Dliteratum%253Aachs%26aulast%3DKador%26aufirst%3DP.%2BF.%26aulast%3DKinoshita%26aufirst%3DJ.%2BH.%26aulast%3DSharpless%26aufirst%3DN.%2BE.%26atitle%3DAldose%2520Reductase%2520Inhibitors%253A%2520A%2520Potential%2520New%2520Class%2520of%2520Agents%2520for%2520the%2520Pharmacological%2520Control%2520of%2520Certain%2520Diabetic%2520Complications%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1985%26volume%3D28%26issue%3D7%26spage%3D841%26epage%3D849%26doi%3D10.1021%2Fjm00145a001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearlstein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kador, P. F.</span></span> <span> </span><span class="NLM_article-title">Molecular Modeling Studies of Aldose Reductase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">787</span>– <span class="NLM_lpage">792</span>, <span class="refDoi"> DOI: 10.1021/jm00032a011</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00032a011" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADyaK2cXivV2ns7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1994&pages=787-792&issue=6&author=Y.+S.+Leeauthor=R.+Pearlsteinauthor=P.+F.+Kador&title=Molecular+Modeling+Studies+of+Aldose+Reductase+Inhibitors&doi=10.1021%2Fjm00032a011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Modeling Studies of Aldose Reductase Inhibitors</span></div><div class="casAuthors">Lee, Yong S.; Pearlstein, Robert; Kador, Peter F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">787-92</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">Mol. modeling studies using the AM1 quantum chem. method and a torsional fitting method have been conducted on a series of aldose reductase inhibitors (ARIs) possessing an ionizable group and/or functional group susceptible to nucleophilic attack with the aim of defining the spatial position of ARI pharmacophores.  AM1 quantum chem. calcns. were conducted on ARIs possessing only an ionizable group to obtain their optimized geometries.  These optimized structures were then superimposed on the model compd. spirofluorene-9,5'-imidazolidine-2',4'-dione.  This superposition study suggests that a neg. charge center residing in the vicinity of the 2'-oxygen of the imidazolidine-2',4'-dione ring participates in the binding interactions.  In addn., the optimized geometries of ARIs possessing both an ionizable group and an electroneg. functional group were superimposed on spirofluorene-9,5'-imidazolidine-2',4'-dione.  The latter results also suggest the presence of a region where nucleophilic substitution can occur.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrt99a3kLI4vLVg90H21EOLACvtfcHk0lgAaH-EQb55WA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXivV2ns7k%253D&md5=84977b327dd1c8d656b149df996bd389</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Fjm00032a011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00032a011%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DY.%2BS.%26aulast%3DPearlstein%26aufirst%3DR.%26aulast%3DKador%26aufirst%3DP.%2BF.%26atitle%3DMolecular%2520Modeling%2520Studies%2520of%2520Aldose%2520Reductase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1994%26volume%3D37%26issue%3D6%26spage%3D787%26epage%3D792%26doi%3D10.1021%2Fjm00032a011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naylor, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgins, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varty, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lachowicz, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, E. M.</span></span> <span> </span><span class="NLM_article-title">Rolapitant (SCH 619734): A Potent, Selective and Orally Active Neurokinin NK1 Receptor Antagonist with Centrally-Mediated Antiemetic Effects in Ferrets</span>. <i>Pharmacol., Biochem. Behav.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>102</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">100</span>, <span class="refDoi"> DOI: 10.1016/j.pbb.2012.03.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2Fj.pbb.2012.03.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=22497992" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC38XntFagu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2012&pages=95-100&issue=1&author=R.+A.+Duffyauthor=C.+Morganauthor=R.+Naylorauthor=G.+A.+Higginsauthor=G.+B.+Vartyauthor=J.+E.+Lachowiczauthor=E.+M.+Parker&title=Rolapitant+%28SCH+619734%29%3A+A+Potent%2C+Selective+and+Orally+Active+Neurokinin+NK1+Receptor+Antagonist+with+Centrally-Mediated+Antiemetic+Effects+in+Ferrets&doi=10.1016%2Fj.pbb.2012.03.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Rolapitant (SCH 619734): A potent, selective and orally active neurokinin NK1 receptor antagonist with centrally-mediated antiemetic effects in ferrets</span></div><div class="casAuthors">Duffy, Ruth A.; Morgan, Cynthia; Naylor, Robert; Higgins, Guy A.; Varty, Geoffrey B.; Lachowicz, Jean E.; Parker, Eric M.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology, Biochemistry and Behavior</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">95-100</span>CODEN:
                <span class="NLM_cas:coden">PBBHAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-3057</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">NK1 receptor antagonists have been shown to have a variety of physiol. and potential therapeutic effects in animal models and in humans.  The present studies demonstrate that Rolapitant (SCH 619734, (5S)-8(S)-[[1(R)-[3,5 bis(trifluoromethyl)phenyl]ethoxy]methyl]-8-phenyl-1,7-diazaspiro[4,5]decan-2-one) is a selective, bioavailable, CNS penetrant neurokinin NK1 receptor antagonist that shows behavioral effects in animals models of emesis.  In vitro studies indicate that rolapitant has a high affinity for the human NK1 receptor of 0.66 nM and high selectivity over the human NK2 and NK3 subtypes of > 1000-fold, as well as preferential affinity for human, guinea pig, gerbil and monkey NK1 receptors over rat, mouse and rabbit.  Rolapitant is a functionally competitive antagonist, as measured by calcium efflux, with a calcd. Kb of 0.17 nM.  Rolapitant reversed NK1 agonist-induced foot tapping in gerbils following both i.v. and oral administration up to 24 h at a minimal ED (MED) of 0.1 mg/kg.  Rolapitant was active at 0.1 and 1 mg/kg in both acute and delayed emesis models in ferrets, resp., consistent with clin. data for other NK1 antagonists.  Clin. efficacy of anti-emetics is highly correlated with efficacy in the ferret emesis model, suggesting rolapitant is a viable clin. candidate for this indication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeOZ_Iy_LTMLVg90H21EOLACvtfcHk0liz80wMRjDt9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntFagu7w%253D&md5=a2eeef1c15adfb885e89c0c2a5ab4cbe</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.pbb.2012.03.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pbb.2012.03.021%26sid%3Dliteratum%253Aachs%26aulast%3DDuffy%26aufirst%3DR.%2BA.%26aulast%3DMorgan%26aufirst%3DC.%26aulast%3DNaylor%26aufirst%3DR.%26aulast%3DHiggins%26aufirst%3DG.%2BA.%26aulast%3DVarty%26aufirst%3DG.%2BB.%26aulast%3DLachowicz%26aufirst%3DJ.%2BE.%26aulast%3DParker%26aufirst%3DE.%2BM.%26atitle%3DRolapitant%2520%2528SCH%2520619734%2529%253A%2520A%2520Potent%252C%2520Selective%2520and%2520Orally%2520Active%2520Neurokinin%2520NK1%2520Receptor%2520Antagonist%2520with%2520Centrally-Mediated%2520Antiemetic%2520Effects%2520in%2520Ferrets%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D2012%26volume%3D102%26issue%3D1%26spage%3D95%26epage%3D100%26doi%3D10.1016%2Fj.pbb.2012.03.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paliwal, S.</span>; <span class="NLM_string-name">Reichard, G.</span>; <span class="NLM_string-name">Wang, C.</span>; <span class="NLM_string-name">Xiao, D.</span>; <span class="NLM_string-name">Tsui, H.-C.</span>; <span class="NLM_string-name">Shih, N.-Y.</span>; <span class="NLM_string-name">Arredondo, J.</span>; <span class="NLM_string-name">Wrobleski, M.</span>; <span class="NLM_string-name">Palani, A.</span></span> <span> </span><span class="NLM_article-title">NK 1 Antagonists</span>. <span class="NLM_patent">US20030158173A1</span>, <span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=S.+Paliwal&author=G.+Reichard&author=C.+Wang&author=D.+Xiao&author=H.-C.+Tsui&author=N.-Y.+Shih&author=J.+Arredondo&author=M.+Wrobleski&author=A.+Palani&title=NK+1+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPaliwal%26aufirst%3DS.%26atitle%3DNK%25201%2520Antagonists%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mergelsberg, I.</span>; <span class="NLM_string-name">Scherer, D. H.</span>; <span class="NLM_string-name">Huttenloch, M. E.</span>; <span class="NLM_string-name">Tsui, H.-C.</span>; <span class="NLM_string-name">Paliwal, S.</span>; <span class="NLM_string-name">Shih, N.-Y.</span></span> <span> </span><span class="NLM_article-title">Process and Intermediates for the Synthesis of 8-[{1-(3,5-Bis-(Trifluoromethyl)Phenyl)-Ethoxy}-Methyl]-8-Phenyl-1,7-Diaza-Spiro[4.5]Decan-2-One Compounds</span>. <span class="NLM_patent">WO2008118328A2</span>, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=I.+Mergelsberg&author=D.+H.+Scherer&author=M.+E.+Huttenloch&author=H.-C.+Tsui&author=S.+Paliwal&author=N.-Y.+Shih&title=Process+and+Intermediates+for+the+Synthesis+of+8-%5B%7B1-%283%2C5-Bis-%28Trifluoromethyl%29Phenyl%29-Ethoxy%7D-Methyl%5D-8-Phenyl-1%2C7-Diaza-Spiro%5B4.5%5DDecan-2-One+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMergelsberg%26aufirst%3DI.%26atitle%3DProcess%2520and%2520Intermediates%2520for%2520the%2520Synthesis%2520of%25208-%255B%257B1-%25283%252C5-Bis-%2528Trifluoromethyl%2529Phenyl%2529-Ethoxy%257D-Methyl%255D-8-Phenyl-1%252C7-Diaza-Spiro%255B4.5%255DDecan-2-One%2520Compounds%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheeler, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ene, D.</span></span> <span> </span><span class="NLM_article-title">Olefin Metathesis in Drug Discovery and Development—Examples from Recent Patent Literature</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1938</span>– <span class="NLM_lpage">1962</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.7b00319</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.7b00319" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsl2gsrbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2017&pages=1938-1962&issue=12&author=D.+Hughesauthor=P.+Wheelerauthor=D.+Ene&title=Olefin+Metathesis+in+Drug+Discovery+and+Development%E2%80%94Examples+from+Recent+Patent+Literature&doi=10.1021%2Facs.oprd.7b00319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Olefin Metathesis in Drug Discovery and Development-Examples from Recent Patent Literature</span></div><div class="casAuthors">Hughes, David; Wheeler, Philip; Ene, Doina</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1938-1962</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review that summarizes applications of the metathesis reactions in drug discovery and development in the pharmaceutical industry disclosed in the patent literature from Jan. 2016 to August 2017.  The olefin metathesis reaction is finding increasing use in drug discovery and process chem., with a no. of applications now implemented at com. manufg. scale.  Catalyst improvements over the past decade have allowed use of the metathesis reaction with highly functionalized substrates, allowing chemists to access increasingly diverse chem. space, including most notably macrocycles, constrained small ring spirocycles, and fused-ring systems.  For scientists employed in the pharmaceutical industry, the patent literature is the primary avenue for communication of synthetic routes to drug candidates.  While most examples of the metathesis reaction in the patent literature offer only sketchy exptl. details and provide little context on reaction development, the wide scope of substrates within the pharmaceutical patent literature provides a true indication of reaction scope and functional group compatibility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwS-l_9Wgak7Vg90H21EOLACvtfcHk0liz80wMRjDt9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsl2gsrbP&md5=8fcebbc4105e77751d56724d758535ac</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.7b00319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.7b00319%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DD.%26aulast%3DWheeler%26aufirst%3DP.%26aulast%3DEne%26aufirst%3DD.%26atitle%3DOlefin%2520Metathesis%2520in%2520Drug%2520Discovery%2520and%2520Development%25E2%2580%2594Examples%2520from%2520Recent%2520Patent%2520Literature%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2017%26volume%3D21%26issue%3D12%26spage%3D1938%26epage%3D1962%26doi%3D10.1021%2Facs.oprd.7b00319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharpless, N. E.</span>; <span class="NLM_string-name">Strum, J. C.</span>; <span class="NLM_string-name">Bisi, J. E.</span>; <span class="NLM_string-name">Roberts, P. J.</span>; <span class="NLM_string-name">Tavares, F. X.</span></span> <span> </span><span class="NLM_article-title">Highly Active Anti-Neoplastic and Anti-Proliferative Agents</span>. <span class="NLM_patent">WO2014144740A2</span>, September 18, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=N.+E.+Sharpless&author=J.+C.+Strum&author=J.+E.+Bisi&author=P.+J.+Roberts&author=F.+X.+Tavares&title=Highly+Active+Anti-Neoplastic+and+Anti-Proliferative+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSharpless%26aufirst%3DN.%2BE.%26atitle%3DHighly%2520Active%2520Anti-Neoplastic%2520and%2520Anti-Proliferative%2520Agents%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span>; <span class="NLM_string-name">White, H. S.</span>; <span class="NLM_string-name">Tavares, F. X.</span>; <span class="NLM_string-name">Krasutsky, S.</span>; <span class="NLM_string-name">Chen, J.-X.</span>; <span class="NLM_string-name">Dorrow, R. L.</span>; <span class="NLM_string-name">Zhong, H.</span></span> <span> </span><span class="NLM_article-title">Synthesis of N-(Heteroaryl)-Pyrrolo[3,2-d]Pyrimidin-2-Amines</span>. <span class="NLM_patent">WO2018005865A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=A.+Smith&author=H.+S.+White&author=F.+X.+Tavares&author=S.+Krasutsky&author=J.-X.+Chen&author=R.+L.+Dorrow&author=H.+Zhong&title=Synthesis+of+N-%28Heteroaryl%29-Pyrrolo%5B3%2C2-d%5DPyrimidin-2-Amines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DA.%26atitle%3DSynthesis%2520of%2520N-%2528Heteroaryl%2529-Pyrrolo%255B3%252C2-d%255DPyrimidin-2-Amines%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ratni, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers-Evans, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bissantz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grundschober, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuler, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez
Sanchez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnider, P.</span></span> <span> </span><span class="NLM_article-title">Discovery of Highly Selective Brain-Penetrant Vasopressin 1a Antagonists for the Potential Treatment of Autism via a Chemogenomic and Scaffold Hopping Approach</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2275</span>– <span class="NLM_lpage">2289</span>, <span class="refDoi"> DOI: 10.1021/jm501745f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501745f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2MXit1Sgtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2275-2289&issue=5&author=H.+Ratniauthor=M.+Rogers-Evansauthor=C.+Bissantzauthor=C.+Grundschoberauthor=J.-L.+Moreauauthor=F.+Schulerauthor=H.+Fischerauthor=R.+Alvarez%0ASanchezauthor=P.+Schnider&title=Discovery+of+Highly+Selective+Brain-Penetrant+Vasopressin+1a+Antagonists+for+the+Potential+Treatment+of+Autism+via+a+Chemogenomic+and+Scaffold+Hopping+Approach&doi=10.1021%2Fjm501745f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Highly Selective Brain-Penetrant Vasopressin 1a Antagonists for the Potential Treatment of Autism via a Chemogenomic and Scaffold Hopping Approach</span></div><div class="casAuthors">Ratni, Hasane; Rogers-Evans, Mark; Bissantz, Caterina; Grundschober, Christophe; Moreau, Jean-Luc; Schuler, Franz; Fischer, Holger; Alvarez Sanchez, Ruben; Schnider, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2275-2289</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">From a micromolar high throughput screening hit 7, the successful complementary application of a chemogenomic approach and of a scaffold hopping exercise rapidly led to a low single digit nanomolar human vasopressin 1a (hV1a) receptor antagonist 38.  Initial optimization of the mouse V1a activities delivered suitable tool compds. which demonstrated a V1a mediated central in vivo effect.  This novel series was further optimized through parallel synthesis with a focus on balancing lipophilicity to achieve robust aq. soly. while avoiding P-gp mediated efflux.  These efforts led to the discovery of the highly potent and selective brain-penetrant hV1a antagonist RO5028442 (8) suitable for human clin. studies in people with autism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpyc3A24J_GLVg90H21EOLACvtfcHk0ljzobf6xEXF2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXit1Sgtrc%253D&md5=587fbafaf38372123378586ecd87f10a</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Fjm501745f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501745f%26sid%3Dliteratum%253Aachs%26aulast%3DRatni%26aufirst%3DH.%26aulast%3DRogers-Evans%26aufirst%3DM.%26aulast%3DBissantz%26aufirst%3DC.%26aulast%3DGrundschober%26aufirst%3DC.%26aulast%3DMoreau%26aufirst%3DJ.-L.%26aulast%3DSchuler%26aufirst%3DF.%26aulast%3DFischer%26aufirst%3DH.%26aulast%3DAlvarez%2BSanchez%26aufirst%3DR.%26aulast%3DSchnider%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520Highly%2520Selective%2520Brain-Penetrant%2520Vasopressin%25201a%2520Antagonists%2520for%2520the%2520Potential%2520Treatment%2520of%2520Autism%2520via%2520a%2520Chemogenomic%2520and%2520Scaffold%2520Hopping%2520Approach%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D5%26spage%3D2275%26epage%3D2289%26doi%3D10.1021%2Fjm501745f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bissantz, C.</span>; <span class="NLM_string-name">Grundschober, C.</span>; <span class="NLM_string-name">Ratni, H.</span>; <span class="NLM_string-name">Rogers-Evans, M.</span>; <span class="NLM_string-name">Schnider, P.</span></span> <span> </span><span class="NLM_article-title">Indol-3-Carbonyl-Spiro-Piperidine Derivatives as V1a Receptor Antagonists</span>. <span class="NLM_patent">WO2007006688A1</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=C.+Bissantz&author=C.+Grundschober&author=H.+Ratni&author=M.+Rogers-Evans&author=P.+Schnider&title=Indol-3-Carbonyl-Spiro-Piperidine+Derivatives+as+V1a+Receptor+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBissantz%26aufirst%3DC.%26atitle%3DIndol-3-Carbonyl-Spiro-Piperidine%2520Derivatives%2520as%2520V1a%2520Receptor%2520Antagonists%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohtake, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taka, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohmori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeu, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuoka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morikawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of Tofogliflozin, a Novel C-Arylglucoside with an O-Spiroketal Ring System, as a Highly Selective Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">7828</span>– <span class="NLM_lpage">7840</span>, <span class="refDoi"> DOI: 10.1021/jm300884k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300884k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFOrurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7828-7840&issue=17&author=Y.+Ohtakeauthor=T.+Satoauthor=T.+Kobayashiauthor=M.+Nishimotoauthor=N.+Takaauthor=K.+Takanoauthor=K.+Yamamotoauthor=M.+Ohmoriauthor=M.+Yamaguchiauthor=K.+Takamiauthor=S.-Y.+Yeuauthor=K.-H.+Ahnauthor=H.+Matsuokaauthor=K.+Morikawaauthor=M.+Suzukiauthor=H.+Hagitaauthor=K.+Ozawaauthor=K.+Yamaguchiauthor=M.+Katoauthor=S.+Ikeda&title=Discovery+of+Tofogliflozin%2C+a+Novel+C-Arylglucoside+with+an+O-Spiroketal+Ring+System%2C+as+a+Highly+Selective+Sodium+Glucose+Cotransporter+2+%28SGLT2%29+Inhibitor+for+the+Treatment+of+Type+2+Diabetes&doi=10.1021%2Fjm300884k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Tofogliflozin, a Novel C-Arylglucoside with an O-Spiroketal Ring System, as a Highly Selective Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes</span></div><div class="casAuthors">Ohtake, Yoshihito; Sato, Tsutomu; Kobayashi, Takamitsu; Nishimoto, Masahiro; Taka, Naoki; Takano, Koji; Yamamoto, Keisuke; Ohmori, Masayuki; Yamaguchi, Marina; Takami, Kyoko; Yeu, Sang-Yong; Ahn, Koo-Hyeon; Matsuoka, Hiroharu; Morikawa, Kazumi; Suzuki, Masayuki; Hagita, Hitoshi; Ozawa, Kazuharu; Yamaguchi, Koji; Kato, Motohiro; Ikeda, Sachiya</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7828-7840</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of sodium glucose cotransporter 2 (SGLT2) has been proposed as a novel therapeutic approach to treat type 2 diabetes.  In our efforts to discover novel inhibitors of SGLT2, we first generated a 3D pharmacophore model based on the superposition of known inhibitors.  A search of the Cambridge Structural Database using a series of pharmacophore queries led to the discovery of an O-spiroketal C-arylglucoside scaffold.  Subsequent chem. examn. combined with computational modeling resulted in the identification of the clin. candidate CSG452 (tofogliflozin), which is currently under phase III clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeIDNjd6qaWLVg90H21EOLACvtfcHk0ljWDAnoDHBkJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFOrurfN&md5=174a0538c13a286dd320a52395e1dd85</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1021%2Fjm300884k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300884k%26sid%3Dliteratum%253Aachs%26aulast%3DOhtake%26aufirst%3DY.%26aulast%3DSato%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DNishimoto%26aufirst%3DM.%26aulast%3DTaka%26aufirst%3DN.%26aulast%3DTakano%26aufirst%3DK.%26aulast%3DYamamoto%26aufirst%3DK.%26aulast%3DOhmori%26aufirst%3DM.%26aulast%3DYamaguchi%26aufirst%3DM.%26aulast%3DTakami%26aufirst%3DK.%26aulast%3DYeu%26aufirst%3DS.-Y.%26aulast%3DAhn%26aufirst%3DK.-H.%26aulast%3DMatsuoka%26aufirst%3DH.%26aulast%3DMorikawa%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DHagita%26aufirst%3DH.%26aulast%3DOzawa%26aufirst%3DK.%26aulast%3DYamaguchi%26aufirst%3DK.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DIkeda%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520Tofogliflozin%252C%2520a%2520Novel%2520C-Arylglucoside%2520with%2520an%2520O-Spiroketal%2520Ring%2520System%252C%2520as%2520a%2520Highly%2520Selective%2520Sodium%2520Glucose%2520Cotransporter%25202%2520%2528SGLT2%2529%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Type%25202%2520Diabetes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D17%26spage%3D7828%26epage%3D7840%26doi%3D10.1021%2Fjm300884k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Biological Evaluation of Pyridone-Aminal Derivatives as MNK1/2 Inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1211</span>– <span class="NLM_lpage">1225</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2019.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2Fj.bmc.2019.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=30824167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjvFSqt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=1211-1225&issue=7&author=X.+Yuanauthor=H.+Wuauthor=H.+Buauthor=P.+Zhengauthor=J.+Zhouauthor=H.+Zhang&title=Design%2C+Synthesis+and+Biological+Evaluation+of+Pyridone-Aminal+Derivatives+as+MNK1%2F2+Inhibitors&doi=10.1016%2Fj.bmc.2019.02.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of pyridone-aminal derivatives as MNK1/2 inhibitors</span></div><div class="casAuthors">Yuan, Xinrui; Wu, Hanshu; Bu, Hong; Zheng, Peiyuan; Zhou, Jinpei; Zhang, Huibin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1211-1225</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Excessive phosphorylation of eukaryotic translation initiation factor 4E (eIF4E) plays a major role in the dysregulation of mRNA translation and the activation of tumor cell signaling. eIF4E is exclusively phosphorylated by mitogen-activated protein kinase interacting kinases 1 and 2 (MNK1/2) on Ser209.  So, MNK1/2 inhibitors could decrease the level of p-eIF4E and regulate tumor-assocd. signaling pathways.  A series of pyridone-aminal derivs. were synthesized and evaluated as MNK1/2 inhibitors.  Several compds. exhibited great inhibitory activity against MNK1/2 and selected compds. showed moderate to excellent anti-proliferative potency against hematol. cancer cell lines.  In particular, compd. 42i (MNK1 IC50 = 7.0 nM; MNK2 IC50 = 6.1 nM) proved to be the most potent compd. against TMD-8 cell line with IC50 value of 0.91 μM.  Furthermore, 42i could block the phosphorylation level of eIF4E in CT-26 cell line, and 42i inhibited the tumor growth of CT-26 allograft model significantly.  These results indicated that compd. 42i was a promising MNK1/2 inhibitor for the potent treatment of colon cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcZ3pb7Sl3ALVg90H21EOLACvtfcHk0ljWDAnoDHBkJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjvFSqt7o%253D&md5=d7016309d8f865d289f19aa97f50f115</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2019.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2019.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DBu%26aufirst%3DH.%26aulast%3DZheng%26aufirst%3DP.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Biological%2520Evaluation%2520of%2520Pyridone-Aminal%2520Derivatives%2520as%2520MNK1%252F2%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2019%26volume%3D27%26issue%3D7%26spage%3D1211%26epage%3D1225%26doi%3D10.1016%2Fj.bmc.2019.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reich, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprengeler, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appleman, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarine, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goel, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, E. Z. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, I. N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jemison, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jessen, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaghafi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperry, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staunton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stumpf, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webber, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wegerski, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, K. R.</span></span> <span> </span><span class="NLM_article-title">Structure-Based Design of Pyridone-Aminal EFT508 Targeting Dysregulated Translation by Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">3516</span>– <span class="NLM_lpage">3540</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01795</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01795" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktlGhs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=3516-3540&issue=8&author=S.+H.+Reichauthor=P.+A.+Sprengelerauthor=G.+G.+Chiangauthor=J.+R.+Applemanauthor=J.+Chenauthor=J.+Clarineauthor=B.+Eamauthor=J.+T.+Ernstauthor=Q.+Hanauthor=V.+K.+Goelauthor=E.+Z.+R.+Hanauthor=V.+Huangauthor=I.+N.+J.+Hungauthor=A.+Jemisonauthor=K.+A.+Jessenauthor=J.+Molterauthor=D.+Murphyauthor=M.+Nealauthor=G.+S.+Parkerauthor=M.+Shaghafiauthor=S.+Sperryauthor=J.+Stauntonauthor=C.+R.+Stumpfauthor=P.+A.+Thompsonauthor=C.+Tranauthor=S.+E.+Webberauthor=C.+J.+Wegerskiauthor=H.+Zhengauthor=K.+R.+Webster&title=Structure-Based+Design+of+Pyridone-Aminal+EFT508+Targeting+Dysregulated+Translation+by+Selective+Mitogen-Activated+Protein+Kinase+Interacting+Kinases+1+and+2+%28MNK1%2F2%29+Inhibition&doi=10.1021%2Facs.jmedchem.7b01795"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based Design of Pyridone-Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition</span></div><div class="casAuthors">Reich, Siegfried H.; Sprengeler, Paul A.; Chiang, Gary G.; Appleman, James R.; Chen, Joan; Clarine, Jeff; Eam, Boreth; Ernst, Justin T.; Han, Qing; Goel, Vikas K.; Han, Edward Z. R.; Huang, Vera; Hung, Ivy N. J.; Jemison, Adrianna; Jessen, Katti A.; Molter, Jolene; Murphy, Douglas; Neal, Melissa; Parker, Gregory S.; Shaghafi, Michael; Sperry, Samuel; Staunton, Jocelyn; Stumpf, Craig R.; Thompson, Peggy A.; Tran, Chinh; Webber, Stephen E.; Wegerski, Christopher J.; Zheng, Hong; Webster, Kevin R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3516-3540</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dysregulated translation of mRNA plays a major role in tumorigenesis.  Mitogen-activated protein kinase interacting kinases (MNK)1/2 are key regulators of mRNA translation integrating signals from oncogenic and immune signaling pathways through phosphorylation of eIF4E and other mRNA binding proteins.  Modulation of these key effector proteins regulates mRNA, which controls tumor/stromal cell signaling.  Compd. 23 (eFT508, 6'-((6-aminopyrimidin-4-yl)amino)-8'-methyl-2'H-spiro-[cyclohexane-1,3'-imidazo[1,5-a]pyridine]-1',5'-dione hydrochloride), an exquisitely selective, potent dual MNK1/2 inhibitor, was designed to assess the potential for control of oncogene signaling at the level of mRNA translation.  The crystal structure-guided design leverages stereoelectronic interactions unique to MNK culminating in a novel pyridone-aminal structure described for the first time in the kinase literature.  Compd. 23 has potent in vivo antitumor activity in models of diffuse large cell B-cell lymphoma and solid tumors, suggesting that controlling dysregulated translation has real therapeutic potential.  Compd. 23 is currently being evaluated in Phase 2 clin. trials in solid tumors and lymphoma.  Compd. 23 is the first highly selective dual MNK inhibitor targeting dysregulated translation being assessed clin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAp-3GOuZu8bVg90H21EOLACvtfcHk0ljfThThTh6vzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktlGhs7s%253D&md5=1254b674aa7e6d2037a06bc10e64e4da</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01795&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01795%26sid%3Dliteratum%253Aachs%26aulast%3DReich%26aufirst%3DS.%2BH.%26aulast%3DSprengeler%26aufirst%3DP.%2BA.%26aulast%3DChiang%26aufirst%3DG.%2BG.%26aulast%3DAppleman%26aufirst%3DJ.%2BR.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DClarine%26aufirst%3DJ.%26aulast%3DEam%26aufirst%3DB.%26aulast%3DErnst%26aufirst%3DJ.%2BT.%26aulast%3DHan%26aufirst%3DQ.%26aulast%3DGoel%26aufirst%3DV.%2BK.%26aulast%3DHan%26aufirst%3DE.%2BZ.%2BR.%26aulast%3DHuang%26aufirst%3DV.%26aulast%3DHung%26aufirst%3DI.%2BN.%2BJ.%26aulast%3DJemison%26aufirst%3DA.%26aulast%3DJessen%26aufirst%3DK.%2BA.%26aulast%3DMolter%26aufirst%3DJ.%26aulast%3DMurphy%26aufirst%3DD.%26aulast%3DNeal%26aufirst%3DM.%26aulast%3DParker%26aufirst%3DG.%2BS.%26aulast%3DShaghafi%26aufirst%3DM.%26aulast%3DSperry%26aufirst%3DS.%26aulast%3DStaunton%26aufirst%3DJ.%26aulast%3DStumpf%26aufirst%3DC.%2BR.%26aulast%3DThompson%26aufirst%3DP.%2BA.%26aulast%3DTran%26aufirst%3DC.%26aulast%3DWebber%26aufirst%3DS.%2BE.%26aulast%3DWegerski%26aufirst%3DC.%2BJ.%26aulast%3DZheng%26aufirst%3DH.%26aulast%3DWebster%26aufirst%3DK.%2BR.%26atitle%3DStructure-Based%2520Design%2520of%2520Pyridone-Aminal%2520EFT508%2520Targeting%2520Dysregulated%2520Translation%2520by%2520Selective%2520Mitogen-Activated%2520Protein%2520Kinase%2520Interacting%2520Kinases%25201%2520and%25202%2520%2528MNK1%252F2%2529%2520Inhibition%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D8%26spage%3D3516%26epage%3D3540%26doi%3D10.1021%2Facs.jmedchem.7b01795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, C.</span></span> <span> </span><span class="NLM_article-title">Combination of a Bace Inhibitor and an Antibody or Antigen-Binding Fragment for the Treatment of a Disorder Associated with the Accumulation of Amyloid Beta</span>. <span class="NLM_patent">WO2017158064A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=C.+Johnston&title=Combination+of+a+Bace+Inhibitor+and+an+Antibody+or+Antigen-Binding+Fragment+for+the+Treatment+of+a+Disorder+Associated+with+the+Accumulation+of+Amyloid+Beta"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJohnston%26aufirst%3DC.%26atitle%3DCombination%2520of%2520a%2520Bace%2520Inhibitor%2520and%2520an%2520Antibody%2520or%2520Antigen-Binding%2520Fragment%2520for%2520the%2520Treatment%2520of%2520a%2520Disorder%2520Associated%2520with%2520the%2520Accumulation%2520of%2520Amyloid%2520Beta%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Panza, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozupone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watling, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imbimbo, B. P.</span></span> <span> </span><span class="NLM_article-title">Do BACE Inhibitor Failures in Alzheimer Patients Challenge the Amyloid Hypothesis of the Disease?</span>. <i>Expert Rev. Neurother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">599</span>– <span class="NLM_lpage">602</span>, <span class="refDoi"> DOI: 10.1080/14737175.2019.1621751</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1080%2F14737175.2019.1621751" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=31112433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVGhs7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=599-602&issue=7&author=F.+Panzaauthor=M.+Lozuponeauthor=M.+Watlingauthor=B.+P.+Imbimbo&title=Do+BACE+Inhibitor+Failures+in+Alzheimer+Patients+Challenge+the+Amyloid+Hypothesis+of+the+Disease%3F&doi=10.1080%2F14737175.2019.1621751"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Do BACE inhibitor failures in Alzheimer's patients challenge the amyloid hypothesis of the disease?</span></div><div class="casAuthors">Panza, Francesco; Lozupone, Madia; Watling, Mark; Imbimbo, Bruno Pietro</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Neurotherapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">599-602</span>CODEN:
                <span class="NLM_cas:coden">ERNXAR</span>;
        ISSN:<span class="NLM_cas:issn">1473-7175</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMWoN30kZDtbVg90H21EOLACvtfcHk0ljfThThTh6vzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVGhs7fP&md5=7f68c44c61c9f3e720f6b905bc831563</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1080%2F14737175.2019.1621751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14737175.2019.1621751%26sid%3Dliteratum%253Aachs%26aulast%3DPanza%26aufirst%3DF.%26aulast%3DLozupone%26aufirst%3DM.%26aulast%3DWatling%26aufirst%3DM.%26aulast%3DImbimbo%26aufirst%3DB.%2BP.%26atitle%3DDo%2520BACE%2520Inhibitor%2520Failures%2520in%2520Alzheimer%2520Patients%2520Challenge%2520the%2520Amyloid%2520Hypothesis%2520of%2520the%2520Disease%253F%26jtitle%3DExpert%2520Rev.%2520Neurother.%26date%3D2019%26volume%3D19%26issue%3D7%26spage%3D599%26epage%3D602%26doi%3D10.1080%2F14737175.2019.1621751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez Barrat, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodward, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inglesby, P. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis of 2-Oxopropanethioamide for the Manufacture of Lanabecestat: A New Route for Control, Robustness, and Operational Improvements</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1404</span>– <span class="NLM_lpage">1412</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.7b00170</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.7b00170" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFegsL%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2017&pages=1404-1412&issue=9&author=B.+Taylorauthor=C.+Fernandez+Barratauthor=R.+L.+Woodwardauthor=P.+A.+Inglesby&title=Synthesis+of+2-Oxopropanethioamide+for+the+Manufacture+of+Lanabecestat%3A+A+New+Route+for+Control%2C+Robustness%2C+and+Operational+Improvements&doi=10.1021%2Facs.oprd.7b00170"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of 2-Oxopropanethioamide for the Manufacture of Lanabecestat: A New Route for Control, Robustness, and Operational Improvements</span></div><div class="casAuthors">Taylor, Brian; Fernandez Barrat, Cristina; Woodward, Robert L.; Inglesby, Phillip A.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1404-1412</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new route to 2-oxopropanethioamide, a key intermediate in the synthesis of lanabecestat (AZD3293/LY3314814), is described by employing com. available 2,2-diethoxypropionitrile as a raw material.  In contrast to the previous route, this work offers several advantages, for example, the raw material is safer to manuf. and handle, highly toxic hydrogen sulfide gas is no longer required as a reagent and in situ FTIR spectroscopy monitoring has provided manufg. controls and robustness.  Addnl., this route offers a hold- and control-point by virtue of an isolable cryst. intermediate, which in turn provides improved quality that is evident in the downstream synthesis.  An extensive design-of-expt. anal. was undertaken to understand multi-factor interdependencies, build a model, visualize factor relationships, map the process parameter reaction space, identify potential process operating conditions and predict their performance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrILs_CNHAbK7Vg90H21EOLACvtfcHk0lgIl3aTTp64nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFegsL%252FF&md5=096c63a7672af6e2b95d5d1e6228e9b6</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.7b00170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.7b00170%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DB.%26aulast%3DFernandez%2BBarrat%26aufirst%3DC.%26aulast%3DWoodward%26aufirst%3DR.%2BL.%26aulast%3DInglesby%26aufirst%3DP.%2BA.%26atitle%3DSynthesis%2520of%25202-Oxopropanethioamide%2520for%2520the%2520Manufacture%2520of%2520Lanabecestat%253A%2520A%2520New%2520Route%2520for%2520Control%252C%2520Robustness%252C%2520and%2520Operational%2520Improvements%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2017%26volume%3D21%26issue%3D9%26spage%3D1404%26epage%3D1412%26doi%3D10.1021%2Facs.oprd.7b00170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ashworth, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherryman, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crampton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eden-Rump, E. G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKeever-Abbas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meadows, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skilling, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, D. T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodward, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inglesby, P. A.</span></span> <span> </span><span class="NLM_article-title">Process Development of a Suzuki Reaction Used in the Manufacture of Lanabecestat</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1801</span>– <span class="NLM_lpage">1808</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.8b00312</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.8b00312" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFagurvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2018&pages=1801-1808&issue=12&author=I.+W.+Ashworthauthor=A.+D.+Campbellauthor=J.+H.+Cherrymanauthor=J.+Clarkauthor=A.+Cramptonauthor=E.+G.+B.+Eden-Rumpauthor=M.+Evansauthor=M.+F.+Jonesauthor=S.+McKeever-Abbasauthor=R.+E.+Meadowsauthor=K.+Skillingauthor=D.+T.+E.+Whittakerauthor=R.+L.+Woodwardauthor=P.+A.+Inglesby&title=Process+Development+of+a+Suzuki+Reaction+Used+in+the+Manufacture+of+Lanabecestat&doi=10.1021%2Facs.oprd.8b00312"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Process Development of a Suzuki Reaction Used in the Manufacture of Lanabecestat</span></div><div class="casAuthors">Ashworth, Ian W.; Campbell, Andrew D.; Cherryman, Janette H.; Clark, Jemma; Crampton, Alex; Eden-Rump, Edward G. B.; Evans, Matthew; Jones, Martin F.; McKeever-Abbas, Sahar; Meadows, Rebecca E.; Skilling, Kathryn; Whittaker, David T. E.; Woodward, Robert L.; Inglesby, Phillip A.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1801-1808</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A process for prepn. of the potential anti-Alzheimer's agent lanabecestat was developed by coupling of an alkynylpyridinylboronic acid diethanolamine ester with a bromodispirocyclohexaneindaneimidazole in the presence of Pd(AmPhos)2Cl2 and K3PO4 in EtOH/H2O; the new process reduced the need for solvent changes and difficult isolation steps and decreased the amt. of palladium detected in the final product without the use of solid-phase extractants.  The kinetics of hydrolysis of the diethanolamine boronate and the free boronic acid was detd.; diethanolamine generated in the hydrolysis decreased the rate of coupling but likely improved the purge of palladium from the product.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP4yqA1DlbgbVg90H21EOLACvtfcHk0lgIl3aTTp64nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFagurvO&md5=cff322c98ae1cd9d8f8af50db2795b92</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.8b00312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.8b00312%26sid%3Dliteratum%253Aachs%26aulast%3DAshworth%26aufirst%3DI.%2BW.%26aulast%3DCampbell%26aufirst%3DA.%2BD.%26aulast%3DCherryman%26aufirst%3DJ.%2BH.%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DCrampton%26aufirst%3DA.%26aulast%3DEden-Rump%26aufirst%3DE.%2BG.%2BB.%26aulast%3DEvans%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DM.%2BF.%26aulast%3DMcKeever-Abbas%26aufirst%3DS.%26aulast%3DMeadows%26aufirst%3DR.%2BE.%26aulast%3DSkilling%26aufirst%3DK.%26aulast%3DWhittaker%26aufirst%3DD.%2BT.%2BE.%26aulast%3DWoodward%26aufirst%3DR.%2BL.%26aulast%3DInglesby%26aufirst%3DP.%2BA.%26atitle%3DProcess%2520Development%2520of%2520a%2520Suzuki%2520Reaction%2520Used%2520in%2520the%2520Manufacture%2520of%2520Lanabecestat%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2018%26volume%3D22%26issue%3D12%26spage%3D1801%26epage%3D1808%26doi%3D10.1021%2Facs.oprd.8b00312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krasavin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lukin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagnyukova, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhurilo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golovanov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zozulya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahanich, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tikhonova, I. G.</span></span> <span> </span><span class="NLM_article-title">Polar Aromatic Periphery Increases Agonist Potency of Spirocyclic Free Fatty Acid Receptor (GPR40) Agonists Inspired by LY2881835</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">357</span>– <span class="NLM_lpage">368</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.01.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2Fj.ejmech.2017.01.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=28076825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotlCqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2017&pages=357-368&author=M.+Krasavinauthor=A.+Lukinauthor=D.+Bagnyukovaauthor=N.+Zhuriloauthor=A.+Golovanovauthor=S.+Zozulyaauthor=I.+Zahanichauthor=D.+Mooreauthor=I.+G.+Tikhonova&title=Polar+Aromatic+Periphery+Increases+Agonist+Potency+of+Spirocyclic+Free+Fatty+Acid+Receptor+%28GPR40%29+Agonists+Inspired+by+LY2881835&doi=10.1016%2Fj.ejmech.2017.01.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Polar aromatic periphery increases agonist potency of spirocyclic free fatty acid receptor (GPR40) agonists inspired by LY2881835</span></div><div class="casAuthors">Krasavin, Mikhail; Lukin, Alexey; Bagnyukova, Daria; Zhurilo, Nikolay; Golovanov, Aleksei; Zozulya, Sergey; Zahanich, Ihor; Moore, Daniel; Tikhonova, Irina G.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">357-368</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of spirocyclic compds. inspired by Eli Lilly's phase 1 antidiabetic FFA1 receptor agonist LY2881835 was designed to include polar arom. periphery groups and explore a possibility of building addnl. contacts with the target near the agonist binding site.  The frontrunner compd. in the series (9i) was shown to be a potent (EC50 = 260 nM) FFA1 agonist with excellent aq. (PBS) soly. and good Caco-2 permeability.  The obsd. structure-activity relationships were rationalized by a docking study.  The new series significantly expands the ligand landscape for the ongoing quest for new potent and more polar FFA1 agonists as fundamentally new class of therapeutic agents against type 2 diabetes mellitus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr7HOd2sruvrVg90H21EOLACvtfcHk0lgIl3aTTp64nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotlCqsQ%253D%253D&md5=195aceb726cbc5e14186dd135a32ff92</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.01.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.01.005%26sid%3Dliteratum%253Aachs%26aulast%3DKrasavin%26aufirst%3DM.%26aulast%3DLukin%26aufirst%3DA.%26aulast%3DBagnyukova%26aufirst%3DD.%26aulast%3DZhurilo%26aufirst%3DN.%26aulast%3DGolovanov%26aufirst%3DA.%26aulast%3DZozulya%26aufirst%3DS.%26aulast%3DZahanich%26aufirst%3DI.%26aulast%3DMoore%26aufirst%3DD.%26aulast%3DTikhonova%26aufirst%3DI.%2BG.%26atitle%3DPolar%2520Aromatic%2520Periphery%2520Increases%2520Agonist%2520Potency%2520of%2520Spirocyclic%2520Free%2520Fatty%2520Acid%2520Receptor%2520%2528GPR40%2529%2520Agonists%2520Inspired%2520by%2520LY2881835%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D127%26spage%3D357%26epage%3D368%26doi%3D10.1016%2Fj.ejmech.2017.01.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billington, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middlemiss, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, E. H.</span></span> <span> </span><span class="NLM_article-title">Spiropiperidines as High-Affinity, Selective Sigma Ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2033</span>– <span class="NLM_lpage">2039</span>, <span class="refDoi"> DOI: 10.1021/jm00089a013</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00089a013" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADyaK38XisFGntrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1992&pages=2033-2039&issue=11&author=M.+S.+Chambersauthor=R.+Bakerauthor=D.+C.+Billingtonauthor=A.+K.+Knightauthor=D.+N.+Middlemissauthor=E.+H.+Wong&title=Spiropiperidines+as+High-Affinity%2C+Selective+Sigma+Ligands&doi=10.1021%2Fjm00089a013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Spiropiperidines as high-affinity, selective σ ligands.</span></div><div class="casAuthors">Chambers, Mark S.; Baker, Raymond; Billington, David C.; Knight, Anthony K.; Middlemiss, D. N.; Wong, Eric H. F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2033-9</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">A variety of achiral conformationally restricted spirocyclic piperidines were prepd. in an attempt to investigate the functional role of the central σ recognition site.  All compds. possessed a lipophilic N-substituent incorporating either a tetralin (I; n = 2, R = PhCH2, Bu, hexyl, 2-picolyl, cyclohexylmethyl, CH2CH:CH2, 2-furylmethyl, 2-thienylmethyl, CH2CH:CMe2, etc.), indan (I; n = 1, R = PhCH2, PhCH2CH2, CH2CH:CMe2, Bu, etc.), or benzocycloheptane skeleton (I; n = 3, R = PhCH2, Bu).  Their in vitro affinity at the σ site was assessed in radioligand displacement expts. with guinea pig cerebellum homogenates using the σ-specific radioligand N,N-di-o-[5-3H]-tolylguanidine (II).  A study of the structure-activity relationships identified the N-Bu and N-dimethylallyl substituents as the optimum groups for high affinity and selectivity at the σ site, e.g., I (n = 1, R = CH2CH:CMe2), pIC50 = 8.9 vs II and >10,000-fold selective over the dopamine D2 receptor.  Such compds. are amongst the highest affinity σ ligands reported to date, with excellent selectivity over the dopamine D2 receptor, and may serve as a useful tool for exploring the physiol. role of the σ site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr90qP5qz7Mm7Vg90H21EOLACvtfcHk0ljKRJbhc_s9aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XisFGntrg%253D&md5=1d61ff31c46c1c2febdfccd3673799da</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1021%2Fjm00089a013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00089a013%26sid%3Dliteratum%253Aachs%26aulast%3DChambers%26aufirst%3DM.%2BS.%26aulast%3DBaker%26aufirst%3DR.%26aulast%3DBillington%26aufirst%3DD.%2BC.%26aulast%3DKnight%26aufirst%3DA.%2BK.%26aulast%3DMiddlemiss%26aufirst%3DD.%2BN.%26aulast%3DWong%26aufirst%3DE.%2BH.%26atitle%3DSpiropiperidines%2520as%2520High-Affinity%252C%2520Selective%2520Sigma%2520Ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1992%26volume%3D35%26issue%3D11%26spage%3D2033%26epage%3D2039%26doi%3D10.1021%2Fjm00089a013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamdouchi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahl, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel
Lewis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardona, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zink, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eessalu, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ficorilli, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcelo, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otto, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilbur, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lineswala, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piper, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coffey, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweetana, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratt, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belin, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deeg, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cannady, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yumibe, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maiti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montrose-Rafizadeh, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reifel Miller, A.</span></span> <span> </span><span class="NLM_article-title">The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">10891</span>– <span class="NLM_lpage">10916</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00892</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00892" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1yks7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=10891-10916&issue=24&author=C.+Hamdouchiauthor=S.+D.+Kahlauthor=A.+Patel%0ALewisauthor=G.+R.+Cardonaauthor=R.+W.+Zinkauthor=K.+Chenauthor=T.+E.+Eessaluauthor=J.+V.+Ficorilliauthor=M.+C.+Marceloauthor=K.+A.+Ottoauthor=K.+L.+Wilburauthor=J.+P.+Lineswalaauthor=J.+L.+Piperauthor=D.+S.+Coffeyauthor=S.+A.+Sweetanaauthor=J.+V.+Haasauthor=D.+A.+Brooksauthor=E.+J.+Prattauthor=R.+M.+Belinauthor=M.+A.+Deegauthor=X.+Maauthor=E.+A.+Cannadyauthor=J.+T.+Johnsonauthor=N.+P.+Yumibeauthor=Q.+Chenauthor=P.+Maitiauthor=C.+Montrose-Rafizadehauthor=Y.+Chenauthor=A.+Reifel+Miller&title=The+Discovery%2C+Preclinical%2C+and+Early+Clinical+Development+of+Potent+and+Selective+GPR40+Agonists+for+the+Treatment+of+Type+2+Diabetes+Mellitus+%28LY2881835%2C+LY2922083%2C+and+LY2922470%29&doi=10.1021%2Facs.jmedchem.6b00892"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)</span></div><div class="casAuthors">Hamdouchi, Chafiq; Kahl, Steven D.; Patel Lewis, Anjana; Cardona, Guemalli R.; Zink, Richard W.; Chen, Keyue; Eessalu, Thomas E.; Ficorilli, James V.; Marcelo, Marialuisa C.; Otto, Keith A.; Wilbur, Kelly L.; Lineswala, Jayana P.; Piper, Jared L.; Coffey, D. Scott; Sweetana, Stephanie A.; Haas, Joseph V.; Brooks, Dawn A.; Pratt, Edward J.; Belin, Ruth M.; Deeg, Mark A.; Ma, Xiaosu; Cannady, Ellen A.; Johnson, Jason T.; Yumibe, Nathan P.; Chen, Qi; Maiti, Pranab; Montrose-Rafizadeh, Chahrzad; Chen, Yanyun; Reifel Miller, Anne</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10891-10916</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The G protein-coupled receptor 40 (GPR40) also known as Free Fatty Acid Receptor 1 (FFAR1) is highly expressed in pancreatic, islet β-cells and responds to endogenous fatty acids resulting in amplification of insulin secretion only in the presence of elevated glucose levels.  Hypothesis driven structural modifications to endogenous FFAs, focused on breaking planarity and reducing lipophilicity, led to the identification of spiropiperidine and tetrahydroquinoline acid derivs. as GPR40 agonists with unique pharmacol., selectivity and pharmacokinetic properties.  Compds. 1 (LY2881835), 2 (LY2922083) and 3 (LY2922470) demonstrated potent, efficacious and durable dose dependent redns. in glucose levels along with significant increases in insulin and GLP-1 secretion during preclin. testing.  A clin. study with 3 administered to subjects with T2DM provided proof of concept of 3 as a potential glucose-lowering therapy.  This manuscript summarizes the scientific rationale, medicinal chem., preclin. and early development data of this new class of GPR40 agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJDHJpZ9o4lLVg90H21EOLACvtfcHk0ljKRJbhc_s9aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1yks7zF&md5=9e36cc1791d7e7e0e54aa725fe3e0cc3</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00892&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00892%26sid%3Dliteratum%253Aachs%26aulast%3DHamdouchi%26aufirst%3DC.%26aulast%3DKahl%26aufirst%3DS.%2BD.%26aulast%3DPatel%2BLewis%26aufirst%3DA.%26aulast%3DCardona%26aufirst%3DG.%2BR.%26aulast%3DZink%26aufirst%3DR.%2BW.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DEessalu%26aufirst%3DT.%2BE.%26aulast%3DFicorilli%26aufirst%3DJ.%2BV.%26aulast%3DMarcelo%26aufirst%3DM.%2BC.%26aulast%3DOtto%26aufirst%3DK.%2BA.%26aulast%3DWilbur%26aufirst%3DK.%2BL.%26aulast%3DLineswala%26aufirst%3DJ.%2BP.%26aulast%3DPiper%26aufirst%3DJ.%2BL.%26aulast%3DCoffey%26aufirst%3DD.%2BS.%26aulast%3DSweetana%26aufirst%3DS.%2BA.%26aulast%3DHaas%26aufirst%3DJ.%2BV.%26aulast%3DBrooks%26aufirst%3DD.%2BA.%26aulast%3DPratt%26aufirst%3DE.%2BJ.%26aulast%3DBelin%26aufirst%3DR.%2BM.%26aulast%3DDeeg%26aufirst%3DM.%2BA.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DCannady%26aufirst%3DE.%2BA.%26aulast%3DJohnson%26aufirst%3DJ.%2BT.%26aulast%3DYumibe%26aufirst%3DN.%2BP.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DMaiti%26aufirst%3DP.%26aulast%3DMontrose-Rafizadeh%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DReifel%2BMiller%26aufirst%3DA.%26atitle%3DThe%2520Discovery%252C%2520Preclinical%252C%2520and%2520Early%2520Clinical%2520Development%2520of%2520Potent%2520and%2520Selective%2520GPR40%2520Agonists%2520for%2520the%2520Treatment%2520of%2520Type%25202%2520Diabetes%2520Mellitus%2520%2528LY2881835%252C%2520LY2922083%252C%2520and%2520LY2922470%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D24%26spage%3D10891%26epage%3D10916%26doi%3D10.1021%2Facs.jmedchem.6b00892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dodick, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipton, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ailani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finnegan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trugman, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szegedi, A.</span></span> <span> </span><span class="NLM_article-title">Ubrogepant for the Treatment of Migraine</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>381</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">2230</span>– <span class="NLM_lpage">2241</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1813049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1056%2FNEJMoa1813049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=31800988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVylsL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=381&publication_year=2019&pages=2230-2241&issue=23&author=D.+W.+Dodickauthor=R.+B.+Liptonauthor=J.+Ailaniauthor=K.+Luauthor=M.+Finneganauthor=J.+M.+Trugmanauthor=A.+Szegedi&title=Ubrogepant+for+the+Treatment+of+Migraine&doi=10.1056%2FNEJMoa1813049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Ubrogepant for the treatment of migraine</span></div><div class="casAuthors">Dodick, David W.; Lipton, Richard B.; Ailani, Jessica; Lu, Kaifeng; Finnegan, Michelle; Trugman, Joel M.; Szegedi, Armin</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">381</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2230-2241</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Ubrogepant is an oral, small-mol. calcitonin gene-related peptide receptor antagonist for acute migraine treatment. methods We conducted a randomized trial to evaluate the efficacy, safety, and side-effect profile of ubrogepant.  We assigned adults with migraine, with or without aura, in a 1:1:1 ratio to receive an initial dose of placebo, ubrogepant at a dose of 50 mg, or ubrogepant at a dose of 100 mg for treatment of a single migraine attack, with the option to take a second dose.  The coprimary efficacy end points were freedom from pain at 2 h after the initial dose and absence of the most bothersome migraine-assocd. symptom at 2 h.  Secondary end points included pain relief (at 2 h), sustained pain relief (from 2 to 24 h), sustained freedom from pain (from 2 to 24 h), and absence of symptoms assocd. with migraine (photophobia, phonophobia, and nausea) at 2 h. results A total of 1672 participants were enrolled; 559 were assigned to receive placebo, 556 to receive 50 mg of ubrogepant, and 557 to receive 100 mg of ubrogepant.  The percentage of participants who had freedom from pain at 2 h was 11.8% in the placebo group, 19.2% in the 50-mg ubrogepant group (P = 0.002, adjusted for multiplicity, for the comparison with placebo), and 21.2% in the 100-mg ubrogepant group (P<0.001).  The percentage of participants who had freedom from the most bothersome symptom at 2 h was 27.8% in the placebo group, 38.6% in the 50-mg ubrogepant group (P = 0.002), and 37.7% in the 100-mg ubrogepant group (P = 0.002).  Adverse events within 48 h after the initial or optional second dose were reported in 12.8% of participants in the placebo group, in 9.4% in the 50-mg ubrogepant group, and in 16.3% in the 100-mg ubrogepant group.  The most common adverse events were nausea, somnolence, and dry mouth (reported in 0.4 to 4.1%); these events were more frequent in the 100-mg ubrogepant group (reported in 2.1 to 4.1%).  Serious adverse events reported within 30 days in the ubrogepant groups included appendicitis, spontaneous abortion, pericardial effusion, and seizure; none of the events occurred within 48 h after the dose. conclusions A higher percentage of participants who received ubrogepant than of those who received placebo had freedom from pain and absence of the most bothersome symptom at 2 h after the dose.  The most commonly reported adverse events were nausea, somnolence, and dry mouth.  Further trials are needed to det. the durability and safety of ubrogepant for acute migraine treatment and to compare it with other drugs for migraine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozl_vTLCa_ALVg90H21EOLACvtfcHk0liBJFdFU31Atg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVylsL3K&md5=3ac0c00c8b4d6216e24fb20ec4ce75dc</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1813049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1813049%26sid%3Dliteratum%253Aachs%26aulast%3DDodick%26aufirst%3DD.%2BW.%26aulast%3DLipton%26aufirst%3DR.%2BB.%26aulast%3DAilani%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DK.%26aulast%3DFinnegan%26aufirst%3DM.%26aulast%3DTrugman%26aufirst%3DJ.%2BM.%26aulast%3DSzegedi%26aufirst%3DA.%26atitle%3DUbrogepant%2520for%2520the%2520Treatment%2520of%2520Migraine%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2019%26volume%3D381%26issue%3D23%26spage%3D2230%26epage%3D2241%26doi%3D10.1056%2FNEJMoa1813049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleator, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosjek, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, S.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belyk, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullens, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodyear, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishop, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceglia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belardi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMichele, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reamer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabirol, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span> <span> </span><span class="NLM_article-title">Practical Asymmetric Synthesis of a Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist Ubrogepant</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1851</span>– <span class="NLM_lpage">1858</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.7b00293</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.7b00293" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1yhsLfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2017&pages=1851-1858&issue=11&author=N.+Yasudaauthor=E.+Cleatorauthor=B.+Kosjekauthor=J.+Yinauthor=B.+Xiangauthor=F.+Chenauthor=S.-C.+Kuoauthor=K.+Belykauthor=P.+R.+Mullensauthor=A.+Goodyearauthor=J.+S.+Edwardsauthor=B.+Bishopauthor=S.+Cegliaauthor=J.+Belardiauthor=L.+Tanauthor=Z.+J.+Songauthor=L.+DiMicheleauthor=R.+Reamerauthor=F.+L.+Cabirolauthor=W.+L.+Tangauthor=G.+Liu&title=Practical+Asymmetric+Synthesis+of+a+Calcitonin+Gene-Related+Peptide+%28CGRP%29+Receptor+Antagonist+Ubrogepant&doi=10.1021%2Facs.oprd.7b00293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Practical Asymmetric Synthesis of a Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist Ubrogepant</span></div><div class="casAuthors">Yasuda, Nobuyoshi; Cleator, Ed; Kosjek, Birgit; Yin, Jianguo; Xiang, Bangping; Chen, Frank; Kuo, Shen-Chun; Belyk, Kevin; Mullens, Peter R.; Goodyear, Adrian; Edwards, John S.; Bishop, Brian; Ceglia, Scott; Belardi, Justin; Tan, Lushi; Song, Zhiguo J.; DiMichele, Lisa; Reamer, Robert; Cabirol, Fabien L.; Tang, Weng Lin; Liu, Guiquan</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1851-1858</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development of a scalable asym. route to a new calcitonin gene-related peptide (CGRP) receptor antagonist is described.  The synthesis of the two key fragments was redefined, and the intermediates were accessed through novel chem.  Chiral lactam I was prepd. by an enzyme mediated dynamic kinetic transamination which simultaneously set two stereocenters.  Enzyme evolution resulted in an optimized transaminase providing the desired configuration in >60:1 syn/anti.  The final chiral center was set via a crystn. induced diastereomeric transformation.  The asym. spirocyclization to form the second fragment, chiral spiro acid intermediate II, was catalyzed by a novel doubly quaternized phase transfer catalyst and provided optically pure material on isolation.  With the two fragments in hand, development of their final union by amide bond formation and subsequent direct isolation is described.  The described chem. has been used to deliver over 100 kg of our desired target, ubrogepant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr70PHPVaaWYrVg90H21EOLACvtfcHk0liBJFdFU31Atg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1yhsLfJ&md5=b3745d6fb5671bff49b9e022f868dab5</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.7b00293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.7b00293%26sid%3Dliteratum%253Aachs%26aulast%3DYasuda%26aufirst%3DN.%26aulast%3DCleator%26aufirst%3DE.%26aulast%3DKosjek%26aufirst%3DB.%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DXiang%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DKuo%26aufirst%3DS.-C.%26aulast%3DBelyk%26aufirst%3DK.%26aulast%3DMullens%26aufirst%3DP.%2BR.%26aulast%3DGoodyear%26aufirst%3DA.%26aulast%3DEdwards%26aufirst%3DJ.%2BS.%26aulast%3DBishop%26aufirst%3DB.%26aulast%3DCeglia%26aufirst%3DS.%26aulast%3DBelardi%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DL.%26aulast%3DSong%26aufirst%3DZ.%2BJ.%26aulast%3DDiMichele%26aufirst%3DL.%26aulast%3DReamer%26aufirst%3DR.%26aulast%3DCabirol%26aufirst%3DF.%2BL.%26aulast%3DTang%26aufirst%3DW.%2BL.%26aulast%3DLiu%26aufirst%3DG.%26atitle%3DPractical%2520Asymmetric%2520Synthesis%2520of%2520a%2520Calcitonin%2520Gene-Related%2520Peptide%2520%2528CGRP%2529%2520Receptor%2520Antagonist%2520Ubrogepant%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2017%26volume%3D21%26issue%3D11%26spage%3D1851%26epage%3D1858%26doi%3D10.1021%2Facs.oprd.7b00293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marron, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prime, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storer, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swain, N. A.</span></span> <span> </span><span class="NLM_article-title">Recent Progress in Sodium Channel Modulators for Pain</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">3690</span>– <span class="NLM_lpage">3699</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.06.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2Fj.bmcl.2014.06.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=25060923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Wls7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=3690-3699&issue=16&author=S.+K.+Bagalauthor=M.+L.+Chapmanauthor=B.+E.+Marronauthor=R.+Primeauthor=R.+I.+Storerauthor=N.+A.+Swain&title=Recent+Progress+in+Sodium+Channel+Modulators+for+Pain&doi=10.1016%2Fj.bmcl.2014.06.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Recent progress in sodium channel modulators for pain</span></div><div class="casAuthors">Bagal, Sharan K.; Chapman, Mark L.; Marron, Brian E.; Prime, Rebecca; Storer, R. Ian; Swain, Nigel A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3690-3699</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Voltage-gated sodium channels (Navs) are an important family of transmembrane ion channel proteins and Nav drug discovery is an exciting field.  Pharmaceutical investment in Navs for pain therapeutics has expanded exponentially due to genetic data such as SCN10A mutations and an improved ability to establish an effective screen sequence for example IonWorks Barracuda, Synchropatch and Qube.  Moreover, emerging clin. data (AZD-3161, XEN402, CNV1014802, PF-05089771, PF-04531083) combined with recent breakthroughs in Nav structural biol. pave the way for a future of fruitful prospective Nav drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbT6en4xkVxLVg90H21EOLACvtfcHk0liBJFdFU31Atg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Wls7vL&md5=c8bae40b70509e2aa3dce106e2c41677</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.06.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.06.038%26sid%3Dliteratum%253Aachs%26aulast%3DBagal%26aufirst%3DS.%2BK.%26aulast%3DChapman%26aufirst%3DM.%2BL.%26aulast%3DMarron%26aufirst%3DB.%2BE.%26aulast%3DPrime%26aufirst%3DR.%26aulast%3DStorer%26aufirst%3DR.%2BI.%26aulast%3DSwain%26aufirst%3DN.%2BA.%26atitle%3DRecent%2520Progress%2520in%2520Sodium%2520Channel%2520Modulators%2520for%2520Pain%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26issue%3D16%26spage%3D3690%26epage%3D3699%26doi%3D10.1016%2Fj.bmcl.2014.06.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sclafani, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reese, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mudipalli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neville, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakale, R. P.</span></span> <span> </span><span class="NLM_article-title">The First Asymmetric Pilot-Scale Synthesis of TV-45070</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1616</span>– <span class="NLM_lpage">1624</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.7b00237</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.7b00237" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVGhsr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2017&pages=1616-1624&issue=10&author=J.+A.+Sclafaniauthor=J.+Chenauthor=D.+V.+Levyauthor=H.+Reeseauthor=M.+Dimitriauthor=P.+Mudipalliauthor=M.+Christieauthor=C.+J.+Nevilleauthor=M.+Olsenauthor=R.+P.+Bakale&title=The+First+Asymmetric+Pilot-Scale+Synthesis+of+TV-45070&doi=10.1021%2Facs.oprd.7b00237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">The First Asymmetric Pilot-Scale Synthesis of TV-45070</span></div><div class="casAuthors">Sclafani, Joseph A.; Chen, Jian; Levy, Daniel V.; Reese, Harlan; Dimitri, Mina; Mudipalli, Partha; Christie, Michael; Neville, Christopher J.; Olsen, Mark; Bakale, Roger P.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1616-1624</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">TV-45070 (formerly XEN-402) is a small-mol. lactam contg. a chiral spiro-ether that is reported as a potential topical therapy for pain assocd. with the Nav1.7 Na ion channel encoded by the gene SCN9A.  A pilot-scale synthesis is presented that is highlighted by an asym. aldol coupling at ambient temp., used to create a quaternary chiral center.  Although only a moderate ee was obtained, the removal of the undesired isomer is achieved through preferential pptn. of a near racemic mixt. from the reaction, leaving the enantiopure isomer in soln.  Cyclization to form the final API uses an uncommon diphenylphosphine-based leaving group which proved successful on the neopentyl system when other traditional leaving groups failed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvvJXHK7roRLVg90H21EOLACvtfcHk0lgiFJOPKWgFkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVGhsr3E&md5=0be4812d90881ccd423f3b70a64ea395</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.7b00237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.7b00237%26sid%3Dliteratum%253Aachs%26aulast%3DSclafani%26aufirst%3DJ.%2BA.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DLevy%26aufirst%3DD.%2BV.%26aulast%3DReese%26aufirst%3DH.%26aulast%3DDimitri%26aufirst%3DM.%26aulast%3DMudipalli%26aufirst%3DP.%26aulast%3DChristie%26aufirst%3DM.%26aulast%3DNeville%26aufirst%3DC.%2BJ.%26aulast%3DOlsen%26aufirst%3DM.%26aulast%3DBakale%26aufirst%3DR.%2BP.%26atitle%3DThe%2520First%2520Asymmetric%2520Pilot-Scale%2520Synthesis%2520of%2520TV-45070%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2017%26volume%3D21%26issue%3D10%26spage%3D1616%26epage%3D1624%26doi%3D10.1021%2Facs.oprd.7b00237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harris, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberson, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, T. M.</span></span> <span> </span><span class="NLM_article-title">Biosynthesis of Griseofulvin</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1976</span>,  <span class="NLM_volume"><i>98</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">5380</span>– <span class="NLM_lpage">5386</span>, <span class="refDoi"> DOI: 10.1021/ja00433a053</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00433a053" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADyaE28XltF2nsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=1976&pages=5380-5386&issue=17&author=C.+M.+Harrisauthor=J.+S.+Robersonauthor=T.+M.+Harris&title=Biosynthesis+of+Griseofulvin&doi=10.1021%2Fja00433a053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Biosynthesis of griseofulvin</span></div><div class="casAuthors">Harris, Constance M.; Roberson, Jill S.; Harris, Thomas M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1976</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5380-6</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">The antifungal antibiotic griseofulvin (I) is a polyketide metabolite of Penicillium griseofulvum [patulum].  There are ≤ 2 and probably 3 O-Me groups which are introduced after both carbocyclic rings are formed.  2,4,4',6-Tetrahydroxy-2'-methoxy-6'-methylbenzophenone, the monomethylated precursor predicted by earlier workers, was not detected in cultures by carrier diln. expts.  Instead 2,2',4',6-tetrahydroxy-4-methoxy-6'-methylbenzophenone (II) is a precursor of I as indicated by a feeding expt. in which II contg. a tritium label in the O-Me group was incorporated (14%) into I.  Demethylation of labeled I 1st to griseofulvic acid and then to grisan showed that < 10% randomization of the label occurred during biotransformation of II into I.  The possibility that nonmethylated 2,2',4,4',6-pentahydroxy-6'-methylbenzophenone (III) was the precursor of II was considered, but synthetic III was too unstable for use in carrier dilution or incorporation expts., undergoing facile cyclization to xanthone (IV).  The latter compd. was, however, a metabolite of P. griseofulvum, which lends support to the hypothesis that both II and IV arise in the fungal culture from III.  Earlier workers had postulated that the grisan ring is formed by oxidative cyclization of griseophenone A to give dehydrogriseofulvin but in vivo confirmation of this process has not been obtained.  Another possible precursor to dehydrogriseofulvin, normethyldehydrogriseofulvin was synthesized and incorporated (44%) into I.  These findings support the biosynthetic sequence: acetate → heptaacetic acid → III → II → griseophenone C → griseophenone B → normethyldehydrogriseofulvin → dehydrogriseofulvin → I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZXnQXoFJeWLVg90H21EOLACvtfcHk0lgiFJOPKWgFkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE28XltF2nsr8%253D&md5=006150becfafca13d20c9e9bd537e38a</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1021%2Fja00433a053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00433a053%26sid%3Dliteratum%253Aachs%26aulast%3DHarris%26aufirst%3DC.%2BM.%26aulast%3DRoberson%26aufirst%3DJ.%2BS.%26aulast%3DHarris%26aufirst%3DT.%2BM.%26atitle%3DBiosynthesis%2520of%2520Griseofulvin%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1976%26volume%3D98%26issue%3D17%26spage%3D5380%26epage%3D5386%26doi%3D10.1021%2Fja00433a053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rønnest, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clausen, M. H.</span></span> <span> </span><span class="NLM_article-title">The Chemistry of Griseofulvin</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>114</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">12088</span>– <span class="NLM_lpage">12107</span>, <span class="refDoi"> DOI: 10.1021/cr400368e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr400368e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVegtbnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2014&pages=12088-12107&issue=24&author=A.+B.+Petersenauthor=M.+H.+R%C3%B8nnestauthor=T.+O.+Larsenauthor=M.+H.+Clausen&title=The+Chemistry+of+Griseofulvin&doi=10.1021%2Fcr400368e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">The Chemistry of Griseofulvin</span></div><div class="casAuthors">Petersen, Asger B.; Roennest, Mads H.; Larsen, Thomas O.; Clausen, Mads H.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">12088-12107</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The natural product griseofulvin, (2S,6'R)-7-chloro-4,6-dimethoxybenzofuran-3-one-2-spiro-1'-(2'-methoxy-6'-methylcyclohex-2'-en-4'-one) (1), has a rich chem. dating back to the early 1950s.  Griseofulvin has been in clin. use for the treatment of ringworm in animals and humans since, and recently, griseofulvin has attracted renewed attention due to reports of complementary bioactivity in mammalian systems, including antiviral and anticancer activity.  Here, the authors present the history of griseofulvin, its biosynthesis, an introduction to the biol. of the compd. class, total synthesis of 1 and its analogs, as well as chem. used to prep. analogs of griseofulvin starting from the natural product.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpW-GgIzqAAgLVg90H21EOLACvtfcHk0lgiFJOPKWgFkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVegtbnP&md5=aff1b198c19a546a317f5200718bf884</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1021%2Fcr400368e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr400368e%26sid%3Dliteratum%253Aachs%26aulast%3DPetersen%26aufirst%3DA.%2BB.%26aulast%3DR%25C3%25B8nnest%26aufirst%3DM.%2BH.%26aulast%3DLarsen%26aufirst%3DT.%2BO.%26aulast%3DClausen%26aufirst%3DM.%2BH.%26atitle%3DThe%2520Chemistry%2520of%2520Griseofulvin%26jtitle%3DChem.%2520Rev.%26date%3D2014%26volume%3D114%26issue%3D24%26spage%3D12088%26epage%3D12107%26doi%3D10.1021%2Fcr400368e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pirrung, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rege, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laughton, P.</span></span> <span> </span><span class="NLM_article-title">Total Synthesis of (+)-Griseofulvin</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>113</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">8561</span>– <span class="NLM_lpage">8562</span>, <span class="refDoi"> DOI: 10.1021/ja00022a075</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00022a075" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADyaK3MXmsl2lt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=1991&pages=8561-8562&issue=22&author=M.+C.+Pirrungauthor=W.+L.+Brownauthor=S.+Regeauthor=P.+Laughton&title=Total+Synthesis+of+%28%2B%29-Griseofulvin&doi=10.1021%2Fja00022a075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Total synthesis of (+)-griseofulvin</span></div><div class="casAuthors">Pirrung, Michael C.; Brown, William L.; Rege, Sushil; Laughton, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8561-2</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">The first asym. total synthesis of the antifungal antibiotic griseofulvin (I; R = Me) has been completed by the prepn. of I (R = H) using the intramol. generation and rearrangement of an oxonium ylide to establish both relative and abs. stereochem.  The lack of products derived from an O-Me ylide suggests that ylide formation is reversible and that the rate-detg. step is the sigmatropic rearrangement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOabaOl3tYurVg90H21EOLACvtfcHk0lgA99kU6MJZDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXmsl2lt70%253D&md5=260a49b92420b332ca107838171977c8</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1021%2Fja00022a075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00022a075%26sid%3Dliteratum%253Aachs%26aulast%3DPirrung%26aufirst%3DM.%2BC.%26aulast%3DBrown%26aufirst%3DW.%2BL.%26aulast%3DRege%26aufirst%3DS.%26aulast%3DLaughton%26aufirst%3DP.%26atitle%3DTotal%2520Synthesis%2520of%2520%2528%252B%2529-Griseofulvin%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1991%26volume%3D113%26issue%3D22%26spage%3D8561%26epage%3D8562%26doi%3D10.1021%2Fja00022a075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esler, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amor, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagley, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beysen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvajal-Gonzalez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doran, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limberakis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathiowetz, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McPherson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravussin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonnenberg, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Southers, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweet, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajdos, F. F.</span></span> <span> </span><span class="NLM_article-title">Decreasing the Rate of Metabolic Ketone Reduction in the Discovery of a Clinical Acetyl-CoA Carboxylase Inhibitor for the Treatment of Diabetes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">10512</span>– <span class="NLM_lpage">10526</span>, <span class="refDoi"> DOI: 10.1021/jm5016022</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5016022" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFOht73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=10512-10526&issue=24&author=D.+A.+Griffithauthor=D.+W.+Kungauthor=W.+P.+Eslerauthor=P.+A.+Amorauthor=S.+W.+Bagleyauthor=C.+Beysenauthor=S.+Carvajal-Gonzalezauthor=S.+D.+Doranauthor=C.+Limberakisauthor=A.+M.+Mathiowetzauthor=K.+McPhersonauthor=D.+A.+Priceauthor=E.+Ravussinauthor=G.+E.+Sonnenbergauthor=J.+A.+Southersauthor=L.+J.+Sweetauthor=S.+M.+Turnerauthor=F.+F.+Vajdos&title=Decreasing+the+Rate+of+Metabolic+Ketone+Reduction+in+the+Discovery+of+a+Clinical+Acetyl-CoA+Carboxylase+Inhibitor+for+the+Treatment+of+Diabetes&doi=10.1021%2Fjm5016022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Decreasing the Rate of Metabolic Ketone Reduction in the Discovery of a Clinical Acetyl-CoA Carboxylase Inhibitor for the Treatment of Diabetes</span></div><div class="casAuthors">Griffith, David A.; Kung, Daniel W.; Esler, William P.; Amor, Paul A.; Bagley, Scott W.; Beysen, Carine; Carvajal-Gonzalez, Santos; Doran, Shawn D.; Limberakis, Chris; Mathiowetz, Alan M.; McPherson, Kirk; Price, David A.; Ravussin, Eric; Sonnenberg, Gabriele E.; Southers, James A.; Sweet, Laurel J.; Turner, Scott M.; Vajdos, Felix F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10512-10526</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Acetyl-Co-A carboxylase (ACC) inhibitors offer significant potential for the treatment of type 2 diabetes mellitus (T2DM), hepatic steatosis, and cancer.  However, the identification of tool compds. suitable to test the hypothesis in human trials has been challenging.  An advanced series of spirocyclic ketone-contg. ACC inhibitors recently reported by Pfizer were metabolized in vivo by ketone redn., which complicated human pharmacol. projections.  The authors disclose that this metabolic redn. can be greatly attenuated through introduction of steric hindrance adjacent to the ketone carbonyl.  Incorporation of weakly basic functionality improved soly. and led to the identification of I as a clin. candidate for the treatment of T2DM.  Phase I clin. studies demonstrated dose-proportional increases in exposure, single-dose inhibition of de novo lipogenesis (DNL), and changes in indirect calorimetry consistent with increased whole-body fatty acid oxidn.  This demonstration of target engagement validates the use of compd. I to evaluate the role of DNL in human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWcJ9T4Kbj57Vg90H21EOLACvtfcHk0lgA99kU6MJZDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFOht73O&md5=2af2cc745bf8a4e27396849b3011017c</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1021%2Fjm5016022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5016022%26sid%3Dliteratum%253Aachs%26aulast%3DGriffith%26aufirst%3DD.%2BA.%26aulast%3DKung%26aufirst%3DD.%2BW.%26aulast%3DEsler%26aufirst%3DW.%2BP.%26aulast%3DAmor%26aufirst%3DP.%2BA.%26aulast%3DBagley%26aufirst%3DS.%2BW.%26aulast%3DBeysen%26aufirst%3DC.%26aulast%3DCarvajal-Gonzalez%26aufirst%3DS.%26aulast%3DDoran%26aufirst%3DS.%2BD.%26aulast%3DLimberakis%26aufirst%3DC.%26aulast%3DMathiowetz%26aufirst%3DA.%2BM.%26aulast%3DMcPherson%26aufirst%3DK.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DRavussin%26aufirst%3DE.%26aulast%3DSonnenberg%26aufirst%3DG.%2BE.%26aulast%3DSouthers%26aufirst%3DJ.%2BA.%26aulast%3DSweet%26aufirst%3DL.%2BJ.%26aulast%3DTurner%26aufirst%3DS.%2BM.%26aulast%3DVajdos%26aufirst%3DF.%2BF.%26atitle%3DDecreasing%2520the%2520Rate%2520of%2520Metabolic%2520Ketone%2520Reduction%2520in%2520the%2520Discovery%2520of%2520a%2520Clinical%2520Acetyl-CoA%2520Carboxylase%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Diabetes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D24%26spage%3D10512%26epage%3D10526%26doi%3D10.1021%2Fjm5016022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Esler, W. P.</span>; <span class="NLM_string-name">Sonnenberg, G. E.</span></span> <span> </span><span class="NLM_article-title">Use of Acetyl-Coa Carboxylase Inhibitors for Treating Acne Vulgaris</span>. <span class="NLM_patent">WO2015036892A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=W.+P.+Esler&author=G.+E.+Sonnenberg&title=Use+of+Acetyl-Coa+Carboxylase+Inhibitors+for+Treating+Acne+Vulgaris"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DEsler%26aufirst%3DW.%2BP.%26atitle%3DUse%2520of%2520Acetyl-Coa%2520Carboxylase%2520Inhibitors%2520for%2520Treating%2520Acne%2520Vulgaris%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soupart, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legros, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alföldi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annane, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heshmati, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decaux, G.</span></span> <span> </span><span class="NLM_article-title">Successful Long-Term Treatment of Hyponatremia in Syndrome of Inappropriate Antidiuretic Hormone Secretion with Satavaptan (SR121463B), an Orally Active Nonpeptide Vasopressin V2-Receptor Antagonist</span>. <i>Clin. J. Am. Soc. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1154</span>– <span class="NLM_lpage">1160</span>, <span class="refDoi"> DOI: 10.2215/CJN.00160106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.2215%2FCJN.00160106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=17699341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1GntbzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2006&pages=1154-1160&issue=6&author=A.+Soupartauthor=P.+Grossauthor=J.-J.+Legrosauthor=S.+Alf%C3%B6ldiauthor=D.+Annaneauthor=H.+M.+Heshmatiauthor=G.+Decaux&title=Successful+Long-Term+Treatment+of+Hyponatremia+in+Syndrome+of+Inappropriate+Antidiuretic+Hormone+Secretion+with+Satavaptan+%28SR121463B%29%2C+an+Orally+Active+Nonpeptide+Vasopressin+V2-Receptor+Antagonist&doi=10.2215%2FCJN.00160106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist</span></div><div class="casAuthors">Soupart, Alain; Gross, Peter; Legros, Jean-Jacques; Alfoldi, Sandor; Annane, Djillali; Heshmati, Hassan M.; Decaux, Guy</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Journal of the American Society of Nephrology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1154-1160</span>CODEN:
                <span class="NLM_cas:coden">CJASC7</span>;
        ISSN:<span class="NLM_cas:issn">1555-9041</span>.
    
            (<span class="NLM_cas:orgname">American Society of Nephrology</span>)
        </div><div class="casAbstract">The effects of satavaptan (SR121463B), a novel long-acting orally active vasopressin V2-receptor antagonist, were investigated in patients with the syndrome of inappropriate antidiuretic hormone secretion (SIADH).  In the first part of this randomized, double-blind study, 34 patients first were treated with satavaptan (vs. placebo) for up to 5 d and then during 23 d of open-label dosage-adjustment period.  In the second part of the study, long-term efficacy and safety of satavaptan was assessed in an open-label trial during at least 12 mo.  Mean (±SD) serum sodium (SNa) levels before treatment were 127 ± 2 mmol/L (placebo, n = 8), 125 ± 6 mmol/L (25 mg, n = 14), and 127 ± 5 mmol/L (50 mg, n = 12).  Responders (patients SNa levels normalized or increased by at least 5 mmol/L from baseline during the double-blind period) were 79% in the 25-mg group (SNa 136 ± 3 mmol/L; P = 0.006), 83% in the 50-mg group (SNa 140 ± 6 mmol/L; P = 0.005), and 13% in the placebo group (SNa 130 ± 5 mmol/L).  No drug-related serious adverse events were recorded.  During the long-term treatment, 15 of 18 enrolled patients achieved 6 mo and 10 achieved 12 mo of treatment.  The SNa response was maintained during this time with a good tolerance.  The new oral vasopressin V2-receptor antagonist satavaptan adequately corrects mild or moderate hyponatremia in patients with SIADH and has a good safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiP6hV6PXzT7Vg90H21EOLACvtfcHk0lgTxMJ43vwcHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1GntbzK&md5=c63cb756959cb3f0a52da838c08e2a71</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.2215%2FCJN.00160106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2215%252FCJN.00160106%26sid%3Dliteratum%253Aachs%26aulast%3DSoupart%26aufirst%3DA.%26aulast%3DGross%26aufirst%3DP.%26aulast%3DLegros%26aufirst%3DJ.-J.%26aulast%3DAlf%25C3%25B6ldi%26aufirst%3DS.%26aulast%3DAnnane%26aufirst%3DD.%26aulast%3DHeshmati%26aufirst%3DH.%2BM.%26aulast%3DDecaux%26aufirst%3DG.%26atitle%3DSuccessful%2520Long-Term%2520Treatment%2520of%2520Hyponatremia%2520in%2520Syndrome%2520of%2520Inappropriate%2520Antidiuretic%2520Hormone%2520Secretion%2520with%2520Satavaptan%2520%2528SR121463B%2529%252C%2520an%2520Orally%2520Active%2520Nonpeptide%2520Vasopressin%2520V2-Receptor%2520Antagonist%26jtitle%3DClin.%2520J.%2520Am.%2520Soc.%2520Nephrol.%26date%3D2006%26volume%3D1%26issue%3D6%26spage%3D1154%26epage%3D1160%26doi%3D10.2215%2FCJN.00160106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Venkatesan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altas, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liotta, D. C.</span></span> <span> </span><span class="NLM_article-title">Total Synthesis of SR 121463 A, a Highly Potent and Selective Vasopressin v(2) Receptor Antagonist</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>66</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">3653</span>– <span class="NLM_lpage">3661</span>, <span class="refDoi"> DOI: 10.1021/jo0004658</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo0004658" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BD3MXisl2rsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2001&pages=3653-3661&issue=11&author=H.+Venkatesanauthor=M.+C.+Davisauthor=Y.+Altasauthor=J.+P.+Snyderauthor=D.+C.+Liotta&title=Total+Synthesis+of+SR+121463+A%2C+a+Highly+Potent+and+Selective+Vasopressin+v%282%29+Receptor+Antagonist&doi=10.1021%2Fjo0004658"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Total Synthesis of SR 121463 A, a Highly Potent and Selective Vasopressin V2 Receptor Antagonist</span></div><div class="casAuthors">Venkatesan, Hariharan; Davis, Matthew C.; Altas, Yesim; Snyder, James P.; Liotta, Dennis C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3653-3661</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">SR 121463 A was prepd. from the fragments 4,3-ClSO2(MeO)C6H3CONHCMe3 (I), 2,2-bis(2-bromoethyl)-1,3-dioxolane, and 1-benzyl-5-ethoxy-2-indolinone in good overall yield, each step proceeding in greater than 80% yield.  In addn., I and the syn isomer of SR 121463 A were prepd. with complete control of stereochem.  Mol. mechanics calcns. with the MM3* and MMFF force fields underscore geometric and energetic aspects of the reaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRp0k7IL_tq7Vg90H21EOLACvtfcHk0lgTxMJ43vwcHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXisl2rsb8%253D&md5=425ee77a6e8a0e865f4505fb2c236060</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1021%2Fjo0004658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo0004658%26sid%3Dliteratum%253Aachs%26aulast%3DVenkatesan%26aufirst%3DH.%26aulast%3DDavis%26aufirst%3DM.%2BC.%26aulast%3DAltas%26aufirst%3DY.%26aulast%3DSnyder%26aufirst%3DJ.%2BP.%26aulast%3DLiotta%26aufirst%3DD.%2BC.%26atitle%3DTotal%2520Synthesis%2520of%2520SR%2520121463%2520A%252C%2520a%2520Highly%2520Potent%2520and%2520Selective%2520Vasopressin%2520v%25282%2529%2520Receptor%2520Antagonist%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2001%26volume%3D66%26issue%3D11%26spage%3D3653%26epage%3D3661%26doi%3D10.1021%2Fjo0004658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hermecz, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sánta-Csutor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gönczi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Héja, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Csikós, É.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smelkó-Esek, Á.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podányi, B.</span></span> <span> </span><span class="NLM_article-title">Chemical Development of the Vasopressin Receptor 2 Antagonist SR-121463</span>. <i>Pure Appl. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>73</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1401</span>– <span class="NLM_lpage">1409</span>, <span class="refDoi"> DOI: 10.1351/pac200173091401</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1351%2Fpac200173091401" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BD3MXptFGlsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2001&pages=1401-1409&issue=9&author=I.+Hermeczauthor=A.+S%C3%A1nta-Csutorauthor=C.+G%C3%B6ncziauthor=G.+H%C3%A9jaauthor=%C3%89.+Csik%C3%B3sauthor=K.+Simonauthor=%C3%81.+Smelk%C3%B3-Esekauthor=B.+Pod%C3%A1nyi&title=Chemical+Development+of+the+Vasopressin+Receptor+2+Antagonist+SR-121463&doi=10.1351%2Fpac200173091401"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical development of the vasopressin receptor 2 antagonist SR-121463</span></div><div class="casAuthors">Hermecz, Istvan; Santa-Csutor, Andrea; Gonczi, Csaba; Heja, Gergely; Csikos, Eva; Simon, Kalman; Smelko-Esek, Agota; Podanyi, Benjamin</div><div class="citationInfo"><span class="NLM_cas:title">Pure and Applied Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1401-1409</span>CODEN:
                <span class="NLM_cas:coden">PACHAS</span>;
        ISSN:<span class="NLM_cas:issn">0033-4545</span>.
    
            (<span class="NLM_cas:orgname">International Union of Pure and Applied Chemistry</span>)
        </div><div class="casAbstract">A facile convergent total synthesis of the selective, potent, and orally active V, non-peptide antagonist, SR-121463, was developed by modification of the discovery route.  One of the late intermediates, the sulfonyl chloride , was synthesized from 3-hydroxybenzoic acid by regioselective sulfonation, O-methylation and amidation in four steps.  In this way, the indolin-2-one was synthesized from p-phenetidine in six steps.  Finally. acylation of the indolin-2-one was achieved with the sulfonyl chloride in the presence of KOtBu in DMSO (DMSO) at room temp.  This synthetic route proved to be applicable for the large-scale synthesis of SR-121463.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7K0-gYtDbhbVg90H21EOLACvtfcHk0lgTxMJ43vwcHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXptFGlsr8%253D&md5=c3ca97ddab9bea1dbdc813bbf1ff0f4b</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1351%2Fpac200173091401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1351%252Fpac200173091401%26sid%3Dliteratum%253Aachs%26aulast%3DHermecz%26aufirst%3DI.%26aulast%3DS%25C3%25A1nta-Csutor%26aufirst%3DA.%26aulast%3DG%25C3%25B6nczi%26aufirst%3DC.%26aulast%3DH%25C3%25A9ja%26aufirst%3DG.%26aulast%3DCsik%25C3%25B3s%26aufirst%3D%25C3%2589.%26aulast%3DSimon%26aufirst%3DK.%26aulast%3DSmelk%25C3%25B3-Esek%26aufirst%3D%25C3%2581.%26aulast%3DPod%25C3%25A1nyi%26aufirst%3DB.%26atitle%3DChemical%2520Development%2520of%2520the%2520Vasopressin%2520Receptor%25202%2520Antagonist%2520SR-121463%26jtitle%3DPure%2520Appl.%2520Chem.%26date%3D2001%26volume%3D73%26issue%3D9%26spage%3D1401%26epage%3D1409%26doi%3D10.1351%2Fpac200173091401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foulon, L.</span>; <span class="NLM_string-name">Garcia, G.</span>; <span class="NLM_string-name">Gal, C. S.-L.</span>; <span class="NLM_string-name">Valette, G.</span></span> <span> </span><span class="NLM_article-title">Derives 3-spiro-indolin-2-one comme ligands des recepteurs de la vasopressine et/ou de l’ocytocine</span>. <span class="NLM_patent">WO1997015556A1</span>, <span class="NLM_year">1997</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1997&author=L.+Foulon&author=G.+Garcia&author=C.+S.-L.+Gal&author=G.+Valette&title=Derives+3-spiro-indolin-2-one+comme+ligands+des+recepteurs+de+la+vasopressine+et%2Fou+de+l%E2%80%99ocytocine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFoulon%26aufirst%3DL.%26atitle%3DDerives%25203-spiro-indolin-2-one%2520comme%2520ligands%2520des%2520recepteurs%2520de%2520la%2520vasopressine%2520et%252Fou%2520de%2520l%25E2%2580%2599ocytocine%26date%3D1997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janssens, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leenaerts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diels, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Boeck, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Megens, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langlois, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Rossem, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beetens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgers, M.</span></span> <span> </span><span class="NLM_article-title">Norpiperidine Imidazoazepines as a New Class of Potent, Selective, and Nonsedative H1 Antihistamines</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2154</span>– <span class="NLM_lpage">2166</span>, <span class="refDoi"> DOI: 10.1021/jm049495j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049495j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtFCiu7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=2154-2166&issue=6&author=F.+Janssensauthor=J.+Leenaertsauthor=G.+Dielsauthor=B.+De+Boeckauthor=A.+Megensauthor=X.+Langloisauthor=K.+van+Rossemauthor=J.+Beetensauthor=M.+Borgers&title=Norpiperidine+Imidazoazepines+as+a+New+Class+of+Potent%2C+Selective%2C+and+Nonsedative+H1+Antihistamines&doi=10.1021%2Fjm049495j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Norpiperidine imidazoazepines as a new class of potent, selective, and nonsedative H1 antihistamines</span></div><div class="casAuthors">Janssens, Frans; Leenaerts, Jos; Diels, Gaston; De Boeck, Benoit; Megens, Anton; Langlois, Xavier; van Rossem, Koen; Beetens, Johan; Borgers, Marcel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2154-2166</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Clin. doses of available H1 antihistamines are limited mainly by sedative side effects.  However, higher doses are often required to obtain optimal therapeutic activity, esp. in dermatol.  The synthesis of three norpiperidine imidazoazepines, e.g., I, representative of a class of selective and nonsedating H1 antihistamines is reported.  The compds. were at least as potent as cetirizine and loratadine as measured by H1 receptor binding affinity, by protection against compd. 48/80- and histamine-induced lethality in rats and guinea pigs, resp., and by skin reaction tests in rats, guinea pigs, and dogs.  The compds., in particular I, were less prone than the ref. compds. to penetrate the brain and to occupy central H1 receptors, suggesting absence of sedative side effects.  In vitro and in vivo cardiovascular safety tests showed that I had no intrinsic potential to prolong ventricular repolarization or induce cardiac arrhythmias.  I has been selected for further clin. development, mainly for application in dermatol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp76QOrOdzxObVg90H21EOLACvtfcHk0lhs14iI6s5fwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtFCiu7fI&md5=79fb5ed6420beaad9e9932bb26f7a7bc</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1021%2Fjm049495j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049495j%26sid%3Dliteratum%253Aachs%26aulast%3DJanssens%26aufirst%3DF.%26aulast%3DLeenaerts%26aufirst%3DJ.%26aulast%3DDiels%26aufirst%3DG.%26aulast%3DDe%2BBoeck%26aufirst%3DB.%26aulast%3DMegens%26aufirst%3DA.%26aulast%3DLanglois%26aufirst%3DX.%26aulast%3Dvan%2BRossem%26aufirst%3DK.%26aulast%3DBeetens%26aufirst%3DJ.%26aulast%3DBorgers%26aufirst%3DM.%26atitle%3DNorpiperidine%2520Imidazoazepines%2520as%2520a%2520New%2520Class%2520of%2520Potent%252C%2520Selective%252C%2520and%2520Nonsedative%2520H1%2520Antihistamines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26issue%3D6%26spage%3D2154%26epage%3D2166%26doi%3D10.1021%2Fjm049495j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janssens, F. E.</span>; <span class="NLM_string-name">Leenaerts, J. E.</span></span> <span> </span><span class="NLM_article-title">Antihistaminic Spiro Compounds</span>. <span class="NLM_patent">WO2000037470A1</span>, <span class="NLM_year">2000</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&author=F.+E.+Janssens&author=J.+E.+Leenaerts&title=Antihistaminic+Spiro+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJanssens%26aufirst%3DF.%2BE.%26atitle%3DAntihistaminic%2520Spiro%2520Compounds%26date%3D2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G. G.</span>; <span class="NLM_string-name">Werne, G.</span>; <span class="NLM_string-name">Fu, X.</span>; <span class="NLM_string-name">Orr, R. K.</span>; <span class="NLM_string-name">Chen, F. X.</span>; <span class="NLM_string-name">Cui, J.</span>; <span class="NLM_string-name">Sprague, V. M.</span>; <span class="NLM_string-name">Zhang, F.</span>; <span class="NLM_string-name">Xie, J.</span>; <span class="NLM_string-name">Zeng, L.</span>; <span class="NLM_string-name">Castellanos, L. P.</span>; <span class="NLM_string-name">Chen, Y.</span>; <span class="NLM_string-name">Poirier, M.</span>; <span class="NLM_string-name">Mergelsberg, I.</span></span> <span> </span><span class="NLM_article-title">Process and Intermediates for the Synthesis of 8-[{1-(3,5-Bis-(Trifluoromethyl)Phenyl)-Ethoxy}-Methyl]-8-Phenyl-1,7-Diaza-Spiro[4.5]Decan-2-One Compounds</span>. <span class="NLM_patent">US9249144B2</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=G.+G.+Wu&author=G.+Werne&author=X.+Fu&author=R.+K.+Orr&author=F.+X.+Chen&author=J.+Cui&author=V.+M.+Sprague&author=F.+Zhang&author=J.+Xie&author=L.+Zeng&author=L.+P.+Castellanos&author=Y.+Chen&author=M.+Poirier&author=I.+Mergelsberg&title=Process+and+Intermediates+for+the+Synthesis+of+8-%5B%7B1-%283%2C5-Bis-%28Trifluoromethyl%29Phenyl%29-Ethoxy%7D-Methyl%5D-8-Phenyl-1%2C7-Diaza-Spiro%5B4.5%5DDecan-2-One+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DG.%2BG.%26atitle%3DProcess%2520and%2520Intermediates%2520for%2520the%2520Synthesis%2520of%25208-%255B%257B1-%25283%252C5-Bis-%2528Trifluoromethyl%2529Phenyl%2529-Ethoxy%257D-Methyl%255D-8-Phenyl-1%252C7-Diaza-Spiro%255B4.5%255DDecan-2-One%2520Compounds%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Müller, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berkenbosch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benningshof, J. C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stumpfe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajorath, J.</span></span> <span> </span><span class="NLM_article-title">Charting Biologically Relevant Spirocyclic Compound Space</span>. <i>Chem. - Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">703</span>– <span class="NLM_lpage">710</span>, <span class="refDoi"> DOI: 10.1002/chem.201604714</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1002%2Fchem.201604714" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=27859909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVWmsb3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=703-710&issue=3&author=G.+M%C3%BCllerauthor=T.+Berkenboschauthor=J.+C.+J.+Benningshofauthor=D.+Stumpfeauthor=J.+Bajorath&title=Charting+Biologically+Relevant+Spirocyclic+Compound+Space&doi=10.1002%2Fchem.201604714"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Charting Biologically Relevant Spirocyclic Compound Space</span></div><div class="casAuthors">Mueller, Gerhard; Berkenbosch, Tim; Benningshof, Jorg C. J.; Stumpfe, Dagmar; Bajorath, Juergen</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">703-710</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Spirocycles frequently occur in natural products and experience increasing interest in drug discovery, given their richness in Sp3 centers and distinct three-dimensionality.  The authors have systematically explored chem. space populated with currently available bioactive spirocycles.  Compds. contg. spiro systems were classified and their scaffolds and spirocyclic ring combinations analyzed.  Nearly 47,000 compds. were identified that contained spirocycles in different structural contexts and were active against roughly 200 targets, among which several pharmaceutically relevant members of the G protein-coupled receptor (GPCR) family were identified.  Spirocycles and corresponding compds. displayed notable scaffold diversity but contained only limited nos. of combinations of differently sized rings.  These observations indicate that there should be significant potential to further expand spirocyclic chem. space for drug discovery, exploiting the privileged substructure concept.  Inspired by those findings, the authors embarked on the design and chem. synthesis of three distinct novel spirocyclic scaffolds that qualify for downstream library synthesis, thus exploring principally new chem. space with high potential for pharmaceutical research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUvVwE8kzXULVg90H21EOLACvtfcHk0lhs14iI6s5fwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVWmsb3O&md5=92293477499539b602abd928891de11b</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1002%2Fchem.201604714&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201604714%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DG.%26aulast%3DBerkenbosch%26aufirst%3DT.%26aulast%3DBenningshof%26aufirst%3DJ.%2BC.%2BJ.%26aulast%3DStumpfe%26aufirst%3DD.%26aulast%3DBajorath%26aufirst%3DJ.%26atitle%3DCharting%2520Biologically%2520Relevant%2520Spirocyclic%2520Compound%2520Space%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D2017%26volume%3D23%26issue%3D3%26spage%3D703%26epage%3D710%26doi%3D10.1002%2Fchem.201604714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">King, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortensen, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">North, A. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sore, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spring, D. R.</span></span> <span> </span><span class="NLM_article-title">Cycloaddition Strategies for the Synthesis of Diverse Heterocyclic Spirocycles for Fragment-Based Drug Discovery</span>. <i>Eur. J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>2019</i></span> (<span class="NLM_issue">31–32</span>),  <span class="NLM_fpage">5219</span>– <span class="NLM_lpage">5229</span>, <span class="refDoi"> DOI: 10.1002/ejoc.201900847</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1002%2Fejoc.201900847" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=31598091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVGqs7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2019&publication_year=2019&pages=5219-5229&issue=31%E2%80%9332&author=T.+A.+Kingauthor=H.+L.+Stewartauthor=K.+T.+Mortensenauthor=A.+J.+P.+Northauthor=H.+F.+Soreauthor=D.+R.+Spring&title=Cycloaddition+Strategies+for+the+Synthesis+of+Diverse+Heterocyclic+Spirocycles+for+Fragment-Based+Drug+Discovery&doi=10.1002%2Fejoc.201900847"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Cycloaddition Strategies for the Synthesis of Diverse Heterocyclic Spirocycles for Fragment-Based Drug Discovery</span></div><div class="casAuthors">King, Thomas A.; Stewart, Hannah L.; Mortensen, Kim T.; North, Andrew J. P.; Sore, Hannah F.; Spring, David R.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">2019</span>
        (<span class="NLM_cas:issue">31-32</span>),
    <span class="NLM_cas:pages">5219-5229</span>CODEN:
                <span class="NLM_cas:coden">EJOCFK</span>;
        ISSN:<span class="NLM_cas:issn">1099-0690</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The step-efficient routes to a no. of biol. relevant, fragment-like heterocyclic spirocycles I (R = Boc, H; n = 1, 2; m = 1, 2, 3, 4), II, III and IV have been reported.  The use of both electron-deficient and electron-rich 2-atom donors was explored in complexity-generating [3+2]-cycloaddns. to furnish products in 3 steps from com. available starting materials.  The resulting compds. were primed for further fragment elaboration through the inclusion of synthetic handles from the outset of the syntheses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGi_W-0wJvl7Vg90H21EOLACvtfcHk0ljJExpkIXXm6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVGqs7vF&md5=122c4545db07adc7fd537a162ab2a250</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1002%2Fejoc.201900847&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.201900847%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DT.%2BA.%26aulast%3DStewart%26aufirst%3DH.%2BL.%26aulast%3DMortensen%26aufirst%3DK.%2BT.%26aulast%3DNorth%26aufirst%3DA.%2BJ.%2BP.%26aulast%3DSore%26aufirst%3DH.%2BF.%26aulast%3DSpring%26aufirst%3DD.%2BR.%26atitle%3DCycloaddition%2520Strategies%2520for%2520the%2520Synthesis%2520of%2520Diverse%2520Heterocyclic%2520Spirocycles%2520for%2520Fragment-Based%2520Drug%2520Discovery%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2019%26volume%3D2019%26issue%3D31%25E2%2580%259332%26spage%3D5219%26epage%3D5229%26doi%3D10.1002%2Fejoc.201900847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sveiczer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">North, A. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mateu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kidd, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sore, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spring, D. R.</span></span> <span> </span><span class="NLM_article-title">Spirocycles as Rigidified Sp3-Rich Scaffolds for a Fragment Collection</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">4600</span>– <span class="NLM_lpage">4604</span>, <span class="refDoi"> DOI: 10.1021/acs.orglett.9b01499</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.orglett.9b01499" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVGgtL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2019&pages=4600-4604&issue=12&author=A.+Sveiczerauthor=A.+J.+P.+Northauthor=N.+Mateuauthor=S.+L.+Kiddauthor=H.+F.+Soreauthor=D.+R.+Spring&title=Spirocycles+as+Rigidified+Sp3-Rich+Scaffolds+for+a+Fragment+Collection&doi=10.1021%2Facs.orglett.9b01499"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Spirocycles as Rigidified sp3-Rich Scaffolds for a Fragment Collection</span></div><div class="casAuthors">Sveiczer, Attila; North, Andrew J. P.; Mateu, Natalia; Kidd, Sarah L.; Sore, Hannah F.; Spring, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4600-4604</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel divergent methodol. to access sp3-rich spirocyclic fragments is reported.  First, a robust modular synthesis of bis-alkene amino ester building blocks was developed.  Three different carbocycles and six heterocycles were then constructed to assemble eight spirocycles.  Importantly, strategic exit vectors were incorporated within each scaffold to aid fragment growth and were elaborated via chem. modifications.  Finally, computational methods demonstrate higher levels of rigidity, three-dimensionality, and structural diversity of the library compared to a com. collection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphL0xwX1UyhbVg90H21EOLACvtfcHk0ljJExpkIXXm6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVGgtL%252FP&md5=d1abfa0263af3e98d8e1855c2001a8e7</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1021%2Facs.orglett.9b01499&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.orglett.9b01499%26sid%3Dliteratum%253Aachs%26aulast%3DSveiczer%26aufirst%3DA.%26aulast%3DNorth%26aufirst%3DA.%2BJ.%2BP.%26aulast%3DMateu%26aufirst%3DN.%26aulast%3DKidd%26aufirst%3DS.%2BL.%26aulast%3DSore%26aufirst%3DH.%2BF.%26aulast%3DSpring%26aufirst%3DD.%2BR.%26atitle%3DSpirocycles%2520as%2520Rigidified%2520Sp3-Rich%2520Scaffolds%2520for%2520a%2520Fragment%2520Collection%26jtitle%3DOrg.%2520Lett.%26date%3D2019%26volume%3D21%26issue%3D12%26spage%3D4600%26epage%3D4604%26doi%3D10.1021%2Facs.orglett.9b01499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolaou, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirberger, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pomerantz, W. C. K.</span></span> <span> </span><span class="NLM_article-title">Evaluating the Advantages of Using 3D-Enriched Fragments for Targeting BET Bromodomains</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1648</span>– <span class="NLM_lpage">1654</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00414</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00414" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1Wktr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1648-1654&issue=12&author=J.+A.+Johnsonauthor=C.+A.+Nicolaouauthor=S.+E.+Kirbergerauthor=A.+K.+Pandeyauthor=H.+Huauthor=W.+C.+K.+Pomerantz&title=Evaluating+the+Advantages+of+Using+3D-Enriched+Fragments+for+Targeting+BET+Bromodomains&doi=10.1021%2Facsmedchemlett.9b00414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluating the Advantages of Using 3D-Enriched Fragments for Targeting BET Bromodomains</span></div><div class="casAuthors">Johnson, Jorden A.; Nicolaou, Christos A.; Kirberger, Steven E.; Pandey, Anil K.; Hu, Haitao; Pomerantz, William C. K.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1648-1654</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Fragment-based ligand discovery has been successful in targeting diverse proteins.  Despite drug-like mols. having more 3D-character, traditional fragment libraries are largely comprised of flat, arom. fragments.  The use of 3D-enriched fragments for enhancing library diversity is underexplored esp. against protein-protein interactions.  Here, we evaluate using 3D-enriched fragments against bromodomains.  Bromodomains are highly ligandable, but selectivity remains challenging, particularly for bromodomain and extraterminal (BET) family bromodomains.  We screened a 3D-enriched fragment library against BRD4(D1) via 1H CPMG NMR with a protein-obsd. 19F NMR secondary assay.  The screen led to 29% of the hits that are selective over two related bromodomains, BRDT(D1) and BPTF, and the identification of underrepresented chem. bromodomain inhibitor scaffolds.  Initial structure-activity relationship studies guided by x-ray crystallog., led to a ligand-efficient thiazepane, with good selectivity and affinity for BET bromodomains.  These results suggest that the incorporation of 3D-enriched fragments to increase library diversity can benefit bromodomain screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5zqdGd6HlQrVg90H21EOLACvtfcHk0liBgYKfyCk-zQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1Wktr7E&md5=dd67906bdd6366a4f06f5d18d8bf7a97</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00414%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DJ.%2BA.%26aulast%3DNicolaou%26aufirst%3DC.%2BA.%26aulast%3DKirberger%26aufirst%3DS.%2BE.%26aulast%3DPandey%26aufirst%3DA.%2BK.%26aulast%3DHu%26aufirst%3DH.%26aulast%3DPomerantz%26aufirst%3DW.%2BC.%2BK.%26atitle%3DEvaluating%2520the%2520Advantages%2520of%2520Using%25203D-Enriched%2520Fragments%2520for%2520Targeting%2520BET%2520Bromodomains%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26issue%3D12%26spage%3D1648%26epage%3D1654%26doi%3D10.1021%2Facsmedchemlett.9b00414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeGrado, W. F.</span></span> <span> </span><span class="NLM_article-title">Exploring Organosilane Amines as Potent Inhibitors and Structural Probes of Influenza a Virus M2 Proton Channel</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>133</i></span> (<span class="NLM_issue">35</span>),  <span class="NLM_fpage">13844</span>– <span class="NLM_lpage">13847</span>, <span class="refDoi"> DOI: 10.1021/ja2050666</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja2050666" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVSrtL3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2011&pages=13844-13847&issue=35&author=J.+Wangauthor=C.+Maauthor=Y.+Wuauthor=R.+A.+Lambauthor=L.+H.+Pintoauthor=W.+F.+DeGrado&title=Exploring+Organosilane+Amines+as+Potent+Inhibitors+and+Structural+Probes+of+Influenza+a+Virus+M2+Proton+Channel&doi=10.1021%2Fja2050666"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring Organosilane Amines as Potent Inhibitors and Structural Probes of Influenza A Virus M2 Proton Channel</span></div><div class="casAuthors">Wang, Jun; Ma, Chunlong; Wu, Yibing; Lamb, Robert A.; Pinto, Lawrence H.; DeGrado, William F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">13844-13847</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We describe the use of organosilanes as inhibitors and structural probes of a membrane protein, the M2 proton channel from influenza A virus.  Organosilane amine inhibitors were found to be generally as potent as their carbon analogs in targeting WT A/M2 and more potent against the drug-resistant A/M2-V27A mutant.  In addn., intermol. NOESY spectra with dimethyl-substituted organosilane amine inhibitors clearly located the drug binding site at the N-terminal lumen of the A/M2 channel close to V27.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodM11JsKORRLVg90H21EOLACvtfcHk0liBgYKfyCk-zQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVSrtL3E&md5=28cf0b24fbe543718a92d2c2c862ef76</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1021%2Fja2050666&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja2050666%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DLamb%26aufirst%3DR.%2BA.%26aulast%3DPinto%26aufirst%3DL.%2BH.%26aulast%3DDeGrado%26aufirst%3DW.%2BF.%26atitle%3DExploring%2520Organosilane%2520Amines%2520as%2520Potent%2520Inhibitors%2520and%2520Structural%2520Probes%2520of%2520Influenza%2520a%2520Virus%2520M2%2520Proton%2520Channel%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2011%26volume%3D133%26issue%3D35%26spage%3D13844%26epage%3D13847%26doi%3D10.1021%2Fja2050666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tacke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertermann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burschka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dörrich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerhans, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wünsch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnason, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjornsson, R.</span></span> <span> </span><span class="NLM_article-title">High-Affinity, Selective σ Ligands of the 1,2,3,4-Tetrahydro-1,4’-Silaspiro[Naphthalene-1,4’-Piperidine] Type: Syntheses, Structures, and Pharmacological Properties</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">523</span>– <span class="NLM_lpage">532</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201100423</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1002%2Fcmdc.201100423" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=22076883" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVCktr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=523-532&issue=3&author=R.+Tackeauthor=R.+Bertermannauthor=C.+Burschkaauthor=S.+D%C3%B6rrichauthor=M.+Fischerauthor=B.+M%C3%BCllerauthor=G.+Meyerhansauthor=D.+Schepmannauthor=B.+W%C3%BCnschauthor=I.+Arnasonauthor=R.+Bjornsson&title=High-Affinity%2C+Selective+%CF%83+Ligands+of+the+1%2C2%2C3%2C4-Tetrahydro-1%2C4%E2%80%99-Silaspiro%5BNaphthalene-1%2C4%E2%80%99-Piperidine%5D+Type%3A+Syntheses%2C+Structures%2C+and+Pharmacological+Properties&doi=10.1002%2Fcmdc.201100423"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">High-Affinity, Selective σ Ligands of the 1,2,3,4-tetrahydro-1,4'-silaspiro[naphthalene-1,4'-piperidine] Type: Syntheses, Structures, and Pharmacological Properties</span></div><div class="casAuthors">Tacke, Reinhold; Bertermann, Ruediger; Burschka, Christian; Doerrich, Steffen; Fischer, Markus; Mueller, Barbara; Meyerhans, Geraldine; Schepmann, Dirk; Wuensch, Bernhard; Arnason, Ingvar; Bjornsson, Ragnar</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">523-532</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The 1'-organyl-1,2,3,4-tetrahydrospiro[naphthalene-1,4'-piperidine] derivs. 1a-4a [for which organyl = benzyl (1a), 4-methoxybenzyl (2a), 2-phenylethyl (3a), or 3-methylbut-2-enyl (4a)] are high-affinity, selective σ1 ligands.  The corresponding sila-analogs 1b-4b (replacement of the carbon spirocenter with a silicon atom) were synthesized in multistep syntheses, starting from dichlorodivinylsilane, and were isolated as the hydrochlorides 1b·HCl-4b·HCl.  Compds. 1a·HCl-4a·HCl and 1b·HCl-4b·HCl were structurally characterized by NMR spectroscopy (1H, 13C, 29Si) in soln., and the C/Si analogs 3a·HCl and 3b·HCl were studied by single-crystal x-ray diffraction.  These structural investigations were complemented by computational studies.  The σ1 and σ2 receptor affinities of the C/Si pairs 1a/1b-4a/4b were studied with radioligand binding assays.  The σ1 receptor affinity of the silicon compds. 1b-4b is slightly higher than that of the corresponding carbon analogs 1a-4a.  Because affinity for the σ2 receptor is decreased by the C/Si exchange, the σ1/σ2 selectivity of the silicon compds. is considerably improved, indicating that the C→Si switch strategy is a powerful tool for modulating both pharmacol. potency and selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx8E6SDujuvLVg90H21EOLACvtfcHk0liBgYKfyCk-zQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVCktr3N&md5=a0acc209982a90476d82e8e3be133b9c</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201100423&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201100423%26sid%3Dliteratum%253Aachs%26aulast%3DTacke%26aufirst%3DR.%26aulast%3DBertermann%26aufirst%3DR.%26aulast%3DBurschka%26aufirst%3DC.%26aulast%3DD%25C3%25B6rrich%26aufirst%3DS.%26aulast%3DFischer%26aufirst%3DM.%26aulast%3DM%25C3%25BCller%26aufirst%3DB.%26aulast%3DMeyerhans%26aufirst%3DG.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DW%25C3%25BCnsch%26aufirst%3DB.%26aulast%3DArnason%26aufirst%3DI.%26aulast%3DBjornsson%26aufirst%3DR.%26atitle%3DHigh-Affinity%252C%2520Selective%2520%25CF%2583%2520Ligands%2520of%2520the%25201%252C2%252C3%252C4-Tetrahydro-1%252C4%25E2%2580%2599-Silaspiro%255BNaphthalene-1%252C4%25E2%2580%2599-Piperidine%255D%2520Type%253A%2520Syntheses%252C%2520Structures%252C%2520and%2520Pharmacological%2520Properties%26jtitle%3DChemMedChem%26date%3D2012%26volume%3D7%26issue%3D3%26spage%3D523%26epage%3D532%26doi%3D10.1002%2Fcmdc.201100423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pissarnitski, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josien, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clader, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burnett, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terracina, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyde, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, E. M.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Novel, Potent Spirocyclic Series of γ-Secretase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">8806</span>– <span class="NLM_lpage">8817</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00774</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00774" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslWltrjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8806-8817&issue=22&author=Z.+Zhaoauthor=D.+A.+Pissarnitskiauthor=H.+B.+Josienauthor=W.-L.+Wuauthor=R.+Xuauthor=H.+Liauthor=J.+W.+Claderauthor=D.+A.+Burnettauthor=G.+Terracinaauthor=L.+Hydeauthor=J.+Leeauthor=L.+Songauthor=L.+Zhangauthor=E.+M.+Parker&title=Discovery+of+a+Novel%2C+Potent+Spirocyclic+Series+of+%CE%B3-Secretase+Inhibitors&doi=10.1021%2Facs.jmedchem.5b00774"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Novel, Potent Spirocyclic Series of γ-Secretase Inhibitors</span></div><div class="casAuthors">Zhao, Zhiqiang; Pissarnitski, Dmitri A.; Josien, Hubert B.; Wu, Wen-Lian; Xu, Ruo; Li, Hongmei; Clader, John W.; Burnett, Duane A.; Terracina, Giuseppe; Hyde, Lynn; Lee, Julie; Song, Lixin; Zhang, Lili; Parker, Eric M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8806-8817</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the present paper, we described the design, synthesis, SAR, and biol. profile of a novel spirocyclic sulfone series of γ-secretase inhibitors (GSIs) related to MRK-560.  We utilized an addnl. spirocyclic ring system to stabilize the active chair conformation of the parent γ-secretase inhibitors.  The resulting series is devoid of the CYP2C9 inhibition liability of MRK-560.  A few representative analogs were assessed in a nontransgenic animal model of Alzheimer's disease (AD), demonstrating redn. of amyloid-β (Aβ) in the CNS after acute oral dosing.  A spirocyclic phosphonate was identified as the optimal ring system for both potency and pharmacokinetics.  Compared to GSIs studied in the clinic, representative spirocyclic phosphonate 18a(-) features improved selectivity for the inhibition of the PS-1 isoform of γ-secretase (33-fold vs PS-2), which may alleviate the adverse effect profile of the clin. GSIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7tRDNg55f57Vg90H21EOLACvtfcHk0lg2j9UX15GY4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslWltrjO&md5=18b4d8358b5768006308934f471a2c3b</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00774&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00774%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DPissarnitski%26aufirst%3DD.%2BA.%26aulast%3DJosien%26aufirst%3DH.%2BB.%26aulast%3DWu%26aufirst%3DW.-L.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DClader%26aufirst%3DJ.%2BW.%26aulast%3DBurnett%26aufirst%3DD.%2BA.%26aulast%3DTerracina%26aufirst%3DG.%26aulast%3DHyde%26aufirst%3DL.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DSong%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DParker%26aufirst%3DE.%2BM.%26atitle%3DDiscovery%2520of%2520a%2520Novel%252C%2520Potent%2520Spirocyclic%2520Series%2520of%2520%25CE%25B3-Secretase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D22%26spage%3D8806%26epage%3D8817%26doi%3D10.1021%2Facs.jmedchem.5b00774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elshahawi, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trindade-Silva, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanora, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flores, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vizzoni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrago, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soares, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Concepcion, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Distel, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haygood, M. G.</span></span> <span> </span><span class="NLM_article-title">Boronated Tartrolon Antibiotic Produced by Symbiotic Cellulose-Degrading Bacteria in Shipworm Gills</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">E295</span>– <span class="NLM_lpage">304</span>, <span class="refDoi"> DOI: 10.1073/pnas.1213892110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1073%2Fpnas.1213892110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=23288898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFCgtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=E295-304&issue=4&author=S.+I.+Elshahawiauthor=A.+E.+Trindade-Silvaauthor=A.+Hanoraauthor=A.+W.+Hanauthor=M.+S.+Floresauthor=V.+Vizzoniauthor=C.+G.+Schragoauthor=C.+A.+Soaresauthor=G.+P.+Concepcionauthor=D.+L.+Distelauthor=E.+W.+Schmidtauthor=M.+G.+Haygood&title=Boronated+Tartrolon+Antibiotic+Produced+by+Symbiotic+Cellulose-Degrading+Bacteria+in+Shipworm+Gills&doi=10.1073%2Fpnas.1213892110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Boronated tartrolon antibiotic produced by symbiotic cellulose-degrading bacteria in shipworm gills</span></div><div class="casAuthors">Elshahawi, Sherif I.; Trindade-Silva, Amaro E.; Hanora, Amro; Han, Andrew W.; Flores, Malem S.; Vizzoni, Vinicius; Schrago, Carlos G.; Soares, Carlos A.; Concepcion, Gisela P.; Distel, Dan L.; Schmidt, Eric W.; Haygood, Margo G.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">E295-E304, SE295/1-SE295/12</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Shipworms are marine wood-boring bivalve mollusks (family Teredinidae) that harbor a community of closely related Gammaproteobacteria as intracellular endosymbionts in their gills.  These symbionts have been proposed to assist the shipworm host in cellulose digestion and have been shown to play a role in nitrogen fixation.  The genome of one strain of Teredinibacter turnerae, the first shipworm symbiont to be cultivated, was sequenced, revealing potential as a rich source of polyketides and nonribosomal peptides.  Bioassay-guided fractionation led to the isolation and identification of two macrodioloide polyketides belonging to the tartrolon class.  Both compds. were found to possess antibacterial properties, and the major compd. was found to inhibit other shipworm symbiont strains and various pathogenic bacteria.  The gene cluster responsible for the synthesis of these compds. was identified and characterized, and the ketosynthase domains were analyzed phylogenetically.  Reverse-transcription PCR in addn. to liq. chromatog. and high-resoln. mass spectrometry and tandem mass spectrometry revealed the transcription of these genes and the presence of the compds. in the shipworm, suggesting that the gene cluster is expressed in vivo and that the compds. may fulfill a specific function for the shipworm host.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqP328LON6w7rVg90H21EOLACvtfcHk0lg2j9UX15GY4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFCgtL8%253D&md5=61392a6667c2af2379c1057d14ed891a</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1213892110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1213892110%26sid%3Dliteratum%253Aachs%26aulast%3DElshahawi%26aufirst%3DS.%2BI.%26aulast%3DTrindade-Silva%26aufirst%3DA.%2BE.%26aulast%3DHanora%26aufirst%3DA.%26aulast%3DHan%26aufirst%3DA.%2BW.%26aulast%3DFlores%26aufirst%3DM.%2BS.%26aulast%3DVizzoni%26aufirst%3DV.%26aulast%3DSchrago%26aufirst%3DC.%2BG.%26aulast%3DSoares%26aufirst%3DC.%2BA.%26aulast%3DConcepcion%26aufirst%3DG.%2BP.%26aulast%3DDistel%26aufirst%3DD.%2BL.%26aulast%3DSchmidt%26aufirst%3DE.%2BW.%26aulast%3DHaygood%26aufirst%3DM.%2BG.%26atitle%3DBoronated%2520Tartrolon%2520Antibiotic%2520Produced%2520by%2520Symbiotic%2520Cellulose-Degrading%2520Bacteria%2520in%2520Shipworm%2520Gills%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26issue%3D4%26spage%3DE295%26epage%3D304%26doi%3D10.1073%2Fpnas.1213892110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murugan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinnapattu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, F.-R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, P. S.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Novel Benzoxaborinin-4-ones and Its Application in Indolin-2-ones Synthesis Using a Suzuki–Miyaura Reaction Protocol</span>. <i>RSC Adv.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">46</span>),  <span class="NLM_fpage">36902</span>– <span class="NLM_lpage">36905</span>, <span class="refDoi"> DOI: 10.1039/C5RA05755H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1039%2FC5RA05755H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsFelt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=36902-36905&issue=46&author=K.+Muruganauthor=M.+Chinnapattuauthor=F.-R.+N.+Khanauthor=P.+S.+Iyer&title=Synthesis+of+Novel+Benzoxaborinin-4-ones+and+Its+Application+in+Indolin-2-ones+Synthesis+Using+a+Suzuki%E2%80%93Miyaura+Reaction+Protocol&doi=10.1039%2FC5RA05755H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of novel benzoxaborinin-4-ones and its application in indolin-2-ones synthesis using a Suzuki-Miyaura reaction protocol</span></div><div class="casAuthors">Murugan, Kannan; Chinnapattu, Murugan; Nawaz Khan, Fazlur-Rahman; Iyer, Pravin S.</div><div class="citationInfo"><span class="NLM_cas:title">RSC Advances</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">36902-36905</span>CODEN:
                <span class="NLM_cas:coden">RSCACL</span>;
        ISSN:<span class="NLM_cas:issn">2046-2069</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The synthesis of novel benzoxaborinin-4-one from substituted isatins and 2-acetyl phenylboronic acid is reported.  Furthermore, the application of these boronic acids to synthesize indolin-2-ones (Z isomer) I (R1 = H, Me, F, Cl, Br; R2 = H, Me; Ar = 4-ClC6H4, 4-CNC6H4, 2-trifluoromethyl-pyridin-5-yl) regioselectively using Suzuki-Miyaura reaction is demonstrated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8gFbsii1kdbVg90H21EOLACvtfcHk0lhuVhxg-n91QQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsFelt78%253D&md5=e4e29f1119da39dc928d6d44a64a5621</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1039%2FC5RA05755H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5RA05755H%26sid%3Dliteratum%253Aachs%26aulast%3DMurugan%26aufirst%3DK.%26aulast%3DChinnapattu%26aufirst%3DM.%26aulast%3DKhan%26aufirst%3DF.-R.%2BN.%26aulast%3DIyer%26aufirst%3DP.%2BS.%26atitle%3DSynthesis%2520of%2520Novel%2520Benzoxaborinin-4-ones%2520and%2520Its%2520Application%2520in%2520Indolin-2-ones%2520Synthesis%2520Using%2520a%2520Suzuki%25E2%2580%2593Miyaura%2520Reaction%2520Protocol%26jtitle%3DRSC%2520Adv.%26date%3D2015%26volume%3D5%26issue%3D46%26spage%3D36902%26epage%3D36905%26doi%3D10.1039%2FC5RA05755H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Natsutani, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamai, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishida, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagaoka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sumiyoshi, T.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Evaluations of Spiro-Fused Benzoxaborin Derivatives as Novel Boron-Containing Compounds</span>. <i>Chem. Biol. Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>93</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">657</span>– <span class="NLM_lpage">665</span>, <span class="refDoi"> DOI: 10.1111/cbdd.13496</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1111%2Fcbdd.13496" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=30721578" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1MXltFynsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2019&pages=657-665&issue=5&author=I.+Natsutaniauthor=R.+Iwataauthor=Y.-S.+Yamaiauthor=K.+Ishidaauthor=Y.+Nagaokaauthor=T.+Sumiyoshi&title=Design%2C+Synthesis+and+Evaluations+of+Spiro-Fused+Benzoxaborin+Derivatives+as+Novel+Boron-Containing+Compounds&doi=10.1111%2Fcbdd.13496"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and evaluations of spiro-fused benzoxaborin derivatives as novel boron-containing compounds</span></div><div class="casAuthors">Natsutani, Itaru; Iwata, Riyo; Yamai, Yu-suke; Ishida, Kyoji; Nagaoka, Yasuo; Sumiyoshi, Takaaki</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">657-665</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Drug design using boron-contg. heterocycles has attracted a great deal of attention because these compds. are believed to possess high biol. activity.  However, information on the synthetic methodol. and pharmacokinetic profiling of boron-contg. compds. is limited.  In this study, we provide a new synthetic route for prepn. of spiro-fused benzoxaborin derivs. and investigate their in vitro pharmacokinetic properties.  Our efforts led to the successful construction of a chem. library of spiro-fused benzoxaborin derivs. with appropriate physicochem. and in vitro pharmacokinetic properties for oral drugs.  These results indicate that the synthesized boron-contg. compds. are therefore eligible for classification in a novel chem. library.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_AUoXSaMKgLVg90H21EOLACvtfcHk0lhuVhxg-n91QQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXltFynsrw%253D&md5=1250bb65fff9cca98d1adc66f410e176</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1111%2Fcbdd.13496&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcbdd.13496%26sid%3Dliteratum%253Aachs%26aulast%3DNatsutani%26aufirst%3DI.%26aulast%3DIwata%26aufirst%3DR.%26aulast%3DYamai%26aufirst%3DY.-S.%26aulast%3DIshida%26aufirst%3DK.%26aulast%3DNagaoka%26aufirst%3DY.%26aulast%3DSumiyoshi%26aufirst%3DT.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Evaluations%2520of%2520Spiro-Fused%2520Benzoxaborin%2520Derivatives%2520as%2520Novel%2520Boron-Containing%2520Compounds%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2019%26volume%3D93%26issue%3D5%26spage%3D657%26epage%3D665%26doi%3D10.1111%2Fcbdd.13496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meazza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rios, R.</span></span> <span> </span><span class="NLM_article-title">New Development in the Enantioselective Synthesis of Spiro Compounds</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>47</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">5946</span>– <span class="NLM_lpage">5996</span>, <span class="refDoi"> DOI: 10.1039/C6CS00825A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1039%2FC6CS00825A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=29953153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1WqtbnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2018&pages=5946-5996&issue=15&author=A.+Dingauthor=M.+Meazzaauthor=H.+Guoauthor=J.+W.+Yangauthor=R.+Rios&title=New+Development+in+the+Enantioselective+Synthesis+of+Spiro+Compounds&doi=10.1039%2FC6CS00825A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">New development in the enantioselective synthesis of spiro compounds</span></div><div class="casAuthors">Ding, Aishun; Meazza, Marta; Guo, Hao; Yang, Jung Woon; Rios, Ramon</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5946-5996</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The enantioselective synthesis of spirocycles has long been pursued by org. chemists.  Despite their unique 3D properties and presence in several natural products, the difficulty in their enantioselective synthesis makes them underrepresented in pharmaceutical libraries.  Since the first pioneering reports of the enantioselective construction of spirosilanes by Tamao et al., significant effort has been devoted towards the development of new promising asym. methodologies.  Remarkably, with the advent of organocatalysis, particularly over six years, the reported methodologies for the synthesis of spirocycles have increased exponentially.  The aim of this review is to summarize the latest trends and developments in the enantioselective synthesis of spirocompounds during these last six years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtCZ_qMqIu3bVg90H21EOLACvtfcHk0lhuVhxg-n91QQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1WqtbnE&md5=25b8984f3ac4125a61794afe6e627634</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1039%2FC6CS00825A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6CS00825A%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DA.%26aulast%3DMeazza%26aufirst%3DM.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DJ.%2BW.%26aulast%3DRios%26aufirst%3DR.%26atitle%3DNew%2520Development%2520in%2520the%2520Enantioselective%2520Synthesis%2520of%2520Spiro%2520Compounds%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2018%26volume%3D47%26issue%3D15%26spage%3D5946%26epage%3D5996%26doi%3D10.1039%2FC6CS00825A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leong, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seah, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karuna, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Susila, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diagana, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dix, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, P.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. W.</span></span> <span> </span><span class="NLM_article-title">Lead Optimization of Spiropyrazolopyridones: A New and Potent Class of Dengue Virus Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">344</span>– <span class="NLM_lpage">348</span>, <span class="refDoi"> DOI: 10.1021/ml500521r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500521r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFehsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=344-348&issue=3&author=B.+Zouauthor=W.+L.+Chanauthor=M.+Dingauthor=S.+Y.+Leongauthor=S.+Nilarauthor=P.+G.+Seahauthor=W.+Liuauthor=R.+Karunaauthor=F.+Blascoauthor=A.+Yipauthor=A.+Chaoauthor=A.+Susilaauthor=H.+Dongauthor=Q.+Y.+Wangauthor=H.+Y.+Xuauthor=K.+Chanauthor=K.+F.+Wanauthor=F.+Guauthor=T.+T.+Diaganaauthor=T.+Wagnerauthor=I.+Dixauthor=P.-Y.+Shiauthor=P.+W.+Smith&title=Lead+Optimization+of+Spiropyrazolopyridones%3A+A+New+and+Potent+Class+of+Dengue+Virus+Inhibitors&doi=10.1021%2Fml500521r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Lead optimization of spiropyrazolopyridones: a new and potent class of Dengue virus inhibitors</span></div><div class="casAuthors">Zou, Bin; Chan, Wai Ling; Ding, Mei; Leong, Seh Yong; Nilar, Shahul; Seah, Peck Gee; Liu, Wei; Karuna, Ratna; Blasco, Francesca; Yip, Andy; Chao, Alex; Susila, Agatha; Dong, Hongping; Wang, Qing Yin; Xu, Hao Ying; Chan, Katherine; Wan, Kah Fei; Gu, Feng; Diagana, Thierry T.; Wagner, Trixie; Dix, Ina; Shi, Pei-Yong; Smith, Paul W.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">344-348</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Spiropyrazolopyridone I was identified, as a novel dengue virus (DENV) inhibitor, from a DENV serotype 2 (DENV-2) high-throughput phenotypic screen.  As a general trend within this chem. class, chiral resoln. of the racemate revealed that R enantiomer was significantly more potent than the S.  Cell-based lead optimization of the spiropyrazolopyridones focusing on improving the physicochem. properties is described.  As a result, an optimal compd. II, with balanced in vitro potency and pharmacokinetic profile, achieved about 1.9 log viremia redn. at 3 × 50 mg/kg (bid) or 3 × 100 mg/kg (QD) oral doses in the dengue in vivo mouse efficacy model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6sl_5dOn9m7Vg90H21EOLACvtfcHk0ljyEt2G6Ajtnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFehsbY%253D&md5=25972b876e5b117d711213db3c179159</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1021%2Fml500521r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500521r%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DB.%26aulast%3DChan%26aufirst%3DW.%2BL.%26aulast%3DDing%26aufirst%3DM.%26aulast%3DLeong%26aufirst%3DS.%2BY.%26aulast%3DNilar%26aufirst%3DS.%26aulast%3DSeah%26aufirst%3DP.%2BG.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DKaruna%26aufirst%3DR.%26aulast%3DBlasco%26aufirst%3DF.%26aulast%3DYip%26aufirst%3DA.%26aulast%3DChao%26aufirst%3DA.%26aulast%3DSusila%26aufirst%3DA.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DQ.%2BY.%26aulast%3DXu%26aufirst%3DH.%2BY.%26aulast%3DChan%26aufirst%3DK.%26aulast%3DWan%26aufirst%3DK.%2BF.%26aulast%3DGu%26aufirst%3DF.%26aulast%3DDiagana%26aufirst%3DT.%2BT.%26aulast%3DWagner%26aufirst%3DT.%26aulast%3DDix%26aufirst%3DI.%26aulast%3DShi%26aufirst%3DP.-Y.%26aulast%3DSmith%26aufirst%3DP.%2BW.%26atitle%3DLead%2520Optimization%2520of%2520Spiropyrazolopyridones%253A%2520A%2520New%2520and%2520Potent%2520Class%2520of%2520Dengue%2520Virus%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26issue%3D3%26spage%3D344%26epage%3D348%26doi%3D10.1021%2Fml500521r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tai, V. W.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrido, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maynard, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pouliot, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seal, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creech, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kryn, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baughman, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peat, A. J.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Spirocyclic Compounds as HCV Replication Inhibitors by Targeting Viral NS4B Protein</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2288</span>– <span class="NLM_lpage">2294</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.03.080</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2Fj.bmcl.2014.03.080" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=24731273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmt1Wlu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=2288-2294&issue=10&author=V.+W.-F.+Taiauthor=D.+Garridoauthor=D.+J.+Priceauthor=A.+Maynardauthor=J.+J.+Pouliotauthor=Z.+Xiongauthor=J.+W.+Sealauthor=K.+L.+Creechauthor=L.+H.+Krynauthor=T.+M.+Baughmanauthor=A.+J.+Peat&title=Design+and+Synthesis+of+Spirocyclic+Compounds+as+HCV+Replication+Inhibitors+by+Targeting+Viral+NS4B+Protein&doi=10.1016%2Fj.bmcl.2014.03.080"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of spirocyclic compounds as HCV replication inhibitors by targeting viral NS4B protein</span></div><div class="casAuthors">Tai, Vincent W.-F.; Garrido, Dulce; Price, Daniel J.; Maynard, Andrew; Pouliot, Jeffrey J.; Xiong, Zhiping; Seal, John W.; Creech, Katrina L.; Kryn, Luz H.; Baughman, Todd M.; Peat, Andrew J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2288-2294</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Pyrazolo[1,5-a]pyridinecarbonyl-substituted spiropiperidines such as pyrazolo[1,5-a]pyridinecarbonyl dispirocyclopropanedioxanepiperidinol I and pyrazolo[1,5-a]pyridinecarbonyl hydroxyspiropiperidineoxazolidinone II were prepd. as inhibitors of hepatitis C viral protein NS4B; their inhibition of HCV replicons 1a and 1b and their lack of cytotoxicity in human cells at concns. < 25 μM were detd.  Spirocyclic piperidine ketals such as I were prepd. which showed in vitro anti-HCV activities; for example, I showed EC50 of 1.5 nM and 1.2 nM against genotype 1a and 1b replicons, resp., in vitro.  Spirocyclic piperidine oxazolidinones such as II were prepd.; II showed EC50 values of 10.9 nM and 6.1 nM against HCV 1a and 1b replicons, resp.  The solubilities, permeabilities in the presence of P-gp transporters, half-life, and calcd. lipophilicities, polar surface areas, and lipophilic ligand efficiencies were detd. for selected compds. including I and II.  Both I and II bound directly to non-structural NS4B protein in vitro (IC50 values of 10.2 nM and 30.4 nM, resp.); I and II exhibited reduced potency (27-185-fold increases in EC50 values) in replicons contg. resistance mutations encoding changes (H94N and V105M) in the NS4B protein.  The structure of a dispirocyclopropanedioxanepiperidine di-O-p-toluoyltartrate salt used in the prepn. of I was detd. by X-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0Tcrswh6YCrVg90H21EOLACvtfcHk0ljyEt2G6Ajtnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmt1Wlu7s%253D&md5=e221782d8c961d7b60348c98d3de0da1</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.03.080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.03.080%26sid%3Dliteratum%253Aachs%26aulast%3DTai%26aufirst%3DV.%2BW.-F.%26aulast%3DGarrido%26aufirst%3DD.%26aulast%3DPrice%26aufirst%3DD.%2BJ.%26aulast%3DMaynard%26aufirst%3DA.%26aulast%3DPouliot%26aufirst%3DJ.%2BJ.%26aulast%3DXiong%26aufirst%3DZ.%26aulast%3DSeal%26aufirst%3DJ.%2BW.%26aulast%3DCreech%26aufirst%3DK.%2BL.%26aulast%3DKryn%26aufirst%3DL.%2BH.%26aulast%3DBaughman%26aufirst%3DT.%2BM.%26aulast%3DPeat%26aufirst%3DA.%2BJ.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Spirocyclic%2520Compounds%2520as%2520HCV%2520Replication%2520Inhibitors%2520by%2520Targeting%2520Viral%2520NS4B%2520Protein%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26issue%3D10%26spage%3D2288%26epage%3D2294%26doi%3D10.1016%2Fj.bmcl.2014.03.080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwatani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morishita, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakanishi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maezaki, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of Spiro[Indole-3,2’-Pyrrolidin]-2(1H)-One Based Inhibitors Targeting Brr2, a Core Component of the U5 SnRNP</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">4753</span>– <span class="NLM_lpage">4767</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2017.07.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2Fj.bmc.2017.07.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=28751196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1egsLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=4753-4767&issue=17&author=M.+Itoauthor=M.+Iwataniauthor=T.+Yamamotoauthor=T.+Tanakaauthor=T.+Kawamotoauthor=D.+Morishitaauthor=A.+Nakanishiauthor=H.+Maezaki&title=Discovery+of+Spiro%5BIndole-3%2C2%E2%80%99-Pyrrolidin%5D-2%281H%29-One+Based+Inhibitors+Targeting+Brr2%2C+a+Core+Component+of+the+U5+SnRNP&doi=10.1016%2Fj.bmc.2017.07.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of spiro[indole-3,2'-pyrrolidin]-2(1H)-one based inhibitors targeting Brr2, a core component of the U5 snRNP</span></div><div class="casAuthors">Ito, Masahiro; Iwatani, Misa; Yamamoto, Takeshi; Tanaka, Toshio; Kawamoto, Tomohiro; Morishita, Daisuke; Nakanishi, Atsushi; Maezaki, Hironobu</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4753-4767</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Bad response to refrigeration 2 (Brr2) is a member of the Ski2-like RNA helicases, and an essential component of the U5 small nuclear ribonucleoprotein (snRNP).  A particularly important role of Brr2 is the ATP-dependent unwinding of the U4/U6 RNA duplex, which is a crit. step in spliceosomal activation.  Despite its biol. importance, selective inhibitor for Brr2 had not been reported until the authors' recent report.  Here, the authors describe novel and structurally distinct spiro[indole-3,2'-pyrrolidin]-2(1H)-one based Brr2 inhibitors with superior activity to the previously reported 4,6-dihydropyrido[4,3-d]pyrimidine-2,7(1H,3H)-dione series.  Using an RNA dependent ATPase assay as a guide, high-throughput screening, hit validation by structure-activity relationship (SAR) study, and subsequent chem. optimization to increase the ATPase inhibitory activity were performed.  Thereafter, selectivity and helicase inhibitory activity of optimized compds. were confirmed.  In the course of the study, compds. were synthesized using a three-component reaction, which accelerated the optimization process.  All these efforts finally culminated in the discovery of the potent and selective Brr2 inhibitors (32a (3S,3'R,5'S)-5-fluoro-5'-isobutyl-3'-methyl-1'-((1-methyl-1H-imidazol-4-yl)carbonyl)spiro[indole-3,2'-pyrrolidin]-2(1H)-one) and 33a ((3S,3'R,5'S)-1'-((1-Benzyl-1H-imidazol-4-yl)carbonyl)-5-fluoro-5-isobutyl-3-methylspiro[indole-3,2-pyrrolidin]-2(1H)-one) exhibiting helicase inhibitory activity at submicromolar concns.  Thus, compds. 32a and 33a could be valuable mol. probes to study the functions of Brr2 and mol. machinery of RNA splicing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtRxC2SlBj6rVg90H21EOLACvtfcHk0lj_gHSS5N09PA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1egsLnL&md5=7356fbabe559b6d177b59cd49c316c7e</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.07.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.07.017%26sid%3Dliteratum%253Aachs%26aulast%3DIto%26aufirst%3DM.%26aulast%3DIwatani%26aufirst%3DM.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DKawamoto%26aufirst%3DT.%26aulast%3DMorishita%26aufirst%3DD.%26aulast%3DNakanishi%26aufirst%3DA.%26aulast%3DMaezaki%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520Spiro%255BIndole-3%252C2%25E2%2580%2599-Pyrrolidin%255D-2%25281H%2529-One%2520Based%2520Inhibitors%2520Targeting%2520Brr2%252C%2520a%2520Core%2520Component%2520of%2520the%2520U5%2520SnRNP%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26issue%3D17%26spage%3D4753%26epage%3D4767%26doi%3D10.1016%2Fj.bmc.2017.07.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Imaeda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ono, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hori, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsukawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takagi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujioka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarui, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imanishi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inatomi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kajino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itoh, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishida, H.</span></span> <span> </span><span class="NLM_article-title">Discovery, Synthesis, and Structure-Activity Relations of 3,4-Dihydro-1H-Spiro(Naphthalene-2,2’-Piperidin)-1-Ones as Potassium-Competitive Acid Blockers</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">3719</span>– <span class="NLM_lpage">3735</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2017.05.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2Fj.bmc.2017.05.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=28522264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvVSjtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=3719-3735&issue=14&author=T.+Imaedaauthor=K.+Onoauthor=K.+Nakaiauthor=Y.+Horiauthor=J.+Matsukawaauthor=T.+Takagiauthor=Y.+Fujiokaauthor=N.+Taruiauthor=M.+Kondoauthor=A.+Imanishiauthor=N.+Inatomiauthor=M.+Kajinoauthor=F.+Itohauthor=H.+Nishida&title=Discovery%2C+Synthesis%2C+and+Structure-Activity+Relations+of+3%2C4-Dihydro-1H-Spiro%28Naphthalene-2%2C2%E2%80%99-Piperidin%29-1-Ones+as+Potassium-Competitive+Acid+Blockers&doi=10.1016%2Fj.bmc.2017.05.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery, synthesis, and structure-activity relations of 3,4-dihydro-1H-spiro(naphthalene-2,2'-piperidin)-1-ones as potassium-competitive acid blockers</span></div><div class="casAuthors">Imaeda, Toshihiro; Ono, Koji; Nakai, Kazuo; Hori, Yasunobu; Matsukawa, Jun; Takagi, Terufumi; Fujioka, Yasushi; Tarui, Naoki; Kondo, Mitsuyo; Imanishi, Akio; Inatomi, Nobuhiro; Kajino, Masahiro; Itoh, Fumio; Nishida, Haruyuki</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3719-3735</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">With the aim to discover a gastric antisecretory agent more potent than the existing proton pump inhibitors, novel 3,4-dihydro-1H-spiro(naphthalene-2,2'-piperidin)-1-one derivs., which could occupy two important lipophilic pockets (described as LP-1 and LP-2) of H+,K+-ATPase and can strongly bind to the K+-binding site, were designed based on a docking model.  Among the compds. synthesized, compd. I showed a strong H+,K+-ATPase-inhibitory activity and a high stomach concn. in rats, resulting in potent inhibitory action on histamine-stimulated gastric acid secretion in rats.  Furthermore, I exerted significant inhibitory action on histamine-stimulated gastric-acid secretion in rats with a rapid onset and moderate duration of action after the administration.  These findings may lead to a new insight into the drug design of potassium-competitive acid blockers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwWczD6yvNbLVg90H21EOLACvtfcHk0lj_gHSS5N09PA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvVSjtL8%253D&md5=2cc4366eab35eb4e50d30b714bda3c0d</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.05.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.05.012%26sid%3Dliteratum%253Aachs%26aulast%3DImaeda%26aufirst%3DT.%26aulast%3DOno%26aufirst%3DK.%26aulast%3DNakai%26aufirst%3DK.%26aulast%3DHori%26aufirst%3DY.%26aulast%3DMatsukawa%26aufirst%3DJ.%26aulast%3DTakagi%26aufirst%3DT.%26aulast%3DFujioka%26aufirst%3DY.%26aulast%3DTarui%26aufirst%3DN.%26aulast%3DKondo%26aufirst%3DM.%26aulast%3DImanishi%26aufirst%3DA.%26aulast%3DInatomi%26aufirst%3DN.%26aulast%3DKajino%26aufirst%3DM.%26aulast%3DItoh%26aufirst%3DF.%26aulast%3DNishida%26aufirst%3DH.%26atitle%3DDiscovery%252C%2520Synthesis%252C%2520and%2520Structure-Activity%2520Relations%2520of%25203%252C4-Dihydro-1H-Spiro%2528Naphthalene-2%252C2%25E2%2580%2599-Piperidin%2529-1-Ones%2520as%2520Potassium-Competitive%2520Acid%2520Blockers%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26issue%3D14%26spage%3D3719%26epage%3D3735%26doi%3D10.1016%2Fj.bmc.2017.05.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Michaelides, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kluge, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patane, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Drie, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Risi, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantei, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hertel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karukurichi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nesterov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McElligott, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vries, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langston, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marmorstein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasko, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bromberg, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kesicki, E. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of Spiro Oxazolidinediones as Selective, Orally Bioavailable Inhibitors of P300/CBP Histone Acetyltransferases</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">28</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00395</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00395" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFOqsrnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=28-33&issue=1&author=M.+R.+Michaelidesauthor=A.+Klugeauthor=M.+Pataneauthor=J.+H.+Van+Drieauthor=C.+Wangauthor=T.+M.+Hansenauthor=R.+M.+Risiauthor=R.+Manteiauthor=C.+Hertelauthor=K.+Karukurichiauthor=A.+Nesterovauthor=D.+McElligottauthor=P.+de+Vriesauthor=J.+W.+Langstonauthor=P.+A.+Coleauthor=R.+Marmorsteinauthor=H.+Liuauthor=L.+Laskoauthor=K.+D.+Brombergauthor=A.+Laiauthor=E.+A.+Kesicki&title=Discovery+of+Spiro+Oxazolidinediones+as+Selective%2C+Orally+Bioavailable+Inhibitors+of+P300%2FCBP+Histone+Acetyltransferases&doi=10.1021%2Facsmedchemlett.7b00395"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Spiro Oxazolidinediones as Selective, Orally Bioavailable Inhibitors of p300/CBP Histone Acetyltransferases</span></div><div class="casAuthors">Michaelides, Michael R.; Kluge, Arthur; Patane, Michael; Van Drie, John H.; Wang, Ce; Hansen, T. Matthew; Risi, Roberto M.; Mantei, Robert; Hertel, Carmen; Karukurichi, Kannan; Nesterov, Alexandre; McElligott, David; de Vries, Peter; Langston, J. William; Cole, Philip A.; Marmorstein, Ronen; Liu, Hong; Lasko, Loren; Bromberg, Kenneth D.; Lai, Albert; Kesicki, Edward A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-33</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">P300 and its paralog CBP can acetylate histones and other proteins and have been implicated in a no. of diseases characterized by aberrant gene activation, such as cancer.  A novel, highly selective, orally bioavailable histone acetyltransferase (HAT) domain inhibitor has been identified through virtual ligand screening and subsequent optimization of a unique hydantoin screening hit.  Conformational restraint in the form of a spirocyclization followed by substitution with a urea led to a significant improvement in potency.  Replacement of the hydantoin moiety with an oxazolidinedione followed by fluoro substitution led to A-485, which exhibits potent cell activity, low clearance, and high oral bioavailability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ091OW0sfXbVg90H21EOLACvtfcHk0lj_gHSS5N09PA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFOqsrnE&md5=3ba083fc5e148d06457d2e4015ac7475</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00395%26sid%3Dliteratum%253Aachs%26aulast%3DMichaelides%26aufirst%3DM.%2BR.%26aulast%3DKluge%26aufirst%3DA.%26aulast%3DPatane%26aufirst%3DM.%26aulast%3DVan%2BDrie%26aufirst%3DJ.%2BH.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DHansen%26aufirst%3DT.%2BM.%26aulast%3DRisi%26aufirst%3DR.%2BM.%26aulast%3DMantei%26aufirst%3DR.%26aulast%3DHertel%26aufirst%3DC.%26aulast%3DKarukurichi%26aufirst%3DK.%26aulast%3DNesterov%26aufirst%3DA.%26aulast%3DMcElligott%26aufirst%3DD.%26aulast%3Dde%2BVries%26aufirst%3DP.%26aulast%3DLangston%26aufirst%3DJ.%2BW.%26aulast%3DCole%26aufirst%3DP.%2BA.%26aulast%3DMarmorstein%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DLasko%26aufirst%3DL.%26aulast%3DBromberg%26aufirst%3DK.%2BD.%26aulast%3DLai%26aufirst%3DA.%26aulast%3DKesicki%26aufirst%3DE.%2BA.%26atitle%3DDiscovery%2520of%2520Spiro%2520Oxazolidinediones%2520as%2520Selective%252C%2520Orally%2520Bioavailable%2520Inhibitors%2520of%2520P300%252FCBP%2520Histone%2520Acetyltransferases%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26issue%3D1%26spage%3D28%26epage%3D33%26doi%3D10.1021%2Facsmedchemlett.7b00395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Volgraf, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huestis, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purkey, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geck Do, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyssikatos, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rana, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vigers, G. P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis, Characterization, and PK/PD Studies of a Series of Spirocyclic Pyranochromene BACE1 Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2477</span>– <span class="NLM_lpage">2480</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.04.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2Fj.bmcl.2014.04.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=24780121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnt1elsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=2477-2480&issue=11&author=M.+Volgrafauthor=L.+Chanauthor=M.+P.+Huestisauthor=H.+E.+Purkeyauthor=M.+Burkardauthor=M.+Geck+Doauthor=J.+Harrisauthor=K.+W.+Huntauthor=X.+Liuauthor=J.+P.+Lyssikatosauthor=S.+Ranaauthor=A.+A.+Thomasauthor=G.+P.+A.+Vigersauthor=M.+Siu&title=Synthesis%2C+Characterization%2C+and+PK%2FPD+Studies+of+a+Series+of+Spirocyclic+Pyranochromene+BACE1+Inhibitors&doi=10.1016%2Fj.bmcl.2014.04.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, characterization, and PK/PD studies of a series of spirocyclic pyranochromene BACE1 inhibitors</span></div><div class="casAuthors">Volgraf, Matthew; Chan, Lina; Huestis, Malcolm P.; Purkey, Hans E.; Burkard, Michael; Geck Do, Mary; Harris, Julie; Hunt, Kevin W.; Liu, Xingrong; Lyssikatos, Joseph P.; Rana, Sumeet; Thomas, Allen A.; Vigers, Guy P. A.; Siu, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2477-2480</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The development of 1,3,4,4a,5,10a-hexahydropyrano[3,4-b]chromene analogs as BACE1 inhibitors is described.  Introduction of the spirocyclic pyranochromene scaffold yielded several advantages over previous generation cores, including increased potency, reduced efflux, and reduced CYP2D6 inhibition.  Compd. I (BACE1 IC50 = 110 nM) demonstrated a redn. in CSF Aβ in wild type rats after a single dose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruGUhiyWMFFLVg90H21EOLACvtfcHk0lgkqEQG9XHwCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnt1elsLc%253D&md5=b18305c310576e6fb976e5dc9c98a4f6</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.04.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.04.012%26sid%3Dliteratum%253Aachs%26aulast%3DVolgraf%26aufirst%3DM.%26aulast%3DChan%26aufirst%3DL.%26aulast%3DHuestis%26aufirst%3DM.%2BP.%26aulast%3DPurkey%26aufirst%3DH.%2BE.%26aulast%3DBurkard%26aufirst%3DM.%26aulast%3DGeck%2BDo%26aufirst%3DM.%26aulast%3DHarris%26aufirst%3DJ.%26aulast%3DHunt%26aufirst%3DK.%2BW.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLyssikatos%26aufirst%3DJ.%2BP.%26aulast%3DRana%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DA.%2BA.%26aulast%3DVigers%26aufirst%3DG.%2BP.%2BA.%26aulast%3DSiu%26aufirst%3DM.%26atitle%3DSynthesis%252C%2520Characterization%252C%2520and%2520PK%252FPD%2520Studies%2520of%2520a%2520Series%2520of%2520Spirocyclic%2520Pyranochromene%2520BACE1%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26issue%3D11%26spage%3D2477%26epage%3D2480%26doi%3D10.1016%2Fj.bmcl.2014.04.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chao, W.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, T.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhari, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, B.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, P.-T.</span></span> <span> </span><span class="NLM_article-title">The Azatryptophan-Based Fluorescent Platform for in Vitro Rapid Screening of Inhibitors Disrupting IKKβ-NEMO Interaction</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">504</span>– <span class="NLM_lpage">511</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2018.09.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2Fj.bioorg.2018.09.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=30245232" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslOjt7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2018&pages=504-511&author=W.-C.+Chaoauthor=T.-H.+Chiangauthor=P.+D.+Chaudhariauthor=L.-J.+Linauthor=J.-F.+Luauthor=B.-C.+Hongauthor=J.-S.+Wangauthor=T.-C.+Linauthor=J.-Y.+Shenauthor=P.-T.+Chou&title=The+Azatryptophan-Based+Fluorescent+Platform+for+in+Vitro+Rapid+Screening+of+Inhibitors+Disrupting+IKK%CE%B2-NEMO+Interaction&doi=10.1016%2Fj.bioorg.2018.09.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">The azatryptophan-based fluorescent platform for in vitro rapid screening of inhibitors disrupting IKKβ-NEMO interaction</span></div><div class="casAuthors">Chao, Wei-Chih; Chiang, Tzu-Hsuan; Chaudhari, Prakash D.; Lin, Li-Ju; Lu, Jyh-Feng; Hong, Bor-Cherng; Wang, Jinn-Shyan; Lin, Ta-Chun; Shen, Jiun-Yi; Chou, Pi-Tai</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">504-511</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The nuclear factor-κB (NF-κB) plays an important role in inflammatory and immune responses.  Aberrant NF-κB signaling is implicated in multiple disorders, including cancer.  Targeting the regulatory scaffold subunit IκB kinase γ (IKKγ/NEMO) as therapeutic interventions could be promising due to its specific involvement in canonical NF-κB activation without interfering with non-canonical signaling.  In this study, the use of unnatural amino acid substituted IKKβ with unique photophys. activity to sense water environment changes upon interaction with NEMO provides a powerful in vitro screening platform that would greatly facilitate the identification of compds. having the potential to disrupt IKKβ-NEMO interaction, and thus specifically modulate the canonical NF-κB pathway.  We then utilized a competitive binding platform to screen the binding ability of a no. of potential mols. being synthesized.  Our results suggest that a lead compd. (-)-PDC-099 is a potent agent with ascertained potency to disrupt IKKβ-NEMO complex for modulating NF-κB canonical pathway. er of spirocyclic oxindoles derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVqOXDT_1qmbVg90H21EOLACvtfcHk0lgkqEQG9XHwCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslOjt7fP&md5=29823ffc15da407aec3aaedcc47e9dcc</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2018.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2018.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DChao%26aufirst%3DW.-C.%26aulast%3DChiang%26aufirst%3DT.-H.%26aulast%3DChaudhari%26aufirst%3DP.%2BD.%26aulast%3DLin%26aufirst%3DL.-J.%26aulast%3DLu%26aufirst%3DJ.-F.%26aulast%3DHong%26aufirst%3DB.-C.%26aulast%3DWang%26aufirst%3DJ.-S.%26aulast%3DLin%26aufirst%3DT.-C.%26aulast%3DShen%26aufirst%3DJ.-Y.%26aulast%3DChou%26aufirst%3DP.-T.%26atitle%3DThe%2520Azatryptophan-Based%2520Fluorescent%2520Platform%2520for%2520in%2520Vitro%2520Rapid%2520Screening%2520of%2520Inhibitors%2520Disrupting%2520IKK%25CE%25B2-NEMO%2520Interaction%26jtitle%3DBioorg.%2520Chem.%26date%3D2018%26volume%3D81%26spage%3D504%26epage%3D511%26doi%3D10.1016%2Fj.bioorg.2018.09.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hill, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwuagwu, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zusi, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mate, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knox, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Post-Munson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Easton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lentz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benitex, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodge, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaczek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denton, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bristow, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, R.</span></span> <span> </span><span class="NLM_article-title">Development of 4-Heteroarylamino-1’-Azaspiro[Oxazole-5,3’-Bicyclo[2.2.2]Octanes] as Α7 Nicotinic Receptor Agonists</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">137</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00471</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00471" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFynt7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=133-137&issue=1&author=M.+D.+Hillauthor=H.+Fangauthor=H.+D.+Kingauthor=C.+I.+Iwuagwuauthor=I.+M.+McDonaldauthor=J.+Cookauthor=F.+C.+Zusiauthor=R.+A.+Mateauthor=R.+J.+Knoxauthor=D.+Post-Munsonauthor=A.+Eastonauthor=R.+Millerauthor=K.+Lentzauthor=W.+Clarkeauthor=Y.+Benitexauthor=N.+Lodgeauthor=R.+Zaczekauthor=R.+Dentonauthor=D.+Morganauthor=L.+Bristowauthor=J.+E.+Macorauthor=R.+Olson&title=Development+of+4-Heteroarylamino-1%E2%80%99-Azaspiro%5BOxazole-5%2C3%E2%80%99-Bicyclo%5B2.2.2%5DOctanes%5D+as+%CE%917+Nicotinic+Receptor+Agonists&doi=10.1021%2Facsmedchemlett.6b00471"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Development of 4-Heteroarylamino-1'-azaspiro[oxazole-5,3'-bicyclo[2.2.2]octanes] as α7 Nicotinic Receptor Agonists</span></div><div class="casAuthors">Hill, Matthew D.; Fang, Haiquan; King, H. Dalton; Iwuagwu, Christiana I.; McDonald, Ivar M.; Cook, James; Zusi, F. Christopher; Mate, Robert A.; Knox, Ronald J.; Post-Munson, Debra; Easton, Amy; Miller, Regina; Lentz, Kimberley; Clarke, Wendy; Benitex, Yulia; Lodge, Nicholas; Zaczek, Robert; Denton, Rex; Morgan, Daniel; Bristow, Linda; Macor, John E.; Olson, Richard</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">133-137</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We describe the synthesis of quinuclidine-contg. spiroimidates and their utility as α7 nicotinic acetylcholine receptor (nAChR) partial agonists.  A convergent synthetic route allowed for rapid SAR investigation and provided a diverse set of fused 6,5-heteroaryl analogs.  Two potent and selective α7 nAChR partial agonists, (1'S,3'R,4'S)-N-(7-bromopyrrolo[2,1-f][1,2,4]triazin-4-yl)-4H-1'-azaspiro[oxazole-5,3'-bicyclo[2.2.2]octan]-2-amine (I) and (1'S,3'R,4'S)-N-(7-chloropyrrolo[2,1-f][1,2,4]triazin-4-yl)-4H-1'-azaspiro[oxazole-5,3'-bicyclo[2.2.2]octan]-2-amine (II), were identified.  Both agonists improved cognition in a preclin. rodent model of learning and memory.  Addnl., 5-HT3A receptor SAR suggested the presence of a steric site that when engaged led to significant loss of affinity at that receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoA1RntsoZE9bVg90H21EOLACvtfcHk0linL8gfesQa3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFynt7rJ&md5=262caed08cdc8876c90da6bdc855408e</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00471%26sid%3Dliteratum%253Aachs%26aulast%3DHill%26aufirst%3DM.%2BD.%26aulast%3DFang%26aufirst%3DH.%26aulast%3DKing%26aufirst%3DH.%2BD.%26aulast%3DIwuagwu%26aufirst%3DC.%2BI.%26aulast%3DMcDonald%26aufirst%3DI.%2BM.%26aulast%3DCook%26aufirst%3DJ.%26aulast%3DZusi%26aufirst%3DF.%2BC.%26aulast%3DMate%26aufirst%3DR.%2BA.%26aulast%3DKnox%26aufirst%3DR.%2BJ.%26aulast%3DPost-Munson%26aufirst%3DD.%26aulast%3DEaston%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DR.%26aulast%3DLentz%26aufirst%3DK.%26aulast%3DClarke%26aufirst%3DW.%26aulast%3DBenitex%26aufirst%3DY.%26aulast%3DLodge%26aufirst%3DN.%26aulast%3DZaczek%26aufirst%3DR.%26aulast%3DDenton%26aufirst%3DR.%26aulast%3DMorgan%26aufirst%3DD.%26aulast%3DBristow%26aufirst%3DL.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26aulast%3DOlson%26aufirst%3DR.%26atitle%3DDevelopment%2520of%25204-Heteroarylamino-1%25E2%2580%2599-Azaspiro%255BOxazole-5%252C3%25E2%2580%2599-Bicyclo%255B2.2.2%255DOctanes%255D%2520as%2520%25CE%25917%2520Nicotinic%2520Receptor%2520Agonists%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26issue%3D1%26spage%3D133%26epage%3D137%26doi%3D10.1021%2Facsmedchemlett.6b00471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scheepstra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrei, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unver, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, A. K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leysen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunsveld, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milroy, L.-G.</span></span> <span> </span><span class="NLM_article-title">Designed Spiroketal Protein Modulation</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">5480</span>– <span class="NLM_lpage">5484</span>, <span class="refDoi"> DOI: 10.1002/anie.201612504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1002%2Fanie.201612504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtVyhuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=5480-5484&issue=20&author=M.+Scheepstraauthor=S.+A.+Andreiauthor=M.+Y.+Unverauthor=A.+K.+H.+Hirschauthor=S.+Leysenauthor=C.+Ottmannauthor=L.+Brunsveldauthor=L.-G.+Milroy&title=Designed+Spiroketal+Protein+Modulation&doi=10.1002%2Fanie.201612504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Designed Spiroketal Protein Modulation</span></div><div class="casAuthors">Scheepstra, Marcel; Andrei, Sebastian A.; Unver, M. Yagiz; Hirsch, Anna K. H.; Leysen, Seppe; Ottmann, Christian; Brunsveld, Luc; Milroy, Lech-Gustav</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5480-5484</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Spiroketals are structural motifs found in many biol. active natural products, which has stimulated considerable efforts toward their synthesis and interest in their use as drug lead compds.  Despite this, the use of spiroketals, and esp. bisbenzanulated spiroketals, in a structure-based drug discovery setting has not been convincingly demonstrated.  Herein, the authors report the rational design of a bisbenzannulated spiroketal that potently binds to the retinoid X receptor (RXR) thereby inducing partial co-activator recruitment.  The authors solved the crystal structure of the spiroketal-hRXRα-TIF2 ternary complex, and identified a canonical allosteric mechanism as a possible explanation for the partial agonist behavior of the authors' spiroketal.  The authors' co-crystal structure, the first of a designed spiroketal-protein complex, suggests that spiroketals can be designed to selectively target other nuclear receptor subtypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouYihEqEJmHbVg90H21EOLACvtfcHk0linL8gfesQa3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtVyhuro%253D&md5=3207dde07ce4489a44c2485811ed10f9</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1002%2Fanie.201612504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201612504%26sid%3Dliteratum%253Aachs%26aulast%3DScheepstra%26aufirst%3DM.%26aulast%3DAndrei%26aufirst%3DS.%2BA.%26aulast%3DUnver%26aufirst%3DM.%2BY.%26aulast%3DHirsch%26aufirst%3DA.%2BK.%2BH.%26aulast%3DLeysen%26aufirst%3DS.%26aulast%3DOttmann%26aufirst%3DC.%26aulast%3DBrunsveld%26aufirst%3DL.%26aulast%3DMilroy%26aufirst%3DL.-G.%26atitle%3DDesigned%2520Spiroketal%2520Protein%2520Modulation%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2017%26volume%3D56%26issue%3D20%26spage%3D5480%26epage%3D5484%26doi%3D10.1002%2Fanie.201612504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tömböly, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feytens, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kövér, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borics, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Khrasani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fürst, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tóth, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benyhe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tourwé, D.</span></span> <span> </span><span class="NLM_article-title">Endomorphin-2 with a β-Turn Backbone Constraint Retains the Potent μ-Opioid Receptor Agonist Properties</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">173</span>– <span class="NLM_lpage">177</span>, <span class="refDoi"> DOI: 10.1021/jm7010222</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm7010222" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFKksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=173-177&issue=1&author=C.+T%C3%B6mb%C3%B6lyauthor=S.+Balletauthor=D.+Feytensauthor=K.+E.+K%C3%B6v%C3%A9rauthor=A.+Boricsauthor=S.+Lovasauthor=M.+Al-Khrasaniauthor=Z.+F%C3%BCrstauthor=G.+T%C3%B3thauthor=S.+Benyheauthor=D.+Tourw%C3%A9&title=Endomorphin-2+with+a+%CE%B2-Turn+Backbone+Constraint+Retains+the+Potent+%CE%BC-Opioid+Receptor+Agonist+Properties&doi=10.1021%2Fjm7010222"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Endomorphin-2 with a β-Turn Backbone Constraint Retains the Potent μ-Opioid Receptor Agonist Properties</span></div><div class="casAuthors">Tomboly, Csaba; Ballet, Steven; Feytens, Debby; Kover, Katalin E.; Borics, Attila; Lovas, Sandor; Al-Khrasani, Mahmoud; Furst, Zsuzsanna; Toth, Geza; Benyhe, Sandor; Tourwe, Dirk</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">173-177</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The constitutional similarity with different secondary structure preference between the Aba-Gly and the spiro-Aba-Gly scaffolds were exploited to design the novel endomorphin-2 analogs Tyr-spiro-(R/S)-Aba-Gly-Phe-NH2 and Tyr-(R/S)-Aba-Gly-Phe-NH2.  The (R)-spiro analog was found to be a potent and selective μ-opioid agonist/partial agonist (Kiμ = 29.3 nM, IC50 = 50 nM, Ke = 0.57).  NMR expts. and mol. modeling indicated that its backbone adopts mainly a β-turn in aq. soln.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpq7SJw3GipQbVg90H21EOLACvtfcHk0linL8gfesQa3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFKksw%253D%253D&md5=cff97d602690e90950c03bcb2c33b8e7</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1021%2Fjm7010222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7010222%26sid%3Dliteratum%253Aachs%26aulast%3DT%25C3%25B6mb%25C3%25B6ly%26aufirst%3DC.%26aulast%3DBallet%26aufirst%3DS.%26aulast%3DFeytens%26aufirst%3DD.%26aulast%3DK%25C3%25B6v%25C3%25A9r%26aufirst%3DK.%2BE.%26aulast%3DBorics%26aufirst%3DA.%26aulast%3DLovas%26aufirst%3DS.%26aulast%3DAl-Khrasani%26aufirst%3DM.%26aulast%3DF%25C3%25BCrst%26aufirst%3DZ.%26aulast%3DT%25C3%25B3th%26aufirst%3DG.%26aulast%3DBenyhe%26aufirst%3DS.%26aulast%3DTourw%25C3%25A9%26aufirst%3DD.%26atitle%3DEndomorphin-2%2520with%2520a%2520%25CE%25B2-Turn%2520Backbone%2520Constraint%2520Retains%2520the%2520Potent%2520%25CE%25BC-Opioid%2520Receptor%2520Agonist%2520Properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26issue%3D1%26spage%3D173%26epage%3D177%26doi%3D10.1021%2Fjm7010222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arkin, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, J. A.</span></span> <span> </span><span class="NLM_article-title">Small-Molecule Inhibitors of Protein-Protein Interactions: Progressing toward the Reality</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1102</span>– <span class="NLM_lpage">1114</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2014.09.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2Fj.chembiol.2014.09.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=25237857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFyrur7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=1102-1114&issue=9&author=M.+R.+Arkinauthor=Y.+Tangauthor=J.+A.+Wells&title=Small-Molecule+Inhibitors+of+Protein-Protein+Interactions%3A+Progressing+toward+the+Reality&doi=10.1016%2Fj.chembiol.2014.09.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Inhibitors of Protein-Protein Interactions: Progressing toward the Reality</span></div><div class="casAuthors">Arkin, Michelle R.; Tang, Yinyan; Wells, James A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1102-1114</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The past 20 years have seen many advances in our understanding of protein-protein interactions (PPIs) and how to target them with small-mol. therapeutics.  In 2004, we reviewed some early successes; since then, potent inhibitors have been developed for diverse protein complexes, and compds. are now in clin. trials for six targets.  Surprisingly, many of these PPI clin. candidates have efficiency metrics typical of "lead-like" or "drug-like" mols. and are orally available.  Successful discovery efforts have integrated multiple disciplines and make use of all the modern tools of target-based discovery-structure, computation, screening, and biomarkers.  PPIs become progressively more challenging as the interfaces become more complex, i.e., as binding epitopes are displayed on primary, secondary, or tertiary structures.  Here, we review the last 10 years of progress, focusing on the properties of PPI inhibitors that have advanced to clin. trials and prospects for the future of PPI drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP01wt-4lfE7Vg90H21EOLACvtfcHk0lhiwPQliaGoIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFyrur7J&md5=aec3897dc9bc66656723bc56c8d69155</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2014.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2014.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DArkin%26aufirst%3DM.%2BR.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DWells%26aufirst%3DJ.%2BA.%26atitle%3DSmall-Molecule%2520Inhibitors%2520of%2520Protein-Protein%2520Interactions%253A%2520Progressing%2520toward%2520the%2520Reality%26jtitle%3DChem.%2520Biol.%26date%3D2014%26volume%3D21%26issue%3D9%26spage%3D1102%26epage%3D1114%26doi%3D10.1016%2Fj.chembiol.2014.09.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayly, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skidmore, J.</span></span> <span> </span><span class="NLM_article-title">Small Molecules, Big Targets: Drug Discovery Faces the Protein-Protein Interaction Challenge</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">533</span>– <span class="NLM_lpage">550</span>, <span class="refDoi"> DOI: 10.1038/nrd.2016.29</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1038%2Fnrd.2016.29" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=27050677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsFOgur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=533-550&issue=8&author=D.+E.+Scottauthor=A.+R.+Baylyauthor=C.+Abellauthor=J.+Skidmore&title=Small+Molecules%2C+Big+Targets%3A+Drug+Discovery+Faces+the+Protein-Protein+Interaction+Challenge&doi=10.1038%2Fnrd.2016.29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecules, big targets: drug discovery faces the protein-protein interaction challenge</span></div><div class="casAuthors">Scott, Duncan E.; Bayly, Andrew R.; Abell, Chris; Skidmore, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">533-550</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Protein-protein interactions (PPIs) are of pivotal importance in the regulation of biol. systems and are consequently implicated in the development of disease states.  Recent work has begun to show that, with the right tools, certain classes of PPI can yield to the efforts of medicinal chemists to develop inhibitors, and the first PPI inhibitors have reached clin. development.  In this Review, we describe the research leading to these breakthroughs and highlight the existence of groups of structurally related PPIs within the PPI target class.  For each of these groups, we use examples of successful discovery efforts to illustrate the research strategies that have proved most useful.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK-aGzHa9mP7Vg90H21EOLACvtfcHk0lhiwPQliaGoIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsFOgur4%253D&md5=9f0953567ae9338b8b36aa78b8160655</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.29&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.29%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DD.%2BE.%26aulast%3DBayly%26aufirst%3DA.%2BR.%26aulast%3DAbell%26aufirst%3DC.%26aulast%3DSkidmore%26aufirst%3DJ.%26atitle%3DSmall%2520Molecules%252C%2520Big%2520Targets%253A%2520Drug%2520Discovery%2520Faces%2520the%2520Protein-Protein%2520Interaction%2520Challenge%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2016%26volume%3D15%26issue%3D8%26spage%3D533%26epage%3D550%26doi%3D10.1038%2Fnrd.2016.29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sarver, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagdanoff, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fodor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortanet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hentemann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaBonte, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeill, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohseni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sendzik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spence, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tichkule, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMarche, M. J.</span></span> <span> </span><span class="NLM_article-title">6-Amino-3-Methylpyrimidinones as Potent, Selective, and Orally Efficacious SHP2 Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1793</span>– <span class="NLM_lpage">1802</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01726</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01726" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFKisLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1793-1802&issue=4&author=P.+Sarverauthor=M.+Ackerauthor=J.+T.+Bagdanoffauthor=Z.+Chenauthor=Y.-N.+Chenauthor=H.+Chanauthor=B.+Firestoneauthor=M.+Fodorauthor=J.+Fortanetauthor=H.+Haoauthor=M.+Hentemannauthor=M.+Katoauthor=R.+Koenigauthor=L.+R.+LaBonteauthor=G.+Liuauthor=S.+Liuauthor=C.+Liuauthor=E.+McNeillauthor=M.+Mohseniauthor=M.+Sendzikauthor=T.+Stamsauthor=S.+Spenceauthor=V.+Tamezauthor=R.+Tichkuleauthor=C.+Towlerauthor=H.+Wangauthor=P.+Wangauthor=S.+L.+Williamsauthor=B.+Yuauthor=M.+J.+LaMarche&title=6-Amino-3-Methylpyrimidinones+as+Potent%2C+Selective%2C+and+Orally+Efficacious+SHP2+Inhibitors&doi=10.1021%2Facs.jmedchem.8b01726"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">6-Amino-3-methylpyrimidinones as Potent, Selective, and Orally Efficacious SHP2 Inhibitors</span></div><div class="casAuthors">Sarver, Patrick; Acker, Michael; Bagdanoff, Jeffrey T.; Chen, Zhouliang; Chen, Ying-Nan; Chan, Homan; Firestone, Brant; Fodor, Michelle; Fortanet, Jorge; Hao, Huaixiang; Hentemann, Murphy; Koenig, Robert; Kato, Mitsunori; LaBonte, Laura R.; Liu, Gang; Liu, Shumei; Liu, Chen; McNeill, Eric; Mohseni, Morvarid; Sendzik, Martin; Stams, Travis; Spence, Stan; Tamez, Victoriano; Tichkule, Ritesh; Towler, Christopher; Wang, Hongyun; Wang, Ping; Williams, Sarah L.; Yu, Bing; LaMarche, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1793-1802</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Protein tyrosine phosphatase SHP2 is an oncoprotein assocd. with cancer as well as a potential immune modulator because of its role in the programmed cell death PD-L1/PD-1 pathway.  In the preceding manuscript, we described the optimization of a fused, bicyclic screening hit for potency, selectivity, and physicochem. properties in order to further expand the chem. diversity of allosteric SHP2 inhibitors.  In this manuscript, we describe the further expansion of our approach, morphing the fused, bicyclic system into a novel monocyclic pyrimidinone scaffold through our understanding of SAR and use of structure-based design.  These studies led to the identification of SHP394 (1), an orally efficacious inhibitor of SHP2, with high lipophilic efficiency, improved potency, and enhanced pharmacokinetic properties.  We also report other pyrimidinone analogs with favorable pharmacokinetic and potency profiles.  Overall, this work improves upon our previously described allosteric inhibitors and exemplifies and extends the range of permissible chem. templates that inhibit SHP2 via the allosteric mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaRey6_uE0ULVg90H21EOLACvtfcHk0li743XG-BHWmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFKisLs%253D&md5=29c357236b7ff51596385e3e256320a5</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01726&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01726%26sid%3Dliteratum%253Aachs%26aulast%3DSarver%26aufirst%3DP.%26aulast%3DAcker%26aufirst%3DM.%26aulast%3DBagdanoff%26aufirst%3DJ.%2BT.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DY.-N.%26aulast%3DChan%26aufirst%3DH.%26aulast%3DFirestone%26aufirst%3DB.%26aulast%3DFodor%26aufirst%3DM.%26aulast%3DFortanet%26aufirst%3DJ.%26aulast%3DHao%26aufirst%3DH.%26aulast%3DHentemann%26aufirst%3DM.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DKoenig%26aufirst%3DR.%26aulast%3DLaBonte%26aufirst%3DL.%2BR.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DMcNeill%26aufirst%3DE.%26aulast%3DMohseni%26aufirst%3DM.%26aulast%3DSendzik%26aufirst%3DM.%26aulast%3DStams%26aufirst%3DT.%26aulast%3DSpence%26aufirst%3DS.%26aulast%3DTamez%26aufirst%3DV.%26aulast%3DTichkule%26aufirst%3DR.%26aulast%3DTowler%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWilliams%26aufirst%3DS.%2BL.%26aulast%3DYu%26aufirst%3DB.%26aulast%3DLaMarche%26aufirst%3DM.%2BJ.%26atitle%3D6-Amino-3-Methylpyrimidinones%2520as%2520Potent%252C%2520Selective%252C%2520and%2520Orally%2520Efficacious%2520SHP2%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D4%26spage%3D1793%26epage%3D1802%26doi%3D10.1021%2Facs.jmedchem.8b01726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bagdanoff, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dore, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fodor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortanet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hentemann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaBonte, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohseni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ntaganda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarver, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sendzik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spence, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMarche, M. J.</span></span> <span> </span><span class="NLM_article-title">Optimization of Fused Bicyclic Allosteric SHP2 Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1781</span>– <span class="NLM_lpage">1792</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01725</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01725" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFKjtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1781-1792&issue=4&author=J.+T.+Bagdanoffauthor=Z.+Chenauthor=M.+Ackerauthor=Y.-N.+Chenauthor=H.+Chanauthor=M.+Doreauthor=B.+Firestoneauthor=M.+Fodorauthor=J.+Fortanetauthor=M.+Hentemannauthor=M.+Katoauthor=R.+Koenigauthor=L.+R.+LaBonteauthor=S.+Liuauthor=M.+Mohseniauthor=R.+Ntagandaauthor=P.+Sarverauthor=T.+Smithauthor=M.+Sendzikauthor=T.+Stamsauthor=S.+Spenceauthor=C.+Towlerauthor=H.+Wangauthor=P.+Wangauthor=S.+L.+Williamsauthor=M.+J.+LaMarche&title=Optimization+of+Fused+Bicyclic+Allosteric+SHP2+Inhibitors&doi=10.1021%2Facs.jmedchem.8b01725"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of Fused Bicyclic Allosteric SHP2 Inhibitors</span></div><div class="casAuthors">Bagdanoff, Jeffrey T.; Chen, Zhouliang; Acker, Michael; Chen, Ying-Nan; Chan, Homan; Dore, Michael; Firestone, Brant; Fodor, Michelle; Fortanet, Jorge; Hentemann, Murphy; Kato, Mitsunori; Koenig, Robert; La Bonte, Laura R.; Liu, Shumei; Mohseni, Movarid; Ntaganda, Rukundo; Sarver, Patrick; Smith, Troy; Sendzik, Martin; Stams, Travis; Spence, Stan; Towler, Christopher; Wang, Hongyun; Wang, Ping; Williams, Sarah L.; La Marche, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1781-1792</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">SHP2 is a nonreceptor protein tyrosine phosphatase within the mitogen-activated protein kinase (MAPK) pathway controlling cell growth, differentiation, and oncogenic transformation.  SHP2 also participates in the programed cell death pathway (PD-1/PD-L1) governing immune surveillance.  Small-mol. inhibition of SHP2 has been widely investigated, including in our previous reports describing SHP099 (2), which binds to a tunnel-like allosteric binding site.  To broaden our approach to allosteric inhibition of SHP2, we conducted addnl. hit finding, evaluation, and structure-based scaffold morphing.  These studies, reported here in the first of two papers, led to the identification of multiple 5,6-fused bicyclic scaffolds that bind to the same allosteric tunnel as 2.  We demonstrate the structural diversity permitted by the tunnel pharmacophore and culminated in the identification of pyrazolopyrimidinones (e.g., SHP389, 1) that modulate MAPK signaling in vivo.  These studies also served as the basis for further scaffold morphing and optimization, detailed in the following manuscript.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra2OF_vrNnP7Vg90H21EOLACvtfcHk0li743XG-BHWmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFKjtbo%253D&md5=e810a8a6bd1d1fb7bfadc5bc1448ff22</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01725&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01725%26sid%3Dliteratum%253Aachs%26aulast%3DBagdanoff%26aufirst%3DJ.%2BT.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DAcker%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.-N.%26aulast%3DChan%26aufirst%3DH.%26aulast%3DDore%26aufirst%3DM.%26aulast%3DFirestone%26aufirst%3DB.%26aulast%3DFodor%26aufirst%3DM.%26aulast%3DFortanet%26aufirst%3DJ.%26aulast%3DHentemann%26aufirst%3DM.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DKoenig%26aufirst%3DR.%26aulast%3DLaBonte%26aufirst%3DL.%2BR.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DMohseni%26aufirst%3DM.%26aulast%3DNtaganda%26aufirst%3DR.%26aulast%3DSarver%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DT.%26aulast%3DSendzik%26aufirst%3DM.%26aulast%3DStams%26aufirst%3DT.%26aulast%3DSpence%26aufirst%3DS.%26aulast%3DTowler%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWilliams%26aufirst%3DS.%2BL.%26aulast%3DLaMarche%26aufirst%3DM.%2BJ.%26atitle%3DOptimization%2520of%2520Fused%2520Bicyclic%2520Allosteric%2520SHP2%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D4%26spage%3D1781%26epage%3D1792%26doi%3D10.1021%2Facs.jmedchem.8b01725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Lombaert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aiello, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourassa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barucci, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paralkar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentine, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zavadoski, W.</span></span> <span> </span><span class="NLM_article-title">Discovery of Spirocyclic Proline Tryptophan Hydroxylase-1 Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1124</span>– <span class="NLM_lpage">1129</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.01.064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2Fj.bmcl.2016.01.064" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=26821821" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVSit70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=1124-1129&issue=4&author=D.+R.+Goldbergauthor=S.+De+Lombaertauthor=R.+Aielloauthor=P.+Bourassaauthor=N.+Barucciauthor=Q.+Zhangauthor=V.+Paralkarauthor=J.+Valentineauthor=W.+Zavadoski&title=Discovery+of+Spirocyclic+Proline+Tryptophan+Hydroxylase-1+Inhibitors&doi=10.1016%2Fj.bmcl.2016.01.064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of spirocyclic proline tryptophan hydroxylase-1 inhibitors</span></div><div class="casAuthors">Goldberg, Daniel R.; De Lombaert, Stephane; Aiello, Robert; Bourassa, Patricia; Barucci, Nicole; Zhang, Qing; Paralkar, Vishwas; Valentine, James; Zavadoski, William</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1124-1129</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The central role of the biogenic monoamine serotonin (5-hydroxytryptamine, 5-HT) as a neurotransmitter with important cognitive and behavioral functions is well known.  However, 5-HT produced in the brain only accounts for approx. 5% of the total amt. of 5-HT generated in the body.  At the onset of our work, it appeared that substituted phenylalanine derivs. or related aryl amino acids were required to produce potent inhibitors of TPH1, as significant losses of inhibitory activity were noted in the absence of this structural element.  We disclose herein the discovery of a new class of TPH1 inhibitors that significantly lower peripherally 5-HT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVsjFU6kxEsbVg90H21EOLACvtfcHk0lihD10IA6Y9Wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVSit70%253D&md5=1cef593698e5951cc3a5e225d93a2248</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.01.064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.01.064%26sid%3Dliteratum%253Aachs%26aulast%3DGoldberg%26aufirst%3DD.%2BR.%26aulast%3DDe%2BLombaert%26aufirst%3DS.%26aulast%3DAiello%26aufirst%3DR.%26aulast%3DBourassa%26aufirst%3DP.%26aulast%3DBarucci%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DParalkar%26aufirst%3DV.%26aulast%3DValentine%26aufirst%3DJ.%26aulast%3DZavadoski%26aufirst%3DW.%26atitle%3DDiscovery%2520of%2520Spirocyclic%2520Proline%2520Tryptophan%2520Hydroxylase-1%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26issue%3D4%26spage%3D1124%26epage%3D1129%26doi%3D10.1016%2Fj.bmcl.2016.01.064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Lombaert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aiello, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourassa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barucci, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paralkar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentine, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zavadoski, W.</span></span> <span> </span><span class="NLM_article-title">Optimization of Spirocyclic Proline Tryptophan Hydroxylase-1 Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">419</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.12.053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2Fj.bmcl.2016.12.053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=28041831" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVCqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=413-419&issue=3&author=D.+R.+Goldbergauthor=S.+De+Lombaertauthor=R.+Aielloauthor=P.+Bourassaauthor=N.+Barucciauthor=Q.+Zhangauthor=V.+Paralkarauthor=A.+J.+Steinauthor=M.+Holtauthor=J.+Valentineauthor=W.+Zavadoski&title=Optimization+of+Spirocyclic+Proline+Tryptophan+Hydroxylase-1+Inhibitors&doi=10.1016%2Fj.bmcl.2016.12.053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of spirocyclic proline tryptophan hydroxylase-1 inhibitors</span></div><div class="casAuthors">Goldberg, Daniel R.; De Lombaert, Stephane; Aiello, Robert; Bourassa, Patricia; Barucci, Nicole; Zhang, Qing; Paralkar, Vishwas; Stein, Adam J.; Holt, Melissa; Valentine, Jim; Zavadoski, William</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">413-419</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">As a follow-up to the discovery of our spirocyclic proline-based TPH1 inhibitor lead, we describe the optimization of this scaffold.  Through a combination of X-ray co-crystal structure guided design and an in vivo screen, new substitutions in the lipophilic region of the inhibitors were identified.  This effort led to new TPH1 inhibitors with in vivo efficacy when dosed as their corresponding Et ester prodrugs.  In particular, 15b (KAR5585), the prodrug of the potent TPH1 inhibitor 15a (KAR5417), showed robust redn. of intestinal serotonin (5-HT) levels in mice.  Furthermore, oral administration of 15b generated high and sustained systemic exposure of the active parent 15a in rats and dogs.  KAR5585 was selected for further pharmacol. evaluation in disease models assocd. with a dysfunctional peripheral 5-HT system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWCaHTagCD0rVg90H21EOLACvtfcHk0lihD10IA6Y9Wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVCqtw%253D%253D&md5=0b12863d265ba1ec4bc9ae8ccd1ee33d</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.12.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.12.053%26sid%3Dliteratum%253Aachs%26aulast%3DGoldberg%26aufirst%3DD.%2BR.%26aulast%3DDe%2BLombaert%26aufirst%3DS.%26aulast%3DAiello%26aufirst%3DR.%26aulast%3DBourassa%26aufirst%3DP.%26aulast%3DBarucci%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DParalkar%26aufirst%3DV.%26aulast%3DStein%26aufirst%3DA.%2BJ.%26aulast%3DHolt%26aufirst%3DM.%26aulast%3DValentine%26aufirst%3DJ.%26aulast%3DZavadoski%26aufirst%3DW.%26atitle%3DOptimization%2520of%2520Spirocyclic%2520Proline%2520Tryptophan%2520Hydroxylase-1%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26issue%3D3%26spage%3D413%26epage%3D419%26doi%3D10.1016%2Fj.bmcl.2016.12.053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cianchetta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stouch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tari, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanson, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span> <span> </span><span class="NLM_article-title">Mechanism of Inhibition of Novel Tryptophan Hydroxylase Inhibitors Revealed by Co-Crystal Structures and Kinetic Analysis</span>. <i>Curr. Chem. Genomics</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.2174/1875397301004010019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.2174%2F1875397301004010019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=20556201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC3cXls1Gqurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2010&pages=19-26&author=G.+Cianchettaauthor=T.+Stouchauthor=W.+Yuauthor=Z.-C.+Shiauthor=L.+W.+Tariauthor=R.+V.+Swansonauthor=M.+J.+Hunterauthor=I.+D.+Hoffmanauthor=Q.+Liu&title=Mechanism+of+Inhibition+of+Novel+Tryptophan+Hydroxylase+Inhibitors+Revealed+by+Co-Crystal+Structures+and+Kinetic+Analysis&doi=10.2174%2F1875397301004010019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of inhibition of novel tryptophan hydroxylase inhibitors revealed by co-crystal structures and kinetic analysis</span></div><div class="casAuthors">Cianchetta, Giovanni; Stouch, Terry; Yu, Wangsheng; Shi, Zhi-Cai; Tari, Leslie W.; Swanson, Ronald V.; Hunter, Michael J.; Hoffman, Isaac D.; Liu, Qingyun</div><div class="citationInfo"><span class="NLM_cas:title">Current Chemical Genomics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">19-26</span>CODEN:
                <span class="NLM_cas:coden">CCGUAQ</span>;
        ISSN:<span class="NLM_cas:issn">1875-3973</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Trytophan Hydroxylase Type I (TPH1), most abundantly expressed in the gastrointestinal tract, initiates the synthesis of serotonin by catalyzing hydroxylation of tryptophan in the presence of biopterin and oxygen.  We have previously described three series of novel, periphery-specific TPH1 inhibitors that selectively deplete serotonin in the gastrointestinal tract.  We have now detd. co-crystal structures of TPH1 with three of these inhibitors at high resoln.  Anal. of the structural data showed that each of the three inhibitors fills the tryptophan binding pocket of TPH1 without reaching into the binding site of the cofactor pterin, and induces major conformational changes of the enzyme.  The enzyme-inhibitor complexes assume a compact conformation that is similar to the one in tryptophan complex.  Kinetic anal. showed that all three inhibitors are competitive vs. the substrate tryptophan, consistent with the structural data that the compds. occupy the tryptophan binding site.  On the other hand, all three inhibitors appear to be uncompetitive vs. the cofactor 6-methyltetrahydropterin, which is not only consistent with the structural data but also indicate that the hydroxylation reaction follows an ordered binding mechanism in which a productive complex is formed only if tryptophan binds only after pterin, similar to the kinetic mechanisms of tyrosine and phenylalanine hydroxylase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp22pfPYGY92bVg90H21EOLACvtfcHk0lihD10IA6Y9Wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXls1Gqurs%253D&md5=be3da659eabc36a9fc143b82ecb20a22</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.2174%2F1875397301004010019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1875397301004010019%26sid%3Dliteratum%253Aachs%26aulast%3DCianchetta%26aufirst%3DG.%26aulast%3DStouch%26aufirst%3DT.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DShi%26aufirst%3DZ.-C.%26aulast%3DTari%26aufirst%3DL.%2BW.%26aulast%3DSwanson%26aufirst%3DR.%2BV.%26aulast%3DHunter%26aufirst%3DM.%2BJ.%26aulast%3DHoffman%26aufirst%3DI.%2BD.%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DMechanism%2520of%2520Inhibition%2520of%2520Novel%2520Tryptophan%2520Hydroxylase%2520Inhibitors%2520Revealed%2520by%2520Co-Crystal%2520Structures%2520and%2520Kinetic%2520Analysis%26jtitle%3DCurr.%2520Chem.%2520Genomics%26date%3D2010%26volume%3D4%26spage%3D19%26epage%3D26%26doi%3D10.2174%2F1875397301004010019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwertz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witschel, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rottmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leartsakulpanich, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chitnumsub, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaruwat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amornwatcharapong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ittarat, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schäfer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aponte, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trapp, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaiyen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diederich, F.</span></span> <span> </span><span class="NLM_article-title">Potent Inhibitors of Plasmodial Serine Hydroxymethyltransferase (SHMT) Featuring a Spirocyclic Scaffold</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">931</span>– <span class="NLM_lpage">943</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201800053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1002%2Fcmdc.201800053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=29655285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1cXns1Sls7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=931-943&issue=9&author=G.+Schwertzauthor=M.+C.+Witschelauthor=M.+Rottmannauthor=U.+Leartsakulpanichauthor=P.+Chitnumsubauthor=A.+Jaruwatauthor=W.+Amornwatcharapongauthor=W.+Ittaratauthor=A.+Sch%C3%A4ferauthor=R.+A.+Aponteauthor=N.+Trappauthor=P.+Chaiyenauthor=F.+Diederich&title=Potent+Inhibitors+of+Plasmodial+Serine+Hydroxymethyltransferase+%28SHMT%29+Featuring+a+Spirocyclic+Scaffold&doi=10.1002%2Fcmdc.201800053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Potent Inhibitors of Plasmodial Serine Hydroxymethyltransferase (SHMT) Featuring a Spirocyclic Scaffold</span></div><div class="casAuthors">Schwertz, Geoffrey; Witschel, Matthias C.; Rottmann, Matthias; Leartsakulpanich, Ubolsree; Chitnumsub, Penchit; Jaruwat, Aritsara; Amornwatcharapong, Watcharee; Ittarat, Wanwipa; Schaefer, Anja; Aponte, Raphael A.; Trapp, Nils; Chaiyen, Pimchai; Diederich, Francois</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">931-943</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">With the discovery that serine hydroxymethyltransferase (SHMT) is a druggable target for antimalarials, the aim of this study was to design novel inhibitors of this key enzyme in the folate biosynthesis cycle.  Herein, 19 novel spirocyclic ligands based on either 2-indolinone or dihydroindene scaffolds and featuring a pyrazolopyran core are reported.  Strong target affinities for Plasmodium falciparum (Pf) SHMT (14-76 nM) and cellular potencies in the low nanomolar range (165-334 nM) were measured together with interesting selectivity against human cytosolic SHMT1 (hSHMT1).  Four co-crystal structures with Plasmodium vivax (Pv) SHMT solved at 2.2-2.4 Å resoln. revealed the key role of the vinylogous cyanamide for anchoring ligands within the active site.  The spirocyclic motif in the mols. enforces the pyrazolopyran core to adopt a substantially more curved conformation than that of previous non-spirocyclic analogs.  Finally, solvation of the spirocyclic lactam ring of the receptor-bound ligands is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvpAcjSWkTV7Vg90H21EOLACvtfcHk0lh7Ak4s5CusWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXns1Sls7k%253D&md5=5517df4e263d7214d2fc8400b269d652</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201800053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201800053%26sid%3Dliteratum%253Aachs%26aulast%3DSchwertz%26aufirst%3DG.%26aulast%3DWitschel%26aufirst%3DM.%2BC.%26aulast%3DRottmann%26aufirst%3DM.%26aulast%3DLeartsakulpanich%26aufirst%3DU.%26aulast%3DChitnumsub%26aufirst%3DP.%26aulast%3DJaruwat%26aufirst%3DA.%26aulast%3DAmornwatcharapong%26aufirst%3DW.%26aulast%3DIttarat%26aufirst%3DW.%26aulast%3DSch%25C3%25A4fer%26aufirst%3DA.%26aulast%3DAponte%26aufirst%3DR.%2BA.%26aulast%3DTrapp%26aufirst%3DN.%26aulast%3DChaiyen%26aufirst%3DP.%26aulast%3DDiederich%26aufirst%3DF.%26atitle%3DPotent%2520Inhibitors%2520of%2520Plasmodial%2520Serine%2520Hydroxymethyltransferase%2520%2528SHMT%2529%2520Featuring%2520a%2520Spirocyclic%2520Scaffold%26jtitle%3DChemMedChem%26date%3D2018%26volume%3D13%26issue%3D9%26spage%3D931%26epage%3D943%26doi%3D10.1002%2Fcmdc.201800053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahlholm, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacome, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luedtke, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">Highly Selective Dopamine D3 Receptor Antagonists with Arylated Diazaspiro Alkane Cores</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">9905</span>– <span class="NLM_lpage">9910</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01248</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01248" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsl2gsbjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=9905-9910&issue=23&author=S.+W.+Reillyauthor=S.+Griffinauthor=M.+Taylorauthor=K.+Sahlholmauthor=C.-C.+Wengauthor=K.+Xuauthor=D.+A.+Jacomeauthor=R.+R.+Luedtkeauthor=R.+H.+Mach&title=Highly+Selective+Dopamine+D3+Receptor+Antagonists+with+Arylated+Diazaspiro+Alkane+Cores&doi=10.1021%2Facs.jmedchem.7b01248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Highly Selective Dopamine D3 Receptor Antagonists with Arylated Diazaspiro Alkane Cores</span></div><div class="casAuthors">Reilly, Sean W.; Griffin, Suzy; Taylor, Michelle; Sahlholm, Kristoffer; Weng, Chi-Chang; Xu, Kuiying; Jacome, Daniel A.; Luedtke, Robert R.; Mach, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9905-9910</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aryldiazaspirocyclylpropyl phenyltriazolyl thioethers such as I (R = 2-MeOC6H4, 4-FC6H4, 4-MeOC6H4, 2-pyridinyl, 3-NCC6H4, 2,3-Cl2C6H3) were prepd. as selective dopamine D3 receptor (D3R) antagonists; their selectivities for D3R over D2R and for selected compds. over 5-HT1a, 5-HT2a, and 5-HT2c receptors and adenylyl cyclase were detd.  I (R = 2-MeOC6H4, 4-FC6H4) showed favorable D3R affinities (Ki = 12-25.6 nM) and were 264- to 905-fold selective for D3R vs D2R.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHLC1nn5_14LVg90H21EOLACvtfcHk0lh7Ak4s5CusWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsl2gsbjL&md5=a60ed8b0524189901b7155e11025d3c6</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01248%26sid%3Dliteratum%253Aachs%26aulast%3DReilly%26aufirst%3DS.%2BW.%26aulast%3DGriffin%26aufirst%3DS.%26aulast%3DTaylor%26aufirst%3DM.%26aulast%3DSahlholm%26aufirst%3DK.%26aulast%3DWeng%26aufirst%3DC.-C.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DJacome%26aufirst%3DD.%2BA.%26aulast%3DLuedtke%26aufirst%3DR.%2BR.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DHighly%2520Selective%2520Dopamine%2520D3%2520Receptor%2520Antagonists%2520with%2520Arylated%2520Diazaspiro%2520Alkane%2520Cores%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D23%26spage%3D9905%26epage%3D9910%26doi%3D10.1021%2Facs.jmedchem.7b01248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riad, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, C.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahlholm, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacome, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirschner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luedtke, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malhotra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karanicolas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">Leveraging a Low-Affinity Diazaspiro Orthosteric Fragment to Reduce Dopamine D3 Receptor (D3R) Ligand Promiscuity across Highly Conserved Aminergic G-Protein-Coupled Receptors (GPCRs)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">5132</span>– <span class="NLM_lpage">5147</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00412</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00412" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1MXot1Sntrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=5132-5147&issue=10&author=S.+W.+Reillyauthor=A.+A.+Riadauthor=C.-J.+Hsiehauthor=K.+Sahlholmauthor=D.+A.+Jacomeauthor=S.+Griffinauthor=M.+Taylorauthor=C.-C.+Wengauthor=K.+Xuauthor=N.+Kirschnerauthor=R.+R.+Luedtkeauthor=C.+Parryauthor=S.+Malhotraauthor=J.+Karanicolasauthor=R.+H.+Mach&title=Leveraging+a+Low-Affinity+Diazaspiro+Orthosteric+Fragment+to+Reduce+Dopamine+D3+Receptor+%28D3R%29+Ligand+Promiscuity+across+Highly+Conserved+Aminergic+G-Protein-Coupled+Receptors+%28GPCRs%29&doi=10.1021%2Facs.jmedchem.9b00412"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Leveraging a Low-Affinity Diazaspiro Orthosteric Fragment to Reduce Dopamine D3 Receptor (D3R) Ligand Promiscuity across Highly Conserved Aminergic G-Protein-Coupled Receptors (GPCRs)</span></div><div class="casAuthors">Reilly, Sean W.; Riad, Aladdin A.; Hsieh, Chia-Ju; Sahlholm, Kristoffer; Jacome, Daniel A.; Griffin, Suzy; Taylor, Michelle; Weng, Chi-Chang; Xu, Kuiying; Kirschner, Nathan; Luedtke, Robert R.; Parry, Christopher; Malhotra, Shipra; Karanicolas, John; Mach, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5132-5147</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Previously, we reported a 3-(2-methoxyphenyl)-9-(3-((4-methyl-5-phenyl-4H-1,2,4-triazol-3-yl)thio)propyl)-3,9-diazaspiro[5.5]undecane (I) compd. with excellent dopamine D3 receptor (D3R) affinity (D3R Ki = 12.0 nM) and selectivity (D2R/D3R ratio = 905).  Herein, we present derivs. of I with comparable D3R affinity (II, D3R Ki = 3.2 nM, D2R/D3R ratio = 60) and selectivity (III, D3R Ki = 21.0 nM, D2R/D3R ratio = 934).  Fragmentation of I revealed orthosteric fragment IV to express an unusually low D3R affinity (Ki = 2.7 μM).  Compared to piperazine congener V, which retains a high-affinity orthosteric fragment (VI, D3R Ki = 23.9 nM), I was found to be more selective for the D3R among D1- and D2-like receptors and exhibited negligible off-target interactions at serotoninergic and adrenergic G-protein-coupled receptors (GPCRs), common off-target sites for piperazine-contg. D3R scaffolds.  This study provides a unique rationale for implementing weakly potent orthosteric fragments into D3R ligand systems to minimize drug promiscuity at other aminergic GPCR sites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0AsYC3qYsr7Vg90H21EOLACvtfcHk0lh7Ak4s5CusWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXot1Sntrs%253D&md5=ce936e36f3007e1f5587edf9275479ff</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00412%26sid%3Dliteratum%253Aachs%26aulast%3DReilly%26aufirst%3DS.%2BW.%26aulast%3DRiad%26aufirst%3DA.%2BA.%26aulast%3DHsieh%26aufirst%3DC.-J.%26aulast%3DSahlholm%26aufirst%3DK.%26aulast%3DJacome%26aufirst%3DD.%2BA.%26aulast%3DGriffin%26aufirst%3DS.%26aulast%3DTaylor%26aufirst%3DM.%26aulast%3DWeng%26aufirst%3DC.-C.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DKirschner%26aufirst%3DN.%26aulast%3DLuedtke%26aufirst%3DR.%2BR.%26aulast%3DParry%26aufirst%3DC.%26aulast%3DMalhotra%26aufirst%3DS.%26aulast%3DKaranicolas%26aufirst%3DJ.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DLeveraging%2520a%2520Low-Affinity%2520Diazaspiro%2520Orthosteric%2520Fragment%2520to%2520Reduce%2520Dopamine%2520D3%2520Receptor%2520%2528D3R%2529%2520Ligand%2520Promiscuity%2520across%2520Highly%2520Conserved%2520Aminergic%2520G-Protein-Coupled%2520Receptors%2520%2528GPCRs%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D10%26spage%3D5132%26epage%3D5147%26doi%3D10.1021%2Facs.jmedchem.9b00412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puentes, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, C.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makvandi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">Examination of Diazaspiro Cores as Piperazine Bioisosteres in the Olaparib Framework Shows Reduced DNA Damage and Cytotoxicity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">5367</span>– <span class="NLM_lpage">5379</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00576</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00576" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVKktbzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5367-5379&issue=12&author=S.+W.+Reillyauthor=L.+N.+Puentesauthor=K.+Wilsonauthor=C.-J.+Hsiehauthor=C.-C.+Wengauthor=M.+Makvandiauthor=R.+H.+Mach&title=Examination+of+Diazaspiro+Cores+as+Piperazine+Bioisosteres+in+the+Olaparib+Framework+Shows+Reduced+DNA+Damage+and+Cytotoxicity&doi=10.1021%2Facs.jmedchem.8b00576"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Examination of Diazaspiro Cores as Piperazine Bioisosteres in the Olaparib Framework Shows Reduced DNA Damage and Cytotoxicity</span></div><div class="casAuthors">Reilly, Sean W.; Puentes, Laura N.; Wilson, Khadija; Hsieh, Chia-Ju; Weng, Chi-Chang; Makvandi, Mehran; Mach, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5367-5379</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Development of poly(ADP-ribose) polymerase inhibitors (PARPi's) continues to be an attractive area of research due to synthetic lethality in DNA repair deficient cancers; however, PARPi's also have potential as therapeutics to prevent harmful inflammation.  We investigated the pharmacol. impact of incorporating spirodiamine motifs into the phthalazine architecture of FDA approved PARPi olaparib.  Synthesized analogs were screened for PARP-1 affinity, enzyme specificity, catalytic inhibition, DNA damage, and cytotoxicity.  This work led to the identification of 10e (12.6 ± 1.1 nM), which did not induce DNA damage at similar drug concns. as olaparib.  Interestingly, several worst in class compds. with low PARP-1 affinity, including 15b (4397 ± 1.1 nM), induced DNA damage at micromolar concns., which can explain the cytotoxicity obsd. in vitro.  This work provides further evidence that high affinity PARPi's can be developed without DNA damaging properties offering potential new drugs for treating inflammatory related diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnTC4dTcUAdrVg90H21EOLACvtfcHk0lirastmjPRQuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVKktbzE&md5=e352b0777c5f53f2c126288a1c5ff4c1</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00576%26sid%3Dliteratum%253Aachs%26aulast%3DReilly%26aufirst%3DS.%2BW.%26aulast%3DPuentes%26aufirst%3DL.%2BN.%26aulast%3DWilson%26aufirst%3DK.%26aulast%3DHsieh%26aufirst%3DC.-J.%26aulast%3DWeng%26aufirst%3DC.-C.%26aulast%3DMakvandi%26aufirst%3DM.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DExamination%2520of%2520Diazaspiro%2520Cores%2520as%2520Piperazine%2520Bioisosteres%2520in%2520the%2520Olaparib%2520Framework%2520Shows%2520Reduced%2520DNA%2520Damage%2520and%2520Cytotoxicity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D12%26spage%3D5367%26epage%3D5379%26doi%3D10.1021%2Facs.jmedchem.8b00576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feichtinger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasem, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrader, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frazer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unett, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grottick, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whelan, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sage, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Semple, G.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Lead Series of Potent Benzodiazepine 5-HT2C Receptor Agonists with High Selectivity in Functional and Binding Assays</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">126929</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.126929</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2Fj.bmcl.2019.126929" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=31952960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFCmsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=126929&issue=5&author=A.+Renauthor=X.+Zhuauthor=K.+Feichtingerauthor=J.+Lehmanauthor=M.+Kasemauthor=T.+O.+Schraderauthor=A.+Wongauthor=H.+Dangauthor=M.+Leauthor=J.+Frazerauthor=D.+J.+Unettauthor=A.+J.+Grottickauthor=K.+T.+Whelanauthor=M.+E.+Morganauthor=C.+R.+Sageauthor=G.+Semple&title=Discovery+of+a+Lead+Series+of+Potent+Benzodiazepine+5-HT2C+Receptor+Agonists+with+High+Selectivity+in+Functional+and+Binding+Assays&doi=10.1016%2Fj.bmcl.2019.126929"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a lead series of potent benzodiazepine 5-HT2C receptor agonists with high selectivity in functional and binding assays</span></div><div class="casAuthors">Ren, Albert; Zhu, Xiuwen; Feichtinger, Konrad; Lehman, Juerg; Kasem, Michelle; Schrader, Thomas O.; Wong, Amy; Dang, Huong; Le, Minh; Frazer, John; Unett, David J.; Grottick, Andrew J.; Whelan, Kevin T.; Morgan, Michael E.; Sage, Carleton R.; Semple, Graeme</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">126929</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of potential new 5-HT2 receptor scaffolds based on a simplification of the clin. studied, 5-HT2CR agonist vabicaserin, were designed.  An in vivo feeding assay early in our screening process played an instrumental part in the lead identification process, leading us to focus on a 6,5,7-tricyclic scaffold.  A subsequent early SAR investigation provided potent agonists of the 5-HT2C receptor that were highly selective in both functional and binding assays, had good rat PK properties and that significantly reduced acute food intake in the rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_fMa9no0QxLVg90H21EOLACvtfcHk0lirastmjPRQuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFCmsLk%253D&md5=18051138ef182fcc71575cd2d7c293f0</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.126929&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.126929%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DA.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DFeichtinger%26aufirst%3DK.%26aulast%3DLehman%26aufirst%3DJ.%26aulast%3DKasem%26aufirst%3DM.%26aulast%3DSchrader%26aufirst%3DT.%2BO.%26aulast%3DWong%26aufirst%3DA.%26aulast%3DDang%26aufirst%3DH.%26aulast%3DLe%26aufirst%3DM.%26aulast%3DFrazer%26aufirst%3DJ.%26aulast%3DUnett%26aufirst%3DD.%2BJ.%26aulast%3DGrottick%26aufirst%3DA.%2BJ.%26aulast%3DWhelan%26aufirst%3DK.%2BT.%26aulast%3DMorgan%26aufirst%3DM.%2BE.%26aulast%3DSage%26aufirst%3DC.%2BR.%26aulast%3DSemple%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520a%2520Lead%2520Series%2520of%2520Potent%2520Benzodiazepine%25205-HT2C%2520Receptor%2520Agonists%2520with%2520High%2520Selectivity%2520in%2520Functional%2520and%2520Binding%2520Assays%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26issue%3D5%26spage%3D126929%26doi%3D10.1016%2Fj.bmcl.2019.126929" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">García, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Virgili, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alegret, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Port, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascual, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monroy, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vidal-Torres, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serafini, M.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almansa, C.</span></span> <span> </span><span class="NLM_article-title">4-Aryl-1-Oxa-4,9-Diazaspiro[5.5]Undecane Derivatives as Dual μ-Opioid Receptor Agonists and σ1 Receptor Antagonists for the Treatment of Pain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2434</span>– <span class="NLM_lpage">2454</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01256</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01256" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitF2nur3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=2434-2454&issue=5&author=M.+Garc%C3%ADaauthor=M.+Virgiliauthor=M.+Alonsoauthor=C.+Alegretauthor=B.+Fern%C3%A1ndezauthor=A.+Portauthor=R.+Pascualauthor=X.+Monroyauthor=A.+Vidal-Torresauthor=M.-T.+Serafiniauthor=J.+M.+Velaauthor=C.+Almansa&title=4-Aryl-1-Oxa-4%2C9-Diazaspiro%5B5.5%5DUndecane+Derivatives+as+Dual+%CE%BC-Opioid+Receptor+Agonists+and+%CF%831+Receptor+Antagonists+for+the+Treatment+of+Pain&doi=10.1021%2Facs.jmedchem.9b01256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">4-Aryl-1-oxa-4,9-diazaspiro[5.5]undecane derivatives as dual μ-opioid receptor agonists and σ1 receptor antagonists for the treatment of pain</span></div><div class="casAuthors">Garcia, Monica; Virgili, Marina; Alonso, Monica; Alegret, Carles; Fernandez, Begona; Port, Adriana; Pascual, Rosalia; Monroy, Xavier; Vidal-Torres, Alba; Serafini, Maria-Teresa; Vela, Jose Miguel; Almansa, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2434-2454</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis and pharmacol. activity of a new series of 1-oxa-4,9-diazaspiro[5.5]undecane derivs. as potent dual ligands for the sigma-1 receptor (σ1R) and the μ-opioid receptor (MOR) are reported.  The different positions of the central scaffold, designed using a merging strategy of both targets pharmacophores, were explored using a versatile synthetic approach.  Phenethyl derivs. in position 9, substituted pyridyl moieties in position 4 and small alkyl groups in position 2 provided the best profiles.  One of the best compds., I, showed a balanced dual profile (i.e. MOR agonism and sigma antagonism) and potent analgesic activity, comparable to the MOR agonist oxycodone in the paw pressure test in mice.  Contrary to oxycodone, as expected from the addn. of σ1R antagonism, I showed local, peripheral activity in this test, which was reversed by the σ1R agonist PRE-084.  At equianalgesic doses, I showed less constipation than oxycodone, providing evidence that dual MOR agonism and σ1R antagonism may be a useful strategy for obtaining potent and safer analgesics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpN_96WgxDmIbVg90H21EOLACvtfcHk0ljEK5Q34v8XlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitF2nur3M&md5=6ff458638f9069ade1ccca8adabebb9a</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01256%26sid%3Dliteratum%253Aachs%26aulast%3DGarc%25C3%25ADa%26aufirst%3DM.%26aulast%3DVirgili%26aufirst%3DM.%26aulast%3DAlonso%26aufirst%3DM.%26aulast%3DAlegret%26aufirst%3DC.%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DB.%26aulast%3DPort%26aufirst%3DA.%26aulast%3DPascual%26aufirst%3DR.%26aulast%3DMonroy%26aufirst%3DX.%26aulast%3DVidal-Torres%26aufirst%3DA.%26aulast%3DSerafini%26aufirst%3DM.-T.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26aulast%3DAlmansa%26aufirst%3DC.%26atitle%3D4-Aryl-1-Oxa-4%252C9-Diazaspiro%255B5.5%255DUndecane%2520Derivatives%2520as%2520Dual%2520%25CE%25BC-Opioid%2520Receptor%2520Agonists%2520and%2520%25CF%25831%2520Receptor%2520Antagonists%2520for%2520the%2520Treatment%2520of%2520Pain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26issue%3D5%26spage%3D2434%26epage%3D2454%26doi%3D10.1021%2Facs.jmedchem.9b01256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Degorce, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodnarchuk, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. S.</span></span> <span> </span><span class="NLM_article-title">Lowering Lipophilicity by Adding Carbon: AzaSpiroHeptanes, a LogD Lowering Twist</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1198</span>– <span class="NLM_lpage">1204</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00248</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00248" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVSqtrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1198-1204&issue=8&author=S.+L.+Degorceauthor=M.+S.+Bodnarchukauthor=J.+S.+Scott&title=Lowering+Lipophilicity+by+Adding+Carbon%3A+AzaSpiroHeptanes%2C+a+LogD+Lowering+Twist&doi=10.1021%2Facsmedchemlett.9b00248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Lowering Lipophilicity by Adding Carbon: AzaSpiroHeptanes, a logD Lowering Twist</span></div><div class="casAuthors">Degorce, Sebastien L.; Bodnarchuk, Michael S.; Scott, James S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1198-1204</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have conducted an anal. of azaspiro[3.3]heptanes used as replacements for morpholines, piperidines, and piperazines in a medicinal chem. context.  In most cases, introducing a spirocyclic center lowered the measured logD7.4 of the corresponding mols. by as much as -1.0 relative to the more usual heterocycle.  This may seem counterintuitive, as the net change in the mol. is the addn. of a single carbon atom, but it may be rationalized in terms of increased basicity.  An exception to this was found with N-linked 2-azaspiro[3.3]heptane, where logD7.4 increased by as much as +0.5, consistent with the addn. of carbon.  During our investigation, we also concluded that azaspiro[3.3]heptanes are most likely not suitable bioisosteres for morpholines, piperidines, and piperazines, when not used as terminal groups, due to significant changes in their geometry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnW86KrUzcELVg90H21EOLACvtfcHk0ljEK5Q34v8XlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVSqtrrI&md5=8309b277d9a4071fbdfe198efaecce6e</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00248%26sid%3Dliteratum%253Aachs%26aulast%3DDegorce%26aufirst%3DS.%2BL.%26aulast%3DBodnarchuk%26aufirst%3DM.%2BS.%26aulast%3DScott%26aufirst%3DJ.%2BS.%26atitle%3DLowering%2520Lipophilicity%2520by%2520Adding%2520Carbon%253A%2520AzaSpiroHeptanes%252C%2520a%2520LogD%2520Lowering%2520Twist%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26issue%3D8%26spage%3D1198%26epage%3D1204%26doi%3D10.1021%2Facsmedchemlett.9b00248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wuitschik, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers-Evans, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernasconi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Märki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parrilla, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuler, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweizer, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carreira, E. M.</span></span> <span> </span><span class="NLM_article-title">Spirocyclic Oxetanes: Synthesis and Properties</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>47</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">4512</span>– <span class="NLM_lpage">4515</span>, <span class="refDoi"> DOI: 10.1002/anie.200800450</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1002%2Fanie.200800450" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BD1cXns1yrurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=4512-4515&issue=24&author=G.+Wuitschikauthor=M.+Rogers-Evansauthor=A.+Bucklauthor=M.+Bernasconiauthor=M.+M%C3%A4rkiauthor=T.+Godelauthor=H.+Fischerauthor=B.+Wagnerauthor=I.+Parrillaauthor=F.+Schulerauthor=J.+Schneiderauthor=A.+Alkerauthor=W.+B.+Schweizerauthor=K.+M%C3%BCllerauthor=E.+M.+Carreira&title=Spirocyclic+Oxetanes%3A+Synthesis+and+Properties&doi=10.1002%2Fanie.200800450"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Spirocyclic oxetanes: synthesis and properties</span></div><div class="casAuthors">Wuitschik, Georg; Rogers-Evans, Mark; Buckl, Andreas; Bernasconi, Maurizio; Marki, Moritz; Godel, Thierry; Fischer, Holger; Wagner, Bjorn; Parrilla, Isabelle; Schuler, Franz; Schneider, Josef; Alker, Andre; Schweizer, W. Bernd; Muller, Klaus; Carreira, Erick M.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">4512-4515</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Spirocyclic oxetanes are described as analogs of morpholine and also as topol. siblings of their carbonyl counterparts.  They are particularly promising in terms of both their physicochem. properties and the ease with which they can be grafted onto mol. structures.  The data collected highlight oxetanes as both the hydrophilic sister of a gem-di-Me unit and the carbonyl group's lipophilic brother.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpjICUKXgpt7Vg90H21EOLACvtfcHk0ljEK5Q34v8XlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXns1yrurs%253D&md5=9522eb5cfb870b872d8f9c1f06ae2946</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1002%2Fanie.200800450&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200800450%26sid%3Dliteratum%253Aachs%26aulast%3DWuitschik%26aufirst%3DG.%26aulast%3DRogers-Evans%26aufirst%3DM.%26aulast%3DBuckl%26aufirst%3DA.%26aulast%3DBernasconi%26aufirst%3DM.%26aulast%3DM%25C3%25A4rki%26aufirst%3DM.%26aulast%3DGodel%26aufirst%3DT.%26aulast%3DFischer%26aufirst%3DH.%26aulast%3DWagner%26aufirst%3DB.%26aulast%3DParrilla%26aufirst%3DI.%26aulast%3DSchuler%26aufirst%3DF.%26aulast%3DSchneider%26aufirst%3DJ.%26aulast%3DAlker%26aufirst%3DA.%26aulast%3DSchweizer%26aufirst%3DW.%2BB.%26aulast%3DM%25C3%25BCller%26aufirst%3DK.%26aulast%3DCarreira%26aufirst%3DE.%2BM.%26atitle%3DSpirocyclic%2520Oxetanes%253A%2520Synthesis%2520and%2520Properties%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2008%26volume%3D47%26issue%3D24%26spage%3D4512%26epage%3D4515%26doi%3D10.1002%2Fanie.200800450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burkhard, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuler, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carreira, E. M.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Azaspirocycles and Their Evaluation in Drug Discovery</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">3524</span>– <span class="NLM_lpage">3527</span>, <span class="refDoi"> DOI: 10.1002/anie.200907108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1002%2Fanie.200907108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsFCnsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=3524-3527&issue=20&author=J.+A.+Burkhardauthor=B.+Wagnerauthor=H.+Fischerauthor=F.+Schulerauthor=K.+M%C3%BCllerauthor=E.+M.+Carreira&title=Synthesis+of+Azaspirocycles+and+Their+Evaluation+in+Drug+Discovery&doi=10.1002%2Fanie.200907108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Azaspirocycles and their Evaluation in Drug Discovery</span></div><div class="casAuthors">Burkhard, Johannes A.; Wagner, Bjoern; Fischer, Holger; Schuler, Franz; Mueller, Klaus; Carreira, Erick M.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3524-3527, S3524/1-S3524/60</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Readily synthesized heteroatom-substituted spiro[3.3]heptanes generally show higher aq. soly. than their cyclohexane analogs, and show a trend towards higher metabolic stability.  The novel framework can be mounted onto scaffolds of druglike structures, such as fluoroquinolones, to afford active compds. with similar or even improved metabolic stability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpW-R9uvaVrXLVg90H21EOLACvtfcHk0ljbCnoJ9soloA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsFCnsbY%253D&md5=0367b2cb751889a3df1cb1c8d2b24bc6</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1002%2Fanie.200907108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200907108%26sid%3Dliteratum%253Aachs%26aulast%3DBurkhard%26aufirst%3DJ.%2BA.%26aulast%3DWagner%26aufirst%3DB.%26aulast%3DFischer%26aufirst%3DH.%26aulast%3DSchuler%26aufirst%3DF.%26aulast%3DM%25C3%25BCller%26aufirst%3DK.%26aulast%3DCarreira%26aufirst%3DE.%2BM.%26atitle%3DSynthesis%2520of%2520Azaspirocycles%2520and%2520Their%2520Evaluation%2520in%2520Drug%2520Discovery%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2010%26volume%3D49%26issue%3D20%26spage%3D3524%26epage%3D3527%26doi%3D10.1002%2Fanie.200907108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sampson, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feher, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forrest, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ban, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awrey, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plotnikova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiarash, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chirgadze, N. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauls, H. W.</span></span> <span> </span><span class="NLM_article-title">The Discovery of Polo-like Kinase 4 Inhibitors: Design and Optimization of Spiro[Cyclopropane-1,3’[3H]Indol]-2’(1’H).Ones as Orally Bioavailable Antitumor Agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">130</span>– <span class="NLM_lpage">146</span>, <span class="refDoi"> DOI: 10.1021/jm500537u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500537u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2cXos1Wktro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=130-146&issue=1&author=P.+B.+Sampsonauthor=Y.+Liuauthor=N.+K.+Patelauthor=M.+Feherauthor=B.+Forrestauthor=S.-W.+Liauthor=L.+Edwardsauthor=R.+Lauferauthor=Y.+Langauthor=F.+Banauthor=D.+E.+Awreyauthor=G.+Maoauthor=O.+Plotnikovaauthor=G.+Leungauthor=R.+Hodgsonauthor=J.+M.+Masonauthor=X.+Weiauthor=R.+Kiarashauthor=E.+Greenauthor=W.+Qiuauthor=N.+Y.+Chirgadzeauthor=T.+W.+Makauthor=G.+Panauthor=H.+W.+Pauls&title=The+Discovery+of+Polo-like+Kinase+4+Inhibitors%3A+Design+and+Optimization+of+Spiro%5BCyclopropane-1%2C3%E2%80%99%5B3H%5DIndol%5D-2%E2%80%99%281%E2%80%99H%29.Ones+as+Orally+Bioavailable+Antitumor+Agents&doi=10.1021%2Fjm500537u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">The Discovery of Polo-Like Kinase 4 Inhibitors: Design and Optimization of Spiro[cyclopropane-1,3'[3H]indol]-2'(1'H)-ones as Orally Bioavailable Antitumor Agents</span></div><div class="casAuthors">Sampson, Peter B.; Liu, Yong; Patel, Narendra Kumar; Feher, Miklos; Forrest, Bryan; Li, Sze-Wan; Edwards, Louise; Laufer, Radoslaw; Lang, Yunhui; Ban, Fuqiang; Awrey, Donald E.; Mao, Guodong; Plotnikova, Olga; Leung, Genie; Hodgson, Richard; Mason, Jacqueline; Wei, Xin; Kiarash, Reza; Green, Erin; Qiu, Wei; Chirgadze, Nickolay Y.; Mak, Tak W.; Pan, Guohua; Pauls, Henry W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">130-146</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Polo-like kinase 4 (PLK4), a unique member of the polo-like kinase family of serine-threonine kinases, is a master regulator of centriole duplication that is important for maintaining genome integrity.  Overexpression of PLK4 is found in several human cancers and is linked with a predisposition to tumorigenesis.  Previous efforts to identify potent and efficacious PLK4 inhibitors resulted in the discovery of (E)-3-((1H-indazol-6-yl)methylene)indolin-2-ones, which are superseded by the bioisosteric 2-(1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-ones reported herein.  Optimization of this new cyclopropane-linked series was based on a computational model of a PLK4 x-ray structure and SAR attained from the analogous alkene-linked series.  The racemic cyclopropane-linked compds. showed PLK4 affinity and antiproliferative activity comparable to their alkene-linked congeners with improved physicochem., ADME, and pharmacokinetic properties.  Pos. xenograft results from the MDA-MB-468 human breast cancer xenograft model for compd. I support the investigation of PLK4 inhibitors as anticancer therapeutics.  A PLK4 x-ray co-structure with compd. I revealed preferential binding of the 1R,2S enantiomer to the PLK4 kinase domain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_nQjbJy_sMLVg90H21EOLACvtfcHk0ljbCnoJ9soloA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXos1Wktro%253D&md5=90d60867ee5d6c27f597ebe32db64278</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1021%2Fjm500537u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500537u%26sid%3Dliteratum%253Aachs%26aulast%3DSampson%26aufirst%3DP.%2BB.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DPatel%26aufirst%3DN.%2BK.%26aulast%3DFeher%26aufirst%3DM.%26aulast%3DForrest%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DS.-W.%26aulast%3DEdwards%26aufirst%3DL.%26aulast%3DLaufer%26aufirst%3DR.%26aulast%3DLang%26aufirst%3DY.%26aulast%3DBan%26aufirst%3DF.%26aulast%3DAwrey%26aufirst%3DD.%2BE.%26aulast%3DMao%26aufirst%3DG.%26aulast%3DPlotnikova%26aufirst%3DO.%26aulast%3DLeung%26aufirst%3DG.%26aulast%3DHodgson%26aufirst%3DR.%26aulast%3DMason%26aufirst%3DJ.%2BM.%26aulast%3DWei%26aufirst%3DX.%26aulast%3DKiarash%26aufirst%3DR.%26aulast%3DGreen%26aufirst%3DE.%26aulast%3DQiu%26aufirst%3DW.%26aulast%3DChirgadze%26aufirst%3DN.%2BY.%26aulast%3DMak%26aufirst%3DT.%2BW.%26aulast%3DPan%26aufirst%3DG.%26aulast%3DPauls%26aufirst%3DH.%2BW.%26atitle%3DThe%2520Discovery%2520of%2520Polo-like%2520Kinase%25204%2520Inhibitors%253A%2520Design%2520and%2520Optimization%2520of%2520Spiro%255BCyclopropane-1%252C3%25E2%2580%2599%255B3H%255DIndol%255D-2%25E2%2580%2599%25281%25E2%2580%2599H%2529.Ones%2520as%2520Orally%2520Bioavailable%2520Antitumor%2520Agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D1%26spage%3D130%26epage%3D146%26doi%3D10.1021%2Fjm500537u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mallinger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crumpler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pichowicz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waalboer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stubbs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adeniji-Popoola, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thai, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henley, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georgi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Court, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobbs, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Box, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz-Ruiz, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valenti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Haven
Brandon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">TePoele, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leuthner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aherne, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poeschke, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dale, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wienke, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esdar, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohdich, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eccles, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stieber, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiemann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of Potent, Orally Bioavailable, Small-Molecule Inhibitors of WNT Signaling from a Cell-Based Pathway Screen</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1717</span>– <span class="NLM_lpage">1735</span>, <span class="refDoi"> DOI: 10.1021/jm501436m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501436m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2MXislGjur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=1717-1735&issue=4&author=A.+Mallingerauthor=S.+Crumplerauthor=M.+Pichowiczauthor=D.+Waalboerauthor=M.+Stubbsauthor=O.+Adeniji-Popoolaauthor=B.+Woodauthor=E.+Smithauthor=C.+Thaiauthor=A.+T.+Henleyauthor=K.+Georgiauthor=W.+Courtauthor=S.+Hobbsauthor=G.+Boxauthor=M.-J.+Ortiz-Ruizauthor=M.+Valentiauthor=A.+De+Haven%0ABrandonauthor=R.+TePoeleauthor=B.+Leuthnerauthor=P.+Workmanauthor=W.+Aherneauthor=O.+Poeschkeauthor=T.+Daleauthor=D.+Wienkeauthor=C.+Esdarauthor=F.+Rohdichauthor=F.+Raynaudauthor=P.+A.+Clarkeauthor=S.+A.+Ecclesauthor=F.+Stieberauthor=K.+Schiemannauthor=J.+Blagg&title=Discovery+of+Potent%2C+Orally+Bioavailable%2C+Small-Molecule+Inhibitors+of+WNT+Signaling+from+a+Cell-Based+Pathway+Screen&doi=10.1021%2Fjm501436m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent, Orally Bioavailable, Small-Molecule Inhibitors of WNT Signaling from a Cell-Based Pathway Screen</span></div><div class="casAuthors">Mallinger, Aurelie; Crumpler, Simon; Pichowicz, Mark; Waalboer, Dennis; Stubbs, Mark; Adeniji-Popoola, Olajumoke; Wood, Bozena; Smith, Elizabeth; Thai, Ching; Henley, Alan T.; Georgi, Katrin; Court, William; Hobbs, Steve; Box, Gary; Ortiz-Ruiz, Maria-Jesus; Valenti, Melanie; De Haven Brandon, Alexis; Te Poele, Robert; Leuthner, Birgitta; Workman, Paul; Aherne, Wynne; Poeschke, Oliver; Dale, Trevor; Wienke, Dirk; Esdar, Christina; Rohdich, Felix; Raynaud, Florence; Clarke, Paul A.; Eccles, Suzanne A.; Stieber, Frank; Schiemann, Kai; Blagg, Julian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1717-1735</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">WNT signaling is frequently deregulated in malignancy, particularly in colon cancer, and plays a key role in the generation and maintenance of cancer stem cells.  The authors report the discovery and optimization of a 3,4,5-trisubstituted pyridine, 1-(3,5-Dichloropyridin-4-yl)piperidine-4-carboxamide (9), using a high-throughput cell-based reporter assay of WNT pathway activity.  The authors demonstrate a twisted conformation about the pyridine-piperidine bond of (9) by small-mol. x-ray crystallog.  Medicinal chem. optimization to maintain this twisted conformation, cognisant of physicochem. properties likely to maintain good cell permeability, led to 8-[3-Chloro-5-[4-(1-methyl-1H-pyrazol-4-yl)phenyl]pyridin-4-yl]-2,8-diazaspiro[4,5]decan-1-one (74) (CCT251545), a potent small-mol. inhibitor of WNT signaling with good oral pharmacokinetics.  The authors demonstrate inhibition of WNT pathway activity in a solid human tumor xenograft model with evidence for tumor growth inhibition following oral dosing.  This work provides a successful example of hypothesis-driven medicinal chem. optimization from a singleton hit against a cell-based pathway assay without knowledge of the biochem. target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGX6wdTc3jeLVg90H21EOLACvtfcHk0li0rI5tS3kv9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXislGjur4%253D&md5=eab7f23a8288cb3da6665ef000558f95</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1021%2Fjm501436m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501436m%26sid%3Dliteratum%253Aachs%26aulast%3DMallinger%26aufirst%3DA.%26aulast%3DCrumpler%26aufirst%3DS.%26aulast%3DPichowicz%26aufirst%3DM.%26aulast%3DWaalboer%26aufirst%3DD.%26aulast%3DStubbs%26aufirst%3DM.%26aulast%3DAdeniji-Popoola%26aufirst%3DO.%26aulast%3DWood%26aufirst%3DB.%26aulast%3DSmith%26aufirst%3DE.%26aulast%3DThai%26aufirst%3DC.%26aulast%3DHenley%26aufirst%3DA.%2BT.%26aulast%3DGeorgi%26aufirst%3DK.%26aulast%3DCourt%26aufirst%3DW.%26aulast%3DHobbs%26aufirst%3DS.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DOrtiz-Ruiz%26aufirst%3DM.-J.%26aulast%3DValenti%26aufirst%3DM.%26aulast%3DDe%2BHaven%2BBrandon%26aufirst%3DA.%26aulast%3DTePoele%26aufirst%3DR.%26aulast%3DLeuthner%26aufirst%3DB.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DAherne%26aufirst%3DW.%26aulast%3DPoeschke%26aufirst%3DO.%26aulast%3DDale%26aufirst%3DT.%26aulast%3DWienke%26aufirst%3DD.%26aulast%3DEsdar%26aufirst%3DC.%26aulast%3DRohdich%26aufirst%3DF.%26aulast%3DRaynaud%26aufirst%3DF.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DStieber%26aufirst%3DF.%26aulast%3DSchiemann%26aufirst%3DK.%26aulast%3DBlagg%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520Potent%252C%2520Orally%2520Bioavailable%252C%2520Small-Molecule%2520Inhibitors%2520of%2520WNT%2520Signaling%2520from%2520a%2520Cell-Based%2520Pathway%2520Screen%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D4%26spage%3D1717%26epage%3D1735%26doi%3D10.1021%2Fjm501436m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johansson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Löfberg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonsson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Unge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Judkins, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ploj, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benthem, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindén, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wennerberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fredenwall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettersen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gennemark, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogner, A.</span></span> <span> </span><span class="NLM_article-title">Discovery of (3-(4-(2-Oxa-6-Azaspiro[3.3]Heptan-6-Ylmethyl)Phenoxy)Azetidin-1-Yl)(5-(4-Methoxyphenyl)-1,3,4-Oxadiazol-2-Yl)Methanone (AZD1979), a Melanin Concentrating Hormone Receptor 1 (MCHr1) Antagonist with Favorable Physicochemical Properties</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2497</span>– <span class="NLM_lpage">2511</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01654</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01654" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC28XktFCnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2497-2511&issue=6&author=A.+Johanssonauthor=C.+L%C3%B6fbergauthor=M.+Antonssonauthor=S.+von+Ungeauthor=M.+A.+Hayesauthor=R.+Judkinsauthor=K.+Plojauthor=L.+Benthemauthor=D.+Lind%C3%A9nauthor=P.+Brodinauthor=M.+Wennerbergauthor=M.+Fredenwallauthor=L.+Liauthor=J.+Perssonauthor=R.+Bergmanauthor=A.+Pettersenauthor=P.+Gennemarkauthor=A.+Hogner&title=Discovery+of+%283-%284-%282-Oxa-6-Azaspiro%5B3.3%5DHeptan-6-Ylmethyl%29Phenoxy%29Azetidin-1-Yl%29%285-%284-Methoxyphenyl%29-1%2C3%2C4-Oxadiazol-2-Yl%29Methanone+%28AZD1979%29%2C+a+Melanin+Concentrating+Hormone+Receptor+1+%28MCHr1%29+Antagonist+with+Favorable+Physicochemical+Properties&doi=10.1021%2Facs.jmedchem.5b01654"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (3-(4-(2-Oxa-6-azaspiro[3.3]heptan-6-ylmethyl)phenoxy)azetidin-1-yl)(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)methanone (AZD1979), a Melanin Concentrating Hormone Receptor 1 (MCHr1) Antagonist with Favorable Physicochemical Properties</span></div><div class="casAuthors">Johansson, Anders; Loefberg, Christian; Antonsson, Madeleine; von Unge, Sverker; Hayes, Martin A.; Judkins, Robert; Ploj, Karolina; Benthem, Lambertus; Linden, Daniel; Brodin, Peter; Wennerberg, Marie; Fredenwall, Marlene; Li, Lanna; Persson, Joachim; Bergman, Rolf; Pettersen, Anna; Gennemark, Peter; Hogner, Anders</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2497-2511</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of melanin concg. hormone receptor 1 (MCHr1) antagonists were the starting point for a drug discovery program that culminated in the discovery of 103 (AZD1979).  The lead optimization program was conducted with a focus on reducing lipophilicity and understanding the physicochem. properties governing CNS exposure and undesired off-target pharmacol. such as hERG interactions.  An integrated approach was taken where the key assay was ex vivo receptor occupancy in mice.  The candidate compd. 103 displayed appropriate lipophilicity for a CNS indication and showed excellent permeability with no efflux.  Preclin. GLP toxicol. and safety pharmacol. studies were without major findings and 103 was taken into clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJJvE6-qb7C7Vg90H21EOLACvtfcHk0li0rI5tS3kv9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktFCnsg%253D%253D&md5=98ac16f6fd4be62e681f2ebb094e985e</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01654%26sid%3Dliteratum%253Aachs%26aulast%3DJohansson%26aufirst%3DA.%26aulast%3DL%25C3%25B6fberg%26aufirst%3DC.%26aulast%3DAntonsson%26aufirst%3DM.%26aulast%3Dvon%2BUnge%26aufirst%3DS.%26aulast%3DHayes%26aufirst%3DM.%2BA.%26aulast%3DJudkins%26aufirst%3DR.%26aulast%3DPloj%26aufirst%3DK.%26aulast%3DBenthem%26aufirst%3DL.%26aulast%3DLind%25C3%25A9n%26aufirst%3DD.%26aulast%3DBrodin%26aufirst%3DP.%26aulast%3DWennerberg%26aufirst%3DM.%26aulast%3DFredenwall%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DPersson%26aufirst%3DJ.%26aulast%3DBergman%26aufirst%3DR.%26aulast%3DPettersen%26aufirst%3DA.%26aulast%3DGennemark%26aufirst%3DP.%26aulast%3DHogner%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520%25283-%25284-%25282-Oxa-6-Azaspiro%255B3.3%255DHeptan-6-Ylmethyl%2529Phenoxy%2529Azetidin-1-Yl%2529%25285-%25284-Methoxyphenyl%2529-1%252C3%252C4-Oxadiazol-2-Yl%2529Methanone%2520%2528AZD1979%2529%252C%2520a%2520Melanin%2520Concentrating%2520Hormone%2520Receptor%25201%2520%2528MCHr1%2529%2520Antagonist%2520with%2520Favorable%2520Physicochemical%2520Properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D6%26spage%3D2497%26epage%3D2511%26doi%3D10.1021%2Facs.jmedchem.5b01654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bryan, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drobnick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobbi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolesnikov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajapaksa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ndubaku, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choo, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMent, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ran, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sujatha-Bhaskar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brightbill, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiPasquale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenzie, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupardus, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrin, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiefer, J. R.</span></span> <span> </span><span class="NLM_article-title">Development of Potent and Selective Pyrazolopyrimidine IRAK4 Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">6223</span>– <span class="NLM_lpage">6240</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00439</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00439" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1MXptlOjsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=6223-6240&issue=13&author=M.+C.+Bryanauthor=J.+Drobnickauthor=A.+Gobbiauthor=A.+Kolesnikovauthor=Y.+Chenauthor=N.+Rajapaksaauthor=C.+Ndubakuauthor=J.+Fengauthor=W.+Changauthor=R.+Francisauthor=C.+Yuauthor=E.+F.+Chooauthor=K.+DeMentauthor=Y.+Ranauthor=L.+Anauthor=C.+Emsonauthor=Z.+Huangauthor=S.+Sujatha-Bhaskarauthor=H.+Brightbillauthor=A.+DiPasqualeauthor=J.+Maherauthor=J.+Waiauthor=B.+S.+McKenzieauthor=P.+J.+Lupardusauthor=A.+A.+Zarrinauthor=J.+R.+Kiefer&title=Development+of+Potent+and+Selective+Pyrazolopyrimidine+IRAK4+Inhibitors&doi=10.1021%2Facs.jmedchem.9b00439"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Potent and Selective Pyrazolopyrimidine IRAK4 Inhibitors</span></div><div class="casAuthors">Bryan, Marian C.; Drobnick, Joy; Gobbi, Alberto; Kolesnikov, Aleksandr; Chen, Yongsheng; Rajapaksa, Naomi; Ndubaku, Chudi; Feng, Jianwen; Chang, Willy; Francis, Ross; Yu, Christine; Choo, Edna F.; DeMent, Kevin; Ran, Yingqing; An, Le; Emson, Claire; Huang, Zhiyu; Sujatha-Bhaskar, Swathi; Brightbill, Hans; DiPasquale, Antonio; Maher, Jonathan; Wai, John; McKenzie, Brent S.; Lupardus, Patrick J.; Zarrin, Ali A.; Kiefer, James R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6223-6240</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of pyrazolopyrimidine inhibitors of IRAK4 were developed from a high-throughput screen (HTS).  Modification of an HTS hit led to a series of bicyclic heterocycles with improved potency and kinase selectivity but lacking sufficient soly. to progress in vivo.  Structure-based drug design, informed by cocrystal structures with the protein and small-mol. crystal structures, yielded a series of dihydrobenzofurans.  This semisatd. bicycle provided superior druglike properties while maintaining excellent potency and selectivity.  Improved physicochem. properties allowed for progression into in vivo expts., where lead mols. exhibited low clearance and showed target-based inhibition of IRAK4 signaling in an inflammation-mediated PK/PD mouse model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGdG1FWD_TrbVg90H21EOLACvtfcHk0lhyt-heW5JLUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXptlOjsr8%253D&md5=edf86550908249af0c0c2a5be32abe06</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00439%26sid%3Dliteratum%253Aachs%26aulast%3DBryan%26aufirst%3DM.%2BC.%26aulast%3DDrobnick%26aufirst%3DJ.%26aulast%3DGobbi%26aufirst%3DA.%26aulast%3DKolesnikov%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DRajapaksa%26aufirst%3DN.%26aulast%3DNdubaku%26aufirst%3DC.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DW.%26aulast%3DFrancis%26aufirst%3DR.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DChoo%26aufirst%3DE.%2BF.%26aulast%3DDeMent%26aufirst%3DK.%26aulast%3DRan%26aufirst%3DY.%26aulast%3DAn%26aufirst%3DL.%26aulast%3DEmson%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DSujatha-Bhaskar%26aufirst%3DS.%26aulast%3DBrightbill%26aufirst%3DH.%26aulast%3DDiPasquale%26aufirst%3DA.%26aulast%3DMaher%26aufirst%3DJ.%26aulast%3DWai%26aufirst%3DJ.%26aulast%3DMcKenzie%26aufirst%3DB.%2BS.%26aulast%3DLupardus%26aufirst%3DP.%2BJ.%26aulast%3DZarrin%26aufirst%3DA.%2BA.%26aulast%3DKiefer%26aufirst%3DJ.%2BR.%26atitle%3DDevelopment%2520of%2520Potent%2520and%2520Selective%2520Pyrazolopyrimidine%2520IRAK4%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D13%26spage%3D6223%26epage%3D6240%26doi%3D10.1021%2Facs.jmedchem.9b00439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizukami, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadowaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuda, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suwa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inaba, T.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Novel and Potent GPR119 Agonists with a Spirocyclic Structure</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1228</span>– <span class="NLM_lpage">1233</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.02.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2Fj.bmcl.2018.02.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=29519733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjvVGiu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=1228-1233&issue=7&author=K.+Haradaauthor=J.+Mizukamiauthor=S.+Kadowakiauthor=I.+Matsudaauthor=T.+Watanabeauthor=Y.+Oeauthor=Y.+Kodamaauthor=K.+Aokiauthor=K.+Suwaauthor=S.+Fukudaauthor=S.+Yataauthor=T.+Inaba&title=Design+and+Synthesis+of+Novel+and+Potent+GPR119+Agonists+with+a+Spirocyclic+Structure&doi=10.1016%2Fj.bmcl.2018.02.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of novel and potent GPR119 agonists with a spirocyclic structure</span></div><div class="casAuthors">Harada, Kazuhito; Mizukami, Jun; Kadowaki, Sho; Matsuda, Isamu; Watanabe, Takashi; Oe, Yasuhiro; Kodama, Yoshitoshi; Aoki, Kenta; Suwa, Katsunori; Fukuda, Sumiaki; Yata, Shinji; Inaba, Takashi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1228-1233</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Exploration of alternative structures for the substituted piperidine or piperazine ring, which are characteristic in most of the reported GPR119 agonists, provided novel spirocyclic cyclohexane derivs.  The representative I with a high three-dimensionality exhibited potent agonistic activity (EC50 = 4 nM) with no CYP inhibitory activity (IC50 >10 μM).  Compd. I also displayed hypoglycemic activity with insulin secretion dependent on glucose concn. in an i.p. glucose tolerance test in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqF9WCkY_OYwLVg90H21EOLACvtfcHk0lhyt-heW5JLUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjvVGiu7Y%253D&md5=ab7eb53347e4f59e2c3af5dfe603b3ed</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.02.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.02.044%26sid%3Dliteratum%253Aachs%26aulast%3DHarada%26aufirst%3DK.%26aulast%3DMizukami%26aufirst%3DJ.%26aulast%3DKadowaki%26aufirst%3DS.%26aulast%3DMatsuda%26aufirst%3DI.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DOe%26aufirst%3DY.%26aulast%3DKodama%26aufirst%3DY.%26aulast%3DAoki%26aufirst%3DK.%26aulast%3DSuwa%26aufirst%3DK.%26aulast%3DFukuda%26aufirst%3DS.%26aulast%3DYata%26aufirst%3DS.%26aulast%3DInaba%26aufirst%3DT.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Novel%2520and%2520Potent%2520GPR119%2520Agonists%2520with%2520a%2520Spirocyclic%2520Structure%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26issue%3D7%26spage%3D1228%26epage%3D1233%26doi%3D10.1016%2Fj.bmcl.2018.02.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schade, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagener, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christian, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordhoff, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merla, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunkern, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahrenberg, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratcliffe, P.</span></span> <span> </span><span class="NLM_article-title">Fragment-Based Discovery of Novel Potent Sepiapterin Reductase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">6391</span>– <span class="NLM_lpage">6397</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00218</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00218" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1eis7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=6391-6397&issue=13&author=J.+Alenauthor=M.+Schadeauthor=M.+Wagenerauthor=F.+Christianauthor=S.+Nordhoffauthor=B.+Merlaauthor=T.+R.+Dunkernauthor=G.+Bahrenbergauthor=P.+Ratcliffe&title=Fragment-Based+Discovery+of+Novel+Potent+Sepiapterin+Reductase+Inhibitors&doi=10.1021%2Facs.jmedchem.9b00218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-Based Discovery of Novel Potent Sepiapterin Reductase Inhibitors</span></div><div class="casAuthors">Alen, Jo; Schade, Markus; Wagener, Markus; Christian, Frank; Nordhoff, Sonja; Merla, Beatrix; Dunkern, Torsten R.; Bahrenberg, Gregor; Ratcliffe, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6391-6397</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Genome-wide-assocn. studies in chronic low back pain patients identified sepiapterin reductase as a high interest target for developing new analgesics.  Here we used 19F NMR fragment screening for the discovery of novel, ligand-efficient SPR inhibitors.  We report the crystal structures of six chem. diverse inhibitors complexed with SPR, identifying relevant interactions and binding modes in the sepiapterin pocket.  Exploration of our initial fragment screening hit led to double-digit nanomolar inhibitors of SPR with excellent ligand efficiency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqE9wu7xlixaLVg90H21EOLACvtfcHk0li8oQBruiFhgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1eis7%252FJ&md5=dda81abbe438a32ce68d141e4094cf09</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00218%26sid%3Dliteratum%253Aachs%26aulast%3DAlen%26aufirst%3DJ.%26aulast%3DSchade%26aufirst%3DM.%26aulast%3DWagener%26aufirst%3DM.%26aulast%3DChristian%26aufirst%3DF.%26aulast%3DNordhoff%26aufirst%3DS.%26aulast%3DMerla%26aufirst%3DB.%26aulast%3DDunkern%26aufirst%3DT.%2BR.%26aulast%3DBahrenberg%26aufirst%3DG.%26aulast%3DRatcliffe%26aufirst%3DP.%26atitle%3DFragment-Based%2520Discovery%2520of%2520Novel%2520Potent%2520Sepiapterin%2520Reductase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D13%26spage%3D6391%26epage%3D6397%26doi%3D10.1021%2Facs.jmedchem.9b00218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mould, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremberg, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cartic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geitmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maiques-Diaz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGonagle, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somervaille, T. C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turlais, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogilvie, D.</span></span> <span> </span><span class="NLM_article-title">Development of (4-Cyanophenyl)Glycine Derivatives as Reversible Inhibitors of Lysine Specific Demethylase 1</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">7984</span>– <span class="NLM_lpage">7999</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00462</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00462" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVKqsrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7984-7999&issue=19&author=D.+P.+Mouldauthor=C.+Alliauthor=U.+Brembergauthor=S.+Carticauthor=A.+M.+Jordanauthor=M.+Geitmannauthor=A.+Maiques-Diazauthor=A.+E.+McGonagleauthor=T.+C.+P.+Somervailleauthor=G.+J.+Spencerauthor=F.+Turlaisauthor=D.+Ogilvie&title=Development+of+%284-Cyanophenyl%29Glycine+Derivatives+as+Reversible+Inhibitors+of+Lysine+Specific+Demethylase+1&doi=10.1021%2Facs.jmedchem.7b00462"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Development of (4-Cyanophenyl)glycine Derivatives as Reversible Inhibitors of Lysine Specific Demethylase 1</span></div><div class="casAuthors">Mould, Daniel P.; Alli, Cristina; Bremberg, Ulf; Cartic, Sharon; Jordan, Allan M.; Geitmann, Matthis; Maiques-Diaz, Alba; McGonagle, Alison E.; Somervaille, Tim C. P.; Spencer, Gary J.; Turlais, Fabrice; Ogilvie, Donald</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7984-7999</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of lysine specific demethylase 1 (LSD1) has been shown to induce the differentiation of leukemia stem cells in acute myeloid leukemia (AML).  Irreversible inhibitors developed from the nonspecific inhibitor tranylcypromine have entered clin. trials; however, the development of effective reversible inhibitors has proved more challenging.  Herein, we describe our efforts to identify reversible inhibitors of LSD1 from a high throughput screen and subsequent in silico modeling approaches.  From a single hit (12) validated by biochem. and biophys. assays, we describe our efforts to develop acyclic scaffold-hops from GSK-690 (1).  A further scaffold modification to a (4-cyanophenyl)glycinamide (e.g., 29a) led to the development of compd. 32, with a Kd value of 32 nM and an EC50 value of 0.67 μM in a surrogate cellular biomarker assay.  Moreover, this deriv. does not display the same level of hERG liability as obsd. with 1 and represents a promising lead for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5NyXkmZPOqrVg90H21EOLACvtfcHk0li8oQBruiFhgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVKqsrrJ&md5=af673e7b3a2815aa09fe7264a3e4247b</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00462&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00462%26sid%3Dliteratum%253Aachs%26aulast%3DMould%26aufirst%3DD.%2BP.%26aulast%3DAlli%26aufirst%3DC.%26aulast%3DBremberg%26aufirst%3DU.%26aulast%3DCartic%26aufirst%3DS.%26aulast%3DJordan%26aufirst%3DA.%2BM.%26aulast%3DGeitmann%26aufirst%3DM.%26aulast%3DMaiques-Diaz%26aufirst%3DA.%26aulast%3DMcGonagle%26aufirst%3DA.%2BE.%26aulast%3DSomervaille%26aufirst%3DT.%2BC.%2BP.%26aulast%3DSpencer%26aufirst%3DG.%2BJ.%26aulast%3DTurlais%26aufirst%3DF.%26aulast%3DOgilvie%26aufirst%3DD.%26atitle%3DDevelopment%2520of%2520%25284-Cyanophenyl%2529Glycine%2520Derivatives%2520as%2520Reversible%2520Inhibitors%2520of%2520Lysine%2520Specific%2520Demethylase%25201%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D19%26spage%3D7984%26epage%3D7999%26doi%3D10.1021%2Facs.jmedchem.7b00462" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bulterys, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartberger, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorth, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Boyle, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Virgil, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoltz, B. M.</span></span> <span> </span><span class="NLM_article-title">Incorporation of a Chiral Gem-Disubstituted Nitrogen Heterocycle Yields an Oxazolidinone Antibiotic with Reduced Mitochondrial Toxicity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">2686</span>– <span class="NLM_lpage">2689</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.07.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2Fj.bmcl.2019.07.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=31383589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFWlsLrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=2686-2689&issue=18&author=A.+W.+Sunauthor=P.+L.+Bulterysauthor=M.+D.+Bartbergerauthor=P.+A.+Jorthauthor=B.+M.+O%E2%80%99Boyleauthor=S.+C.+Virgilauthor=J.+F.+Millerauthor=B.+M.+Stoltz&title=Incorporation+of+a+Chiral+Gem-Disubstituted+Nitrogen+Heterocycle+Yields+an+Oxazolidinone+Antibiotic+with+Reduced+Mitochondrial+Toxicity&doi=10.1016%2Fj.bmcl.2019.07.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Incorporation of a chiral gem-disubstituted nitrogen heterocycle yields an oxazolidinone antibiotic with reduced mitochondrial toxicity</span></div><div class="casAuthors">Sun, Alexander W.; Bulterys, Philip L.; Bartberger, Michael D.; Jorth, Peter A.; O'Boyle, Brendan M.; Virgil, Scott C.; Miller, Jeff F.; Stoltz, Brian M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2686-2689</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Gem-Disubstituted N-heterocycles are rarely found in drugs, despite their potential to improve the drug-like properties of small mol. pharmaceuticals.  Linezolid, a morpholine heterocycle-contg. oxazolidinone antibiotic, exhibits significant side effects assocd. with human mitochondrial protein synthesis inhibition.  We synthesized a gem-disubstituted linezolid analog that when compared to linezolid, maintains comparable (albeit slightly diminished) activity against bacteria, comparable in vitro physicochem. properties, and a decrease in undesired mitochondrial protein synthesis (MPS) inhibition.  This research contributes to the structure-activity-relationship data surrounding oxazolidinone MPS inhibition, and may inspire investigations into the utility of gem-disubstituted N-heterocycles in medicinal chem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRZtX-WyPmJLVg90H21EOLACvtfcHk0li8oQBruiFhgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFWlsLrF&md5=eb7107345c1072299513c49db192d5b8</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.07.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.07.024%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DA.%2BW.%26aulast%3DBulterys%26aufirst%3DP.%2BL.%26aulast%3DBartberger%26aufirst%3DM.%2BD.%26aulast%3DJorth%26aufirst%3DP.%2BA.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DB.%2BM.%26aulast%3DVirgil%26aufirst%3DS.%2BC.%26aulast%3DMiller%26aufirst%3DJ.%2BF.%26aulast%3DStoltz%26aufirst%3DB.%2BM.%26atitle%3DIncorporation%2520of%2520a%2520Chiral%2520Gem-Disubstituted%2520Nitrogen%2520Heterocycle%2520Yields%2520an%2520Oxazolidinone%2520Antibiotic%2520with%2520Reduced%2520Mitochondrial%2520Toxicity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26issue%3D18%26spage%3D2686%26epage%3D2689%26doi%3D10.1016%2Fj.bmcl.2019.07.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gehringer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S. A.</span></span> <span> </span><span class="NLM_article-title">Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">5673</span>– <span class="NLM_lpage">5724</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01153</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01153" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFKiur%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=5673-5724&issue=12&author=M.+Gehringerauthor=S.+A.+Laufer&title=Emerging+and+Re-Emerging+Warheads+for+Targeted+Covalent+Inhibitors%3A+Applications+in+Medicinal+Chemistry+and+Chemical+Biology&doi=10.1021%2Facs.jmedchem.8b01153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology</span></div><div class="casAuthors">Gehringer, Matthias; Laufer, Stefan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5673-5724</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Targeted covalent inhibitors (TCIs) are designed to bind poorly conserved amino acids by means of reactive groups, the so-called warheads.  Currently, targeting noncatalytic cysteine residues with acrylamides and other α,β-unsatd. carbonyl compds. is the predominant strategy in TCI development.  The recent ascent of covalent drugs has stimulated considerable efforts to characterize alternative warheads for the covalent-reversible and irreversible engagement of noncatalytic cysteine residues as well as other amino acids.  This Perspective article provides an overview of warheads-beyond α,β-unsatd. amides-recently used in the design of targeted covalent ligands.  Promising reactive groups that have not yet demonstrated their utility in TCI development are also highlighted.  Special emphasis is placed on the discussion of reactivity and of case studies illustrating applications in medicinal chem. and chem. biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDhc4PWV293LVg90H21EOLACvtfcHk0lh5JUscSyC-pQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFKiur%252FL&md5=4623733558ff99aadebfc13950b816ad</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01153%26sid%3Dliteratum%253Aachs%26aulast%3DGehringer%26aufirst%3DM.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26atitle%3DEmerging%2520and%2520Re-Emerging%2520Warheads%2520for%2520Targeted%2520Covalent%2520Inhibitors%253A%2520Applications%2520in%2520Medicinal%2520Chemistry%2520and%2520Chemical%2520Biology%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D12%26spage%3D5673%26epage%3D5724%26doi%3D10.1021%2Facs.jmedchem.8b01153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adams, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niccoli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chowdhury, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esarik, A. N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lees, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rempel, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phenix, C. P.</span></span> <span> </span><span class="NLM_article-title">N-Alkylated Aziridines Are Easily-Prepared, Potent, Specific and Cell-Permeable Covalent Inhibitors of Human β-Glucocerebrosidase</span>. <i>Chem. Commun. (Cambridge, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">57</span>),  <span class="NLM_fpage">11390</span>– <span class="NLM_lpage">11393</span>, <span class="refDoi"> DOI: 10.1039/C5CC03828F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1039%2FC5CC03828F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=26085065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVCmu7nI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2015&pages=11390-11393&issue=57&author=B.+T.+Adamsauthor=S.+Niccoliauthor=M.+A.+Chowdhuryauthor=A.+N.+K.+Esarikauthor=S.+J.+Leesauthor=B.+P.+Rempelauthor=C.+P.+Phenix&title=N-Alkylated+Aziridines+Are+Easily-Prepared%2C+Potent%2C+Specific+and+Cell-Permeable+Covalent+Inhibitors+of+Human+%CE%B2-Glucocerebrosidase&doi=10.1039%2FC5CC03828F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">N-Alkylated aziridines are easily-prepared, potent, specific and cell-permeable covalent inhibitors of human β-glucocerebrosidase</span></div><div class="casAuthors">Adams, B. T.; Niccoli, S.; Chowdhury, M. A.; Esarik, A. N. K.; Lees, S. J.; Rempel, B. P.; Phenix, C. P.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">57</span>),
    <span class="NLM_cas:pages">11390-11393</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">β-Glucocerebrosidase deficiency leads to Gaucher disease and is a potential marker of Parkinson's disease.  The authors have identified N-octyl conduritol aziridine as a potent and specific covalent inactivator of GBA1 in living cells.  This compd. is a promising lead towards a positron emission tomog. probe intended to image GBA1 activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmhETyb_KKSrVg90H21EOLACvtfcHk0lh5JUscSyC-pQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVCmu7nI&md5=c5f088dbe0d16ac976f5070113e6f74b</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1039%2FC5CC03828F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5CC03828F%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DB.%2BT.%26aulast%3DNiccoli%26aufirst%3DS.%26aulast%3DChowdhury%26aufirst%3DM.%2BA.%26aulast%3DEsarik%26aufirst%3DA.%2BN.%2BK.%26aulast%3DLees%26aufirst%3DS.%2BJ.%26aulast%3DRempel%26aufirst%3DB.%2BP.%26aulast%3DPhenix%26aufirst%3DC.%2BP.%26atitle%3DN-Alkylated%2520Aziridines%2520Are%2520Easily-Prepared%252C%2520Potent%252C%2520Specific%2520and%2520Cell-Permeable%2520Covalent%2520Inhibitors%2520of%2520Human%2520%25CE%25B2-Glucocerebrosidase%26jtitle%3DChem.%2520Commun.%2520%2528Cambridge%252C%2520U.%2520K.%2529%26date%3D2015%26volume%3D51%26issue%3D57%26spage%3D11390%26epage%3D11393%26doi%3D10.1039%2FC5CC03828F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fernández, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Testero, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vendrell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avilés, F. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mobashery, S.</span></span> <span> </span><span class="NLM_article-title">The X-Ray Structure of Carboxypeptidase A Inhibited by a Thiirane Mechanism-Based Inhibitor</span>. <i>Chem. Biol. Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>75</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1111/j.1747-0285.2009.00907.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1111%2Fj.1747-0285.2009.00907.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=19895506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1WhsbfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2010&pages=29-34&issue=1&author=D.+Fern%C3%A1ndezauthor=S.+Testeroauthor=J.+Vendrellauthor=F.+X.+Avil%C3%A9sauthor=S.+Mobashery&title=The+X-Ray+Structure+of+Carboxypeptidase+A+Inhibited+by+a+Thiirane+Mechanism-Based+Inhibitor&doi=10.1111%2Fj.1747-0285.2009.00907.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">The X-ray structure of carboxypeptidase A inhibited by a thiirane mechanism-based inhibitor</span></div><div class="casAuthors">Fernandez, Daniel; Testero, Sebastian; Vendrell, Josep; Aviles, Francesc X.; Mobashery, Shahriar</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-34</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The three-dimensional x-ray crystal structure of carboxypeptidase A, a zinc-dependent hydrolase, covalently modified by a mechanism-based thiirane inactivator, 2-benzyl-3,4-epithiobutanoic acid, has been solved to 1.38 Å resoln.  The interaction of the thiirane moiety of the inhibitor with the active site zinc ion promotes its covalent modification of Glu 270 with the attendant opening of the thiirane ring.  The crystal structure detn. at high resoln. allowed for the clear visualization of the covalent ester bond to the glutamate side chain.  The newly generated thiol from the inhibitor binds to the catalytic zinc ion in a monodentate manner, inducing a change in the zinc ion geometry and coordination, while its benzyl group fits into the S1' specificity pocket of the enzyme.  The inhibitor mol. is distorted at the position of the carbon atom that is involved in the ester bond linkage on one side and the zinc coordination on the other.  This particular type of thiirane-based metalloprotease inhibitor is for the first time analyzed in complex to the target protease at high resoln. and may be used as a general model for zinc-dependent proteases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpf9jy2XAHRg7Vg90H21EOLACvtfcHk0lh5JUscSyC-pQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1WhsbfI&md5=d96fae82f80848419cce9f0989bc7a54</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2009.00907.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2009.00907.x%26sid%3Dliteratum%253Aachs%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DD.%26aulast%3DTestero%26aufirst%3DS.%26aulast%3DVendrell%26aufirst%3DJ.%26aulast%3DAvil%25C3%25A9s%26aufirst%3DF.%2BX.%26aulast%3DMobashery%26aufirst%3DS.%26atitle%3DThe%2520X-Ray%2520Structure%2520of%2520Carboxypeptidase%2520A%2520Inhibited%2520by%2520a%2520Thiirane%2520Mechanism-Based%2520Inhibitor%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2010%26volume%3D75%26issue%3D1%26spage%3D29%26epage%3D34%26doi%3D10.1111%2Fj.1747-0285.2009.00907.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Forbes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hesek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llarrull, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gossing, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mobashery, S.</span></span> <span> </span><span class="NLM_article-title">Active Site Ring-Opening of a Thiirane Moiety and Picomolar Inhibition of Gelatinases</span>. <i>Chem. Biol. Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>74</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">527</span>– <span class="NLM_lpage">534</span>, <span class="refDoi"> DOI: 10.1111/j.1747-0285.2009.00881.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1111%2Fj.1747-0285.2009.00881.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=19807733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVGku7nF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2009&pages=527-534&issue=6&author=C.+Forbesauthor=Q.+Shiauthor=J.+F.+Fisherauthor=M.+Leeauthor=D.+Hesekauthor=L.+I.+Llarrullauthor=M.+Tothauthor=M.+Gossingauthor=R.+Fridmanauthor=S.+Mobashery&title=Active+Site+Ring-Opening+of+a+Thiirane+Moiety+and+Picomolar+Inhibition+of+Gelatinases&doi=10.1111%2Fj.1747-0285.2009.00881.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Active site ring-opening of a thiirane moiety and picomolar inhibition of gelatinases</span></div><div class="casAuthors">Forbes, Christopher; Shi, Qicun; Fisher, Jed F.; Lee, Mijoon; Hesek, Dusan; Llarrull, Leticia I.; Toth, Marta; Gossing, Michael; Fridman, Rafael; Mobashery, Shahriar</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">527-534</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">(±)-2-[(4-Phenoxyphenylsulfonyl)methyl]thiirane (1) is a potent and selective mechanism-based inhibitor of the gelatinase sub-class of the zinc-dependent matrix metalloproteinase family.  Inhibitor 1 has excellent activity in in vivo models of gelatinase-dependent disease.  We demonstrate that the mechanism of inhibition is a rate-limiting gelatinase-catalyzed thiolate generation via deprotonation adjacent to the thiirane, with concomitant thiirane opening.  A corollary to this mechanism is the prediction that thiol-contg. structures, related to thiirane-opened 1, will possess potent matrix metalloproteinase inhibitory activity.  This prediction was validated by the synthesis of the product of this enzyme-catalyzed reaction on 1, which exhibited a remarkable Ki of 530 pM against matrix metalloproteinase-2.  Thiirane 1 acts as a caged thiol, unmasked selectively in the active sites of gelatinases.  This mechanism is unprecedented in the substantial literature on inhibition of zinc-dependent hydrolases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj4TF4L9ayFLVg90H21EOLACvtfcHk0ljrpmmsoLWqDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVGku7nF&md5=11ec87b9c4ddd1627d67bf5fb4e43362</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2009.00881.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2009.00881.x%26sid%3Dliteratum%253Aachs%26aulast%3DForbes%26aufirst%3DC.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DFisher%26aufirst%3DJ.%2BF.%26aulast%3DLee%26aufirst%3DM.%26aulast%3DHesek%26aufirst%3DD.%26aulast%3DLlarrull%26aufirst%3DL.%2BI.%26aulast%3DToth%26aufirst%3DM.%26aulast%3DGossing%26aufirst%3DM.%26aulast%3DFridman%26aufirst%3DR.%26aulast%3DMobashery%26aufirst%3DS.%26atitle%3DActive%2520Site%2520Ring-Opening%2520of%2520a%2520Thiirane%2520Moiety%2520and%2520Picomolar%2520Inhibition%2520of%2520Gelatinases%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2009%26volume%3D74%26issue%3D6%26spage%3D527%26epage%3D534%26doi%3D10.1111%2Fj.1747-0285.2009.00881.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evans, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saghatelian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorensen, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">Target Discovery in Small-Molecule Cell-Based Screens by in Situ Proteome Reactivity Profiling</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1303</span>– <span class="NLM_lpage">1307</span>, <span class="refDoi"> DOI: 10.1038/nbt1149</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1038%2Fnbt1149" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=16200062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVOhu7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=1303-1307&issue=10&author=M.+J.+Evansauthor=A.+Saghatelianauthor=E.+J.+Sorensenauthor=B.+F.+Cravatt&title=Target+Discovery+in+Small-Molecule+Cell-Based+Screens+by+in+Situ+Proteome+Reactivity+Profiling&doi=10.1038%2Fnbt1149"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Target discovery in small-molecule cell-based screens by in situ proteome reactivity profiling</span></div><div class="casAuthors">Evans, Michael J.; Saghatelian, Alan; Sorensen, Erik J.; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1303-1307</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Chem. genomics aims to discover small mols. that affect biol. processes through the perturbation of protein function.  However, detg. the protein targets of bioactive compds. remains a formidable challenge.  The authors address this problem here through the creation of a natural product-inspired small-mol. library bearing protein-reactive elements.  Cell-based screening identified a compd., MJE3 (I), that inhibits breast cancer cell proliferation.  In situ proteome reactivity profiling revealed that MJE3, but not other library members, covalently labeled the glycolytic enzyme phosphoglycerate mutase 1 (PGAM1), resulting in enzyme inhibition.  Interestingly, MJE3 labeling and inhibition of PGAM1 were obsd. exclusively in intact cells.  These results support the hypothesis that cancer cells depend on glycolysis for viability and promote PGAM1 as a potential therapeutic target.  More generally, the incorporation of protein-reactive compds. into chem. genomics screens offers a means to discover targets of bioactive small mols. in living systems, thereby enabling downstream mechanistic investigations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo42WGtb4x11bVg90H21EOLACvtfcHk0ljrpmmsoLWqDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVOhu7nP&md5=1fc3d093fe8c7c7ccd7d610f10df105c</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1038%2Fnbt1149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1149%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DM.%2BJ.%26aulast%3DSaghatelian%26aufirst%3DA.%26aulast%3DSorensen%26aufirst%3DE.%2BJ.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DTarget%2520Discovery%2520in%2520Small-Molecule%2520Cell-Based%2520Screens%2520by%2520in%2520Situ%2520Proteome%2520Reactivity%2520Profiling%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26issue%3D10%26spage%3D1303%26epage%3D1307%26doi%3D10.1038%2Fnbt1149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schröder, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kallemeijn, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debets, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobala, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hakki, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beenakker, T. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aerts, J. M. F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Marel, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Codée, J. D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H. S.</span></span> <span> </span><span class="NLM_article-title">Spiro-Epoxyglycosides as Activity-Based Probes for Glycoside Hydrolase Family 99 Endomannosidase/Endomannanase</span>. <i>Chem. - Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">39</span>),  <span class="NLM_fpage">9983</span>– <span class="NLM_lpage">9992</span>, <span class="refDoi"> DOI: 10.1002/chem.201801902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1002%2Fchem.201801902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=29797675" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=9983-9992&issue=39&author=S.+P.+Schr%C3%B6derauthor=W.+W.+Kallemeijnauthor=M.+F.+Debetsauthor=T.+Hansenauthor=L.+F.+Sobalaauthor=Z.+Hakkiauthor=S.+J.+Williamsauthor=T.+J.+M.+Beenakkerauthor=J.+M.+F.+G.+Aertsauthor=G.+A.+van+der+Marelauthor=J.+D.+C.+Cod%C3%A9eauthor=G.+J.+Daviesauthor=H.+S.+Overkleeft&title=Spiro-Epoxyglycosides+as+Activity-Based+Probes+for+Glycoside+Hydrolase+Family+99+Endomannosidase%2FEndomannanase&doi=10.1002%2Fchem.201801902"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1002%2Fchem.201801902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201801902%26sid%3Dliteratum%253Aachs%26aulast%3DSchr%25C3%25B6der%26aufirst%3DS.%2BP.%26aulast%3DKallemeijn%26aufirst%3DW.%2BW.%26aulast%3DDebets%26aufirst%3DM.%2BF.%26aulast%3DHansen%26aufirst%3DT.%26aulast%3DSobala%26aufirst%3DL.%2BF.%26aulast%3DHakki%26aufirst%3DZ.%26aulast%3DWilliams%26aufirst%3DS.%2BJ.%26aulast%3DBeenakker%26aufirst%3DT.%2BJ.%2BM.%26aulast%3DAerts%26aufirst%3DJ.%2BM.%2BF.%2BG.%26aulast%3Dvan%2Bder%2BMarel%26aufirst%3DG.%2BA.%26aulast%3DCod%25C3%25A9e%26aufirst%3DJ.%2BD.%2BC.%26aulast%3DDavies%26aufirst%3DG.%2BJ.%26aulast%3DOverkleeft%26aufirst%3DH.%2BS.%26atitle%3DSpiro-Epoxyglycosides%2520as%2520Activity-Based%2520Probes%2520for%2520Glycoside%2520Hydrolase%2520Family%252099%2520Endomannosidase%252FEndomannanase%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D2018%26volume%3D24%26issue%3D39%26spage%3D9983%26epage%3D9992%26doi%3D10.1002%2Fchem.201801902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morgen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jöst, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janowski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niessing, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunkel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, A. K.</span></span> <span> </span><span class="NLM_article-title">Spiroepoxytriazoles Are Fumagillin-like Irreversible Inhibitors of MetAP2 with Potent Cellular Activity</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1001</span>– <span class="NLM_lpage">1011</span>, <span class="refDoi"> DOI: 10.1021/acschembio.5b00755</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.5b00755" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVGitbvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=1001-1011&issue=4&author=M.+Morgenauthor=C.+J%C3%B6stauthor=M.+Malzauthor=R.+Janowskiauthor=D.+Niessingauthor=C.+D.+Kleinauthor=N.+Gunkelauthor=A.+K.+Miller&title=Spiroepoxytriazoles+Are+Fumagillin-like+Irreversible+Inhibitors+of+MetAP2+with+Potent+Cellular+Activity&doi=10.1021%2Facschembio.5b00755"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Spiroepoxytriazoles Are Fumagillin-like Irreversible Inhibitors of MetAP2 with Potent Cellular Activity</span></div><div class="casAuthors">Morgen, Michael; Joest, Christian; Malz, Mona; Janowski, Robert; Niessing, Dierk; Klein, Christian D.; Gunkel, Nikolas; Miller, Aubry K.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1001-1011</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Methionine aminopeptidases (MetAPs) are responsible for the cotranslational cleavage of initiator methionines from nascent proteins.  The MetAP2 subtype is up-regulated in many cancers, and selective inhibition of MetAP2 suppresses both vascularization and growth of tumors in animal models.  The natural product fumagillin is a selective and potent irreversible inhibitor of MetAP2, and semisynthetic derivs. of fumagillin have shown promise in clin. studies for the treatment of cancer, and, more recently, for obesity.  Further development of fumagillin derivs. has been complicated, however, by their generally poor pharmacokinetics.  In an attempt to overcome these limitations, we developed an easily diversifiable synthesis of a novel class of MetAP2 inhibitors that were designed to mimic fumagillin's mol. scaffold but have improved pharmacol. profiles.  These substances were found to be potent and selective inhibitors of MetAP2, as demonstrated in biochem. enzymic assays against three MetAP isoforms.  Inhibitors with the same relative and abs. stereoconfiguration as fumagillin displayed significantly higher activity than their diastereomeric and enantiomeric isomers.  X-ray crystallog. anal. revealed that the inhibitors covalently modify His231 in the MetAP2 active site via ring-opening of a spiroepoxide.  Biochem. active substances inhibited the growth of endothelial cells and a MetAP2-sensitive cancer cell line, while closely related inactive isomers had little effect on the proliferation of either cell type.  These effects correlated with altered N-terminal processing of the protein 14-3-3-γ.  Finally, selected substances were found to have improved stabilities in mouse plasma and microsomes relative to the clin. investigated fumagillin deriv. beloranib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0EkuP-YaxhrVg90H21EOLACvtfcHk0ljxbBNthv1BYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVGitbvO&md5=f83da1a8a3c4717b16cd0e90cc05f8a8</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1021%2Facschembio.5b00755&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.5b00755%26sid%3Dliteratum%253Aachs%26aulast%3DMorgen%26aufirst%3DM.%26aulast%3DJ%25C3%25B6st%26aufirst%3DC.%26aulast%3DMalz%26aufirst%3DM.%26aulast%3DJanowski%26aufirst%3DR.%26aulast%3DNiessing%26aufirst%3DD.%26aulast%3DKlein%26aufirst%3DC.%2BD.%26aulast%3DGunkel%26aufirst%3DN.%26aulast%3DMiller%26aufirst%3DA.%2BK.%26atitle%3DSpiroepoxytriazoles%2520Are%2520Fumagillin-like%2520Irreversible%2520Inhibitors%2520of%2520MetAP2%2520with%2520Potent%2520Cellular%2520Activity%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2016%26volume%3D11%26issue%3D4%26spage%3D1001%26epage%3D1011%26doi%3D10.1021%2Facschembio.5b00755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martyloga, O. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myronenko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tkachenko, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matvienko, V. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuchkovska, Y. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grygorenko, O. O.</span></span> <span> </span><span class="NLM_article-title">Multigram Synthesis of Functionalized Spirocyclic Diazirines</span>. <i>Eur. J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>2019</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">3744</span>– <span class="NLM_lpage">3750</span>, <span class="refDoi"> DOI: 10.1002/ejoc.201900485</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1002%2Fejoc.201900485" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1Wmt73E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2019&publication_year=2019&pages=3744-3750&issue=23&author=O.+V.+Martylogaauthor=A.+Myronenkoauthor=A.+M.+Tkachenkoauthor=V.+O.+Matvienkoauthor=Y.+O.+Kuchkovskaauthor=O.+O.+Grygorenko&title=Multigram+Synthesis+of+Functionalized+Spirocyclic+Diazirines&doi=10.1002%2Fejoc.201900485"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Multigram Synthesis of Functionalized Spirocyclic Diazirines</span></div><div class="casAuthors">Martyloga, Oleksandr V.; Myronenko, Artamon; Tkachenko, Anton M.; Matvienko, Vitalii O.; Kuchkovska, Yuliya O.; Grygorenko, Oleksandr O.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">2019</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3744-3750</span>CODEN:
                <span class="NLM_cas:coden">EJOCFK</span>;
        ISSN:<span class="NLM_cas:issn">1099-0690</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">An approach to the synthesis of spirocyclic diazirines, e.g., I from cyclic ketones, e.g., tert-Bu 2-oxo-7-azabicyclo[2.2.1]heptane-7-carboxylate was examd. on a series of carbo- and heterocyclic substrates contg. amine or carboxylic acid moiety.  A mini-library of stereochem. diverse functionalized spirocyclic diazirines was synthesized on a multigram scale with 30-81% yield.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6l0uxcUo6C7Vg90H21EOLACvtfcHk0ljxbBNthv1BYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1Wmt73E&md5=8f8c7449e7dfc0107c76754ff978b21f</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1002%2Fejoc.201900485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.201900485%26sid%3Dliteratum%253Aachs%26aulast%3DMartyloga%26aufirst%3DO.%2BV.%26aulast%3DMyronenko%26aufirst%3DA.%26aulast%3DTkachenko%26aufirst%3DA.%2BM.%26aulast%3DMatvienko%26aufirst%3DV.%2BO.%26aulast%3DKuchkovska%26aufirst%3DY.%2BO.%26aulast%3DGrygorenko%26aufirst%3DO.%2BO.%26atitle%3DMultigram%2520Synthesis%2520of%2520Functionalized%2520Spirocyclic%2520Diazirines%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2019%26volume%3D2019%26issue%3D23%26spage%3D3744%26epage%3D3750%26doi%3D10.1002%2Fejoc.201900485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohgami, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugii, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curphey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, T.-Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Biochemical Properties of a New Photoactivatable Cholesterol Analog 7,7-Azocholestanol and Its Linoleate Ester in Chinese Hamster Ovary Cell Lines</span>. <i>J. Lipid Res.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>43</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1341</span>– <span class="NLM_lpage">1347</span>, <span class="refDoi"> DOI: 10.1194/jlr.M200015-JLR200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1194%2Fjlr.M200015-JLR200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=12177179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BD38XntFWktb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2002&pages=1341-1347&issue=8&author=J.+C.+Cruzauthor=M.+Thomasauthor=E.+Wongauthor=N.+Ohgamiauthor=S.+Sugiiauthor=T.+Curpheyauthor=C.+C.+Y.+Changauthor=T.-Y.+Chang&title=Synthesis+and+Biochemical+Properties+of+a+New+Photoactivatable+Cholesterol+Analog+7%2C7-Azocholestanol+and+Its+Linoleate+Ester+in+Chinese+Hamster+Ovary+Cell+Lines&doi=10.1194%2Fjlr.M200015-JLR200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biochemical properties of a new photoactivatable cholesterol analog 7,7-azocholestanol and its linoleate ester in Chinese hamster ovary cell lines</span></div><div class="casAuthors">Cruz, Jonathan C.; Thomas, Matthew; Wong, Edmund; Ohgami, Nobutaka; Sugii, Shigeki; Curphey, Thomas; Chang, Catherine C. Y.; Chang, Ta-Yuan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Lipid Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1341-1347</span>CODEN:
                <span class="NLM_cas:coden">JLPRAW</span>;
        ISSN:<span class="NLM_cas:issn">0022-2275</span>.
    
            (<span class="NLM_cas:orgname">Lipid Research, Inc.</span>)
        </div><div class="casAbstract">We report the chem. synthesis of a new photoactivatable cholesterol analog 7,7-azocholestanol (AC) and its linoleate ester (ACL).  We also examd. the biochem. properties of the sterol and its ester by employing several different mutant Chinese hamster ovary (CHO) cell lines with defined abnormalities in cholesterol metab. as tools.  AC mimics cholesterol in supporting the growth of a mutant cell line (M19) that requires cholesterol for growth.  In normal cells, tritiated ACL present in low-d. lipoprotein (LDL) was hydrolyzed and reesterified in a manner similar to tritiated cholesteryl linoleate (CL) in LDL.  Also, in the mutant cell line (AC29) lacking the enzyme acyl-CoA:cholesterol acyltransferase or in the mutant cell line (CT60) defective in the Niemann-Pick type C1 protein, the hydrolysis of ACL in LDL was normal, but the reesterification of the liberated AC was defective.  Therefore, the metab. of ACL in LDL is very similar to that of CL in LDL.  Tritium-labeled AC delivered to intact CHO cells as a cyclodextrin complex was shown to photoaffinity label several discrete polypeptides, including caveolin-1.  These results demonstrate AC as an effective reagent for studying cholesterol-protein interactions involved in intracellular cholesterol trafficking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVO0Op3StP2LVg90H21EOLACvtfcHk0ljxbBNthv1BYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XntFWktb4%253D&md5=17671a1d29ca9eaf699fba7db02a34d0</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1194%2Fjlr.M200015-JLR200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1194%252Fjlr.M200015-JLR200%26sid%3Dliteratum%253Aachs%26aulast%3DCruz%26aufirst%3DJ.%2BC.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DE.%26aulast%3DOhgami%26aufirst%3DN.%26aulast%3DSugii%26aufirst%3DS.%26aulast%3DCurphey%26aufirst%3DT.%26aulast%3DChang%26aufirst%3DC.%2BC.%2BY.%26aulast%3DChang%26aufirst%3DT.-Y.%26atitle%3DSynthesis%2520and%2520Biochemical%2520Properties%2520of%2520a%2520New%2520Photoactivatable%2520Cholesterol%2520Analog%25207%252C7-Azocholestanol%2520and%2520Its%2520Linoleate%2520Ester%2520in%2520Chinese%2520Hamster%2520Ovary%2520Cell%2520Lines%26jtitle%3DJ.%2520Lipid%2520Res.%26date%3D2002%26volume%3D43%26issue%3D8%26spage%3D1341%26epage%3D1347%26doi%3D10.1194%2Fjlr.M200015-JLR200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramdas, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talwar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walke, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borhade, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhayagude, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loriya, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gote, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bommakanti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivaram, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goswami, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nigade, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallurwar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dash, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuldharan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narasimham, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gundu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamboj, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palle, V. P.</span></span> <span> </span><span class="NLM_article-title">Discovery and Characterization of Potent Pan-Genotypic HCV NS5A Inhibitors Containing Novel Tricyclic Central Core Leading to Clinical Candidate</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">10563</span>– <span class="NLM_lpage">10582</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01562</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01562" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFeqsr%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=10563-10582&issue=23&author=V.+Ramdasauthor=R.+Talwarauthor=M.+Banerjeeauthor=A.+A.+Joshiauthor=A.+K.+Dasauthor=D.+S.+Walkeauthor=P.+Borhadeauthor=U.+Dhayagudeauthor=R.+Loriyaauthor=G.+Goteauthor=A.+Bommakantiauthor=A.+Sivaramauthor=G.+Agarwalauthor=A.+Goswamiauthor=P.+Nigadeauthor=M.+Mehtaauthor=V.+Patilauthor=D.+Modiauthor=H.+Kumarauthor=S.+Mallurwarauthor=A.+Dashauthor=F.+Modiauthor=S.+Kuldharanauthor=P.+Srivastavaauthor=M.+Singhauthor=L.+Narasimhamauthor=J.+Gunduauthor=S.+Sharmaauthor=R.+K.+Kambojauthor=V.+P.+Palle&title=Discovery+and+Characterization+of+Potent+Pan-Genotypic+HCV+NS5A+Inhibitors+Containing+Novel+Tricyclic+Central+Core+Leading+to+Clinical+Candidate&doi=10.1021%2Facs.jmedchem.9b01562"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Characterization of Potent Pan-Genotypic HCV NS5A Inhibitors Containing Novel Tricyclic Central Core Leading to Clinical Candidate</span></div><div class="casAuthors">Ramdas, Vidya; Talwar, Rashmi; Banerjee, Moloy; Joshi, Advait Arun; Das, Amit Kumar; Walke, Deepak Sahebrao; Borhade, Prashant; Dhayagude, Usha; Loriya, Rajesh; Gote, Ganesh; Bommakanti, Apparao; Sivaram, Aruna; Agarwal, Gautam; Goswami, Arnab; Nigade, Prashant; Mehta, Maneesh; Patil, Vinod; Modi, Dipak; Kumar, Hemant; Mallurwar, Sadanand; Dash, Amruta; Modi, Falguni; Kuldharan, Sandip; Srivastava, Pratima; Singh, Minakshi; Narasimham, Lakshmi; Gundu, Jayasagar; Sharma, Sharad; Kamboj, Rajender Kumar; Palle, Venkata P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10563-10582</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Identification of a novel class of potent pan-genotypic NS5A inhibitors with good pharmacokinetic profile suitable for potential use in treating HCV infections are disclosed here.  Present series of compds. are with less complex tricyclic central core, identified through a systematic SAR study carried out on biphenyl moiety.  The SAR outcome has confirmed the requirement of near planar and linear conformation of the mol. to achieve the best pan-genotypic activity.  In addn., SAR with substituted imidazoles on improvement of antiviral activity is disclosed.  The newly identified compds. 12, 16, 19-21 have shown desirable pharmacokinetic profile with a favorable uptake of compds. in liver and maintained a significant concn. for up to 8 h in the liver.  In addn., compds. 20 and 21 have shown superior pan-genotypic anti-HCV activity compared to ledipasvir and daclatasvir.  Addnl. characterization and preliminary safety assessment resulted in identification of compd. 20 as a potential clin. candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonkEOeBLBCurVg90H21EOLACvtfcHk0liAK3-rtiYujQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFeqsr%252FK&md5=be4b419bf7d32cd7d52cc414da0255e3</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01562%26sid%3Dliteratum%253Aachs%26aulast%3DRamdas%26aufirst%3DV.%26aulast%3DTalwar%26aufirst%3DR.%26aulast%3DBanerjee%26aufirst%3DM.%26aulast%3DJoshi%26aufirst%3DA.%2BA.%26aulast%3DDas%26aufirst%3DA.%2BK.%26aulast%3DWalke%26aufirst%3DD.%2BS.%26aulast%3DBorhade%26aufirst%3DP.%26aulast%3DDhayagude%26aufirst%3DU.%26aulast%3DLoriya%26aufirst%3DR.%26aulast%3DGote%26aufirst%3DG.%26aulast%3DBommakanti%26aufirst%3DA.%26aulast%3DSivaram%26aufirst%3DA.%26aulast%3DAgarwal%26aufirst%3DG.%26aulast%3DGoswami%26aufirst%3DA.%26aulast%3DNigade%26aufirst%3DP.%26aulast%3DMehta%26aufirst%3DM.%26aulast%3DPatil%26aufirst%3DV.%26aulast%3DModi%26aufirst%3DD.%26aulast%3DKumar%26aufirst%3DH.%26aulast%3DMallurwar%26aufirst%3DS.%26aulast%3DDash%26aufirst%3DA.%26aulast%3DModi%26aufirst%3DF.%26aulast%3DKuldharan%26aufirst%3DS.%26aulast%3DSrivastava%26aufirst%3DP.%26aulast%3DSingh%26aufirst%3DM.%26aulast%3DNarasimham%26aufirst%3DL.%26aulast%3DGundu%26aufirst%3DJ.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DKamboj%26aufirst%3DR.%2BK.%26aulast%3DPalle%26aufirst%3DV.%2BP.%26atitle%3DDiscovery%2520and%2520Characterization%2520of%2520Potent%2520Pan-Genotypic%2520HCV%2520NS5A%2520Inhibitors%2520Containing%2520Novel%2520Tricyclic%2520Central%2520Core%2520Leading%2520to%2520Clinical%2520Candidate%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D23%26spage%3D10563%26epage%3D10582%26doi%3D10.1021%2Facs.jmedchem.9b01562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasgar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danchik, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baljinnyam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheff, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lal-Nag, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunford, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oppermann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasiliou, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeonov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jadhav, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, D. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of Orally Bioavailable, Quinoline-Based Aldehyde Dehydrogenase 1A1 (ALDH1A1) Inhibitors with Potent Cellular Activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">4883</span>– <span class="NLM_lpage">4903</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00270</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00270" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1cXps12msL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4883-4903&issue=11&author=S.-M.+Yangauthor=N.+J.+Martinezauthor=A.+Yasgarauthor=C.+Danchikauthor=C.+Johanssonauthor=Y.+Wangauthor=B.+Baljinnyamauthor=A.+Q.+Wangauthor=X.+Xuauthor=P.+Shahauthor=D.+Cheffauthor=X.+S.+Wangauthor=J.+Rothauthor=M.+Lal-Nagauthor=J.+E.+Dunfordauthor=U.+Oppermannauthor=V.+Vasiliouauthor=A.+Simeonovauthor=A.+Jadhavauthor=D.+J.+Maloney&title=Discovery+of+Orally+Bioavailable%2C+Quinoline-Based+Aldehyde+Dehydrogenase+1A1+%28ALDH1A1%29+Inhibitors+with+Potent+Cellular+Activity&doi=10.1021%2Facs.jmedchem.8b00270"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Orally Bioavailable, Quinoline-Based Aldehyde Dehydrogenase 1A1 (ALDH1A1) Inhibitors with Potent Cellular Activity</span></div><div class="casAuthors">Yang, Shyh-Ming; Martinez, Natalia J.; Yasgar, Adam; Danchik, Carina; Johansson, Catrine; Wang, Yuhong; Baljinnyam, Bolormaa; Wang, Amy Q.; Xu, Xin; Shah, Pranav; Cheff, Dorian; Wang, Xinran S.; Roth, Jacob; Lal-Nag, Madhu; Dunford, James E.; Oppermann, Udo; Vasiliou, Vasilis; Simeonov, Anton; Jadhav, Ajit; Maloney, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4883-4903</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aldehyde dehydrogenases (ALDHs) are responsible for the metab. of aldehydes (exogenous and endogenous) and possess vital physiol. and toxicol. functions in areas such as CNS, inflammation, metabolic disorders, and cancers.  Overexpression of certain ALDHs (e.g., ALDH1A1) is an important biomarker in cancers and cancer stem cells (CSCs) indicating the potential need for the identification and development of small mol. ALDH inhibitors.  Herein, a newly designed series of quinoline-based analogs of ALDH1A1 inhibitors is described.  Extensive medicinal chem. optimization and biol. characterization led to the identification of analogs with significantly improved enzymic and cellular ALDH inhibition.  Selected analogs, e.g., 86 (NCT-505) and 91 (NCT-506), demonstrated target engagement in a cellular thermal shift assay (CETSA), inhibited the formation of 3D spheroid cultures of OV-90 cancer cells, and potentiated the cytotoxicity of paclitaxel in SKOV-3-TR, a paclitaxel resistant ovarian cancer cell line.  Lead compds. also exhibit high specificity over other ALDH isoenzymes and unrelated dehydrogenases.  The in vitro ADME profiles and pharmacokinetic evaluation of selected analogs are also highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMdOrSgvA10rVg90H21EOLACvtfcHk0liAK3-rtiYujQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXps12msL8%253D&md5=6f63e6c9803cb8f0e113fb1f81bebf8a</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00270%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DS.-M.%26aulast%3DMartinez%26aufirst%3DN.%2BJ.%26aulast%3DYasgar%26aufirst%3DA.%26aulast%3DDanchik%26aufirst%3DC.%26aulast%3DJohansson%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DBaljinnyam%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DA.%2BQ.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DShah%26aufirst%3DP.%26aulast%3DCheff%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DX.%2BS.%26aulast%3DRoth%26aufirst%3DJ.%26aulast%3DLal-Nag%26aufirst%3DM.%26aulast%3DDunford%26aufirst%3DJ.%2BE.%26aulast%3DOppermann%26aufirst%3DU.%26aulast%3DVasiliou%26aufirst%3DV.%26aulast%3DSimeonov%26aufirst%3DA.%26aulast%3DJadhav%26aufirst%3DA.%26aulast%3DMaloney%26aufirst%3DD.%2BJ.%26atitle%3DDiscovery%2520of%2520Orally%2520Bioavailable%252C%2520Quinoline-Based%2520Aldehyde%2520Dehydrogenase%25201A1%2520%2528ALDH1A1%2529%2520Inhibitors%2520with%2520Potent%2520Cellular%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D11%26spage%3D4883%26epage%3D4903%26doi%3D10.1021%2Facs.jmedchem.8b00270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naidu, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorenson, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matiskella, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dicker, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terry, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higley, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">The Discovery and Preclinical Evaluation of BMS-707035, a Potent HIV-1 Integrase Strand Transfer Inhibitor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2124</span>– <span class="NLM_lpage">2130</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.05.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2Fj.bmcl.2018.05.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=29779976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpvVKjur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=2124-2130&issue=12&author=B.+N.+Naiduauthor=M.+A.+Walkerauthor=M.+E.+Sorensonauthor=Y.+Uedaauthor=J.+D.+Matiskellaauthor=T.+P.+Connollyauthor=I.+B.+Dickerauthor=Z.+Linauthor=S.+Bolliniauthor=B.+J.+Terryauthor=H.+Higleyauthor=M.+Zhengauthor=D.+D.+Parkerauthor=D.+Wuauthor=S.+Adamsauthor=M.+R.+Krystalauthor=N.+A.+Meanwell&title=The+Discovery+and+Preclinical+Evaluation+of+BMS-707035%2C+a+Potent+HIV-1+Integrase+Strand+Transfer+Inhibitor&doi=10.1016%2Fj.bmcl.2018.05.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery and preclinical evaluation of BMS-707035, a potent HIV-1 integrase strand transfer inhibitor</span></div><div class="casAuthors">Naidu, B. Narasimhulu; Walker, Michael A.; Sorenson, Margaret E.; Ueda, Yasutsugu; Matiskella, John D.; Connolly, Timothy P.; Dicker, Ira B.; Lin, Zeyu; Bollini, Sagarika; Terry, Brian J.; Higley, Helen; Zheng, Ming; Parker, Dawn D.; Wu, Dedong; Adams, Stephen; Krystal, Mark R.; Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2124-2130</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">BMS-707035 is an HIV-1 integrase strand transfer inhibitor (INSTI) discovered by systematic optimization of N-methylpyrimidinone carboxamides guided by structure-activity relationships (SARs) and the single crystal x-ray structure of compd. 10 (I).  It was rationalized that the unexpectedly advantageous profiles of N-methylpyrimidinone carboxamides with a satd. C2-substitutent may be due, in part, to the geometric relationship between the C2-substituent and the pyrimidinone core.  The single crystal x-ray structure of 10 provided support for this reasoning and guided the design of a spirocyclic series 12 which led to discovery of the morpholino-fused pyrimidinone series 13.  Several carboxamides derived from this bicyclic scaffold displayed improved antiviral activity and pharmacokinetic profiles when compared with corresponding spirocyclic analogs.  Based on the excellent antiviral activity, preclin. profiles and acceptable in vitro and in vivo toxicity profiles, 13a (BMS-707035) was selected for advancement into phase I clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBipQIkcGe_rVg90H21EOLACvtfcHk0ljV67esGvwGEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpvVKjur8%253D&md5=92cf04a143ca99ed7950220c91945e79</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.05.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.05.027%26sid%3Dliteratum%253Aachs%26aulast%3DNaidu%26aufirst%3DB.%2BN.%26aulast%3DWalker%26aufirst%3DM.%2BA.%26aulast%3DSorenson%26aufirst%3DM.%2BE.%26aulast%3DUeda%26aufirst%3DY.%26aulast%3DMatiskella%26aufirst%3DJ.%2BD.%26aulast%3DConnolly%26aufirst%3DT.%2BP.%26aulast%3DDicker%26aufirst%3DI.%2BB.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DBollini%26aufirst%3DS.%26aulast%3DTerry%26aufirst%3DB.%2BJ.%26aulast%3DHigley%26aufirst%3DH.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DParker%26aufirst%3DD.%2BD.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DAdams%26aufirst%3DS.%26aulast%3DKrystal%26aufirst%3DM.%2BR.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DThe%2520Discovery%2520and%2520Preclinical%2520Evaluation%2520of%2520BMS-707035%252C%2520a%2520Potent%2520HIV-1%2520Integrase%2520Strand%2520Transfer%2520Inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26issue%3D12%26spage%3D2124%26epage%3D2130%26doi%3D10.1016%2Fj.bmcl.2018.05.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Velázquez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chelliah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clasby, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neelamkavil, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soriano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatraman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chackalamannil, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, I. W.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of P2-P4 Macrocycles Containing a Unique Spirocyclic Proline: A New Class of HCV NS3/4A Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1173</span>– <span class="NLM_lpage">1178</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00321</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00321" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1yks7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=1173-1178&issue=12&author=F.+Vel%C3%A1zquezauthor=M.+Chelliahauthor=M.+Clasbyauthor=Z.+Guoauthor=J.+Howeauthor=R.+Millerauthor=S.+Neelamkavilauthor=U.+Shahauthor=A.+Sorianoauthor=Y.+Xiaauthor=S.+Venkatramanauthor=S.+Chackalamannilauthor=I.+W.+Davies&title=Design+and+Synthesis+of+P2-P4+Macrocycles+Containing+a+Unique+Spirocyclic+Proline%3A+A+New+Class+of+HCV+NS3%2F4A+Inhibitors&doi=10.1021%2Facsmedchemlett.6b00321"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of P2-P4 macrocycles containing a unique spirocyclic proline: A new class of HCV NS3/4A inhibitors</span></div><div class="casAuthors">Velazquez, Francisco; Chelliah, Mariappan; Clasby, Martin; Guo, Zhuyan; Howe, John; Miller, Randy; Neelamkavil, Santhosh; Shah, Unmesh; Soriano, Aileen; Xia, Yan; Venkatraman, Srikanth; Chackalamannil, Samuel; Davies, Ian W.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1173-1178</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new class of hepatitis C NS3/4A inhibitors was identified by introducing a novel spirocyclic proline-P2 surrogate onto the P2-P4 macrocyclic core of MK-5172 (grazoprevir).  The potency profile of new analogs showed excellent pan-genotypic activity for most compds.  The potency evaluation included the most difficult genotype 3a (EC50 values ≤10 nM) and other key genotype 1b mutants.  Mol. modeling was used to design new target compds. and rationalize our results.  A synthetic approach based on the Julia-Kocienski olefination and macrolactamization to assemble the P2-P4 macrocyclic core contg. the novel spirocyclic proline-P2 moiety is presented as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopIMrKI6Cq2bVg90H21EOLACvtfcHk0ljV67esGvwGEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1yks7zK&md5=e988dfb6bd402e437e0291b8458d2e1f</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00321%26sid%3Dliteratum%253Aachs%26aulast%3DVel%25C3%25A1zquez%26aufirst%3DF.%26aulast%3DChelliah%26aufirst%3DM.%26aulast%3DClasby%26aufirst%3DM.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DHowe%26aufirst%3DJ.%26aulast%3DMiller%26aufirst%3DR.%26aulast%3DNeelamkavil%26aufirst%3DS.%26aulast%3DShah%26aufirst%3DU.%26aulast%3DSoriano%26aufirst%3DA.%26aulast%3DXia%26aufirst%3DY.%26aulast%3DVenkatraman%26aufirst%3DS.%26aulast%3DChackalamannil%26aufirst%3DS.%26aulast%3DDavies%26aufirst%3DI.%2BW.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520P2-P4%2520Macrocycles%2520Containing%2520a%2520Unique%2520Spirocyclic%2520Proline%253A%2520A%2520New%2520Class%2520of%2520HCV%2520NS3%252F4A%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26issue%3D12%26spage%3D1173%26epage%3D1178%26doi%3D10.1021%2Facsmedchemlett.6b00321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rudd, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butcher, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romano, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bush, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liverton, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiFilippo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summa, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swestock, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritzen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burlein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMuzio, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gates, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHale, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahlhut, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chase, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soriano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fandozzi, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trainor, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludmerer, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCauley, J. A.</span></span> <span> </span><span class="NLM_article-title">P2-Quinazolinones and Bis-Macrocycles as New Templates for next-Generation Hepatitis C Virus NS3/4a Protease Inhibitors: Discovery of MK-2748 and MK-6325</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">727</span>– <span class="NLM_lpage">735</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201402558</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1002%2Fcmdc.201402558" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=25759009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvVShurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=727-735&issue=4&author=M.+T.+Ruddauthor=J.+W.+Butcherauthor=K.+T.+Nguyenauthor=C.+J.+McIntyreauthor=J.+J.+Romanoauthor=K.+F.+Gilbertauthor=K.+J.+Bushauthor=N.+J.+Livertonauthor=M.+K.+Hollowayauthor=S.+Harperauthor=M.+Ferraraauthor=M.+DiFilippoauthor=V.+Summaauthor=J.+Swestockauthor=J.+Fritzenauthor=S.+S.+Carrollauthor=C.+Burleinauthor=J.+M.+DiMuzioauthor=A.+Gatesauthor=D.+J.+Grahamauthor=Q.+Huangauthor=S.+McClainauthor=C.+McHaleauthor=M.+W.+Stahlhutauthor=S.+Blackauthor=R.+Chaseauthor=A.+Sorianoauthor=C.+M.+Fandozziauthor=A.+Taylorauthor=N.+Trainorauthor=D.+B.+Olsenauthor=P.+J.+Colemanauthor=S.+W.+Ludmererauthor=J.+A.+McCauley&title=P2-Quinazolinones+and+Bis-Macrocycles+as+New+Templates+for+next-Generation+Hepatitis+C+Virus+NS3%2F4a+Protease+Inhibitors%3A+Discovery+of+MK-2748+and+MK-6325&doi=10.1002%2Fcmdc.201402558"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">P2-Quinazolinones and Bis-Macrocycles as New Templates for Next-Generation Hepatitis C Virus NS3/4a Protease Inhibitors: Discovery of MK-2748 and MK-6325</span></div><div class="casAuthors">Rudd, Michael T.; Butcher, John W.; Nguyen, Kevin T.; McIntyre, Charles J.; Romano, Joseph J.; Gilbert, Kevin F.; Bush, Kimberly J.; Liverton, Nigel J.; Holloway, M. Katharine; Harper, Steven; Ferrara, Marco; DiFilippo, Marcello; Summa, Vincenzo; Swestock, John; Fritzen, Jeff; Carroll, Steven S.; Burlein, Christine; DiMuzio, Jillian M.; Gates, Adam; Graham, Donald J.; Huang, Qian; McClain, Stephanie; McHale, Carolyn; Stahlhut, Mark W.; Black, Stuart; Chase, Robert; Soriano, Aileen; Fandozzi, Christine M.; Taylor, Anne; Trainor, Nicole; Olsen, David B.; Coleman, Paul J.; Ludmerer, Steven W.; McCauley, John A.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">727-735</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">With the goal of identifying inhibitors of hepatitis C virus (HCV) NS3/4a protease that are potent against a wide range of genotypes and clin. relevant mutant viruses, several subseries of macrocycles were investigated based on observations made during the discovery of MK-5172.  Quinazolinone-contg. macrocycles were identified as promising leads, and optimization for superior cross-genotype and mutant enzyme potency as well as rat liver and plasma concns. following oral dosing, led to the development of MK-2748 I.  Addnl. investigation of a series of bis-macrocycles contg. a fused 18- and 15-membered ring system were also optimized for the same properties, leading to the discovery of MK-6325 II.  Both compds. display the broad genotype and mutant potency necessary for clin. development as next-generation HCV NS3/4a protease inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4cK2wuPGi1rVg90H21EOLACvtfcHk0lhfjExObmR8aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvVShurc%253D&md5=65834635e5b209b0674ec60fe905e2a9</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201402558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201402558%26sid%3Dliteratum%253Aachs%26aulast%3DRudd%26aufirst%3DM.%2BT.%26aulast%3DButcher%26aufirst%3DJ.%2BW.%26aulast%3DNguyen%26aufirst%3DK.%2BT.%26aulast%3DMcIntyre%26aufirst%3DC.%2BJ.%26aulast%3DRomano%26aufirst%3DJ.%2BJ.%26aulast%3DGilbert%26aufirst%3DK.%2BF.%26aulast%3DBush%26aufirst%3DK.%2BJ.%26aulast%3DLiverton%26aufirst%3DN.%2BJ.%26aulast%3DHolloway%26aufirst%3DM.%2BK.%26aulast%3DHarper%26aufirst%3DS.%26aulast%3DFerrara%26aufirst%3DM.%26aulast%3DDiFilippo%26aufirst%3DM.%26aulast%3DSumma%26aufirst%3DV.%26aulast%3DSwestock%26aufirst%3DJ.%26aulast%3DFritzen%26aufirst%3DJ.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26aulast%3DBurlein%26aufirst%3DC.%26aulast%3DDiMuzio%26aufirst%3DJ.%2BM.%26aulast%3DGates%26aufirst%3DA.%26aulast%3DGraham%26aufirst%3DD.%2BJ.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DMcClain%26aufirst%3DS.%26aulast%3DMcHale%26aufirst%3DC.%26aulast%3DStahlhut%26aufirst%3DM.%2BW.%26aulast%3DBlack%26aufirst%3DS.%26aulast%3DChase%26aufirst%3DR.%26aulast%3DSoriano%26aufirst%3DA.%26aulast%3DFandozzi%26aufirst%3DC.%2BM.%26aulast%3DTaylor%26aufirst%3DA.%26aulast%3DTrainor%26aufirst%3DN.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DColeman%26aufirst%3DP.%2BJ.%26aulast%3DLudmerer%26aufirst%3DS.%2BW.%26aulast%3DMcCauley%26aufirst%3DJ.%2BA.%26atitle%3DP2-Quinazolinones%2520and%2520Bis-Macrocycles%2520as%2520New%2520Templates%2520for%2520next-Generation%2520Hepatitis%2520C%2520Virus%2520NS3%252F4a%2520Protease%2520Inhibitors%253A%2520Discovery%2520of%2520MK-2748%2520and%2520MK-6325%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26issue%3D4%26spage%3D727%26epage%3D735%26doi%3D10.1002%2Fcmdc.201402558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chobanian, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pio, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teumelsan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clements, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas-Fowlkes, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felix, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priest, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hampton, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pai, L.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corona, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metzger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasternak, A.</span></span> <span> </span><span class="NLM_article-title">The Design and Synthesis of Novel Spirocyclic Heterocyclic Sulfone ROMK Inhibitors as Diuretics</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1109</span>– <span class="NLM_lpage">1114</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.10.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2Fj.bmcl.2016.10.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=28111141" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVehs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=1109-1114&issue=4&author=H.+R.+Chobanianauthor=Y.+Guoauthor=B.+Pioauthor=H.+Tangauthor=N.+Teumelsanauthor=M.+Clementsauthor=J.+Frieauthor=R.+Fergusonauthor=Z.+Guoauthor=B.+S.+Thomas-Fowlkesauthor=J.+P.+Felixauthor=J.+Liuauthor=M.+Kohlerauthor=B.+Priestauthor=C.+Hamptonauthor=L.-Y.+Paiauthor=A.+Coronaauthor=J.+Metzgerauthor=V.+Tongauthor=E.+M.+Joshiauthor=L.+Xuauthor=K.+Owensauthor=K.+Maloneyauthor=K.+Sullivanauthor=A.+Pasternak&title=The+Design+and+Synthesis+of+Novel+Spirocyclic+Heterocyclic+Sulfone+ROMK+Inhibitors+as+Diuretics&doi=10.1016%2Fj.bmcl.2016.10.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">The design and synthesis of novel spirocyclic heterocyclic sulfone ROMK inhibitors as diuretics</span></div><div class="casAuthors">Chobanian, Harry R.; Guo, Yan; Pio, Barbara; Tang, Haifeng; Teumelsan, Nardos; Clements, Matthew; Frie, Jessica; Ferguson, Ronald; Guo, Zach; Thomas-Fowlkes, Brande S.; Felix, John P.; Liu, Jessica; Kohler, Martin; Priest, Birgit; Hampton, Caryn; Pai, Lee-Yuh; Corona, Aaron; Metzger, Joseph; Tong, Vincent; Joshi, Elizabeth M.; Xu, Ling; Owens, Karen; Maloney, Kevin; Sullivan, Kathleen; Pasternak, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1109-1114</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A spirocyclic class of ROMK inhibitors was developed contg. a structurally diverse heterocyclic sulfone moiety and spirocyclic core starting from lead 1.  These compds. not only displayed exquisite ROMK potency but significantly improved selectivity over hERG.  The lead compds. were found to have favorable pharmacokinetic properties and displayed robust diuretic, natriuretic and blood pressure lowering effects in spontaneously hypertensive rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsxktlvW_zbrVg90H21EOLACvtfcHk0lhfjExObmR8aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVehs7g%253D&md5=eb7449c00304bb21e4d1b292c4c4d6d6</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.10.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.10.032%26sid%3Dliteratum%253Aachs%26aulast%3DChobanian%26aufirst%3DH.%2BR.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DPio%26aufirst%3DB.%26aulast%3DTang%26aufirst%3DH.%26aulast%3DTeumelsan%26aufirst%3DN.%26aulast%3DClements%26aufirst%3DM.%26aulast%3DFrie%26aufirst%3DJ.%26aulast%3DFerguson%26aufirst%3DR.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DThomas-Fowlkes%26aufirst%3DB.%2BS.%26aulast%3DFelix%26aufirst%3DJ.%2BP.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DKohler%26aufirst%3DM.%26aulast%3DPriest%26aufirst%3DB.%26aulast%3DHampton%26aufirst%3DC.%26aulast%3DPai%26aufirst%3DL.-Y.%26aulast%3DCorona%26aufirst%3DA.%26aulast%3DMetzger%26aufirst%3DJ.%26aulast%3DTong%26aufirst%3DV.%26aulast%3DJoshi%26aufirst%3DE.%2BM.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DOwens%26aufirst%3DK.%26aulast%3DMaloney%26aufirst%3DK.%26aulast%3DSullivan%26aufirst%3DK.%26aulast%3DPasternak%26aufirst%3DA.%26atitle%3DThe%2520Design%2520and%2520Synthesis%2520of%2520Novel%2520Spirocyclic%2520Heterocyclic%2520Sulfone%2520ROMK%2520Inhibitors%2520as%2520Diuretics%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26issue%3D4%26spage%3D1109%26epage%3D1114%26doi%3D10.1016%2Fj.bmcl.2016.10.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pettus, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booker, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cee, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastwood, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herberich, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanman, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laszlo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipford, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rex, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sastri, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamayo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winston, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurz, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tasker, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.-L.</span></span> <span> </span><span class="NLM_article-title">Discovery and Optimization of Quinazolinone-Pyrrolopyrrolones as Potent and Orally Bioavailable Pan-Pim Kinase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">6407</span>– <span class="NLM_lpage">6430</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00610</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00610" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsF2msbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=6407-6430&issue=13&author=L.+H.+Pettusauthor=K.+L.+Andrewsauthor=S.+K.+Bookerauthor=J.+Chenauthor=V.+J.+Ceeauthor=F.+Chavezauthor=Y.+Chenauthor=H.+Eastwoodauthor=N.+Guerreroauthor=B.+Herberichauthor=D.+Hickmanauthor=B.+A.+Lanmanauthor=J.+Laszloauthor=M.+R.+Leeauthor=J.+R.+Lipfordauthor=B.+Mattsonauthor=C.+Mohrauthor=Y.+Nguyenauthor=M.+H.+Normanauthor=D.+Powersauthor=A.+B.+Reedauthor=K.+Rexauthor=C.+Sastriauthor=N.+Tamayoauthor=P.+Wangauthor=J.+T.+Winstonauthor=B.+Wuauthor=T.+Wuauthor=R.+P.+Wurzauthor=Y.+Xuauthor=Y.+Zhouauthor=A.+S.+Taskerauthor=H.-L.+Wang&title=Discovery+and+Optimization+of+Quinazolinone-Pyrrolopyrrolones+as+Potent+and+Orally+Bioavailable+Pan-Pim+Kinase+Inhibitors&doi=10.1021%2Facs.jmedchem.6b00610"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Optimization of Quinazolinone-pyrrolopyrrolones as Potent and Orally Bioavailable Pan-Pim Kinase Inhibitors</span></div><div class="casAuthors">Pettus, Liping H.; Andrews, Kristin L.; Booker, Shon K.; Chen, Jie; Cee, Victor J.; Chavez, Frank, Jr.; Chen, Yuping; Eastwood, Heather; Guerrero, Nadia; Herberich, Bradley; Hickman, Dean; Lanman, Brian A.; Laszlo, Jimmy, III; Lee, Matthew R.; Lipford, J. Russell; Mattson, Bethany; Mohr, Christopher; Nguyen, Yen; Norman, Mark H.; Powers, David; Reed, Anthony B.; Rex, Karen; Sastri, Christine; Tamayo, Nuria; Wang, Paul; Winston, Jeffrey T.; Wu, Bin; Wu, Tian; Wurz, Ryan P.; Xu, Yang; Zhou, Yihong; Tasker, Andrew S.; Wang, Hui-Ling</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6407-6430</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The high expression of proviral insertion site of Moloney murine leukemia virus kinases (Pim-1, -2, and -3) in cancers, particularly the hematopoietic malignancies, is believed to play a role in promoting cell survival and proliferation while suppressing apoptosis.  The three isoforms of Pim protein appear largely redundant in their oncogenic functions.  Thus, a pan-Pim kinase inhibitor is highly desirable.  However, cell active pan-Pim inhibitors have proven difficult to develop because Pim-2 has a low Km for ATP and therefore requires a very potent inhibitor to effectively block the kinase activity at cellular ATP concns.  Herein, the authors report a series of quinazolinone-pyrrolopyrrolones as potent and selective pan-Pim inhibitors.  In particular, compd. (R)-2-(tert-butylamino)-3-methyl-8-(6-methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4-b]pyrrol-2-yl)quinazolin-4(3H)-one (17) is orally efficacious in a mouse xenograft model (KMS-12 BM) of multiple myeloma, with 93% tumor growth inhibition at 50 mg/kg QD upon oral dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2s5EkmHtIBbVg90H21EOLACvtfcHk0ljhn6Lkj6uUFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsF2msbc%253D&md5=0ac3b462493e0abee1a774aa7854c87d</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00610%26sid%3Dliteratum%253Aachs%26aulast%3DPettus%26aufirst%3DL.%2BH.%26aulast%3DAndrews%26aufirst%3DK.%2BL.%26aulast%3DBooker%26aufirst%3DS.%2BK.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DCee%26aufirst%3DV.%2BJ.%26aulast%3DChavez%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DEastwood%26aufirst%3DH.%26aulast%3DGuerrero%26aufirst%3DN.%26aulast%3DHerberich%26aufirst%3DB.%26aulast%3DHickman%26aufirst%3DD.%26aulast%3DLanman%26aufirst%3DB.%2BA.%26aulast%3DLaszlo%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DM.%2BR.%26aulast%3DLipford%26aufirst%3DJ.%2BR.%26aulast%3DMattson%26aufirst%3DB.%26aulast%3DMohr%26aufirst%3DC.%26aulast%3DNguyen%26aufirst%3DY.%26aulast%3DNorman%26aufirst%3DM.%2BH.%26aulast%3DPowers%26aufirst%3DD.%26aulast%3DReed%26aufirst%3DA.%2BB.%26aulast%3DRex%26aufirst%3DK.%26aulast%3DSastri%26aufirst%3DC.%26aulast%3DTamayo%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWinston%26aufirst%3DJ.%2BT.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DWurz%26aufirst%3DR.%2BP.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DTasker%26aufirst%3DA.%2BS.%26aulast%3DWang%26aufirst%3DH.-L.%26atitle%3DDiscovery%2520and%2520Optimization%2520of%2520Quinazolinone-Pyrrolopyrrolones%2520as%2520Potent%2520and%2520Orally%2520Bioavailable%2520Pan-Pim%2520Kinase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D13%26spage%3D6407%26epage%3D6430%26doi%3D10.1021%2Facs.jmedchem.6b00610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dransfield, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasparian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vimolratana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattaropong, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houze, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaminath, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartberger, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correll, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, D. C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, J. C.</span></span> <span> </span><span class="NLM_article-title">Discovery and Optimization of Potent GPR40 Full Agonists Containing Tricyclic Spirocycles</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">551</span>– <span class="NLM_lpage">555</span>, <span class="refDoi"> DOI: 10.1021/ml300427u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300427u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntVOktLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=551-555&issue=6&author=Y.+Wangauthor=J.+J.+Liuauthor=P.+J.+Dransfieldauthor=L.+Zhuauthor=Z.+Wangauthor=X.+Duauthor=X.+Jiaoauthor=Y.+Suauthor=A.-R.+Liauthor=S.+P.+Brownauthor=A.+Kasparianauthor=M.+Vimolratanaauthor=M.+Yuauthor=V.+Pattaropongauthor=J.+B.+Houzeauthor=G.+Swaminathauthor=T.+Tranauthor=K.+Nguyenauthor=Q.+Guoauthor=J.+Zhangauthor=R.+Zhuangauthor=F.+Liauthor=L.+Miaoauthor=M.+D.+Bartbergerauthor=T.+L.+Correllauthor=D.+Chowauthor=S.+Wongauthor=J.+Luoauthor=D.+C.-H.+Linauthor=J.+C.+Medina&title=Discovery+and+Optimization+of+Potent+GPR40+Full+Agonists+Containing+Tricyclic+Spirocycles&doi=10.1021%2Fml300427u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Optimization of Potent GPR40 Full Agonists Containing Tricyclic Spirocycles</span></div><div class="casAuthors">Wang, Yingcai; Liu, Jiwen; Dransfield, Paul J.; Zhu, Liusheng; Wang, Zhongyu; Du, Xiaohui; Jiao, Xianyun; Su, Yongli; Li, An-rong; Brown, Sean P.; Kasparian, Annie; Vimolratana, Marc; Yu, Ming; Pattaropong, Vatee; Houze, Jonathan B.; Swaminath, Gayathri; Tran, Thanhvien; Nguyen, Khanh; Guo, Qi; Zhang, Jane; Zhuang, Run; Li, Frank; Miao, Lynn; Bartberger, Michael D.; Correll, Tiffany L.; Chow, David; Wong, Simon; Luo, Jian; Lin, Daniel C.-H.; Medina, Julio C.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">551-555</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">GPR40 (FFAR1 or FFA1) is a target of high interest being pursued to treat type II diabetes due to its unique mechanism leading to little risk of hypoglycemia.  The authors recently reported the discovery of AM-1638 (I), a potent full agonist of GPR40.  In this report, they present the discovery of GPR40 full agonists contg. conformationally constrained tricyclic spirocycles and their structure-activity relationships leading to more potent agonists such as AM-5262 (II) with improved rat PK profile and general selectivity profile.  AM-5262 enhanced glucose stimulated insulin secretion (mouse and human islets) and improved glucose homeostasis in vivo (OGTT in HF/STZ mice) when compared to AM-1638.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgX9JpdxT4OrVg90H21EOLACvtfcHk0ljhn6Lkj6uUFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntVOktLY%253D&md5=7f4681a65e80ba0f45642f63c6a33b22</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1021%2Fml300427u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300427u%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%2BJ.%26aulast%3DDransfield%26aufirst%3DP.%2BJ.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DDu%26aufirst%3DX.%26aulast%3DJiao%26aufirst%3DX.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DA.-R.%26aulast%3DBrown%26aufirst%3DS.%2BP.%26aulast%3DKasparian%26aufirst%3DA.%26aulast%3DVimolratana%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DPattaropong%26aufirst%3DV.%26aulast%3DHouze%26aufirst%3DJ.%2BB.%26aulast%3DSwaminath%26aufirst%3DG.%26aulast%3DTran%26aufirst%3DT.%26aulast%3DNguyen%26aufirst%3DK.%26aulast%3DGuo%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhuang%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DMiao%26aufirst%3DL.%26aulast%3DBartberger%26aufirst%3DM.%2BD.%26aulast%3DCorrell%26aufirst%3DT.%2BL.%26aulast%3DChow%26aufirst%3DD.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DD.%2BC.-H.%26aulast%3DMedina%26aufirst%3DJ.%2BC.%26atitle%3DDiscovery%2520and%2520Optimization%2520of%2520Potent%2520GPR40%2520Full%2520Agonists%2520Containing%2520Tricyclic%2520Spirocycles%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26issue%3D6%26spage%3D551%26epage%3D555%26doi%3D10.1021%2Fml300427u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sherwood, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowley, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paton, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggerstaff, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuenswander, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kivell, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prisinzano, T. E.</span></span> <span> </span><span class="NLM_article-title">Addressing Structural Flexibility at the A-Ring on Salvinorin A: Discovery of a Potent Kappa-Opioid Agonist with Enhanced Metabolic Stability</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">3866</span>– <span class="NLM_lpage">3878</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00148</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00148" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2sXls1Gls7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=3866-3878&issue=9&author=A.+M.+Sherwoodauthor=R.+S.+Crowleyauthor=K.+F.+Patonauthor=A.+Biggerstaffauthor=B.+Neuenswanderauthor=V.+W.+Dayauthor=B.+M.+Kivellauthor=T.+E.+Prisinzano&title=Addressing+Structural+Flexibility+at+the+A-Ring+on+Salvinorin+A%3A+Discovery+of+a+Potent+Kappa-Opioid+Agonist+with+Enhanced+Metabolic+Stability&doi=10.1021%2Facs.jmedchem.7b00148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Addressing Structural Flexibility at the A-Ring on Salvinorin A: Discovery of a Potent Kappa-Opioid Agonist with Enhanced Metabolic Stability</span></div><div class="casAuthors">Sherwood, Alexander M.; Crowley, Rachel Saylor; Paton, Kelly F.; Biggerstaff, Andrew; Neuenswander, Benjamin; Day, Victor W.; Kivell, Bronwyn M.; Prisinzano, Thomas E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3866-3878</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Previous structure-activity studies on the neoclerodane diterpenoid salvinorin A have demonstrated the importance of the acetoxy functionality on the A-ring in its activity as a kappa opioid receptor agonist.  Few studies have focused on understanding the role of conformation in these interactions.  Herein we describe the synthesis and evaluation of both flexible and conformationally restricted compds. derived from salvinorin A.  One such compd., spirobutyrolactone (I), was synthesized in a single step from salvinorin B and had similar potency and selectivity to salvinorin A (EC50 = 0.6 ± 0.2 nM at κ >10,000 nM at μ and δ).  Microsomal stability studies demonstrated that 14 was more metabolically resistant than salvinorin A.  Evaluation of analgesic and anti-inflammatory properties revealed similar in vivo effects between 14 and salvinorin A.  To our knowledge, this study represents the first example of bioisosteric replacement of an acetate group by a spirobutyrolactone to produce a metabolically resistant deriv.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphQfDVKsiZz7Vg90H21EOLACvtfcHk0lhIT8hEYs_3aA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXls1Gls7s%253D&md5=32073a4c5da4fb19e2d9adc0bba34d2d</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00148%26sid%3Dliteratum%253Aachs%26aulast%3DSherwood%26aufirst%3DA.%2BM.%26aulast%3DCrowley%26aufirst%3DR.%2BS.%26aulast%3DPaton%26aufirst%3DK.%2BF.%26aulast%3DBiggerstaff%26aufirst%3DA.%26aulast%3DNeuenswander%26aufirst%3DB.%26aulast%3DDay%26aufirst%3DV.%2BW.%26aulast%3DKivell%26aufirst%3DB.%2BM.%26aulast%3DPrisinzano%26aufirst%3DT.%2BE.%26atitle%3DAddressing%2520Structural%2520Flexibility%2520at%2520the%2520A-Ring%2520on%2520Salvinorin%2520A%253A%2520Discovery%2520of%2520a%2520Potent%2520Kappa-Opioid%2520Agonist%2520with%2520Enhanced%2520Metabolic%2520Stability%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D9%26spage%3D3866%26epage%3D3878%26doi%3D10.1021%2Facs.jmedchem.7b00148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toselli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fredenwall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svensson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weidolf, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, M. A.</span></span> <span> </span><span class="NLM_article-title">Hip To Be Square: Oxetanes as Design Elements To Alter Metabolic Pathways</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">7383</span>– <span class="NLM_lpage">7399</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00030</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00030" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtl2jt7bP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7383-7399&issue=16&author=F.+Toselliauthor=M.+Fredenwallauthor=P.+Svenssonauthor=X.-Q.+Liauthor=A.+Johanssonauthor=L.+Weidolfauthor=M.+A.+Hayes&title=Hip+To+Be+Square%3A+Oxetanes+as+Design+Elements+To+Alter+Metabolic+Pathways&doi=10.1021%2Facs.jmedchem.9b00030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Hip To Be Square: Oxetanes as Design Elements To Alter Metabolic Pathways</span></div><div class="casAuthors">Toselli, Francesca; Fredenwall, Marlene; Svensson, Peder; Li, Xue-Qing; Johansson, Anders; Weidolf, Lars; Hayes, Martin A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7383-7399</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oxetane-contg. ring systems are increasingly used in medicinal chem. programs to modulate druglike properties.  We have shown previously that oxetanes are hydrolyzed to diols by human microsomal epoxide hydrolase (mEH).  Mapping the enzymes that contribute to drug metab. is important since an exaggerated dependence on one specific isoenzyme increases the risk of drug-drug interactions with co-administered drugs.  Herein, we illustrate that mEH-catalyzed hydrolysis is an important metabolic pathway for a set of more structurally diverse oxetanes and the degree of hydrolysis is modulated by minor structural modifications.  A homol. model based on the Bombyx mori EH crystal structure was used to rationalize substrate binding.  This study shows that oxetanes can be used as drug design elements for directing metabolic clearance via mEH, thus potentially decreasing the dependence on cytochromes P 450.  Metab. by mEH should be assessed early in the design process to understand the complete metabolic fate of oxetane-contg. compds., and further study is required to allow accurate pharmacokinetic predictions of its substrates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMLs6g2Qt2aLVg90H21EOLACvtfcHk0ljRUivWpdG0XQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtl2jt7bP&md5=78a21c62c543e11c5a71f287e9252603</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00030%26sid%3Dliteratum%253Aachs%26aulast%3DToselli%26aufirst%3DF.%26aulast%3DFredenwall%26aufirst%3DM.%26aulast%3DSvensson%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DX.-Q.%26aulast%3DJohansson%26aufirst%3DA.%26aulast%3DWeidolf%26aufirst%3DL.%26aulast%3DHayes%26aufirst%3DM.%2BA.%26atitle%3DHip%2520To%2520Be%2520Square%253A%2520Oxetanes%2520as%2520Design%2520Elements%2520To%2520Alter%2520Metabolic%2520Pathways%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D16%26spage%3D7383%26epage%3D7399%26doi%3D10.1021%2Facs.jmedchem.9b00030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grönberg, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berggren, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castagnoli, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weidolf, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Novel Microsomal Epoxide Hydrolase-Catalyzed Hydration of a Spiro Oxetane</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>44</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1341</span>– <span class="NLM_lpage">1348</span>, <span class="refDoi"> DOI: 10.1124/dmd.116.071142</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1124%2Fdmd.116.071142" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=27256986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhsl2gur3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2016&pages=1341-1348&issue=8&author=X.-Q.+Liauthor=M.+A.+Hayesauthor=G.+Gr%C3%B6nbergauthor=K.+Berggrenauthor=N.+Castagnoliauthor=L.+Weidolf&title=Discovery+of+a+Novel+Microsomal+Epoxide+Hydrolase-Catalyzed+Hydration+of+a+Spiro+Oxetane&doi=10.1124%2Fdmd.116.071142"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a novel microsomal epoxide hydrolase-catalyzed hydration of a spiro oxetane</span></div><div class="casAuthors">Li, Xue-Qing; Hayes, Martin A.; Gronberg, Gunnar; Berggren, Kristina; Castagnoli, Jr. Neal; Weidolf, Lars</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1341-1348</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Oxetane moieties are increasingly being used by the pharmaceutical industry as building blocks in drug candidates because of their pronounced ability to improve physicochem. parameters and metabolic stability of drug candidates.  The enzymes that catalyze the biotransformation of the oxetane moiety are, however, not well studied.  The in vitro metab. of a spiro oxetane-contg. compd. AZD1979 [(3-(4-(2-oxa-6-azaspiro[3.3]heptan-6-ylmethyl) phenoxy)azetidin-1-yl)(5-(4-ethoxyphenyl)-1,3,4-oxadiazol- 2-yl)methanone] was studied and one of its metabolites, M1, attracted our interest because its formation was NAD(P)H independent.  The focus of this work was to elucidate the structure of M1 and to understand the mechanism(s) of its formation.  We established that M1 was formed via hydration and ring opening of the oxetanyl moiety of AZD1979.  Incubations of AZD1979 using various human liver subcellular fractions revealed that the hydration reaction leading to M1 occurred mainly in the microsomal fraction.  The underlying mechanism as a hydration, rather than an oxidn. reaction, was supported by the incorporation of 18O from H218O into M1.  Enzyme kinetics were performed probing the formation of M1 in human liver microsomes.  The formation of M1 was substantially inhibited by progabide, a microsomal epoxide hydrolase inhibitor, but not by trans-4-[4-(1-adamantylcarbamoylamino)cyclohexyloxy]- benzoic acid, a sol. epoxide hydrolase inhibitor.  On the basis of these results, we propose that microsomal epoxide hydrolase catalyzes the formation of M1.  The substrate specificity of microsomal epoxide hydrolase should therefore be expanded to include not only epoxides but also the oxetanyl ring system present in AZD1979.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNrbQCNYH9F7Vg90H21EOLACvtfcHk0ljRUivWpdG0XQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhsl2gur3E&md5=a1a857a6ff437193d8f07b170fb608c8</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1124%2Fdmd.116.071142&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.116.071142%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.-Q.%26aulast%3DHayes%26aufirst%3DM.%2BA.%26aulast%3DGr%25C3%25B6nberg%26aufirst%3DG.%26aulast%3DBerggren%26aufirst%3DK.%26aulast%3DCastagnoli%26aufirst%3DN.%26aulast%3DWeidolf%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520a%2520Novel%2520Microsomal%2520Epoxide%2520Hydrolase-Catalyzed%2520Hydration%2520of%2520a%2520Spiro%2520Oxetane%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2016%26volume%3D44%26issue%3D8%26spage%3D1341%26epage%3D1348%26doi%3D10.1124%2Fdmd.116.071142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grönberg, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bangur, E.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castagnoli, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weidolf, L.</span></span> <span> </span><span class="NLM_article-title">Metabolism of Strained Rings: Glutathione S-Transferase-Catalyzed Formation of a Glutathione-Conjugated Spiro-Azetidine without Prior Bioactivation</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>47</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1247</span>– <span class="NLM_lpage">1256</span>, <span class="refDoi"> DOI: 10.1124/dmd.119.088658</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1124%2Fdmd.119.088658" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=31492694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlCntb3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2019&pages=1247-1256&issue=11&author=X.-Q.+Liauthor=G.+Gr%C3%B6nbergauthor=E.-H.+Bangurauthor=M.+A.+Hayesauthor=N.+Castagnoliauthor=L.+Weidolf&title=Metabolism+of+Strained+Rings%3A+Glutathione+S-Transferase-Catalyzed+Formation+of+a+Glutathione-Conjugated+Spiro-Azetidine+without+Prior+Bioactivation&doi=10.1124%2Fdmd.119.088658"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism of strained rings: glutathione S-transferase-catalyzed formation of a glutathione-conjugated spiro-azetidine without prior bioactivation</span></div><div class="casAuthors">Li, Xue-Qing; Groenberg, Gunnar; Bangur, Eva-Henriette; Hayes, Martin A.; Castagnoli, Neal; Weidolf, Lars</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1247-1256</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">AZD1979 [(3-(4-(2-oxa-6-azaspiro[3.3]heptan-6-ylmethyl)phenoxy)azetidin-1-yl)(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)methanone] is a melanin-concg. hormone receptor 1 antagonist designed for the treatment of obesity.  In this study, metabolite profiles of AZD1979 in human hepatocytes revealed a series of glutathione-related metabolites, including the glutathionyl, cysteinyl, cysteinylglycinyl, and mercapturic acid conjugates.  The formation of these metabolites was not inhibited by coincubation with the cytochrome P 450 (P 450) inhibitor 1-aminobenzotriazole.  In efforts to identify the mechanistic features of this pathway, investigations were performed to characterize the structure of the glutathionyl conjugate M12 of AZD1979 and to identify the enzyme system catalyzing its formation.  Studies with various human liver subcellular fractions established that the formation of M12 was NAD(P)H-independent and proceeded in cytosol and S9 fractions but not in microsomal or mitochondrial fractions.  Metabolite M12 was purified from rat liver S9 incubations and its structure elucidated by NMR.  These results establish that M12 is the product of the GST-catalyzed glutathione attack on the carbon atom a to the nitrogen atom of the strained spiro-azetidinyl moiety to give, after ring opening, the corresponding amino-thioether conjugate product, a direct conjugation pathway that occurs without the prior substrate bioactivation by P 450.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrPA57-Kg_vrVg90H21EOLACvtfcHk0ljmNIL7YeLuAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlCntb3O&md5=0c59a3f2baa40d89a84b8a11843e67c0</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1124%2Fdmd.119.088658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.119.088658%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.-Q.%26aulast%3DGr%25C3%25B6nberg%26aufirst%3DG.%26aulast%3DBangur%26aufirst%3DE.-H.%26aulast%3DHayes%26aufirst%3DM.%2BA.%26aulast%3DCastagnoli%26aufirst%3DN.%26aulast%3DWeidolf%26aufirst%3DL.%26atitle%3DMetabolism%2520of%2520Strained%2520Rings%253A%2520Glutathione%2520S-Transferase-Catalyzed%2520Formation%2520of%2520a%2520Glutathione-Conjugated%2520Spiro-Azetidine%2520without%2520Prior%2520Bioactivation%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2019%26volume%3D47%26issue%3D11%26spage%3D1247%26epage%3D1256%26doi%3D10.1124%2Fdmd.119.088658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 8 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Mina Hariri, Fatemeh Darvish, Karen-Pacelye Mengue Me Ndong, Nora Sechet, Geraud Chacktas, Hooriye Boosaliki, Minh Loan Tran Do, Gabin Mwande-Maguene, Jacques Lebibi, Alexander R. Burilov, Tahar Ayad, David Virieux, <span class="NLM_string-name hlFld-ContribAuthor">Jean-Luc Pirat</span>. </span><span class="cited-content_cbyCitation_article-title">Gold-Catalyzed Access to Isophosphinoline 2-Oxides. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>86 </em>
                                    (11)
                                     , 7813-7824. <a href="https://doi.org/10.1021/acs.joc.1c00648" title="DOI URL">https://doi.org/10.1021/acs.joc.1c00648</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.1c00648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.1c00648%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DGold-Catalyzed%252BAccess%252Bto%252BIsophosphinoline%252B2-Oxides%26aulast%3DHariri%26aufirst%3DMina%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D18032021%26date%3D19052021%26volume%3D86%26issue%3D11%26spage%3D7813%26epage%3D7824" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Marta Serafini, Sarah Cargnin, Alberto Massarotti, Gian Cesare Tron, Tracey Pirali, <span class="NLM_string-name hlFld-ContribAuthor">Armando A. Genazzani</span>. </span><span class="cited-content_cbyCitation_article-title">What’s in a Name? Drug Nomenclature and Medicinal Chemistry Trends using INN Publications. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (8)
                                     , 4410-4429. <a href="https://doi.org/10.1021/acs.jmedchem.1c00181" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00181</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00181%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DWhat%2525E2%252580%252599s%252Bin%252Ba%252BName%25253F%252BDrug%252BNomenclature%252Band%252BMedicinal%252BChemistry%252BTrends%252Busing%252BINN%252BPublications%26aulast%3DSerafini%26aufirst%3DMarta%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D01022021%26date%3D13042021%26volume%3D64%26issue%3D8%26spage%3D4410%26epage%3D4429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Philip R. D. Murray, Willem M. M. Bussink, Geraint H. M. Davies, Farid W. van der Mei, Alyssa H. Antropow, Jacob T. Edwards, Laura Akullian D’Agostino, J. Michael Ellis, Lawrence G. Hamann, Fedor Romanov-Michailidis, <span class="NLM_string-name hlFld-ContribAuthor">Robert R. Knowles</span>. </span><span class="cited-content_cbyCitation_article-title">Intermolecular Crossed [2 + 2] Cycloaddition Promoted by Visible-Light Triplet Photosensitization: Expedient Access to Polysubstituted 2-Oxaspiro[3.3]heptanes. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2021,</strong> <em>143 </em>
                                    (10)
                                     , 4055-4063. <a href="https://doi.org/10.1021/jacs.1c01173" title="DOI URL">https://doi.org/10.1021/jacs.1c01173</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.1c01173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.1c01173%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DIntermolecular%252BCrossed%252B%25255B2%252B%25252B%252B2%25255D%252BCycloaddition%252BPromoted%252Bby%252BVisible-Light%252BTriplet%252BPhotosensitization%25253A%252BExpedient%252BAccess%252Bto%252BPolysubstituted%252B2-Oxaspiro%25255B3.3%25255Dheptanes%26aulast%3DMurray%26aufirst%3DPhilip%2BR.%2BD.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D30012021%26date%3D05032021%26volume%3D143%26issue%3D10%26spage%3D4055%26epage%3D4063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Priyadeep Bhutani, Gaurav Joshi, Nivethitha Raja, Namrata Bachhav, Prabhakar K. Rajanna, Hemant Bhutani, Atish T. Paul, <span class="NLM_string-name hlFld-ContribAuthor">Raj Kumar</span>. </span><span class="cited-content_cbyCitation_article-title">U.S. FDA Approved Drugs from 2015–June 2020: A Perspective. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (5)
                                     , 2339-2381. <a href="https://doi.org/10.1021/acs.jmedchem.0c01786" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01786</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01786%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DU.S.%252BFDA%252BApproved%252BDrugs%252Bfrom%252B2015%2525E2%252580%252593June%252B2020%25253A%252BA%252BPerspective%26aulast%3DBhutani%26aufirst%3DPriyadeep%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D12102020%26date%3D22022021%26volume%3D64%26issue%3D5%26spage%3D2339%26epage%3D2381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Helmut M.  Hügel</span>, <span class="hlFld-ContribAuthor ">Nilamuni H.  de Silva</span>, <span class="hlFld-ContribAuthor ">Aimen  Siddiqui</span>, <span class="hlFld-ContribAuthor ">Ewan  Blanch</span>, <span class="hlFld-ContribAuthor ">Anthony  Lingham</span>. </span><span class="cited-content_cbyCitation_article-title">Natural spirocyclic alkaloids and polyphenols as multi target dementia leads. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>43 </em>, 116270. <a href="https://doi.org/10.1016/j.bmc.2021.116270" title="DOI URL">https://doi.org/10.1016/j.bmc.2021.116270</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2021.116270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2021.116270%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DNatural%252Bspirocyclic%252Balkaloids%252Band%252Bpolyphenols%252Bas%252Bmulti%252Btarget%252Bdementia%252Bleads%26aulast%3DH%25C3%25BCgel%26aufirst%3DHelmut%2BM.%26date%3D2021%26volume%3D43%26spage%3D116270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kanokwan  Jaithum</span>, <span class="hlFld-ContribAuthor ">Jumreang  Tummatorn</span>, <span class="hlFld-ContribAuthor ">Bundet  Boekfa</span>, <span class="hlFld-ContribAuthor ">Charnsak  Thongsornkleeb</span>, <span class="hlFld-ContribAuthor ">Kittipong  Chainok</span>, <span class="hlFld-ContribAuthor ">Somsak  Ruchirawat</span>. </span><span class="cited-content_cbyCitation_article-title">Diastereoselective Synthesis of Spirocyclic Ether from
              ortho
              ‐Carbonylarylacetylenols via Silver‐Catalyzed Cyclization under Acidic Conditions. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2021,</strong> <em>6 </em><a href="https://doi.org/10.1002/adsc.202100548" title="DOI URL">https://doi.org/10.1002/adsc.202100548</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.202100548&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.202100548%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DDiastereoselective%252BSynthesis%252Bof%252BSpirocyclic%252BEther%252Bfrom%252Bortho%252B%2525E2%252580%252590Carbonylarylacetylenols%252Bvia%252BSilver%2525E2%252580%252590Catalyzed%252BCyclization%252Bunder%252BAcidic%252BConditions%26aulast%3DJaithum%26aufirst%3DKanokwan%26date%3D2021%26date%3D2021%26volume%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Martina  Palomba</span>, <span class="hlFld-ContribAuthor ">Italo  Franco Coelho Dias</span>, <span class="hlFld-ContribAuthor ">Ornelio  Rosati</span>, <span class="hlFld-ContribAuthor ">Francesca  Marini</span>. </span><span class="cited-content_cbyCitation_article-title">Modern Synthetic Strategies with Organoselenium Reagents: A Focus on Vinyl Selenones. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (11)
                                     , 3148. <a href="https://doi.org/10.3390/molecules26113148" title="DOI URL">https://doi.org/10.3390/molecules26113148</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26113148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26113148%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DModern%252BSynthetic%252BStrategies%252Bwith%252BOrganoselenium%252BReagents%25253A%252BA%252BFocus%252Bon%252BVinyl%252BSelenones%26aulast%3DPalomba%26aufirst%3DMartina%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D11%26spage%3D3148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Davit  Hayrapetyan</span>, <span class="hlFld-ContribAuthor ">Valeriya  Stepanova</span>. </span><span class="cited-content_cbyCitation_article-title">Facile Synthesis of Spirocyclic Lactams via [3+2] and [3+3] Aza‐Annulation Reactions. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em> </em><a href="https://doi.org/10.1002/ejoc.202100255" title="DOI URL">https://doi.org/10.1002/ejoc.202100255</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.202100255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.202100255%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DFacile%252BSynthesis%252Bof%252BSpirocyclic%252BLactams%252Bvia%252B%25255B3%25252B2%25255D%252Band%252B%25255B3%25252B3%25255D%252BAza%2525E2%252580%252590Annulation%252BReactions%26aulast%3DHayrapetyan%26aufirst%3DDavit%26date%3D2021%26date%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0067.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0067.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Number of publications with the key word “spiro” in medicinal chemistry journals (<i>J. Med. Chem.</i>, <i>Eur. J. Med. Chem.</i>, <i>ACS Med. Chem. Lett.</i>, <i>ChemMedChem</i>, <i>Bioorg. Med. Chem.</i>, <i>Bioorg. Med. Chem. Lett.</i>, <i>Bioorg. Chem.</i>, and <i>MedChemComm</i>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0032.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthetic Route of <b>26</b> (AZD-2115)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0033.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Commercial Synthesis of <b>8</b> (Fenspiride)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0034.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Commercial Synthesis of <b>6</b> (Cevimeline Hydrochloride)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0035.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0035.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of <b>36</b> (Cebranopadol)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0036.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0036.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Antimalarial <b>37</b> (Cipargamin)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0036.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0037.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0037.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of <b>43</b> (NOP-1A)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0037.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0038.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0038.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Oliceridine</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0038.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0039.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0039.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of the MCL-1 Inhibitor <b>49</b> (AMG-176)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0039.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0040.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0040.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthesis of the Ghrelin Reverse Agonist <b>53</b> (PF-5190457)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0040.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0041.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0041.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Syntheses of <b>4</b> (Apalutamide)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0041.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0042.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0042.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. ArQule Synthesis of <b>13</b> (Irbesartan)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0042.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch12" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0043.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0043.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 12. Synthesis of PTHR1 Agonist <b>66</b> (PCO-371)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0043.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch13" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0044.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0044.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 13. Syntheses of <b>17</b> (Spiperone) and <b>9</b> (Fluspirilene)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0044.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch14" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0045.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0045.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 14. Synthesis of <b>76</b> (Ranirestat) Reported by Dainippon Sumitomo</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0045.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch15" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0046.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0046.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 15. Synthesis of <b>82</b> (Rolapitant) by Schering-Plough</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0046.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch16" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0047.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0047.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 16. Alternative Approaches to <b>87</b> (Trilaciclib) Synthesis</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0047.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch17" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0048.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0048.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 17. Synthesis of <b>98</b> (RO-5028442)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0048.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch18" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0049.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0049.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 18. Original Synthesis of <b>19</b> by Chugai Pharmaceutical Co.</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0049.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch19" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Scheme 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0050.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0050.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 19. Synthesis of <b>110</b> (Tomivosertib) by Effector Therapeutics</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0050.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch20" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Scheme 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0051.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0051.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 20. Synthesis of <b>113</b> (Lanabecestat) by AstraZeneca</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0051.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch21" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Scheme 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0052.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0052.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 21. Synthesis of <b>119</b> (LY-2881835)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0052.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch22" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Scheme 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0053.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0053.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 22. Synthesis of <b>20</b> (Ubrogepant)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0053.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch23" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Scheme 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0054.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0054.jpeg" id="rightTab-gr25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 23. Pilot-Scale Synthesis of <b>136</b> (Funapide)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0054.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch24" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Scheme 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0055.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0055.jpeg" id="rightTab-gr26" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 24. Synthesis of <b>11</b> (Griseofulvin) Developed by Pirrung and Co-Workers</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0055.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch25" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Scheme 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0056.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0056.jpeg" id="rightTab-gr27" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 25. Synthesis of Pfizer’s Acetyl-CoA Carboxylase Inhibitor <b>147</b> (PF-05175157)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0056.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch26" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Scheme 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0057.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0057.jpeg" id="rightTab-gr28" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 26. Synthesis of <b>154</b> (Satavaptan)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0057.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch27" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Scheme 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0058.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0058.jpeg" id="rightTab-gr29" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 27. Synthesis of <b>158</b> (Vapitadine)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0058.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch28" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Scheme 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0059.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0059.jpeg" id="rightTab-gr30" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 28. RCM-Based Synthesis of <b>82</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0059.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch28"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0002.jpeg" id="rightTab-gr31" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Organosilane antiviral spirocycles.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0003.jpeg" id="rightTab-gr32" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Bioisosteric replacement of phosphonate-containing spirocycle.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0004.jpeg" id="rightTab-gr33" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Boron-containing spirocyclic compound series.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0005.jpeg" id="rightTab-gr34" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Spirocyclic chiral NS4B inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0006.jpeg" id="rightTab-gr35" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Spirocyclic chiral ATPase inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0007.jpeg" id="rightTab-gr36" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Spiroindane based HAT inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="36" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0008.jpeg" id="rightTab-gr37" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Spirocyclic BACE1 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="37" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0009.jpeg" id="rightTab-gr38" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Various spirocyclic structures: (A) inhibitor targeting PPI; (B) partial agonist of nAChR; (C) spiroketal partial RXR agonist.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="38" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0010.jpeg" id="rightTab-gr39" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Structure-based introduction of spiroindane leads to discovery of MCL-1 inhibitor <b>49</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="39" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0011.jpeg" id="rightTab-gr41" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Structure-based introduction of a spirocyclic moiety into TPH1 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="40" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0012.jpeg" id="rightTab-gr42" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Structure-based introduction of a spirocyclic moiety into SHMT inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="41" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0013.jpeg" id="rightTab-gr44" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Replacement of piperazine by diazaspiro[3.3]heptane in <b>196</b> (olaparib).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="42" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0014.jpeg" id="rightTab-gr45" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Spirocyclic 5-HT<sub>2C</sub>R agonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="43" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0015.jpeg" id="rightTab-gr46" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Dual μ-opioid receptor agonists/σ<sub>1</sub> receptor antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="44" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0016.jpeg" id="rightTab-gr47" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Replacement of an alkene with a spirocyclic moiety leads to PLK4 inhibitors with improved physicochemical properties.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="45" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0017.jpeg" id="rightTab-gr48" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Introduction of a spirocycle into WNT inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="46" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0018.jpeg" id="rightTab-gr49" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Spirocyclic MCHr1 antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="47" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0019.jpeg" id="rightTab-gr50" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. IRAK4 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig20" data-index="48" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0020.jpeg" id="rightTab-gr51" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. GPR119 agonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig21" data-index="49" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0021.jpeg" id="rightTab-gr52" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. SPR inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig21a" data-index="50" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0022.jpeg" id="rightTab-gr53" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. LSD1 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig21a"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig22" data-index="51" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0023.jpeg" id="rightTab-gr54" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Linezolid and its spirocyclic analogue.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig23" data-index="52" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0024.jpeg" id="rightTab-gr55" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Compounds bearing an electrophilic spirocyclic epoxide.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig24" data-index="53" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0025.jpeg" id="rightTab-gr56" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. Spirocyclic diazirines: example and general reaction procedure.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig25" data-index="54" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0026.jpeg" id="rightTab-gr57" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. NS5A inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig26" data-index="55" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0027.jpeg" id="rightTab-gr59" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. Spirocyclic HIV-1 integrase strand transfer inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig27" data-index="56" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0028.jpeg" id="rightTab-gr60" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. NS3/4A protease inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig28" data-index="57" class="article__inlineFigure"><h2 class="fig-label">Figure 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0029.jpeg" id="rightTab-gr62" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 29. Spirocyclic Pim kinase inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig29" data-index="58" class="article__inlineFigure"><h2 class="fig-label">Figure 30</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0030.jpeg" id="rightTab-gr63" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 30. GPR40 agonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig29"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig30" data-index="59" class="article__inlineFigure"><h2 class="fig-label">Figure 31</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0031.jpeg" id="rightTab-gr64" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 31. κ-Opioid receptor agonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=fig30"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch29" data-index="60" class="article__inlineFigure"><h2 class="fig-label">Scheme 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/medium/jm0c01473_0060.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0060.jpeg" id="rightTab-gr65" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 29. Metabolization of Oxetane-Containing Spirocycles</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01473/20210107/images/large/jm0c01473_0060.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01473&amp;id=sch29"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i69">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85842" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85842" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 162 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moss, G. P.</span></span> <span> </span><span class="NLM_article-title">Extension and Revision of the Nomenclature for Spiro Compounds</span>. <i>Pure Appl. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>71</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">531</span>– <span class="NLM_lpage">558</span>, <span class="refDoi"> DOI: 10.1351/pac199971030531</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1351%2Fpac199971030531" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADyaK1MXlt1Cksbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=1999&pages=531-558&issue=3&author=G.+P.+Moss&title=Extension+and+Revision+of+the+Nomenclature+for+Spiro+Compounds&doi=10.1351%2Fpac199971030531"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Extension and revision of the nomenclature for spiro compounds</span></div><div class="casAuthors">Moss, G. P.</div><div class="citationInfo"><span class="NLM_cas:title">Pure and Applied Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">531-558</span>CODEN:
                <span class="NLM_cas:coden">PACHAS</span>;
        ISSN:<span class="NLM_cas:issn">0033-4545</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">The nomenclature of spiro compds. is described in detail and is extended to cover branched polyspiro systems and compds. where 3 rings have 1 common spiro atom.  A new notation, based on the von Baeyer method of naming spiro systems where all components are monocyclic, allows both unbranched and branched polyspiro systems to be named without ambiguity.  It also enables the names to be readily interpreted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdeugzlS3FDrVg90H21EOLACvtfcHk0lgZgIqcBtRZ9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlt1Cksbg%253D&md5=b6f6f0e0a3a0c832bffb6fef9c35fbc0</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1351%2Fpac199971030531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1351%252Fpac199971030531%26sid%3Dliteratum%253Aachs%26aulast%3DMoss%26aufirst%3DG.%2BP.%26atitle%3DExtension%2520and%2520Revision%2520of%2520the%2520Nomenclature%2520for%2520Spiro%2520Compounds%26jtitle%3DPure%2520Appl.%2520Chem.%26date%3D1999%26volume%3D71%26issue%3D3%26spage%3D531%26epage%3D558%26doi%3D10.1351%2Fpac199971030531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bikker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humblet, C.</span></span> <span> </span><span class="NLM_article-title">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">6752</span>– <span class="NLM_lpage">6756</span>, <span class="refDoi"> DOI: 10.1021/jm901241e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901241e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6752-6756&issue=21&author=F.+Loveringauthor=J.+Bikkerauthor=C.+Humblet&title=Escape+from+Flatland%3A+Increasing+Saturation+as+an+Approach+to+Improving+Clinical+Success&doi=10.1021%2Fjm901241e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span></div><div class="casAuthors">Lovering, Frank; Bikker, Jack; Humblet, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6752-6756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has become increasingly aware of the value of tracking calcd. phys. properties such as mol. wt., topol. polar surface area, rotatable bonds, and hydrogen bond donors and acceptors.  The authors hypothesized that the shift to high-throughput synthetic practices over the past decade may be another factor that may predispose mols. to fail by steering discovery efforts toward achiral, arom. compds.  The authors have proposed two simple and interpretable measures of the complexity of mols. prepd. as potential drug candidates.  The first is carbon bond satn. as defined by fraction Sp3 (Fsp3) where Fsp3 = (no. of Sp3 hybridized carbons/total carbon count).  The second is simply whether a chiral carbon exists in the mol.  The authors demonstrate that both complexity (as measured by Fsp3) and the presence of chiral centers correlate with success as compds. transition from discovery, through clin. testing, to drugs.  To explain these observations, the authors further demonstrate that satn. correlates with soly., an exptl. phys. property important to success in the drug discovery setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC1f3Ed7nUBbVg90H21EOLACvtfcHk0lhfvVxiy5KVbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN&md5=4ca92c30c17c53d77ad376719bad951e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Fjm901241e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901241e%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26aulast%3DBikker%26aufirst%3DJ.%26aulast%3DHumblet%26aufirst%3DC.%26atitle%3DEscape%2520from%2520Flatland%253A%2520Increasing%2520Saturation%2520as%2520an%2520Approach%2520to%2520Improving%2520Clinical%2520Success%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26issue%3D21%26spage%3D6752%26epage%3D6756%26doi%3D10.1021%2Fjm901241e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Talele, T. T.</span></span> <span> </span><span class="NLM_article-title">Opportunities for Tapping into Three-Dimensional Chemical Space Through a Quaternary Carbon</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">13291</span>– <span class="NLM_lpage">13315</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00829</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00829" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1WktLbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=13291-13315&issue=22&author=T.+T.+Talele&title=Opportunities+for+Tapping+into+Three-Dimensional+Chemical+Space+Through+a+Quaternary+Carbon&doi=10.1021%2Facs.jmedchem.0c00829"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Opportunities for Tapping into Three-Dimensional Chemical Space through a Quaternary Carbon</span></div><div class="casAuthors">Talele, Tanaji T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">13291-13315</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A quaternary carbon bears four other carbon substituents or combination of four non-hydrogen substituents at four vertices of a tetrahedron.  The spirocyclic quaternary carbon positioned at the center of a bioactive mol. offers conformational rigidity, which in turn reduces the penalty for conformational entropy.  The quaternary carbon is a predominant feature of natural product structures and has been assocd. with more effective and selective binding to target proteins compared to planar compds. with a high sp2 count.  The presence of a quaternary carbon stereocenter allows the exploration of novel chem. space to obtain new mols. with enhanced three-dimensionality.  These characteristics, coupled to an increasing awareness to develop sp3-rich mols., boosted utility of quaternary carbon stereocenters in bioactive compds.  It is hoped that this Perspective will inspire the chemist to utilize quaternary carbon stereocenters to enhance potency, selectivity, and other drug-like properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMfj5wUL80Z7Vg90H21EOLACvtfcHk0lhfvVxiy5KVbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1WktLbL&md5=4aebceb05cdc84702ea15908488a4e58</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00829%26sid%3Dliteratum%253Aachs%26aulast%3DTalele%26aufirst%3DT.%2BT.%26atitle%3DOpportunities%2520for%2520Tapping%2520into%2520Three-Dimensional%2520Chemical%2520Space%2520Through%2520a%2520Quaternary%2520Carbon%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26issue%3D22%26spage%3D13291%26epage%3D13315%26doi%3D10.1021%2Facs.jmedchem.0c00829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wei, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherukupalli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, P.</span></span> <span> </span><span class="NLM_article-title">Fsp3: A New Parameter for Drug-Likeness</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1839</span>– <span class="NLM_lpage">1845</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2020.07.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2Fj.drudis.2020.07.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFSmtbvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2020&pages=1839-1845&author=W.+Weiauthor=S.+Cherukupalliauthor=L.+Jingauthor=X.+Liuauthor=P.+Zhan&title=Fsp3%3A+A+New+Parameter+for+Drug-Likeness&doi=10.1016%2Fj.drudis.2020.07.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Fsp3: A new parameter for drug-likeness</span></div><div class="casAuthors">Wei, Wenxiu; Cherukupalli, Srinivasulu; Jing, Lanlan; Liu, Xinyong; Zhan, Peng</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1839-1845</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The drug-likeness of a compd. is a key factor during the initial phases of drug discovery.  It can be defined as the similarity between compds. and drugs.  Here, we collate research related to the fraction of sp3 carbon atoms (Fsp3), including related high-throughput screening (HTS) cases, structural modifications based on Fsp3, and strategies to improve it.  We also introduce new synthetic methods for spirocyclic scaffolds.  It is likely that the reasonable rigidity of spirocyclic scaffolds will provide a new generation of drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF35W9sn4g07Vg90H21EOLACvtfcHk0ljhxiRobZIBhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFSmtbvO&md5=a39174fbd58b911b911587bdea949d1d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2020.07.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2020.07.017%26sid%3Dliteratum%253Aachs%26aulast%3DWei%26aufirst%3DW.%26aulast%3DCherukupalli%26aufirst%3DS.%26aulast%3DJing%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DZhan%26aufirst%3DP.%26atitle%3DFsp3%253A%2520A%2520New%2520Parameter%2520for%2520Drug-Likeness%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2020%26volume%3D25%26spage%3D1839%26epage%3D1845%26doi%3D10.1016%2Fj.drudis.2020.07.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garthwaite, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMahon, E. G.</span></span> <span> </span><span class="NLM_article-title">The Evolution of Aldosterone Antagonists</span>. <i>Mol. Cell. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>217</i></span> (<span class="NLM_issue">1–2</span>),  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.1016/j.mce.2003.10.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2Fj.mce.2003.10.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=15134797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjvVeqtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=217&publication_year=2004&pages=27-31&issue=1%E2%80%932&author=S.+M.+Garthwaiteauthor=E.+G.+McMahon&title=The+Evolution+of+Aldosterone+Antagonists&doi=10.1016%2Fj.mce.2003.10.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The evolution of aldosterone antagonists</span></div><div class="casAuthors">Garthwaite, Susan M.; McMahon, Ellen G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">217</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">27-31</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Since the isolation and purifn. of aldosterone from adrenal exts. 50 yr ago (Experientia 9 (1953) 33), scientists have learned a great deal about how and where aldosterone acts, the factors that control its release, what is its role in the pathophysiol. of cardiovascular disease, how to make and study aldosterone antagonists, and for what medical purposes these agents are useful.  In this paper, the authors will discuss the evolution of aldosterone antagonists from the relatively nonselective spironolactone (Aldactone), to the highly selective eplerenone (Inspra).  Eplerenone represents a mol. with improved steroid receptor selectivity and pharmacokinetic properties in man compared to spironolactone.  Recent clin. results have demonstrated that these improvements translate into tolerability and efficacy in patients with cardiovascular disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBhCstj43wZLVg90H21EOLACvtfcHk0ljhxiRobZIBhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjvVeqtbw%253D&md5=57c4a98a199541b20662d05e7253b642</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.mce.2003.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mce.2003.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DGarthwaite%26aufirst%3DS.%2BM.%26aulast%3DMcMahon%26aufirst%3DE.%2BG.%26atitle%3DThe%2520Evolution%2520of%2520Aldosterone%2520Antagonists%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2004%26volume%3D217%26issue%3D1%25E2%2580%25932%26spage%3D27%26epage%3D31%26doi%3D10.1016%2Fj.mce.2003.10.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cella, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burtner, R. R.</span></span> <span> </span><span class="NLM_article-title">Steroidal Aldosterone Blockers. I.</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1959</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">743</span>– <span class="NLM_lpage">748</span>, <span class="refDoi"> DOI: 10.1021/jo01088a004</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo01088a004" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADyaF3cXisVCm" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1959&pages=743-748&issue=6&author=J.+A.+Cellaauthor=E.+A.+Brownauthor=R.+R.+Burtner&title=Steroidal+Aldosterone+Blockers.+I.&doi=10.1021%2Fjo01088a004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Steroidal aldosterone blockers. I</span></div><div class="casAuthors">Cella, John A.; Brown, Edward A.; Burtner, Robert R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1959</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">743-8</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    </div><div class="casAbstract">The synthetic and specific biol. activities of a variety of steroidal 5- and 6-membered spirolactones are presented.  The 19-nor compd. with a 5-membered lactone is the most potent aldosterone blocker.  Procedure A.  The ethynylated steroid (1 g.) in 5 ml. tetrahydrofuran was refluxed 24 hrs. with 6 ml. 3M MeMgBr in 15 ml. tetrahydrofuran, a slight pos. pressure maintained over the soln. for 24 hrs., poured into ice cold 0.2M H2SO4, most of the solvent removed in vacuo, the crude granular product collected, washed, and dried.  Procedure B.  The 17α-steroidylalkynoic acid (1 g.) in 10 ml. dioxane contg. 1 ml. C5H5N was stirred under H at atm. pressure over 0.3 g. 5% Pd-CaCO3, the catalyst removed, the solvent evapd., the residue dissolved in 10 ml. cold alc. and 1.4 ml. concd. HCl, left 5 min., dild. with 175 ml. cold H2O, and the crude unsatd. lactone collected and dried.  Procedure C.  The 3β-hydroxy-5-ene lactone (1 g.) in 25 ml. PhMe and 8 ml. cyclohexanone refluxed 20 min. with 0.5 g. Al(iso-PrO)3 in 5 ml. PhMe, cooled to 95°, 5 ml. H2O added, the mixt. cooled to room temp., and made strongly acid, the layers sepd., washed, and each back-extd., the combined org. layers steam distd., the cooled distn. residue extd. with CHCl3, this ext. dried, and evapd. to dryness gave the crude 3-oxo-4-ene lactone.  Procedure D.  The aromatic acid or salt (10 g.) in 150 ml. tert-BuOH and 150 ml. tetrahydrofuran was treated with 650 ml. anhyd. NH3, 5.5 g. Li wire added during 0.5 hr., after 3 hrs. 25 ml. alc. added, an addnl. 25 ml. alc. added, the condenser removed, the NH3 allowed to evap. under N, 200 ml. H2O added, the mixt. distd., and the residue worked up in a suitable way described for each compd. CH≡CCH2Br (64.2 g.) was added during 20 min. to a refluxing suspension of 35.2 g. 20 mesh Zn and 36 g. dehydroisoandrosterone acetate in 1 l. tetrahydrofuran and about half the bromide added before vigorous reaction began; after 5 min. the reaction subsided, and the remaining bromide was added, the mixt. refluxed 15 min., cooled, poured into 2 l. H2O contg. 100 ml. 12M HCl, extd. with C6H6, and the solvent removed to give the crude acetate, which was refluxed 0.5 hr. under N with 25 g. KOH in 1 l. MeOH, dild. with 8 l. H2O, the ppt. collected, rinsed free of base, and dried.  The crude product refluxed with 15 g. Girard T reagent and 15 ml. AcOH in 380 ml. alc. for 0.5 hr. gave 20 g. 17α-propargyl-5-androstene-3β,17β-diol (I), m. 152-4°.  The prepn. of 3-methoxy-17α-propargyl-1,3,5-(10)-estratrien-17β-ol (II) was the same as for I, but the reaction was more sluggish and was refluxed 2 hrs.  The crude II sepd. and treated with Girard T gave 6 g. II (from 10 g. starting material), m. 59-60° (MeOH)) λ 2.82, 3.05 μ.  Procedure A was used on 25 g. 17α-ethynyl-5-androstene-3β,17β-diol, and the crude product was dissolved in 250 ml. tetrahydrofuran, 12.1 g. NEt3 added, the 28.8 g. of salt dissolved in 300 ml. 50% aq. dioxane and the refluxing soln. acidified to give 20 g. 3-(3β,17β-dihydroxy-5-androsten-17α-yl)propynoic acid-H2O (III), m. 234-5° (decompn.), [α]D -132.5° (dioxane).  I (4.58 g.) gave by procedure A 3.5 g. 4-(3β17β-dihydroxy-5-androsten-17α-yl)-2-butynoic acid (IV), m. 203-6° (MeCN).  Procedure A with 132 g. 17α-ethynyl-3-methoxy-1,3,5(10)-estratrien-17β-ol gave 108 g. crude 3-(3-methoxy-17β-hydroxy-1,3,5(10)-estratrien-17α-yl)propynoic acid (V), m. 204-7° (decompn.), [α]D -17.7° (dioxane).  Procedure A with 6.5 g. II gave 7 g. crude 4-(3-methoxy-17β-hydroxy-1,3,5(10)-estratrien-17α-yl)-2-butynoic acid (VI), m. 187.5-91.5° (decompn.) (50% aq. alc.).  Procedure B with 0.2 g. III gave 0.07 g. 3-(3β,17β-dihydroxy-5-androsten-17α-yl)propenoic acid lactone (VII), m. 201-3° (aq. MeOH), [α]D 2° (CHCl3), λ 220 mμ, ε 9550.  Procedure B used on 3 g. IV gave crude 4-(3β,17β-dihydroxy-5-androsten-17α-yl)-2-butenoic acid (VIII), not characterized.  Procedure B used on 5 g. V gave 2.55 g. 3-(3-methoxy-17β-hydroxy-1,3,5(10)-estratrien-17α-yl)propenoic acid (IX), m. 170-3° (EtOAc), [α]D 94° (dioxane).  Procedure C with 0.81 g. VII gave 0.30 g. 3-(3-oxo-17β-hydroxy-4-androsten-17α-yl)propenoic acid lactone, m. 153.5-4.5° (EtOAc-cyclohexane), [α]D 203.5° (CHCl3), λ 237 mμ (ε 20,200), λ 5.78 μ.  VII (20 g.) in 225 ml. alc. hydrogenated at atm. pressure and room temp. over 4 g. 5% Pd-C gave 14 g. 3-(3β,17β-dihydroxy-5-androsten-17α-yl)propanoic acid lactone (X), m. 190-1° (EtOAc), [α]D -91.5° (CHCl3).  Crude VIII in 50 ml. alc. contg. 0.1 ml. HCl hydrogenated at atm. pressure over 0.5 5% Pd-C gave 3 g. 4-(3β,17β-dihydroxy-5-androsten-17α-yl)butanoic acid lactone (XI), viscous oil, λ 5.80 μ.  IX (2.55 g.) in 150 ml. EtOAc hydrogenated at 21° over 0.5 g. 5% Pd-C gave 1.8 g. 3-(3-methoxy-17β-hydroxy-1,3,5(10)-estratrien-17-α-yl)propanoic acid lactone, m. 150-2° (EtOAc-iso-Pr2O), [α]D 12.5° (dioxane).  VI (6.5 g.) in 130 ml. alc. hydrogenated over 1 g. 5% Pd-C at room temp. and 24 lb./sq. in. in the presence of 2 ml. NEt3 gave 4.05 g. 4-(3-methoxy-17β-hydroxy-1,3,5(10)-estratrien-17α-yl)butanoic acid (XII), m. 164-8.5° (decompn.) (EtOAc).  XII (3.1 g.) with 100 ml. p-MeC6H4SO3H in 500 ml. C6H6 slowly distd. to 100 ml., the soln. washed, dried, and distd. gave 1.5 g. lactone, m. 161-6° (EtOAc).  Procedure C was used on 10 g. X to give 4.8 g. 3-(3-oxo-17β-hydroxy-4-androsten-17α-yl)propanoic acid lactone (XIII), m. 148-50° (EtOAc), [α]D 76.5° (CHCl3), λ 241 mμ, ε 17,000.  Crude XI oxidized according to procedure C and the product chromatographed over silica gave 0.7 g. 4-(3-oxo-17β-hydroxy-4-androsten-17α-yl)butanoic acid lactone (XIV), m. 192-3° (EtOAc-iso-Pr2O), λ 240 mμ, ε 17,000, λ 5.77 μ.  V (7.8 g.) in 500 ml. tert-BuOH and 1 l. NH3 treated during 0.5 hr. with 8 g. Li, after 2 hrs. the Li had reacted, the NH3 evapd., the soln. quenched with 250 ml. H2O, alc. removed, soln. made acid, extd. with Et2O, the product in 50 ml. MeOH treated 1 hr. with 2 ml. HCl, and the crude product chromatographed on silica gave 0.14 g. 3-(3-oxo-17β-hydroxy-19-nor-4-androsten-17α-yl)propenoic acid lactone, m. 117-18° (EtOAc-iso-Pr2O), [α]D 55.2° (dioxane), λ 239.5 mμ, ε 18,700, λ 5.78 μ.  Elution with 15% EtOAc gave 1 g. 3-(3-oxo-17β-hydroxy-19-nor-4-androsten-17α-yl)propanoic acid lactone (XV), m. 135.5-7.10° (EtOAc), [α]D 22.7° (CHCl3), λ 240 mμ, ε 17,500.  V (124 g.) and 40.4 g. NEt3 in 1 l. alc. hydrogenated over 12.4 g. 5% Pd-C at 500 lb./sq. in. in 25 min., mixt. left 5 hrs. with 28 g. NaOH in 200 ml. MeOH, salt collected, rinsed with 100 ml. alc., and dried 12 hrs. at 75° in vacuo gave 116 g. Na 3-(3-methoxy-17β-hydroxy-1,3,5(10)-estratrien-17α-yl)propanoate (XVI).  The mother liquor from XVI evapd. and poured into dil. HCl gave 10 g. 3-methoxy-17β-hydroxy-1,3,5(10)-estratrien-17α-ylpropanoic acid, m. 150-2° (decompn.).  Heating this acid a few min. at 160° led to loss of H2O and conversion to X.  Lactonization may be achieved by treatment of a concd. soln. of the acid in alc. with small amt. of 3N HCl.  Procedure D was applied to 114 g. XVI in 3 l. H2O and the reaction mixt. acidified by addn. of 600 ml. AcOH; after 2 hrs. the solid was collected and this enol ether hydrolyzed 2 hrs. in 200 ml. HCl and 360 ml. H2O in 2 l. MeOH to give 79.1 g. crude XV.  Procedure D was followed on 3.7 g. XVI to the point where excess NH3 was evapd.; addn. of 250 ml. H2O produced a 2-phase soln., and the upper solvent layer was sepd., acidified, and dild. with H2O to give 0.470 g. 3-(3-oxo-17β-hydroxy-19-nor-5(10)-androsten-17α-yl)propanoic acid lactone, m. 173-7° (EtOAc).  Procedure D used on 6.9 g. XII, with the dil. aq. soln. contg. crude Li salt acidified with dil. HCl gave 1.45 g. 4-(3-oxo-17β-hydroxy-19-nor-5(10)-androsten-17α-yl)butanoic acid, m. 108-11° (EtOAc).  The EtOAc mother liquors evapd. to dryness, dissolved in 500 ml. C6H6, treated with 150 mg. p-MeC6H4SO3H, the soln. distd. to 100 ml. vol., washed, dried, and chromatographed on silica gel gave 84 mg. 4-(3-oxo-17β-hydroxy-19-nor-4-androsten-17α-yl)butanoic acid lactone, m. 143-5°, λ 240 mμ, ε 17,700.  XIII (1 g.) in 25 ml. EtOAc treated with H at atm. pressure at 30° in the presence of 0.2 g. 5% Pd-C and the crude product chromatographed over silica gave 0.50 g. 3-(3-oxo-17β-hydroxy-5α-androstan-17α-yl)propanoic acid lactone (XVII), m. 178-9° (EtOAc), [α]D 5.2° (CHCl3).  The later eluates gave 0.14 g. 3-(3-oxo-17β-hydroxy-5β-androstan-17α-yl)propanoic acid lactone, m. 183-5° (EtOAc), [α]D 6.8° (CHCl3).  XIV (7.5 g.) similarly hydrogenated over 1.5 g. 5% Pd-C in alc. and the crude product chromatographed on silica gave 260 mg. 4-(3-oxo-17β-hydroxy-5α-androstan-17α-yl)butanoic acid lactone, white needles, m. 191-3° (EtOAc-iso-Pr2O), [α]D 30° (CHCl3).  Late in the 10% EtOAc eluate 1.7 g. crude 4-(3-oxo-17β-hydroxy-5β-androstan-17α-yl)butanoic acid lactone was collected, m. 196-7°, [α]D 28.6° (CHCl3).  XV (6 g.) in 100 ml. EtOAc at 30° treated with H at atm. pressure in the presence of 1 g. 5% Pd-C, soln. filtered, evapd. to dryness, and the residue chromatographed over silica gave 0.45 g. 3-(3-oxo17β-hydroxy-19-nor-5α-androstan-17α-yl)propanoic acid lactone (XVIII), m. 198-201° (EtOAc), [α]D 9.7° (dioxane).  The middle fractions of this eluate contd. a mixt. of XVIII and 3-(3-oxo-17β-hydroxy-19-nor-5β-androstan- 17α-yl)propanoic acid lactone (XIX).  Pure XIX was obtained by crystn., m. 218-22° (EtOAc), [α]D 0.0° (dioxane).  X (0.6 g.) in 20 ml. alc. treated with H at 24° over 0.1 g. 5% Pd-C for 7 hrs. gave 0.40 g. 3-(3-β,17β-dihydroxy-5α-androstan-17α-yl)propanoic acid lactone (XX), m. 199-201° (EtOAc), [α]D -20.0° (CHCl3).  Procedure C used on 10 g. XX gave 7.1 g. XVII.  XV (1.5 g.) in 50 ml. tert-BuOH, 50 ml. tetrahydrofuran, and 150 ml. NH3 treated with Li, the solvents removed, the residue treated with H2O, and made strongly acid, and the ppt. suspended in 150 ml. Me2CO and treated with 3.5 ml. 6N CrO3-H2SO4 gave 0.65 g. XVIII.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgALduxRvOZLVg90H21EOLACvtfcHk0ljhxiRobZIBhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF3cXisVCm&md5=a3a2c2b196c3331bafdcfd087035aa1d</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fjo01088a004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo01088a004%26sid%3Dliteratum%253Aachs%26aulast%3DCella%26aufirst%3DJ.%2BA.%26aulast%3DBrown%26aufirst%3DE.%2BA.%26aulast%3DBurtner%26aufirst%3DR.%2BR.%26atitle%3DSteroidal%2520Aldosterone%2520Blockers.%2520I.%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1959%26volume%3D24%26issue%3D6%26spage%3D743%26epage%3D748%26doi%3D10.1021%2Fjo01088a004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cella, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tweit, R. C.</span></span> <span> </span><span class="NLM_article-title">Steroidal Aldosterone Blockers. II1</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1959</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1109</span>– <span class="NLM_lpage">1110</span>, <span class="refDoi"> DOI: 10.1021/jo01090a019</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo01090a019" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADyaF3cXivV2mtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1959&pages=1109-1110&issue=8&author=J.+A.+Cellaauthor=R.+C.+Tweit&title=Steroidal+Aldosterone+Blockers.+II1&doi=10.1021%2Fjo01090a019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Steroidal aldosterone blockers. II</span></div><div class="casAuthors">Cella, John A.; Tweit, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1959</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1109-10</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    </div><div class="casAbstract">The synthesis and biol. activities of several new steroidal 17-spirolactones were presented.  Introduction of unsatn. and the acylthio grouping enhanced oral aldosterone blocking activity in this series of compds. 3-(3-Oxo-17β-hydroxy-4-androsten-17α-yl)propionic acid lactone (I) (50 g.) and 1 g. HgCl2 in 3 l. tert-BuOH and 30 ml. AcOH refluxed 8 hrs. under N with 17.8 g. selenious acid, a further portion of 17.8 g. selenious acid added, and refluxed an addnl. 13 hrs. gave 16.3 g. 3-(3-oxo-17β-hydroxy-1,4-androstadien-17α-yl)propionic acid (II), m. 179-80° (EtOAc), [α]D 22° (dioxane), λ 245 mμ, ε 14,900.  I (2.5 g.), 2.5 g. chloranil, and 0.025 g. p-MeC6H4SO3H.H2O in 250 ml. xylene refluxed 20 hrs., the residue taken up in C6H6, and chromatographed on silica gave 0.44 g. 3-(3-oxo-17β-hydroxy-4,6-androstadien-16α-yl)propionic acid lactone (III), m. 149-51° (EtOAc), [α]D 24.5°, λ 283 mμ, ε 26,700.  3-(3-Oxo-17β-hydroxy-19-nor-4-androsten-17α-yl)propionic acid lactone (4.05 g.), 3.34 g. chloranil, and 0.01 g. p-MeC6H4SO3H.H2O in 400 ml. xylene refluxed 1 hr. and the crude product chromatographed on silica gel gave 0.26 g. 3-(3-oxo-17β-hydroxy-19-nor-4,6-androstadien-17α-yl)propionic acid lactone (IV), m. 235-9° (EtOAc), [α]D -44°, λ 283 mμ, ε 27,000.  III (0.34 g.) treated with a total of 0.155 g. selenious acid in 50 ml. tert-BuOH contg. 0.5 ml. AcOH and the product chromatographed over silica gave 0.05 g. 3-(3-oxo-17β-hydroxy-1,4,6-androstatrien-17α-yl)propionic acid lactone, m. 97-100° (decompn.), rem. 136-8°, [α]D 0°, λ 222 mμ, ε 11,100, λ 266 mμ, ε 10,700, λ 296 mμ, ε 13,700.  II (1 g.) in 1 ml. ethanethiolic acid heated 0.5 hr., part of the excess thiolic acid evapd. under N, the residue dissolved in EtOAc-Et2O, and cooled gave 0.40 g. 3-(3-oxo-1α-acetylthio-17β-hydroxy-4-androsten-17α-yl)propionic acid lactone, m. 199-200° (decompn.), [α]D 56°, λ 240.5 mμ, ε 16,200.  II (0.35 g.) in 0.5 ml. propanethiolic acid heated 1.25 hrs. on the steam bath and left overnight gave 0.08 g. 3-(3-oxo-1α-propionylthio-17β-hydroxy-4-androsten-17α-yl)propionic acid lactone, m. 176-8° (decompn.), λ 240.5 mμ, ε 16,500.  III (0.75 g.) in 0.75 ml. ethanethiolic acid heated 1 hr. gave 0.45 g. 3-(3-oxo-7α-acetylthio-17β-hydroxy-4-androsten-17α-yl)propionic acid, m. 134-5°, resolidified and m. 201-2° (decompn.), [α]D -33.5°, λ 238 mμ, ε 20,200.  III (0.65 g.) in 0.5 ml. propanethiolic acid similarly heated 0.5 hr. gave 0.34 g. 3-(3oxo-7α-propionylthio-17β-hydroxy-4-androsten-17α-yl)propionic acid lactone, m. 192-4° (decompn.), [α]D -37°, λ 238 mμ, ε 19,800.  IV (170 mg.) in 0.5 ml. ethanethiolic acid heated 1.5 hrs. gave 87 mg. 3-(3-oxo-7α-acetylthio-17β-hydroxy-19-nor-4-androsten-17α-yl)propionic acid lactone, m. 111-13°, λ 237 mμ, ε 21,000.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSYmaV8LxsBbVg90H21EOLACvtfcHk0lhiYwdDi3LiBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF3cXivV2mtA%253D%253D&md5=de8871136b0ddde6ec0af6a7c5383480</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fjo01090a019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo01090a019%26sid%3Dliteratum%253Aachs%26aulast%3DCella%26aufirst%3DJ.%2BA.%26aulast%3DTweit%26aufirst%3DR.%2BC.%26atitle%3DSteroidal%2520Aldosterone%2520Blockers.%2520II1%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1959%26volume%3D24%26issue%3D8%26spage%3D1109%26epage%3D1110%26doi%3D10.1021%2Fjo01090a019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quintavalla, A.</span></span> <span> </span><span class="NLM_article-title">Spirolactones: Recent Advances in Natural Products, Bioactive Compounds and Synthetic Strategies</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">917</span>– <span class="NLM_lpage">962</span>, <span class="refDoi"> DOI: 10.2174/0929867324666171106162259</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.2174%2F0929867324666171106162259" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=29110593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntVCku74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=917-962&issue=8&author=A.+Quintavalla&title=Spirolactones%3A+Recent+Advances+in+Natural+Products%2C+Bioactive+Compounds+and+Synthetic+Strategies&doi=10.2174%2F0929867324666171106162259"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Spirolactones: Recent Advances in Natural Products, Bioactive Compounds and Synthetic Strategies</span></div><div class="casAuthors">Quintavalla, Arianna</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">917-962</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Background: The spirocyclic compds. have always aroused a great interest because this motif is present as structural core in a no. of natural products and bioactive compds.  In particular, the spirolactone moiety has been recognized in a wide array of natural and non-natural scaffolds showing a variety of useful pharmacol. properties.  Methods: Extensive literature search using SciFinder (Databases: CA Plus, CAS Registry, CAS React, Chemlist, Chemcat and Medline) and Web of Science (Database: Web of Science Core Collection) was conducted.  Results: Nowadays, many efforts are being devoted to the discovery of new natural products contg. the promising spirolactone framework and to the disclosure of the potential bioactivities of these chem. entities.  Moreover, the medicinal relevance of many spirolactones makes these scaffolds attractive targets for the design and development of innovative and efficient synthetic strategies, enabling the construction of complex and variably substituted products.  Conclusion: This review gives an overview on the recent advances in the spirolactones field, in terms of new compds. isolated from natural sources, recently detd. bioactivity profiles and innovative synthetic approaches.  The collected data demonstrate the key role played by spirolactones in medicinal chem. and the great attention still devoted by the scientific community to these compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKLtKKJM1H-bVg90H21EOLACvtfcHk0lhiYwdDi3LiBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntVCku74%253D&md5=a58880c41c26fb3a9c3356bb5d68b1b0</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.2174%2F0929867324666171106162259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867324666171106162259%26sid%3Dliteratum%253Aachs%26aulast%3DQuintavalla%26aufirst%3DA.%26atitle%3DSpirolactones%253A%2520Recent%2520Advances%2520in%2520Natural%2520Products%252C%2520Bioactive%2520Compounds%2520and%2520Synthetic%2520Strategies%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2018%26volume%3D25%26issue%3D8%26spage%3D917%26epage%3D962%26doi%3D10.2174%2F0929867324666171106162259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollow, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garfield, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, S. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillisch, A.</span></span> <span> </span><span class="NLM_article-title">Conception and Pharmacodynamic Profile of Drospirenone</span>. <i>Steroids</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>68</i></span> (<span class="NLM_issue">10–13</span>),  <span class="NLM_fpage">891</span>– <span class="NLM_lpage">905</span>, <span class="refDoi"> DOI: 10.1016/j.steroids.2003.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2Fj.steroids.2003.08.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=14667981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BD3sXps1Olurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2003&pages=891-905&issue=10%E2%80%9313&author=W.+Elgerauthor=S.+Beierauthor=K.+Pollowauthor=R.+Garfieldauthor=S.+Q.+Shiauthor=A.+Hillisch&title=Conception+and+Pharmacodynamic+Profile+of+Drospirenone&doi=10.1016%2Fj.steroids.2003.08.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Conception and pharmacodynamic profile of drospirenone</span></div><div class="casAuthors">Elger, Walter; Beier, Sybille; Pollow, Kunhard; Garfield, Robert; Shi, Shao Qing; Hillisch, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Steroids</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">10-13</span>),
    <span class="NLM_cas:pages">891-905</span>CODEN:
                <span class="NLM_cas:coden">STEDAM</span>;
        ISSN:<span class="NLM_cas:issn">0039-128X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Progesterone is more than a progestin.  Beyond functions in cycle and pregnancy, progesterone binds with high affinity to the mineralocorticoid receptor (MR) acting as an antagonist, with obvious significance for electrolyte homeostasis, an array of MR-related functions in the circulation as well as in the CNS.  Progesterone induces natriuresis at physiol. concns.  Lack of anti-mineralocorticoid activity with conventional progestins may account for sodium and water retention, minor elevation of blood pressure and "pill hypertension" in susceptible women on oral contraceptives.  Ethinylestradiol (EE) contributes to this problem by distinct activation of the renin-angiotensin-aldosterone (RAAS) system.  Drospirenone (DRSP: 6β,7β,15β,16β-dimethylene-3-oxo 17α-pregn-4-ene-21,17 carbolactone) is the first synthetic progestin with anti-aldosterone activity.  DRSP and progesterone bind to PR in uterine (affinity of both is about 30% of R5020) and MR in kidney cytosol (affinity about 230 and 100% of aldosterone, resp.).  Intrauterine administration of DRSP in silastic tubes induced max. local progestational effects in rabbits.  At systemic s.c. administration (McPhail-assay) full endometrial transformation was obtained at 1 mg per animal per day.  At 1-3 mg DRSP per animal per day s.c., pregnancy maintenance after ovariectomy, antiovulatory activity, and anti-mineralocorticoid activity were seen in the resp. assays in rats.  The latter activity indicates about eight-fold higher potency than spironolactone.  DRSP decreased blood pressure in male hypertensive rats, whereas an increase was noted under conventional progestins.  DRSP also prevented hypertension and fetal growth retardation in pregnant rats after l-NAME, an inhibitor of nitric oxide synthase.  DRSP has antiandrogenic activity.  Feminizing effects were recorded during sexual differentiation in male fetuses at high doses.  Powerful antiandrogenic effects were also seen in gonad intact and testosterone substituted castrated male rats.  The antiandrogenic potency of DRSP is superior to that of spironolactone but below that of cyproterone acetate.  Endometrial transformation, inhibition of ovulation, and anti-mineralocorticoid, i.e. natriuretic effects and mild antiandrogenic effects were recorded at the same range of oral doses (0.5-4 mg per day) in humans.  Combined with EE (3 mg DRSP + 30 μg EE), DRSP provides effective inhibition of ovulation and cycle control.  Body wt. compared to conventional oral contraceptives was reduced.  DRSP (3 mg per day + 15, 20, or 30 μg ethinyl estradiol per day) prevented the mild increase of blood pressure seen under a conventional levonorgestrel-contg. contraceptive and even tended to reduce pretreatment blood pressure.  Studies on modulation (i.e. inhibition) of glucocorticoid effects at the MR in the CNS remain an unexplored and interesting area for research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoW2WqlqLlZP7Vg90H21EOLACvtfcHk0lhiYwdDi3LiBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXps1Olurs%253D&md5=8e50f46e00c8e5eb819af6f0f10156b8</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.steroids.2003.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.steroids.2003.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DElger%26aufirst%3DW.%26aulast%3DBeier%26aufirst%3DS.%26aulast%3DPollow%26aufirst%3DK.%26aulast%3DGarfield%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DS.%2BQ.%26aulast%3DHillisch%26aufirst%3DA.%26atitle%3DConception%2520and%2520Pharmacodynamic%2520Profile%2520of%2520Drospirenone%26jtitle%3DSteroids%26date%3D2003%26volume%3D68%26issue%3D10%25E2%2580%259313%26spage%3D891%26epage%3D905%26doi%3D10.1016%2Fj.steroids.2003.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chupakhin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babich, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prosekov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asyakina, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krasavin, M.</span></span> <span> </span><span class="NLM_article-title">Spirocyclic Motifs in Natural Products</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">4165</span>, <span class="refDoi"> DOI: 10.3390/molecules24224165</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.3390%2Fmolecules24224165" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlyrsb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=4165&issue=22&author=E.+Chupakhinauthor=O.+Babichauthor=A.+Prosekovauthor=L.+Asyakinaauthor=M.+Krasavin&title=Spirocyclic+Motifs+in+Natural+Products&doi=10.3390%2Fmolecules24224165"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Spirocyclic motifs in natural products</span></div><div class="casAuthors">Chupakhin, Evgeny; Babich, Olga; Prosekov, Alexander; Asyakina, Lyudmila; Krasavin, Mikhail</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">4165</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Spirocyclic motifs are emerging privileged structures for drug discovery.  They are also omnipresent in the natural products domain.  However, until today, no attempt to analyze the structural diversity of various spirocyclic motifs occurring in natural products and their relative populations with unique compds. reported in the literature has been undertaken.  This review aims to fill that void and analyze the diversity of structurally unique natural products contg. spirocyclic moieties of various sizes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGri8MkVeKg0lrVg90H21EOLACvtfcHk0lhE5FCI_dZHQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlyrsb3N&md5=45ccad33af7d4da522b9118263fefb5b</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.3390%2Fmolecules24224165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules24224165%26sid%3Dliteratum%253Aachs%26aulast%3DChupakhin%26aufirst%3DE.%26aulast%3DBabich%26aufirst%3DO.%26aulast%3DProsekov%26aufirst%3DA.%26aulast%3DAsyakina%26aufirst%3DL.%26aulast%3DKrasavin%26aufirst%3DM.%26atitle%3DSpirocyclic%2520Motifs%2520in%2520Natural%2520Products%26jtitle%3DMolecules%26date%3D2019%26volume%3D24%26issue%3D22%26spage%3D4165%26doi%3D10.3390%2Fmolecules24224165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tice, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, S. B.</span></span> <span> </span><span class="NLM_article-title">The Use of Spirocyclic Scaffolds in Drug Discovery</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">3673</span>– <span class="NLM_lpage">3682</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.06.081</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2Fj.bmcl.2014.06.081" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=25052427" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFykt7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=3673-3682&issue=16&author=Y.+Zhengauthor=C.+M.+Ticeauthor=S.+B.+Singh&title=The+Use+of+Spirocyclic+Scaffolds+in+Drug+Discovery&doi=10.1016%2Fj.bmcl.2014.06.081"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The use of spirocyclic scaffolds in drug discovery</span></div><div class="casAuthors">Zheng, Yajun; Tice, Colin M.; Singh, Suresh B.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3673-3682</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Owing to their inherent three-dimensionality and structural novelty, spiro scaffolds have been increasingly utilized in drug discovery.  In this brief review, we highlight selected examples from the primary medicinal chem. literature during the last three years to demonstrate the versatility of spiro scaffolds.  With recent progress in synthetic methods providing access to spiro building blocks, spiro scaffolds are likely to be used more frequently in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqzTjJrsRkyLVg90H21EOLACvtfcHk0lhE5FCI_dZHQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFykt7bM&md5=9a2a644cf2b97edf7876b43b6457f6d5</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.06.081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.06.081%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DTice%26aufirst%3DC.%2BM.%26aulast%3DSingh%26aufirst%3DS.%2BB.%26atitle%3DThe%2520Use%2520of%2520Spirocyclic%2520Scaffolds%2520in%2520Drug%2520Discovery%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26issue%3D16%26spage%3D3673%26epage%3D3682%26doi%3D10.1016%2Fj.bmcl.2014.06.081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tice, C. M.</span></span> <span> </span><span class="NLM_article-title">The Utilization of Spirocyclic Scaffolds in Novel Drug Discovery</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">831</span>– <span class="NLM_lpage">834</span>, <span class="refDoi"> DOI: 10.1080/17460441.2016.1195367</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1080%2F17460441.2016.1195367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=27233084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252FktVGkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=831-834&issue=9&author=Y.-J.+Zhengauthor=C.+M.+Tice&title=The+Utilization+of+Spirocyclic+Scaffolds+in+Novel+Drug+Discovery&doi=10.1080%2F17460441.2016.1195367"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The utilization of spirocyclic scaffolds in novel drug discovery</span></div><div class="casAuthors">Zheng Ya-Jun; Tice Colin M</div><div class="citationInfo"><span class="NLM_cas:title">Expert opinion on drug discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">831-4</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTYAtKgZnFeprYtC3U5jeOifW6udTcc2eawct39RLohTbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252FktVGkug%253D%253D&md5=a736a7ecb934f323069bef58eaed9bbe</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1080%2F17460441.2016.1195367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17460441.2016.1195367%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DY.-J.%26aulast%3DTice%26aufirst%3DC.%2BM.%26atitle%3DThe%2520Utilization%2520of%2520Spirocyclic%2520Scaffolds%2520in%2520Novel%2520Drug%2520Discovery%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2016%26volume%3D11%26issue%3D9%26spage%3D831%26epage%3D834%26doi%3D10.1080%2F17460441.2016.1195367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benabdallah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talhi, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nouali, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choukchou-Braham, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachari, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, A. M. S.</span></span> <span> </span><span class="NLM_article-title">Advances in Spirocyclic Hybrids: Chemistry and Medicinal Actions</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">31</span>),  <span class="NLM_fpage">3748</span>– <span class="NLM_lpage">3767</span>, <span class="refDoi"> DOI: 10.2174/0929867325666180309124821</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.2174%2F0929867325666180309124821" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=29521213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFWjsrbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=3748-3767&issue=31&author=M.+Benabdallahauthor=O.+Talhiauthor=F.+Noualiauthor=N.+Choukchou-Brahamauthor=K.+Bachariauthor=A.+M.+S.+Silva&title=Advances+in+Spirocyclic+Hybrids%3A+Chemistry+and+Medicinal+Actions&doi=10.2174%2F0929867325666180309124821"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in Spirocyclic Hybrids: Chemistry and Medicinal Actions</span></div><div class="casAuthors">Benabdallah, Mohammed; Talhi, Oualid; Nouali, Fatiha; Choukchou-Braham, Nouredine; Bachari, Khaldoun; Silva, Artur M. S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">3748-3767</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">The present review deals with the progress in medicinal chem. of spirocyclic compds., a wider class of natural and synthetic org. mols., defined as a hybrid of two mol. entities covalently linked via a unique tetrahedral carbon.  This spiro central carbon confers to the mols. a tridimensional structurally oriented framework, which is found in many medicinally relevant compds., a well-known example is the antihypertensive spironolactone.  Various bioactive natural products possess the privileged spiro linkage and different chemo-types thereof become synthetically accessible since the 20th century.  Actually, there has been a growing interest in the synthesis of heterocyclic hybrids gathered via a spiro carbon.  Most of these combinations are two moieties in one scaffold being able to interfere with biol. systems through sequential mechanisms.  Spirocyclic hybrids contg. indole or oxindole units are compds. exhibiting higher interaction with biol. receptors by protein inhibition or enzymic pathways and their recognition as promising anticancer agents in targeted chemotherapy is foreseen.  These specific, low-wt. and noncomplex spirocyclic hybrids are potent inhibitors of SIRT1, Mdm2-p53 and PLK4, showing affinity for anaplastic lymphoma kinase (ALK) receptor.  They are also known as excellent DNA binders, acting on cellular division by arresting the cell cycle at different phases and inducing apoptotic cell death.  A structural diversity of spirocyclic hybrids has proved neuroprotective effects, anti-HIV, antiviral and antibacterial activities.  Hundred of papers are mentioned in this review underlying chem. issues and pharmacol. potencies of spiro compds., which render them impressive synthetic hits for innovative drug conception.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1fwEbDhLz47Vg90H21EOLACvtfcHk0lj3lt6_mz082Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFWjsrbJ&md5=ac62940ca3a589d38314883855772c66</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.2174%2F0929867325666180309124821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867325666180309124821%26sid%3Dliteratum%253Aachs%26aulast%3DBenabdallah%26aufirst%3DM.%26aulast%3DTalhi%26aufirst%3DO.%26aulast%3DNouali%26aufirst%3DF.%26aulast%3DChoukchou-Braham%26aufirst%3DN.%26aulast%3DBachari%26aufirst%3DK.%26aulast%3DSilva%26aufirst%3DA.%2BM.%2BS.%26atitle%3DAdvances%2520in%2520Spirocyclic%2520Hybrids%253A%2520Chemistry%2520and%2520Medicinal%2520Actions%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2018%26volume%3D25%26issue%3D31%26spage%3D3748%26epage%3D3767%26doi%3D10.2174%2F0929867325666180309124821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cortijo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naline, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berto, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girard, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malbezin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Advenier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morcillo, E. J.</span></span> <span> </span><span class="NLM_article-title">Effects of Fenspiride on Human Bronchial Cyclic Nucleotide Phosphodiesterase Isoenzymes: Functional and Biochemical Study</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>341</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">79</span>– <span class="NLM_lpage">86</span>, <span class="refDoi"> DOI: 10.1016/S0014-2999(97)01439-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2FS0014-2999%2897%2901439-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=9489859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADyaK1cXjslelug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=1998&pages=79-86&issue=1&author=J.+Cortijoauthor=E.+Nalineauthor=J.+L.+Ortizauthor=L.+Bertoauthor=V.+Girardauthor=M.+Malbezinauthor=C.+Advenierauthor=E.+J.+Morcillo&title=Effects+of+Fenspiride+on+Human+Bronchial+Cyclic+Nucleotide+Phosphodiesterase+Isoenzymes%3A+Functional+and+Biochemical+Study&doi=10.1016%2FS0014-2999%2897%2901439-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of fenspiride on human bronchial cyclic nucleotide phosphodiesterase isoenzymes: Functional and biochemical study</span></div><div class="casAuthors">Cortijo, Julio; Naline, Enmanuel; Ortiz, Jose L.; Berto, Luisa; Girard, Valerie; Malbezin, Muriel; Advenier, Charles; Morcillo, Esteban J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">79-86</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">We have investigated the role of human bronchial cyclic nucleotide phosphodiesterases in the effects of fenspiride, a drug endowed with bronchodilator and anti-inflammatory properties.  Functional studies on human isolated bronchi showed that fenspiride (10-6-3×10-3 M, 30 min) induced a shift to the left of the concn.-response curves for isoprenaline and sodium nitroprusside with -log EC50 values of 4.1±0.1 (n=7) and 3.5±0.2 (n=8), resp.  Biochem. studies were carried out on three human bronchi in which sepn. of cyclic nucleotide phosphodiesterase isoenzymes was performed by ion exchange chromatog. followed by detn. of phosphodiesterase activity with a radioisotopic method.  Phosphodiesterase 4 (cAMP-specific) and phosphodiesterase 5 (cyclic GMP-specific) were the major phosphodiesterase isoforms present in the human bronchial tissue.  The presence of phosphodiesterase 1 (Ca2+/calmodulin-stimulated), phosphodiesterase 2 (cyclic GMP-stimulated) and, in two cases, phosphodiesterase 3 (cyclic GMP-inhibited) was also identified.  Fenspiride inhibited phosphodiesterase 4 and phosphodiesterase 3 activities with -log IC50 values of 4.16±0.09 and 3.44±0.12, resp.  Phosphodiesterase 5 activity was also inhibited with a -log IC50 value of ∼3.8.  Fenspiride (≤10-3 M) produced less than 25% inhibition of phosphodiesterase 1 and phosphodiesterase 2 activities.  In conclusion, fenspiride is an effective inhibitor of both cAMP and cyclic GMP hydrolytic activity in human bronchial tissues and this action may contribute to its airway effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdsNvRk7RVU7Vg90H21EOLACvtfcHk0lj3lt6_mz082Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjslelug%253D%253D&md5=2c6e6d3363dc37b1ed08ae3594a15629</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2897%2901439-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252897%252901439-8%26sid%3Dliteratum%253Aachs%26aulast%3DCortijo%26aufirst%3DJ.%26aulast%3DNaline%26aufirst%3DE.%26aulast%3DOrtiz%26aufirst%3DJ.%2BL.%26aulast%3DBerto%26aufirst%3DL.%26aulast%3DGirard%26aufirst%3DV.%26aulast%3DMalbezin%26aufirst%3DM.%26aulast%3DAdvenier%26aufirst%3DC.%26aulast%3DMorcillo%26aufirst%3DE.%2BJ.%26atitle%3DEffects%2520of%2520Fenspiride%2520on%2520Human%2520Bronchial%2520Cyclic%2520Nucleotide%2520Phosphodiesterase%2520Isoenzymes%253A%2520Functional%2520and%2520Biochemical%2520Study%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1998%26volume%3D341%26issue%3D1%26spage%3D79%26epage%3D86%26doi%3D10.1016%2FS0014-2999%2897%2901439-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jankowski, R.</span></span> <span> </span><span class="NLM_article-title">[ENT Inflammation and Importance of Fenspiride]</span>. <i>Presse Med.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">Spec No 1</span>),  <span class="NLM_fpage">HS7-10</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=12378970" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2002&pages=HS7-10&issue=Spec+No+1&author=R.+Jankowski&title=%5BENT+Inflammation+and+Importance+of+Fenspiride%5D"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJankowski%26aufirst%3DR.%26atitle%3D%255BENT%2520Inflammation%2520and%2520Importance%2520of%2520Fenspiride%255D%26jtitle%3DPresse%2520Med.%26date%3D2002%26volume%3D31%26issue%3DSpec%2520No%25201%26spage%3DHS7-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kulakova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galkin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Southall, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marugan, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herzberg, O.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel Antigiardiasis Drug Candidates</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">7303</span>– <span class="NLM_lpage">7311</span>, <span class="refDoi"> DOI: 10.1128/AAC.03834-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1128%2FAAC.03834-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=25267663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVymsb3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=7303-7311&issue=12&author=L.+Kulakovaauthor=A.+Galkinauthor=C.+Z.+Chenauthor=N.+Southallauthor=J.+J.+Maruganauthor=W.+Zhengauthor=O.+Herzberg&title=Discovery+of+Novel+Antigiardiasis+Drug+Candidates&doi=10.1128%2FAAC.03834-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel antigiardiasis drug candidates</span></div><div class="casAuthors">Kulakova, Liudmila; Galkin, Andrey; Chen, Catherine Z.; Southall, Noel; Marugan, Juan J.; Zheng, Wei; Herzberg, Osnat</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">7303-7311, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Giardiasis is a severe intestinal parasitic disease caused by Giardia lamblia, which inflicts many people in poor regions and is the most common parasitic infection in the United States.  Current std. care drugs are assocd. with undesirable side effects, treatment failures, and an increasing incidence of drug resistance.  As follow-up to a high-throughput screening of an approved drug library, which identified compds. lethal to G. lamblia trophozoites, we have detd. the min. lethal concns. of 28 drugs and advanced 10 of them to in vivo studies in mice.  The results were compared to treatment with the std. care drug, metronidazole, in order to identify drugs with equal or better anti-Giardia activities.  Three drugs, fumagillin, carbadox, and tioxidazole, were identified.  These compds. were also potent against metronidazole-resistant human G. lamblia isolates (assemblages A and B), as detd. in in vitro assays.  Of these three compds., fumagillin is currently an orphan drug used within the European Union to treat microsporidiosis in immunocompromised individuals, whereas carbadox and tioxidazole are used in veterinary medicine.  A dose-dependent study of fumagillin in a giardiasis mouse model revealed that the ED of fumagillin was ∼100-fold lower than the metronidazole dose.  Therefore, fumagillin may be advanced to further studies as an alternative treatment for giardiasis when metronidazole fails.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobXV8bNxbN8rVg90H21EOLACvtfcHk0lj3lt6_mz082Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVymsb3E&md5=e7425b8ad898544b6e18f45293997f8b</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1128%2FAAC.03834-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.03834-14%26sid%3Dliteratum%253Aachs%26aulast%3DKulakova%26aufirst%3DL.%26aulast%3DGalkin%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DC.%2BZ.%26aulast%3DSouthall%26aufirst%3DN.%26aulast%3DMarugan%26aufirst%3DJ.%2BJ.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DHerzberg%26aufirst%3DO.%26atitle%3DDiscovery%2520of%2520Novel%2520Antigiardiasis%2520Drug%2520Candidates%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26issue%3D12%26spage%3D7303%26epage%3D7311%26doi%3D10.1128%2FAAC.03834-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henkin, J.</span></span> <span> </span><span class="NLM_article-title">Selective Inhibition of Endothelial Cell Proliferation by Fumagillin Is Not Due to Differential Expression of Methionine Aminopeptidases</span>. <i>J. Cell. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">465</span>– <span class="NLM_lpage">473</span>, <span class="refDoi"> DOI: 10.1002/(SICI)1097-4644(20000601)77:3<465::AID-JCB11>3.0.CO;2-M</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1002%2F%28SICI%291097-4644%2820000601%2977%3A3%3C465%3A%3AAID-JCB11%3E3.0.CO%3B2-M" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10760954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BD3cXivFWju7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2000&pages=465-473&issue=3&author=J.+Wangauthor=P.+Louauthor=J.+Henkin&title=Selective+Inhibition+of+Endothelial+Cell+Proliferation+by+Fumagillin+Is+Not+Due+to+Differential+Expression+of+Methionine+Aminopeptidases&doi=10.1002%2F%28SICI%291097-4644%2820000601%2977%3A3%3C465%3A%3AAID-JCB11%3E3.0.CO%3B2-M"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Selective inhibition of endothelial cell proliferation by fumagillin is not due to differential expression of methionine aminopeptidases</span></div><div class="casAuthors">Wang, Jieyi; Lou, Pingping; Henkin, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Biochemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">465-473</span>CODEN:
                <span class="NLM_cas:coden">JCEBD5</span>;
        ISSN:<span class="NLM_cas:issn">0730-2312</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The angiogenesis inhibitors fumagillin and TNP-470 selectively inhibit the proliferation of endothelial cells, as compared with most other cell types.  The mechanism of this selective inhibition remains uncertain, although methionine aminopeptidase-2 (MetAP2) has recently been found to be a target for fumagillin or TNP-470, which inactivates MetAP2 enzyme activity through covalent modification.  Primary cultures of human endothelial cells and six other non-endothelial cell types were treated with fumagillin to det. its effect on cell proliferation.  Only the growth of endothelial cells was completely inhibited at low concns. of fumagillin.  MetAP1 and MetAP2 levels in these cells were investigated to det. whether differential enzyme expression plays a role in the selective action of fumagillin.  Western blot anal. and RT-PCR data showed that MetAP1 and MetAP2 were both expressed in these different types of cells, thus, ruling out differential expression of MetAP1 and MetAP2 as an explanation for the cell specificity of fumagillin.  Expression of MetAP2, but not of MetAP1, is regulated.  Treatment of human microvascular endothelial cells (HMVEC) with fumagillin resulted in threefold increases of MetAP2 protein in the cells, while MetAP1 remained const.  Similar upregulation of MetAP2 by exposure to fumagillin was also obsd. in non-endothelial cells, eliminating this response as an explanation for cell specificity.  Taken together, these results indicate that while MetAP2 plays a crit. role in the effect of fumagillin on endothelial cell proliferation, differential endogenous expression or fumagillin-induced upregulation of methionine aminopeptidases is not responsible for this obsd. selective inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnEHBXHmConLVg90H21EOLACvtfcHk0liU4m-w4ANcIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXivFWju7k%253D&md5=f05de66bc107cb486c48ee6a81991234</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291097-4644%2820000601%2977%3A3%3C465%3A%3AAID-JCB11%3E3.0.CO%3B2-M&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291097-4644%252820000601%252977%253A3%253C465%253A%253AAID-JCB11%253E3.0.CO%253B2-M%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLou%26aufirst%3DP.%26aulast%3DHenkin%26aufirst%3DJ.%26atitle%3DSelective%2520Inhibition%2520of%2520Endothelial%2520Cell%2520Proliferation%2520by%2520Fumagillin%2520Is%2520Not%2520Due%2520to%2520Differential%2520Expression%2520of%2520Methionine%2520Aminopeptidases%26jtitle%3DJ.%2520Cell.%2520Biochem.%26date%3D2000%26volume%3D77%26issue%3D3%26spage%3D465%26epage%3D473%26doi%3D10.1002%2F%28SICI%291097-4644%2820000601%2977%3A3%3C465%3A%3AAID-JCB11%3E3.0.CO%3B2-M" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. L.</span></span> <span> </span><span class="NLM_article-title">Sitafloxacin Hydrate for Bacterial Infections</span>. <i>Drugs Today</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>44</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">489</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1358/dot.2008.44.7.1219561</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1358%2Fdot.2008.44.7.1219561" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1ShtrfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2008&pages=489-501&issue=7&author=D.+L.+Anderson&title=Sitafloxacin+Hydrate+for+Bacterial+Infections&doi=10.1358%2Fdot.2008.44.7.1219561"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Sitafloxacin hydrate for bacterial infections</span></div><div class="casAuthors">Anderson, David Leif</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of Today</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">489-501</span>CODEN:
                <span class="NLM_cas:coden">MDACAP</span>;
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Sitafloxacin hydrate (DU-6859a, Gracevit), a new-generation, broad-spectrum oral fluoroquinolone that is very active against many Gram-pos., Gram-neg. and anaerobic clin. isolates, including strains resistant to other fluoroquinolones, was recently approved in Japan for the treatment of respiratory and urinary tract infections.  Sitafloxacin is active against methicillin-resistant staphylococci, Streptococcus pneumoniae and other streptococci with reduced susceptibility to levofloxacin and other quinolones and enterococci.  Sitafloxacin has also demonstrated activity against clin. isolates of Klebsiella pneumoniae (including about 67% of strains producing extended-spectrum, β-lactamases and resistant to ciprofloxacin), Enterobacter cloacae, Pseudomonas aeruginosa with some activity against quinolone-resistant strains and Acinetobacter baumannii.  The in vitro activity against anaerobes is comparable to imipenem or metronidazole.  In a published phase II randomized, open-label, multicenter study of patients hospitalized with pneumonia, sitafloxacin (400 mg once daily) was comparable to imipenem/cilastatin (500 mg three times a day).  Results of the phase III trials of sitafloxacin are not available in English.  The clin. safety profile of sitafloxacin has been characterized from 1,059 patients who participated in 10 clin. trials.  The most common events with 50 or 100 mg twice daily were gastrointestinal disorders (17.2%),mostly diarrhea, and abnormal lab. test results (16.2%), mostly liver enzyme elevations.  For Japanese patients, sitafloxacin provides the broad-spectrum coverage promised by clinafloxacin and trovafloxacin and comparable to carbapenems.  While it is currently limited by its potential for phototoxicity in Caucasians, phototoxicity is essentially irrelevant if sitafloxacin is used in hospitals and esp. in intensive care units.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIM0gx8FYiJ7Vg90H21EOLACvtfcHk0liU4m-w4ANcIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1ShtrfL&md5=87f8f6395c6e311bd8e634ef57d1cc44</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1358%2Fdot.2008.44.7.1219561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2008.44.7.1219561%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DD.%2BL.%26atitle%3DSitafloxacin%2520Hydrate%2520for%2520Bacterial%2520Infections%26jtitle%3DDrugs%2520Today%26date%3D2008%26volume%3D44%26issue%3D7%26spage%3D489%26epage%3D501%26doi%3D10.1358%2Fdot.2008.44.7.1219561" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okumura, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onodera, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoshino, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, T.</span></span> <span> </span><span class="NLM_article-title">Dual-Targeting Properties of the 3-Aminopyrrolidyl Quinolones, DC-159a and Sitafloxacin, against DNA Gyrase and Topoisomerase IV: Contribution to Reducing in Vitro Emergence of Quinolone-Resistant Streptococcus Pneumoniae</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">98</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.1093/jac/dkn136</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1093%2Fjac%2Fdkn136" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=18390884" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnt1Sms7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2008&pages=98-104&issue=1&author=R.+Okumuraauthor=T.+Hirataauthor=Y.+Onoderaauthor=K.+Hoshinoauthor=T.+Otaniauthor=T.+Yamamoto&title=Dual-Targeting+Properties+of+the+3-Aminopyrrolidyl+Quinolones%2C+DC-159a+and+Sitafloxacin%2C+against+DNA+Gyrase+and+Topoisomerase+IV%3A+Contribution+to+Reducing+in+Vitro+Emergence+of+Quinolone-Resistant+Streptococcus+Pneumoniae&doi=10.1093%2Fjac%2Fdkn136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae</span></div><div class="casAuthors">Okumura, Ryo; Hirata, Tsuyoshi; Onodera, Yoshikuni; Hoshino, Kazuki; Otani, Tsuyoshi; Yamamoto, Tomoko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">98-104</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">DC-159a (a novel quinolone) and sitafloxacin (DU-6859a) are structurally related quinolones, bearing a 3-aminopyrrolidyl substitution.  We investigated the relationship between the target preferences of these 3-aminopyrrolidyl quinolones, in vitro potencies and emergence of quinolone-resistant mutants in Streptococcus pneumoniae, compared with other quinolones.  MICs, resistance frequencies and mutant prevention concns. (MPCs) were detd. using quinolone-susceptible strains and first-step parC mutant strains of S. pneumoniae.  Target preferences were tested by the following two methods: antibacterial activities against gyrA or parC mutants and in vitro enzyme assays for the detn. of 50% inhibition (IC50) values.  DC-159a and sitafloxacin exhibited potent antibacterial activities, low frequencies of mutant selection, low MPCs and narrow mutant selection windows against both quinolone-susceptible strains and first-step parC mutants of S. pneumoniae, compared with gatifloxacin, moxifloxacin and other quinolones tested.  DC-159a and sitafloxacin showed relatively low MIC ratios against single gyrA or parC mutants relative to the wild-type strain and low IC50 ratios against DNA gyrase and topoisomerase IV.  Conclusions: DC-159a and sitafloxacin demonstrated a more balanced dual-targeting activity than gatifloxacin, moxifloxacin and other quinolones tested.  In addn., DC-159a and sitafloxacin have a lower propensity for selecting first- and second-step resistant mutants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWChG-7CogrbVg90H21EOLACvtfcHk0liU4m-w4ANcIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnt1Sms7Y%253D&md5=efd7a23d1718e54884b906bbc5fa464f</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkn136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkn136%26sid%3Dliteratum%253Aachs%26aulast%3DOkumura%26aufirst%3DR.%26aulast%3DHirata%26aufirst%3DT.%26aulast%3DOnodera%26aufirst%3DY.%26aulast%3DHoshino%26aufirst%3DK.%26aulast%3DOtani%26aufirst%3DT.%26aulast%3DYamamoto%26aufirst%3DT.%26atitle%3DDual-Targeting%2520Properties%2520of%2520the%25203-Aminopyrrolidyl%2520Quinolones%252C%2520DC-159a%2520and%2520Sitafloxacin%252C%2520against%2520DNA%2520Gyrase%2520and%2520Topoisomerase%2520IV%253A%2520Contribution%2520to%2520Reducing%2520in%2520Vitro%2520Emergence%2520of%2520Quinolone-Resistant%2520Streptococcus%2520Pneumoniae%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2008%26volume%3D62%26issue%3D1%26spage%3D98%26epage%3D104%26doi%3D10.1093%2Fjac%2Fdkn136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hess, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creese, I.</span></span> <span> </span><span class="NLM_article-title">Chronic Treatment with Dopamine Receptor Antagonists: Behavioral and Pharmacologic Effects on D1 and D2 Dopamine Receptors</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2361</span>– <span class="NLM_lpage">2370</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.08-07-02361.1988</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1523%2FJNEUROSCI.08-07-02361.1988" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=2907912" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADyaL1cXlt1agt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1988&pages=2361-2370&issue=7&author=E.+J.+Hessauthor=A.+B.+Normanauthor=I.+Creese&title=Chronic+Treatment+with+Dopamine+Receptor+Antagonists%3A+Behavioral+and+Pharmacologic+Effects+on+D1+and+D2+Dopamine+Receptors&doi=10.1523%2FJNEUROSCI.08-07-02361.1988"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic treatment with dopamine receptor antagonists:  behavioral and pharmacologic effects on D1 and D2 dopamine receptors</span></div><div class="casAuthors">Hess, Ellen J.; Norman, Andrew B.; Creese, Ian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2361-70</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    </div><div class="casAbstract">Chronic treatment with the D1 receptor-selective antagonist SCH23390 resulted in a significant and selective increase in the D1 dopamine receptor d. in brain tissue.  Likewise chronic treatment with the D2 dopamine receptor-selective antagonist spiperone selectively increased the D2 dopamine receptor d.  However, chronic treatment with the mixed D1/D2 receptor antagonist cis-flupentixol resulted in the up-regulation of D2 dopamine receptors only while the D1 dopamine receptor d. was unchanged.  In in vivo studies using N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline, which irreversibly inactivates D1 and D2 dopamine receptors, it was demonstrated that cis-flupentixol preferentially interacts with D2 dopamine receptors.  Rats were tested for their cataleptic response to the administered drug over the course of the chronic drug treatment.  Catalepsy scores of rats receiving spiperone decreased over the course of treatment, with a significant redn. in catalepsy occurring by treatment day 5.  The profound catalepsy obsd. in rats receiving SCH23390 did not change over the 21 days of treatment.  Rats receiving cis-flupentixol demonstrated tolerance to its cataleptogenic effects, with a significant redn. in catalepsy obsd. by treatment day 7.  During the 3 wk treatment, the time between drug injection and a full cataleptic response to cis-flupentixol increased from 20 to 60 min, suggesting a tolerance to the D2, but not D1, dopamine receptor antagonism by cis-flupentixol.  A group of rats treated with SCH23390 for 21 days received a final acute injection of spiperone on day 22.  These rats were as tolerant to the cataleptogenic effects of spiperone as were those rats tested on day 21 of chronic spiperone treatment.  Conversely, rats challenged with an acute dose of SCH23390 after 21 days spiperone treatment were profoundly cataleptic.  Thus, D2 dopamine receptor up-regulation is not necessary for the development of behavioral tolerance to D2 dopamine receptor antagonism, whereas behavioral tolerance to D1 dopamine receptor antagonism was not obsd. in these studies in spite of a D1 dopamine receptor up-regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsYyVHlEovXLVg90H21EOLACvtfcHk0lg_W4PzuCQS9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXlt1agt7o%253D&md5=5ea16645d476d29989832775cbcd0bca</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.08-07-02361.1988&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.08-07-02361.1988%26sid%3Dliteratum%253Aachs%26aulast%3DHess%26aufirst%3DE.%2BJ.%26aulast%3DNorman%26aufirst%3DA.%2BB.%26aulast%3DCreese%26aufirst%3DI.%26atitle%3DChronic%2520Treatment%2520with%2520Dopamine%2520Receptor%2520Antagonists%253A%2520Behavioral%2520and%2520Pharmacologic%2520Effects%2520on%2520D1%2520and%2520D2%2520Dopamine%2520Receptors%26jtitle%3DJ.%2520Neurosci.%26date%3D1988%26volume%3D8%26issue%3D7%26spage%3D2361%26epage%3D2370%26doi%3D10.1523%2FJNEUROSCI.08-07-02361.1988" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poole, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prossler, J. E.</span></span> <span> </span><span class="NLM_article-title">Tofogliflozin: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">939</span>– <span class="NLM_lpage">944</span>, <span class="refDoi"> DOI: 10.1007/s40265-014-0229-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1007%2Fs40265-014-0229-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=24848755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2cXoslCgsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=939-944&issue=8&author=R.+M.+Pooleauthor=J.+E.+Prossler&title=Tofogliflozin%3A+First+Global+Approval&doi=10.1007%2Fs40265-014-0229-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Tofogliflozin: First Global Approval</span></div><div class="casAuthors">Poole, Raewyn M.; Prossler, Jennifer E.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">939-944</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Tofogliflozin (Apleway, Deberza [Japan]), an orally active small mol. sodium-glucose co-transporter type 2 (SGLT2) inhibitor, has been developed by Chugai Pharmaceutical for the treatment of type 2 diabetes mellitus (T2DM), and a marketing authorization application was filed in Japan in 2013 by licensees Sanofi K.  K. and Kowa.  Tofogliflozin has received its first global approval for this indication in Japan as either monotherapy or in combination with other antihyperglycemic agents.  This article summarizes the milestones in the development of tofogliflozin leading to this first approval for the treatment of T2DM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoP5PjlYV_ierVg90H21EOLACvtfcHk0lg_W4PzuCQS9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXoslCgsrY%253D&md5=68c66f591167857548fb3b3fd6685f34</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1007%2Fs40265-014-0229-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-014-0229-1%26sid%3Dliteratum%253Aachs%26aulast%3DPoole%26aufirst%3DR.%2BM.%26aulast%3DProssler%26aufirst%3DJ.%2BE.%26atitle%3DTofogliflozin%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2014%26volume%3D74%26issue%3D8%26spage%3D939%26epage%3D944%26doi%3D10.1007%2Fs40265-014-0229-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alcaraz, L.</span>; <span class="NLM_string-name">Bailey, A.</span>; <span class="NLM_string-name">Kindon, N.</span></span> <span> </span><span class="NLM_article-title">Compounds - 801</span>. <span class="NLM_patent">WO2011012896A2</span>, February 3, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=L.+Alcaraz&author=A.+Bailey&author=N.+Kindon&title=Compounds+-+801"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAlcaraz%26aufirst%3DL.%26atitle%3DCompounds%2520-%2520801%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corey, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaykovsky, M.</span></span> <span> </span><span class="NLM_article-title">Dimethyloxosulfonium Methylide ((CH3)2SOCH2) and Dimethylsulfonium Methylide ((CH3)2SCH2). Formation and Application to Organic Synthesis</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1965</span>,  <span class="NLM_volume"><i>87</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1353</span>– <span class="NLM_lpage">1364</span>, <span class="refDoi"> DOI: 10.1021/ja01084a034</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja01084a034" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADyaF2MXntlGrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=1965&pages=1353-1364&issue=6&author=E.+J.+Coreyauthor=M.+Chaykovsky&title=Dimethyloxosulfonium+Methylide+%28%28CH3%292SOCH2%29+and+Dimethylsulfonium+Methylide+%28%28CH3%292SCH2%29.+Formation+and+Application+to+Organic+Synthesis&doi=10.1021%2Fja01084a034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Dimethyloxosulfonium methylide and dimethylsulfonium methylide. Formation and application to organic synthesis</span></div><div class="casAuthors">Corey, E. J.; Chaykovsky, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1965</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1353-64</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">The generation of dimethyloxosulfonium methylide (Me2SOCH2) and dimethylsulfonium methylide (Me2SCH2) as reactive intermediates is described.  Both ylides are nucleophiles and both function to transfer methylene to certain electrophilic unsatd. linkages, including C:O, C:N, C:S, and in certain cases, C:C.  The less reactive oxosulfonium ylide interacts with the carbonyl function of aromatic and nonconjugated aldehydes and ketones to form oxiranes and with α,β-unsatd. ketones which are Michael receptors to form cyclopropyl ketones.  The sulfonium ylide reacts with the same substrates to give oxiranes exclusively even with the α,β-unsatd. carbonyl systems.  These reactions are quite general and, therefore, of considerable practical value.  The stereochemistry of carbonyl addn. to cyclohexanones varies depending on the ylide; the oxosulfonium ylide reacts by equatorial addn. (i.e., of methylene) and the sulfonium ylide shows a preference for axial addn.  A no. of other reactions of these ylides are described including "over-all methylene insertion," and a differential comparison of their chem. properties is made.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqt0xfN-tNfFLVg90H21EOLACvtfcHk0lggs51kzYcsdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2MXntlGrtw%253D%253D&md5=ae22573e36db50409c7832e5950df7f1</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fja01084a034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja01084a034%26sid%3Dliteratum%253Aachs%26aulast%3DCorey%26aufirst%3DE.%2BJ.%26aulast%3DChaykovsky%26aufirst%3DM.%26atitle%3DDimethyloxosulfonium%2520Methylide%2520%2528%2528CH3%25292SOCH2%2529%2520and%2520Dimethylsulfonium%2520Methylide%2520%2528%2528CH3%25292SCH2%2529.%2520Formation%2520and%2520Application%2520to%2520Organic%2520Synthesis%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1965%26volume%3D87%26issue%3D6%26spage%3D1353%26epage%3D1364%26doi%3D10.1021%2Fja01084a034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stocks, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcaraz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowers, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donald, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kindon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pairaudeau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theaker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, D. J.</span></span> <span> </span><span class="NLM_article-title">The Discovery of New Spirocyclic Muscarinic M3 Antagonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">7458</span>– <span class="NLM_lpage">7461</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.10.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2Fj.bmcl.2010.10.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=21036043" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVKjtbrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=7458-7461&issue=24&author=M.+J.+Stocksauthor=L.+Alcarazauthor=A.+Baileyauthor=K.+Bowersauthor=D.+Donaldauthor=H.+Edwardsauthor=F.+Huntauthor=N.+Kindonauthor=G.+Pairaudeauauthor=J.+Theakerauthor=D.+J.+Warner&title=The+Discovery+of+New+Spirocyclic+Muscarinic+M3+Antagonists&doi=10.1016%2Fj.bmcl.2010.10.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery of new spirocyclic muscarinic M3 antagonists</span></div><div class="casAuthors">Stocks, Michael J.; Alcaraz, Lilian; Bailey, Andrew; Bowers, Keith; Donald, David; Edwards, Helen; Hunt, Fraser; Kindon, Nicholas; Pairaudeau, Garry; Theaker, Jill; Warner, Daniel J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7458-7461</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The optimization of a new series of spirocyclic high potency muscarinic M3 antagonists, e.g., I, derived from high throughput screening library hits, is described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKoe2HBqvb_7Vg90H21EOLACvtfcHk0lggs51kzYcsdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVKjtbrP&md5=4c90afe6e914d1becb38a9441b69d4d1</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.10.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.10.016%26sid%3Dliteratum%253Aachs%26aulast%3DStocks%26aufirst%3DM.%2BJ.%26aulast%3DAlcaraz%26aufirst%3DL.%26aulast%3DBailey%26aufirst%3DA.%26aulast%3DBowers%26aufirst%3DK.%26aulast%3DDonald%26aufirst%3DD.%26aulast%3DEdwards%26aufirst%3DH.%26aulast%3DHunt%26aufirst%3DF.%26aulast%3DKindon%26aufirst%3DN.%26aulast%3DPairaudeau%26aufirst%3DG.%26aulast%3DTheaker%26aufirst%3DJ.%26aulast%3DWarner%26aufirst%3DD.%2BJ.%26atitle%3DThe%2520Discovery%2520of%2520New%2520Spirocyclic%2520Muscarinic%2520M3%2520Antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26issue%3D24%26spage%3D7458%26epage%3D7461%26doi%3D10.1016%2Fj.bmcl.2010.10.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Volkova, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budkova, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filonova, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khristolyubova, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutuzova, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koroleva, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radzivil, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aminova, Z. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuchalin, A. G.</span></span> <span> </span><span class="NLM_article-title">Efficacy of Supplemental Anti-Inflammatory Therapy with Fenspiride in Chronic Obstructive and Nonobstructive Bronchitis</span>. <i>Clin. Drug Invest.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">257</span>– <span class="NLM_lpage">264</span>, <span class="refDoi"> DOI: 10.2165/00044011-200525040-00005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.2165%2F00044011-200525040-00005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=17523776" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1aiu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2005&pages=257-264&issue=4&author=L.+I.+Volkovaauthor=A.+A.+Budkovaauthor=N.+N.+Filonovaauthor=E.+I.+Khristolyubovaauthor=E.+B.+Kutuzovaauthor=N.+V.+Korolevaauthor=T.+T.+Radzivilauthor=Z.+R.+Aminovaauthor=A.+G.+Chuchalin&title=Efficacy+of+Supplemental+Anti-Inflammatory+Therapy+with+Fenspiride+in+Chronic+Obstructive+and+Nonobstructive+Bronchitis&doi=10.2165%2F00044011-200525040-00005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of supplemental anti-inflammatory therapy with fenspiride in chronic obstructive and nonobstructive bronchitis</span></div><div class="casAuthors">Volkova, L. I.; Budkova, A. A.; Filonova, N. N.; Khristolyubova, E. I.; Kutuzova, E. B.; Koroleva, N. V.; Radzivil, T. T.; Aminova, Z. R.; Chuchalin, A. G.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Drug Investigation</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">257-264</span>CODEN:
                <span class="NLM_cas:coden">CDINFR</span>;
        ISSN:<span class="NLM_cas:issn">1173-2563</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">Objective: The objective of this randomized, nonblind study was to assess the efficacy of fenspiride as complementary anti-inflammatory therapy in combination with ipratropium bromide in patients with chronic bronchitis (CB).  A comparison was made with ipratropium bromide alone, the generally accepted std. therapy for CB.  Methods and subjects: The study population comprised 20 patients with chronic obstructive bronchitis (COB) and 60 patients without signs of obstruction.  Fifty-one males (64%) and 29 females (36%) aged from 25 to 65 years were studied over a 6-mo treatment period.  Combined therapy with fenspiride (160 mg/day) and ipratropium bromide (160 μg/day) was prescribed to 39 patients (28 with CB and 11 with COB) for 6 mo, and monotherapy with ipratropium bromide (160 μg/day) was prescribed for 41 patients (32 with CB and nine with COB).  Results: The combined therapy group had a reduced intensity of dyspnoea, improvements in sputum nature and quantity of exudation, and a reduced intensity of coughing.  The monotherapy group showed redns. in sputum exudation and cough intensity.  Improvements in lung respiratory function were obsd. in both groups, but were greater in the combined therapy group of patients.  Reduced cytosis, percentage and abs. content of neutrophils, and abs. content of lymphocytes and eosinophils in induced sputum were obsd. with CB patients in the combined therapy group.  A reduced content of lymphocytes and an increase in macrophages were obsd. with CB patients in the monotherapy group.  A significant decline in tumor necrosis factor (TNF)-α content in sputum was obsd. with both therapeutic regimens, although a statistically significant decline in serum TNFα (10.85 ng/L to 5.58 ng/L; p = 0.03) and reduced interleukin-8 in sputum (311.94 ng/L to 122.02 ng/L; p = 0.027) were obsd. with patients given combined therapy.  Conclusion: The study showed greater efficacy of long-term treatment with fenspiride and ipratropium bromide compared with ipratropium bromide alone in patients with CB.  This combination regimen can be recommended for the redn. of inflammation and prevention of disease progression in patients with CB and may also be useful in patients with COB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGMt6oKsKK8bVg90H21EOLACvtfcHk0lggs51kzYcsdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1aiu7Y%253D&md5=99b4a9164bd287f0cfaf1a64badf9c15</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.2165%2F00044011-200525040-00005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00044011-200525040-00005%26sid%3Dliteratum%253Aachs%26aulast%3DVolkova%26aufirst%3DL.%2BI.%26aulast%3DBudkova%26aufirst%3DA.%2BA.%26aulast%3DFilonova%26aufirst%3DN.%2BN.%26aulast%3DKhristolyubova%26aufirst%3DE.%2BI.%26aulast%3DKutuzova%26aufirst%3DE.%2BB.%26aulast%3DKoroleva%26aufirst%3DN.%2BV.%26aulast%3DRadzivil%26aufirst%3DT.%2BT.%26aulast%3DAminova%26aufirst%3DZ.%2BR.%26aulast%3DChuchalin%26aufirst%3DA.%2BG.%26atitle%3DEfficacy%2520of%2520Supplemental%2520Anti-Inflammatory%2520Therapy%2520with%2520Fenspiride%2520in%2520Chronic%2520Obstructive%2520and%2520Nonobstructive%2520Bronchitis%26jtitle%3DClin.%2520Drug%2520Invest.%26date%3D2005%26volume%3D25%26issue%3D4%26spage%3D257%26epage%3D264%26doi%3D10.2165%2F00044011-200525040-00005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Somanathan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivero, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuñez, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellberg, L. H.</span></span> <span> </span><span class="NLM_article-title">Convenient Synthesis of 1-Oxa-3,8-Diazaspiro [4,5] Decan-2-Ones</span>. <i>Synth. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1483</span>– <span class="NLM_lpage">1487</span>, <span class="refDoi"> DOI: 10.1080/00397919408011753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1080%2F00397919408011753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADyaK2cXkvVeisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1994&pages=1483-1487&issue=10&author=R.+Somanathanauthor=I.+A.+Riveroauthor=G.+I.+Nu%C3%B1ezauthor=L.+H.+Hellberg&title=Convenient+Synthesis+of+1-Oxa-3%2C8-Diazaspiro+%5B4%2C5%5D+Decan-2-Ones&doi=10.1080%2F00397919408011753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Convenient synthesis of 1-oxa-3,8-diazaspiro[4,5]decan-2-ones</span></div><div class="casAuthors">Somanathan R.; Rivero, I. A.; Nunez, G. I.; Hellberg, L. H.</div><div class="citationInfo"><span class="NLM_cas:title">Synthetic Communications</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1483-7</span>CODEN:
                <span class="NLM_cas:coden">SYNCAV</span>;
        ISSN:<span class="NLM_cas:issn">0039-7911</span>.
    </div><div class="casAbstract">Addn. reaction of Me3SiCN to 4-pyridones in the presence of ZnI2 gave cyanosilylppiperidones I (n = 1, 2) which on LiAlH4 desilylation followed by cyclization with triphosgene gave title compds. II.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_qlswvUTT4rVg90H21EOLACvtfcHk0lhkgERn7sALKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXkvVeisb4%253D&md5=eacb59014595a46a1041666b17e19900</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1080%2F00397919408011753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00397919408011753%26sid%3Dliteratum%253Aachs%26aulast%3DSomanathan%26aufirst%3DR.%26aulast%3DRivero%26aufirst%3DI.%2BA.%26aulast%3DNu%25C3%25B1ez%26aufirst%3DG.%2BI.%26aulast%3DHellberg%26aufirst%3DL.%2BH.%26atitle%3DConvenient%2520Synthesis%2520of%25201-Oxa-3%252C8-Diazaspiro%2520%255B4%252C5%255D%2520Decan-2-Ones%26jtitle%3DSynth.%2520Commun.%26date%3D1994%26volume%3D24%26issue%3D10%26spage%3D1483%26epage%3D1487%26doi%3D10.1080%2F00397919408011753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taccone, I.</span></span> <span> </span><span class="NLM_article-title">Method for the Preparation of Derivatives of Spiro (4,5)-Decane and Derivatives Thus Obtained</span>. <span class="NLM_patent">US4028351A</span>, <span class="NLM_year">1977</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1977&author=I.+Taccone&title=Method+for+the+Preparation+of+Derivatives+of+Spiro+%284%2C5%29-Decane+and+Derivatives+Thus+Obtained"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTaccone%26aufirst%3DI.%26atitle%3DMethod%2520for%2520the%2520Preparation%2520of%2520Derivatives%2520of%2520Spiro%2520%25284%252C5%2529-Decane%2520and%2520Derivatives%2520Thus%2520Obtained%26date%3D1977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, R.</span>; <span class="NLM_string-name">Roger, C.</span>; <span class="NLM_string-name">Le, D. J.-C.</span></span> <span> </span><span class="NLM_article-title">1-Oxa-2-Oxo 3, 8-Diaza Spiro (4, 5) Decanes</span>. <span class="NLM_patent">US3399192A</span>, <span class="NLM_year">1968</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1968&author=R.+Gilbert&author=C.+Roger&author=D.+J.-C.+Le&title=1-Oxa-2-Oxo+3%2C+8-Diaza+Spiro+%284%2C+5%29+Decanes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGilbert%26aufirst%3DR.%26atitle%3D1-Oxa-2-Oxo%25203%252C%25208-Diaza%2520Spiro%2520%25284%252C%25205%2529%2520Decanes%26date%3D1968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Regnier, G.</span>; <span class="NLM_string-name">Guillonneau, C.</span>; <span class="NLM_string-name">Duhault, J.</span>; <span class="NLM_string-name">Lonchampt, M.</span></span> <span> </span><span class="NLM_article-title">Spiro (4,5) Decone Compounds</span>. <span class="NLM_patent">US4824836A</span>, <span class="NLM_year">1989</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1989&author=G.+Regnier&author=C.+Guillonneau&author=J.+Duhault&author=M.+Lonchampt&title=Spiro+%284%2C5%29+Decone+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRegnier%26aufirst%3DG.%26atitle%3DSpiro%2520%25284%252C5%2529%2520Decone%2520Compounds%26date%3D1989" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pramanik, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bapat, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotharkar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">More, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotrane, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaskar, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripathy, N. K.</span></span> <span> </span><span class="NLM_article-title">Nitro-Aldol Approach for Commercial Manufacturing of Fenspiride Hydrochloride</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1252</span>– <span class="NLM_lpage">1256</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.9b00022</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.9b00022" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1MXptFymt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2019&pages=1252-1256&issue=6&author=C.+Pramanikauthor=K.+Bapatauthor=P.+Patilauthor=S.+Kotharkarauthor=Y.+Moreauthor=D.+Gotraneauthor=S.+P.+Chaskarauthor=U.+Mahajanauthor=N.+K.+Tripathy&title=Nitro-Aldol+Approach+for+Commercial+Manufacturing+of+Fenspiride+Hydrochloride&doi=10.1021%2Facs.oprd.9b00022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Nitro-Aldol Approach for Commercial Manufacturing of Fenspiride Hydrochloride</span></div><div class="casAuthors">Pramanik, Chinmoy; Bapat, Kiran; Patil, Pradip; Kotharkar, Sandeep; More, Yogesh; Gotrane, Dinkar; Chaskar, Sudhir P.; Mahajan, Ulhas; Tripathy, Narendra K.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1252-1256</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An efficient, short manufg. process for fenspiride hydrochloride is reported.  Nitro-aldol condensation is the key reaction in the developed process.  Improved routes to key building blocks are demonstrated by expedient multikilogram prodn.  Hazardous reactions are avoided.  API produced following this new route meets the quality requirement NLT 99.70% purity by HPLC with any individual impurity NMT 0.10% with very good yield.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomLVnQCgqx4LVg90H21EOLACvtfcHk0lhkgERn7sALKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXptFymt7c%253D&md5=7bddbcba67ae65d44b1dec9fcf29825f</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.9b00022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.9b00022%26sid%3Dliteratum%253Aachs%26aulast%3DPramanik%26aufirst%3DC.%26aulast%3DBapat%26aufirst%3DK.%26aulast%3DPatil%26aufirst%3DP.%26aulast%3DKotharkar%26aufirst%3DS.%26aulast%3DMore%26aufirst%3DY.%26aulast%3DGotrane%26aufirst%3DD.%26aulast%3DChaskar%26aufirst%3DS.%2BP.%26aulast%3DMahajan%26aufirst%3DU.%26aulast%3DTripathy%26aufirst%3DN.%2BK.%26atitle%3DNitro-Aldol%2520Approach%2520for%2520Commercial%2520Manufacturing%2520of%2520Fenspiride%2520Hydrochloride%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2019%26volume%3D23%26issue%3D6%26spage%3D1252%26epage%3D1256%26doi%3D10.1021%2Facs.oprd.9b00022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cornec, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pers, J.-O.</span></span> <span> </span><span class="NLM_article-title">Sjögren’s Syndrome: Where Do We Stand, and Where Shall We Go?</span>. <i>J. Autoimmun.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">109</span>– <span class="NLM_lpage">114</span>, <span class="refDoi"> DOI: 10.1016/j.jaut.2014.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2Fj.jaut.2014.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=24612946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A280%3ADC%252BC2crisVSgsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2014&pages=109-114&author=D.+Cornecauthor=C.+Jaminauthor=J.-O.+Pers&title=Sj%C3%B6gren%E2%80%99s+Syndrome%3A+Where+Do+We+Stand%2C+and+Where+Shall+We+Go%3F&doi=10.1016%2Fj.jaut.2014.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Sjogren's syndrome: where do we stand, and where shall we go?</span></div><div class="casAuthors">Cornec Divi; Jamin Christophe; Pers Jacques-Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of autoimmunity</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">109-14</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Primary Sjogren's syndrome (pSS) is one of the most frequent autoimmune systemic diseases, mainly characterized by ocular and oral dryness due to the progressive destruction of lachrymal and salivary glands by an inflammatory process.  A noteworthy proportion of patients also features extraglandular manifestations, sometimes severe and life-threatening.  Until now, its management relies mostly on symptomatic interventions, long-term monitoring, and, in patients with severe systemic complications, immunosuppressive drugs can be provided.  However, recent years have seen great progresses in the understanding of the pathological processes of the disease.  The central role of regulatory lymphocytes, the implication of the type 1 interferon pathway in some patients or the importance of epigenetics have been highlighted.  New classification criteria have been recently published and have shed in light an international attempt for a better recognition of the patients, probably thanks to the development of new diagnostic procedures such as salivary gland ultrasonography.  To facilitate the detection of treatment efficacy in clinical trials and to help in determining which subgroups of patients would have benefits from intensive therapies, a better definition of activity scores and the availability of new prognostic markers are urgent.  Thereby, the development of future therapies should be based on specific molecular signatures that will enable a personalized management of each patient.  This review focuses on the most striking advances in the fields of pathophysiology, diagnosis and treatment of pSS, which generate a great hope for pSS patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSU4Ml3861NqBLDWw4HIq2sfW6udTcc2eYUdyOiymiKGbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2crisVSgsw%253D%253D&md5=fdba0d4200603f38bd917f7763590a8e</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.jaut.2014.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaut.2014.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DCornec%26aufirst%3DD.%26aulast%3DJamin%26aufirst%3DC.%26aulast%3DPers%26aufirst%3DJ.-O.%26atitle%3DSj%25C3%25B6gren%25E2%2580%2599s%2520Syndrome%253A%2520Where%2520Do%2520We%2520Stand%252C%2520and%2520Where%2520Shall%2520We%2520Go%253F%26jtitle%3DJ.%2520Autoimmun.%26date%3D2014%26volume%3D51%26spage%3D109%26epage%3D114%26doi%3D10.1016%2Fj.jaut.2014.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, A.</span>; <span class="NLM_string-name">Karton, I.</span>; <span class="NLM_string-name">Heldman, E.</span>; <span class="NLM_string-name">Levy, A.</span>; <span class="NLM_string-name">Grunfeld, Y.</span></span> <span> </span><span class="NLM_article-title">Derivatives of Quinuclidine</span>. <span class="NLM_patent">US4855290A</span>, <span class="NLM_year">1989</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1989&author=A.+Fisher&author=I.+Karton&author=E.+Heldman&author=A.+Levy&author=Y.+Grunfeld&title=Derivatives+of+Quinuclidine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFisher%26aufirst%3DA.%26atitle%3DDerivatives%2520of%2520Quinuclidine%26date%3D1989" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schunk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinze, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frormann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oberbörsch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundermann, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zemolka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Englberger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Germann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christoph, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kögel, B.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schröder, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harlfinger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kless, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schick, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonnenschein, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Potent Analgesic NOP and Opioid Receptor Agonist: Cebranopadol</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">857</span>– <span class="NLM_lpage">862</span>, <span class="refDoi"> DOI: 10.1021/ml500117c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500117c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVentLfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=857-862&issue=8&author=S.+Schunkauthor=K.+Linzauthor=C.+Hinzeauthor=S.+Frormannauthor=S.+Oberb%C3%B6rschauthor=B.+Sundermannauthor=S.+Zemolkaauthor=W.+Englbergerauthor=T.+Germannauthor=T.+Christophauthor=B.-Y.+K%C3%B6gelauthor=W.+Schr%C3%B6derauthor=S.+Harlfingerauthor=D.+Saundersauthor=A.+Klessauthor=H.+Schickauthor=H.+Sonnenschein&title=Discovery+of+a+Potent+Analgesic+NOP+and+Opioid+Receptor+Agonist%3A+Cebranopadol&doi=10.1021%2Fml500117c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent Analgesic NOP and Opioid Receptor Agonist: Cebranopadol</span></div><div class="casAuthors">Schunk, Stefan; Linz, Klaus; Hinze, Claudia; Frormann, Sven; Oberboersch, Stefan; Sundermann, Bernd; Zemolka, Saskia; Englberger, Werner; Germann, Tieno; Christoph, Thomas; Koegel, Babette-Y.; Schroeder, Wolfgang; Harlfinger, Stephanie; Saunders, Derek; Kless, Achim; Schick, Hans; Sonnenschein, Helmut</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">857-862</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In a previous communication, our efforts leading from 1 to the identification of spiro[cyclohexane-dihydropyrano[3,4-b]indole]-amine 2a as analgesic NOP and opioid receptor agonist were disclosed and their favorable in vitro and in vivo pharmacol. properties revealed.  We herein report our efforts to further optimize lead 2a, toward trans-6'-fluoro-4',9'-dihydro-N,N-dimethyl-4-phenyl-spiro[cyclohexane-1,1'(3'H)-pyrano[3,4-b]indol]-4-amine (cebranopadol, 3a), which is currently in clin. development for the treatment of severe chronic nociceptive and neuropathic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_oo_6lpPHoLVg90H21EOLACvtfcHk0lipnjGs6AhUDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVentLfL&md5=270b1eef8252dcae7ce2e84c17d78b81</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fml500117c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500117c%26sid%3Dliteratum%253Aachs%26aulast%3DSchunk%26aufirst%3DS.%26aulast%3DLinz%26aufirst%3DK.%26aulast%3DHinze%26aufirst%3DC.%26aulast%3DFrormann%26aufirst%3DS.%26aulast%3DOberb%25C3%25B6rsch%26aufirst%3DS.%26aulast%3DSundermann%26aufirst%3DB.%26aulast%3DZemolka%26aufirst%3DS.%26aulast%3DEnglberger%26aufirst%3DW.%26aulast%3DGermann%26aufirst%3DT.%26aulast%3DChristoph%26aufirst%3DT.%26aulast%3DK%25C3%25B6gel%26aufirst%3DB.-Y.%26aulast%3DSchr%25C3%25B6der%26aufirst%3DW.%26aulast%3DHarlfinger%26aufirst%3DS.%26aulast%3DSaunders%26aufirst%3DD.%26aulast%3DKless%26aufirst%3DA.%26aulast%3DSchick%26aufirst%3DH.%26aulast%3DSonnenschein%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520a%2520Potent%2520Analgesic%2520NOP%2520and%2520Opioid%2520Receptor%2520Agonist%253A%2520Cebranopadol%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26issue%3D8%26spage%3D857%26epage%3D862%26doi%3D10.1021%2Fml500117c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanter, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sui, Z.</span></span> <span> </span><span class="NLM_article-title">Silicon-Directed Oxa-Pictet-Spengler Cyclization and an Unusual Dimerization of 2-Trimethylsilanyl Tryptophols</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2043</span>– <span class="NLM_lpage">2046</span>, <span class="refDoi"> DOI: 10.1021/ol050623n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol050623n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtVOitrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=2043-2046&issue=10&author=X.+Zhangauthor=X.+Liauthor=J.+C.+Lanterauthor=Z.+Sui&title=Silicon-Directed+Oxa-Pictet-Spengler+Cyclization+and+an+Unusual+Dimerization+of+2-Trimethylsilanyl+Tryptophols&doi=10.1021%2Fol050623n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Silicon-Directed Oxa-Pictet-Spengler Cyclization and an Unusual Dimerization of 2-Trimethylsilanyl Tryptophols</span></div><div class="casAuthors">Zhang, Xuqing; Li, Xiaojie; Lanter, James C.; Sui, Zhihua</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2043-2046</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The tetrahydropyrano[3,4-b]indoles I (n = 1, 2; R1 = H, CN, Cl, NO2, F, CF3, CO2Me; R2 = H, CF3, Cl; R3 = Me; R4 = Me, MeS, EtS, BnS) were synthesized from 2-(2-trimethylsilanyl-1H-indol-3-yl)alkanols II and various ketones or aldehydes through silicon-directed oxa-Pictet-Spengler cyclizations.  An unusual reaction led to the dimeric products III when some of II was treated with acetone using BF3 as the catalyst.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN6Rri3huVu7Vg90H21EOLACvtfcHk0lgPSNRA0l1ORg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtVOitrs%253D&md5=75259d3e604c1568449e42ac8def0c47</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fol050623n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol050623n%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLanter%26aufirst%3DJ.%2BC.%26aulast%3DSui%26aufirst%3DZ.%26atitle%3DSilicon-Directed%2520Oxa-Pictet-Spengler%2520Cyclization%2520and%2520an%2520Unusual%2520Dimerization%2520of%25202-Trimethylsilanyl%2520Tryptophols%26jtitle%3DOrg.%2520Lett.%26date%3D2005%26volume%3D7%26issue%3D10%26spage%3D2043%26epage%3D2046%26doi%3D10.1021%2Fol050623n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pruehs, S.</span>; <span class="NLM_string-name">Griebel, C.</span>; <span class="NLM_string-name">Hell, W.</span></span> <span> </span><span class="NLM_article-title">Process for the Preparation of (1r,4r)-6’-Fluoro-(N,N-Dimethyl- and N-Methyl)-4-Phenyl-4’,9’-Dihydro-3’H-Spiro[Cyclohexane-1,1’-Pyrano-[3,4,b]Indol]-4-Amine</span>. <span class="NLM_patent">US20130150590A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=S.+Pruehs&author=C.+Griebel&author=W.+Hell&title=Process+for+the+Preparation+of+%281r%2C4r%29-6%E2%80%99-Fluoro-%28N%2CN-Dimethyl-+and+N-Methyl%29-4-Phenyl-4%E2%80%99%2C9%E2%80%99-Dihydro-3%E2%80%99H-Spiro%5BCyclohexane-1%2C1%E2%80%99-Pyrano-%5B3%2C4%2Cb%5DIndol%5D-4-Amine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPruehs%26aufirst%3DS.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520%25281r%252C4r%2529-6%25E2%2580%2599-Fluoro-%2528N%252CN-Dimethyl-%2520and%2520N-Methyl%2529-4-Phenyl-4%25E2%2580%2599%252C9%25E2%2580%2599-Dihydro-3%25E2%2580%2599H-Spiro%255BCyclohexane-1%252C1%25E2%2580%2599-Pyrano-%255B3%252C4%252Cb%255DIndol%255D-4-Amine%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rottmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, B. K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seitz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plouffe, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dharia, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González-Páez, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakshminarayana, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suwanarusk, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jegla, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, H.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosten, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dartois, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diagana, T. T.</span></span> <span> </span><span class="NLM_article-title">Spiroindolones, a Potent Compound Class for the Treatment of Malaria</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>329</i></span> (<span class="NLM_issue">5996</span>),  <span class="NLM_fpage">1175</span>– <span class="NLM_lpage">1180</span>, <span class="refDoi"> DOI: 10.1126/science.1193225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1126%2Fscience.1193225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=20813948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtV2hsr%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=329&publication_year=2010&pages=1175-1180&issue=5996&author=M.+Rottmannauthor=C.+McNamaraauthor=B.+K.+S.+Yeungauthor=M.+C.+S.+Leeauthor=B.+Zouauthor=B.+Russellauthor=P.+Seitzauthor=D.+M.+Plouffeauthor=N.+V.+Dhariaauthor=J.+Tanauthor=S.+B.+Cohenauthor=K.+R.+Spencerauthor=G.+E.+Gonz%C3%A1lez-P%C3%A1ezauthor=S.+B.+Lakshminarayanaauthor=A.+Gohauthor=R.+Suwanaruskauthor=T.+Jeglaauthor=E.+K.+Schmittauthor=H.-P.+Beckauthor=R.+Brunauthor=F.+Nostenauthor=L.+Reniaauthor=V.+Dartoisauthor=T.+H.+Kellerauthor=D.+A.+Fidockauthor=E.+A.+Winzelerauthor=T.+T.+Diagana&title=Spiroindolones%2C+a+Potent+Compound+Class+for+the+Treatment+of+Malaria&doi=10.1126%2Fscience.1193225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Spiroindolones, a Potent Compound Class for the Treatment of Malaria</span></div><div class="casAuthors">Rottmann, Matthias; McNamara, Case; Yeung, Bryan K. S.; Lee, Marcus C. S.; Zou, Bin; Russell, Bruce; Seitz, Patrick; Plouffe, David M.; Dharia, Neekesh V.; Tan, Jocelyn; Cohen, Steven B.; Spencer, Kathryn R.; Gonzalez-Paez, Gonzalo E.; Lakshminarayana, Suresh B.; Goh, Anne; Suwanarusk, Rossarin; Jegla, Timothy; Schmitt, Esther K.; Beck, Hans-Peter; Brun, Reto; Nosten, Francois; Renia, Laurent; Dartois, Veronique; Keller, Thomas H.; Fidock, David A.; Winzeler, Elizabeth A.; Diagana, Thierry T.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">329</span>
        (<span class="NLM_cas:issue">5996</span>),
    <span class="NLM_cas:pages">1175-1180</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Recent reports of increased tolerance to artemisinin derivs.-the most recently adopted class of antimalarials-have prompted a need for new treatments.  The spirotetrahydro-β-carbolines, or spiroindolones, are potent drugs that kill the blood stages of Plasmodium falciparum and Plasmodium vivax clin. isolates at low nanomolar concn.  Spiroindolones rapidly inhibit protein synthesis in P. falciparum, an effect that is ablated in parasites bearing nonsynonymous mutations in the gene encoding the P-type cation-transporter ATPase4 (PfATP4).  The optimized spiroindolone NITD609 shows pharmacokinetic properties compatible with once-daily oral dosing and has single-dose efficacy in a rodent malaria model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqI6O1WaX-1b7Vg90H21EOLACvtfcHk0lhv06KQb5SSEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtV2hsr%252FJ&md5=239bc9babd5cb5f07e2be38741038e2c</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1126%2Fscience.1193225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1193225%26sid%3Dliteratum%253Aachs%26aulast%3DRottmann%26aufirst%3DM.%26aulast%3DMcNamara%26aufirst%3DC.%26aulast%3DYeung%26aufirst%3DB.%2BK.%2BS.%26aulast%3DLee%26aufirst%3DM.%2BC.%2BS.%26aulast%3DZou%26aufirst%3DB.%26aulast%3DRussell%26aufirst%3DB.%26aulast%3DSeitz%26aufirst%3DP.%26aulast%3DPlouffe%26aufirst%3DD.%2BM.%26aulast%3DDharia%26aufirst%3DN.%2BV.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DCohen%26aufirst%3DS.%2BB.%26aulast%3DSpencer%26aufirst%3DK.%2BR.%26aulast%3DGonz%25C3%25A1lez-P%25C3%25A1ez%26aufirst%3DG.%2BE.%26aulast%3DLakshminarayana%26aufirst%3DS.%2BB.%26aulast%3DGoh%26aufirst%3DA.%26aulast%3DSuwanarusk%26aufirst%3DR.%26aulast%3DJegla%26aufirst%3DT.%26aulast%3DSchmitt%26aufirst%3DE.%2BK.%26aulast%3DBeck%26aufirst%3DH.-P.%26aulast%3DBrun%26aufirst%3DR.%26aulast%3DNosten%26aufirst%3DF.%26aulast%3DRenia%26aufirst%3DL.%26aulast%3DDartois%26aufirst%3DV.%26aulast%3DKeller%26aufirst%3DT.%2BH.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26aulast%3DDiagana%26aufirst%3DT.%2BT.%26atitle%3DSpiroindolones%252C%2520a%2520Potent%2520Compound%2520Class%2520for%2520the%2520Treatment%2520of%2520Malaria%26jtitle%3DScience%26date%3D2010%26volume%3D329%26issue%3D5996%26spage%3D1175%26epage%3D1180%26doi%3D10.1126%2Fscience.1193225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonntag, L.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leong, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, B. K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, T. H.</span></span> <span> </span><span class="NLM_article-title">Mechanistic Study of the Spiroindolones: A New Class of Antimalarials</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">10131</span>– <span class="NLM_lpage">10141</span>, <span class="refDoi"> DOI: 10.3390/molecules170910131</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.3390%2Fmolecules170910131" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=22922283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht12htLbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=10131-10141&issue=9&author=B.+Zouauthor=P.+Yapauthor=L.-S.+Sonntagauthor=S.+Y.+Leongauthor=B.+K.+S.+Yeungauthor=T.+H.+Keller&title=Mechanistic+Study+of+the+Spiroindolones%3A+A+New+Class+of+Antimalarials&doi=10.3390%2Fmolecules170910131"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic study of the spiroindolones: a new class of antimalarials</span></div><div class="casAuthors">Zou, Bin; Yap, Peiling; Sonntag, Louis-Sebastian; Leong, Seh Yong; Yeung, Bryan K. S.; Keller, Thomas H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10131-10141</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">During the synthesis of the new antimalarial drug candidate NITD609, a high degree of diastereoselectivity was obsd. in the Pictet-Spengler reaction.  By isolating both the 4E and 4Z imine intermediates, a systematic mechanistic study of the reaction under both kinetic and thermodn. conditions was conducted.  This study provides insight into the source of the diastereoselectivity for this important class of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruzD1qORJEkrVg90H21EOLACvtfcHk0lhv06KQb5SSEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht12htLbL&md5=5d8c1df74fd2ed4801a220da4b7d0fb1</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.3390%2Fmolecules170910131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules170910131%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DB.%26aulast%3DYap%26aufirst%3DP.%26aulast%3DSonntag%26aufirst%3DL.-S.%26aulast%3DLeong%26aufirst%3DS.%2BY.%26aulast%3DYeung%26aufirst%3DB.%2BK.%2BS.%26aulast%3DKeller%26aufirst%3DT.%2BH.%26atitle%3DMechanistic%2520Study%2520of%2520the%2520Spiroindolones%253A%2520A%2520New%2520Class%2520of%2520Antimalarials%26jtitle%3DMolecules%26date%3D2012%26volume%3D17%26issue%3D9%26spage%3D10131%26epage%3D10141%26doi%3D10.3390%2Fmolecules170910131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ang, S. H.</span>; <span class="NLM_string-name">Krastel, P.</span>; <span class="NLM_string-name">Leong, S. Y.</span>; <span class="NLM_string-name">Tan, L. J.</span>; <span class="NLM_string-name">Wong, W. L. J.</span>; <span class="NLM_string-name">Yeung, B. K.</span>; <span class="NLM_string-name">Zou, B.</span></span> <span> </span><span class="NLM_article-title">Spiro-Indole Derivatives for the Treatment of Parasitic Diseases</span>. <span class="NLM_patent">WO2009132921A1</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=S.+H.+Ang&author=P.+Krastel&author=S.+Y.+Leong&author=L.+J.+Tan&author=W.+L.+J.+Wong&author=B.+K.+Yeung&author=B.+Zou&title=Spiro-Indole+Derivatives+for+the+Treatment+of+Parasitic+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAng%26aufirst%3DS.%2BH.%26atitle%3DSpiro-Indole%2520Derivatives%2520for%2520the%2520Treatment%2520of%2520Parasitic%2520Diseases%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pike, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rash, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedregal, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Statnick, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoghbi, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toledo, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gackenheimer, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tauscher, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Innis, R. B.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Evaluation of Radioligands for Imaging Brain Nociceptin/Orphanin FQ Peptide (NOP) Receptors with Positron Emission Tomography</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2687</span>– <span class="NLM_lpage">2700</span>, <span class="refDoi"> DOI: 10.1021/jm101487v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101487v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvVSisLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2687-2700&issue=8&author=V.+W.+Pikeauthor=K.+S.+Rashauthor=Z.+Chenauthor=C.+Pedregalauthor=M.+A.+Statnickauthor=Y.+Kimuraauthor=J.+Hongauthor=S.+S.+Zoghbiauthor=M.+Fujitaauthor=M.+A.+Toledoauthor=N.+Diazauthor=S.+L.+Gackenheimerauthor=J.+T.+Tauscherauthor=V.+N.+Barthauthor=R.+B.+Innis&title=Synthesis+and+Evaluation+of+Radioligands+for+Imaging+Brain+Nociceptin%2FOrphanin+FQ+Peptide+%28NOP%29+Receptors+with+Positron+Emission+Tomography&doi=10.1021%2Fjm101487v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of radioligands for imaging brain nociceptin/orphanin FQ peptide (NOP) receptors with positron emission tomography</span></div><div class="casAuthors">Pike, Victor W.; Rash, Karen S.; Chen, Zhaogen; Pedregal, Concepcion; Statnick, Michael A.; Kimura, Yasuyuki; Hong, Jinsoo; Zoghbi, Sami S.; Fujita, Masahiro; Toledo, Miguel A.; Diaz, Nuria; Gackenheimer, Susan L.; Tauscher, Johannes T.; Barth, Vanessa N.; Innis, Robert B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2687-2700</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Positron emission tomog. (PET) coupled to an effective radioligand could provide an important tool for understanding possible links between neuropsychiatric disorders and brain NOP (nociceptin/orphanin FQ peptide) receptors.  We sought to develop such a PET radioligand.  High-affinity NOP ligands were synthesized based on a 3-(2'-fluoro-4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran]-1-yl)-2(2-halobenzyl)-N-alkylpropanamide scaffold and from exptl. screens in rats, with ex vivo LC-MS/MS measures, three ligands were identified for labeling with carbon-11 and evaluation with PET in monkey.  Each ligand was labeled by 11C-methylation of an N-demethyl precursor and studied in monkey under baseline and NOP receptor-preblock conditions.  The three radioligands, [11C](S)-I (X = F, Cl, R = H; X = F, R = iPr) gave similar results.  Baseline scans showed high entry of radioactivity into the brain to give a distribution reflecting that expected for NOP receptors.  Preblock expts. showed high early peak levels of brain radioactivity, which rapidly declined to a much lower level than seen in baseline scans, thereby indicating a high level of receptor-specific binding in baseline expts.  Overall, [11C](S)-I (X = F, R = iPr) showed the most favorable receptor-specific signal and kinetics and is now selected for evaluation in human subjects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLbdZG2H-gRLVg90H21EOLACvtfcHk0ljM26UGUgFnpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvVSisLk%253D&md5=7519fa250770248d3c73c58e20eca3f1</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm101487v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101487v%26sid%3Dliteratum%253Aachs%26aulast%3DPike%26aufirst%3DV.%2BW.%26aulast%3DRash%26aufirst%3DK.%2BS.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DPedregal%26aufirst%3DC.%26aulast%3DStatnick%26aufirst%3DM.%2BA.%26aulast%3DKimura%26aufirst%3DY.%26aulast%3DHong%26aufirst%3DJ.%26aulast%3DZoghbi%26aufirst%3DS.%2BS.%26aulast%3DFujita%26aufirst%3DM.%26aulast%3DToledo%26aufirst%3DM.%2BA.%26aulast%3DDiaz%26aufirst%3DN.%26aulast%3DGackenheimer%26aufirst%3DS.%2BL.%26aulast%3DTauscher%26aufirst%3DJ.%2BT.%26aulast%3DBarth%26aufirst%3DV.%2BN.%26aulast%3DInnis%26aufirst%3DR.%2BB.%26atitle%3DSynthesis%2520and%2520Evaluation%2520of%2520Radioligands%2520for%2520Imaging%2520Brain%2520Nociceptin%252FOrphanin%2520FQ%2520Peptide%2520%2528NOP%2529%2520Receptors%2520with%2520Positron%2520Emission%2520Tomography%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D8%26spage%3D2687%26epage%3D2700%26doi%3D10.1021%2Fjm101487v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pedregal, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toledo, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafuente, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Grau, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiménez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benito, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mudra, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahl, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rash, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Statnick, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, V. N.</span></span> <span> </span><span class="NLM_article-title">Development of LC-MS/MS-Based Receptor Occupancy Tracers and Positron Emission Tomography Radioligands for the Nociceptin/Orphanin FQ (NOP) Receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">4955</span>– <span class="NLM_lpage">4967</span>, <span class="refDoi"> DOI: 10.1021/jm201629q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201629q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmt1Oqu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4955-4967&issue=11&author=C.+Pedregalauthor=E.+M.+Joshiauthor=M.+A.+Toledoauthor=C.+Lafuenteauthor=N.+Diazauthor=M.+A.+Martinez-Grauauthor=A.+Jim%C3%A9nezauthor=A.+Benitoauthor=A.+Navarroauthor=Z.+Chenauthor=D.+R.+Mudraauthor=S.+D.+Kahlauthor=K.+S.+Rashauthor=M.+A.+Statnickauthor=V.+N.+Barth&title=Development+of+LC-MS%2FMS-Based+Receptor+Occupancy+Tracers+and+Positron+Emission+Tomography+Radioligands+for+the+Nociceptin%2FOrphanin+FQ+%28NOP%29+Receptor&doi=10.1021%2Fjm201629q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Development of LC-MS/MS-Based Receptor Occupancy Tracers and Positron Emission Tomography Radioligands for the Nociceptin/Orphanin FQ (NOP) Receptor</span></div><div class="casAuthors">Pedregal, Concepcion; Joshi, Elizabeth M.; Toledo, Miguel A.; Lafuente, Celia; Diaz, Nuria; Martinez-Grau, Maria A.; Jimenez, Alma; Benito, Ana; Navarro, Antonio; Chen, Zhaogen; Mudra, Daniel R.; Kahl, Steven D.; Rash, Karen S.; Statnick, Michael A.; Barth, Vanessa N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4955-4967</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Currently, a lack of sufficient tools has limited the understanding of the relation between neuropsychiatric disorders and the nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptor.  Herein, we describe the discovery and development of an antagonist NOP receptor occupancy (RO) tracer and a novel positron emission tomog. (PET) radioligand suitable to probe the NOP receptor in human clin. studies.  A thorough structure-activity relation (SAR) around the high-affinity 3-(2'-fluoro-4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran]-1-yl)-2-(2-halobenzyl)-N-alkylpropanamide scaffold identified a series of subnanomolar, highly selective NOP antagonists.  Subsequently, these unlabeled NOP ligands were evaluated in vivo by liq. chromatog.-tandem mass spectrometry (LC-MS/MS) in rat to det. brain uptake, kinetics and specific binding.  Three compds. were selected for evaluation in nonhuman primates as PET tracers.  Carbon-11 labeling yielded [11C]I, which exhibited minimal generation of central nervous system (CNS) penetrant radiometabolites, improved brain uptake, and was an excellent PET radioligand in both rat and monkey.  Currently [11C]I is being evaluated as a PET radiotracer for the NOP receptor in human subjects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9BUDm4qd1VrVg90H21EOLACvtfcHk0ljM26UGUgFnpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmt1Oqu7c%253D&md5=37ba5b3497d5300a487c179a668a9055</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm201629q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201629q%26sid%3Dliteratum%253Aachs%26aulast%3DPedregal%26aufirst%3DC.%26aulast%3DJoshi%26aufirst%3DE.%2BM.%26aulast%3DToledo%26aufirst%3DM.%2BA.%26aulast%3DLafuente%26aufirst%3DC.%26aulast%3DDiaz%26aufirst%3DN.%26aulast%3DMartinez-Grau%26aufirst%3DM.%2BA.%26aulast%3DJim%25C3%25A9nez%26aufirst%3DA.%26aulast%3DBenito%26aufirst%3DA.%26aulast%3DNavarro%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DMudra%26aufirst%3DD.%2BR.%26aulast%3DKahl%26aufirst%3DS.%2BD.%26aulast%3DRash%26aufirst%3DK.%2BS.%26aulast%3DStatnick%26aufirst%3DM.%2BA.%26aulast%3DBarth%26aufirst%3DV.%2BN.%26atitle%3DDevelopment%2520of%2520LC-MS%252FMS-Based%2520Receptor%2520Occupancy%2520Tracers%2520and%2520Positron%2520Emission%2520Tomography%2520Radioligands%2520for%2520the%2520Nociceptin%252FOrphanin%2520FQ%2520%2528NOP%2529%2520Receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D11%26spage%3D4955%26epage%3D4967%26doi%3D10.1021%2Fjm201629q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, D.</span>; <span class="NLM_string-name">Gotchev, D.</span>; <span class="NLM_string-name">Pitis, P.</span>; <span class="NLM_string-name">Chen, X.-T.</span>; <span class="NLM_string-name">Liu, G.</span>; <span class="NLM_string-name">Yuan, C. C. K.</span></span> <span> </span><span class="NLM_article-title">Opioid Receptor Ligands and Methods of Using and Making Same</span>. <span class="NLM_patent">WO2012129495A1</span>, September 27, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=D.+Yamashita&author=D.+Gotchev&author=P.+Pitis&author=X.-T.+Chen&author=G.+Liu&author=C.+C.+K.+Yuan&title=Opioid+Receptor+Ligands+and+Methods+of+Using+and+Making+Same"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYamashita%26aufirst%3DD.%26atitle%3DOpioid%2520Receptor%2520Ligands%2520and%2520Methods%2520of%2520Using%2520and%2520Making%2520Same%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span> <span> </span><span class="NLM_article-title">Oliceridine: First Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>80</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">1739</span>– <span class="NLM_lpage">1744</span>, <span class="refDoi"> DOI: 10.1007/s40265-020-01414-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1007%2Fs40265-020-01414-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=33025536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVKhu7%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2020&pages=1739-1744&issue=16&author=A.+Markham&title=Oliceridine%3A+First+Approval&doi=10.1007%2Fs40265-020-01414-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Oliceridine: First Approval</span></div><div class="casAuthors">Markham, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1739-1744</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Oliceridine (Olinvyk, Trevena, Inc.) is a novel μ opioid agonist that was recently approved in the USA for use in adults for the management of acute pain severe enough to require an i.v. opioid analgesic and for whom alternative treatments are inadequate.  Unlike opioid agonists currently in use, the interaction of oliceridine with the opioid receptor is selective to the G protein pathway, with low potency for β-arrestin recruitment, which may lead to fewer opioid-related adverse events.  This article summarizes the milestones in the development of oliceridine leading to this first approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1fHqCB19-nLVg90H21EOLACvtfcHk0lh0KPWJKqtRog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVKhu7%252FF&md5=a5c8fe4dd05f7991a98686077eec4a80</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1007%2Fs40265-020-01414-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-020-01414-9%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26atitle%3DOliceridine%253A%2520First%2520Approval%26jtitle%3DDrugs%26date%3D2020%26volume%3D80%26issue%3D16%26spage%3D1739%26epage%3D1744%26doi%3D10.1007%2Fs40265-020-01414-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotchev, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rominger, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koblish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewire, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crombie, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Violin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, D. S.</span></span> <span> </span><span class="NLM_article-title">Structure-Activity Relationships and Discovery of a G Protein Biased μ Opioid Receptor Ligand, [(3-Methoxythiophen-2-Yl)Methyl]({2-[(9R)-9-(Pyridin-2-Yl)-6-Oxaspiro-[4.5]Decan-9-Yl]Ethyl})Amine (TRV130), for the Treatment of Acute Severe Pain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">8019</span>– <span class="NLM_lpage">8031</span>, <span class="refDoi"> DOI: 10.1021/jm4010829</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4010829" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFSmsrjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8019-8031&issue=20&author=X.-T.+Chenauthor=P.+Pitisauthor=G.+Liuauthor=C.+Yuanauthor=D.+Gotchevauthor=C.+L.+Cowanauthor=D.+H.+Romingerauthor=M.+Koblishauthor=S.+M.+Dewireauthor=A.+L.+Crombieauthor=J.+D.+Violinauthor=D.+S.+Yamashita&title=Structure-Activity+Relationships+and+Discovery+of+a+G+Protein+Biased+%CE%BC+Opioid+Receptor+Ligand%2C+%5B%283-Methoxythiophen-2-Yl%29Methyl%5D%28%7B2-%5B%289R%29-9-%28Pyridin-2-Yl%29-6-Oxaspiro-%5B4.5%5DDecan-9-Yl%5DEthyl%7D%29Amine+%28TRV130%29%2C+for+the+Treatment+of+Acute+Severe+Pain&doi=10.1021%2Fjm4010829"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationships and Discovery of a G Protein Biased μ Opioid Receptor Ligand, [(3-Methoxythiophen-2-yl)methyl]({2-[(9R)9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the Treatment of Acute Severe Pain</span></div><div class="casAuthors">Chen, Xiao-Tao; Pitis, Philip; Liu, Guodong; Yuan, Catherine; Gotchev, Dimitar; Cowan, Conrad L.; Rominger, David H.; Koblish, Michael; DeWire, Scott M.; Crombie, Aimee L.; Violin, Jonathan D.; Yamashita, Dennis S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8019-8031</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The concept of ligand bias at G protein coupled receptors has been introduced to describe ligands which preferentially stimulate one intracellular signaling pathway over another.  There is growing interest in developing biased G protein coupled receptor ligands to yield safer, better tolerated, and more efficacious drugs.  The classical μ opioid morphine elicited increased efficacy and duration of analgesic response with reduced side effects in β-arrestin-2 knockout mice compared to wild-type mice, suggesting that G protein biased μ opioid receptor agonists would be more efficacious with reduced adverse events.  Here we describe our efforts to identify a potent, selective, and G protein biased μ opioid receptor agonist, TRV130 (I).  This novel mol. demonstrated an improved therapeutic index (analgesia vs adverse effects) in rodent models and characteristics appropriate for clin. development.  It is currently being evaluated in human clin. trials for the treatment of acute severe pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-rI0Et_vFqrVg90H21EOLACvtfcHk0lh0KPWJKqtRog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFSmsrjK&md5=c80bd62062f31418f18392f97c880bea</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjm4010829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4010829%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.-T.%26aulast%3DPitis%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DYuan%26aufirst%3DC.%26aulast%3DGotchev%26aufirst%3DD.%26aulast%3DCowan%26aufirst%3DC.%2BL.%26aulast%3DRominger%26aufirst%3DD.%2BH.%26aulast%3DKoblish%26aufirst%3DM.%26aulast%3DDewire%26aufirst%3DS.%2BM.%26aulast%3DCrombie%26aufirst%3DA.%2BL.%26aulast%3DViolin%26aufirst%3DJ.%2BD.%26aulast%3DYamashita%26aufirst%3DD.%2BS.%26atitle%3DStructure-Activity%2520Relationships%2520and%2520Discovery%2520of%2520a%2520G%2520Protein%2520Biased%2520%25CE%25BC%2520Opioid%2520Receptor%2520Ligand%252C%2520%255B%25283-Methoxythiophen-2-Yl%2529Methyl%255D%2528%257B2-%255B%25289R%2529-9-%2528Pyridin-2-Yl%2529-6-Oxaspiro-%255B4.5%255DDecan-9-Yl%255DEthyl%257D%2529Amine%2520%2528TRV130%2529%252C%2520for%2520the%2520Treatment%2520of%2520Acute%2520Severe%2520Pain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D20%26spage%3D8019%26epage%3D8031%26doi%3D10.1021%2Fjm4010829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caenepeel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belmontes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moody, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chui, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poppe, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardozo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houze, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paras, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taygerly, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vimolratana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zancanella, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cajulis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osgood, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egan, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greninger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClanaghan, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moujalled, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pomilio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beltran, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benes, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coxon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, P. E.</span></span> <span> </span><span class="NLM_article-title">AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1582</span>– <span class="NLM_lpage">1597</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-18-0387</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1158%2F2159-8290.CD-18-0387" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=30254093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFOmsb7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=1582-1597&issue=12&author=S.+Caenepeelauthor=S.+P.+Brownauthor=B.+Belmontesauthor=G.+Moodyauthor=K.+S.+Keeganauthor=D.+Chuiauthor=D.+A.+Whittingtonauthor=X.+Huangauthor=L.+Poppeauthor=A.+C.+Chengauthor=M.+Cardozoauthor=J.+Houzeauthor=Y.+Liauthor=B.+Lucasauthor=N.+A.+Parasauthor=X.+Wangauthor=J.+P.+Taygerlyauthor=M.+Vimolratanaauthor=M.+Zancanellaauthor=L.+Zhuauthor=E.+Cajulisauthor=T.+Osgoodauthor=J.+Sunauthor=L.+Damonauthor=R.+K.+Eganauthor=P.+Greningerauthor=J.+D.+McClanaghanauthor=J.+Gongauthor=D.+Moujalledauthor=G.+Pomilioauthor=P.+Beltranauthor=C.+H.+Benesauthor=A.+W.+Robertsauthor=D.+C.+Huangauthor=A.+Weiauthor=J.+Canonauthor=A.+Coxonauthor=P.+E.+Hughes&title=AMG+176%2C+a+Selective+MCL1+Inhibitor%2C+Is+Effective+in+Hematologic+Cancer+Models+Alone+and+in+Combination+with+Established+Therapies&doi=10.1158%2F2159-8290.CD-18-0387"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies</span></div><div class="casAuthors">Caenepeel, Sean; Brown, Sean P.; Belmontes, Brian; Moody, Gordon; Keegan, Kathleen S.; Chui, Danny; Whittington, Douglas A.; Huang, Xin; Poppe, Leszek; Cheng, Alan C.; Cardozo, Mario; Houze, Jonathan; Li, Yunxiao; Lucas, Brian; Paras, Nick A.; Wang, Xianghong; Taygerly, Joshua P.; Vimolratana, Marc; Zancanella, Manuel; Zhu, Liusheng; Cajulis, Elaina; Osgood, Tao; Sun, Jan; Damon, Leah; Egan, Regina K.; Greninger, Patricia; McClanaghan, Joseph D.; Gong, Jianan; Moujalled, Donia; Pomilio, Giovanna; Beltran, Pedro; Benes, Cyril H.; Roberts, Andrew W.; Huang, David C.; Wei, Andrew; Canon, Jude; Coxon, Angela; Hughes, Paul E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1582-1597</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The prosurvival BCL2 family member MCL1 is frequently dysregulated in cancer.  To overcome the significant challenges assocd. with inhibition of MCL1 protein-protein interactions, we rigorously applied small-mol. conformational restriction, which culminated in the discovery of AMG 176, the first selective MCL1 inhibitor to be studied in humans.  We demonstrate that MCL1 inhibition induces a rapid and committed step toward apoptosis in subsets of hematol. cancer cell lines, tumor xenograft models, and primary patient samples.  With the use of a human MCL1 knock-in mouse, we demonstrate that MCL1 inhibition at active doses of AMG 176 is tolerated and correlates with clear pharmacodynamic effects, demonstrated by redns. in B cells, monocytes, and neutrophils.  Furthermore, the combination of AMG 176 and venetoclax is synergistic in acute myeloid leukemia (AML) tumor models and in primary patient samples at tolerated doses.  These results highlight the therapeutic promise of AMG 176 and the potential for combinations with other BH3 mimetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUtMExVVtn5rVg90H21EOLACvtfcHk0lhoLOOBRmrnow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFOmsb7E&md5=795a713908c3635bbd5e9fc3d95f3ae0</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-18-0387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-18-0387%26sid%3Dliteratum%253Aachs%26aulast%3DCaenepeel%26aufirst%3DS.%26aulast%3DBrown%26aufirst%3DS.%2BP.%26aulast%3DBelmontes%26aufirst%3DB.%26aulast%3DMoody%26aufirst%3DG.%26aulast%3DKeegan%26aufirst%3DK.%2BS.%26aulast%3DChui%26aufirst%3DD.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DPoppe%26aufirst%3DL.%26aulast%3DCheng%26aufirst%3DA.%2BC.%26aulast%3DCardozo%26aufirst%3DM.%26aulast%3DHouze%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLucas%26aufirst%3DB.%26aulast%3DParas%26aufirst%3DN.%2BA.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DTaygerly%26aufirst%3DJ.%2BP.%26aulast%3DVimolratana%26aufirst%3DM.%26aulast%3DZancanella%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DCajulis%26aufirst%3DE.%26aulast%3DOsgood%26aufirst%3DT.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DDamon%26aufirst%3DL.%26aulast%3DEgan%26aufirst%3DR.%2BK.%26aulast%3DGreninger%26aufirst%3DP.%26aulast%3DMcClanaghan%26aufirst%3DJ.%2BD.%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DMoujalled%26aufirst%3DD.%26aulast%3DPomilio%26aufirst%3DG.%26aulast%3DBeltran%26aufirst%3DP.%26aulast%3DBenes%26aufirst%3DC.%2BH.%26aulast%3DRoberts%26aufirst%3DA.%2BW.%26aulast%3DHuang%26aufirst%3DD.%2BC.%26aulast%3DWei%26aufirst%3DA.%26aulast%3DCanon%26aufirst%3DJ.%26aulast%3DCoxon%26aufirst%3DA.%26aulast%3DHughes%26aufirst%3DP.%2BE.%26atitle%3DAMG%2520176%252C%2520a%2520Selective%2520MCL1%2520Inhibitor%252C%2520Is%2520Effective%2520in%2520Hematologic%2520Cancer%2520Models%2520Alone%2520and%2520in%2520Combination%2520with%2520Established%2520Therapies%26jtitle%3DCancer%2520Discovery%26date%3D2018%26volume%3D8%26issue%3D12%26spage%3D1582%26epage%3D1597%26doi%3D10.1158%2F2159-8290.CD-18-0387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, S. P.</span>; <span class="NLM_string-name">Li, Y.</span>; <span class="NLM_string-name">Lizarzaburu, M. E.</span>; <span class="NLM_string-name">Lucas, B. S.</span>; <span class="NLM_string-name">Paras, N. A.</span>; <span class="NLM_string-name">Taygerly, J.</span>; <span class="NLM_string-name">Vimolratana, M.</span>; <span class="NLM_string-name">Wang, X.</span>; <span class="NLM_string-name">Yu, M.</span>; <span class="NLM_string-name">Zancanella, M.</span>; <span class="NLM_string-name">Zhu, L.</span>; <span class="NLM_string-name">Buenrostro, A. G.</span>; <span class="NLM_string-name">Li, Z.</span></span> <span> </span><span class="NLM_article-title">Tetrahydronaphthalene Derivatives That Inhibit Mcl-1 Protein</span>. <span class="NLM_patent">WO2016033486A1</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=S.+P.+Brown&author=Y.+Li&author=M.+E.+Lizarzaburu&author=B.+S.+Lucas&author=N.+A.+Paras&author=J.+Taygerly&author=M.+Vimolratana&author=X.+Wang&author=M.+Yu&author=M.+Zancanella&author=L.+Zhu&author=A.+G.+Buenrostro&author=Z.+Li&title=Tetrahydronaphthalene+Derivatives+That+Inhibit+Mcl-1+Protein"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DS.%2BP.%26atitle%3DTetrahydronaphthalene%2520Derivatives%2520That%2520Inhibit%2520Mcl-1%2520Protein%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rescourio, G.</span>; <span class="NLM_string-name">Buenrostro, A. G.</span>; <span class="NLM_string-name">Brown, S. P.</span>; <span class="NLM_string-name">Lizarzaburu, M.</span>; <span class="NLM_string-name">Medina, J. C.</span>; <span class="NLM_string-name">Jabri, S. Y.</span>; <span class="NLM_string-name">Sun, D.</span>; <span class="NLM_string-name">Simonovich, S. P.</span>; <span class="NLM_string-name">Yan, X.</span>; <span class="NLM_string-name">Li, Y.</span>; <span class="NLM_string-name">Rew, Y.</span></span> <span> </span><span class="NLM_article-title">Alpha-Hydroxy Phenylacetic Acid Pharmacophore or Bioisostere Mcl-1 Protein Antagonists</span>. <span class="NLM_patent">WO2019173181A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=G.+Rescourio&author=A.+G.+Buenrostro&author=S.+P.+Brown&author=M.+Lizarzaburu&author=J.+C.+Medina&author=S.+Y.+Jabri&author=D.+Sun&author=S.+P.+Simonovich&author=X.+Yan&author=Y.+Li&author=Y.+Rew&title=Alpha-Hydroxy+Phenylacetic+Acid+Pharmacophore+or+Bioisostere+Mcl-1+Protein+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRescourio%26aufirst%3DG.%26atitle%3DAlpha-Hydroxy%2520Phenylacetic%2520Acid%2520Pharmacophore%2520or%2520Bioisostere%2520Mcl-1%2520Protein%2520Antagonists%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, S. K.</span>; <span class="NLM_string-name">Cameron, K. O.</span>; <span class="NLM_string-name">Fernando, D. P.</span>; <span class="NLM_string-name">Kung, D. W.-S.</span>; <span class="NLM_string-name">Londregan, A. T.</span>; <span class="NLM_string-name">Mcclure, K. F.</span>; <span class="NLM_string-name">Simila, S. T. M.</span></span> <span> </span><span class="NLM_article-title">2,3 Dihydro-1h-Inden-1-Yl- 2,7-Diazaspiro [3.6] Nonane Derivatives and Their Use as Antagonists or Inverse Agonists of the Ghrelin Receptor</span>. <span class="NLM_patent">WO2011114271A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=S.+K.+Bhattacharya&author=K.+O.+Cameron&author=D.+P.+Fernando&author=D.+W.-S.+Kung&author=A.+T.+Londregan&author=K.+F.+Mcclure&author=S.+T.+M.+Simila&title=2%2C3+Dihydro-1h-Inden-1-Yl-+2%2C7-Diazaspiro+%5B3.6%5D+Nonane+Derivatives+and+Their+Use+as+Antagonists+or+Inverse+Agonists+of+the+Ghrelin+Receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBhattacharya%26aufirst%3DS.%2BK.%26atitle%3D2%252C3%2520Dihydro-1h-Inden-1-Yl-%25202%252C7-Diazaspiro%2520%255B3.6%255D%2520Nonane%2520Derivatives%2520and%2520Their%2520Use%2520as%2520Antagonists%2520or%2520Inverse%2520Agonists%2520of%2520the%2520Ghrelin%2520Receptor%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beveridge, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, K. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernando, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hepworth, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khot, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosa, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapham, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loria, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Londregan, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClure, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orr, S. T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saenz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stock, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VanVolkenburg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vrieze, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of PF-5190457, a Potent, Selective, and Orally Bioavailable Ghrelin Receptor Inverse Agonist Clinical Candidate</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">474</span>– <span class="NLM_lpage">479</span>, <span class="refDoi"> DOI: 10.1021/ml400473x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml400473x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtVeqsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=474-479&issue=5&author=S.+K.+Bhattacharyaauthor=K.+Andrewsauthor=R.+Beveridgeauthor=K.+O.+Cameronauthor=C.+Chenauthor=M.+Dunnauthor=D.+Fernandoauthor=H.+Gaoauthor=D.+Hepworthauthor=V.+M.+Jacksonauthor=V.+Khotauthor=J.+Kongauthor=R.+E.+Kosaauthor=K.+Laphamauthor=P.+M.+Loriaauthor=A.+T.+Londreganauthor=K.+F.+McClureauthor=S.+T.+M.+Orrauthor=J.+Patelauthor=C.+Roseauthor=J.+Saenzauthor=I.+A.+Stockauthor=G.+Storerauthor=M.+VanVolkenburgauthor=D.+Vriezeauthor=G.+Wangauthor=J.+Xiaoauthor=Y.+Zhang&title=Discovery+of+PF-5190457%2C+a+Potent%2C+Selective%2C+and+Orally+Bioavailable+Ghrelin+Receptor+Inverse+Agonist+Clinical+Candidate&doi=10.1021%2Fml400473x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of PF-5190457, a Potent, Selective, and Orally Bioavailable Ghrelin Receptor Inverse Agonist Clinical Candidate</span></div><div class="casAuthors">Bhattacharya, Samit K.; Andrews, Kim; Beveridge, Ramsay; Cameron, Kimberly O.; Chen, Chiliu; Dunn, Matthew; Fernando, Dilinie; Gao, Hua; Hepworth, David; Jackson, V. Margaret; Khot, Vishal; Kong, Jimmy; Kosa, Rachel E.; Lapham, Kimberly; Loria, Paula M.; Londregan, Allyn T.; McClure, Kim F.; Orr, Suvi T. M.; Patel, Jigna; Rose, Colin; Saenz, James; Stock, Ingrid A.; Storer, Gregory; Van Volkenburg, Maria; Vrieze, Derek; Wang, Guoqiang; Xiao, Jun; Zhang, Yingxin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">474-479</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The identification of potent, highly selective orally bioavailable ghrelin receptor inverse agonists from a spiro-azetidino-piperidine series is described.  Examples from this series have promising in vivo pharmacokinetics and increase glucose-stimulated insulin secretion in human whole and dispersed islets.  A physicochem.-based strategy to increase lipophilic efficiency for ghrelin receptor potency and retain low clearance and satisfactory permeability while reducing off-target pharmacol. led to the discovery of I.  Compd. I has a superior balance of ghrelin receptor pharmacol. and off-target selectivity.  On the basis of its promising pharmacol. and safety profile, I was advanced to human clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohmbqWISrADbVg90H21EOLACvtfcHk0lgT-ucIeIoBcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtVeqsbc%253D&md5=32382b6183ae39e9aa34e17729e314b3</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fml400473x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400473x%26sid%3Dliteratum%253Aachs%26aulast%3DBhattacharya%26aufirst%3DS.%2BK.%26aulast%3DAndrews%26aufirst%3DK.%26aulast%3DBeveridge%26aufirst%3DR.%26aulast%3DCameron%26aufirst%3DK.%2BO.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DDunn%26aufirst%3DM.%26aulast%3DFernando%26aufirst%3DD.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DHepworth%26aufirst%3DD.%26aulast%3DJackson%26aufirst%3DV.%2BM.%26aulast%3DKhot%26aufirst%3DV.%26aulast%3DKong%26aufirst%3DJ.%26aulast%3DKosa%26aufirst%3DR.%2BE.%26aulast%3DLapham%26aufirst%3DK.%26aulast%3DLoria%26aufirst%3DP.%2BM.%26aulast%3DLondregan%26aufirst%3DA.%2BT.%26aulast%3DMcClure%26aufirst%3DK.%2BF.%26aulast%3DOrr%26aufirst%3DS.%2BT.%2BM.%26aulast%3DPatel%26aufirst%3DJ.%26aulast%3DRose%26aufirst%3DC.%26aulast%3DSaenz%26aufirst%3DJ.%26aulast%3DStock%26aufirst%3DI.%2BA.%26aulast%3DStorer%26aufirst%3DG.%26aulast%3DVanVolkenburg%26aufirst%3DM.%26aulast%3DVrieze%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DXiao%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520PF-5190457%252C%2520a%2520Potent%252C%2520Selective%252C%2520and%2520Orally%2520Bioavailable%2520Ghrelin%2520Receptor%2520Inverse%2520Agonist%2520Clinical%2520Candidate%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26issue%3D5%26spage%3D474%26epage%3D479%26doi%3D10.1021%2Fml400473x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, D. L.</span></span> <span> </span><span class="NLM_article-title">Review of Synthetic Routes and Crystalline Forms of the Antiandrogen Oncology Drugs Enzalutamide, Apalutamide, and Darolutamide</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">347</span>– <span class="NLM_lpage">362</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.0c00005</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.0c00005" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjtl2ku7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2020&pages=347-362&issue=3&author=D.+L.+Hughes&title=Review+of+Synthetic+Routes+and+Crystalline+Forms+of+the+Antiandrogen+Oncology+Drugs+Enzalutamide%2C+Apalutamide%2C+and+Darolutamide&doi=10.1021%2Facs.oprd.0c00005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Review of Synthetic Routes and Crystalline Forms of the Anti-Androgen Oncology Drugs Enzalutamide, Apalutamide, and Darolutamide</span></div><div class="casAuthors">Hughes, David L.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">347-362</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This article reviewed the synthetic routes and final cryst. forms of recently approved anti-androgen drugs enzalutamide, apalutamide, and darolutamide, used for treatment of prostate cancer.  The patent literature was the primary source of information.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJxg3gDFfY3bVg90H21EOLACvtfcHk0lh34GKGxcNSrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjtl2ku7k%253D&md5=4e5ef1b009701200500f5ea16744b1fa</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.0c00005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.0c00005%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DD.%2BL.%26atitle%3DReview%2520of%2520Synthetic%2520Routes%2520and%2520Crystalline%2520Forms%2520of%2520the%2520Antiandrogen%2520Oncology%2520Drugs%2520Enzalutamide%252C%2520Apalutamide%252C%2520and%2520Darolutamide%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2020%26volume%3D24%26issue%3D3%26spage%3D347%26epage%3D362%26doi%3D10.1021%2Facs.oprd.0c00005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Al-Salama, Z. T.</span></span> <span> </span><span class="NLM_article-title">Apalutamide: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">699</span>– <span class="NLM_lpage">705</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0900-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1007%2Fs40265-018-0900-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=29626324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnsVaqtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=699-705&issue=6&author=Z.+T.+Al-Salama&title=Apalutamide%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-0900-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Apalutamide: First Global Approval</span></div><div class="casAuthors">Al-Salama, Zaina T.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">699-705</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Apalutamide (ErleadaTM) is a next-generation oral androgen receptor (AR) inhibitor that is being developed by Janssen for the treatment of prostate cancer (PC).  It binds directly to the ligand-binding domain of the AR and blocks the effects of androgens.  In Feb. 2018, apalutamide received its first global approval in the USA for the treatment of non-metastatic castration-resistant PC (nmCRPC).  Apalutamide is undergoing phase III investigation in chemotherapy-naive patients with metastatic CRPC (in combination with abiraterone acetate plus prednisone), patients with high-risk localized or locally advanced PC receiving primary radiation therapy, and in patients with metastatic hormone-sensitive PC and biochem.-relapsed PC.  This article summarizes the milestones in the development of apalutamide leading to this first approval in nmCRPC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfajxysBf-c7Vg90H21EOLACvtfcHk0lh34GKGxcNSrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnsVaqtr8%253D&md5=b6a8295485956422287476b4192ee789</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0900-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0900-z%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Salama%26aufirst%3DZ.%2BT.%26atitle%3DApalutamide%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26issue%3D6%26spage%3D699%26epage%3D705%26doi%3D10.1007%2Fs40265-018-0900-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M. E.</span>; <span class="NLM_string-name">Sawyers, C. L.</span>; <span class="NLM_string-name">Ouk, S.</span>; <span class="NLM_string-name">Tran, C.</span>; <span class="NLM_string-name">Wongvipat, J.</span></span> <span> </span><span class="NLM_article-title">Androgen Receptor Modulator for the Treatment of Prostate Cancer and Androgen Receptor-Associated Diseases</span>. <span class="NLM_patent">WO2007126765A2</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=M.+E.+Jung&author=C.+L.+Sawyers&author=S.+Ouk&author=C.+Tran&author=J.+Wongvipat&title=Androgen+Receptor+Modulator+for+the+Treatment+of+Prostate+Cancer+and+Androgen+Receptor-Associated+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJung%26aufirst%3DM.%2BE.%26atitle%3DAndrogen%2520Receptor%2520Modulator%2520for%2520the%2520Treatment%2520of%2520Prostate%2520Cancer%2520and%2520Androgen%2520Receptor-Associated%2520Diseases%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DiPoto, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span> <span> </span><span class="NLM_article-title">Synthesis of 2-Aminoimidazolones and Imidazolones by (3 + 2) Annulation of Azaoxyallyl Cations</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">499</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1021/acs.orglett.7b03719</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.orglett.7b03719" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A280%3ADC%252BC1MzptlGmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2018&pages=499-501&issue=3&author=M.+C.+DiPotoauthor=J.+Wu&title=Synthesis+of+2-Aminoimidazolones+and+Imidazolones+by+%283+%2B+2%29+Annulation+of+Azaoxyallyl+Cations&doi=10.1021%2Facs.orglett.7b03719"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of 2-Aminoimidazolones and Imidazolones by (3 + 2) Annulation of Azaoxyallyl Cations</span></div><div class="casAuthors">DiPoto Maria C; Wu Jimmy</div><div class="citationInfo"><span class="NLM_cas:title">Organic letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">499-501</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The first examples of (3 + 2) annulations between azaoxyallyl cations and cyanamides and nitriles to give the corresponding 2-aminoimidazolones and imidazolones are reported.  On the basis of the isolation of unexpected imidate products with certain substrates, it is proposed that the reaction proceeds via fast kinetic O-alkylation followed by rearrangement to the thermodynamically favored 2-aminoimidazolones and imidazolones.  The method was applied to the formal synthesis of the antihypertensive drug irbesartan.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSP0nNOO6781GGmni0r9GoKfW6udTcc2eYF4rUbGaZd57ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MzptlGmtg%253D%253D&md5=c28e260c72ad6637a437feedd17cff55</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Facs.orglett.7b03719&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.orglett.7b03719%26sid%3Dliteratum%253Aachs%26aulast%3DDiPoto%26aufirst%3DM.%2BC.%26aulast%3DWu%26aufirst%3DJ.%26atitle%3DSynthesis%2520of%25202-Aminoimidazolones%2520and%2520Imidazolones%2520by%2520%25283%2520%252B%25202%2529%2520Annulation%2520of%2520Azaoxyallyl%2520Cations%26jtitle%3DOrg.%2520Lett.%26date%3D2018%26volume%3D20%26issue%3D3%26spage%3D499%26epage%3D501%26doi%3D10.1021%2Facs.orglett.7b03719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Satyanarayana, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sumalatha, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhar, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatraman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, P. P.</span></span> <span> </span><span class="NLM_article-title">A New Entry to Antihypertensive Active Pharmaceutical Ingredient, Irbesartan and Its Analogues</span>. <i>Heterocycl. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">328</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1515%2FHC.2006.12.5.323" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1GksLvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=323-328&issue=5&author=B.+Satyanarayanaauthor=Y.+Sumalathaauthor=C.+Sridharauthor=S.+Venkatramanauthor=P.+P.+Reddy&title=A+New+Entry+to+Antihypertensive+Active+Pharmaceutical+Ingredient%2C+Irbesartan+and+Its+Analogues"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">A new entry to antihypertensive active pharmaceutical ingredient, irbesartan and its analogues</span></div><div class="casAuthors">Satyanarayana, Bollikonda; Sumalatha, Yasareni; Sridhar, Chaganti; Venkatraman, Sundaram; Reddy, Padi Pratap</div><div class="citationInfo"><span class="NLM_cas:title">Heterocyclic Communications</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">323-328</span>CODEN:
                <span class="NLM_cas:coden">HCOMEX</span>;
        ISSN:<span class="NLM_cas:issn">0793-0283</span>.
    
            (<span class="NLM_cas:orgname">Freund Publishing House Ltd.</span>)
        </div><div class="casAbstract">A new synthesis of Irbesartan, an antihypertensive active pharmaceutical ingredient and its analogs is reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFvSRsitADuLVg90H21EOLACvtfcHk0liG5NfHbWg-ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1GksLvE&md5=af6fcf44941bc711f64701859716efb0</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1515%2FHC.2006.12.5.323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1515%252FHC.2006.12.5.323%26sid%3Dliteratum%253Aachs%26aulast%3DSatyanarayana%26aufirst%3DB.%26aulast%3DSumalatha%26aufirst%3DY.%26aulast%3DSridhar%26aufirst%3DC.%26aulast%3DVenkatraman%26aufirst%3DS.%26aulast%3DReddy%26aufirst%3DP.%2BP.%26atitle%3DA%2520New%2520Entry%2520to%2520Antihypertensive%2520Active%2520Pharmaceutical%2520Ingredient%252C%2520Irbesartan%2520and%2520Its%2520Analogues%26jtitle%3DHeterocycl.%2520Commun.%26date%3D2006%26volume%3D12%26issue%3D5%26spage%3D323%26epage%3D328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ye, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sargent, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yohannes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span> <span> </span><span class="NLM_article-title">Novel and Expeditious Microwave-Assisted Three-Component Reactions for the Synthesis of Spiroimidazolin-4-Ones</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>71</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">3137</span>– <span class="NLM_lpage">3140</span>, <span class="refDoi"> DOI: 10.1021/jo060228q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo060228q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BD28Xis1Ogu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2006&pages=3137-3140&issue=8&author=P.+Yeauthor=K.+Sargentauthor=E.+Stewartauthor=J.-F.+Liuauthor=D.+Yohannesauthor=L.+Yu&title=Novel+and+Expeditious+Microwave-Assisted+Three-Component+Reactions+for+the+Synthesis+of+Spiroimidazolin-4-Ones&doi=10.1021%2Fjo060228q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Novel and Expeditious Microwave-Assisted Three-Component Reactions for the Synthesis of Spiroimidazolin-4-ones</span></div><div class="casAuthors">Ye, Ping; Sargent, Katie; Stewart, Ethan; Liu, Ji-Feng; Yohannes, Daniel; Yu, Libing</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3137-3140</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Highly efficient methods for the syntheses of spiroimidazolinones via microwave-assisted three-component one-pot sequential reactions or one-pot domino reactions are described.  E.g., microwave-assisted three-component one-pot sequential reaction of Me 1-amino-1-cyclopentanecarboxylic acid hydrochloride, BuCO2H, and BnNH2 gave 75% spiroimidazolinone I.  The efficiency and utility of the methods have been demonstrated by quickly accessing the antihypertensive drug irbesartan.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-vO4uk69_vLVg90H21EOLACvtfcHk0liG5NfHbWg-ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xis1Ogu7k%253D&md5=260a8be73322585a0e7f678fdc0d90d1</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fjo060228q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo060228q%26sid%3Dliteratum%253Aachs%26aulast%3DYe%26aufirst%3DP.%26aulast%3DSargent%26aufirst%3DK.%26aulast%3DStewart%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DJ.-F.%26aulast%3DYohannes%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DL.%26atitle%3DNovel%2520and%2520Expeditious%2520Microwave-Assisted%2520Three-Component%2520Reactions%2520for%2520the%2520Synthesis%2520of%2520Spiroimidazolin-4-Ones%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2006%26volume%3D71%26issue%3D8%26spage%3D3137%26epage%3D3140%26doi%3D10.1021%2Fjo060228q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deshpande, P. B.</span>; <span class="NLM_string-name">Luthra, P. K.</span>; <span class="NLM_string-name">Rathod, D. M.</span>; <span class="NLM_string-name">Patel, H. K.</span>; <span class="NLM_string-name">Parikh, P. T.</span></span> <span> </span><span class="NLM_article-title">An Improved Process for Preparation of Irbesartan</span>. <span class="NLM_patent">WO2007049293A1</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=P.+B.+Deshpande&author=P.+K.+Luthra&author=D.+M.+Rathod&author=H.+K.+Patel&author=P.+T.+Parikh&title=An+Improved+Process+for+Preparation+of+Irbesartan"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDeshpande%26aufirst%3DP.%2BB.%26atitle%3DAn%2520Improved%2520Process%2520for%2520Preparation%2520of%2520Irbesartan%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joyashiki, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoshino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinosaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyake, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitamura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawabe, Y.</span></span> <span> </span><span class="NLM_article-title">Identification of an Orally Active Small-Molecule PTHR1 Agonist for the Treatment of Hypoparathyroidism</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">13384</span>, <span class="refDoi"> DOI: 10.1038/ncomms13384</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1038%2Fncomms13384" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=27857062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjtVCmsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=13384&author=T.+Tamuraauthor=H.+Nodaauthor=E.+Joyashikiauthor=M.+Hoshinoauthor=T.+Watanabeauthor=M.+Kinosakiauthor=Y.+Nishimuraauthor=T.+Esakiauthor=K.+Ogawaauthor=T.+Miyakeauthor=S.+Araiauthor=M.+Shimizuauthor=H.+Kitamuraauthor=H.+Satoauthor=Y.+Kawabe&title=Identification+of+an+Orally+Active+Small-Molecule+PTHR1+Agonist+for+the+Treatment+of+Hypoparathyroidism&doi=10.1038%2Fncomms13384"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of an orally active small-molecule PTHR1 agonist for the treatment of hypoparathyroidism</span></div><div class="casAuthors">Tamura, Tatsuya; Noda, Hiroshi; Joyashiki, Eri; Hoshino, Maiko; Watanabe, Tomoyuki; Kinosaki, Masahiko; Nishimura, Yoshikazu; Esaki, Tohru; Ogawa, Kotaro; Miyake, Taiji; Arai, Shinichi; Shimizu, Masaru; Kitamura, Hidetomo; Sato, Haruhiko; Kawabe, Yoshiki</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">13384</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Parathyroid hormone (PTH) is essential for calcium homeostasis and its action is mediated by the PTH type 1 receptor (PTHR1), a class B G-protein-coupled receptor.  Hypoparathyroidism and osteoporosis can be treated with PTH injections; however, no orally effective PTH analog is available.  Here we show that PCO371 is a novel, orally active small mol. that acts as a full agonist of PTHR1.  PCO371 does not affect the PTH type 2 receptor (PTHR2), and anal. using PTHR1-PTHR2 chimeric receptors indicated that Proline 415 of PTHR1 is crit. for PCO371-mediated PTHR1 activation.  Oral administration of PCO371 to osteopenic rats provokes a significant increase in bone turnover with limited increase in bone mass.  In hypocalcemic rats, PCO371 restores serum calcium levels without increasing urinary calcium, and with stronger and longer-lasting effects than PTH injections.  These results strongly suggest that PCO371 can provide a new treatment option for PTH-related disorders, including hypoparathyroidism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnV-D_JlrJgLVg90H21EOLACvtfcHk0ljA7Tc8HWsSjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjtVCmsrs%253D&md5=99fb78e7bbc692aafb60e3d4718a5f0c</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fncomms13384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms13384%26sid%3Dliteratum%253Aachs%26aulast%3DTamura%26aufirst%3DT.%26aulast%3DNoda%26aufirst%3DH.%26aulast%3DJoyashiki%26aufirst%3DE.%26aulast%3DHoshino%26aufirst%3DM.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DKinosaki%26aufirst%3DM.%26aulast%3DNishimura%26aufirst%3DY.%26aulast%3DEsaki%26aufirst%3DT.%26aulast%3DOgawa%26aufirst%3DK.%26aulast%3DMiyake%26aufirst%3DT.%26aulast%3DArai%26aufirst%3DS.%26aulast%3DShimizu%26aufirst%3DM.%26aulast%3DKitamura%26aufirst%3DH.%26aulast%3DSato%26aufirst%3DH.%26aulast%3DKawabe%26aufirst%3DY.%26atitle%3DIdentification%2520of%2520an%2520Orally%2520Active%2520Small-Molecule%2520PTHR1%2520Agonist%2520for%2520the%2520Treatment%2520of%2520Hypoparathyroidism%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D13384%26doi%3D10.1038%2Fncomms13384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gundlach, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Largent, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, S. H.</span></span> <span> </span><span class="NLM_article-title">125I-Spiperone: A Novel Ligand for D2 Dopamine Receptors</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">1981</span>– <span class="NLM_lpage">1988</span>, <span class="refDoi"> DOI: 10.1016/0024-3205(84)90479-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2F0024-3205%2884%2990479-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=6149442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADyaL2cXmt1ehurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1984&pages=1981-1988&issue=19&author=A.+L.+Gundlachauthor=B.+L.+Largentauthor=S.+H.+Snyder&title=125I-Spiperone%3A+A+Novel+Ligand+for+D2+Dopamine+Receptors&doi=10.1016%2F0024-3205%2884%2990479-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">125I-Spiperone:  a novel ligand for D2 dopamine receptors</span></div><div class="casAuthors">Gundlach, Andrew L.; Largent, Brian L.; Snyder, Solomon H.</div><div class="citationInfo"><span class="NLM_cas:title">Life Sciences</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1981-8</span>CODEN:
                <span class="NLM_cas:coden">LIFSAK</span>;
        ISSN:<span class="NLM_cas:issn">0024-3205</span>.
    </div><div class="casAbstract">125I-labeled 4-iodospiperone (I)  [85562-22-7] binds with high affinity (equil. dissocn. const. = 0.3 nM) to a single specific site (binding site capacity = 34 pmol/g wet wt.) in homogenates of rat corpus striatum.  Specific binding is ∼40-60% of total binding and is displaced stereospecifically by butaclamol and clopenthixol.  Neuroleptic drugs of various classes are potent inhibitors of [125I]I binding (inhibitory const. (Ki) = 1-10 nM).  Selective dopamine antagonists such as sulpiride (Ki 50 nM) and dopamine agonists such as apomorphine (Ki 200 nM) are also potent inhibitors.  The drug specificity of [125I]I binding correlates well with that of [3H]spiperone binding, indicating that [125I]I labels D2 dopamine receptors in striatal membranes.  [125I]I, with its high specific activity (2200 Ci/mmol), may be a useful ligand in studies examg. D2 dopamine receptors in sol. prepns. and by autoradiog.  Iodinated spiperone may also be useful in radioreceptor assays of neuroleptic drug levels and, in a 123I-labeled form, for imaging of dopamine receptors in vivo using single photon tomog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpymr04vuJKyLVg90H21EOLACvtfcHk0lh_0Gk6Gkn_8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXmt1ehurs%253D&md5=d680d3c43111a697c3fec5c02c45709a</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2F0024-3205%2884%2990479-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0024-3205%252884%252990479-X%26sid%3Dliteratum%253Aachs%26aulast%3DGundlach%26aufirst%3DA.%2BL.%26aulast%3DLargent%26aufirst%3DB.%2BL.%26aulast%3DSnyder%26aufirst%3DS.%2BH.%26atitle%3D125I-Spiperone%253A%2520A%2520Novel%2520Ligand%2520for%2520D2%2520Dopamine%2520Receptors%26jtitle%3DLife%2520Sci.%26date%3D1984%26volume%3D35%26issue%3D19%26spage%3D1981%26epage%3D1988%26doi%3D10.1016%2F0024-3205%2884%2990479-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niemegeers, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schellekens, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenaerts, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verbruggen, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Nueten, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsboom, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hérin, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaper, W. K.</span></span> <span> </span><span class="NLM_article-title">The Pharmacology of Fluspirilene (R 6218), a Potent, Long-Acting and Injectable Neuroleptic Drug</span>. <i>Arzneimittelforschung</i> <span class="NLM_year" style="font-weight: bold;">1970</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1689</span>– <span class="NLM_lpage">1698</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=4992598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A280%3ADyaE3M%252Fns1yrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1970&pages=1689-1698&issue=11&author=P.+A.+Janssenauthor=C.+J.+Niemegeersauthor=K.+H.+Schellekensauthor=F.+M.+Lenaertsauthor=F.+J.+Verbruggenauthor=J.+M.+van+Nuetenauthor=R.+H.+Marsboomauthor=V.+V.+H%C3%A9rinauthor=W.+K.+Schaper&title=The+Pharmacology+of+Fluspirilene+%28R+6218%29%2C+a+Potent%2C+Long-Acting+and+Injectable+Neuroleptic+Drug"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">The pharmacology of fluspirilene (R 6218), a potent, long-acting and injectable neuroleptic drug</span></div><div class="casAuthors">Janssen P A; Niemegeers C J; Schellekens K H; Lenaerts F M; Verbruggen F J; van Nueten J M; Marsboom R H; Herin V V; Schaper W K</div><div class="citationInfo"><span class="NLM_cas:title">Arzneimittel-Forschung</span>
        (<span class="NLM_cas:date">1970</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1689-98</span>
        ISSN:<span class="NLM_cas:issn">0004-4172</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQkNaa24B2a8hjv2lLSLOxFfW6udTcc2eZukd3NcVgvJ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE3M%252Fns1yrtg%253D%253D&md5=3c0013ffb85571124c2e2e15d2bf1934</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJanssen%26aufirst%3DP.%2BA.%26aulast%3DNiemegeers%26aufirst%3DC.%2BJ.%26aulast%3DSchellekens%26aufirst%3DK.%2BH.%26aulast%3DLenaerts%26aufirst%3DF.%2BM.%26aulast%3DVerbruggen%26aufirst%3DF.%2BJ.%26aulast%3Dvan%2BNueten%26aufirst%3DJ.%2BM.%26aulast%3DMarsboom%26aufirst%3DR.%2BH.%26aulast%3DH%25C3%25A9rin%26aufirst%3DV.%2BV.%26aulast%3DSchaper%26aufirst%3DW.%2BK.%26atitle%3DThe%2520Pharmacology%2520of%2520Fluspirilene%2520%2528R%25206218%2529%252C%2520a%2520Potent%252C%2520Long-Acting%2520and%2520Injectable%2520Neuroleptic%2520Drug%26jtitle%3DArzneimittelforschung%26date%3D1970%26volume%3D20%26issue%3D11%26spage%3D1689%26epage%3D1698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morciano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedriali, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aquila, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Missiroli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fantinati, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caroccia, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacifico, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonora, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talarico, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morganti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieckowski, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giorgi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trapella, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinton, P.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel 1,3,8-Triazaspiro[4.5]Decane Derivatives That Target the c Subunit of F1/FO-Adenosine Triphosphate (ATP) Synthase for the Treatment of Reperfusion Damage in Myocardial Infarction</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">7131</span>– <span class="NLM_lpage">7143</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00278</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00278" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVSrsbzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7131-7143&issue=16&author=G.+Morcianoauthor=D.+Pretiauthor=G.+Pedrialiauthor=G.+Aquilaauthor=S.+Missiroliauthor=A.+Fantinatiauthor=N.+Carocciaauthor=S.+Pacificoauthor=M.+Bonoraauthor=A.+Talaricoauthor=C.+Morgantiauthor=P.+Rizzoauthor=R.+Ferrariauthor=M.+R.+Wieckowskiauthor=G.+Campoauthor=C.+Giorgiauthor=C.+Trapellaauthor=P.+Pinton&title=Discovery+of+Novel+1%2C3%2C8-Triazaspiro%5B4.5%5DDecane+Derivatives+That+Target+the+c+Subunit+of+F1%2FFO-Adenosine+Triphosphate+%28ATP%29+Synthase+for+the+Treatment+of+Reperfusion+Damage+in+Myocardial+Infarction&doi=10.1021%2Facs.jmedchem.8b00278"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel 1,3,8-Triazaspiro[4.5]decane Derivatives That Target the c Subunit of F1/FO-Adenosine Triphosphate (ATP) Synthase for the Treatment of Reperfusion Damage in Myocardial Infarction</span></div><div class="casAuthors">Morciano, Giampaolo; Preti, Delia; Pedriali, Gaia; Aquila, Giorgio; Missiroli, Sonia; Fantinati, Anna; Caroccia, Natascia; Pacifico, Salvatore; Bonora, Massimo; Talarico, Anna; Morganti, Claudia; Rizzo, Paola; Ferrari, Roberto; Wieckowski, Mariusz R.; Campo, Gianluca; Giorgi, Carlotta; Trapella, Claudio; Pinton, Paolo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7131-7143</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Recent cardiol. research studies have reported the role, function, and structure of the mitochondrial permeability transition pore (mPTP) and have shown that its opening plays a key role in the progression of myocardial cell death secondary to reperfusion.  In this manuscript, we validated a new pharmacol. approach as an adjunct to reperfusion in myocardial infarction (MI) treatment and describe the discovery, optimization, and structure-activity relationship (SAR) studies of the first small-mol. mPTP opening inhibitors based on a 1,3,8-triazaspiro[4.5]decane scaffold that targets the c subunit of the F1/FO-ATP synthase complex.  We identified three potential compds. with good mPTP inhibitory activity and beneficial effects in a model of MI, including a decreased apoptotic rate in the whole heart and overall improvement of cardiac function upon administration during reperfusion.  The selected compds. did not show off-target effects at the cellular and mitochondrial levels.  Moreover, the compds. preserved the mitochondrial ATP content despite interacting with the ATP synthase complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3Sy5k_30UJbVg90H21EOLACvtfcHk0lh_0Gk6Gkn_8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVSrsbzJ&md5=03c973541392b13f41a2c0d65ac6c61a</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00278&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00278%26sid%3Dliteratum%253Aachs%26aulast%3DMorciano%26aufirst%3DG.%26aulast%3DPreti%26aufirst%3DD.%26aulast%3DPedriali%26aufirst%3DG.%26aulast%3DAquila%26aufirst%3DG.%26aulast%3DMissiroli%26aufirst%3DS.%26aulast%3DFantinati%26aufirst%3DA.%26aulast%3DCaroccia%26aufirst%3DN.%26aulast%3DPacifico%26aufirst%3DS.%26aulast%3DBonora%26aufirst%3DM.%26aulast%3DTalarico%26aufirst%3DA.%26aulast%3DMorganti%26aufirst%3DC.%26aulast%3DRizzo%26aufirst%3DP.%26aulast%3DFerrari%26aufirst%3DR.%26aulast%3DWieckowski%26aufirst%3DM.%2BR.%26aulast%3DCampo%26aufirst%3DG.%26aulast%3DGiorgi%26aufirst%3DC.%26aulast%3DTrapella%26aufirst%3DC.%26aulast%3DPinton%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520Novel%25201%252C3%252C8-Triazaspiro%255B4.5%255DDecane%2520Derivatives%2520That%2520Target%2520the%2520c%2520Subunit%2520of%2520F1%252FFO-Adenosine%2520Triphosphate%2520%2528ATP%2529%2520Synthase%2520for%2520the%2520Treatment%2520of%2520Reperfusion%2520Damage%2520in%2520Myocardial%2520Infarction%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D16%26spage%3D7131%26epage%3D7143%26doi%3D10.1021%2Facs.jmedchem.8b00278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, X.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Biological Evaluation of 2-Arylaminopyrimidine Derivatives Bearing 1,3,8-Triazaspiro[4,5]Decan-4-One or Piperidine-3-Carboxamide Moiety as Novel Type-I1/2 ALK Inhibitors</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">103456</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2019.103456</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2Fj.bioorg.2019.103456" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=31787343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit12ktr3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2020&pages=103456&author=X.+Miaoauthor=L.+Xingauthor=M.+Guoauthor=H.+Zhangauthor=S.+Liuauthor=S.+Yinauthor=P.+Gongauthor=D.+Zhangauthor=X.+Zhai&title=Design%2C+Synthesis+and+Biological+Evaluation+of+2-Arylaminopyrimidine+Derivatives+Bearing+1%2C3%2C8-Triazaspiro%5B4%2C5%5DDecan-4-One+or+Piperidine-3-Carboxamide+Moiety+as+Novel+Type-I1%2F2+ALK+Inhibitors&doi=10.1016%2Fj.bioorg.2019.103456"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of 2-arylaminopyrimidine derivatives bearing 1,3,8-triazaspiro[4,5]decan-4-one or piperidine-3-carboxamide moiety as novel Type-I1/2 ALK inhibitors</span></div><div class="casAuthors">Miao, Xiuqi; Xing, Lingyun; Guo, Ming; Zhang, Hong; Liu, Sicong; Yin, Shiliang; Gong, Ping; Zhang, Dajun; Zhai, Xin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">103456</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Aiming to develop novel Type-I1/2 inhibitors of ALK to overcome extensive resistance mutations, esp. the L1196M mutation surrounding the ATP pocket, two series of 2-arylaminopyrimidine derivs. (I (R1 = pyrrolidin-1-yl, piperidin-1-yl, 4-methylpiperazin-1-yl, 4-(2-hydroxyethyl)piperazin-1-yl), II (R2 = 4-methylpiperazin-1-yl, 4-(2-hydroxyethyl)piperazin-1-yl) and III (R3 = ethoxycarbonylmethylamino, 2-(piperidin-1-yl)acetamido, 2-(4-methylpiperazin-1-yl)acetamido, etc.), IV (R4 = allyl, cyclopropanecarbonyl, 2-carboxyethyl, etc.)) were designed based on scaffold hopping.  The extensive structural elaboration discovered compd. IV ((A), R4 = 3-ethoxy-3-oxopropyl) which possessed excellent IC50 values of 0.06 and 0.23μM against ALK-pos. Karpas299 and H2228 cell lines, resp.  Meanwhile, (A) displayed encouraging inhibitory potency in the ALKWT (2.5 nM) and ALKL1196M (6.5 nM) enzymic assays.  Furthermore, the AO/EB and Hoechst 33258 assays illustrated that (A) could induce cell apoptosis in a dose-dependent manner.  Eventually, the mol. docking of (A) with ALK clearly presented the vital interactions within the active site, which was in accordance with Type-I1/2 inhibitor binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7Mhke0Lt_N7Vg90H21EOLACvtfcHk0liHjWlGSKFPxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit12ktr3M&md5=07590ede380018be938f43168c281e7a</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2019.103456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2019.103456%26sid%3Dliteratum%253Aachs%26aulast%3DMiao%26aufirst%3DX.%26aulast%3DXing%26aufirst%3DL.%26aulast%3DGuo%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DYin%26aufirst%3DS.%26aulast%3DGong%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DZhai%26aufirst%3DX.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Biological%2520Evaluation%2520of%25202-Arylaminopyrimidine%2520Derivatives%2520Bearing%25201%252C3%252C8-Triazaspiro%255B4%252C5%255DDecan-4-One%2520or%2520Piperidine-3-Carboxamide%2520Moiety%2520as%2520Novel%2520Type-I1%252F2%2520ALK%2520Inhibitors%26jtitle%3DBioorg.%2520Chem.%26date%3D2020%26volume%3D94%26spage%3D103456%26doi%3D10.1016%2Fj.bioorg.2019.103456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kador, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinoshita, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpless, N. E.</span></span> <span> </span><span class="NLM_article-title">Aldose Reductase Inhibitors: A Potential New Class of Agents for the Pharmacological Control of Certain Diabetic Complications</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">841</span>– <span class="NLM_lpage">849</span>, <span class="refDoi"> DOI: 10.1021/jm00145a001</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00145a001" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADyaL2MXktVSjsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=1985&pages=841-849&issue=7&author=P.+F.+Kadorauthor=J.+H.+Kinoshitaauthor=N.+E.+Sharpless&title=Aldose+Reductase+Inhibitors%3A+A+Potential+New+Class+of+Agents+for+the+Pharmacological+Control+of+Certain+Diabetic+Complications&doi=10.1021%2Fjm00145a001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Aldose reductase inhibitors:  a potential new class of agents for the pharmacological control of certain diabetic complications</span></div><div class="casAuthors">Kador, Peter F.; Kinoshita, Jin H.; Sharpless, Norman E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">841-9</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">A review with 94 refs.  The polyol concept and the role of aldose reductase (I)  [9028-31-3] in the pathogenesis of diabetic complications such as cataract, keropathy, microangiopathy, neuropathy and nephropathy, the biol. evaluation of I inhibitors, their common mol. features, and a proposed inhibitor site model is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNtvBgXC-_KbVg90H21EOLACvtfcHk0liHjWlGSKFPxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXktVSjsrs%253D&md5=bc09417a4dda641e144b290bb845cfe5</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fjm00145a001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00145a001%26sid%3Dliteratum%253Aachs%26aulast%3DKador%26aufirst%3DP.%2BF.%26aulast%3DKinoshita%26aufirst%3DJ.%2BH.%26aulast%3DSharpless%26aufirst%3DN.%2BE.%26atitle%3DAldose%2520Reductase%2520Inhibitors%253A%2520A%2520Potential%2520New%2520Class%2520of%2520Agents%2520for%2520the%2520Pharmacological%2520Control%2520of%2520Certain%2520Diabetic%2520Complications%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1985%26volume%3D28%26issue%3D7%26spage%3D841%26epage%3D849%26doi%3D10.1021%2Fjm00145a001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearlstein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kador, P. F.</span></span> <span> </span><span class="NLM_article-title">Molecular Modeling Studies of Aldose Reductase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">787</span>– <span class="NLM_lpage">792</span>, <span class="refDoi"> DOI: 10.1021/jm00032a011</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00032a011" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADyaK2cXivV2ns7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1994&pages=787-792&issue=6&author=Y.+S.+Leeauthor=R.+Pearlsteinauthor=P.+F.+Kador&title=Molecular+Modeling+Studies+of+Aldose+Reductase+Inhibitors&doi=10.1021%2Fjm00032a011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Modeling Studies of Aldose Reductase Inhibitors</span></div><div class="casAuthors">Lee, Yong S.; Pearlstein, Robert; Kador, Peter F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">787-92</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">Mol. modeling studies using the AM1 quantum chem. method and a torsional fitting method have been conducted on a series of aldose reductase inhibitors (ARIs) possessing an ionizable group and/or functional group susceptible to nucleophilic attack with the aim of defining the spatial position of ARI pharmacophores.  AM1 quantum chem. calcns. were conducted on ARIs possessing only an ionizable group to obtain their optimized geometries.  These optimized structures were then superimposed on the model compd. spirofluorene-9,5'-imidazolidine-2',4'-dione.  This superposition study suggests that a neg. charge center residing in the vicinity of the 2'-oxygen of the imidazolidine-2',4'-dione ring participates in the binding interactions.  In addn., the optimized geometries of ARIs possessing both an ionizable group and an electroneg. functional group were superimposed on spirofluorene-9,5'-imidazolidine-2',4'-dione.  The latter results also suggest the presence of a region where nucleophilic substitution can occur.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrt99a3kLI4vLVg90H21EOLACvtfcHk0liHjWlGSKFPxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXivV2ns7k%253D&md5=84977b327dd1c8d656b149df996bd389</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Fjm00032a011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00032a011%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DY.%2BS.%26aulast%3DPearlstein%26aufirst%3DR.%26aulast%3DKador%26aufirst%3DP.%2BF.%26atitle%3DMolecular%2520Modeling%2520Studies%2520of%2520Aldose%2520Reductase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1994%26volume%3D37%26issue%3D6%26spage%3D787%26epage%3D792%26doi%3D10.1021%2Fjm00032a011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naylor, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgins, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varty, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lachowicz, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, E. M.</span></span> <span> </span><span class="NLM_article-title">Rolapitant (SCH 619734): A Potent, Selective and Orally Active Neurokinin NK1 Receptor Antagonist with Centrally-Mediated Antiemetic Effects in Ferrets</span>. <i>Pharmacol., Biochem. Behav.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>102</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">100</span>, <span class="refDoi"> DOI: 10.1016/j.pbb.2012.03.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2Fj.pbb.2012.03.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=22497992" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC38XntFagu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2012&pages=95-100&issue=1&author=R.+A.+Duffyauthor=C.+Morganauthor=R.+Naylorauthor=G.+A.+Higginsauthor=G.+B.+Vartyauthor=J.+E.+Lachowiczauthor=E.+M.+Parker&title=Rolapitant+%28SCH+619734%29%3A+A+Potent%2C+Selective+and+Orally+Active+Neurokinin+NK1+Receptor+Antagonist+with+Centrally-Mediated+Antiemetic+Effects+in+Ferrets&doi=10.1016%2Fj.pbb.2012.03.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Rolapitant (SCH 619734): A potent, selective and orally active neurokinin NK1 receptor antagonist with centrally-mediated antiemetic effects in ferrets</span></div><div class="casAuthors">Duffy, Ruth A.; Morgan, Cynthia; Naylor, Robert; Higgins, Guy A.; Varty, Geoffrey B.; Lachowicz, Jean E.; Parker, Eric M.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology, Biochemistry and Behavior</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">95-100</span>CODEN:
                <span class="NLM_cas:coden">PBBHAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-3057</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">NK1 receptor antagonists have been shown to have a variety of physiol. and potential therapeutic effects in animal models and in humans.  The present studies demonstrate that Rolapitant (SCH 619734, (5S)-8(S)-[[1(R)-[3,5 bis(trifluoromethyl)phenyl]ethoxy]methyl]-8-phenyl-1,7-diazaspiro[4,5]decan-2-one) is a selective, bioavailable, CNS penetrant neurokinin NK1 receptor antagonist that shows behavioral effects in animals models of emesis.  In vitro studies indicate that rolapitant has a high affinity for the human NK1 receptor of 0.66 nM and high selectivity over the human NK2 and NK3 subtypes of > 1000-fold, as well as preferential affinity for human, guinea pig, gerbil and monkey NK1 receptors over rat, mouse and rabbit.  Rolapitant is a functionally competitive antagonist, as measured by calcium efflux, with a calcd. Kb of 0.17 nM.  Rolapitant reversed NK1 agonist-induced foot tapping in gerbils following both i.v. and oral administration up to 24 h at a minimal ED (MED) of 0.1 mg/kg.  Rolapitant was active at 0.1 and 1 mg/kg in both acute and delayed emesis models in ferrets, resp., consistent with clin. data for other NK1 antagonists.  Clin. efficacy of anti-emetics is highly correlated with efficacy in the ferret emesis model, suggesting rolapitant is a viable clin. candidate for this indication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeOZ_Iy_LTMLVg90H21EOLACvtfcHk0li_3yxh8cY5jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntFagu7w%253D&md5=a2eeef1c15adfb885e89c0c2a5ab4cbe</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.pbb.2012.03.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pbb.2012.03.021%26sid%3Dliteratum%253Aachs%26aulast%3DDuffy%26aufirst%3DR.%2BA.%26aulast%3DMorgan%26aufirst%3DC.%26aulast%3DNaylor%26aufirst%3DR.%26aulast%3DHiggins%26aufirst%3DG.%2BA.%26aulast%3DVarty%26aufirst%3DG.%2BB.%26aulast%3DLachowicz%26aufirst%3DJ.%2BE.%26aulast%3DParker%26aufirst%3DE.%2BM.%26atitle%3DRolapitant%2520%2528SCH%2520619734%2529%253A%2520A%2520Potent%252C%2520Selective%2520and%2520Orally%2520Active%2520Neurokinin%2520NK1%2520Receptor%2520Antagonist%2520with%2520Centrally-Mediated%2520Antiemetic%2520Effects%2520in%2520Ferrets%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D2012%26volume%3D102%26issue%3D1%26spage%3D95%26epage%3D100%26doi%3D10.1016%2Fj.pbb.2012.03.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paliwal, S.</span>; <span class="NLM_string-name">Reichard, G.</span>; <span class="NLM_string-name">Wang, C.</span>; <span class="NLM_string-name">Xiao, D.</span>; <span class="NLM_string-name">Tsui, H.-C.</span>; <span class="NLM_string-name">Shih, N.-Y.</span>; <span class="NLM_string-name">Arredondo, J.</span>; <span class="NLM_string-name">Wrobleski, M.</span>; <span class="NLM_string-name">Palani, A.</span></span> <span> </span><span class="NLM_article-title">NK 1 Antagonists</span>. <span class="NLM_patent">US20030158173A1</span>, <span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=S.+Paliwal&author=G.+Reichard&author=C.+Wang&author=D.+Xiao&author=H.-C.+Tsui&author=N.-Y.+Shih&author=J.+Arredondo&author=M.+Wrobleski&author=A.+Palani&title=NK+1+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPaliwal%26aufirst%3DS.%26atitle%3DNK%25201%2520Antagonists%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mergelsberg, I.</span>; <span class="NLM_string-name">Scherer, D. H.</span>; <span class="NLM_string-name">Huttenloch, M. E.</span>; <span class="NLM_string-name">Tsui, H.-C.</span>; <span class="NLM_string-name">Paliwal, S.</span>; <span class="NLM_string-name">Shih, N.-Y.</span></span> <span> </span><span class="NLM_article-title">Process and Intermediates for the Synthesis of 8-[{1-(3,5-Bis-(Trifluoromethyl)Phenyl)-Ethoxy}-Methyl]-8-Phenyl-1,7-Diaza-Spiro[4.5]Decan-2-One Compounds</span>. <span class="NLM_patent">WO2008118328A2</span>, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=I.+Mergelsberg&author=D.+H.+Scherer&author=M.+E.+Huttenloch&author=H.-C.+Tsui&author=S.+Paliwal&author=N.-Y.+Shih&title=Process+and+Intermediates+for+the+Synthesis+of+8-%5B%7B1-%283%2C5-Bis-%28Trifluoromethyl%29Phenyl%29-Ethoxy%7D-Methyl%5D-8-Phenyl-1%2C7-Diaza-Spiro%5B4.5%5DDecan-2-One+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMergelsberg%26aufirst%3DI.%26atitle%3DProcess%2520and%2520Intermediates%2520for%2520the%2520Synthesis%2520of%25208-%255B%257B1-%25283%252C5-Bis-%2528Trifluoromethyl%2529Phenyl%2529-Ethoxy%257D-Methyl%255D-8-Phenyl-1%252C7-Diaza-Spiro%255B4.5%255DDecan-2-One%2520Compounds%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheeler, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ene, D.</span></span> <span> </span><span class="NLM_article-title">Olefin Metathesis in Drug Discovery and Development—Examples from Recent Patent Literature</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1938</span>– <span class="NLM_lpage">1962</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.7b00319</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.7b00319" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsl2gsrbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2017&pages=1938-1962&issue=12&author=D.+Hughesauthor=P.+Wheelerauthor=D.+Ene&title=Olefin+Metathesis+in+Drug+Discovery+and+Development%E2%80%94Examples+from+Recent+Patent+Literature&doi=10.1021%2Facs.oprd.7b00319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Olefin Metathesis in Drug Discovery and Development-Examples from Recent Patent Literature</span></div><div class="casAuthors">Hughes, David; Wheeler, Philip; Ene, Doina</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1938-1962</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review that summarizes applications of the metathesis reactions in drug discovery and development in the pharmaceutical industry disclosed in the patent literature from Jan. 2016 to August 2017.  The olefin metathesis reaction is finding increasing use in drug discovery and process chem., with a no. of applications now implemented at com. manufg. scale.  Catalyst improvements over the past decade have allowed use of the metathesis reaction with highly functionalized substrates, allowing chemists to access increasingly diverse chem. space, including most notably macrocycles, constrained small ring spirocycles, and fused-ring systems.  For scientists employed in the pharmaceutical industry, the patent literature is the primary avenue for communication of synthetic routes to drug candidates.  While most examples of the metathesis reaction in the patent literature offer only sketchy exptl. details and provide little context on reaction development, the wide scope of substrates within the pharmaceutical patent literature provides a true indication of reaction scope and functional group compatibility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwS-l_9Wgak7Vg90H21EOLACvtfcHk0li_3yxh8cY5jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsl2gsrbP&md5=8fcebbc4105e77751d56724d758535ac</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.7b00319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.7b00319%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DD.%26aulast%3DWheeler%26aufirst%3DP.%26aulast%3DEne%26aufirst%3DD.%26atitle%3DOlefin%2520Metathesis%2520in%2520Drug%2520Discovery%2520and%2520Development%25E2%2580%2594Examples%2520from%2520Recent%2520Patent%2520Literature%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2017%26volume%3D21%26issue%3D12%26spage%3D1938%26epage%3D1962%26doi%3D10.1021%2Facs.oprd.7b00319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharpless, N. E.</span>; <span class="NLM_string-name">Strum, J. C.</span>; <span class="NLM_string-name">Bisi, J. E.</span>; <span class="NLM_string-name">Roberts, P. J.</span>; <span class="NLM_string-name">Tavares, F. X.</span></span> <span> </span><span class="NLM_article-title">Highly Active Anti-Neoplastic and Anti-Proliferative Agents</span>. <span class="NLM_patent">WO2014144740A2</span>, September 18, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=N.+E.+Sharpless&author=J.+C.+Strum&author=J.+E.+Bisi&author=P.+J.+Roberts&author=F.+X.+Tavares&title=Highly+Active+Anti-Neoplastic+and+Anti-Proliferative+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSharpless%26aufirst%3DN.%2BE.%26atitle%3DHighly%2520Active%2520Anti-Neoplastic%2520and%2520Anti-Proliferative%2520Agents%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span>; <span class="NLM_string-name">White, H. S.</span>; <span class="NLM_string-name">Tavares, F. X.</span>; <span class="NLM_string-name">Krasutsky, S.</span>; <span class="NLM_string-name">Chen, J.-X.</span>; <span class="NLM_string-name">Dorrow, R. L.</span>; <span class="NLM_string-name">Zhong, H.</span></span> <span> </span><span class="NLM_article-title">Synthesis of N-(Heteroaryl)-Pyrrolo[3,2-d]Pyrimidin-2-Amines</span>. <span class="NLM_patent">WO2018005865A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=A.+Smith&author=H.+S.+White&author=F.+X.+Tavares&author=S.+Krasutsky&author=J.-X.+Chen&author=R.+L.+Dorrow&author=H.+Zhong&title=Synthesis+of+N-%28Heteroaryl%29-Pyrrolo%5B3%2C2-d%5DPyrimidin-2-Amines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DA.%26atitle%3DSynthesis%2520of%2520N-%2528Heteroaryl%2529-Pyrrolo%255B3%252C2-d%255DPyrimidin-2-Amines%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ratni, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers-Evans, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bissantz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grundschober, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuler, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez
Sanchez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnider, P.</span></span> <span> </span><span class="NLM_article-title">Discovery of Highly Selective Brain-Penetrant Vasopressin 1a Antagonists for the Potential Treatment of Autism via a Chemogenomic and Scaffold Hopping Approach</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2275</span>– <span class="NLM_lpage">2289</span>, <span class="refDoi"> DOI: 10.1021/jm501745f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501745f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2MXit1Sgtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2275-2289&issue=5&author=H.+Ratniauthor=M.+Rogers-Evansauthor=C.+Bissantzauthor=C.+Grundschoberauthor=J.-L.+Moreauauthor=F.+Schulerauthor=H.+Fischerauthor=R.+Alvarez%0ASanchezauthor=P.+Schnider&title=Discovery+of+Highly+Selective+Brain-Penetrant+Vasopressin+1a+Antagonists+for+the+Potential+Treatment+of+Autism+via+a+Chemogenomic+and+Scaffold+Hopping+Approach&doi=10.1021%2Fjm501745f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Highly Selective Brain-Penetrant Vasopressin 1a Antagonists for the Potential Treatment of Autism via a Chemogenomic and Scaffold Hopping Approach</span></div><div class="casAuthors">Ratni, Hasane; Rogers-Evans, Mark; Bissantz, Caterina; Grundschober, Christophe; Moreau, Jean-Luc; Schuler, Franz; Fischer, Holger; Alvarez Sanchez, Ruben; Schnider, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2275-2289</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">From a micromolar high throughput screening hit 7, the successful complementary application of a chemogenomic approach and of a scaffold hopping exercise rapidly led to a low single digit nanomolar human vasopressin 1a (hV1a) receptor antagonist 38.  Initial optimization of the mouse V1a activities delivered suitable tool compds. which demonstrated a V1a mediated central in vivo effect.  This novel series was further optimized through parallel synthesis with a focus on balancing lipophilicity to achieve robust aq. soly. while avoiding P-gp mediated efflux.  These efforts led to the discovery of the highly potent and selective brain-penetrant hV1a antagonist RO5028442 (8) suitable for human clin. studies in people with autism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpyc3A24J_GLVg90H21EOLACvtfcHk0liKBjqubwuVGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXit1Sgtrc%253D&md5=587fbafaf38372123378586ecd87f10a</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Fjm501745f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501745f%26sid%3Dliteratum%253Aachs%26aulast%3DRatni%26aufirst%3DH.%26aulast%3DRogers-Evans%26aufirst%3DM.%26aulast%3DBissantz%26aufirst%3DC.%26aulast%3DGrundschober%26aufirst%3DC.%26aulast%3DMoreau%26aufirst%3DJ.-L.%26aulast%3DSchuler%26aufirst%3DF.%26aulast%3DFischer%26aufirst%3DH.%26aulast%3DAlvarez%2BSanchez%26aufirst%3DR.%26aulast%3DSchnider%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520Highly%2520Selective%2520Brain-Penetrant%2520Vasopressin%25201a%2520Antagonists%2520for%2520the%2520Potential%2520Treatment%2520of%2520Autism%2520via%2520a%2520Chemogenomic%2520and%2520Scaffold%2520Hopping%2520Approach%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D5%26spage%3D2275%26epage%3D2289%26doi%3D10.1021%2Fjm501745f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bissantz, C.</span>; <span class="NLM_string-name">Grundschober, C.</span>; <span class="NLM_string-name">Ratni, H.</span>; <span class="NLM_string-name">Rogers-Evans, M.</span>; <span class="NLM_string-name">Schnider, P.</span></span> <span> </span><span class="NLM_article-title">Indol-3-Carbonyl-Spiro-Piperidine Derivatives as V1a Receptor Antagonists</span>. <span class="NLM_patent">WO2007006688A1</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=C.+Bissantz&author=C.+Grundschober&author=H.+Ratni&author=M.+Rogers-Evans&author=P.+Schnider&title=Indol-3-Carbonyl-Spiro-Piperidine+Derivatives+as+V1a+Receptor+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBissantz%26aufirst%3DC.%26atitle%3DIndol-3-Carbonyl-Spiro-Piperidine%2520Derivatives%2520as%2520V1a%2520Receptor%2520Antagonists%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohtake, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taka, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohmori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeu, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuoka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morikawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of Tofogliflozin, a Novel C-Arylglucoside with an O-Spiroketal Ring System, as a Highly Selective Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">7828</span>– <span class="NLM_lpage">7840</span>, <span class="refDoi"> DOI: 10.1021/jm300884k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300884k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFOrurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7828-7840&issue=17&author=Y.+Ohtakeauthor=T.+Satoauthor=T.+Kobayashiauthor=M.+Nishimotoauthor=N.+Takaauthor=K.+Takanoauthor=K.+Yamamotoauthor=M.+Ohmoriauthor=M.+Yamaguchiauthor=K.+Takamiauthor=S.-Y.+Yeuauthor=K.-H.+Ahnauthor=H.+Matsuokaauthor=K.+Morikawaauthor=M.+Suzukiauthor=H.+Hagitaauthor=K.+Ozawaauthor=K.+Yamaguchiauthor=M.+Katoauthor=S.+Ikeda&title=Discovery+of+Tofogliflozin%2C+a+Novel+C-Arylglucoside+with+an+O-Spiroketal+Ring+System%2C+as+a+Highly+Selective+Sodium+Glucose+Cotransporter+2+%28SGLT2%29+Inhibitor+for+the+Treatment+of+Type+2+Diabetes&doi=10.1021%2Fjm300884k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Tofogliflozin, a Novel C-Arylglucoside with an O-Spiroketal Ring System, as a Highly Selective Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes</span></div><div class="casAuthors">Ohtake, Yoshihito; Sato, Tsutomu; Kobayashi, Takamitsu; Nishimoto, Masahiro; Taka, Naoki; Takano, Koji; Yamamoto, Keisuke; Ohmori, Masayuki; Yamaguchi, Marina; Takami, Kyoko; Yeu, Sang-Yong; Ahn, Koo-Hyeon; Matsuoka, Hiroharu; Morikawa, Kazumi; Suzuki, Masayuki; Hagita, Hitoshi; Ozawa, Kazuharu; Yamaguchi, Koji; Kato, Motohiro; Ikeda, Sachiya</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7828-7840</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of sodium glucose cotransporter 2 (SGLT2) has been proposed as a novel therapeutic approach to treat type 2 diabetes.  In our efforts to discover novel inhibitors of SGLT2, we first generated a 3D pharmacophore model based on the superposition of known inhibitors.  A search of the Cambridge Structural Database using a series of pharmacophore queries led to the discovery of an O-spiroketal C-arylglucoside scaffold.  Subsequent chem. examn. combined with computational modeling resulted in the identification of the clin. candidate CSG452 (tofogliflozin), which is currently under phase III clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeIDNjd6qaWLVg90H21EOLACvtfcHk0liKBjqubwuVGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFOrurfN&md5=174a0538c13a286dd320a52395e1dd85</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1021%2Fjm300884k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300884k%26sid%3Dliteratum%253Aachs%26aulast%3DOhtake%26aufirst%3DY.%26aulast%3DSato%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DNishimoto%26aufirst%3DM.%26aulast%3DTaka%26aufirst%3DN.%26aulast%3DTakano%26aufirst%3DK.%26aulast%3DYamamoto%26aufirst%3DK.%26aulast%3DOhmori%26aufirst%3DM.%26aulast%3DYamaguchi%26aufirst%3DM.%26aulast%3DTakami%26aufirst%3DK.%26aulast%3DYeu%26aufirst%3DS.-Y.%26aulast%3DAhn%26aufirst%3DK.-H.%26aulast%3DMatsuoka%26aufirst%3DH.%26aulast%3DMorikawa%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DHagita%26aufirst%3DH.%26aulast%3DOzawa%26aufirst%3DK.%26aulast%3DYamaguchi%26aufirst%3DK.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DIkeda%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520Tofogliflozin%252C%2520a%2520Novel%2520C-Arylglucoside%2520with%2520an%2520O-Spiroketal%2520Ring%2520System%252C%2520as%2520a%2520Highly%2520Selective%2520Sodium%2520Glucose%2520Cotransporter%25202%2520%2528SGLT2%2529%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Type%25202%2520Diabetes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D17%26spage%3D7828%26epage%3D7840%26doi%3D10.1021%2Fjm300884k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Biological Evaluation of Pyridone-Aminal Derivatives as MNK1/2 Inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1211</span>– <span class="NLM_lpage">1225</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2019.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2Fj.bmc.2019.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=30824167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjvFSqt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=1211-1225&issue=7&author=X.+Yuanauthor=H.+Wuauthor=H.+Buauthor=P.+Zhengauthor=J.+Zhouauthor=H.+Zhang&title=Design%2C+Synthesis+and+Biological+Evaluation+of+Pyridone-Aminal+Derivatives+as+MNK1%2F2+Inhibitors&doi=10.1016%2Fj.bmc.2019.02.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of pyridone-aminal derivatives as MNK1/2 inhibitors</span></div><div class="casAuthors">Yuan, Xinrui; Wu, Hanshu; Bu, Hong; Zheng, Peiyuan; Zhou, Jinpei; Zhang, Huibin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1211-1225</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Excessive phosphorylation of eukaryotic translation initiation factor 4E (eIF4E) plays a major role in the dysregulation of mRNA translation and the activation of tumor cell signaling. eIF4E is exclusively phosphorylated by mitogen-activated protein kinase interacting kinases 1 and 2 (MNK1/2) on Ser209.  So, MNK1/2 inhibitors could decrease the level of p-eIF4E and regulate tumor-assocd. signaling pathways.  A series of pyridone-aminal derivs. were synthesized and evaluated as MNK1/2 inhibitors.  Several compds. exhibited great inhibitory activity against MNK1/2 and selected compds. showed moderate to excellent anti-proliferative potency against hematol. cancer cell lines.  In particular, compd. 42i (MNK1 IC50 = 7.0 nM; MNK2 IC50 = 6.1 nM) proved to be the most potent compd. against TMD-8 cell line with IC50 value of 0.91 μM.  Furthermore, 42i could block the phosphorylation level of eIF4E in CT-26 cell line, and 42i inhibited the tumor growth of CT-26 allograft model significantly.  These results indicated that compd. 42i was a promising MNK1/2 inhibitor for the potent treatment of colon cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcZ3pb7Sl3ALVg90H21EOLACvtfcHk0lh7R9l6_TuaDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjvFSqt7o%253D&md5=d7016309d8f865d289f19aa97f50f115</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2019.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2019.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DBu%26aufirst%3DH.%26aulast%3DZheng%26aufirst%3DP.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Biological%2520Evaluation%2520of%2520Pyridone-Aminal%2520Derivatives%2520as%2520MNK1%252F2%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2019%26volume%3D27%26issue%3D7%26spage%3D1211%26epage%3D1225%26doi%3D10.1016%2Fj.bmc.2019.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reich, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprengeler, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appleman, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarine, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goel, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, E. Z. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, I. N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jemison, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jessen, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaghafi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperry, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staunton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stumpf, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webber, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wegerski, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, K. R.</span></span> <span> </span><span class="NLM_article-title">Structure-Based Design of Pyridone-Aminal EFT508 Targeting Dysregulated Translation by Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">3516</span>– <span class="NLM_lpage">3540</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01795</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01795" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktlGhs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=3516-3540&issue=8&author=S.+H.+Reichauthor=P.+A.+Sprengelerauthor=G.+G.+Chiangauthor=J.+R.+Applemanauthor=J.+Chenauthor=J.+Clarineauthor=B.+Eamauthor=J.+T.+Ernstauthor=Q.+Hanauthor=V.+K.+Goelauthor=E.+Z.+R.+Hanauthor=V.+Huangauthor=I.+N.+J.+Hungauthor=A.+Jemisonauthor=K.+A.+Jessenauthor=J.+Molterauthor=D.+Murphyauthor=M.+Nealauthor=G.+S.+Parkerauthor=M.+Shaghafiauthor=S.+Sperryauthor=J.+Stauntonauthor=C.+R.+Stumpfauthor=P.+A.+Thompsonauthor=C.+Tranauthor=S.+E.+Webberauthor=C.+J.+Wegerskiauthor=H.+Zhengauthor=K.+R.+Webster&title=Structure-Based+Design+of+Pyridone-Aminal+EFT508+Targeting+Dysregulated+Translation+by+Selective+Mitogen-Activated+Protein+Kinase+Interacting+Kinases+1+and+2+%28MNK1%2F2%29+Inhibition&doi=10.1021%2Facs.jmedchem.7b01795"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based Design of Pyridone-Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition</span></div><div class="casAuthors">Reich, Siegfried H.; Sprengeler, Paul A.; Chiang, Gary G.; Appleman, James R.; Chen, Joan; Clarine, Jeff; Eam, Boreth; Ernst, Justin T.; Han, Qing; Goel, Vikas K.; Han, Edward Z. R.; Huang, Vera; Hung, Ivy N. J.; Jemison, Adrianna; Jessen, Katti A.; Molter, Jolene; Murphy, Douglas; Neal, Melissa; Parker, Gregory S.; Shaghafi, Michael; Sperry, Samuel; Staunton, Jocelyn; Stumpf, Craig R.; Thompson, Peggy A.; Tran, Chinh; Webber, Stephen E.; Wegerski, Christopher J.; Zheng, Hong; Webster, Kevin R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3516-3540</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dysregulated translation of mRNA plays a major role in tumorigenesis.  Mitogen-activated protein kinase interacting kinases (MNK)1/2 are key regulators of mRNA translation integrating signals from oncogenic and immune signaling pathways through phosphorylation of eIF4E and other mRNA binding proteins.  Modulation of these key effector proteins regulates mRNA, which controls tumor/stromal cell signaling.  Compd. 23 (eFT508, 6'-((6-aminopyrimidin-4-yl)amino)-8'-methyl-2'H-spiro-[cyclohexane-1,3'-imidazo[1,5-a]pyridine]-1',5'-dione hydrochloride), an exquisitely selective, potent dual MNK1/2 inhibitor, was designed to assess the potential for control of oncogene signaling at the level of mRNA translation.  The crystal structure-guided design leverages stereoelectronic interactions unique to MNK culminating in a novel pyridone-aminal structure described for the first time in the kinase literature.  Compd. 23 has potent in vivo antitumor activity in models of diffuse large cell B-cell lymphoma and solid tumors, suggesting that controlling dysregulated translation has real therapeutic potential.  Compd. 23 is currently being evaluated in Phase 2 clin. trials in solid tumors and lymphoma.  Compd. 23 is the first highly selective dual MNK inhibitor targeting dysregulated translation being assessed clin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAp-3GOuZu8bVg90H21EOLACvtfcHk0lh7R9l6_TuaDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktlGhs7s%253D&md5=1254b674aa7e6d2037a06bc10e64e4da</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01795&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01795%26sid%3Dliteratum%253Aachs%26aulast%3DReich%26aufirst%3DS.%2BH.%26aulast%3DSprengeler%26aufirst%3DP.%2BA.%26aulast%3DChiang%26aufirst%3DG.%2BG.%26aulast%3DAppleman%26aufirst%3DJ.%2BR.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DClarine%26aufirst%3DJ.%26aulast%3DEam%26aufirst%3DB.%26aulast%3DErnst%26aufirst%3DJ.%2BT.%26aulast%3DHan%26aufirst%3DQ.%26aulast%3DGoel%26aufirst%3DV.%2BK.%26aulast%3DHan%26aufirst%3DE.%2BZ.%2BR.%26aulast%3DHuang%26aufirst%3DV.%26aulast%3DHung%26aufirst%3DI.%2BN.%2BJ.%26aulast%3DJemison%26aufirst%3DA.%26aulast%3DJessen%26aufirst%3DK.%2BA.%26aulast%3DMolter%26aufirst%3DJ.%26aulast%3DMurphy%26aufirst%3DD.%26aulast%3DNeal%26aufirst%3DM.%26aulast%3DParker%26aufirst%3DG.%2BS.%26aulast%3DShaghafi%26aufirst%3DM.%26aulast%3DSperry%26aufirst%3DS.%26aulast%3DStaunton%26aufirst%3DJ.%26aulast%3DStumpf%26aufirst%3DC.%2BR.%26aulast%3DThompson%26aufirst%3DP.%2BA.%26aulast%3DTran%26aufirst%3DC.%26aulast%3DWebber%26aufirst%3DS.%2BE.%26aulast%3DWegerski%26aufirst%3DC.%2BJ.%26aulast%3DZheng%26aufirst%3DH.%26aulast%3DWebster%26aufirst%3DK.%2BR.%26atitle%3DStructure-Based%2520Design%2520of%2520Pyridone-Aminal%2520EFT508%2520Targeting%2520Dysregulated%2520Translation%2520by%2520Selective%2520Mitogen-Activated%2520Protein%2520Kinase%2520Interacting%2520Kinases%25201%2520and%25202%2520%2528MNK1%252F2%2529%2520Inhibition%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D8%26spage%3D3516%26epage%3D3540%26doi%3D10.1021%2Facs.jmedchem.7b01795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, C.</span></span> <span> </span><span class="NLM_article-title">Combination of a Bace Inhibitor and an Antibody or Antigen-Binding Fragment for the Treatment of a Disorder Associated with the Accumulation of Amyloid Beta</span>. <span class="NLM_patent">WO2017158064A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=C.+Johnston&title=Combination+of+a+Bace+Inhibitor+and+an+Antibody+or+Antigen-Binding+Fragment+for+the+Treatment+of+a+Disorder+Associated+with+the+Accumulation+of+Amyloid+Beta"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJohnston%26aufirst%3DC.%26atitle%3DCombination%2520of%2520a%2520Bace%2520Inhibitor%2520and%2520an%2520Antibody%2520or%2520Antigen-Binding%2520Fragment%2520for%2520the%2520Treatment%2520of%2520a%2520Disorder%2520Associated%2520with%2520the%2520Accumulation%2520of%2520Amyloid%2520Beta%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Panza, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozupone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watling, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imbimbo, B. P.</span></span> <span> </span><span class="NLM_article-title">Do BACE Inhibitor Failures in Alzheimer Patients Challenge the Amyloid Hypothesis of the Disease?</span>. <i>Expert Rev. Neurother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">599</span>– <span class="NLM_lpage">602</span>, <span class="refDoi"> DOI: 10.1080/14737175.2019.1621751</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1080%2F14737175.2019.1621751" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=31112433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVGhs7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=599-602&issue=7&author=F.+Panzaauthor=M.+Lozuponeauthor=M.+Watlingauthor=B.+P.+Imbimbo&title=Do+BACE+Inhibitor+Failures+in+Alzheimer+Patients+Challenge+the+Amyloid+Hypothesis+of+the+Disease%3F&doi=10.1080%2F14737175.2019.1621751"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Do BACE inhibitor failures in Alzheimer's patients challenge the amyloid hypothesis of the disease?</span></div><div class="casAuthors">Panza, Francesco; Lozupone, Madia; Watling, Mark; Imbimbo, Bruno Pietro</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Neurotherapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">599-602</span>CODEN:
                <span class="NLM_cas:coden">ERNXAR</span>;
        ISSN:<span class="NLM_cas:issn">1473-7175</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMWoN30kZDtbVg90H21EOLACvtfcHk0lgbaOOvL2YpoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVGhs7fP&md5=7f68c44c61c9f3e720f6b905bc831563</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1080%2F14737175.2019.1621751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14737175.2019.1621751%26sid%3Dliteratum%253Aachs%26aulast%3DPanza%26aufirst%3DF.%26aulast%3DLozupone%26aufirst%3DM.%26aulast%3DWatling%26aufirst%3DM.%26aulast%3DImbimbo%26aufirst%3DB.%2BP.%26atitle%3DDo%2520BACE%2520Inhibitor%2520Failures%2520in%2520Alzheimer%2520Patients%2520Challenge%2520the%2520Amyloid%2520Hypothesis%2520of%2520the%2520Disease%253F%26jtitle%3DExpert%2520Rev.%2520Neurother.%26date%3D2019%26volume%3D19%26issue%3D7%26spage%3D599%26epage%3D602%26doi%3D10.1080%2F14737175.2019.1621751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez Barrat, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodward, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inglesby, P. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis of 2-Oxopropanethioamide for the Manufacture of Lanabecestat: A New Route for Control, Robustness, and Operational Improvements</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1404</span>– <span class="NLM_lpage">1412</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.7b00170</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.7b00170" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFegsL%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2017&pages=1404-1412&issue=9&author=B.+Taylorauthor=C.+Fernandez+Barratauthor=R.+L.+Woodwardauthor=P.+A.+Inglesby&title=Synthesis+of+2-Oxopropanethioamide+for+the+Manufacture+of+Lanabecestat%3A+A+New+Route+for+Control%2C+Robustness%2C+and+Operational+Improvements&doi=10.1021%2Facs.oprd.7b00170"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of 2-Oxopropanethioamide for the Manufacture of Lanabecestat: A New Route for Control, Robustness, and Operational Improvements</span></div><div class="casAuthors">Taylor, Brian; Fernandez Barrat, Cristina; Woodward, Robert L.; Inglesby, Phillip A.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1404-1412</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new route to 2-oxopropanethioamide, a key intermediate in the synthesis of lanabecestat (AZD3293/LY3314814), is described by employing com. available 2,2-diethoxypropionitrile as a raw material.  In contrast to the previous route, this work offers several advantages, for example, the raw material is safer to manuf. and handle, highly toxic hydrogen sulfide gas is no longer required as a reagent and in situ FTIR spectroscopy monitoring has provided manufg. controls and robustness.  Addnl., this route offers a hold- and control-point by virtue of an isolable cryst. intermediate, which in turn provides improved quality that is evident in the downstream synthesis.  An extensive design-of-expt. anal. was undertaken to understand multi-factor interdependencies, build a model, visualize factor relationships, map the process parameter reaction space, identify potential process operating conditions and predict their performance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrILs_CNHAbK7Vg90H21EOLACvtfcHk0lgbaOOvL2YpoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFegsL%252FF&md5=096c63a7672af6e2b95d5d1e6228e9b6</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.7b00170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.7b00170%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DB.%26aulast%3DFernandez%2BBarrat%26aufirst%3DC.%26aulast%3DWoodward%26aufirst%3DR.%2BL.%26aulast%3DInglesby%26aufirst%3DP.%2BA.%26atitle%3DSynthesis%2520of%25202-Oxopropanethioamide%2520for%2520the%2520Manufacture%2520of%2520Lanabecestat%253A%2520A%2520New%2520Route%2520for%2520Control%252C%2520Robustness%252C%2520and%2520Operational%2520Improvements%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2017%26volume%3D21%26issue%3D9%26spage%3D1404%26epage%3D1412%26doi%3D10.1021%2Facs.oprd.7b00170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ashworth, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherryman, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crampton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eden-Rump, E. G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKeever-Abbas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meadows, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skilling, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, D. T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodward, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inglesby, P. A.</span></span> <span> </span><span class="NLM_article-title">Process Development of a Suzuki Reaction Used in the Manufacture of Lanabecestat</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1801</span>– <span class="NLM_lpage">1808</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.8b00312</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.8b00312" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFagurvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2018&pages=1801-1808&issue=12&author=I.+W.+Ashworthauthor=A.+D.+Campbellauthor=J.+H.+Cherrymanauthor=J.+Clarkauthor=A.+Cramptonauthor=E.+G.+B.+Eden-Rumpauthor=M.+Evansauthor=M.+F.+Jonesauthor=S.+McKeever-Abbasauthor=R.+E.+Meadowsauthor=K.+Skillingauthor=D.+T.+E.+Whittakerauthor=R.+L.+Woodwardauthor=P.+A.+Inglesby&title=Process+Development+of+a+Suzuki+Reaction+Used+in+the+Manufacture+of+Lanabecestat&doi=10.1021%2Facs.oprd.8b00312"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Process Development of a Suzuki Reaction Used in the Manufacture of Lanabecestat</span></div><div class="casAuthors">Ashworth, Ian W.; Campbell, Andrew D.; Cherryman, Janette H.; Clark, Jemma; Crampton, Alex; Eden-Rump, Edward G. B.; Evans, Matthew; Jones, Martin F.; McKeever-Abbas, Sahar; Meadows, Rebecca E.; Skilling, Kathryn; Whittaker, David T. E.; Woodward, Robert L.; Inglesby, Phillip A.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1801-1808</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A process for prepn. of the potential anti-Alzheimer's agent lanabecestat was developed by coupling of an alkynylpyridinylboronic acid diethanolamine ester with a bromodispirocyclohexaneindaneimidazole in the presence of Pd(AmPhos)2Cl2 and K3PO4 in EtOH/H2O; the new process reduced the need for solvent changes and difficult isolation steps and decreased the amt. of palladium detected in the final product without the use of solid-phase extractants.  The kinetics of hydrolysis of the diethanolamine boronate and the free boronic acid was detd.; diethanolamine generated in the hydrolysis decreased the rate of coupling but likely improved the purge of palladium from the product.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP4yqA1DlbgbVg90H21EOLACvtfcHk0lgbaOOvL2YpoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFagurvO&md5=cff322c98ae1cd9d8f8af50db2795b92</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.8b00312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.8b00312%26sid%3Dliteratum%253Aachs%26aulast%3DAshworth%26aufirst%3DI.%2BW.%26aulast%3DCampbell%26aufirst%3DA.%2BD.%26aulast%3DCherryman%26aufirst%3DJ.%2BH.%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DCrampton%26aufirst%3DA.%26aulast%3DEden-Rump%26aufirst%3DE.%2BG.%2BB.%26aulast%3DEvans%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DM.%2BF.%26aulast%3DMcKeever-Abbas%26aufirst%3DS.%26aulast%3DMeadows%26aufirst%3DR.%2BE.%26aulast%3DSkilling%26aufirst%3DK.%26aulast%3DWhittaker%26aufirst%3DD.%2BT.%2BE.%26aulast%3DWoodward%26aufirst%3DR.%2BL.%26aulast%3DInglesby%26aufirst%3DP.%2BA.%26atitle%3DProcess%2520Development%2520of%2520a%2520Suzuki%2520Reaction%2520Used%2520in%2520the%2520Manufacture%2520of%2520Lanabecestat%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2018%26volume%3D22%26issue%3D12%26spage%3D1801%26epage%3D1808%26doi%3D10.1021%2Facs.oprd.8b00312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krasavin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lukin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagnyukova, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhurilo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golovanov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zozulya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahanich, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tikhonova, I. G.</span></span> <span> </span><span class="NLM_article-title">Polar Aromatic Periphery Increases Agonist Potency of Spirocyclic Free Fatty Acid Receptor (GPR40) Agonists Inspired by LY2881835</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">357</span>– <span class="NLM_lpage">368</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.01.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2Fj.ejmech.2017.01.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=28076825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotlCqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2017&pages=357-368&author=M.+Krasavinauthor=A.+Lukinauthor=D.+Bagnyukovaauthor=N.+Zhuriloauthor=A.+Golovanovauthor=S.+Zozulyaauthor=I.+Zahanichauthor=D.+Mooreauthor=I.+G.+Tikhonova&title=Polar+Aromatic+Periphery+Increases+Agonist+Potency+of+Spirocyclic+Free+Fatty+Acid+Receptor+%28GPR40%29+Agonists+Inspired+by+LY2881835&doi=10.1016%2Fj.ejmech.2017.01.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Polar aromatic periphery increases agonist potency of spirocyclic free fatty acid receptor (GPR40) agonists inspired by LY2881835</span></div><div class="casAuthors">Krasavin, Mikhail; Lukin, Alexey; Bagnyukova, Daria; Zhurilo, Nikolay; Golovanov, Aleksei; Zozulya, Sergey; Zahanich, Ihor; Moore, Daniel; Tikhonova, Irina G.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">357-368</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of spirocyclic compds. inspired by Eli Lilly's phase 1 antidiabetic FFA1 receptor agonist LY2881835 was designed to include polar arom. periphery groups and explore a possibility of building addnl. contacts with the target near the agonist binding site.  The frontrunner compd. in the series (9i) was shown to be a potent (EC50 = 260 nM) FFA1 agonist with excellent aq. (PBS) soly. and good Caco-2 permeability.  The obsd. structure-activity relationships were rationalized by a docking study.  The new series significantly expands the ligand landscape for the ongoing quest for new potent and more polar FFA1 agonists as fundamentally new class of therapeutic agents against type 2 diabetes mellitus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr7HOd2sruvrVg90H21EOLACvtfcHk0lhNGT7EI-RCww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotlCqsQ%253D%253D&md5=195aceb726cbc5e14186dd135a32ff92</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.01.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.01.005%26sid%3Dliteratum%253Aachs%26aulast%3DKrasavin%26aufirst%3DM.%26aulast%3DLukin%26aufirst%3DA.%26aulast%3DBagnyukova%26aufirst%3DD.%26aulast%3DZhurilo%26aufirst%3DN.%26aulast%3DGolovanov%26aufirst%3DA.%26aulast%3DZozulya%26aufirst%3DS.%26aulast%3DZahanich%26aufirst%3DI.%26aulast%3DMoore%26aufirst%3DD.%26aulast%3DTikhonova%26aufirst%3DI.%2BG.%26atitle%3DPolar%2520Aromatic%2520Periphery%2520Increases%2520Agonist%2520Potency%2520of%2520Spirocyclic%2520Free%2520Fatty%2520Acid%2520Receptor%2520%2528GPR40%2529%2520Agonists%2520Inspired%2520by%2520LY2881835%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D127%26spage%3D357%26epage%3D368%26doi%3D10.1016%2Fj.ejmech.2017.01.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billington, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middlemiss, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, E. H.</span></span> <span> </span><span class="NLM_article-title">Spiropiperidines as High-Affinity, Selective Sigma Ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2033</span>– <span class="NLM_lpage">2039</span>, <span class="refDoi"> DOI: 10.1021/jm00089a013</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00089a013" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADyaK38XisFGntrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1992&pages=2033-2039&issue=11&author=M.+S.+Chambersauthor=R.+Bakerauthor=D.+C.+Billingtonauthor=A.+K.+Knightauthor=D.+N.+Middlemissauthor=E.+H.+Wong&title=Spiropiperidines+as+High-Affinity%2C+Selective+Sigma+Ligands&doi=10.1021%2Fjm00089a013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Spiropiperidines as high-affinity, selective σ ligands.</span></div><div class="casAuthors">Chambers, Mark S.; Baker, Raymond; Billington, David C.; Knight, Anthony K.; Middlemiss, D. N.; Wong, Eric H. F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2033-9</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">A variety of achiral conformationally restricted spirocyclic piperidines were prepd. in an attempt to investigate the functional role of the central σ recognition site.  All compds. possessed a lipophilic N-substituent incorporating either a tetralin (I; n = 2, R = PhCH2, Bu, hexyl, 2-picolyl, cyclohexylmethyl, CH2CH:CH2, 2-furylmethyl, 2-thienylmethyl, CH2CH:CMe2, etc.), indan (I; n = 1, R = PhCH2, PhCH2CH2, CH2CH:CMe2, Bu, etc.), or benzocycloheptane skeleton (I; n = 3, R = PhCH2, Bu).  Their in vitro affinity at the σ site was assessed in radioligand displacement expts. with guinea pig cerebellum homogenates using the σ-specific radioligand N,N-di-o-[5-3H]-tolylguanidine (II).  A study of the structure-activity relationships identified the N-Bu and N-dimethylallyl substituents as the optimum groups for high affinity and selectivity at the σ site, e.g., I (n = 1, R = CH2CH:CMe2), pIC50 = 8.9 vs II and >10,000-fold selective over the dopamine D2 receptor.  Such compds. are amongst the highest affinity σ ligands reported to date, with excellent selectivity over the dopamine D2 receptor, and may serve as a useful tool for exploring the physiol. role of the σ site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr90qP5qz7Mm7Vg90H21EOLACvtfcHk0lhNGT7EI-RCww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XisFGntrg%253D&md5=1d61ff31c46c1c2febdfccd3673799da</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1021%2Fjm00089a013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00089a013%26sid%3Dliteratum%253Aachs%26aulast%3DChambers%26aufirst%3DM.%2BS.%26aulast%3DBaker%26aufirst%3DR.%26aulast%3DBillington%26aufirst%3DD.%2BC.%26aulast%3DKnight%26aufirst%3DA.%2BK.%26aulast%3DMiddlemiss%26aufirst%3DD.%2BN.%26aulast%3DWong%26aufirst%3DE.%2BH.%26atitle%3DSpiropiperidines%2520as%2520High-Affinity%252C%2520Selective%2520Sigma%2520Ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1992%26volume%3D35%26issue%3D11%26spage%3D2033%26epage%3D2039%26doi%3D10.1021%2Fjm00089a013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamdouchi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahl, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel
Lewis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardona, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zink, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eessalu, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ficorilli, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcelo, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otto, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilbur, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lineswala, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piper, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coffey, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweetana, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratt, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belin, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deeg, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cannady, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yumibe, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maiti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montrose-Rafizadeh, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reifel Miller, A.</span></span> <span> </span><span class="NLM_article-title">The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">10891</span>– <span class="NLM_lpage">10916</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00892</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00892" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1yks7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=10891-10916&issue=24&author=C.+Hamdouchiauthor=S.+D.+Kahlauthor=A.+Patel%0ALewisauthor=G.+R.+Cardonaauthor=R.+W.+Zinkauthor=K.+Chenauthor=T.+E.+Eessaluauthor=J.+V.+Ficorilliauthor=M.+C.+Marceloauthor=K.+A.+Ottoauthor=K.+L.+Wilburauthor=J.+P.+Lineswalaauthor=J.+L.+Piperauthor=D.+S.+Coffeyauthor=S.+A.+Sweetanaauthor=J.+V.+Haasauthor=D.+A.+Brooksauthor=E.+J.+Prattauthor=R.+M.+Belinauthor=M.+A.+Deegauthor=X.+Maauthor=E.+A.+Cannadyauthor=J.+T.+Johnsonauthor=N.+P.+Yumibeauthor=Q.+Chenauthor=P.+Maitiauthor=C.+Montrose-Rafizadehauthor=Y.+Chenauthor=A.+Reifel+Miller&title=The+Discovery%2C+Preclinical%2C+and+Early+Clinical+Development+of+Potent+and+Selective+GPR40+Agonists+for+the+Treatment+of+Type+2+Diabetes+Mellitus+%28LY2881835%2C+LY2922083%2C+and+LY2922470%29&doi=10.1021%2Facs.jmedchem.6b00892"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)</span></div><div class="casAuthors">Hamdouchi, Chafiq; Kahl, Steven D.; Patel Lewis, Anjana; Cardona, Guemalli R.; Zink, Richard W.; Chen, Keyue; Eessalu, Thomas E.; Ficorilli, James V.; Marcelo, Marialuisa C.; Otto, Keith A.; Wilbur, Kelly L.; Lineswala, Jayana P.; Piper, Jared L.; Coffey, D. Scott; Sweetana, Stephanie A.; Haas, Joseph V.; Brooks, Dawn A.; Pratt, Edward J.; Belin, Ruth M.; Deeg, Mark A.; Ma, Xiaosu; Cannady, Ellen A.; Johnson, Jason T.; Yumibe, Nathan P.; Chen, Qi; Maiti, Pranab; Montrose-Rafizadeh, Chahrzad; Chen, Yanyun; Reifel Miller, Anne</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10891-10916</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The G protein-coupled receptor 40 (GPR40) also known as Free Fatty Acid Receptor 1 (FFAR1) is highly expressed in pancreatic, islet β-cells and responds to endogenous fatty acids resulting in amplification of insulin secretion only in the presence of elevated glucose levels.  Hypothesis driven structural modifications to endogenous FFAs, focused on breaking planarity and reducing lipophilicity, led to the identification of spiropiperidine and tetrahydroquinoline acid derivs. as GPR40 agonists with unique pharmacol., selectivity and pharmacokinetic properties.  Compds. 1 (LY2881835), 2 (LY2922083) and 3 (LY2922470) demonstrated potent, efficacious and durable dose dependent redns. in glucose levels along with significant increases in insulin and GLP-1 secretion during preclin. testing.  A clin. study with 3 administered to subjects with T2DM provided proof of concept of 3 as a potential glucose-lowering therapy.  This manuscript summarizes the scientific rationale, medicinal chem., preclin. and early development data of this new class of GPR40 agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJDHJpZ9o4lLVg90H21EOLACvtfcHk0lgU02MLeat3Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1yks7zF&md5=9e36cc1791d7e7e0e54aa725fe3e0cc3</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00892&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00892%26sid%3Dliteratum%253Aachs%26aulast%3DHamdouchi%26aufirst%3DC.%26aulast%3DKahl%26aufirst%3DS.%2BD.%26aulast%3DPatel%2BLewis%26aufirst%3DA.%26aulast%3DCardona%26aufirst%3DG.%2BR.%26aulast%3DZink%26aufirst%3DR.%2BW.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DEessalu%26aufirst%3DT.%2BE.%26aulast%3DFicorilli%26aufirst%3DJ.%2BV.%26aulast%3DMarcelo%26aufirst%3DM.%2BC.%26aulast%3DOtto%26aufirst%3DK.%2BA.%26aulast%3DWilbur%26aufirst%3DK.%2BL.%26aulast%3DLineswala%26aufirst%3DJ.%2BP.%26aulast%3DPiper%26aufirst%3DJ.%2BL.%26aulast%3DCoffey%26aufirst%3DD.%2BS.%26aulast%3DSweetana%26aufirst%3DS.%2BA.%26aulast%3DHaas%26aufirst%3DJ.%2BV.%26aulast%3DBrooks%26aufirst%3DD.%2BA.%26aulast%3DPratt%26aufirst%3DE.%2BJ.%26aulast%3DBelin%26aufirst%3DR.%2BM.%26aulast%3DDeeg%26aufirst%3DM.%2BA.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DCannady%26aufirst%3DE.%2BA.%26aulast%3DJohnson%26aufirst%3DJ.%2BT.%26aulast%3DYumibe%26aufirst%3DN.%2BP.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DMaiti%26aufirst%3DP.%26aulast%3DMontrose-Rafizadeh%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DReifel%2BMiller%26aufirst%3DA.%26atitle%3DThe%2520Discovery%252C%2520Preclinical%252C%2520and%2520Early%2520Clinical%2520Development%2520of%2520Potent%2520and%2520Selective%2520GPR40%2520Agonists%2520for%2520the%2520Treatment%2520of%2520Type%25202%2520Diabetes%2520Mellitus%2520%2528LY2881835%252C%2520LY2922083%252C%2520and%2520LY2922470%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D24%26spage%3D10891%26epage%3D10916%26doi%3D10.1021%2Facs.jmedchem.6b00892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dodick, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipton, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ailani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finnegan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trugman, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szegedi, A.</span></span> <span> </span><span class="NLM_article-title">Ubrogepant for the Treatment of Migraine</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>381</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">2230</span>– <span class="NLM_lpage">2241</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1813049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1056%2FNEJMoa1813049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=31800988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVylsL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=381&publication_year=2019&pages=2230-2241&issue=23&author=D.+W.+Dodickauthor=R.+B.+Liptonauthor=J.+Ailaniauthor=K.+Luauthor=M.+Finneganauthor=J.+M.+Trugmanauthor=A.+Szegedi&title=Ubrogepant+for+the+Treatment+of+Migraine&doi=10.1056%2FNEJMoa1813049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Ubrogepant for the treatment of migraine</span></div><div class="casAuthors">Dodick, David W.; Lipton, Richard B.; Ailani, Jessica; Lu, Kaifeng; Finnegan, Michelle; Trugman, Joel M.; Szegedi, Armin</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">381</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2230-2241</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Ubrogepant is an oral, small-mol. calcitonin gene-related peptide receptor antagonist for acute migraine treatment. methods We conducted a randomized trial to evaluate the efficacy, safety, and side-effect profile of ubrogepant.  We assigned adults with migraine, with or without aura, in a 1:1:1 ratio to receive an initial dose of placebo, ubrogepant at a dose of 50 mg, or ubrogepant at a dose of 100 mg for treatment of a single migraine attack, with the option to take a second dose.  The coprimary efficacy end points were freedom from pain at 2 h after the initial dose and absence of the most bothersome migraine-assocd. symptom at 2 h.  Secondary end points included pain relief (at 2 h), sustained pain relief (from 2 to 24 h), sustained freedom from pain (from 2 to 24 h), and absence of symptoms assocd. with migraine (photophobia, phonophobia, and nausea) at 2 h. results A total of 1672 participants were enrolled; 559 were assigned to receive placebo, 556 to receive 50 mg of ubrogepant, and 557 to receive 100 mg of ubrogepant.  The percentage of participants who had freedom from pain at 2 h was 11.8% in the placebo group, 19.2% in the 50-mg ubrogepant group (P = 0.002, adjusted for multiplicity, for the comparison with placebo), and 21.2% in the 100-mg ubrogepant group (P<0.001).  The percentage of participants who had freedom from the most bothersome symptom at 2 h was 27.8% in the placebo group, 38.6% in the 50-mg ubrogepant group (P = 0.002), and 37.7% in the 100-mg ubrogepant group (P = 0.002).  Adverse events within 48 h after the initial or optional second dose were reported in 12.8% of participants in the placebo group, in 9.4% in the 50-mg ubrogepant group, and in 16.3% in the 100-mg ubrogepant group.  The most common adverse events were nausea, somnolence, and dry mouth (reported in 0.4 to 4.1%); these events were more frequent in the 100-mg ubrogepant group (reported in 2.1 to 4.1%).  Serious adverse events reported within 30 days in the ubrogepant groups included appendicitis, spontaneous abortion, pericardial effusion, and seizure; none of the events occurred within 48 h after the dose. conclusions A higher percentage of participants who received ubrogepant than of those who received placebo had freedom from pain and absence of the most bothersome symptom at 2 h after the dose.  The most commonly reported adverse events were nausea, somnolence, and dry mouth.  Further trials are needed to det. the durability and safety of ubrogepant for acute migraine treatment and to compare it with other drugs for migraine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozl_vTLCa_ALVg90H21EOLACvtfcHk0lgU02MLeat3Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVylsL3K&md5=3ac0c00c8b4d6216e24fb20ec4ce75dc</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1813049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1813049%26sid%3Dliteratum%253Aachs%26aulast%3DDodick%26aufirst%3DD.%2BW.%26aulast%3DLipton%26aufirst%3DR.%2BB.%26aulast%3DAilani%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DK.%26aulast%3DFinnegan%26aufirst%3DM.%26aulast%3DTrugman%26aufirst%3DJ.%2BM.%26aulast%3DSzegedi%26aufirst%3DA.%26atitle%3DUbrogepant%2520for%2520the%2520Treatment%2520of%2520Migraine%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2019%26volume%3D381%26issue%3D23%26spage%3D2230%26epage%3D2241%26doi%3D10.1056%2FNEJMoa1813049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleator, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosjek, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, S.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belyk, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullens, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodyear, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishop, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceglia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belardi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMichele, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reamer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabirol, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span> <span> </span><span class="NLM_article-title">Practical Asymmetric Synthesis of a Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist Ubrogepant</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1851</span>– <span class="NLM_lpage">1858</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.7b00293</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.7b00293" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1yhsLfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2017&pages=1851-1858&issue=11&author=N.+Yasudaauthor=E.+Cleatorauthor=B.+Kosjekauthor=J.+Yinauthor=B.+Xiangauthor=F.+Chenauthor=S.-C.+Kuoauthor=K.+Belykauthor=P.+R.+Mullensauthor=A.+Goodyearauthor=J.+S.+Edwardsauthor=B.+Bishopauthor=S.+Cegliaauthor=J.+Belardiauthor=L.+Tanauthor=Z.+J.+Songauthor=L.+DiMicheleauthor=R.+Reamerauthor=F.+L.+Cabirolauthor=W.+L.+Tangauthor=G.+Liu&title=Practical+Asymmetric+Synthesis+of+a+Calcitonin+Gene-Related+Peptide+%28CGRP%29+Receptor+Antagonist+Ubrogepant&doi=10.1021%2Facs.oprd.7b00293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Practical Asymmetric Synthesis of a Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist Ubrogepant</span></div><div class="casAuthors">Yasuda, Nobuyoshi; Cleator, Ed; Kosjek, Birgit; Yin, Jianguo; Xiang, Bangping; Chen, Frank; Kuo, Shen-Chun; Belyk, Kevin; Mullens, Peter R.; Goodyear, Adrian; Edwards, John S.; Bishop, Brian; Ceglia, Scott; Belardi, Justin; Tan, Lushi; Song, Zhiguo J.; DiMichele, Lisa; Reamer, Robert; Cabirol, Fabien L.; Tang, Weng Lin; Liu, Guiquan</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1851-1858</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development of a scalable asym. route to a new calcitonin gene-related peptide (CGRP) receptor antagonist is described.  The synthesis of the two key fragments was redefined, and the intermediates were accessed through novel chem.  Chiral lactam I was prepd. by an enzyme mediated dynamic kinetic transamination which simultaneously set two stereocenters.  Enzyme evolution resulted in an optimized transaminase providing the desired configuration in >60:1 syn/anti.  The final chiral center was set via a crystn. induced diastereomeric transformation.  The asym. spirocyclization to form the second fragment, chiral spiro acid intermediate II, was catalyzed by a novel doubly quaternized phase transfer catalyst and provided optically pure material on isolation.  With the two fragments in hand, development of their final union by amide bond formation and subsequent direct isolation is described.  The described chem. has been used to deliver over 100 kg of our desired target, ubrogepant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr70PHPVaaWYrVg90H21EOLACvtfcHk0lgV9_RZ1OqLrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1yhsLfJ&md5=b3745d6fb5671bff49b9e022f868dab5</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.7b00293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.7b00293%26sid%3Dliteratum%253Aachs%26aulast%3DYasuda%26aufirst%3DN.%26aulast%3DCleator%26aufirst%3DE.%26aulast%3DKosjek%26aufirst%3DB.%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DXiang%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DKuo%26aufirst%3DS.-C.%26aulast%3DBelyk%26aufirst%3DK.%26aulast%3DMullens%26aufirst%3DP.%2BR.%26aulast%3DGoodyear%26aufirst%3DA.%26aulast%3DEdwards%26aufirst%3DJ.%2BS.%26aulast%3DBishop%26aufirst%3DB.%26aulast%3DCeglia%26aufirst%3DS.%26aulast%3DBelardi%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DL.%26aulast%3DSong%26aufirst%3DZ.%2BJ.%26aulast%3DDiMichele%26aufirst%3DL.%26aulast%3DReamer%26aufirst%3DR.%26aulast%3DCabirol%26aufirst%3DF.%2BL.%26aulast%3DTang%26aufirst%3DW.%2BL.%26aulast%3DLiu%26aufirst%3DG.%26atitle%3DPractical%2520Asymmetric%2520Synthesis%2520of%2520a%2520Calcitonin%2520Gene-Related%2520Peptide%2520%2528CGRP%2529%2520Receptor%2520Antagonist%2520Ubrogepant%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2017%26volume%3D21%26issue%3D11%26spage%3D1851%26epage%3D1858%26doi%3D10.1021%2Facs.oprd.7b00293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marron, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prime, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storer, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swain, N. A.</span></span> <span> </span><span class="NLM_article-title">Recent Progress in Sodium Channel Modulators for Pain</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">3690</span>– <span class="NLM_lpage">3699</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.06.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2Fj.bmcl.2014.06.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=25060923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Wls7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=3690-3699&issue=16&author=S.+K.+Bagalauthor=M.+L.+Chapmanauthor=B.+E.+Marronauthor=R.+Primeauthor=R.+I.+Storerauthor=N.+A.+Swain&title=Recent+Progress+in+Sodium+Channel+Modulators+for+Pain&doi=10.1016%2Fj.bmcl.2014.06.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Recent progress in sodium channel modulators for pain</span></div><div class="casAuthors">Bagal, Sharan K.; Chapman, Mark L.; Marron, Brian E.; Prime, Rebecca; Storer, R. Ian; Swain, Nigel A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3690-3699</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Voltage-gated sodium channels (Navs) are an important family of transmembrane ion channel proteins and Nav drug discovery is an exciting field.  Pharmaceutical investment in Navs for pain therapeutics has expanded exponentially due to genetic data such as SCN10A mutations and an improved ability to establish an effective screen sequence for example IonWorks Barracuda, Synchropatch and Qube.  Moreover, emerging clin. data (AZD-3161, XEN402, CNV1014802, PF-05089771, PF-04531083) combined with recent breakthroughs in Nav structural biol. pave the way for a future of fruitful prospective Nav drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbT6en4xkVxLVg90H21EOLACvtfcHk0lgV9_RZ1OqLrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Wls7vL&md5=c8bae40b70509e2aa3dce106e2c41677</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.06.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.06.038%26sid%3Dliteratum%253Aachs%26aulast%3DBagal%26aufirst%3DS.%2BK.%26aulast%3DChapman%26aufirst%3DM.%2BL.%26aulast%3DMarron%26aufirst%3DB.%2BE.%26aulast%3DPrime%26aufirst%3DR.%26aulast%3DStorer%26aufirst%3DR.%2BI.%26aulast%3DSwain%26aufirst%3DN.%2BA.%26atitle%3DRecent%2520Progress%2520in%2520Sodium%2520Channel%2520Modulators%2520for%2520Pain%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26issue%3D16%26spage%3D3690%26epage%3D3699%26doi%3D10.1016%2Fj.bmcl.2014.06.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sclafani, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reese, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mudipalli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neville, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakale, R. P.</span></span> <span> </span><span class="NLM_article-title">The First Asymmetric Pilot-Scale Synthesis of TV-45070</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1616</span>– <span class="NLM_lpage">1624</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.7b00237</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.7b00237" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVGhsr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2017&pages=1616-1624&issue=10&author=J.+A.+Sclafaniauthor=J.+Chenauthor=D.+V.+Levyauthor=H.+Reeseauthor=M.+Dimitriauthor=P.+Mudipalliauthor=M.+Christieauthor=C.+J.+Nevilleauthor=M.+Olsenauthor=R.+P.+Bakale&title=The+First+Asymmetric+Pilot-Scale+Synthesis+of+TV-45070&doi=10.1021%2Facs.oprd.7b00237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">The First Asymmetric Pilot-Scale Synthesis of TV-45070</span></div><div class="casAuthors">Sclafani, Joseph A.; Chen, Jian; Levy, Daniel V.; Reese, Harlan; Dimitri, Mina; Mudipalli, Partha; Christie, Michael; Neville, Christopher J.; Olsen, Mark; Bakale, Roger P.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1616-1624</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">TV-45070 (formerly XEN-402) is a small-mol. lactam contg. a chiral spiro-ether that is reported as a potential topical therapy for pain assocd. with the Nav1.7 Na ion channel encoded by the gene SCN9A.  A pilot-scale synthesis is presented that is highlighted by an asym. aldol coupling at ambient temp., used to create a quaternary chiral center.  Although only a moderate ee was obtained, the removal of the undesired isomer is achieved through preferential pptn. of a near racemic mixt. from the reaction, leaving the enantiopure isomer in soln.  Cyclization to form the final API uses an uncommon diphenylphosphine-based leaving group which proved successful on the neopentyl system when other traditional leaving groups failed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvvJXHK7roRLVg90H21EOLACvtfcHk0lhICfL4sqrFmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVGhsr3E&md5=0be4812d90881ccd423f3b70a64ea395</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.7b00237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.7b00237%26sid%3Dliteratum%253Aachs%26aulast%3DSclafani%26aufirst%3DJ.%2BA.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DLevy%26aufirst%3DD.%2BV.%26aulast%3DReese%26aufirst%3DH.%26aulast%3DDimitri%26aufirst%3DM.%26aulast%3DMudipalli%26aufirst%3DP.%26aulast%3DChristie%26aufirst%3DM.%26aulast%3DNeville%26aufirst%3DC.%2BJ.%26aulast%3DOlsen%26aufirst%3DM.%26aulast%3DBakale%26aufirst%3DR.%2BP.%26atitle%3DThe%2520First%2520Asymmetric%2520Pilot-Scale%2520Synthesis%2520of%2520TV-45070%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2017%26volume%3D21%26issue%3D10%26spage%3D1616%26epage%3D1624%26doi%3D10.1021%2Facs.oprd.7b00237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harris, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberson, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, T. M.</span></span> <span> </span><span class="NLM_article-title">Biosynthesis of Griseofulvin</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1976</span>,  <span class="NLM_volume"><i>98</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">5380</span>– <span class="NLM_lpage">5386</span>, <span class="refDoi"> DOI: 10.1021/ja00433a053</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00433a053" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADyaE28XltF2nsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=1976&pages=5380-5386&issue=17&author=C.+M.+Harrisauthor=J.+S.+Robersonauthor=T.+M.+Harris&title=Biosynthesis+of+Griseofulvin&doi=10.1021%2Fja00433a053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Biosynthesis of griseofulvin</span></div><div class="casAuthors">Harris, Constance M.; Roberson, Jill S.; Harris, Thomas M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1976</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5380-6</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">The antifungal antibiotic griseofulvin (I) is a polyketide metabolite of Penicillium griseofulvum [patulum].  There are ≤ 2 and probably 3 O-Me groups which are introduced after both carbocyclic rings are formed.  2,4,4',6-Tetrahydroxy-2'-methoxy-6'-methylbenzophenone, the monomethylated precursor predicted by earlier workers, was not detected in cultures by carrier diln. expts.  Instead 2,2',4',6-tetrahydroxy-4-methoxy-6'-methylbenzophenone (II) is a precursor of I as indicated by a feeding expt. in which II contg. a tritium label in the O-Me group was incorporated (14%) into I.  Demethylation of labeled I 1st to griseofulvic acid and then to grisan showed that < 10% randomization of the label occurred during biotransformation of II into I.  The possibility that nonmethylated 2,2',4,4',6-pentahydroxy-6'-methylbenzophenone (III) was the precursor of II was considered, but synthetic III was too unstable for use in carrier dilution or incorporation expts., undergoing facile cyclization to xanthone (IV).  The latter compd. was, however, a metabolite of P. griseofulvum, which lends support to the hypothesis that both II and IV arise in the fungal culture from III.  Earlier workers had postulated that the grisan ring is formed by oxidative cyclization of griseophenone A to give dehydrogriseofulvin but in vivo confirmation of this process has not been obtained.  Another possible precursor to dehydrogriseofulvin, normethyldehydrogriseofulvin was synthesized and incorporated (44%) into I.  These findings support the biosynthetic sequence: acetate → heptaacetic acid → III → II → griseophenone C → griseophenone B → normethyldehydrogriseofulvin → dehydrogriseofulvin → I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZXnQXoFJeWLVg90H21EOLACvtfcHk0lhICfL4sqrFmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE28XltF2nsr8%253D&md5=006150becfafca13d20c9e9bd537e38a</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1021%2Fja00433a053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00433a053%26sid%3Dliteratum%253Aachs%26aulast%3DHarris%26aufirst%3DC.%2BM.%26aulast%3DRoberson%26aufirst%3DJ.%2BS.%26aulast%3DHarris%26aufirst%3DT.%2BM.%26atitle%3DBiosynthesis%2520of%2520Griseofulvin%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1976%26volume%3D98%26issue%3D17%26spage%3D5380%26epage%3D5386%26doi%3D10.1021%2Fja00433a053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rønnest, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clausen, M. H.</span></span> <span> </span><span class="NLM_article-title">The Chemistry of Griseofulvin</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>114</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">12088</span>– <span class="NLM_lpage">12107</span>, <span class="refDoi"> DOI: 10.1021/cr400368e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr400368e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVegtbnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2014&pages=12088-12107&issue=24&author=A.+B.+Petersenauthor=M.+H.+R%C3%B8nnestauthor=T.+O.+Larsenauthor=M.+H.+Clausen&title=The+Chemistry+of+Griseofulvin&doi=10.1021%2Fcr400368e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">The Chemistry of Griseofulvin</span></div><div class="casAuthors">Petersen, Asger B.; Roennest, Mads H.; Larsen, Thomas O.; Clausen, Mads H.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">12088-12107</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The natural product griseofulvin, (2S,6'R)-7-chloro-4,6-dimethoxybenzofuran-3-one-2-spiro-1'-(2'-methoxy-6'-methylcyclohex-2'-en-4'-one) (1), has a rich chem. dating back to the early 1950s.  Griseofulvin has been in clin. use for the treatment of ringworm in animals and humans since, and recently, griseofulvin has attracted renewed attention due to reports of complementary bioactivity in mammalian systems, including antiviral and anticancer activity.  Here, the authors present the history of griseofulvin, its biosynthesis, an introduction to the biol. of the compd. class, total synthesis of 1 and its analogs, as well as chem. used to prep. analogs of griseofulvin starting from the natural product.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpW-GgIzqAAgLVg90H21EOLACvtfcHk0ljZtmuiZ9-OPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVegtbnP&md5=aff1b198c19a546a317f5200718bf884</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1021%2Fcr400368e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr400368e%26sid%3Dliteratum%253Aachs%26aulast%3DPetersen%26aufirst%3DA.%2BB.%26aulast%3DR%25C3%25B8nnest%26aufirst%3DM.%2BH.%26aulast%3DLarsen%26aufirst%3DT.%2BO.%26aulast%3DClausen%26aufirst%3DM.%2BH.%26atitle%3DThe%2520Chemistry%2520of%2520Griseofulvin%26jtitle%3DChem.%2520Rev.%26date%3D2014%26volume%3D114%26issue%3D24%26spage%3D12088%26epage%3D12107%26doi%3D10.1021%2Fcr400368e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pirrung, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rege, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laughton, P.</span></span> <span> </span><span class="NLM_article-title">Total Synthesis of (+)-Griseofulvin</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>113</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">8561</span>– <span class="NLM_lpage">8562</span>, <span class="refDoi"> DOI: 10.1021/ja00022a075</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00022a075" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADyaK3MXmsl2lt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=1991&pages=8561-8562&issue=22&author=M.+C.+Pirrungauthor=W.+L.+Brownauthor=S.+Regeauthor=P.+Laughton&title=Total+Synthesis+of+%28%2B%29-Griseofulvin&doi=10.1021%2Fja00022a075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Total synthesis of (+)-griseofulvin</span></div><div class="casAuthors">Pirrung, Michael C.; Brown, William L.; Rege, Sushil; Laughton, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8561-2</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">The first asym. total synthesis of the antifungal antibiotic griseofulvin (I; R = Me) has been completed by the prepn. of I (R = H) using the intramol. generation and rearrangement of an oxonium ylide to establish both relative and abs. stereochem.  The lack of products derived from an O-Me ylide suggests that ylide formation is reversible and that the rate-detg. step is the sigmatropic rearrangement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOabaOl3tYurVg90H21EOLACvtfcHk0ljZtmuiZ9-OPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXmsl2lt70%253D&md5=260a49b92420b332ca107838171977c8</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1021%2Fja00022a075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00022a075%26sid%3Dliteratum%253Aachs%26aulast%3DPirrung%26aufirst%3DM.%2BC.%26aulast%3DBrown%26aufirst%3DW.%2BL.%26aulast%3DRege%26aufirst%3DS.%26aulast%3DLaughton%26aufirst%3DP.%26atitle%3DTotal%2520Synthesis%2520of%2520%2528%252B%2529-Griseofulvin%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1991%26volume%3D113%26issue%3D22%26spage%3D8561%26epage%3D8562%26doi%3D10.1021%2Fja00022a075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esler, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amor, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagley, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beysen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvajal-Gonzalez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doran, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limberakis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathiowetz, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McPherson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravussin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonnenberg, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Southers, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweet, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajdos, F. F.</span></span> <span> </span><span class="NLM_article-title">Decreasing the Rate of Metabolic Ketone Reduction in the Discovery of a Clinical Acetyl-CoA Carboxylase Inhibitor for the Treatment of Diabetes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">10512</span>– <span class="NLM_lpage">10526</span>, <span class="refDoi"> DOI: 10.1021/jm5016022</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5016022" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFOht73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=10512-10526&issue=24&author=D.+A.+Griffithauthor=D.+W.+Kungauthor=W.+P.+Eslerauthor=P.+A.+Amorauthor=S.+W.+Bagleyauthor=C.+Beysenauthor=S.+Carvajal-Gonzalezauthor=S.+D.+Doranauthor=C.+Limberakisauthor=A.+M.+Mathiowetzauthor=K.+McPhersonauthor=D.+A.+Priceauthor=E.+Ravussinauthor=G.+E.+Sonnenbergauthor=J.+A.+Southersauthor=L.+J.+Sweetauthor=S.+M.+Turnerauthor=F.+F.+Vajdos&title=Decreasing+the+Rate+of+Metabolic+Ketone+Reduction+in+the+Discovery+of+a+Clinical+Acetyl-CoA+Carboxylase+Inhibitor+for+the+Treatment+of+Diabetes&doi=10.1021%2Fjm5016022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Decreasing the Rate of Metabolic Ketone Reduction in the Discovery of a Clinical Acetyl-CoA Carboxylase Inhibitor for the Treatment of Diabetes</span></div><div class="casAuthors">Griffith, David A.; Kung, Daniel W.; Esler, William P.; Amor, Paul A.; Bagley, Scott W.; Beysen, Carine; Carvajal-Gonzalez, Santos; Doran, Shawn D.; Limberakis, Chris; Mathiowetz, Alan M.; McPherson, Kirk; Price, David A.; Ravussin, Eric; Sonnenberg, Gabriele E.; Southers, James A.; Sweet, Laurel J.; Turner, Scott M.; Vajdos, Felix F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10512-10526</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Acetyl-Co-A carboxylase (ACC) inhibitors offer significant potential for the treatment of type 2 diabetes mellitus (T2DM), hepatic steatosis, and cancer.  However, the identification of tool compds. suitable to test the hypothesis in human trials has been challenging.  An advanced series of spirocyclic ketone-contg. ACC inhibitors recently reported by Pfizer were metabolized in vivo by ketone redn., which complicated human pharmacol. projections.  The authors disclose that this metabolic redn. can be greatly attenuated through introduction of steric hindrance adjacent to the ketone carbonyl.  Incorporation of weakly basic functionality improved soly. and led to the identification of I as a clin. candidate for the treatment of T2DM.  Phase I clin. studies demonstrated dose-proportional increases in exposure, single-dose inhibition of de novo lipogenesis (DNL), and changes in indirect calorimetry consistent with increased whole-body fatty acid oxidn.  This demonstration of target engagement validates the use of compd. I to evaluate the role of DNL in human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWcJ9T4Kbj57Vg90H21EOLACvtfcHk0lhXr7VVOcKfvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFOht73O&md5=2af2cc745bf8a4e27396849b3011017c</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1021%2Fjm5016022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5016022%26sid%3Dliteratum%253Aachs%26aulast%3DGriffith%26aufirst%3DD.%2BA.%26aulast%3DKung%26aufirst%3DD.%2BW.%26aulast%3DEsler%26aufirst%3DW.%2BP.%26aulast%3DAmor%26aufirst%3DP.%2BA.%26aulast%3DBagley%26aufirst%3DS.%2BW.%26aulast%3DBeysen%26aufirst%3DC.%26aulast%3DCarvajal-Gonzalez%26aufirst%3DS.%26aulast%3DDoran%26aufirst%3DS.%2BD.%26aulast%3DLimberakis%26aufirst%3DC.%26aulast%3DMathiowetz%26aufirst%3DA.%2BM.%26aulast%3DMcPherson%26aufirst%3DK.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DRavussin%26aufirst%3DE.%26aulast%3DSonnenberg%26aufirst%3DG.%2BE.%26aulast%3DSouthers%26aufirst%3DJ.%2BA.%26aulast%3DSweet%26aufirst%3DL.%2BJ.%26aulast%3DTurner%26aufirst%3DS.%2BM.%26aulast%3DVajdos%26aufirst%3DF.%2BF.%26atitle%3DDecreasing%2520the%2520Rate%2520of%2520Metabolic%2520Ketone%2520Reduction%2520in%2520the%2520Discovery%2520of%2520a%2520Clinical%2520Acetyl-CoA%2520Carboxylase%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Diabetes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D24%26spage%3D10512%26epage%3D10526%26doi%3D10.1021%2Fjm5016022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Esler, W. P.</span>; <span class="NLM_string-name">Sonnenberg, G. E.</span></span> <span> </span><span class="NLM_article-title">Use of Acetyl-Coa Carboxylase Inhibitors for Treating Acne Vulgaris</span>. <span class="NLM_patent">WO2015036892A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=W.+P.+Esler&author=G.+E.+Sonnenberg&title=Use+of+Acetyl-Coa+Carboxylase+Inhibitors+for+Treating+Acne+Vulgaris"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DEsler%26aufirst%3DW.%2BP.%26atitle%3DUse%2520of%2520Acetyl-Coa%2520Carboxylase%2520Inhibitors%2520for%2520Treating%2520Acne%2520Vulgaris%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soupart, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legros, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alföldi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annane, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heshmati, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decaux, G.</span></span> <span> </span><span class="NLM_article-title">Successful Long-Term Treatment of Hyponatremia in Syndrome of Inappropriate Antidiuretic Hormone Secretion with Satavaptan (SR121463B), an Orally Active Nonpeptide Vasopressin V2-Receptor Antagonist</span>. <i>Clin. J. Am. Soc. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1154</span>– <span class="NLM_lpage">1160</span>, <span class="refDoi"> DOI: 10.2215/CJN.00160106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.2215%2FCJN.00160106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=17699341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1GntbzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2006&pages=1154-1160&issue=6&author=A.+Soupartauthor=P.+Grossauthor=J.-J.+Legrosauthor=S.+Alf%C3%B6ldiauthor=D.+Annaneauthor=H.+M.+Heshmatiauthor=G.+Decaux&title=Successful+Long-Term+Treatment+of+Hyponatremia+in+Syndrome+of+Inappropriate+Antidiuretic+Hormone+Secretion+with+Satavaptan+%28SR121463B%29%2C+an+Orally+Active+Nonpeptide+Vasopressin+V2-Receptor+Antagonist&doi=10.2215%2FCJN.00160106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist</span></div><div class="casAuthors">Soupart, Alain; Gross, Peter; Legros, Jean-Jacques; Alfoldi, Sandor; Annane, Djillali; Heshmati, Hassan M.; Decaux, Guy</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Journal of the American Society of Nephrology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1154-1160</span>CODEN:
                <span class="NLM_cas:coden">CJASC7</span>;
        ISSN:<span class="NLM_cas:issn">1555-9041</span>.
    
            (<span class="NLM_cas:orgname">American Society of Nephrology</span>)
        </div><div class="casAbstract">The effects of satavaptan (SR121463B), a novel long-acting orally active vasopressin V2-receptor antagonist, were investigated in patients with the syndrome of inappropriate antidiuretic hormone secretion (SIADH).  In the first part of this randomized, double-blind study, 34 patients first were treated with satavaptan (vs. placebo) for up to 5 d and then during 23 d of open-label dosage-adjustment period.  In the second part of the study, long-term efficacy and safety of satavaptan was assessed in an open-label trial during at least 12 mo.  Mean (±SD) serum sodium (SNa) levels before treatment were 127 ± 2 mmol/L (placebo, n = 8), 125 ± 6 mmol/L (25 mg, n = 14), and 127 ± 5 mmol/L (50 mg, n = 12).  Responders (patients SNa levels normalized or increased by at least 5 mmol/L from baseline during the double-blind period) were 79% in the 25-mg group (SNa 136 ± 3 mmol/L; P = 0.006), 83% in the 50-mg group (SNa 140 ± 6 mmol/L; P = 0.005), and 13% in the placebo group (SNa 130 ± 5 mmol/L).  No drug-related serious adverse events were recorded.  During the long-term treatment, 15 of 18 enrolled patients achieved 6 mo and 10 achieved 12 mo of treatment.  The SNa response was maintained during this time with a good tolerance.  The new oral vasopressin V2-receptor antagonist satavaptan adequately corrects mild or moderate hyponatremia in patients with SIADH and has a good safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiP6hV6PXzT7Vg90H21EOLACvtfcHk0lhXr7VVOcKfvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1GntbzK&md5=c63cb756959cb3f0a52da838c08e2a71</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.2215%2FCJN.00160106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2215%252FCJN.00160106%26sid%3Dliteratum%253Aachs%26aulast%3DSoupart%26aufirst%3DA.%26aulast%3DGross%26aufirst%3DP.%26aulast%3DLegros%26aufirst%3DJ.-J.%26aulast%3DAlf%25C3%25B6ldi%26aufirst%3DS.%26aulast%3DAnnane%26aufirst%3DD.%26aulast%3DHeshmati%26aufirst%3DH.%2BM.%26aulast%3DDecaux%26aufirst%3DG.%26atitle%3DSuccessful%2520Long-Term%2520Treatment%2520of%2520Hyponatremia%2520in%2520Syndrome%2520of%2520Inappropriate%2520Antidiuretic%2520Hormone%2520Secretion%2520with%2520Satavaptan%2520%2528SR121463B%2529%252C%2520an%2520Orally%2520Active%2520Nonpeptide%2520Vasopressin%2520V2-Receptor%2520Antagonist%26jtitle%3DClin.%2520J.%2520Am.%2520Soc.%2520Nephrol.%26date%3D2006%26volume%3D1%26issue%3D6%26spage%3D1154%26epage%3D1160%26doi%3D10.2215%2FCJN.00160106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Venkatesan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altas, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liotta, D. C.</span></span> <span> </span><span class="NLM_article-title">Total Synthesis of SR 121463 A, a Highly Potent and Selective Vasopressin v(2) Receptor Antagonist</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>66</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">3653</span>– <span class="NLM_lpage">3661</span>, <span class="refDoi"> DOI: 10.1021/jo0004658</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo0004658" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BD3MXisl2rsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2001&pages=3653-3661&issue=11&author=H.+Venkatesanauthor=M.+C.+Davisauthor=Y.+Altasauthor=J.+P.+Snyderauthor=D.+C.+Liotta&title=Total+Synthesis+of+SR+121463+A%2C+a+Highly+Potent+and+Selective+Vasopressin+v%282%29+Receptor+Antagonist&doi=10.1021%2Fjo0004658"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Total Synthesis of SR 121463 A, a Highly Potent and Selective Vasopressin V2 Receptor Antagonist</span></div><div class="casAuthors">Venkatesan, Hariharan; Davis, Matthew C.; Altas, Yesim; Snyder, James P.; Liotta, Dennis C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3653-3661</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">SR 121463 A was prepd. from the fragments 4,3-ClSO2(MeO)C6H3CONHCMe3 (I), 2,2-bis(2-bromoethyl)-1,3-dioxolane, and 1-benzyl-5-ethoxy-2-indolinone in good overall yield, each step proceeding in greater than 80% yield.  In addn., I and the syn isomer of SR 121463 A were prepd. with complete control of stereochem.  Mol. mechanics calcns. with the MM3* and MMFF force fields underscore geometric and energetic aspects of the reaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRp0k7IL_tq7Vg90H21EOLACvtfcHk0lgKqnFHymU2Dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXisl2rsb8%253D&md5=425ee77a6e8a0e865f4505fb2c236060</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1021%2Fjo0004658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo0004658%26sid%3Dliteratum%253Aachs%26aulast%3DVenkatesan%26aufirst%3DH.%26aulast%3DDavis%26aufirst%3DM.%2BC.%26aulast%3DAltas%26aufirst%3DY.%26aulast%3DSnyder%26aufirst%3DJ.%2BP.%26aulast%3DLiotta%26aufirst%3DD.%2BC.%26atitle%3DTotal%2520Synthesis%2520of%2520SR%2520121463%2520A%252C%2520a%2520Highly%2520Potent%2520and%2520Selective%2520Vasopressin%2520v%25282%2529%2520Receptor%2520Antagonist%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2001%26volume%3D66%26issue%3D11%26spage%3D3653%26epage%3D3661%26doi%3D10.1021%2Fjo0004658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hermecz, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sánta-Csutor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gönczi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Héja, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Csikós, É.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smelkó-Esek, Á.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podányi, B.</span></span> <span> </span><span class="NLM_article-title">Chemical Development of the Vasopressin Receptor 2 Antagonist SR-121463</span>. <i>Pure Appl. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>73</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1401</span>– <span class="NLM_lpage">1409</span>, <span class="refDoi"> DOI: 10.1351/pac200173091401</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1351%2Fpac200173091401" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BD3MXptFGlsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2001&pages=1401-1409&issue=9&author=I.+Hermeczauthor=A.+S%C3%A1nta-Csutorauthor=C.+G%C3%B6ncziauthor=G.+H%C3%A9jaauthor=%C3%89.+Csik%C3%B3sauthor=K.+Simonauthor=%C3%81.+Smelk%C3%B3-Esekauthor=B.+Pod%C3%A1nyi&title=Chemical+Development+of+the+Vasopressin+Receptor+2+Antagonist+SR-121463&doi=10.1351%2Fpac200173091401"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical development of the vasopressin receptor 2 antagonist SR-121463</span></div><div class="casAuthors">Hermecz, Istvan; Santa-Csutor, Andrea; Gonczi, Csaba; Heja, Gergely; Csikos, Eva; Simon, Kalman; Smelko-Esek, Agota; Podanyi, Benjamin</div><div class="citationInfo"><span class="NLM_cas:title">Pure and Applied Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1401-1409</span>CODEN:
                <span class="NLM_cas:coden">PACHAS</span>;
        ISSN:<span class="NLM_cas:issn">0033-4545</span>.
    
            (<span class="NLM_cas:orgname">International Union of Pure and Applied Chemistry</span>)
        </div><div class="casAbstract">A facile convergent total synthesis of the selective, potent, and orally active V, non-peptide antagonist, SR-121463, was developed by modification of the discovery route.  One of the late intermediates, the sulfonyl chloride , was synthesized from 3-hydroxybenzoic acid by regioselective sulfonation, O-methylation and amidation in four steps.  In this way, the indolin-2-one was synthesized from p-phenetidine in six steps.  Finally. acylation of the indolin-2-one was achieved with the sulfonyl chloride in the presence of KOtBu in DMSO (DMSO) at room temp.  This synthetic route proved to be applicable for the large-scale synthesis of SR-121463.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7K0-gYtDbhbVg90H21EOLACvtfcHk0lgKqnFHymU2Dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXptFGlsr8%253D&md5=c3ca97ddab9bea1dbdc813bbf1ff0f4b</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1351%2Fpac200173091401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1351%252Fpac200173091401%26sid%3Dliteratum%253Aachs%26aulast%3DHermecz%26aufirst%3DI.%26aulast%3DS%25C3%25A1nta-Csutor%26aufirst%3DA.%26aulast%3DG%25C3%25B6nczi%26aufirst%3DC.%26aulast%3DH%25C3%25A9ja%26aufirst%3DG.%26aulast%3DCsik%25C3%25B3s%26aufirst%3D%25C3%2589.%26aulast%3DSimon%26aufirst%3DK.%26aulast%3DSmelk%25C3%25B3-Esek%26aufirst%3D%25C3%2581.%26aulast%3DPod%25C3%25A1nyi%26aufirst%3DB.%26atitle%3DChemical%2520Development%2520of%2520the%2520Vasopressin%2520Receptor%25202%2520Antagonist%2520SR-121463%26jtitle%3DPure%2520Appl.%2520Chem.%26date%3D2001%26volume%3D73%26issue%3D9%26spage%3D1401%26epage%3D1409%26doi%3D10.1351%2Fpac200173091401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foulon, L.</span>; <span class="NLM_string-name">Garcia, G.</span>; <span class="NLM_string-name">Gal, C. S.-L.</span>; <span class="NLM_string-name">Valette, G.</span></span> <span> </span><span class="NLM_article-title">Derives 3-spiro-indolin-2-one comme ligands des recepteurs de la vasopressine et/ou de l’ocytocine</span>. <span class="NLM_patent">WO1997015556A1</span>, <span class="NLM_year">1997</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1997&author=L.+Foulon&author=G.+Garcia&author=C.+S.-L.+Gal&author=G.+Valette&title=Derives+3-spiro-indolin-2-one+comme+ligands+des+recepteurs+de+la+vasopressine+et%2Fou+de+l%E2%80%99ocytocine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFoulon%26aufirst%3DL.%26atitle%3DDerives%25203-spiro-indolin-2-one%2520comme%2520ligands%2520des%2520recepteurs%2520de%2520la%2520vasopressine%2520et%252Fou%2520de%2520l%25E2%2580%2599ocytocine%26date%3D1997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janssens, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leenaerts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diels, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Boeck, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Megens, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langlois, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Rossem, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beetens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgers, M.</span></span> <span> </span><span class="NLM_article-title">Norpiperidine Imidazoazepines as a New Class of Potent, Selective, and Nonsedative H1 Antihistamines</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2154</span>– <span class="NLM_lpage">2166</span>, <span class="refDoi"> DOI: 10.1021/jm049495j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049495j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtFCiu7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=2154-2166&issue=6&author=F.+Janssensauthor=J.+Leenaertsauthor=G.+Dielsauthor=B.+De+Boeckauthor=A.+Megensauthor=X.+Langloisauthor=K.+van+Rossemauthor=J.+Beetensauthor=M.+Borgers&title=Norpiperidine+Imidazoazepines+as+a+New+Class+of+Potent%2C+Selective%2C+and+Nonsedative+H1+Antihistamines&doi=10.1021%2Fjm049495j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Norpiperidine imidazoazepines as a new class of potent, selective, and nonsedative H1 antihistamines</span></div><div class="casAuthors">Janssens, Frans; Leenaerts, Jos; Diels, Gaston; De Boeck, Benoit; Megens, Anton; Langlois, Xavier; van Rossem, Koen; Beetens, Johan; Borgers, Marcel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2154-2166</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Clin. doses of available H1 antihistamines are limited mainly by sedative side effects.  However, higher doses are often required to obtain optimal therapeutic activity, esp. in dermatol.  The synthesis of three norpiperidine imidazoazepines, e.g., I, representative of a class of selective and nonsedating H1 antihistamines is reported.  The compds. were at least as potent as cetirizine and loratadine as measured by H1 receptor binding affinity, by protection against compd. 48/80- and histamine-induced lethality in rats and guinea pigs, resp., and by skin reaction tests in rats, guinea pigs, and dogs.  The compds., in particular I, were less prone than the ref. compds. to penetrate the brain and to occupy central H1 receptors, suggesting absence of sedative side effects.  In vitro and in vivo cardiovascular safety tests showed that I had no intrinsic potential to prolong ventricular repolarization or induce cardiac arrhythmias.  I has been selected for further clin. development, mainly for application in dermatol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp76QOrOdzxObVg90H21EOLACvtfcHk0lgKqnFHymU2Dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtFCiu7fI&md5=79fb5ed6420beaad9e9932bb26f7a7bc</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1021%2Fjm049495j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049495j%26sid%3Dliteratum%253Aachs%26aulast%3DJanssens%26aufirst%3DF.%26aulast%3DLeenaerts%26aufirst%3DJ.%26aulast%3DDiels%26aufirst%3DG.%26aulast%3DDe%2BBoeck%26aufirst%3DB.%26aulast%3DMegens%26aufirst%3DA.%26aulast%3DLanglois%26aufirst%3DX.%26aulast%3Dvan%2BRossem%26aufirst%3DK.%26aulast%3DBeetens%26aufirst%3DJ.%26aulast%3DBorgers%26aufirst%3DM.%26atitle%3DNorpiperidine%2520Imidazoazepines%2520as%2520a%2520New%2520Class%2520of%2520Potent%252C%2520Selective%252C%2520and%2520Nonsedative%2520H1%2520Antihistamines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26issue%3D6%26spage%3D2154%26epage%3D2166%26doi%3D10.1021%2Fjm049495j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janssens, F. E.</span>; <span class="NLM_string-name">Leenaerts, J. E.</span></span> <span> </span><span class="NLM_article-title">Antihistaminic Spiro Compounds</span>. <span class="NLM_patent">WO2000037470A1</span>, <span class="NLM_year">2000</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&author=F.+E.+Janssens&author=J.+E.+Leenaerts&title=Antihistaminic+Spiro+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJanssens%26aufirst%3DF.%2BE.%26atitle%3DAntihistaminic%2520Spiro%2520Compounds%26date%3D2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G. G.</span>; <span class="NLM_string-name">Werne, G.</span>; <span class="NLM_string-name">Fu, X.</span>; <span class="NLM_string-name">Orr, R. K.</span>; <span class="NLM_string-name">Chen, F. X.</span>; <span class="NLM_string-name">Cui, J.</span>; <span class="NLM_string-name">Sprague, V. M.</span>; <span class="NLM_string-name">Zhang, F.</span>; <span class="NLM_string-name">Xie, J.</span>; <span class="NLM_string-name">Zeng, L.</span>; <span class="NLM_string-name">Castellanos, L. P.</span>; <span class="NLM_string-name">Chen, Y.</span>; <span class="NLM_string-name">Poirier, M.</span>; <span class="NLM_string-name">Mergelsberg, I.</span></span> <span> </span><span class="NLM_article-title">Process and Intermediates for the Synthesis of 8-[{1-(3,5-Bis-(Trifluoromethyl)Phenyl)-Ethoxy}-Methyl]-8-Phenyl-1,7-Diaza-Spiro[4.5]Decan-2-One Compounds</span>. <span class="NLM_patent">US9249144B2</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=G.+G.+Wu&author=G.+Werne&author=X.+Fu&author=R.+K.+Orr&author=F.+X.+Chen&author=J.+Cui&author=V.+M.+Sprague&author=F.+Zhang&author=J.+Xie&author=L.+Zeng&author=L.+P.+Castellanos&author=Y.+Chen&author=M.+Poirier&author=I.+Mergelsberg&title=Process+and+Intermediates+for+the+Synthesis+of+8-%5B%7B1-%283%2C5-Bis-%28Trifluoromethyl%29Phenyl%29-Ethoxy%7D-Methyl%5D-8-Phenyl-1%2C7-Diaza-Spiro%5B4.5%5DDecan-2-One+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DG.%2BG.%26atitle%3DProcess%2520and%2520Intermediates%2520for%2520the%2520Synthesis%2520of%25208-%255B%257B1-%25283%252C5-Bis-%2528Trifluoromethyl%2529Phenyl%2529-Ethoxy%257D-Methyl%255D-8-Phenyl-1%252C7-Diaza-Spiro%255B4.5%255DDecan-2-One%2520Compounds%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Müller, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berkenbosch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benningshof, J. C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stumpfe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajorath, J.</span></span> <span> </span><span class="NLM_article-title">Charting Biologically Relevant Spirocyclic Compound Space</span>. <i>Chem. - Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">703</span>– <span class="NLM_lpage">710</span>, <span class="refDoi"> DOI: 10.1002/chem.201604714</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1002%2Fchem.201604714" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=27859909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVWmsb3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=703-710&issue=3&author=G.+M%C3%BCllerauthor=T.+Berkenboschauthor=J.+C.+J.+Benningshofauthor=D.+Stumpfeauthor=J.+Bajorath&title=Charting+Biologically+Relevant+Spirocyclic+Compound+Space&doi=10.1002%2Fchem.201604714"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Charting Biologically Relevant Spirocyclic Compound Space</span></div><div class="casAuthors">Mueller, Gerhard; Berkenbosch, Tim; Benningshof, Jorg C. J.; Stumpfe, Dagmar; Bajorath, Juergen</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">703-710</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Spirocycles frequently occur in natural products and experience increasing interest in drug discovery, given their richness in Sp3 centers and distinct three-dimensionality.  The authors have systematically explored chem. space populated with currently available bioactive spirocycles.  Compds. contg. spiro systems were classified and their scaffolds and spirocyclic ring combinations analyzed.  Nearly 47,000 compds. were identified that contained spirocycles in different structural contexts and were active against roughly 200 targets, among which several pharmaceutically relevant members of the G protein-coupled receptor (GPCR) family were identified.  Spirocycles and corresponding compds. displayed notable scaffold diversity but contained only limited nos. of combinations of differently sized rings.  These observations indicate that there should be significant potential to further expand spirocyclic chem. space for drug discovery, exploiting the privileged substructure concept.  Inspired by those findings, the authors embarked on the design and chem. synthesis of three distinct novel spirocyclic scaffolds that qualify for downstream library synthesis, thus exploring principally new chem. space with high potential for pharmaceutical research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUvVwE8kzXULVg90H21EOLACvtfcHk0lhoE-apYOwCTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVWmsb3O&md5=92293477499539b602abd928891de11b</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1002%2Fchem.201604714&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201604714%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DG.%26aulast%3DBerkenbosch%26aufirst%3DT.%26aulast%3DBenningshof%26aufirst%3DJ.%2BC.%2BJ.%26aulast%3DStumpfe%26aufirst%3DD.%26aulast%3DBajorath%26aufirst%3DJ.%26atitle%3DCharting%2520Biologically%2520Relevant%2520Spirocyclic%2520Compound%2520Space%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D2017%26volume%3D23%26issue%3D3%26spage%3D703%26epage%3D710%26doi%3D10.1002%2Fchem.201604714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">King, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortensen, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">North, A. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sore, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spring, D. R.</span></span> <span> </span><span class="NLM_article-title">Cycloaddition Strategies for the Synthesis of Diverse Heterocyclic Spirocycles for Fragment-Based Drug Discovery</span>. <i>Eur. J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>2019</i></span> (<span class="NLM_issue">31–32</span>),  <span class="NLM_fpage">5219</span>– <span class="NLM_lpage">5229</span>, <span class="refDoi"> DOI: 10.1002/ejoc.201900847</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1002%2Fejoc.201900847" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=31598091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVGqs7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2019&publication_year=2019&pages=5219-5229&issue=31%E2%80%9332&author=T.+A.+Kingauthor=H.+L.+Stewartauthor=K.+T.+Mortensenauthor=A.+J.+P.+Northauthor=H.+F.+Soreauthor=D.+R.+Spring&title=Cycloaddition+Strategies+for+the+Synthesis+of+Diverse+Heterocyclic+Spirocycles+for+Fragment-Based+Drug+Discovery&doi=10.1002%2Fejoc.201900847"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Cycloaddition Strategies for the Synthesis of Diverse Heterocyclic Spirocycles for Fragment-Based Drug Discovery</span></div><div class="casAuthors">King, Thomas A.; Stewart, Hannah L.; Mortensen, Kim T.; North, Andrew J. P.; Sore, Hannah F.; Spring, David R.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">2019</span>
        (<span class="NLM_cas:issue">31-32</span>),
    <span class="NLM_cas:pages">5219-5229</span>CODEN:
                <span class="NLM_cas:coden">EJOCFK</span>;
        ISSN:<span class="NLM_cas:issn">1099-0690</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The step-efficient routes to a no. of biol. relevant, fragment-like heterocyclic spirocycles I (R = Boc, H; n = 1, 2; m = 1, 2, 3, 4), II, III and IV have been reported.  The use of both electron-deficient and electron-rich 2-atom donors was explored in complexity-generating [3+2]-cycloaddns. to furnish products in 3 steps from com. available starting materials.  The resulting compds. were primed for further fragment elaboration through the inclusion of synthetic handles from the outset of the syntheses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGi_W-0wJvl7Vg90H21EOLACvtfcHk0lhoE-apYOwCTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVGqs7vF&md5=122c4545db07adc7fd537a162ab2a250</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1002%2Fejoc.201900847&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.201900847%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DT.%2BA.%26aulast%3DStewart%26aufirst%3DH.%2BL.%26aulast%3DMortensen%26aufirst%3DK.%2BT.%26aulast%3DNorth%26aufirst%3DA.%2BJ.%2BP.%26aulast%3DSore%26aufirst%3DH.%2BF.%26aulast%3DSpring%26aufirst%3DD.%2BR.%26atitle%3DCycloaddition%2520Strategies%2520for%2520the%2520Synthesis%2520of%2520Diverse%2520Heterocyclic%2520Spirocycles%2520for%2520Fragment-Based%2520Drug%2520Discovery%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2019%26volume%3D2019%26issue%3D31%25E2%2580%259332%26spage%3D5219%26epage%3D5229%26doi%3D10.1002%2Fejoc.201900847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sveiczer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">North, A. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mateu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kidd, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sore, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spring, D. R.</span></span> <span> </span><span class="NLM_article-title">Spirocycles as Rigidified Sp3-Rich Scaffolds for a Fragment Collection</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">4600</span>– <span class="NLM_lpage">4604</span>, <span class="refDoi"> DOI: 10.1021/acs.orglett.9b01499</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.orglett.9b01499" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVGgtL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2019&pages=4600-4604&issue=12&author=A.+Sveiczerauthor=A.+J.+P.+Northauthor=N.+Mateuauthor=S.+L.+Kiddauthor=H.+F.+Soreauthor=D.+R.+Spring&title=Spirocycles+as+Rigidified+Sp3-Rich+Scaffolds+for+a+Fragment+Collection&doi=10.1021%2Facs.orglett.9b01499"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Spirocycles as Rigidified sp3-Rich Scaffolds for a Fragment Collection</span></div><div class="casAuthors">Sveiczer, Attila; North, Andrew J. P.; Mateu, Natalia; Kidd, Sarah L.; Sore, Hannah F.; Spring, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4600-4604</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel divergent methodol. to access sp3-rich spirocyclic fragments is reported.  First, a robust modular synthesis of bis-alkene amino ester building blocks was developed.  Three different carbocycles and six heterocycles were then constructed to assemble eight spirocycles.  Importantly, strategic exit vectors were incorporated within each scaffold to aid fragment growth and were elaborated via chem. modifications.  Finally, computational methods demonstrate higher levels of rigidity, three-dimensionality, and structural diversity of the library compared to a com. collection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphL0xwX1UyhbVg90H21EOLACvtfcHk0lh3jIaTlO6jNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVGgtL%252FP&md5=d1abfa0263af3e98d8e1855c2001a8e7</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1021%2Facs.orglett.9b01499&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.orglett.9b01499%26sid%3Dliteratum%253Aachs%26aulast%3DSveiczer%26aufirst%3DA.%26aulast%3DNorth%26aufirst%3DA.%2BJ.%2BP.%26aulast%3DMateu%26aufirst%3DN.%26aulast%3DKidd%26aufirst%3DS.%2BL.%26aulast%3DSore%26aufirst%3DH.%2BF.%26aulast%3DSpring%26aufirst%3DD.%2BR.%26atitle%3DSpirocycles%2520as%2520Rigidified%2520Sp3-Rich%2520Scaffolds%2520for%2520a%2520Fragment%2520Collection%26jtitle%3DOrg.%2520Lett.%26date%3D2019%26volume%3D21%26issue%3D12%26spage%3D4600%26epage%3D4604%26doi%3D10.1021%2Facs.orglett.9b01499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolaou, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirberger, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pomerantz, W. C. K.</span></span> <span> </span><span class="NLM_article-title">Evaluating the Advantages of Using 3D-Enriched Fragments for Targeting BET Bromodomains</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1648</span>– <span class="NLM_lpage">1654</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00414</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00414" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1Wktr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1648-1654&issue=12&author=J.+A.+Johnsonauthor=C.+A.+Nicolaouauthor=S.+E.+Kirbergerauthor=A.+K.+Pandeyauthor=H.+Huauthor=W.+C.+K.+Pomerantz&title=Evaluating+the+Advantages+of+Using+3D-Enriched+Fragments+for+Targeting+BET+Bromodomains&doi=10.1021%2Facsmedchemlett.9b00414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluating the Advantages of Using 3D-Enriched Fragments for Targeting BET Bromodomains</span></div><div class="casAuthors">Johnson, Jorden A.; Nicolaou, Christos A.; Kirberger, Steven E.; Pandey, Anil K.; Hu, Haitao; Pomerantz, William C. K.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1648-1654</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Fragment-based ligand discovery has been successful in targeting diverse proteins.  Despite drug-like mols. having more 3D-character, traditional fragment libraries are largely comprised of flat, arom. fragments.  The use of 3D-enriched fragments for enhancing library diversity is underexplored esp. against protein-protein interactions.  Here, we evaluate using 3D-enriched fragments against bromodomains.  Bromodomains are highly ligandable, but selectivity remains challenging, particularly for bromodomain and extraterminal (BET) family bromodomains.  We screened a 3D-enriched fragment library against BRD4(D1) via 1H CPMG NMR with a protein-obsd. 19F NMR secondary assay.  The screen led to 29% of the hits that are selective over two related bromodomains, BRDT(D1) and BPTF, and the identification of underrepresented chem. bromodomain inhibitor scaffolds.  Initial structure-activity relationship studies guided by x-ray crystallog., led to a ligand-efficient thiazepane, with good selectivity and affinity for BET bromodomains.  These results suggest that the incorporation of 3D-enriched fragments to increase library diversity can benefit bromodomain screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5zqdGd6HlQrVg90H21EOLACvtfcHk0lh3jIaTlO6jNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1Wktr7E&md5=dd67906bdd6366a4f06f5d18d8bf7a97</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00414%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DJ.%2BA.%26aulast%3DNicolaou%26aufirst%3DC.%2BA.%26aulast%3DKirberger%26aufirst%3DS.%2BE.%26aulast%3DPandey%26aufirst%3DA.%2BK.%26aulast%3DHu%26aufirst%3DH.%26aulast%3DPomerantz%26aufirst%3DW.%2BC.%2BK.%26atitle%3DEvaluating%2520the%2520Advantages%2520of%2520Using%25203D-Enriched%2520Fragments%2520for%2520Targeting%2520BET%2520Bromodomains%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26issue%3D12%26spage%3D1648%26epage%3D1654%26doi%3D10.1021%2Facsmedchemlett.9b00414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeGrado, W. F.</span></span> <span> </span><span class="NLM_article-title">Exploring Organosilane Amines as Potent Inhibitors and Structural Probes of Influenza a Virus M2 Proton Channel</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>133</i></span> (<span class="NLM_issue">35</span>),  <span class="NLM_fpage">13844</span>– <span class="NLM_lpage">13847</span>, <span class="refDoi"> DOI: 10.1021/ja2050666</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja2050666" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVSrtL3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2011&pages=13844-13847&issue=35&author=J.+Wangauthor=C.+Maauthor=Y.+Wuauthor=R.+A.+Lambauthor=L.+H.+Pintoauthor=W.+F.+DeGrado&title=Exploring+Organosilane+Amines+as+Potent+Inhibitors+and+Structural+Probes+of+Influenza+a+Virus+M2+Proton+Channel&doi=10.1021%2Fja2050666"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring Organosilane Amines as Potent Inhibitors and Structural Probes of Influenza A Virus M2 Proton Channel</span></div><div class="casAuthors">Wang, Jun; Ma, Chunlong; Wu, Yibing; Lamb, Robert A.; Pinto, Lawrence H.; DeGrado, William F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">13844-13847</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We describe the use of organosilanes as inhibitors and structural probes of a membrane protein, the M2 proton channel from influenza A virus.  Organosilane amine inhibitors were found to be generally as potent as their carbon analogs in targeting WT A/M2 and more potent against the drug-resistant A/M2-V27A mutant.  In addn., intermol. NOESY spectra with dimethyl-substituted organosilane amine inhibitors clearly located the drug binding site at the N-terminal lumen of the A/M2 channel close to V27.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodM11JsKORRLVg90H21EOLACvtfcHk0lh3jIaTlO6jNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVSrtL3E&md5=28cf0b24fbe543718a92d2c2c862ef76</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1021%2Fja2050666&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja2050666%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DLamb%26aufirst%3DR.%2BA.%26aulast%3DPinto%26aufirst%3DL.%2BH.%26aulast%3DDeGrado%26aufirst%3DW.%2BF.%26atitle%3DExploring%2520Organosilane%2520Amines%2520as%2520Potent%2520Inhibitors%2520and%2520Structural%2520Probes%2520of%2520Influenza%2520a%2520Virus%2520M2%2520Proton%2520Channel%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2011%26volume%3D133%26issue%3D35%26spage%3D13844%26epage%3D13847%26doi%3D10.1021%2Fja2050666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tacke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertermann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burschka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dörrich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerhans, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wünsch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnason, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjornsson, R.</span></span> <span> </span><span class="NLM_article-title">High-Affinity, Selective σ Ligands of the 1,2,3,4-Tetrahydro-1,4’-Silaspiro[Naphthalene-1,4’-Piperidine] Type: Syntheses, Structures, and Pharmacological Properties</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">523</span>– <span class="NLM_lpage">532</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201100423</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1002%2Fcmdc.201100423" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=22076883" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVCktr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=523-532&issue=3&author=R.+Tackeauthor=R.+Bertermannauthor=C.+Burschkaauthor=S.+D%C3%B6rrichauthor=M.+Fischerauthor=B.+M%C3%BCllerauthor=G.+Meyerhansauthor=D.+Schepmannauthor=B.+W%C3%BCnschauthor=I.+Arnasonauthor=R.+Bjornsson&title=High-Affinity%2C+Selective+%CF%83+Ligands+of+the+1%2C2%2C3%2C4-Tetrahydro-1%2C4%E2%80%99-Silaspiro%5BNaphthalene-1%2C4%E2%80%99-Piperidine%5D+Type%3A+Syntheses%2C+Structures%2C+and+Pharmacological+Properties&doi=10.1002%2Fcmdc.201100423"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">High-Affinity, Selective σ Ligands of the 1,2,3,4-tetrahydro-1,4'-silaspiro[naphthalene-1,4'-piperidine] Type: Syntheses, Structures, and Pharmacological Properties</span></div><div class="casAuthors">Tacke, Reinhold; Bertermann, Ruediger; Burschka, Christian; Doerrich, Steffen; Fischer, Markus; Mueller, Barbara; Meyerhans, Geraldine; Schepmann, Dirk; Wuensch, Bernhard; Arnason, Ingvar; Bjornsson, Ragnar</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">523-532</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The 1'-organyl-1,2,3,4-tetrahydrospiro[naphthalene-1,4'-piperidine] derivs. 1a-4a [for which organyl = benzyl (1a), 4-methoxybenzyl (2a), 2-phenylethyl (3a), or 3-methylbut-2-enyl (4a)] are high-affinity, selective σ1 ligands.  The corresponding sila-analogs 1b-4b (replacement of the carbon spirocenter with a silicon atom) were synthesized in multistep syntheses, starting from dichlorodivinylsilane, and were isolated as the hydrochlorides 1b·HCl-4b·HCl.  Compds. 1a·HCl-4a·HCl and 1b·HCl-4b·HCl were structurally characterized by NMR spectroscopy (1H, 13C, 29Si) in soln., and the C/Si analogs 3a·HCl and 3b·HCl were studied by single-crystal x-ray diffraction.  These structural investigations were complemented by computational studies.  The σ1 and σ2 receptor affinities of the C/Si pairs 1a/1b-4a/4b were studied with radioligand binding assays.  The σ1 receptor affinity of the silicon compds. 1b-4b is slightly higher than that of the corresponding carbon analogs 1a-4a.  Because affinity for the σ2 receptor is decreased by the C/Si exchange, the σ1/σ2 selectivity of the silicon compds. is considerably improved, indicating that the C→Si switch strategy is a powerful tool for modulating both pharmacol. potency and selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx8E6SDujuvLVg90H21EOLACvtfcHk0lj2XUuv-bfmgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVCktr3N&md5=a0acc209982a90476d82e8e3be133b9c</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201100423&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201100423%26sid%3Dliteratum%253Aachs%26aulast%3DTacke%26aufirst%3DR.%26aulast%3DBertermann%26aufirst%3DR.%26aulast%3DBurschka%26aufirst%3DC.%26aulast%3DD%25C3%25B6rrich%26aufirst%3DS.%26aulast%3DFischer%26aufirst%3DM.%26aulast%3DM%25C3%25BCller%26aufirst%3DB.%26aulast%3DMeyerhans%26aufirst%3DG.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DW%25C3%25BCnsch%26aufirst%3DB.%26aulast%3DArnason%26aufirst%3DI.%26aulast%3DBjornsson%26aufirst%3DR.%26atitle%3DHigh-Affinity%252C%2520Selective%2520%25CF%2583%2520Ligands%2520of%2520the%25201%252C2%252C3%252C4-Tetrahydro-1%252C4%25E2%2580%2599-Silaspiro%255BNaphthalene-1%252C4%25E2%2580%2599-Piperidine%255D%2520Type%253A%2520Syntheses%252C%2520Structures%252C%2520and%2520Pharmacological%2520Properties%26jtitle%3DChemMedChem%26date%3D2012%26volume%3D7%26issue%3D3%26spage%3D523%26epage%3D532%26doi%3D10.1002%2Fcmdc.201100423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pissarnitski, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josien, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clader, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burnett, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terracina, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyde, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, E. M.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Novel, Potent Spirocyclic Series of γ-Secretase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">8806</span>– <span class="NLM_lpage">8817</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00774</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00774" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslWltrjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8806-8817&issue=22&author=Z.+Zhaoauthor=D.+A.+Pissarnitskiauthor=H.+B.+Josienauthor=W.-L.+Wuauthor=R.+Xuauthor=H.+Liauthor=J.+W.+Claderauthor=D.+A.+Burnettauthor=G.+Terracinaauthor=L.+Hydeauthor=J.+Leeauthor=L.+Songauthor=L.+Zhangauthor=E.+M.+Parker&title=Discovery+of+a+Novel%2C+Potent+Spirocyclic+Series+of+%CE%B3-Secretase+Inhibitors&doi=10.1021%2Facs.jmedchem.5b00774"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Novel, Potent Spirocyclic Series of γ-Secretase Inhibitors</span></div><div class="casAuthors">Zhao, Zhiqiang; Pissarnitski, Dmitri A.; Josien, Hubert B.; Wu, Wen-Lian; Xu, Ruo; Li, Hongmei; Clader, John W.; Burnett, Duane A.; Terracina, Giuseppe; Hyde, Lynn; Lee, Julie; Song, Lixin; Zhang, Lili; Parker, Eric M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8806-8817</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the present paper, we described the design, synthesis, SAR, and biol. profile of a novel spirocyclic sulfone series of γ-secretase inhibitors (GSIs) related to MRK-560.  We utilized an addnl. spirocyclic ring system to stabilize the active chair conformation of the parent γ-secretase inhibitors.  The resulting series is devoid of the CYP2C9 inhibition liability of MRK-560.  A few representative analogs were assessed in a nontransgenic animal model of Alzheimer's disease (AD), demonstrating redn. of amyloid-β (Aβ) in the CNS after acute oral dosing.  A spirocyclic phosphonate was identified as the optimal ring system for both potency and pharmacokinetics.  Compared to GSIs studied in the clinic, representative spirocyclic phosphonate 18a(-) features improved selectivity for the inhibition of the PS-1 isoform of γ-secretase (33-fold vs PS-2), which may alleviate the adverse effect profile of the clin. GSIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7tRDNg55f57Vg90H21EOLACvtfcHk0lj2XUuv-bfmgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslWltrjO&md5=18b4d8358b5768006308934f471a2c3b</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00774&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00774%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DPissarnitski%26aufirst%3DD.%2BA.%26aulast%3DJosien%26aufirst%3DH.%2BB.%26aulast%3DWu%26aufirst%3DW.-L.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DClader%26aufirst%3DJ.%2BW.%26aulast%3DBurnett%26aufirst%3DD.%2BA.%26aulast%3DTerracina%26aufirst%3DG.%26aulast%3DHyde%26aufirst%3DL.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DSong%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DParker%26aufirst%3DE.%2BM.%26atitle%3DDiscovery%2520of%2520a%2520Novel%252C%2520Potent%2520Spirocyclic%2520Series%2520of%2520%25CE%25B3-Secretase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D22%26spage%3D8806%26epage%3D8817%26doi%3D10.1021%2Facs.jmedchem.5b00774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elshahawi, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trindade-Silva, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanora, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flores, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vizzoni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrago, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soares, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Concepcion, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Distel, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haygood, M. G.</span></span> <span> </span><span class="NLM_article-title">Boronated Tartrolon Antibiotic Produced by Symbiotic Cellulose-Degrading Bacteria in Shipworm Gills</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">E295</span>– <span class="NLM_lpage">304</span>, <span class="refDoi"> DOI: 10.1073/pnas.1213892110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1073%2Fpnas.1213892110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=23288898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFCgtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=E295-304&issue=4&author=S.+I.+Elshahawiauthor=A.+E.+Trindade-Silvaauthor=A.+Hanoraauthor=A.+W.+Hanauthor=M.+S.+Floresauthor=V.+Vizzoniauthor=C.+G.+Schragoauthor=C.+A.+Soaresauthor=G.+P.+Concepcionauthor=D.+L.+Distelauthor=E.+W.+Schmidtauthor=M.+G.+Haygood&title=Boronated+Tartrolon+Antibiotic+Produced+by+Symbiotic+Cellulose-Degrading+Bacteria+in+Shipworm+Gills&doi=10.1073%2Fpnas.1213892110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Boronated tartrolon antibiotic produced by symbiotic cellulose-degrading bacteria in shipworm gills</span></div><div class="casAuthors">Elshahawi, Sherif I.; Trindade-Silva, Amaro E.; Hanora, Amro; Han, Andrew W.; Flores, Malem S.; Vizzoni, Vinicius; Schrago, Carlos G.; Soares, Carlos A.; Concepcion, Gisela P.; Distel, Dan L.; Schmidt, Eric W.; Haygood, Margo G.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">E295-E304, SE295/1-SE295/12</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Shipworms are marine wood-boring bivalve mollusks (family Teredinidae) that harbor a community of closely related Gammaproteobacteria as intracellular endosymbionts in their gills.  These symbionts have been proposed to assist the shipworm host in cellulose digestion and have been shown to play a role in nitrogen fixation.  The genome of one strain of Teredinibacter turnerae, the first shipworm symbiont to be cultivated, was sequenced, revealing potential as a rich source of polyketides and nonribosomal peptides.  Bioassay-guided fractionation led to the isolation and identification of two macrodioloide polyketides belonging to the tartrolon class.  Both compds. were found to possess antibacterial properties, and the major compd. was found to inhibit other shipworm symbiont strains and various pathogenic bacteria.  The gene cluster responsible for the synthesis of these compds. was identified and characterized, and the ketosynthase domains were analyzed phylogenetically.  Reverse-transcription PCR in addn. to liq. chromatog. and high-resoln. mass spectrometry and tandem mass spectrometry revealed the transcription of these genes and the presence of the compds. in the shipworm, suggesting that the gene cluster is expressed in vivo and that the compds. may fulfill a specific function for the shipworm host.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqP328LON6w7rVg90H21EOLACvtfcHk0lj2XUuv-bfmgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFCgtL8%253D&md5=61392a6667c2af2379c1057d14ed891a</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1213892110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1213892110%26sid%3Dliteratum%253Aachs%26aulast%3DElshahawi%26aufirst%3DS.%2BI.%26aulast%3DTrindade-Silva%26aufirst%3DA.%2BE.%26aulast%3DHanora%26aufirst%3DA.%26aulast%3DHan%26aufirst%3DA.%2BW.%26aulast%3DFlores%26aufirst%3DM.%2BS.%26aulast%3DVizzoni%26aufirst%3DV.%26aulast%3DSchrago%26aufirst%3DC.%2BG.%26aulast%3DSoares%26aufirst%3DC.%2BA.%26aulast%3DConcepcion%26aufirst%3DG.%2BP.%26aulast%3DDistel%26aufirst%3DD.%2BL.%26aulast%3DSchmidt%26aufirst%3DE.%2BW.%26aulast%3DHaygood%26aufirst%3DM.%2BG.%26atitle%3DBoronated%2520Tartrolon%2520Antibiotic%2520Produced%2520by%2520Symbiotic%2520Cellulose-Degrading%2520Bacteria%2520in%2520Shipworm%2520Gills%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26issue%3D4%26spage%3DE295%26epage%3D304%26doi%3D10.1073%2Fpnas.1213892110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murugan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinnapattu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, F.-R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, P. S.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Novel Benzoxaborinin-4-ones and Its Application in Indolin-2-ones Synthesis Using a Suzuki–Miyaura Reaction Protocol</span>. <i>RSC Adv.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">46</span>),  <span class="NLM_fpage">36902</span>– <span class="NLM_lpage">36905</span>, <span class="refDoi"> DOI: 10.1039/C5RA05755H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1039%2FC5RA05755H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsFelt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=36902-36905&issue=46&author=K.+Muruganauthor=M.+Chinnapattuauthor=F.-R.+N.+Khanauthor=P.+S.+Iyer&title=Synthesis+of+Novel+Benzoxaborinin-4-ones+and+Its+Application+in+Indolin-2-ones+Synthesis+Using+a+Suzuki%E2%80%93Miyaura+Reaction+Protocol&doi=10.1039%2FC5RA05755H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of novel benzoxaborinin-4-ones and its application in indolin-2-ones synthesis using a Suzuki-Miyaura reaction protocol</span></div><div class="casAuthors">Murugan, Kannan; Chinnapattu, Murugan; Nawaz Khan, Fazlur-Rahman; Iyer, Pravin S.</div><div class="citationInfo"><span class="NLM_cas:title">RSC Advances</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">36902-36905</span>CODEN:
                <span class="NLM_cas:coden">RSCACL</span>;
        ISSN:<span class="NLM_cas:issn">2046-2069</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The synthesis of novel benzoxaborinin-4-one from substituted isatins and 2-acetyl phenylboronic acid is reported.  Furthermore, the application of these boronic acids to synthesize indolin-2-ones (Z isomer) I (R1 = H, Me, F, Cl, Br; R2 = H, Me; Ar = 4-ClC6H4, 4-CNC6H4, 2-trifluoromethyl-pyridin-5-yl) regioselectively using Suzuki-Miyaura reaction is demonstrated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8gFbsii1kdbVg90H21EOLACvtfcHk0liub8SA9zjOQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsFelt78%253D&md5=e4e29f1119da39dc928d6d44a64a5621</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1039%2FC5RA05755H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5RA05755H%26sid%3Dliteratum%253Aachs%26aulast%3DMurugan%26aufirst%3DK.%26aulast%3DChinnapattu%26aufirst%3DM.%26aulast%3DKhan%26aufirst%3DF.-R.%2BN.%26aulast%3DIyer%26aufirst%3DP.%2BS.%26atitle%3DSynthesis%2520of%2520Novel%2520Benzoxaborinin-4-ones%2520and%2520Its%2520Application%2520in%2520Indolin-2-ones%2520Synthesis%2520Using%2520a%2520Suzuki%25E2%2580%2593Miyaura%2520Reaction%2520Protocol%26jtitle%3DRSC%2520Adv.%26date%3D2015%26volume%3D5%26issue%3D46%26spage%3D36902%26epage%3D36905%26doi%3D10.1039%2FC5RA05755H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Natsutani, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamai, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishida, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagaoka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sumiyoshi, T.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Evaluations of Spiro-Fused Benzoxaborin Derivatives as Novel Boron-Containing Compounds</span>. <i>Chem. Biol. Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>93</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">657</span>– <span class="NLM_lpage">665</span>, <span class="refDoi"> DOI: 10.1111/cbdd.13496</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1111%2Fcbdd.13496" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=30721578" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1MXltFynsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2019&pages=657-665&issue=5&author=I.+Natsutaniauthor=R.+Iwataauthor=Y.-S.+Yamaiauthor=K.+Ishidaauthor=Y.+Nagaokaauthor=T.+Sumiyoshi&title=Design%2C+Synthesis+and+Evaluations+of+Spiro-Fused+Benzoxaborin+Derivatives+as+Novel+Boron-Containing+Compounds&doi=10.1111%2Fcbdd.13496"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and evaluations of spiro-fused benzoxaborin derivatives as novel boron-containing compounds</span></div><div class="casAuthors">Natsutani, Itaru; Iwata, Riyo; Yamai, Yu-suke; Ishida, Kyoji; Nagaoka, Yasuo; Sumiyoshi, Takaaki</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">657-665</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Drug design using boron-contg. heterocycles has attracted a great deal of attention because these compds. are believed to possess high biol. activity.  However, information on the synthetic methodol. and pharmacokinetic profiling of boron-contg. compds. is limited.  In this study, we provide a new synthetic route for prepn. of spiro-fused benzoxaborin derivs. and investigate their in vitro pharmacokinetic properties.  Our efforts led to the successful construction of a chem. library of spiro-fused benzoxaborin derivs. with appropriate physicochem. and in vitro pharmacokinetic properties for oral drugs.  These results indicate that the synthesized boron-contg. compds. are therefore eligible for classification in a novel chem. library.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_AUoXSaMKgLVg90H21EOLACvtfcHk0liub8SA9zjOQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXltFynsrw%253D&md5=1250bb65fff9cca98d1adc66f410e176</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1111%2Fcbdd.13496&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcbdd.13496%26sid%3Dliteratum%253Aachs%26aulast%3DNatsutani%26aufirst%3DI.%26aulast%3DIwata%26aufirst%3DR.%26aulast%3DYamai%26aufirst%3DY.-S.%26aulast%3DIshida%26aufirst%3DK.%26aulast%3DNagaoka%26aufirst%3DY.%26aulast%3DSumiyoshi%26aufirst%3DT.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Evaluations%2520of%2520Spiro-Fused%2520Benzoxaborin%2520Derivatives%2520as%2520Novel%2520Boron-Containing%2520Compounds%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2019%26volume%3D93%26issue%3D5%26spage%3D657%26epage%3D665%26doi%3D10.1111%2Fcbdd.13496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meazza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rios, R.</span></span> <span> </span><span class="NLM_article-title">New Development in the Enantioselective Synthesis of Spiro Compounds</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>47</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">5946</span>– <span class="NLM_lpage">5996</span>, <span class="refDoi"> DOI: 10.1039/C6CS00825A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1039%2FC6CS00825A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=29953153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1WqtbnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2018&pages=5946-5996&issue=15&author=A.+Dingauthor=M.+Meazzaauthor=H.+Guoauthor=J.+W.+Yangauthor=R.+Rios&title=New+Development+in+the+Enantioselective+Synthesis+of+Spiro+Compounds&doi=10.1039%2FC6CS00825A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">New development in the enantioselective synthesis of spiro compounds</span></div><div class="casAuthors">Ding, Aishun; Meazza, Marta; Guo, Hao; Yang, Jung Woon; Rios, Ramon</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5946-5996</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The enantioselective synthesis of spirocycles has long been pursued by org. chemists.  Despite their unique 3D properties and presence in several natural products, the difficulty in their enantioselective synthesis makes them underrepresented in pharmaceutical libraries.  Since the first pioneering reports of the enantioselective construction of spirosilanes by Tamao et al., significant effort has been devoted towards the development of new promising asym. methodologies.  Remarkably, with the advent of organocatalysis, particularly over six years, the reported methodologies for the synthesis of spirocycles have increased exponentially.  The aim of this review is to summarize the latest trends and developments in the enantioselective synthesis of spirocompounds during these last six years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtCZ_qMqIu3bVg90H21EOLACvtfcHk0li_RnvVJSLYYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1WqtbnE&md5=25b8984f3ac4125a61794afe6e627634</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1039%2FC6CS00825A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6CS00825A%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DA.%26aulast%3DMeazza%26aufirst%3DM.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DJ.%2BW.%26aulast%3DRios%26aufirst%3DR.%26atitle%3DNew%2520Development%2520in%2520the%2520Enantioselective%2520Synthesis%2520of%2520Spiro%2520Compounds%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2018%26volume%3D47%26issue%3D15%26spage%3D5946%26epage%3D5996%26doi%3D10.1039%2FC6CS00825A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leong, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seah, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karuna, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Susila, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diagana, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dix, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, P.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. W.</span></span> <span> </span><span class="NLM_article-title">Lead Optimization of Spiropyrazolopyridones: A New and Potent Class of Dengue Virus Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">344</span>– <span class="NLM_lpage">348</span>, <span class="refDoi"> DOI: 10.1021/ml500521r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500521r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFehsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=344-348&issue=3&author=B.+Zouauthor=W.+L.+Chanauthor=M.+Dingauthor=S.+Y.+Leongauthor=S.+Nilarauthor=P.+G.+Seahauthor=W.+Liuauthor=R.+Karunaauthor=F.+Blascoauthor=A.+Yipauthor=A.+Chaoauthor=A.+Susilaauthor=H.+Dongauthor=Q.+Y.+Wangauthor=H.+Y.+Xuauthor=K.+Chanauthor=K.+F.+Wanauthor=F.+Guauthor=T.+T.+Diaganaauthor=T.+Wagnerauthor=I.+Dixauthor=P.-Y.+Shiauthor=P.+W.+Smith&title=Lead+Optimization+of+Spiropyrazolopyridones%3A+A+New+and+Potent+Class+of+Dengue+Virus+Inhibitors&doi=10.1021%2Fml500521r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Lead optimization of spiropyrazolopyridones: a new and potent class of Dengue virus inhibitors</span></div><div class="casAuthors">Zou, Bin; Chan, Wai Ling; Ding, Mei; Leong, Seh Yong; Nilar, Shahul; Seah, Peck Gee; Liu, Wei; Karuna, Ratna; Blasco, Francesca; Yip, Andy; Chao, Alex; Susila, Agatha; Dong, Hongping; Wang, Qing Yin; Xu, Hao Ying; Chan, Katherine; Wan, Kah Fei; Gu, Feng; Diagana, Thierry T.; Wagner, Trixie; Dix, Ina; Shi, Pei-Yong; Smith, Paul W.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">344-348</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Spiropyrazolopyridone I was identified, as a novel dengue virus (DENV) inhibitor, from a DENV serotype 2 (DENV-2) high-throughput phenotypic screen.  As a general trend within this chem. class, chiral resoln. of the racemate revealed that R enantiomer was significantly more potent than the S.  Cell-based lead optimization of the spiropyrazolopyridones focusing on improving the physicochem. properties is described.  As a result, an optimal compd. II, with balanced in vitro potency and pharmacokinetic profile, achieved about 1.9 log viremia redn. at 3 × 50 mg/kg (bid) or 3 × 100 mg/kg (QD) oral doses in the dengue in vivo mouse efficacy model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6sl_5dOn9m7Vg90H21EOLACvtfcHk0li_RnvVJSLYYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFehsbY%253D&md5=25972b876e5b117d711213db3c179159</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1021%2Fml500521r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500521r%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DB.%26aulast%3DChan%26aufirst%3DW.%2BL.%26aulast%3DDing%26aufirst%3DM.%26aulast%3DLeong%26aufirst%3DS.%2BY.%26aulast%3DNilar%26aufirst%3DS.%26aulast%3DSeah%26aufirst%3DP.%2BG.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DKaruna%26aufirst%3DR.%26aulast%3DBlasco%26aufirst%3DF.%26aulast%3DYip%26aufirst%3DA.%26aulast%3DChao%26aufirst%3DA.%26aulast%3DSusila%26aufirst%3DA.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DQ.%2BY.%26aulast%3DXu%26aufirst%3DH.%2BY.%26aulast%3DChan%26aufirst%3DK.%26aulast%3DWan%26aufirst%3DK.%2BF.%26aulast%3DGu%26aufirst%3DF.%26aulast%3DDiagana%26aufirst%3DT.%2BT.%26aulast%3DWagner%26aufirst%3DT.%26aulast%3DDix%26aufirst%3DI.%26aulast%3DShi%26aufirst%3DP.-Y.%26aulast%3DSmith%26aufirst%3DP.%2BW.%26atitle%3DLead%2520Optimization%2520of%2520Spiropyrazolopyridones%253A%2520A%2520New%2520and%2520Potent%2520Class%2520of%2520Dengue%2520Virus%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26issue%3D3%26spage%3D344%26epage%3D348%26doi%3D10.1021%2Fml500521r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tai, V. W.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrido, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maynard, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pouliot, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seal, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creech, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kryn, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baughman, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peat, A. J.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Spirocyclic Compounds as HCV Replication Inhibitors by Targeting Viral NS4B Protein</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2288</span>– <span class="NLM_lpage">2294</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.03.080</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2Fj.bmcl.2014.03.080" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=24731273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmt1Wlu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=2288-2294&issue=10&author=V.+W.-F.+Taiauthor=D.+Garridoauthor=D.+J.+Priceauthor=A.+Maynardauthor=J.+J.+Pouliotauthor=Z.+Xiongauthor=J.+W.+Sealauthor=K.+L.+Creechauthor=L.+H.+Krynauthor=T.+M.+Baughmanauthor=A.+J.+Peat&title=Design+and+Synthesis+of+Spirocyclic+Compounds+as+HCV+Replication+Inhibitors+by+Targeting+Viral+NS4B+Protein&doi=10.1016%2Fj.bmcl.2014.03.080"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of spirocyclic compounds as HCV replication inhibitors by targeting viral NS4B protein</span></div><div class="casAuthors">Tai, Vincent W.-F.; Garrido, Dulce; Price, Daniel J.; Maynard, Andrew; Pouliot, Jeffrey J.; Xiong, Zhiping; Seal, John W.; Creech, Katrina L.; Kryn, Luz H.; Baughman, Todd M.; Peat, Andrew J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2288-2294</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Pyrazolo[1,5-a]pyridinecarbonyl-substituted spiropiperidines such as pyrazolo[1,5-a]pyridinecarbonyl dispirocyclopropanedioxanepiperidinol I and pyrazolo[1,5-a]pyridinecarbonyl hydroxyspiropiperidineoxazolidinone II were prepd. as inhibitors of hepatitis C viral protein NS4B; their inhibition of HCV replicons 1a and 1b and their lack of cytotoxicity in human cells at concns. < 25 μM were detd.  Spirocyclic piperidine ketals such as I were prepd. which showed in vitro anti-HCV activities; for example, I showed EC50 of 1.5 nM and 1.2 nM against genotype 1a and 1b replicons, resp., in vitro.  Spirocyclic piperidine oxazolidinones such as II were prepd.; II showed EC50 values of 10.9 nM and 6.1 nM against HCV 1a and 1b replicons, resp.  The solubilities, permeabilities in the presence of P-gp transporters, half-life, and calcd. lipophilicities, polar surface areas, and lipophilic ligand efficiencies were detd. for selected compds. including I and II.  Both I and II bound directly to non-structural NS4B protein in vitro (IC50 values of 10.2 nM and 30.4 nM, resp.); I and II exhibited reduced potency (27-185-fold increases in EC50 values) in replicons contg. resistance mutations encoding changes (H94N and V105M) in the NS4B protein.  The structure of a dispirocyclopropanedioxanepiperidine di-O-p-toluoyltartrate salt used in the prepn. of I was detd. by X-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0Tcrswh6YCrVg90H21EOLACvtfcHk0ljVR_oe6TVfVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmt1Wlu7s%253D&md5=e221782d8c961d7b60348c98d3de0da1</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.03.080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.03.080%26sid%3Dliteratum%253Aachs%26aulast%3DTai%26aufirst%3DV.%2BW.-F.%26aulast%3DGarrido%26aufirst%3DD.%26aulast%3DPrice%26aufirst%3DD.%2BJ.%26aulast%3DMaynard%26aufirst%3DA.%26aulast%3DPouliot%26aufirst%3DJ.%2BJ.%26aulast%3DXiong%26aufirst%3DZ.%26aulast%3DSeal%26aufirst%3DJ.%2BW.%26aulast%3DCreech%26aufirst%3DK.%2BL.%26aulast%3DKryn%26aufirst%3DL.%2BH.%26aulast%3DBaughman%26aufirst%3DT.%2BM.%26aulast%3DPeat%26aufirst%3DA.%2BJ.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Spirocyclic%2520Compounds%2520as%2520HCV%2520Replication%2520Inhibitors%2520by%2520Targeting%2520Viral%2520NS4B%2520Protein%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26issue%3D10%26spage%3D2288%26epage%3D2294%26doi%3D10.1016%2Fj.bmcl.2014.03.080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwatani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morishita, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakanishi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maezaki, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of Spiro[Indole-3,2’-Pyrrolidin]-2(1H)-One Based Inhibitors Targeting Brr2, a Core Component of the U5 SnRNP</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">4753</span>– <span class="NLM_lpage">4767</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2017.07.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2Fj.bmc.2017.07.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=28751196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1egsLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=4753-4767&issue=17&author=M.+Itoauthor=M.+Iwataniauthor=T.+Yamamotoauthor=T.+Tanakaauthor=T.+Kawamotoauthor=D.+Morishitaauthor=A.+Nakanishiauthor=H.+Maezaki&title=Discovery+of+Spiro%5BIndole-3%2C2%E2%80%99-Pyrrolidin%5D-2%281H%29-One+Based+Inhibitors+Targeting+Brr2%2C+a+Core+Component+of+the+U5+SnRNP&doi=10.1016%2Fj.bmc.2017.07.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of spiro[indole-3,2'-pyrrolidin]-2(1H)-one based inhibitors targeting Brr2, a core component of the U5 snRNP</span></div><div class="casAuthors">Ito, Masahiro; Iwatani, Misa; Yamamoto, Takeshi; Tanaka, Toshio; Kawamoto, Tomohiro; Morishita, Daisuke; Nakanishi, Atsushi; Maezaki, Hironobu</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4753-4767</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Bad response to refrigeration 2 (Brr2) is a member of the Ski2-like RNA helicases, and an essential component of the U5 small nuclear ribonucleoprotein (snRNP).  A particularly important role of Brr2 is the ATP-dependent unwinding of the U4/U6 RNA duplex, which is a crit. step in spliceosomal activation.  Despite its biol. importance, selective inhibitor for Brr2 had not been reported until the authors' recent report.  Here, the authors describe novel and structurally distinct spiro[indole-3,2'-pyrrolidin]-2(1H)-one based Brr2 inhibitors with superior activity to the previously reported 4,6-dihydropyrido[4,3-d]pyrimidine-2,7(1H,3H)-dione series.  Using an RNA dependent ATPase assay as a guide, high-throughput screening, hit validation by structure-activity relationship (SAR) study, and subsequent chem. optimization to increase the ATPase inhibitory activity were performed.  Thereafter, selectivity and helicase inhibitory activity of optimized compds. were confirmed.  In the course of the study, compds. were synthesized using a three-component reaction, which accelerated the optimization process.  All these efforts finally culminated in the discovery of the potent and selective Brr2 inhibitors (32a (3S,3'R,5'S)-5-fluoro-5'-isobutyl-3'-methyl-1'-((1-methyl-1H-imidazol-4-yl)carbonyl)spiro[indole-3,2'-pyrrolidin]-2(1H)-one) and 33a ((3S,3'R,5'S)-1'-((1-Benzyl-1H-imidazol-4-yl)carbonyl)-5-fluoro-5-isobutyl-3-methylspiro[indole-3,2-pyrrolidin]-2(1H)-one) exhibiting helicase inhibitory activity at submicromolar concns.  Thus, compds. 32a and 33a could be valuable mol. probes to study the functions of Brr2 and mol. machinery of RNA splicing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtRxC2SlBj6rVg90H21EOLACvtfcHk0ljVR_oe6TVfVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1egsLnL&md5=7356fbabe559b6d177b59cd49c316c7e</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.07.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.07.017%26sid%3Dliteratum%253Aachs%26aulast%3DIto%26aufirst%3DM.%26aulast%3DIwatani%26aufirst%3DM.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DKawamoto%26aufirst%3DT.%26aulast%3DMorishita%26aufirst%3DD.%26aulast%3DNakanishi%26aufirst%3DA.%26aulast%3DMaezaki%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520Spiro%255BIndole-3%252C2%25E2%2580%2599-Pyrrolidin%255D-2%25281H%2529-One%2520Based%2520Inhibitors%2520Targeting%2520Brr2%252C%2520a%2520Core%2520Component%2520of%2520the%2520U5%2520SnRNP%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26issue%3D17%26spage%3D4753%26epage%3D4767%26doi%3D10.1016%2Fj.bmc.2017.07.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Imaeda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ono, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hori, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsukawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takagi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujioka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarui, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imanishi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inatomi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kajino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itoh, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishida, H.</span></span> <span> </span><span class="NLM_article-title">Discovery, Synthesis, and Structure-Activity Relations of 3,4-Dihydro-1H-Spiro(Naphthalene-2,2’-Piperidin)-1-Ones as Potassium-Competitive Acid Blockers</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">3719</span>– <span class="NLM_lpage">3735</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2017.05.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2Fj.bmc.2017.05.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=28522264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvVSjtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=3719-3735&issue=14&author=T.+Imaedaauthor=K.+Onoauthor=K.+Nakaiauthor=Y.+Horiauthor=J.+Matsukawaauthor=T.+Takagiauthor=Y.+Fujiokaauthor=N.+Taruiauthor=M.+Kondoauthor=A.+Imanishiauthor=N.+Inatomiauthor=M.+Kajinoauthor=F.+Itohauthor=H.+Nishida&title=Discovery%2C+Synthesis%2C+and+Structure-Activity+Relations+of+3%2C4-Dihydro-1H-Spiro%28Naphthalene-2%2C2%E2%80%99-Piperidin%29-1-Ones+as+Potassium-Competitive+Acid+Blockers&doi=10.1016%2Fj.bmc.2017.05.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery, synthesis, and structure-activity relations of 3,4-dihydro-1H-spiro(naphthalene-2,2'-piperidin)-1-ones as potassium-competitive acid blockers</span></div><div class="casAuthors">Imaeda, Toshihiro; Ono, Koji; Nakai, Kazuo; Hori, Yasunobu; Matsukawa, Jun; Takagi, Terufumi; Fujioka, Yasushi; Tarui, Naoki; Kondo, Mitsuyo; Imanishi, Akio; Inatomi, Nobuhiro; Kajino, Masahiro; Itoh, Fumio; Nishida, Haruyuki</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3719-3735</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">With the aim to discover a gastric antisecretory agent more potent than the existing proton pump inhibitors, novel 3,4-dihydro-1H-spiro(naphthalene-2,2'-piperidin)-1-one derivs., which could occupy two important lipophilic pockets (described as LP-1 and LP-2) of H+,K+-ATPase and can strongly bind to the K+-binding site, were designed based on a docking model.  Among the compds. synthesized, compd. I showed a strong H+,K+-ATPase-inhibitory activity and a high stomach concn. in rats, resulting in potent inhibitory action on histamine-stimulated gastric acid secretion in rats.  Furthermore, I exerted significant inhibitory action on histamine-stimulated gastric-acid secretion in rats with a rapid onset and moderate duration of action after the administration.  These findings may lead to a new insight into the drug design of potassium-competitive acid blockers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwWczD6yvNbLVg90H21EOLACvtfcHk0lh3-uMTNIscdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvVSjtL8%253D&md5=2cc4366eab35eb4e50d30b714bda3c0d</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.05.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.05.012%26sid%3Dliteratum%253Aachs%26aulast%3DImaeda%26aufirst%3DT.%26aulast%3DOno%26aufirst%3DK.%26aulast%3DNakai%26aufirst%3DK.%26aulast%3DHori%26aufirst%3DY.%26aulast%3DMatsukawa%26aufirst%3DJ.%26aulast%3DTakagi%26aufirst%3DT.%26aulast%3DFujioka%26aufirst%3DY.%26aulast%3DTarui%26aufirst%3DN.%26aulast%3DKondo%26aufirst%3DM.%26aulast%3DImanishi%26aufirst%3DA.%26aulast%3DInatomi%26aufirst%3DN.%26aulast%3DKajino%26aufirst%3DM.%26aulast%3DItoh%26aufirst%3DF.%26aulast%3DNishida%26aufirst%3DH.%26atitle%3DDiscovery%252C%2520Synthesis%252C%2520and%2520Structure-Activity%2520Relations%2520of%25203%252C4-Dihydro-1H-Spiro%2528Naphthalene-2%252C2%25E2%2580%2599-Piperidin%2529-1-Ones%2520as%2520Potassium-Competitive%2520Acid%2520Blockers%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26issue%3D14%26spage%3D3719%26epage%3D3735%26doi%3D10.1016%2Fj.bmc.2017.05.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Michaelides, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kluge, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patane, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Drie, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Risi, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantei, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hertel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karukurichi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nesterov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McElligott, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vries, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langston, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marmorstein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasko, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bromberg, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kesicki, E. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of Spiro Oxazolidinediones as Selective, Orally Bioavailable Inhibitors of P300/CBP Histone Acetyltransferases</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">28</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00395</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00395" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFOqsrnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=28-33&issue=1&author=M.+R.+Michaelidesauthor=A.+Klugeauthor=M.+Pataneauthor=J.+H.+Van+Drieauthor=C.+Wangauthor=T.+M.+Hansenauthor=R.+M.+Risiauthor=R.+Manteiauthor=C.+Hertelauthor=K.+Karukurichiauthor=A.+Nesterovauthor=D.+McElligottauthor=P.+de+Vriesauthor=J.+W.+Langstonauthor=P.+A.+Coleauthor=R.+Marmorsteinauthor=H.+Liuauthor=L.+Laskoauthor=K.+D.+Brombergauthor=A.+Laiauthor=E.+A.+Kesicki&title=Discovery+of+Spiro+Oxazolidinediones+as+Selective%2C+Orally+Bioavailable+Inhibitors+of+P300%2FCBP+Histone+Acetyltransferases&doi=10.1021%2Facsmedchemlett.7b00395"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Spiro Oxazolidinediones as Selective, Orally Bioavailable Inhibitors of p300/CBP Histone Acetyltransferases</span></div><div class="casAuthors">Michaelides, Michael R.; Kluge, Arthur; Patane, Michael; Van Drie, John H.; Wang, Ce; Hansen, T. Matthew; Risi, Roberto M.; Mantei, Robert; Hertel, Carmen; Karukurichi, Kannan; Nesterov, Alexandre; McElligott, David; de Vries, Peter; Langston, J. William; Cole, Philip A.; Marmorstein, Ronen; Liu, Hong; Lasko, Loren; Bromberg, Kenneth D.; Lai, Albert; Kesicki, Edward A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-33</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">P300 and its paralog CBP can acetylate histones and other proteins and have been implicated in a no. of diseases characterized by aberrant gene activation, such as cancer.  A novel, highly selective, orally bioavailable histone acetyltransferase (HAT) domain inhibitor has been identified through virtual ligand screening and subsequent optimization of a unique hydantoin screening hit.  Conformational restraint in the form of a spirocyclization followed by substitution with a urea led to a significant improvement in potency.  Replacement of the hydantoin moiety with an oxazolidinedione followed by fluoro substitution led to A-485, which exhibits potent cell activity, low clearance, and high oral bioavailability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ091OW0sfXbVg90H21EOLACvtfcHk0ljlYwozDcpOTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFOqsrnE&md5=3ba083fc5e148d06457d2e4015ac7475</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00395%26sid%3Dliteratum%253Aachs%26aulast%3DMichaelides%26aufirst%3DM.%2BR.%26aulast%3DKluge%26aufirst%3DA.%26aulast%3DPatane%26aufirst%3DM.%26aulast%3DVan%2BDrie%26aufirst%3DJ.%2BH.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DHansen%26aufirst%3DT.%2BM.%26aulast%3DRisi%26aufirst%3DR.%2BM.%26aulast%3DMantei%26aufirst%3DR.%26aulast%3DHertel%26aufirst%3DC.%26aulast%3DKarukurichi%26aufirst%3DK.%26aulast%3DNesterov%26aufirst%3DA.%26aulast%3DMcElligott%26aufirst%3DD.%26aulast%3Dde%2BVries%26aufirst%3DP.%26aulast%3DLangston%26aufirst%3DJ.%2BW.%26aulast%3DCole%26aufirst%3DP.%2BA.%26aulast%3DMarmorstein%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DLasko%26aufirst%3DL.%26aulast%3DBromberg%26aufirst%3DK.%2BD.%26aulast%3DLai%26aufirst%3DA.%26aulast%3DKesicki%26aufirst%3DE.%2BA.%26atitle%3DDiscovery%2520of%2520Spiro%2520Oxazolidinediones%2520as%2520Selective%252C%2520Orally%2520Bioavailable%2520Inhibitors%2520of%2520P300%252FCBP%2520Histone%2520Acetyltransferases%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26issue%3D1%26spage%3D28%26epage%3D33%26doi%3D10.1021%2Facsmedchemlett.7b00395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Volgraf, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huestis, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purkey, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geck Do, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyssikatos, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rana, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vigers, G. P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis, Characterization, and PK/PD Studies of a Series of Spirocyclic Pyranochromene BACE1 Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2477</span>– <span class="NLM_lpage">2480</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.04.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2Fj.bmcl.2014.04.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=24780121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnt1elsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=2477-2480&issue=11&author=M.+Volgrafauthor=L.+Chanauthor=M.+P.+Huestisauthor=H.+E.+Purkeyauthor=M.+Burkardauthor=M.+Geck+Doauthor=J.+Harrisauthor=K.+W.+Huntauthor=X.+Liuauthor=J.+P.+Lyssikatosauthor=S.+Ranaauthor=A.+A.+Thomasauthor=G.+P.+A.+Vigersauthor=M.+Siu&title=Synthesis%2C+Characterization%2C+and+PK%2FPD+Studies+of+a+Series+of+Spirocyclic+Pyranochromene+BACE1+Inhibitors&doi=10.1016%2Fj.bmcl.2014.04.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, characterization, and PK/PD studies of a series of spirocyclic pyranochromene BACE1 inhibitors</span></div><div class="casAuthors">Volgraf, Matthew; Chan, Lina; Huestis, Malcolm P.; Purkey, Hans E.; Burkard, Michael; Geck Do, Mary; Harris, Julie; Hunt, Kevin W.; Liu, Xingrong; Lyssikatos, Joseph P.; Rana, Sumeet; Thomas, Allen A.; Vigers, Guy P. A.; Siu, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2477-2480</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The development of 1,3,4,4a,5,10a-hexahydropyrano[3,4-b]chromene analogs as BACE1 inhibitors is described.  Introduction of the spirocyclic pyranochromene scaffold yielded several advantages over previous generation cores, including increased potency, reduced efflux, and reduced CYP2D6 inhibition.  Compd. I (BACE1 IC50 = 110 nM) demonstrated a redn. in CSF Aβ in wild type rats after a single dose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruGUhiyWMFFLVg90H21EOLACvtfcHk0ljlYwozDcpOTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnt1elsLc%253D&md5=b18305c310576e6fb976e5dc9c98a4f6</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.04.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.04.012%26sid%3Dliteratum%253Aachs%26aulast%3DVolgraf%26aufirst%3DM.%26aulast%3DChan%26aufirst%3DL.%26aulast%3DHuestis%26aufirst%3DM.%2BP.%26aulast%3DPurkey%26aufirst%3DH.%2BE.%26aulast%3DBurkard%26aufirst%3DM.%26aulast%3DGeck%2BDo%26aufirst%3DM.%26aulast%3DHarris%26aufirst%3DJ.%26aulast%3DHunt%26aufirst%3DK.%2BW.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLyssikatos%26aufirst%3DJ.%2BP.%26aulast%3DRana%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DA.%2BA.%26aulast%3DVigers%26aufirst%3DG.%2BP.%2BA.%26aulast%3DSiu%26aufirst%3DM.%26atitle%3DSynthesis%252C%2520Characterization%252C%2520and%2520PK%252FPD%2520Studies%2520of%2520a%2520Series%2520of%2520Spirocyclic%2520Pyranochromene%2520BACE1%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26issue%3D11%26spage%3D2477%26epage%3D2480%26doi%3D10.1016%2Fj.bmcl.2014.04.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chao, W.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, T.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhari, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, B.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, P.-T.</span></span> <span> </span><span class="NLM_article-title">The Azatryptophan-Based Fluorescent Platform for in Vitro Rapid Screening of Inhibitors Disrupting IKKβ-NEMO Interaction</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">504</span>– <span class="NLM_lpage">511</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2018.09.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2Fj.bioorg.2018.09.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=30245232" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslOjt7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2018&pages=504-511&author=W.-C.+Chaoauthor=T.-H.+Chiangauthor=P.+D.+Chaudhariauthor=L.-J.+Linauthor=J.-F.+Luauthor=B.-C.+Hongauthor=J.-S.+Wangauthor=T.-C.+Linauthor=J.-Y.+Shenauthor=P.-T.+Chou&title=The+Azatryptophan-Based+Fluorescent+Platform+for+in+Vitro+Rapid+Screening+of+Inhibitors+Disrupting+IKK%CE%B2-NEMO+Interaction&doi=10.1016%2Fj.bioorg.2018.09.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">The azatryptophan-based fluorescent platform for in vitro rapid screening of inhibitors disrupting IKKβ-NEMO interaction</span></div><div class="casAuthors">Chao, Wei-Chih; Chiang, Tzu-Hsuan; Chaudhari, Prakash D.; Lin, Li-Ju; Lu, Jyh-Feng; Hong, Bor-Cherng; Wang, Jinn-Shyan; Lin, Ta-Chun; Shen, Jiun-Yi; Chou, Pi-Tai</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">504-511</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The nuclear factor-κB (NF-κB) plays an important role in inflammatory and immune responses.  Aberrant NF-κB signaling is implicated in multiple disorders, including cancer.  Targeting the regulatory scaffold subunit IκB kinase γ (IKKγ/NEMO) as therapeutic interventions could be promising due to its specific involvement in canonical NF-κB activation without interfering with non-canonical signaling.  In this study, the use of unnatural amino acid substituted IKKβ with unique photophys. activity to sense water environment changes upon interaction with NEMO provides a powerful in vitro screening platform that would greatly facilitate the identification of compds. having the potential to disrupt IKKβ-NEMO interaction, and thus specifically modulate the canonical NF-κB pathway.  We then utilized a competitive binding platform to screen the binding ability of a no. of potential mols. being synthesized.  Our results suggest that a lead compd. (-)-PDC-099 is a potent agent with ascertained potency to disrupt IKKβ-NEMO complex for modulating NF-κB canonical pathway. er of spirocyclic oxindoles derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVqOXDT_1qmbVg90H21EOLACvtfcHk0lg90vGpgXX3PA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslOjt7fP&md5=29823ffc15da407aec3aaedcc47e9dcc</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2018.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2018.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DChao%26aufirst%3DW.-C.%26aulast%3DChiang%26aufirst%3DT.-H.%26aulast%3DChaudhari%26aufirst%3DP.%2BD.%26aulast%3DLin%26aufirst%3DL.-J.%26aulast%3DLu%26aufirst%3DJ.-F.%26aulast%3DHong%26aufirst%3DB.-C.%26aulast%3DWang%26aufirst%3DJ.-S.%26aulast%3DLin%26aufirst%3DT.-C.%26aulast%3DShen%26aufirst%3DJ.-Y.%26aulast%3DChou%26aufirst%3DP.-T.%26atitle%3DThe%2520Azatryptophan-Based%2520Fluorescent%2520Platform%2520for%2520in%2520Vitro%2520Rapid%2520Screening%2520of%2520Inhibitors%2520Disrupting%2520IKK%25CE%25B2-NEMO%2520Interaction%26jtitle%3DBioorg.%2520Chem.%26date%3D2018%26volume%3D81%26spage%3D504%26epage%3D511%26doi%3D10.1016%2Fj.bioorg.2018.09.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hill, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwuagwu, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zusi, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mate, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knox, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Post-Munson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Easton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lentz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benitex, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodge, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaczek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denton, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bristow, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, R.</span></span> <span> </span><span class="NLM_article-title">Development of 4-Heteroarylamino-1’-Azaspiro[Oxazole-5,3’-Bicyclo[2.2.2]Octanes] as Α7 Nicotinic Receptor Agonists</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">137</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00471</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00471" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFynt7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=133-137&issue=1&author=M.+D.+Hillauthor=H.+Fangauthor=H.+D.+Kingauthor=C.+I.+Iwuagwuauthor=I.+M.+McDonaldauthor=J.+Cookauthor=F.+C.+Zusiauthor=R.+A.+Mateauthor=R.+J.+Knoxauthor=D.+Post-Munsonauthor=A.+Eastonauthor=R.+Millerauthor=K.+Lentzauthor=W.+Clarkeauthor=Y.+Benitexauthor=N.+Lodgeauthor=R.+Zaczekauthor=R.+Dentonauthor=D.+Morganauthor=L.+Bristowauthor=J.+E.+Macorauthor=R.+Olson&title=Development+of+4-Heteroarylamino-1%E2%80%99-Azaspiro%5BOxazole-5%2C3%E2%80%99-Bicyclo%5B2.2.2%5DOctanes%5D+as+%CE%917+Nicotinic+Receptor+Agonists&doi=10.1021%2Facsmedchemlett.6b00471"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Development of 4-Heteroarylamino-1'-azaspiro[oxazole-5,3'-bicyclo[2.2.2]octanes] as α7 Nicotinic Receptor Agonists</span></div><div class="casAuthors">Hill, Matthew D.; Fang, Haiquan; King, H. Dalton; Iwuagwu, Christiana I.; McDonald, Ivar M.; Cook, James; Zusi, F. Christopher; Mate, Robert A.; Knox, Ronald J.; Post-Munson, Debra; Easton, Amy; Miller, Regina; Lentz, Kimberley; Clarke, Wendy; Benitex, Yulia; Lodge, Nicholas; Zaczek, Robert; Denton, Rex; Morgan, Daniel; Bristow, Linda; Macor, John E.; Olson, Richard</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">133-137</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We describe the synthesis of quinuclidine-contg. spiroimidates and their utility as α7 nicotinic acetylcholine receptor (nAChR) partial agonists.  A convergent synthetic route allowed for rapid SAR investigation and provided a diverse set of fused 6,5-heteroaryl analogs.  Two potent and selective α7 nAChR partial agonists, (1'S,3'R,4'S)-N-(7-bromopyrrolo[2,1-f][1,2,4]triazin-4-yl)-4H-1'-azaspiro[oxazole-5,3'-bicyclo[2.2.2]octan]-2-amine (I) and (1'S,3'R,4'S)-N-(7-chloropyrrolo[2,1-f][1,2,4]triazin-4-yl)-4H-1'-azaspiro[oxazole-5,3'-bicyclo[2.2.2]octan]-2-amine (II), were identified.  Both agonists improved cognition in a preclin. rodent model of learning and memory.  Addnl., 5-HT3A receptor SAR suggested the presence of a steric site that when engaged led to significant loss of affinity at that receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoA1RntsoZE9bVg90H21EOLACvtfcHk0lg90vGpgXX3PA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFynt7rJ&md5=262caed08cdc8876c90da6bdc855408e</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00471%26sid%3Dliteratum%253Aachs%26aulast%3DHill%26aufirst%3DM.%2BD.%26aulast%3DFang%26aufirst%3DH.%26aulast%3DKing%26aufirst%3DH.%2BD.%26aulast%3DIwuagwu%26aufirst%3DC.%2BI.%26aulast%3DMcDonald%26aufirst%3DI.%2BM.%26aulast%3DCook%26aufirst%3DJ.%26aulast%3DZusi%26aufirst%3DF.%2BC.%26aulast%3DMate%26aufirst%3DR.%2BA.%26aulast%3DKnox%26aufirst%3DR.%2BJ.%26aulast%3DPost-Munson%26aufirst%3DD.%26aulast%3DEaston%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DR.%26aulast%3DLentz%26aufirst%3DK.%26aulast%3DClarke%26aufirst%3DW.%26aulast%3DBenitex%26aufirst%3DY.%26aulast%3DLodge%26aufirst%3DN.%26aulast%3DZaczek%26aufirst%3DR.%26aulast%3DDenton%26aufirst%3DR.%26aulast%3DMorgan%26aufirst%3DD.%26aulast%3DBristow%26aufirst%3DL.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26aulast%3DOlson%26aufirst%3DR.%26atitle%3DDevelopment%2520of%25204-Heteroarylamino-1%25E2%2580%2599-Azaspiro%255BOxazole-5%252C3%25E2%2580%2599-Bicyclo%255B2.2.2%255DOctanes%255D%2520as%2520%25CE%25917%2520Nicotinic%2520Receptor%2520Agonists%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26issue%3D1%26spage%3D133%26epage%3D137%26doi%3D10.1021%2Facsmedchemlett.6b00471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scheepstra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrei, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unver, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, A. K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leysen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunsveld, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milroy, L.-G.</span></span> <span> </span><span class="NLM_article-title">Designed Spiroketal Protein Modulation</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">5480</span>– <span class="NLM_lpage">5484</span>, <span class="refDoi"> DOI: 10.1002/anie.201612504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1002%2Fanie.201612504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtVyhuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=5480-5484&issue=20&author=M.+Scheepstraauthor=S.+A.+Andreiauthor=M.+Y.+Unverauthor=A.+K.+H.+Hirschauthor=S.+Leysenauthor=C.+Ottmannauthor=L.+Brunsveldauthor=L.-G.+Milroy&title=Designed+Spiroketal+Protein+Modulation&doi=10.1002%2Fanie.201612504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Designed Spiroketal Protein Modulation</span></div><div class="casAuthors">Scheepstra, Marcel; Andrei, Sebastian A.; Unver, M. Yagiz; Hirsch, Anna K. H.; Leysen, Seppe; Ottmann, Christian; Brunsveld, Luc; Milroy, Lech-Gustav</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5480-5484</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Spiroketals are structural motifs found in many biol. active natural products, which has stimulated considerable efforts toward their synthesis and interest in their use as drug lead compds.  Despite this, the use of spiroketals, and esp. bisbenzanulated spiroketals, in a structure-based drug discovery setting has not been convincingly demonstrated.  Herein, the authors report the rational design of a bisbenzannulated spiroketal that potently binds to the retinoid X receptor (RXR) thereby inducing partial co-activator recruitment.  The authors solved the crystal structure of the spiroketal-hRXRα-TIF2 ternary complex, and identified a canonical allosteric mechanism as a possible explanation for the partial agonist behavior of the authors' spiroketal.  The authors' co-crystal structure, the first of a designed spiroketal-protein complex, suggests that spiroketals can be designed to selectively target other nuclear receptor subtypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouYihEqEJmHbVg90H21EOLACvtfcHk0lg90vGpgXX3PA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtVyhuro%253D&md5=3207dde07ce4489a44c2485811ed10f9</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1002%2Fanie.201612504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201612504%26sid%3Dliteratum%253Aachs%26aulast%3DScheepstra%26aufirst%3DM.%26aulast%3DAndrei%26aufirst%3DS.%2BA.%26aulast%3DUnver%26aufirst%3DM.%2BY.%26aulast%3DHirsch%26aufirst%3DA.%2BK.%2BH.%26aulast%3DLeysen%26aufirst%3DS.%26aulast%3DOttmann%26aufirst%3DC.%26aulast%3DBrunsveld%26aufirst%3DL.%26aulast%3DMilroy%26aufirst%3DL.-G.%26atitle%3DDesigned%2520Spiroketal%2520Protein%2520Modulation%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2017%26volume%3D56%26issue%3D20%26spage%3D5480%26epage%3D5484%26doi%3D10.1002%2Fanie.201612504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tömböly, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feytens, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kövér, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borics, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Khrasani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fürst, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tóth, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benyhe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tourwé, D.</span></span> <span> </span><span class="NLM_article-title">Endomorphin-2 with a β-Turn Backbone Constraint Retains the Potent μ-Opioid Receptor Agonist Properties</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">173</span>– <span class="NLM_lpage">177</span>, <span class="refDoi"> DOI: 10.1021/jm7010222</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm7010222" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFKksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=173-177&issue=1&author=C.+T%C3%B6mb%C3%B6lyauthor=S.+Balletauthor=D.+Feytensauthor=K.+E.+K%C3%B6v%C3%A9rauthor=A.+Boricsauthor=S.+Lovasauthor=M.+Al-Khrasaniauthor=Z.+F%C3%BCrstauthor=G.+T%C3%B3thauthor=S.+Benyheauthor=D.+Tourw%C3%A9&title=Endomorphin-2+with+a+%CE%B2-Turn+Backbone+Constraint+Retains+the+Potent+%CE%BC-Opioid+Receptor+Agonist+Properties&doi=10.1021%2Fjm7010222"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Endomorphin-2 with a β-Turn Backbone Constraint Retains the Potent μ-Opioid Receptor Agonist Properties</span></div><div class="casAuthors">Tomboly, Csaba; Ballet, Steven; Feytens, Debby; Kover, Katalin E.; Borics, Attila; Lovas, Sandor; Al-Khrasani, Mahmoud; Furst, Zsuzsanna; Toth, Geza; Benyhe, Sandor; Tourwe, Dirk</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">173-177</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The constitutional similarity with different secondary structure preference between the Aba-Gly and the spiro-Aba-Gly scaffolds were exploited to design the novel endomorphin-2 analogs Tyr-spiro-(R/S)-Aba-Gly-Phe-NH2 and Tyr-(R/S)-Aba-Gly-Phe-NH2.  The (R)-spiro analog was found to be a potent and selective μ-opioid agonist/partial agonist (Kiμ = 29.3 nM, IC50 = 50 nM, Ke = 0.57).  NMR expts. and mol. modeling indicated that its backbone adopts mainly a β-turn in aq. soln.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpq7SJw3GipQbVg90H21EOLACvtfcHk0ljuJttjbKbLvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFKksw%253D%253D&md5=cff97d602690e90950c03bcb2c33b8e7</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1021%2Fjm7010222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7010222%26sid%3Dliteratum%253Aachs%26aulast%3DT%25C3%25B6mb%25C3%25B6ly%26aufirst%3DC.%26aulast%3DBallet%26aufirst%3DS.%26aulast%3DFeytens%26aufirst%3DD.%26aulast%3DK%25C3%25B6v%25C3%25A9r%26aufirst%3DK.%2BE.%26aulast%3DBorics%26aufirst%3DA.%26aulast%3DLovas%26aufirst%3DS.%26aulast%3DAl-Khrasani%26aufirst%3DM.%26aulast%3DF%25C3%25BCrst%26aufirst%3DZ.%26aulast%3DT%25C3%25B3th%26aufirst%3DG.%26aulast%3DBenyhe%26aufirst%3DS.%26aulast%3DTourw%25C3%25A9%26aufirst%3DD.%26atitle%3DEndomorphin-2%2520with%2520a%2520%25CE%25B2-Turn%2520Backbone%2520Constraint%2520Retains%2520the%2520Potent%2520%25CE%25BC-Opioid%2520Receptor%2520Agonist%2520Properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26issue%3D1%26spage%3D173%26epage%3D177%26doi%3D10.1021%2Fjm7010222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arkin, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, J. A.</span></span> <span> </span><span class="NLM_article-title">Small-Molecule Inhibitors of Protein-Protein Interactions: Progressing toward the Reality</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1102</span>– <span class="NLM_lpage">1114</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2014.09.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2Fj.chembiol.2014.09.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=25237857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFyrur7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=1102-1114&issue=9&author=M.+R.+Arkinauthor=Y.+Tangauthor=J.+A.+Wells&title=Small-Molecule+Inhibitors+of+Protein-Protein+Interactions%3A+Progressing+toward+the+Reality&doi=10.1016%2Fj.chembiol.2014.09.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Inhibitors of Protein-Protein Interactions: Progressing toward the Reality</span></div><div class="casAuthors">Arkin, Michelle R.; Tang, Yinyan; Wells, James A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1102-1114</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The past 20 years have seen many advances in our understanding of protein-protein interactions (PPIs) and how to target them with small-mol. therapeutics.  In 2004, we reviewed some early successes; since then, potent inhibitors have been developed for diverse protein complexes, and compds. are now in clin. trials for six targets.  Surprisingly, many of these PPI clin. candidates have efficiency metrics typical of "lead-like" or "drug-like" mols. and are orally available.  Successful discovery efforts have integrated multiple disciplines and make use of all the modern tools of target-based discovery-structure, computation, screening, and biomarkers.  PPIs become progressively more challenging as the interfaces become more complex, i.e., as binding epitopes are displayed on primary, secondary, or tertiary structures.  Here, we review the last 10 years of progress, focusing on the properties of PPI inhibitors that have advanced to clin. trials and prospects for the future of PPI drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP01wt-4lfE7Vg90H21EOLACvtfcHk0lhymCFweWccYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFyrur7J&md5=aec3897dc9bc66656723bc56c8d69155</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2014.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2014.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DArkin%26aufirst%3DM.%2BR.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DWells%26aufirst%3DJ.%2BA.%26atitle%3DSmall-Molecule%2520Inhibitors%2520of%2520Protein-Protein%2520Interactions%253A%2520Progressing%2520toward%2520the%2520Reality%26jtitle%3DChem.%2520Biol.%26date%3D2014%26volume%3D21%26issue%3D9%26spage%3D1102%26epage%3D1114%26doi%3D10.1016%2Fj.chembiol.2014.09.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayly, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skidmore, J.</span></span> <span> </span><span class="NLM_article-title">Small Molecules, Big Targets: Drug Discovery Faces the Protein-Protein Interaction Challenge</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">533</span>– <span class="NLM_lpage">550</span>, <span class="refDoi"> DOI: 10.1038/nrd.2016.29</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1038%2Fnrd.2016.29" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=27050677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsFOgur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=533-550&issue=8&author=D.+E.+Scottauthor=A.+R.+Baylyauthor=C.+Abellauthor=J.+Skidmore&title=Small+Molecules%2C+Big+Targets%3A+Drug+Discovery+Faces+the+Protein-Protein+Interaction+Challenge&doi=10.1038%2Fnrd.2016.29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecules, big targets: drug discovery faces the protein-protein interaction challenge</span></div><div class="casAuthors">Scott, Duncan E.; Bayly, Andrew R.; Abell, Chris; Skidmore, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">533-550</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Protein-protein interactions (PPIs) are of pivotal importance in the regulation of biol. systems and are consequently implicated in the development of disease states.  Recent work has begun to show that, with the right tools, certain classes of PPI can yield to the efforts of medicinal chemists to develop inhibitors, and the first PPI inhibitors have reached clin. development.  In this Review, we describe the research leading to these breakthroughs and highlight the existence of groups of structurally related PPIs within the PPI target class.  For each of these groups, we use examples of successful discovery efforts to illustrate the research strategies that have proved most useful.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK-aGzHa9mP7Vg90H21EOLACvtfcHk0lhymCFweWccYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsFOgur4%253D&md5=9f0953567ae9338b8b36aa78b8160655</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.29&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.29%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DD.%2BE.%26aulast%3DBayly%26aufirst%3DA.%2BR.%26aulast%3DAbell%26aufirst%3DC.%26aulast%3DSkidmore%26aufirst%3DJ.%26atitle%3DSmall%2520Molecules%252C%2520Big%2520Targets%253A%2520Drug%2520Discovery%2520Faces%2520the%2520Protein-Protein%2520Interaction%2520Challenge%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2016%26volume%3D15%26issue%3D8%26spage%3D533%26epage%3D550%26doi%3D10.1038%2Fnrd.2016.29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sarver, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagdanoff, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fodor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortanet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hentemann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaBonte, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeill, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohseni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sendzik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spence, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tichkule, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMarche, M. J.</span></span> <span> </span><span class="NLM_article-title">6-Amino-3-Methylpyrimidinones as Potent, Selective, and Orally Efficacious SHP2 Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1793</span>– <span class="NLM_lpage">1802</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01726</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01726" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFKisLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1793-1802&issue=4&author=P.+Sarverauthor=M.+Ackerauthor=J.+T.+Bagdanoffauthor=Z.+Chenauthor=Y.-N.+Chenauthor=H.+Chanauthor=B.+Firestoneauthor=M.+Fodorauthor=J.+Fortanetauthor=H.+Haoauthor=M.+Hentemannauthor=M.+Katoauthor=R.+Koenigauthor=L.+R.+LaBonteauthor=G.+Liuauthor=S.+Liuauthor=C.+Liuauthor=E.+McNeillauthor=M.+Mohseniauthor=M.+Sendzikauthor=T.+Stamsauthor=S.+Spenceauthor=V.+Tamezauthor=R.+Tichkuleauthor=C.+Towlerauthor=H.+Wangauthor=P.+Wangauthor=S.+L.+Williamsauthor=B.+Yuauthor=M.+J.+LaMarche&title=6-Amino-3-Methylpyrimidinones+as+Potent%2C+Selective%2C+and+Orally+Efficacious+SHP2+Inhibitors&doi=10.1021%2Facs.jmedchem.8b01726"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">6-Amino-3-methylpyrimidinones as Potent, Selective, and Orally Efficacious SHP2 Inhibitors</span></div><div class="casAuthors">Sarver, Patrick; Acker, Michael; Bagdanoff, Jeffrey T.; Chen, Zhouliang; Chen, Ying-Nan; Chan, Homan; Firestone, Brant; Fodor, Michelle; Fortanet, Jorge; Hao, Huaixiang; Hentemann, Murphy; Koenig, Robert; Kato, Mitsunori; LaBonte, Laura R.; Liu, Gang; Liu, Shumei; Liu, Chen; McNeill, Eric; Mohseni, Morvarid; Sendzik, Martin; Stams, Travis; Spence, Stan; Tamez, Victoriano; Tichkule, Ritesh; Towler, Christopher; Wang, Hongyun; Wang, Ping; Williams, Sarah L.; Yu, Bing; LaMarche, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1793-1802</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Protein tyrosine phosphatase SHP2 is an oncoprotein assocd. with cancer as well as a potential immune modulator because of its role in the programmed cell death PD-L1/PD-1 pathway.  In the preceding manuscript, we described the optimization of a fused, bicyclic screening hit for potency, selectivity, and physicochem. properties in order to further expand the chem. diversity of allosteric SHP2 inhibitors.  In this manuscript, we describe the further expansion of our approach, morphing the fused, bicyclic system into a novel monocyclic pyrimidinone scaffold through our understanding of SAR and use of structure-based design.  These studies led to the identification of SHP394 (1), an orally efficacious inhibitor of SHP2, with high lipophilic efficiency, improved potency, and enhanced pharmacokinetic properties.  We also report other pyrimidinone analogs with favorable pharmacokinetic and potency profiles.  Overall, this work improves upon our previously described allosteric inhibitors and exemplifies and extends the range of permissible chem. templates that inhibit SHP2 via the allosteric mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaRey6_uE0ULVg90H21EOLACvtfcHk0lgX52wb6ps5eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFKisLs%253D&md5=29c357236b7ff51596385e3e256320a5</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01726&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01726%26sid%3Dliteratum%253Aachs%26aulast%3DSarver%26aufirst%3DP.%26aulast%3DAcker%26aufirst%3DM.%26aulast%3DBagdanoff%26aufirst%3DJ.%2BT.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DY.-N.%26aulast%3DChan%26aufirst%3DH.%26aulast%3DFirestone%26aufirst%3DB.%26aulast%3DFodor%26aufirst%3DM.%26aulast%3DFortanet%26aufirst%3DJ.%26aulast%3DHao%26aufirst%3DH.%26aulast%3DHentemann%26aufirst%3DM.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DKoenig%26aufirst%3DR.%26aulast%3DLaBonte%26aufirst%3DL.%2BR.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DMcNeill%26aufirst%3DE.%26aulast%3DMohseni%26aufirst%3DM.%26aulast%3DSendzik%26aufirst%3DM.%26aulast%3DStams%26aufirst%3DT.%26aulast%3DSpence%26aufirst%3DS.%26aulast%3DTamez%26aufirst%3DV.%26aulast%3DTichkule%26aufirst%3DR.%26aulast%3DTowler%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWilliams%26aufirst%3DS.%2BL.%26aulast%3DYu%26aufirst%3DB.%26aulast%3DLaMarche%26aufirst%3DM.%2BJ.%26atitle%3D6-Amino-3-Methylpyrimidinones%2520as%2520Potent%252C%2520Selective%252C%2520and%2520Orally%2520Efficacious%2520SHP2%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D4%26spage%3D1793%26epage%3D1802%26doi%3D10.1021%2Facs.jmedchem.8b01726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bagdanoff, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dore, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fodor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortanet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hentemann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaBonte, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohseni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ntaganda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarver, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sendzik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spence, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMarche, M. J.</span></span> <span> </span><span class="NLM_article-title">Optimization of Fused Bicyclic Allosteric SHP2 Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1781</span>– <span class="NLM_lpage">1792</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01725</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01725" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFKjtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1781-1792&issue=4&author=J.+T.+Bagdanoffauthor=Z.+Chenauthor=M.+Ackerauthor=Y.-N.+Chenauthor=H.+Chanauthor=M.+Doreauthor=B.+Firestoneauthor=M.+Fodorauthor=J.+Fortanetauthor=M.+Hentemannauthor=M.+Katoauthor=R.+Koenigauthor=L.+R.+LaBonteauthor=S.+Liuauthor=M.+Mohseniauthor=R.+Ntagandaauthor=P.+Sarverauthor=T.+Smithauthor=M.+Sendzikauthor=T.+Stamsauthor=S.+Spenceauthor=C.+Towlerauthor=H.+Wangauthor=P.+Wangauthor=S.+L.+Williamsauthor=M.+J.+LaMarche&title=Optimization+of+Fused+Bicyclic+Allosteric+SHP2+Inhibitors&doi=10.1021%2Facs.jmedchem.8b01725"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of Fused Bicyclic Allosteric SHP2 Inhibitors</span></div><div class="casAuthors">Bagdanoff, Jeffrey T.; Chen, Zhouliang; Acker, Michael; Chen, Ying-Nan; Chan, Homan; Dore, Michael; Firestone, Brant; Fodor, Michelle; Fortanet, Jorge; Hentemann, Murphy; Kato, Mitsunori; Koenig, Robert; La Bonte, Laura R.; Liu, Shumei; Mohseni, Movarid; Ntaganda, Rukundo; Sarver, Patrick; Smith, Troy; Sendzik, Martin; Stams, Travis; Spence, Stan; Towler, Christopher; Wang, Hongyun; Wang, Ping; Williams, Sarah L.; La Marche, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1781-1792</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">SHP2 is a nonreceptor protein tyrosine phosphatase within the mitogen-activated protein kinase (MAPK) pathway controlling cell growth, differentiation, and oncogenic transformation.  SHP2 also participates in the programed cell death pathway (PD-1/PD-L1) governing immune surveillance.  Small-mol. inhibition of SHP2 has been widely investigated, including in our previous reports describing SHP099 (2), which binds to a tunnel-like allosteric binding site.  To broaden our approach to allosteric inhibition of SHP2, we conducted addnl. hit finding, evaluation, and structure-based scaffold morphing.  These studies, reported here in the first of two papers, led to the identification of multiple 5,6-fused bicyclic scaffolds that bind to the same allosteric tunnel as 2.  We demonstrate the structural diversity permitted by the tunnel pharmacophore and culminated in the identification of pyrazolopyrimidinones (e.g., SHP389, 1) that modulate MAPK signaling in vivo.  These studies also served as the basis for further scaffold morphing and optimization, detailed in the following manuscript.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra2OF_vrNnP7Vg90H21EOLACvtfcHk0lgX52wb6ps5eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFKjtbo%253D&md5=e810a8a6bd1d1fb7bfadc5bc1448ff22</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01725&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01725%26sid%3Dliteratum%253Aachs%26aulast%3DBagdanoff%26aufirst%3DJ.%2BT.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DAcker%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.-N.%26aulast%3DChan%26aufirst%3DH.%26aulast%3DDore%26aufirst%3DM.%26aulast%3DFirestone%26aufirst%3DB.%26aulast%3DFodor%26aufirst%3DM.%26aulast%3DFortanet%26aufirst%3DJ.%26aulast%3DHentemann%26aufirst%3DM.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DKoenig%26aufirst%3DR.%26aulast%3DLaBonte%26aufirst%3DL.%2BR.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DMohseni%26aufirst%3DM.%26aulast%3DNtaganda%26aufirst%3DR.%26aulast%3DSarver%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DT.%26aulast%3DSendzik%26aufirst%3DM.%26aulast%3DStams%26aufirst%3DT.%26aulast%3DSpence%26aufirst%3DS.%26aulast%3DTowler%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWilliams%26aufirst%3DS.%2BL.%26aulast%3DLaMarche%26aufirst%3DM.%2BJ.%26atitle%3DOptimization%2520of%2520Fused%2520Bicyclic%2520Allosteric%2520SHP2%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D4%26spage%3D1781%26epage%3D1792%26doi%3D10.1021%2Facs.jmedchem.8b01725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Lombaert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aiello, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourassa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barucci, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paralkar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentine, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zavadoski, W.</span></span> <span> </span><span class="NLM_article-title">Discovery of Spirocyclic Proline Tryptophan Hydroxylase-1 Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1124</span>– <span class="NLM_lpage">1129</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.01.064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2Fj.bmcl.2016.01.064" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=26821821" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVSit70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=1124-1129&issue=4&author=D.+R.+Goldbergauthor=S.+De+Lombaertauthor=R.+Aielloauthor=P.+Bourassaauthor=N.+Barucciauthor=Q.+Zhangauthor=V.+Paralkarauthor=J.+Valentineauthor=W.+Zavadoski&title=Discovery+of+Spirocyclic+Proline+Tryptophan+Hydroxylase-1+Inhibitors&doi=10.1016%2Fj.bmcl.2016.01.064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of spirocyclic proline tryptophan hydroxylase-1 inhibitors</span></div><div class="casAuthors">Goldberg, Daniel R.; De Lombaert, Stephane; Aiello, Robert; Bourassa, Patricia; Barucci, Nicole; Zhang, Qing; Paralkar, Vishwas; Valentine, James; Zavadoski, William</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1124-1129</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The central role of the biogenic monoamine serotonin (5-hydroxytryptamine, 5-HT) as a neurotransmitter with important cognitive and behavioral functions is well known.  However, 5-HT produced in the brain only accounts for approx. 5% of the total amt. of 5-HT generated in the body.  At the onset of our work, it appeared that substituted phenylalanine derivs. or related aryl amino acids were required to produce potent inhibitors of TPH1, as significant losses of inhibitory activity were noted in the absence of this structural element.  We disclose herein the discovery of a new class of TPH1 inhibitors that significantly lower peripherally 5-HT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVsjFU6kxEsbVg90H21EOLACvtfcHk0liWOfQWpwxopQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVSit70%253D&md5=1cef593698e5951cc3a5e225d93a2248</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.01.064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.01.064%26sid%3Dliteratum%253Aachs%26aulast%3DGoldberg%26aufirst%3DD.%2BR.%26aulast%3DDe%2BLombaert%26aufirst%3DS.%26aulast%3DAiello%26aufirst%3DR.%26aulast%3DBourassa%26aufirst%3DP.%26aulast%3DBarucci%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DParalkar%26aufirst%3DV.%26aulast%3DValentine%26aufirst%3DJ.%26aulast%3DZavadoski%26aufirst%3DW.%26atitle%3DDiscovery%2520of%2520Spirocyclic%2520Proline%2520Tryptophan%2520Hydroxylase-1%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26issue%3D4%26spage%3D1124%26epage%3D1129%26doi%3D10.1016%2Fj.bmcl.2016.01.064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Lombaert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aiello, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourassa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barucci, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paralkar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentine, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zavadoski, W.</span></span> <span> </span><span class="NLM_article-title">Optimization of Spirocyclic Proline Tryptophan Hydroxylase-1 Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">419</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.12.053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2Fj.bmcl.2016.12.053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=28041831" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVCqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=413-419&issue=3&author=D.+R.+Goldbergauthor=S.+De+Lombaertauthor=R.+Aielloauthor=P.+Bourassaauthor=N.+Barucciauthor=Q.+Zhangauthor=V.+Paralkarauthor=A.+J.+Steinauthor=M.+Holtauthor=J.+Valentineauthor=W.+Zavadoski&title=Optimization+of+Spirocyclic+Proline+Tryptophan+Hydroxylase-1+Inhibitors&doi=10.1016%2Fj.bmcl.2016.12.053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of spirocyclic proline tryptophan hydroxylase-1 inhibitors</span></div><div class="casAuthors">Goldberg, Daniel R.; De Lombaert, Stephane; Aiello, Robert; Bourassa, Patricia; Barucci, Nicole; Zhang, Qing; Paralkar, Vishwas; Stein, Adam J.; Holt, Melissa; Valentine, Jim; Zavadoski, William</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">413-419</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">As a follow-up to the discovery of our spirocyclic proline-based TPH1 inhibitor lead, we describe the optimization of this scaffold.  Through a combination of X-ray co-crystal structure guided design and an in vivo screen, new substitutions in the lipophilic region of the inhibitors were identified.  This effort led to new TPH1 inhibitors with in vivo efficacy when dosed as their corresponding Et ester prodrugs.  In particular, 15b (KAR5585), the prodrug of the potent TPH1 inhibitor 15a (KAR5417), showed robust redn. of intestinal serotonin (5-HT) levels in mice.  Furthermore, oral administration of 15b generated high and sustained systemic exposure of the active parent 15a in rats and dogs.  KAR5585 was selected for further pharmacol. evaluation in disease models assocd. with a dysfunctional peripheral 5-HT system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWCaHTagCD0rVg90H21EOLACvtfcHk0liWOfQWpwxopQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVCqtw%253D%253D&md5=0b12863d265ba1ec4bc9ae8ccd1ee33d</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.12.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.12.053%26sid%3Dliteratum%253Aachs%26aulast%3DGoldberg%26aufirst%3DD.%2BR.%26aulast%3DDe%2BLombaert%26aufirst%3DS.%26aulast%3DAiello%26aufirst%3DR.%26aulast%3DBourassa%26aufirst%3DP.%26aulast%3DBarucci%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DParalkar%26aufirst%3DV.%26aulast%3DStein%26aufirst%3DA.%2BJ.%26aulast%3DHolt%26aufirst%3DM.%26aulast%3DValentine%26aufirst%3DJ.%26aulast%3DZavadoski%26aufirst%3DW.%26atitle%3DOptimization%2520of%2520Spirocyclic%2520Proline%2520Tryptophan%2520Hydroxylase-1%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26issue%3D3%26spage%3D413%26epage%3D419%26doi%3D10.1016%2Fj.bmcl.2016.12.053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cianchetta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stouch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tari, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanson, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span> <span> </span><span class="NLM_article-title">Mechanism of Inhibition of Novel Tryptophan Hydroxylase Inhibitors Revealed by Co-Crystal Structures and Kinetic Analysis</span>. <i>Curr. Chem. Genomics</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.2174/1875397301004010019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.2174%2F1875397301004010019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=20556201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC3cXls1Gqurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2010&pages=19-26&author=G.+Cianchettaauthor=T.+Stouchauthor=W.+Yuauthor=Z.-C.+Shiauthor=L.+W.+Tariauthor=R.+V.+Swansonauthor=M.+J.+Hunterauthor=I.+D.+Hoffmanauthor=Q.+Liu&title=Mechanism+of+Inhibition+of+Novel+Tryptophan+Hydroxylase+Inhibitors+Revealed+by+Co-Crystal+Structures+and+Kinetic+Analysis&doi=10.2174%2F1875397301004010019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of inhibition of novel tryptophan hydroxylase inhibitors revealed by co-crystal structures and kinetic analysis</span></div><div class="casAuthors">Cianchetta, Giovanni; Stouch, Terry; Yu, Wangsheng; Shi, Zhi-Cai; Tari, Leslie W.; Swanson, Ronald V.; Hunter, Michael J.; Hoffman, Isaac D.; Liu, Qingyun</div><div class="citationInfo"><span class="NLM_cas:title">Current Chemical Genomics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">19-26</span>CODEN:
                <span class="NLM_cas:coden">CCGUAQ</span>;
        ISSN:<span class="NLM_cas:issn">1875-3973</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Trytophan Hydroxylase Type I (TPH1), most abundantly expressed in the gastrointestinal tract, initiates the synthesis of serotonin by catalyzing hydroxylation of tryptophan in the presence of biopterin and oxygen.  We have previously described three series of novel, periphery-specific TPH1 inhibitors that selectively deplete serotonin in the gastrointestinal tract.  We have now detd. co-crystal structures of TPH1 with three of these inhibitors at high resoln.  Anal. of the structural data showed that each of the three inhibitors fills the tryptophan binding pocket of TPH1 without reaching into the binding site of the cofactor pterin, and induces major conformational changes of the enzyme.  The enzyme-inhibitor complexes assume a compact conformation that is similar to the one in tryptophan complex.  Kinetic anal. showed that all three inhibitors are competitive vs. the substrate tryptophan, consistent with the structural data that the compds. occupy the tryptophan binding site.  On the other hand, all three inhibitors appear to be uncompetitive vs. the cofactor 6-methyltetrahydropterin, which is not only consistent with the structural data but also indicate that the hydroxylation reaction follows an ordered binding mechanism in which a productive complex is formed only if tryptophan binds only after pterin, similar to the kinetic mechanisms of tyrosine and phenylalanine hydroxylase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp22pfPYGY92bVg90H21EOLACvtfcHk0lg7z5eRS8G-PQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXls1Gqurs%253D&md5=be3da659eabc36a9fc143b82ecb20a22</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.2174%2F1875397301004010019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1875397301004010019%26sid%3Dliteratum%253Aachs%26aulast%3DCianchetta%26aufirst%3DG.%26aulast%3DStouch%26aufirst%3DT.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DShi%26aufirst%3DZ.-C.%26aulast%3DTari%26aufirst%3DL.%2BW.%26aulast%3DSwanson%26aufirst%3DR.%2BV.%26aulast%3DHunter%26aufirst%3DM.%2BJ.%26aulast%3DHoffman%26aufirst%3DI.%2BD.%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DMechanism%2520of%2520Inhibition%2520of%2520Novel%2520Tryptophan%2520Hydroxylase%2520Inhibitors%2520Revealed%2520by%2520Co-Crystal%2520Structures%2520and%2520Kinetic%2520Analysis%26jtitle%3DCurr.%2520Chem.%2520Genomics%26date%3D2010%26volume%3D4%26spage%3D19%26epage%3D26%26doi%3D10.2174%2F1875397301004010019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwertz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witschel, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rottmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leartsakulpanich, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chitnumsub, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaruwat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amornwatcharapong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ittarat, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schäfer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aponte, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trapp, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaiyen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diederich, F.</span></span> <span> </span><span class="NLM_article-title">Potent Inhibitors of Plasmodial Serine Hydroxymethyltransferase (SHMT) Featuring a Spirocyclic Scaffold</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">931</span>– <span class="NLM_lpage">943</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201800053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1002%2Fcmdc.201800053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=29655285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1cXns1Sls7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=931-943&issue=9&author=G.+Schwertzauthor=M.+C.+Witschelauthor=M.+Rottmannauthor=U.+Leartsakulpanichauthor=P.+Chitnumsubauthor=A.+Jaruwatauthor=W.+Amornwatcharapongauthor=W.+Ittaratauthor=A.+Sch%C3%A4ferauthor=R.+A.+Aponteauthor=N.+Trappauthor=P.+Chaiyenauthor=F.+Diederich&title=Potent+Inhibitors+of+Plasmodial+Serine+Hydroxymethyltransferase+%28SHMT%29+Featuring+a+Spirocyclic+Scaffold&doi=10.1002%2Fcmdc.201800053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Potent Inhibitors of Plasmodial Serine Hydroxymethyltransferase (SHMT) Featuring a Spirocyclic Scaffold</span></div><div class="casAuthors">Schwertz, Geoffrey; Witschel, Matthias C.; Rottmann, Matthias; Leartsakulpanich, Ubolsree; Chitnumsub, Penchit; Jaruwat, Aritsara; Amornwatcharapong, Watcharee; Ittarat, Wanwipa; Schaefer, Anja; Aponte, Raphael A.; Trapp, Nils; Chaiyen, Pimchai; Diederich, Francois</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">931-943</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">With the discovery that serine hydroxymethyltransferase (SHMT) is a druggable target for antimalarials, the aim of this study was to design novel inhibitors of this key enzyme in the folate biosynthesis cycle.  Herein, 19 novel spirocyclic ligands based on either 2-indolinone or dihydroindene scaffolds and featuring a pyrazolopyran core are reported.  Strong target affinities for Plasmodium falciparum (Pf) SHMT (14-76 nM) and cellular potencies in the low nanomolar range (165-334 nM) were measured together with interesting selectivity against human cytosolic SHMT1 (hSHMT1).  Four co-crystal structures with Plasmodium vivax (Pv) SHMT solved at 2.2-2.4 Å resoln. revealed the key role of the vinylogous cyanamide for anchoring ligands within the active site.  The spirocyclic motif in the mols. enforces the pyrazolopyran core to adopt a substantially more curved conformation than that of previous non-spirocyclic analogs.  Finally, solvation of the spirocyclic lactam ring of the receptor-bound ligands is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvpAcjSWkTV7Vg90H21EOLACvtfcHk0lg7z5eRS8G-PQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXns1Sls7k%253D&md5=5517df4e263d7214d2fc8400b269d652</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201800053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201800053%26sid%3Dliteratum%253Aachs%26aulast%3DSchwertz%26aufirst%3DG.%26aulast%3DWitschel%26aufirst%3DM.%2BC.%26aulast%3DRottmann%26aufirst%3DM.%26aulast%3DLeartsakulpanich%26aufirst%3DU.%26aulast%3DChitnumsub%26aufirst%3DP.%26aulast%3DJaruwat%26aufirst%3DA.%26aulast%3DAmornwatcharapong%26aufirst%3DW.%26aulast%3DIttarat%26aufirst%3DW.%26aulast%3DSch%25C3%25A4fer%26aufirst%3DA.%26aulast%3DAponte%26aufirst%3DR.%2BA.%26aulast%3DTrapp%26aufirst%3DN.%26aulast%3DChaiyen%26aufirst%3DP.%26aulast%3DDiederich%26aufirst%3DF.%26atitle%3DPotent%2520Inhibitors%2520of%2520Plasmodial%2520Serine%2520Hydroxymethyltransferase%2520%2528SHMT%2529%2520Featuring%2520a%2520Spirocyclic%2520Scaffold%26jtitle%3DChemMedChem%26date%3D2018%26volume%3D13%26issue%3D9%26spage%3D931%26epage%3D943%26doi%3D10.1002%2Fcmdc.201800053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahlholm, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacome, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luedtke, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">Highly Selective Dopamine D3 Receptor Antagonists with Arylated Diazaspiro Alkane Cores</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">9905</span>– <span class="NLM_lpage">9910</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01248</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01248" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsl2gsbjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=9905-9910&issue=23&author=S.+W.+Reillyauthor=S.+Griffinauthor=M.+Taylorauthor=K.+Sahlholmauthor=C.-C.+Wengauthor=K.+Xuauthor=D.+A.+Jacomeauthor=R.+R.+Luedtkeauthor=R.+H.+Mach&title=Highly+Selective+Dopamine+D3+Receptor+Antagonists+with+Arylated+Diazaspiro+Alkane+Cores&doi=10.1021%2Facs.jmedchem.7b01248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Highly Selective Dopamine D3 Receptor Antagonists with Arylated Diazaspiro Alkane Cores</span></div><div class="casAuthors">Reilly, Sean W.; Griffin, Suzy; Taylor, Michelle; Sahlholm, Kristoffer; Weng, Chi-Chang; Xu, Kuiying; Jacome, Daniel A.; Luedtke, Robert R.; Mach, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9905-9910</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aryldiazaspirocyclylpropyl phenyltriazolyl thioethers such as I (R = 2-MeOC6H4, 4-FC6H4, 4-MeOC6H4, 2-pyridinyl, 3-NCC6H4, 2,3-Cl2C6H3) were prepd. as selective dopamine D3 receptor (D3R) antagonists; their selectivities for D3R over D2R and for selected compds. over 5-HT1a, 5-HT2a, and 5-HT2c receptors and adenylyl cyclase were detd.  I (R = 2-MeOC6H4, 4-FC6H4) showed favorable D3R affinities (Ki = 12-25.6 nM) and were 264- to 905-fold selective for D3R vs D2R.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHLC1nn5_14LVg90H21EOLACvtfcHk0lilIxm_3qMJfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsl2gsbjL&md5=a60ed8b0524189901b7155e11025d3c6</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01248%26sid%3Dliteratum%253Aachs%26aulast%3DReilly%26aufirst%3DS.%2BW.%26aulast%3DGriffin%26aufirst%3DS.%26aulast%3DTaylor%26aufirst%3DM.%26aulast%3DSahlholm%26aufirst%3DK.%26aulast%3DWeng%26aufirst%3DC.-C.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DJacome%26aufirst%3DD.%2BA.%26aulast%3DLuedtke%26aufirst%3DR.%2BR.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DHighly%2520Selective%2520Dopamine%2520D3%2520Receptor%2520Antagonists%2520with%2520Arylated%2520Diazaspiro%2520Alkane%2520Cores%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D23%26spage%3D9905%26epage%3D9910%26doi%3D10.1021%2Facs.jmedchem.7b01248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riad, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, C.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahlholm, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacome, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirschner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luedtke, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malhotra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karanicolas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">Leveraging a Low-Affinity Diazaspiro Orthosteric Fragment to Reduce Dopamine D3 Receptor (D3R) Ligand Promiscuity across Highly Conserved Aminergic G-Protein-Coupled Receptors (GPCRs)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">5132</span>– <span class="NLM_lpage">5147</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00412</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00412" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1MXot1Sntrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=5132-5147&issue=10&author=S.+W.+Reillyauthor=A.+A.+Riadauthor=C.-J.+Hsiehauthor=K.+Sahlholmauthor=D.+A.+Jacomeauthor=S.+Griffinauthor=M.+Taylorauthor=C.-C.+Wengauthor=K.+Xuauthor=N.+Kirschnerauthor=R.+R.+Luedtkeauthor=C.+Parryauthor=S.+Malhotraauthor=J.+Karanicolasauthor=R.+H.+Mach&title=Leveraging+a+Low-Affinity+Diazaspiro+Orthosteric+Fragment+to+Reduce+Dopamine+D3+Receptor+%28D3R%29+Ligand+Promiscuity+across+Highly+Conserved+Aminergic+G-Protein-Coupled+Receptors+%28GPCRs%29&doi=10.1021%2Facs.jmedchem.9b00412"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Leveraging a Low-Affinity Diazaspiro Orthosteric Fragment to Reduce Dopamine D3 Receptor (D3R) Ligand Promiscuity across Highly Conserved Aminergic G-Protein-Coupled Receptors (GPCRs)</span></div><div class="casAuthors">Reilly, Sean W.; Riad, Aladdin A.; Hsieh, Chia-Ju; Sahlholm, Kristoffer; Jacome, Daniel A.; Griffin, Suzy; Taylor, Michelle; Weng, Chi-Chang; Xu, Kuiying; Kirschner, Nathan; Luedtke, Robert R.; Parry, Christopher; Malhotra, Shipra; Karanicolas, John; Mach, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5132-5147</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Previously, we reported a 3-(2-methoxyphenyl)-9-(3-((4-methyl-5-phenyl-4H-1,2,4-triazol-3-yl)thio)propyl)-3,9-diazaspiro[5.5]undecane (I) compd. with excellent dopamine D3 receptor (D3R) affinity (D3R Ki = 12.0 nM) and selectivity (D2R/D3R ratio = 905).  Herein, we present derivs. of I with comparable D3R affinity (II, D3R Ki = 3.2 nM, D2R/D3R ratio = 60) and selectivity (III, D3R Ki = 21.0 nM, D2R/D3R ratio = 934).  Fragmentation of I revealed orthosteric fragment IV to express an unusually low D3R affinity (Ki = 2.7 μM).  Compared to piperazine congener V, which retains a high-affinity orthosteric fragment (VI, D3R Ki = 23.9 nM), I was found to be more selective for the D3R among D1- and D2-like receptors and exhibited negligible off-target interactions at serotoninergic and adrenergic G-protein-coupled receptors (GPCRs), common off-target sites for piperazine-contg. D3R scaffolds.  This study provides a unique rationale for implementing weakly potent orthosteric fragments into D3R ligand systems to minimize drug promiscuity at other aminergic GPCR sites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0AsYC3qYsr7Vg90H21EOLACvtfcHk0lilIxm_3qMJfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXot1Sntrs%253D&md5=ce936e36f3007e1f5587edf9275479ff</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00412%26sid%3Dliteratum%253Aachs%26aulast%3DReilly%26aufirst%3DS.%2BW.%26aulast%3DRiad%26aufirst%3DA.%2BA.%26aulast%3DHsieh%26aufirst%3DC.-J.%26aulast%3DSahlholm%26aufirst%3DK.%26aulast%3DJacome%26aufirst%3DD.%2BA.%26aulast%3DGriffin%26aufirst%3DS.%26aulast%3DTaylor%26aufirst%3DM.%26aulast%3DWeng%26aufirst%3DC.-C.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DKirschner%26aufirst%3DN.%26aulast%3DLuedtke%26aufirst%3DR.%2BR.%26aulast%3DParry%26aufirst%3DC.%26aulast%3DMalhotra%26aufirst%3DS.%26aulast%3DKaranicolas%26aufirst%3DJ.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DLeveraging%2520a%2520Low-Affinity%2520Diazaspiro%2520Orthosteric%2520Fragment%2520to%2520Reduce%2520Dopamine%2520D3%2520Receptor%2520%2528D3R%2529%2520Ligand%2520Promiscuity%2520across%2520Highly%2520Conserved%2520Aminergic%2520G-Protein-Coupled%2520Receptors%2520%2528GPCRs%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D10%26spage%3D5132%26epage%3D5147%26doi%3D10.1021%2Facs.jmedchem.9b00412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puentes, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, C.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makvandi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">Examination of Diazaspiro Cores as Piperazine Bioisosteres in the Olaparib Framework Shows Reduced DNA Damage and Cytotoxicity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">5367</span>– <span class="NLM_lpage">5379</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00576</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00576" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVKktbzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5367-5379&issue=12&author=S.+W.+Reillyauthor=L.+N.+Puentesauthor=K.+Wilsonauthor=C.-J.+Hsiehauthor=C.-C.+Wengauthor=M.+Makvandiauthor=R.+H.+Mach&title=Examination+of+Diazaspiro+Cores+as+Piperazine+Bioisosteres+in+the+Olaparib+Framework+Shows+Reduced+DNA+Damage+and+Cytotoxicity&doi=10.1021%2Facs.jmedchem.8b00576"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Examination of Diazaspiro Cores as Piperazine Bioisosteres in the Olaparib Framework Shows Reduced DNA Damage and Cytotoxicity</span></div><div class="casAuthors">Reilly, Sean W.; Puentes, Laura N.; Wilson, Khadija; Hsieh, Chia-Ju; Weng, Chi-Chang; Makvandi, Mehran; Mach, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5367-5379</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Development of poly(ADP-ribose) polymerase inhibitors (PARPi's) continues to be an attractive area of research due to synthetic lethality in DNA repair deficient cancers; however, PARPi's also have potential as therapeutics to prevent harmful inflammation.  We investigated the pharmacol. impact of incorporating spirodiamine motifs into the phthalazine architecture of FDA approved PARPi olaparib.  Synthesized analogs were screened for PARP-1 affinity, enzyme specificity, catalytic inhibition, DNA damage, and cytotoxicity.  This work led to the identification of 10e (12.6 ± 1.1 nM), which did not induce DNA damage at similar drug concns. as olaparib.  Interestingly, several worst in class compds. with low PARP-1 affinity, including 15b (4397 ± 1.1 nM), induced DNA damage at micromolar concns., which can explain the cytotoxicity obsd. in vitro.  This work provides further evidence that high affinity PARPi's can be developed without DNA damaging properties offering potential new drugs for treating inflammatory related diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnTC4dTcUAdrVg90H21EOLACvtfcHk0lisasw34OST2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVKktbzE&md5=e352b0777c5f53f2c126288a1c5ff4c1</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00576%26sid%3Dliteratum%253Aachs%26aulast%3DReilly%26aufirst%3DS.%2BW.%26aulast%3DPuentes%26aufirst%3DL.%2BN.%26aulast%3DWilson%26aufirst%3DK.%26aulast%3DHsieh%26aufirst%3DC.-J.%26aulast%3DWeng%26aufirst%3DC.-C.%26aulast%3DMakvandi%26aufirst%3DM.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DExamination%2520of%2520Diazaspiro%2520Cores%2520as%2520Piperazine%2520Bioisosteres%2520in%2520the%2520Olaparib%2520Framework%2520Shows%2520Reduced%2520DNA%2520Damage%2520and%2520Cytotoxicity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D12%26spage%3D5367%26epage%3D5379%26doi%3D10.1021%2Facs.jmedchem.8b00576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feichtinger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasem, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrader, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frazer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unett, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grottick, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whelan, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sage, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Semple, G.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Lead Series of Potent Benzodiazepine 5-HT2C Receptor Agonists with High Selectivity in Functional and Binding Assays</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">126929</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.126929</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2Fj.bmcl.2019.126929" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=31952960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFCmsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=126929&issue=5&author=A.+Renauthor=X.+Zhuauthor=K.+Feichtingerauthor=J.+Lehmanauthor=M.+Kasemauthor=T.+O.+Schraderauthor=A.+Wongauthor=H.+Dangauthor=M.+Leauthor=J.+Frazerauthor=D.+J.+Unettauthor=A.+J.+Grottickauthor=K.+T.+Whelanauthor=M.+E.+Morganauthor=C.+R.+Sageauthor=G.+Semple&title=Discovery+of+a+Lead+Series+of+Potent+Benzodiazepine+5-HT2C+Receptor+Agonists+with+High+Selectivity+in+Functional+and+Binding+Assays&doi=10.1016%2Fj.bmcl.2019.126929"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a lead series of potent benzodiazepine 5-HT2C receptor agonists with high selectivity in functional and binding assays</span></div><div class="casAuthors">Ren, Albert; Zhu, Xiuwen; Feichtinger, Konrad; Lehman, Juerg; Kasem, Michelle; Schrader, Thomas O.; Wong, Amy; Dang, Huong; Le, Minh; Frazer, John; Unett, David J.; Grottick, Andrew J.; Whelan, Kevin T.; Morgan, Michael E.; Sage, Carleton R.; Semple, Graeme</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">126929</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of potential new 5-HT2 receptor scaffolds based on a simplification of the clin. studied, 5-HT2CR agonist vabicaserin, were designed.  An in vivo feeding assay early in our screening process played an instrumental part in the lead identification process, leading us to focus on a 6,5,7-tricyclic scaffold.  A subsequent early SAR investigation provided potent agonists of the 5-HT2C receptor that were highly selective in both functional and binding assays, had good rat PK properties and that significantly reduced acute food intake in the rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_fMa9no0QxLVg90H21EOLACvtfcHk0lisasw34OST2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFCmsLk%253D&md5=18051138ef182fcc71575cd2d7c293f0</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.126929&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.126929%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DA.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DFeichtinger%26aufirst%3DK.%26aulast%3DLehman%26aufirst%3DJ.%26aulast%3DKasem%26aufirst%3DM.%26aulast%3DSchrader%26aufirst%3DT.%2BO.%26aulast%3DWong%26aufirst%3DA.%26aulast%3DDang%26aufirst%3DH.%26aulast%3DLe%26aufirst%3DM.%26aulast%3DFrazer%26aufirst%3DJ.%26aulast%3DUnett%26aufirst%3DD.%2BJ.%26aulast%3DGrottick%26aufirst%3DA.%2BJ.%26aulast%3DWhelan%26aufirst%3DK.%2BT.%26aulast%3DMorgan%26aufirst%3DM.%2BE.%26aulast%3DSage%26aufirst%3DC.%2BR.%26aulast%3DSemple%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520a%2520Lead%2520Series%2520of%2520Potent%2520Benzodiazepine%25205-HT2C%2520Receptor%2520Agonists%2520with%2520High%2520Selectivity%2520in%2520Functional%2520and%2520Binding%2520Assays%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26issue%3D5%26spage%3D126929%26doi%3D10.1016%2Fj.bmcl.2019.126929" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">García, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Virgili, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alegret, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Port, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascual, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monroy, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vidal-Torres, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serafini, M.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almansa, C.</span></span> <span> </span><span class="NLM_article-title">4-Aryl-1-Oxa-4,9-Diazaspiro[5.5]Undecane Derivatives as Dual μ-Opioid Receptor Agonists and σ1 Receptor Antagonists for the Treatment of Pain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2434</span>– <span class="NLM_lpage">2454</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01256</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01256" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitF2nur3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=2434-2454&issue=5&author=M.+Garc%C3%ADaauthor=M.+Virgiliauthor=M.+Alonsoauthor=C.+Alegretauthor=B.+Fern%C3%A1ndezauthor=A.+Portauthor=R.+Pascualauthor=X.+Monroyauthor=A.+Vidal-Torresauthor=M.-T.+Serafiniauthor=J.+M.+Velaauthor=C.+Almansa&title=4-Aryl-1-Oxa-4%2C9-Diazaspiro%5B5.5%5DUndecane+Derivatives+as+Dual+%CE%BC-Opioid+Receptor+Agonists+and+%CF%831+Receptor+Antagonists+for+the+Treatment+of+Pain&doi=10.1021%2Facs.jmedchem.9b01256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">4-Aryl-1-oxa-4,9-diazaspiro[5.5]undecane derivatives as dual μ-opioid receptor agonists and σ1 receptor antagonists for the treatment of pain</span></div><div class="casAuthors">Garcia, Monica; Virgili, Marina; Alonso, Monica; Alegret, Carles; Fernandez, Begona; Port, Adriana; Pascual, Rosalia; Monroy, Xavier; Vidal-Torres, Alba; Serafini, Maria-Teresa; Vela, Jose Miguel; Almansa, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2434-2454</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis and pharmacol. activity of a new series of 1-oxa-4,9-diazaspiro[5.5]undecane derivs. as potent dual ligands for the sigma-1 receptor (σ1R) and the μ-opioid receptor (MOR) are reported.  The different positions of the central scaffold, designed using a merging strategy of both targets pharmacophores, were explored using a versatile synthetic approach.  Phenethyl derivs. in position 9, substituted pyridyl moieties in position 4 and small alkyl groups in position 2 provided the best profiles.  One of the best compds., I, showed a balanced dual profile (i.e. MOR agonism and sigma antagonism) and potent analgesic activity, comparable to the MOR agonist oxycodone in the paw pressure test in mice.  Contrary to oxycodone, as expected from the addn. of σ1R antagonism, I showed local, peripheral activity in this test, which was reversed by the σ1R agonist PRE-084.  At equianalgesic doses, I showed less constipation than oxycodone, providing evidence that dual MOR agonism and σ1R antagonism may be a useful strategy for obtaining potent and safer analgesics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpN_96WgxDmIbVg90H21EOLACvtfcHk0lj0qOEhSxpNzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitF2nur3M&md5=6ff458638f9069ade1ccca8adabebb9a</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01256%26sid%3Dliteratum%253Aachs%26aulast%3DGarc%25C3%25ADa%26aufirst%3DM.%26aulast%3DVirgili%26aufirst%3DM.%26aulast%3DAlonso%26aufirst%3DM.%26aulast%3DAlegret%26aufirst%3DC.%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DB.%26aulast%3DPort%26aufirst%3DA.%26aulast%3DPascual%26aufirst%3DR.%26aulast%3DMonroy%26aufirst%3DX.%26aulast%3DVidal-Torres%26aufirst%3DA.%26aulast%3DSerafini%26aufirst%3DM.-T.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26aulast%3DAlmansa%26aufirst%3DC.%26atitle%3D4-Aryl-1-Oxa-4%252C9-Diazaspiro%255B5.5%255DUndecane%2520Derivatives%2520as%2520Dual%2520%25CE%25BC-Opioid%2520Receptor%2520Agonists%2520and%2520%25CF%25831%2520Receptor%2520Antagonists%2520for%2520the%2520Treatment%2520of%2520Pain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26issue%3D5%26spage%3D2434%26epage%3D2454%26doi%3D10.1021%2Facs.jmedchem.9b01256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Degorce, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodnarchuk, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. S.</span></span> <span> </span><span class="NLM_article-title">Lowering Lipophilicity by Adding Carbon: AzaSpiroHeptanes, a LogD Lowering Twist</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1198</span>– <span class="NLM_lpage">1204</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00248</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00248" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVSqtrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1198-1204&issue=8&author=S.+L.+Degorceauthor=M.+S.+Bodnarchukauthor=J.+S.+Scott&title=Lowering+Lipophilicity+by+Adding+Carbon%3A+AzaSpiroHeptanes%2C+a+LogD+Lowering+Twist&doi=10.1021%2Facsmedchemlett.9b00248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Lowering Lipophilicity by Adding Carbon: AzaSpiroHeptanes, a logD Lowering Twist</span></div><div class="casAuthors">Degorce, Sebastien L.; Bodnarchuk, Michael S.; Scott, James S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1198-1204</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have conducted an anal. of azaspiro[3.3]heptanes used as replacements for morpholines, piperidines, and piperazines in a medicinal chem. context.  In most cases, introducing a spirocyclic center lowered the measured logD7.4 of the corresponding mols. by as much as -1.0 relative to the more usual heterocycle.  This may seem counterintuitive, as the net change in the mol. is the addn. of a single carbon atom, but it may be rationalized in terms of increased basicity.  An exception to this was found with N-linked 2-azaspiro[3.3]heptane, where logD7.4 increased by as much as +0.5, consistent with the addn. of carbon.  During our investigation, we also concluded that azaspiro[3.3]heptanes are most likely not suitable bioisosteres for morpholines, piperidines, and piperazines, when not used as terminal groups, due to significant changes in their geometry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnW86KrUzcELVg90H21EOLACvtfcHk0lhgDdpSaLQEZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVSqtrrI&md5=8309b277d9a4071fbdfe198efaecce6e</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00248%26sid%3Dliteratum%253Aachs%26aulast%3DDegorce%26aufirst%3DS.%2BL.%26aulast%3DBodnarchuk%26aufirst%3DM.%2BS.%26aulast%3DScott%26aufirst%3DJ.%2BS.%26atitle%3DLowering%2520Lipophilicity%2520by%2520Adding%2520Carbon%253A%2520AzaSpiroHeptanes%252C%2520a%2520LogD%2520Lowering%2520Twist%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26issue%3D8%26spage%3D1198%26epage%3D1204%26doi%3D10.1021%2Facsmedchemlett.9b00248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wuitschik, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers-Evans, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernasconi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Märki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parrilla, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuler, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweizer, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carreira, E. M.</span></span> <span> </span><span class="NLM_article-title">Spirocyclic Oxetanes: Synthesis and Properties</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>47</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">4512</span>– <span class="NLM_lpage">4515</span>, <span class="refDoi"> DOI: 10.1002/anie.200800450</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1002%2Fanie.200800450" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BD1cXns1yrurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=4512-4515&issue=24&author=G.+Wuitschikauthor=M.+Rogers-Evansauthor=A.+Bucklauthor=M.+Bernasconiauthor=M.+M%C3%A4rkiauthor=T.+Godelauthor=H.+Fischerauthor=B.+Wagnerauthor=I.+Parrillaauthor=F.+Schulerauthor=J.+Schneiderauthor=A.+Alkerauthor=W.+B.+Schweizerauthor=K.+M%C3%BCllerauthor=E.+M.+Carreira&title=Spirocyclic+Oxetanes%3A+Synthesis+and+Properties&doi=10.1002%2Fanie.200800450"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Spirocyclic oxetanes: synthesis and properties</span></div><div class="casAuthors">Wuitschik, Georg; Rogers-Evans, Mark; Buckl, Andreas; Bernasconi, Maurizio; Marki, Moritz; Godel, Thierry; Fischer, Holger; Wagner, Bjorn; Parrilla, Isabelle; Schuler, Franz; Schneider, Josef; Alker, Andre; Schweizer, W. Bernd; Muller, Klaus; Carreira, Erick M.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">4512-4515</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Spirocyclic oxetanes are described as analogs of morpholine and also as topol. siblings of their carbonyl counterparts.  They are particularly promising in terms of both their physicochem. properties and the ease with which they can be grafted onto mol. structures.  The data collected highlight oxetanes as both the hydrophilic sister of a gem-di-Me unit and the carbonyl group's lipophilic brother.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpjICUKXgpt7Vg90H21EOLACvtfcHk0lhgDdpSaLQEZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXns1yrurs%253D&md5=9522eb5cfb870b872d8f9c1f06ae2946</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1002%2Fanie.200800450&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200800450%26sid%3Dliteratum%253Aachs%26aulast%3DWuitschik%26aufirst%3DG.%26aulast%3DRogers-Evans%26aufirst%3DM.%26aulast%3DBuckl%26aufirst%3DA.%26aulast%3DBernasconi%26aufirst%3DM.%26aulast%3DM%25C3%25A4rki%26aufirst%3DM.%26aulast%3DGodel%26aufirst%3DT.%26aulast%3DFischer%26aufirst%3DH.%26aulast%3DWagner%26aufirst%3DB.%26aulast%3DParrilla%26aufirst%3DI.%26aulast%3DSchuler%26aufirst%3DF.%26aulast%3DSchneider%26aufirst%3DJ.%26aulast%3DAlker%26aufirst%3DA.%26aulast%3DSchweizer%26aufirst%3DW.%2BB.%26aulast%3DM%25C3%25BCller%26aufirst%3DK.%26aulast%3DCarreira%26aufirst%3DE.%2BM.%26atitle%3DSpirocyclic%2520Oxetanes%253A%2520Synthesis%2520and%2520Properties%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2008%26volume%3D47%26issue%3D24%26spage%3D4512%26epage%3D4515%26doi%3D10.1002%2Fanie.200800450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burkhard, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuler, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carreira, E. M.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Azaspirocycles and Their Evaluation in Drug Discovery</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">3524</span>– <span class="NLM_lpage">3527</span>, <span class="refDoi"> DOI: 10.1002/anie.200907108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1002%2Fanie.200907108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsFCnsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=3524-3527&issue=20&author=J.+A.+Burkhardauthor=B.+Wagnerauthor=H.+Fischerauthor=F.+Schulerauthor=K.+M%C3%BCllerauthor=E.+M.+Carreira&title=Synthesis+of+Azaspirocycles+and+Their+Evaluation+in+Drug+Discovery&doi=10.1002%2Fanie.200907108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Azaspirocycles and their Evaluation in Drug Discovery</span></div><div class="casAuthors">Burkhard, Johannes A.; Wagner, Bjoern; Fischer, Holger; Schuler, Franz; Mueller, Klaus; Carreira, Erick M.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3524-3527, S3524/1-S3524/60</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Readily synthesized heteroatom-substituted spiro[3.3]heptanes generally show higher aq. soly. than their cyclohexane analogs, and show a trend towards higher metabolic stability.  The novel framework can be mounted onto scaffolds of druglike structures, such as fluoroquinolones, to afford active compds. with similar or even improved metabolic stability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpW-R9uvaVrXLVg90H21EOLACvtfcHk0lhrWv9dqpG2qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsFCnsbY%253D&md5=0367b2cb751889a3df1cb1c8d2b24bc6</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1002%2Fanie.200907108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200907108%26sid%3Dliteratum%253Aachs%26aulast%3DBurkhard%26aufirst%3DJ.%2BA.%26aulast%3DWagner%26aufirst%3DB.%26aulast%3DFischer%26aufirst%3DH.%26aulast%3DSchuler%26aufirst%3DF.%26aulast%3DM%25C3%25BCller%26aufirst%3DK.%26aulast%3DCarreira%26aufirst%3DE.%2BM.%26atitle%3DSynthesis%2520of%2520Azaspirocycles%2520and%2520Their%2520Evaluation%2520in%2520Drug%2520Discovery%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2010%26volume%3D49%26issue%3D20%26spage%3D3524%26epage%3D3527%26doi%3D10.1002%2Fanie.200907108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sampson, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feher, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forrest, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ban, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awrey, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plotnikova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiarash, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chirgadze, N. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauls, H. W.</span></span> <span> </span><span class="NLM_article-title">The Discovery of Polo-like Kinase 4 Inhibitors: Design and Optimization of Spiro[Cyclopropane-1,3’[3H]Indol]-2’(1’H).Ones as Orally Bioavailable Antitumor Agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">130</span>– <span class="NLM_lpage">146</span>, <span class="refDoi"> DOI: 10.1021/jm500537u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500537u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2cXos1Wktro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=130-146&issue=1&author=P.+B.+Sampsonauthor=Y.+Liuauthor=N.+K.+Patelauthor=M.+Feherauthor=B.+Forrestauthor=S.-W.+Liauthor=L.+Edwardsauthor=R.+Lauferauthor=Y.+Langauthor=F.+Banauthor=D.+E.+Awreyauthor=G.+Maoauthor=O.+Plotnikovaauthor=G.+Leungauthor=R.+Hodgsonauthor=J.+M.+Masonauthor=X.+Weiauthor=R.+Kiarashauthor=E.+Greenauthor=W.+Qiuauthor=N.+Y.+Chirgadzeauthor=T.+W.+Makauthor=G.+Panauthor=H.+W.+Pauls&title=The+Discovery+of+Polo-like+Kinase+4+Inhibitors%3A+Design+and+Optimization+of+Spiro%5BCyclopropane-1%2C3%E2%80%99%5B3H%5DIndol%5D-2%E2%80%99%281%E2%80%99H%29.Ones+as+Orally+Bioavailable+Antitumor+Agents&doi=10.1021%2Fjm500537u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">The Discovery of Polo-Like Kinase 4 Inhibitors: Design and Optimization of Spiro[cyclopropane-1,3'[3H]indol]-2'(1'H)-ones as Orally Bioavailable Antitumor Agents</span></div><div class="casAuthors">Sampson, Peter B.; Liu, Yong; Patel, Narendra Kumar; Feher, Miklos; Forrest, Bryan; Li, Sze-Wan; Edwards, Louise; Laufer, Radoslaw; Lang, Yunhui; Ban, Fuqiang; Awrey, Donald E.; Mao, Guodong; Plotnikova, Olga; Leung, Genie; Hodgson, Richard; Mason, Jacqueline; Wei, Xin; Kiarash, Reza; Green, Erin; Qiu, Wei; Chirgadze, Nickolay Y.; Mak, Tak W.; Pan, Guohua; Pauls, Henry W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">130-146</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Polo-like kinase 4 (PLK4), a unique member of the polo-like kinase family of serine-threonine kinases, is a master regulator of centriole duplication that is important for maintaining genome integrity.  Overexpression of PLK4 is found in several human cancers and is linked with a predisposition to tumorigenesis.  Previous efforts to identify potent and efficacious PLK4 inhibitors resulted in the discovery of (E)-3-((1H-indazol-6-yl)methylene)indolin-2-ones, which are superseded by the bioisosteric 2-(1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-ones reported herein.  Optimization of this new cyclopropane-linked series was based on a computational model of a PLK4 x-ray structure and SAR attained from the analogous alkene-linked series.  The racemic cyclopropane-linked compds. showed PLK4 affinity and antiproliferative activity comparable to their alkene-linked congeners with improved physicochem., ADME, and pharmacokinetic properties.  Pos. xenograft results from the MDA-MB-468 human breast cancer xenograft model for compd. I support the investigation of PLK4 inhibitors as anticancer therapeutics.  A PLK4 x-ray co-structure with compd. I revealed preferential binding of the 1R,2S enantiomer to the PLK4 kinase domain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_nQjbJy_sMLVg90H21EOLACvtfcHk0lhrWv9dqpG2qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXos1Wktro%253D&md5=90d60867ee5d6c27f597ebe32db64278</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1021%2Fjm500537u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500537u%26sid%3Dliteratum%253Aachs%26aulast%3DSampson%26aufirst%3DP.%2BB.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DPatel%26aufirst%3DN.%2BK.%26aulast%3DFeher%26aufirst%3DM.%26aulast%3DForrest%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DS.-W.%26aulast%3DEdwards%26aufirst%3DL.%26aulast%3DLaufer%26aufirst%3DR.%26aulast%3DLang%26aufirst%3DY.%26aulast%3DBan%26aufirst%3DF.%26aulast%3DAwrey%26aufirst%3DD.%2BE.%26aulast%3DMao%26aufirst%3DG.%26aulast%3DPlotnikova%26aufirst%3DO.%26aulast%3DLeung%26aufirst%3DG.%26aulast%3DHodgson%26aufirst%3DR.%26aulast%3DMason%26aufirst%3DJ.%2BM.%26aulast%3DWei%26aufirst%3DX.%26aulast%3DKiarash%26aufirst%3DR.%26aulast%3DGreen%26aufirst%3DE.%26aulast%3DQiu%26aufirst%3DW.%26aulast%3DChirgadze%26aufirst%3DN.%2BY.%26aulast%3DMak%26aufirst%3DT.%2BW.%26aulast%3DPan%26aufirst%3DG.%26aulast%3DPauls%26aufirst%3DH.%2BW.%26atitle%3DThe%2520Discovery%2520of%2520Polo-like%2520Kinase%25204%2520Inhibitors%253A%2520Design%2520and%2520Optimization%2520of%2520Spiro%255BCyclopropane-1%252C3%25E2%2580%2599%255B3H%255DIndol%255D-2%25E2%2580%2599%25281%25E2%2580%2599H%2529.Ones%2520as%2520Orally%2520Bioavailable%2520Antitumor%2520Agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D1%26spage%3D130%26epage%3D146%26doi%3D10.1021%2Fjm500537u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mallinger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crumpler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pichowicz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waalboer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stubbs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adeniji-Popoola, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thai, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henley, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georgi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Court, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobbs, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Box, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz-Ruiz, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valenti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Haven
Brandon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">TePoele, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leuthner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aherne, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poeschke, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dale, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wienke, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esdar, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohdich, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eccles, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stieber, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiemann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of Potent, Orally Bioavailable, Small-Molecule Inhibitors of WNT Signaling from a Cell-Based Pathway Screen</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1717</span>– <span class="NLM_lpage">1735</span>, <span class="refDoi"> DOI: 10.1021/jm501436m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501436m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2MXislGjur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=1717-1735&issue=4&author=A.+Mallingerauthor=S.+Crumplerauthor=M.+Pichowiczauthor=D.+Waalboerauthor=M.+Stubbsauthor=O.+Adeniji-Popoolaauthor=B.+Woodauthor=E.+Smithauthor=C.+Thaiauthor=A.+T.+Henleyauthor=K.+Georgiauthor=W.+Courtauthor=S.+Hobbsauthor=G.+Boxauthor=M.-J.+Ortiz-Ruizauthor=M.+Valentiauthor=A.+De+Haven%0ABrandonauthor=R.+TePoeleauthor=B.+Leuthnerauthor=P.+Workmanauthor=W.+Aherneauthor=O.+Poeschkeauthor=T.+Daleauthor=D.+Wienkeauthor=C.+Esdarauthor=F.+Rohdichauthor=F.+Raynaudauthor=P.+A.+Clarkeauthor=S.+A.+Ecclesauthor=F.+Stieberauthor=K.+Schiemannauthor=J.+Blagg&title=Discovery+of+Potent%2C+Orally+Bioavailable%2C+Small-Molecule+Inhibitors+of+WNT+Signaling+from+a+Cell-Based+Pathway+Screen&doi=10.1021%2Fjm501436m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent, Orally Bioavailable, Small-Molecule Inhibitors of WNT Signaling from a Cell-Based Pathway Screen</span></div><div class="casAuthors">Mallinger, Aurelie; Crumpler, Simon; Pichowicz, Mark; Waalboer, Dennis; Stubbs, Mark; Adeniji-Popoola, Olajumoke; Wood, Bozena; Smith, Elizabeth; Thai, Ching; Henley, Alan T.; Georgi, Katrin; Court, William; Hobbs, Steve; Box, Gary; Ortiz-Ruiz, Maria-Jesus; Valenti, Melanie; De Haven Brandon, Alexis; Te Poele, Robert; Leuthner, Birgitta; Workman, Paul; Aherne, Wynne; Poeschke, Oliver; Dale, Trevor; Wienke, Dirk; Esdar, Christina; Rohdich, Felix; Raynaud, Florence; Clarke, Paul A.; Eccles, Suzanne A.; Stieber, Frank; Schiemann, Kai; Blagg, Julian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1717-1735</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">WNT signaling is frequently deregulated in malignancy, particularly in colon cancer, and plays a key role in the generation and maintenance of cancer stem cells.  The authors report the discovery and optimization of a 3,4,5-trisubstituted pyridine, 1-(3,5-Dichloropyridin-4-yl)piperidine-4-carboxamide (9), using a high-throughput cell-based reporter assay of WNT pathway activity.  The authors demonstrate a twisted conformation about the pyridine-piperidine bond of (9) by small-mol. x-ray crystallog.  Medicinal chem. optimization to maintain this twisted conformation, cognisant of physicochem. properties likely to maintain good cell permeability, led to 8-[3-Chloro-5-[4-(1-methyl-1H-pyrazol-4-yl)phenyl]pyridin-4-yl]-2,8-diazaspiro[4,5]decan-1-one (74) (CCT251545), a potent small-mol. inhibitor of WNT signaling with good oral pharmacokinetics.  The authors demonstrate inhibition of WNT pathway activity in a solid human tumor xenograft model with evidence for tumor growth inhibition following oral dosing.  This work provides a successful example of hypothesis-driven medicinal chem. optimization from a singleton hit against a cell-based pathway assay without knowledge of the biochem. target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGX6wdTc3jeLVg90H21EOLACvtfcHk0lgZJfhyvUPujw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXislGjur4%253D&md5=eab7f23a8288cb3da6665ef000558f95</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1021%2Fjm501436m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501436m%26sid%3Dliteratum%253Aachs%26aulast%3DMallinger%26aufirst%3DA.%26aulast%3DCrumpler%26aufirst%3DS.%26aulast%3DPichowicz%26aufirst%3DM.%26aulast%3DWaalboer%26aufirst%3DD.%26aulast%3DStubbs%26aufirst%3DM.%26aulast%3DAdeniji-Popoola%26aufirst%3DO.%26aulast%3DWood%26aufirst%3DB.%26aulast%3DSmith%26aufirst%3DE.%26aulast%3DThai%26aufirst%3DC.%26aulast%3DHenley%26aufirst%3DA.%2BT.%26aulast%3DGeorgi%26aufirst%3DK.%26aulast%3DCourt%26aufirst%3DW.%26aulast%3DHobbs%26aufirst%3DS.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DOrtiz-Ruiz%26aufirst%3DM.-J.%26aulast%3DValenti%26aufirst%3DM.%26aulast%3DDe%2BHaven%2BBrandon%26aufirst%3DA.%26aulast%3DTePoele%26aufirst%3DR.%26aulast%3DLeuthner%26aufirst%3DB.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DAherne%26aufirst%3DW.%26aulast%3DPoeschke%26aufirst%3DO.%26aulast%3DDale%26aufirst%3DT.%26aulast%3DWienke%26aufirst%3DD.%26aulast%3DEsdar%26aufirst%3DC.%26aulast%3DRohdich%26aufirst%3DF.%26aulast%3DRaynaud%26aufirst%3DF.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DStieber%26aufirst%3DF.%26aulast%3DSchiemann%26aufirst%3DK.%26aulast%3DBlagg%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520Potent%252C%2520Orally%2520Bioavailable%252C%2520Small-Molecule%2520Inhibitors%2520of%2520WNT%2520Signaling%2520from%2520a%2520Cell-Based%2520Pathway%2520Screen%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D4%26spage%3D1717%26epage%3D1735%26doi%3D10.1021%2Fjm501436m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johansson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Löfberg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonsson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Unge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Judkins, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ploj, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benthem, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindén, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wennerberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fredenwall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettersen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gennemark, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogner, A.</span></span> <span> </span><span class="NLM_article-title">Discovery of (3-(4-(2-Oxa-6-Azaspiro[3.3]Heptan-6-Ylmethyl)Phenoxy)Azetidin-1-Yl)(5-(4-Methoxyphenyl)-1,3,4-Oxadiazol-2-Yl)Methanone (AZD1979), a Melanin Concentrating Hormone Receptor 1 (MCHr1) Antagonist with Favorable Physicochemical Properties</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2497</span>– <span class="NLM_lpage">2511</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01654</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01654" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC28XktFCnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2497-2511&issue=6&author=A.+Johanssonauthor=C.+L%C3%B6fbergauthor=M.+Antonssonauthor=S.+von+Ungeauthor=M.+A.+Hayesauthor=R.+Judkinsauthor=K.+Plojauthor=L.+Benthemauthor=D.+Lind%C3%A9nauthor=P.+Brodinauthor=M.+Wennerbergauthor=M.+Fredenwallauthor=L.+Liauthor=J.+Perssonauthor=R.+Bergmanauthor=A.+Pettersenauthor=P.+Gennemarkauthor=A.+Hogner&title=Discovery+of+%283-%284-%282-Oxa-6-Azaspiro%5B3.3%5DHeptan-6-Ylmethyl%29Phenoxy%29Azetidin-1-Yl%29%285-%284-Methoxyphenyl%29-1%2C3%2C4-Oxadiazol-2-Yl%29Methanone+%28AZD1979%29%2C+a+Melanin+Concentrating+Hormone+Receptor+1+%28MCHr1%29+Antagonist+with+Favorable+Physicochemical+Properties&doi=10.1021%2Facs.jmedchem.5b01654"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (3-(4-(2-Oxa-6-azaspiro[3.3]heptan-6-ylmethyl)phenoxy)azetidin-1-yl)(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)methanone (AZD1979), a Melanin Concentrating Hormone Receptor 1 (MCHr1) Antagonist with Favorable Physicochemical Properties</span></div><div class="casAuthors">Johansson, Anders; Loefberg, Christian; Antonsson, Madeleine; von Unge, Sverker; Hayes, Martin A.; Judkins, Robert; Ploj, Karolina; Benthem, Lambertus; Linden, Daniel; Brodin, Peter; Wennerberg, Marie; Fredenwall, Marlene; Li, Lanna; Persson, Joachim; Bergman, Rolf; Pettersen, Anna; Gennemark, Peter; Hogner, Anders</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2497-2511</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of melanin concg. hormone receptor 1 (MCHr1) antagonists were the starting point for a drug discovery program that culminated in the discovery of 103 (AZD1979).  The lead optimization program was conducted with a focus on reducing lipophilicity and understanding the physicochem. properties governing CNS exposure and undesired off-target pharmacol. such as hERG interactions.  An integrated approach was taken where the key assay was ex vivo receptor occupancy in mice.  The candidate compd. 103 displayed appropriate lipophilicity for a CNS indication and showed excellent permeability with no efflux.  Preclin. GLP toxicol. and safety pharmacol. studies were without major findings and 103 was taken into clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJJvE6-qb7C7Vg90H21EOLACvtfcHk0lgZJfhyvUPujw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktFCnsg%253D%253D&md5=98ac16f6fd4be62e681f2ebb094e985e</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01654%26sid%3Dliteratum%253Aachs%26aulast%3DJohansson%26aufirst%3DA.%26aulast%3DL%25C3%25B6fberg%26aufirst%3DC.%26aulast%3DAntonsson%26aufirst%3DM.%26aulast%3Dvon%2BUnge%26aufirst%3DS.%26aulast%3DHayes%26aufirst%3DM.%2BA.%26aulast%3DJudkins%26aufirst%3DR.%26aulast%3DPloj%26aufirst%3DK.%26aulast%3DBenthem%26aufirst%3DL.%26aulast%3DLind%25C3%25A9n%26aufirst%3DD.%26aulast%3DBrodin%26aufirst%3DP.%26aulast%3DWennerberg%26aufirst%3DM.%26aulast%3DFredenwall%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DPersson%26aufirst%3DJ.%26aulast%3DBergman%26aufirst%3DR.%26aulast%3DPettersen%26aufirst%3DA.%26aulast%3DGennemark%26aufirst%3DP.%26aulast%3DHogner%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520%25283-%25284-%25282-Oxa-6-Azaspiro%255B3.3%255DHeptan-6-Ylmethyl%2529Phenoxy%2529Azetidin-1-Yl%2529%25285-%25284-Methoxyphenyl%2529-1%252C3%252C4-Oxadiazol-2-Yl%2529Methanone%2520%2528AZD1979%2529%252C%2520a%2520Melanin%2520Concentrating%2520Hormone%2520Receptor%25201%2520%2528MCHr1%2529%2520Antagonist%2520with%2520Favorable%2520Physicochemical%2520Properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D6%26spage%3D2497%26epage%3D2511%26doi%3D10.1021%2Facs.jmedchem.5b01654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bryan, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drobnick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobbi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolesnikov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajapaksa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ndubaku, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choo, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMent, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ran, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sujatha-Bhaskar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brightbill, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiPasquale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenzie, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupardus, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrin, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiefer, J. R.</span></span> <span> </span><span class="NLM_article-title">Development of Potent and Selective Pyrazolopyrimidine IRAK4 Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">6223</span>– <span class="NLM_lpage">6240</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00439</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00439" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1MXptlOjsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=6223-6240&issue=13&author=M.+C.+Bryanauthor=J.+Drobnickauthor=A.+Gobbiauthor=A.+Kolesnikovauthor=Y.+Chenauthor=N.+Rajapaksaauthor=C.+Ndubakuauthor=J.+Fengauthor=W.+Changauthor=R.+Francisauthor=C.+Yuauthor=E.+F.+Chooauthor=K.+DeMentauthor=Y.+Ranauthor=L.+Anauthor=C.+Emsonauthor=Z.+Huangauthor=S.+Sujatha-Bhaskarauthor=H.+Brightbillauthor=A.+DiPasqualeauthor=J.+Maherauthor=J.+Waiauthor=B.+S.+McKenzieauthor=P.+J.+Lupardusauthor=A.+A.+Zarrinauthor=J.+R.+Kiefer&title=Development+of+Potent+and+Selective+Pyrazolopyrimidine+IRAK4+Inhibitors&doi=10.1021%2Facs.jmedchem.9b00439"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Potent and Selective Pyrazolopyrimidine IRAK4 Inhibitors</span></div><div class="casAuthors">Bryan, Marian C.; Drobnick, Joy; Gobbi, Alberto; Kolesnikov, Aleksandr; Chen, Yongsheng; Rajapaksa, Naomi; Ndubaku, Chudi; Feng, Jianwen; Chang, Willy; Francis, Ross; Yu, Christine; Choo, Edna F.; DeMent, Kevin; Ran, Yingqing; An, Le; Emson, Claire; Huang, Zhiyu; Sujatha-Bhaskar, Swathi; Brightbill, Hans; DiPasquale, Antonio; Maher, Jonathan; Wai, John; McKenzie, Brent S.; Lupardus, Patrick J.; Zarrin, Ali A.; Kiefer, James R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6223-6240</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of pyrazolopyrimidine inhibitors of IRAK4 were developed from a high-throughput screen (HTS).  Modification of an HTS hit led to a series of bicyclic heterocycles with improved potency and kinase selectivity but lacking sufficient soly. to progress in vivo.  Structure-based drug design, informed by cocrystal structures with the protein and small-mol. crystal structures, yielded a series of dihydrobenzofurans.  This semisatd. bicycle provided superior druglike properties while maintaining excellent potency and selectivity.  Improved physicochem. properties allowed for progression into in vivo expts., where lead mols. exhibited low clearance and showed target-based inhibition of IRAK4 signaling in an inflammation-mediated PK/PD mouse model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGdG1FWD_TrbVg90H21EOLACvtfcHk0lgPSQoNhWsohA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXptlOjsr8%253D&md5=edf86550908249af0c0c2a5be32abe06</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00439&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00439%26sid%3Dliteratum%253Aachs%26aulast%3DBryan%26aufirst%3DM.%2BC.%26aulast%3DDrobnick%26aufirst%3DJ.%26aulast%3DGobbi%26aufirst%3DA.%26aulast%3DKolesnikov%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DRajapaksa%26aufirst%3DN.%26aulast%3DNdubaku%26aufirst%3DC.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DW.%26aulast%3DFrancis%26aufirst%3DR.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DChoo%26aufirst%3DE.%2BF.%26aulast%3DDeMent%26aufirst%3DK.%26aulast%3DRan%26aufirst%3DY.%26aulast%3DAn%26aufirst%3DL.%26aulast%3DEmson%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DSujatha-Bhaskar%26aufirst%3DS.%26aulast%3DBrightbill%26aufirst%3DH.%26aulast%3DDiPasquale%26aufirst%3DA.%26aulast%3DMaher%26aufirst%3DJ.%26aulast%3DWai%26aufirst%3DJ.%26aulast%3DMcKenzie%26aufirst%3DB.%2BS.%26aulast%3DLupardus%26aufirst%3DP.%2BJ.%26aulast%3DZarrin%26aufirst%3DA.%2BA.%26aulast%3DKiefer%26aufirst%3DJ.%2BR.%26atitle%3DDevelopment%2520of%2520Potent%2520and%2520Selective%2520Pyrazolopyrimidine%2520IRAK4%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D13%26spage%3D6223%26epage%3D6240%26doi%3D10.1021%2Facs.jmedchem.9b00439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizukami, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadowaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuda, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suwa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inaba, T.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Novel and Potent GPR119 Agonists with a Spirocyclic Structure</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1228</span>– <span class="NLM_lpage">1233</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.02.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2Fj.bmcl.2018.02.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=29519733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjvVGiu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=1228-1233&issue=7&author=K.+Haradaauthor=J.+Mizukamiauthor=S.+Kadowakiauthor=I.+Matsudaauthor=T.+Watanabeauthor=Y.+Oeauthor=Y.+Kodamaauthor=K.+Aokiauthor=K.+Suwaauthor=S.+Fukudaauthor=S.+Yataauthor=T.+Inaba&title=Design+and+Synthesis+of+Novel+and+Potent+GPR119+Agonists+with+a+Spirocyclic+Structure&doi=10.1016%2Fj.bmcl.2018.02.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of novel and potent GPR119 agonists with a spirocyclic structure</span></div><div class="casAuthors">Harada, Kazuhito; Mizukami, Jun; Kadowaki, Sho; Matsuda, Isamu; Watanabe, Takashi; Oe, Yasuhiro; Kodama, Yoshitoshi; Aoki, Kenta; Suwa, Katsunori; Fukuda, Sumiaki; Yata, Shinji; Inaba, Takashi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1228-1233</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Exploration of alternative structures for the substituted piperidine or piperazine ring, which are characteristic in most of the reported GPR119 agonists, provided novel spirocyclic cyclohexane derivs.  The representative I with a high three-dimensionality exhibited potent agonistic activity (EC50 = 4 nM) with no CYP inhibitory activity (IC50 >10 μM).  Compd. I also displayed hypoglycemic activity with insulin secretion dependent on glucose concn. in an i.p. glucose tolerance test in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqF9WCkY_OYwLVg90H21EOLACvtfcHk0lgPSQoNhWsohA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjvVGiu7Y%253D&md5=ab7eb53347e4f59e2c3af5dfe603b3ed</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.02.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.02.044%26sid%3Dliteratum%253Aachs%26aulast%3DHarada%26aufirst%3DK.%26aulast%3DMizukami%26aufirst%3DJ.%26aulast%3DKadowaki%26aufirst%3DS.%26aulast%3DMatsuda%26aufirst%3DI.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DOe%26aufirst%3DY.%26aulast%3DKodama%26aufirst%3DY.%26aulast%3DAoki%26aufirst%3DK.%26aulast%3DSuwa%26aufirst%3DK.%26aulast%3DFukuda%26aufirst%3DS.%26aulast%3DYata%26aufirst%3DS.%26aulast%3DInaba%26aufirst%3DT.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Novel%2520and%2520Potent%2520GPR119%2520Agonists%2520with%2520a%2520Spirocyclic%2520Structure%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26issue%3D7%26spage%3D1228%26epage%3D1233%26doi%3D10.1016%2Fj.bmcl.2018.02.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schade, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagener, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christian, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordhoff, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merla, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunkern, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahrenberg, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratcliffe, P.</span></span> <span> </span><span class="NLM_article-title">Fragment-Based Discovery of Novel Potent Sepiapterin Reductase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">6391</span>– <span class="NLM_lpage">6397</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00218</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00218" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1eis7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=6391-6397&issue=13&author=J.+Alenauthor=M.+Schadeauthor=M.+Wagenerauthor=F.+Christianauthor=S.+Nordhoffauthor=B.+Merlaauthor=T.+R.+Dunkernauthor=G.+Bahrenbergauthor=P.+Ratcliffe&title=Fragment-Based+Discovery+of+Novel+Potent+Sepiapterin+Reductase+Inhibitors&doi=10.1021%2Facs.jmedchem.9b00218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-Based Discovery of Novel Potent Sepiapterin Reductase Inhibitors</span></div><div class="casAuthors">Alen, Jo; Schade, Markus; Wagener, Markus; Christian, Frank; Nordhoff, Sonja; Merla, Beatrix; Dunkern, Torsten R.; Bahrenberg, Gregor; Ratcliffe, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6391-6397</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Genome-wide-assocn. studies in chronic low back pain patients identified sepiapterin reductase as a high interest target for developing new analgesics.  Here we used 19F NMR fragment screening for the discovery of novel, ligand-efficient SPR inhibitors.  We report the crystal structures of six chem. diverse inhibitors complexed with SPR, identifying relevant interactions and binding modes in the sepiapterin pocket.  Exploration of our initial fragment screening hit led to double-digit nanomolar inhibitors of SPR with excellent ligand efficiency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqE9wu7xlixaLVg90H21EOLACvtfcHk0lgPSQoNhWsohA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1eis7%252FJ&md5=dda81abbe438a32ce68d141e4094cf09</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00218%26sid%3Dliteratum%253Aachs%26aulast%3DAlen%26aufirst%3DJ.%26aulast%3DSchade%26aufirst%3DM.%26aulast%3DWagener%26aufirst%3DM.%26aulast%3DChristian%26aufirst%3DF.%26aulast%3DNordhoff%26aufirst%3DS.%26aulast%3DMerla%26aufirst%3DB.%26aulast%3DDunkern%26aufirst%3DT.%2BR.%26aulast%3DBahrenberg%26aufirst%3DG.%26aulast%3DRatcliffe%26aufirst%3DP.%26atitle%3DFragment-Based%2520Discovery%2520of%2520Novel%2520Potent%2520Sepiapterin%2520Reductase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D13%26spage%3D6391%26epage%3D6397%26doi%3D10.1021%2Facs.jmedchem.9b00218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mould, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremberg, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cartic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geitmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maiques-Diaz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGonagle, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somervaille, T. C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turlais, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogilvie, D.</span></span> <span> </span><span class="NLM_article-title">Development of (4-Cyanophenyl)Glycine Derivatives as Reversible Inhibitors of Lysine Specific Demethylase 1</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">7984</span>– <span class="NLM_lpage">7999</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00462</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00462" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVKqsrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7984-7999&issue=19&author=D.+P.+Mouldauthor=C.+Alliauthor=U.+Brembergauthor=S.+Carticauthor=A.+M.+Jordanauthor=M.+Geitmannauthor=A.+Maiques-Diazauthor=A.+E.+McGonagleauthor=T.+C.+P.+Somervailleauthor=G.+J.+Spencerauthor=F.+Turlaisauthor=D.+Ogilvie&title=Development+of+%284-Cyanophenyl%29Glycine+Derivatives+as+Reversible+Inhibitors+of+Lysine+Specific+Demethylase+1&doi=10.1021%2Facs.jmedchem.7b00462"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Development of (4-Cyanophenyl)glycine Derivatives as Reversible Inhibitors of Lysine Specific Demethylase 1</span></div><div class="casAuthors">Mould, Daniel P.; Alli, Cristina; Bremberg, Ulf; Cartic, Sharon; Jordan, Allan M.; Geitmann, Matthis; Maiques-Diaz, Alba; McGonagle, Alison E.; Somervaille, Tim C. P.; Spencer, Gary J.; Turlais, Fabrice; Ogilvie, Donald</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7984-7999</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of lysine specific demethylase 1 (LSD1) has been shown to induce the differentiation of leukemia stem cells in acute myeloid leukemia (AML).  Irreversible inhibitors developed from the nonspecific inhibitor tranylcypromine have entered clin. trials; however, the development of effective reversible inhibitors has proved more challenging.  Herein, we describe our efforts to identify reversible inhibitors of LSD1 from a high throughput screen and subsequent in silico modeling approaches.  From a single hit (12) validated by biochem. and biophys. assays, we describe our efforts to develop acyclic scaffold-hops from GSK-690 (1).  A further scaffold modification to a (4-cyanophenyl)glycinamide (e.g., 29a) led to the development of compd. 32, with a Kd value of 32 nM and an EC50 value of 0.67 μM in a surrogate cellular biomarker assay.  Moreover, this deriv. does not display the same level of hERG liability as obsd. with 1 and represents a promising lead for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5NyXkmZPOqrVg90H21EOLACvtfcHk0liUwnLe4Ja_SQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVKqsrrJ&md5=af673e7b3a2815aa09fe7264a3e4247b</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00462&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00462%26sid%3Dliteratum%253Aachs%26aulast%3DMould%26aufirst%3DD.%2BP.%26aulast%3DAlli%26aufirst%3DC.%26aulast%3DBremberg%26aufirst%3DU.%26aulast%3DCartic%26aufirst%3DS.%26aulast%3DJordan%26aufirst%3DA.%2BM.%26aulast%3DGeitmann%26aufirst%3DM.%26aulast%3DMaiques-Diaz%26aufirst%3DA.%26aulast%3DMcGonagle%26aufirst%3DA.%2BE.%26aulast%3DSomervaille%26aufirst%3DT.%2BC.%2BP.%26aulast%3DSpencer%26aufirst%3DG.%2BJ.%26aulast%3DTurlais%26aufirst%3DF.%26aulast%3DOgilvie%26aufirst%3DD.%26atitle%3DDevelopment%2520of%2520%25284-Cyanophenyl%2529Glycine%2520Derivatives%2520as%2520Reversible%2520Inhibitors%2520of%2520Lysine%2520Specific%2520Demethylase%25201%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D19%26spage%3D7984%26epage%3D7999%26doi%3D10.1021%2Facs.jmedchem.7b00462" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bulterys, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartberger, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorth, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Boyle, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Virgil, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoltz, B. M.</span></span> <span> </span><span class="NLM_article-title">Incorporation of a Chiral Gem-Disubstituted Nitrogen Heterocycle Yields an Oxazolidinone Antibiotic with Reduced Mitochondrial Toxicity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">2686</span>– <span class="NLM_lpage">2689</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.07.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2Fj.bmcl.2019.07.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=31383589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFWlsLrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=2686-2689&issue=18&author=A.+W.+Sunauthor=P.+L.+Bulterysauthor=M.+D.+Bartbergerauthor=P.+A.+Jorthauthor=B.+M.+O%E2%80%99Boyleauthor=S.+C.+Virgilauthor=J.+F.+Millerauthor=B.+M.+Stoltz&title=Incorporation+of+a+Chiral+Gem-Disubstituted+Nitrogen+Heterocycle+Yields+an+Oxazolidinone+Antibiotic+with+Reduced+Mitochondrial+Toxicity&doi=10.1016%2Fj.bmcl.2019.07.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Incorporation of a chiral gem-disubstituted nitrogen heterocycle yields an oxazolidinone antibiotic with reduced mitochondrial toxicity</span></div><div class="casAuthors">Sun, Alexander W.; Bulterys, Philip L.; Bartberger, Michael D.; Jorth, Peter A.; O'Boyle, Brendan M.; Virgil, Scott C.; Miller, Jeff F.; Stoltz, Brian M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2686-2689</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Gem-Disubstituted N-heterocycles are rarely found in drugs, despite their potential to improve the drug-like properties of small mol. pharmaceuticals.  Linezolid, a morpholine heterocycle-contg. oxazolidinone antibiotic, exhibits significant side effects assocd. with human mitochondrial protein synthesis inhibition.  We synthesized a gem-disubstituted linezolid analog that when compared to linezolid, maintains comparable (albeit slightly diminished) activity against bacteria, comparable in vitro physicochem. properties, and a decrease in undesired mitochondrial protein synthesis (MPS) inhibition.  This research contributes to the structure-activity-relationship data surrounding oxazolidinone MPS inhibition, and may inspire investigations into the utility of gem-disubstituted N-heterocycles in medicinal chem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRZtX-WyPmJLVg90H21EOLACvtfcHk0liUwnLe4Ja_SQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFWlsLrF&md5=eb7107345c1072299513c49db192d5b8</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.07.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.07.024%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DA.%2BW.%26aulast%3DBulterys%26aufirst%3DP.%2BL.%26aulast%3DBartberger%26aufirst%3DM.%2BD.%26aulast%3DJorth%26aufirst%3DP.%2BA.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DB.%2BM.%26aulast%3DVirgil%26aufirst%3DS.%2BC.%26aulast%3DMiller%26aufirst%3DJ.%2BF.%26aulast%3DStoltz%26aufirst%3DB.%2BM.%26atitle%3DIncorporation%2520of%2520a%2520Chiral%2520Gem-Disubstituted%2520Nitrogen%2520Heterocycle%2520Yields%2520an%2520Oxazolidinone%2520Antibiotic%2520with%2520Reduced%2520Mitochondrial%2520Toxicity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26issue%3D18%26spage%3D2686%26epage%3D2689%26doi%3D10.1016%2Fj.bmcl.2019.07.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gehringer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S. A.</span></span> <span> </span><span class="NLM_article-title">Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">5673</span>– <span class="NLM_lpage">5724</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01153</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01153" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFKiur%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=5673-5724&issue=12&author=M.+Gehringerauthor=S.+A.+Laufer&title=Emerging+and+Re-Emerging+Warheads+for+Targeted+Covalent+Inhibitors%3A+Applications+in+Medicinal+Chemistry+and+Chemical+Biology&doi=10.1021%2Facs.jmedchem.8b01153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology</span></div><div class="casAuthors">Gehringer, Matthias; Laufer, Stefan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5673-5724</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Targeted covalent inhibitors (TCIs) are designed to bind poorly conserved amino acids by means of reactive groups, the so-called warheads.  Currently, targeting noncatalytic cysteine residues with acrylamides and other α,β-unsatd. carbonyl compds. is the predominant strategy in TCI development.  The recent ascent of covalent drugs has stimulated considerable efforts to characterize alternative warheads for the covalent-reversible and irreversible engagement of noncatalytic cysteine residues as well as other amino acids.  This Perspective article provides an overview of warheads-beyond α,β-unsatd. amides-recently used in the design of targeted covalent ligands.  Promising reactive groups that have not yet demonstrated their utility in TCI development are also highlighted.  Special emphasis is placed on the discussion of reactivity and of case studies illustrating applications in medicinal chem. and chem. biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDhc4PWV293LVg90H21EOLACvtfcHk0liUwnLe4Ja_SQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFKiur%252FL&md5=4623733558ff99aadebfc13950b816ad</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01153%26sid%3Dliteratum%253Aachs%26aulast%3DGehringer%26aufirst%3DM.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26atitle%3DEmerging%2520and%2520Re-Emerging%2520Warheads%2520for%2520Targeted%2520Covalent%2520Inhibitors%253A%2520Applications%2520in%2520Medicinal%2520Chemistry%2520and%2520Chemical%2520Biology%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D12%26spage%3D5673%26epage%3D5724%26doi%3D10.1021%2Facs.jmedchem.8b01153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adams, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niccoli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chowdhury, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esarik, A. N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lees, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rempel, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phenix, C. P.</span></span> <span> </span><span class="NLM_article-title">N-Alkylated Aziridines Are Easily-Prepared, Potent, Specific and Cell-Permeable Covalent Inhibitors of Human β-Glucocerebrosidase</span>. <i>Chem. Commun. (Cambridge, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">57</span>),  <span class="NLM_fpage">11390</span>– <span class="NLM_lpage">11393</span>, <span class="refDoi"> DOI: 10.1039/C5CC03828F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1039%2FC5CC03828F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=26085065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVCmu7nI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2015&pages=11390-11393&issue=57&author=B.+T.+Adamsauthor=S.+Niccoliauthor=M.+A.+Chowdhuryauthor=A.+N.+K.+Esarikauthor=S.+J.+Leesauthor=B.+P.+Rempelauthor=C.+P.+Phenix&title=N-Alkylated+Aziridines+Are+Easily-Prepared%2C+Potent%2C+Specific+and+Cell-Permeable+Covalent+Inhibitors+of+Human+%CE%B2-Glucocerebrosidase&doi=10.1039%2FC5CC03828F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">N-Alkylated aziridines are easily-prepared, potent, specific and cell-permeable covalent inhibitors of human β-glucocerebrosidase</span></div><div class="casAuthors">Adams, B. T.; Niccoli, S.; Chowdhury, M. A.; Esarik, A. N. K.; Lees, S. J.; Rempel, B. P.; Phenix, C. P.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">57</span>),
    <span class="NLM_cas:pages">11390-11393</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">β-Glucocerebrosidase deficiency leads to Gaucher disease and is a potential marker of Parkinson's disease.  The authors have identified N-octyl conduritol aziridine as a potent and specific covalent inactivator of GBA1 in living cells.  This compd. is a promising lead towards a positron emission tomog. probe intended to image GBA1 activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmhETyb_KKSrVg90H21EOLACvtfcHk0ljC9fmkjwE_Ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVCmu7nI&md5=c5f088dbe0d16ac976f5070113e6f74b</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1039%2FC5CC03828F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5CC03828F%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DB.%2BT.%26aulast%3DNiccoli%26aufirst%3DS.%26aulast%3DChowdhury%26aufirst%3DM.%2BA.%26aulast%3DEsarik%26aufirst%3DA.%2BN.%2BK.%26aulast%3DLees%26aufirst%3DS.%2BJ.%26aulast%3DRempel%26aufirst%3DB.%2BP.%26aulast%3DPhenix%26aufirst%3DC.%2BP.%26atitle%3DN-Alkylated%2520Aziridines%2520Are%2520Easily-Prepared%252C%2520Potent%252C%2520Specific%2520and%2520Cell-Permeable%2520Covalent%2520Inhibitors%2520of%2520Human%2520%25CE%25B2-Glucocerebrosidase%26jtitle%3DChem.%2520Commun.%2520%2528Cambridge%252C%2520U.%2520K.%2529%26date%3D2015%26volume%3D51%26issue%3D57%26spage%3D11390%26epage%3D11393%26doi%3D10.1039%2FC5CC03828F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fernández, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Testero, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vendrell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avilés, F. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mobashery, S.</span></span> <span> </span><span class="NLM_article-title">The X-Ray Structure of Carboxypeptidase A Inhibited by a Thiirane Mechanism-Based Inhibitor</span>. <i>Chem. Biol. Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>75</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1111/j.1747-0285.2009.00907.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1111%2Fj.1747-0285.2009.00907.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=19895506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1WhsbfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2010&pages=29-34&issue=1&author=D.+Fern%C3%A1ndezauthor=S.+Testeroauthor=J.+Vendrellauthor=F.+X.+Avil%C3%A9sauthor=S.+Mobashery&title=The+X-Ray+Structure+of+Carboxypeptidase+A+Inhibited+by+a+Thiirane+Mechanism-Based+Inhibitor&doi=10.1111%2Fj.1747-0285.2009.00907.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">The X-ray structure of carboxypeptidase A inhibited by a thiirane mechanism-based inhibitor</span></div><div class="casAuthors">Fernandez, Daniel; Testero, Sebastian; Vendrell, Josep; Aviles, Francesc X.; Mobashery, Shahriar</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-34</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The three-dimensional x-ray crystal structure of carboxypeptidase A, a zinc-dependent hydrolase, covalently modified by a mechanism-based thiirane inactivator, 2-benzyl-3,4-epithiobutanoic acid, has been solved to 1.38 Å resoln.  The interaction of the thiirane moiety of the inhibitor with the active site zinc ion promotes its covalent modification of Glu 270 with the attendant opening of the thiirane ring.  The crystal structure detn. at high resoln. allowed for the clear visualization of the covalent ester bond to the glutamate side chain.  The newly generated thiol from the inhibitor binds to the catalytic zinc ion in a monodentate manner, inducing a change in the zinc ion geometry and coordination, while its benzyl group fits into the S1' specificity pocket of the enzyme.  The inhibitor mol. is distorted at the position of the carbon atom that is involved in the ester bond linkage on one side and the zinc coordination on the other.  This particular type of thiirane-based metalloprotease inhibitor is for the first time analyzed in complex to the target protease at high resoln. and may be used as a general model for zinc-dependent proteases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpf9jy2XAHRg7Vg90H21EOLACvtfcHk0ljC9fmkjwE_Ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1WhsbfI&md5=d96fae82f80848419cce9f0989bc7a54</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2009.00907.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2009.00907.x%26sid%3Dliteratum%253Aachs%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DD.%26aulast%3DTestero%26aufirst%3DS.%26aulast%3DVendrell%26aufirst%3DJ.%26aulast%3DAvil%25C3%25A9s%26aufirst%3DF.%2BX.%26aulast%3DMobashery%26aufirst%3DS.%26atitle%3DThe%2520X-Ray%2520Structure%2520of%2520Carboxypeptidase%2520A%2520Inhibited%2520by%2520a%2520Thiirane%2520Mechanism-Based%2520Inhibitor%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2010%26volume%3D75%26issue%3D1%26spage%3D29%26epage%3D34%26doi%3D10.1111%2Fj.1747-0285.2009.00907.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Forbes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hesek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llarrull, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gossing, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mobashery, S.</span></span> <span> </span><span class="NLM_article-title">Active Site Ring-Opening of a Thiirane Moiety and Picomolar Inhibition of Gelatinases</span>. <i>Chem. Biol. Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>74</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">527</span>– <span class="NLM_lpage">534</span>, <span class="refDoi"> DOI: 10.1111/j.1747-0285.2009.00881.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1111%2Fj.1747-0285.2009.00881.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=19807733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVGku7nF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2009&pages=527-534&issue=6&author=C.+Forbesauthor=Q.+Shiauthor=J.+F.+Fisherauthor=M.+Leeauthor=D.+Hesekauthor=L.+I.+Llarrullauthor=M.+Tothauthor=M.+Gossingauthor=R.+Fridmanauthor=S.+Mobashery&title=Active+Site+Ring-Opening+of+a+Thiirane+Moiety+and+Picomolar+Inhibition+of+Gelatinases&doi=10.1111%2Fj.1747-0285.2009.00881.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Active site ring-opening of a thiirane moiety and picomolar inhibition of gelatinases</span></div><div class="casAuthors">Forbes, Christopher; Shi, Qicun; Fisher, Jed F.; Lee, Mijoon; Hesek, Dusan; Llarrull, Leticia I.; Toth, Marta; Gossing, Michael; Fridman, Rafael; Mobashery, Shahriar</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">527-534</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">(±)-2-[(4-Phenoxyphenylsulfonyl)methyl]thiirane (1) is a potent and selective mechanism-based inhibitor of the gelatinase sub-class of the zinc-dependent matrix metalloproteinase family.  Inhibitor 1 has excellent activity in in vivo models of gelatinase-dependent disease.  We demonstrate that the mechanism of inhibition is a rate-limiting gelatinase-catalyzed thiolate generation via deprotonation adjacent to the thiirane, with concomitant thiirane opening.  A corollary to this mechanism is the prediction that thiol-contg. structures, related to thiirane-opened 1, will possess potent matrix metalloproteinase inhibitory activity.  This prediction was validated by the synthesis of the product of this enzyme-catalyzed reaction on 1, which exhibited a remarkable Ki of 530 pM against matrix metalloproteinase-2.  Thiirane 1 acts as a caged thiol, unmasked selectively in the active sites of gelatinases.  This mechanism is unprecedented in the substantial literature on inhibition of zinc-dependent hydrolases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj4TF4L9ayFLVg90H21EOLACvtfcHk0ljC9fmkjwE_Ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVGku7nF&md5=11ec87b9c4ddd1627d67bf5fb4e43362</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2009.00881.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2009.00881.x%26sid%3Dliteratum%253Aachs%26aulast%3DForbes%26aufirst%3DC.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DFisher%26aufirst%3DJ.%2BF.%26aulast%3DLee%26aufirst%3DM.%26aulast%3DHesek%26aufirst%3DD.%26aulast%3DLlarrull%26aufirst%3DL.%2BI.%26aulast%3DToth%26aufirst%3DM.%26aulast%3DGossing%26aufirst%3DM.%26aulast%3DFridman%26aufirst%3DR.%26aulast%3DMobashery%26aufirst%3DS.%26atitle%3DActive%2520Site%2520Ring-Opening%2520of%2520a%2520Thiirane%2520Moiety%2520and%2520Picomolar%2520Inhibition%2520of%2520Gelatinases%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2009%26volume%3D74%26issue%3D6%26spage%3D527%26epage%3D534%26doi%3D10.1111%2Fj.1747-0285.2009.00881.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evans, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saghatelian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorensen, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">Target Discovery in Small-Molecule Cell-Based Screens by in Situ Proteome Reactivity Profiling</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1303</span>– <span class="NLM_lpage">1307</span>, <span class="refDoi"> DOI: 10.1038/nbt1149</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1038%2Fnbt1149" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=16200062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVOhu7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=1303-1307&issue=10&author=M.+J.+Evansauthor=A.+Saghatelianauthor=E.+J.+Sorensenauthor=B.+F.+Cravatt&title=Target+Discovery+in+Small-Molecule+Cell-Based+Screens+by+in+Situ+Proteome+Reactivity+Profiling&doi=10.1038%2Fnbt1149"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Target discovery in small-molecule cell-based screens by in situ proteome reactivity profiling</span></div><div class="casAuthors">Evans, Michael J.; Saghatelian, Alan; Sorensen, Erik J.; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1303-1307</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Chem. genomics aims to discover small mols. that affect biol. processes through the perturbation of protein function.  However, detg. the protein targets of bioactive compds. remains a formidable challenge.  The authors address this problem here through the creation of a natural product-inspired small-mol. library bearing protein-reactive elements.  Cell-based screening identified a compd., MJE3 (I), that inhibits breast cancer cell proliferation.  In situ proteome reactivity profiling revealed that MJE3, but not other library members, covalently labeled the glycolytic enzyme phosphoglycerate mutase 1 (PGAM1), resulting in enzyme inhibition.  Interestingly, MJE3 labeling and inhibition of PGAM1 were obsd. exclusively in intact cells.  These results support the hypothesis that cancer cells depend on glycolysis for viability and promote PGAM1 as a potential therapeutic target.  More generally, the incorporation of protein-reactive compds. into chem. genomics screens offers a means to discover targets of bioactive small mols. in living systems, thereby enabling downstream mechanistic investigations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo42WGtb4x11bVg90H21EOLACvtfcHk0liK_YQhU7vuSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVOhu7nP&md5=1fc3d093fe8c7c7ccd7d610f10df105c</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1038%2Fnbt1149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1149%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DM.%2BJ.%26aulast%3DSaghatelian%26aufirst%3DA.%26aulast%3DSorensen%26aufirst%3DE.%2BJ.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DTarget%2520Discovery%2520in%2520Small-Molecule%2520Cell-Based%2520Screens%2520by%2520in%2520Situ%2520Proteome%2520Reactivity%2520Profiling%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26issue%3D10%26spage%3D1303%26epage%3D1307%26doi%3D10.1038%2Fnbt1149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schröder, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kallemeijn, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debets, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobala, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hakki, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beenakker, T. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aerts, J. M. F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Marel, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Codée, J. D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H. S.</span></span> <span> </span><span class="NLM_article-title">Spiro-Epoxyglycosides as Activity-Based Probes for Glycoside Hydrolase Family 99 Endomannosidase/Endomannanase</span>. <i>Chem. - Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">39</span>),  <span class="NLM_fpage">9983</span>– <span class="NLM_lpage">9992</span>, <span class="refDoi"> DOI: 10.1002/chem.201801902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1002%2Fchem.201801902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=29797675" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=9983-9992&issue=39&author=S.+P.+Schr%C3%B6derauthor=W.+W.+Kallemeijnauthor=M.+F.+Debetsauthor=T.+Hansenauthor=L.+F.+Sobalaauthor=Z.+Hakkiauthor=S.+J.+Williamsauthor=T.+J.+M.+Beenakkerauthor=J.+M.+F.+G.+Aertsauthor=G.+A.+van+der+Marelauthor=J.+D.+C.+Cod%C3%A9eauthor=G.+J.+Daviesauthor=H.+S.+Overkleeft&title=Spiro-Epoxyglycosides+as+Activity-Based+Probes+for+Glycoside+Hydrolase+Family+99+Endomannosidase%2FEndomannanase&doi=10.1002%2Fchem.201801902"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1002%2Fchem.201801902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201801902%26sid%3Dliteratum%253Aachs%26aulast%3DSchr%25C3%25B6der%26aufirst%3DS.%2BP.%26aulast%3DKallemeijn%26aufirst%3DW.%2BW.%26aulast%3DDebets%26aufirst%3DM.%2BF.%26aulast%3DHansen%26aufirst%3DT.%26aulast%3DSobala%26aufirst%3DL.%2BF.%26aulast%3DHakki%26aufirst%3DZ.%26aulast%3DWilliams%26aufirst%3DS.%2BJ.%26aulast%3DBeenakker%26aufirst%3DT.%2BJ.%2BM.%26aulast%3DAerts%26aufirst%3DJ.%2BM.%2BF.%2BG.%26aulast%3Dvan%2Bder%2BMarel%26aufirst%3DG.%2BA.%26aulast%3DCod%25C3%25A9e%26aufirst%3DJ.%2BD.%2BC.%26aulast%3DDavies%26aufirst%3DG.%2BJ.%26aulast%3DOverkleeft%26aufirst%3DH.%2BS.%26atitle%3DSpiro-Epoxyglycosides%2520as%2520Activity-Based%2520Probes%2520for%2520Glycoside%2520Hydrolase%2520Family%252099%2520Endomannosidase%252FEndomannanase%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D2018%26volume%3D24%26issue%3D39%26spage%3D9983%26epage%3D9992%26doi%3D10.1002%2Fchem.201801902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morgen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jöst, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janowski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niessing, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunkel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, A. K.</span></span> <span> </span><span class="NLM_article-title">Spiroepoxytriazoles Are Fumagillin-like Irreversible Inhibitors of MetAP2 with Potent Cellular Activity</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1001</span>– <span class="NLM_lpage">1011</span>, <span class="refDoi"> DOI: 10.1021/acschembio.5b00755</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.5b00755" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVGitbvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=1001-1011&issue=4&author=M.+Morgenauthor=C.+J%C3%B6stauthor=M.+Malzauthor=R.+Janowskiauthor=D.+Niessingauthor=C.+D.+Kleinauthor=N.+Gunkelauthor=A.+K.+Miller&title=Spiroepoxytriazoles+Are+Fumagillin-like+Irreversible+Inhibitors+of+MetAP2+with+Potent+Cellular+Activity&doi=10.1021%2Facschembio.5b00755"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Spiroepoxytriazoles Are Fumagillin-like Irreversible Inhibitors of MetAP2 with Potent Cellular Activity</span></div><div class="casAuthors">Morgen, Michael; Joest, Christian; Malz, Mona; Janowski, Robert; Niessing, Dierk; Klein, Christian D.; Gunkel, Nikolas; Miller, Aubry K.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1001-1011</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Methionine aminopeptidases (MetAPs) are responsible for the cotranslational cleavage of initiator methionines from nascent proteins.  The MetAP2 subtype is up-regulated in many cancers, and selective inhibition of MetAP2 suppresses both vascularization and growth of tumors in animal models.  The natural product fumagillin is a selective and potent irreversible inhibitor of MetAP2, and semisynthetic derivs. of fumagillin have shown promise in clin. studies for the treatment of cancer, and, more recently, for obesity.  Further development of fumagillin derivs. has been complicated, however, by their generally poor pharmacokinetics.  In an attempt to overcome these limitations, we developed an easily diversifiable synthesis of a novel class of MetAP2 inhibitors that were designed to mimic fumagillin's mol. scaffold but have improved pharmacol. profiles.  These substances were found to be potent and selective inhibitors of MetAP2, as demonstrated in biochem. enzymic assays against three MetAP isoforms.  Inhibitors with the same relative and abs. stereoconfiguration as fumagillin displayed significantly higher activity than their diastereomeric and enantiomeric isomers.  X-ray crystallog. anal. revealed that the inhibitors covalently modify His231 in the MetAP2 active site via ring-opening of a spiroepoxide.  Biochem. active substances inhibited the growth of endothelial cells and a MetAP2-sensitive cancer cell line, while closely related inactive isomers had little effect on the proliferation of either cell type.  These effects correlated with altered N-terminal processing of the protein 14-3-3-γ.  Finally, selected substances were found to have improved stabilities in mouse plasma and microsomes relative to the clin. investigated fumagillin deriv. beloranib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0EkuP-YaxhrVg90H21EOLACvtfcHk0liK_YQhU7vuSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVGitbvO&md5=f83da1a8a3c4717b16cd0e90cc05f8a8</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1021%2Facschembio.5b00755&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.5b00755%26sid%3Dliteratum%253Aachs%26aulast%3DMorgen%26aufirst%3DM.%26aulast%3DJ%25C3%25B6st%26aufirst%3DC.%26aulast%3DMalz%26aufirst%3DM.%26aulast%3DJanowski%26aufirst%3DR.%26aulast%3DNiessing%26aufirst%3DD.%26aulast%3DKlein%26aufirst%3DC.%2BD.%26aulast%3DGunkel%26aufirst%3DN.%26aulast%3DMiller%26aufirst%3DA.%2BK.%26atitle%3DSpiroepoxytriazoles%2520Are%2520Fumagillin-like%2520Irreversible%2520Inhibitors%2520of%2520MetAP2%2520with%2520Potent%2520Cellular%2520Activity%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2016%26volume%3D11%26issue%3D4%26spage%3D1001%26epage%3D1011%26doi%3D10.1021%2Facschembio.5b00755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martyloga, O. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myronenko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tkachenko, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matvienko, V. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuchkovska, Y. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grygorenko, O. O.</span></span> <span> </span><span class="NLM_article-title">Multigram Synthesis of Functionalized Spirocyclic Diazirines</span>. <i>Eur. J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>2019</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">3744</span>– <span class="NLM_lpage">3750</span>, <span class="refDoi"> DOI: 10.1002/ejoc.201900485</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1002%2Fejoc.201900485" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1Wmt73E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2019&publication_year=2019&pages=3744-3750&issue=23&author=O.+V.+Martylogaauthor=A.+Myronenkoauthor=A.+M.+Tkachenkoauthor=V.+O.+Matvienkoauthor=Y.+O.+Kuchkovskaauthor=O.+O.+Grygorenko&title=Multigram+Synthesis+of+Functionalized+Spirocyclic+Diazirines&doi=10.1002%2Fejoc.201900485"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Multigram Synthesis of Functionalized Spirocyclic Diazirines</span></div><div class="casAuthors">Martyloga, Oleksandr V.; Myronenko, Artamon; Tkachenko, Anton M.; Matvienko, Vitalii O.; Kuchkovska, Yuliya O.; Grygorenko, Oleksandr O.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">2019</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3744-3750</span>CODEN:
                <span class="NLM_cas:coden">EJOCFK</span>;
        ISSN:<span class="NLM_cas:issn">1099-0690</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">An approach to the synthesis of spirocyclic diazirines, e.g., I from cyclic ketones, e.g., tert-Bu 2-oxo-7-azabicyclo[2.2.1]heptane-7-carboxylate was examd. on a series of carbo- and heterocyclic substrates contg. amine or carboxylic acid moiety.  A mini-library of stereochem. diverse functionalized spirocyclic diazirines was synthesized on a multigram scale with 30-81% yield.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6l0uxcUo6C7Vg90H21EOLACvtfcHk0lgADJfqgwgxwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1Wmt73E&md5=8f8c7449e7dfc0107c76754ff978b21f</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1002%2Fejoc.201900485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.201900485%26sid%3Dliteratum%253Aachs%26aulast%3DMartyloga%26aufirst%3DO.%2BV.%26aulast%3DMyronenko%26aufirst%3DA.%26aulast%3DTkachenko%26aufirst%3DA.%2BM.%26aulast%3DMatvienko%26aufirst%3DV.%2BO.%26aulast%3DKuchkovska%26aufirst%3DY.%2BO.%26aulast%3DGrygorenko%26aufirst%3DO.%2BO.%26atitle%3DMultigram%2520Synthesis%2520of%2520Functionalized%2520Spirocyclic%2520Diazirines%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2019%26volume%3D2019%26issue%3D23%26spage%3D3744%26epage%3D3750%26doi%3D10.1002%2Fejoc.201900485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohgami, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugii, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curphey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, T.-Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Biochemical Properties of a New Photoactivatable Cholesterol Analog 7,7-Azocholestanol and Its Linoleate Ester in Chinese Hamster Ovary Cell Lines</span>. <i>J. Lipid Res.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>43</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1341</span>– <span class="NLM_lpage">1347</span>, <span class="refDoi"> DOI: 10.1194/jlr.M200015-JLR200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1194%2Fjlr.M200015-JLR200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=12177179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BD38XntFWktb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2002&pages=1341-1347&issue=8&author=J.+C.+Cruzauthor=M.+Thomasauthor=E.+Wongauthor=N.+Ohgamiauthor=S.+Sugiiauthor=T.+Curpheyauthor=C.+C.+Y.+Changauthor=T.-Y.+Chang&title=Synthesis+and+Biochemical+Properties+of+a+New+Photoactivatable+Cholesterol+Analog+7%2C7-Azocholestanol+and+Its+Linoleate+Ester+in+Chinese+Hamster+Ovary+Cell+Lines&doi=10.1194%2Fjlr.M200015-JLR200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biochemical properties of a new photoactivatable cholesterol analog 7,7-azocholestanol and its linoleate ester in Chinese hamster ovary cell lines</span></div><div class="casAuthors">Cruz, Jonathan C.; Thomas, Matthew; Wong, Edmund; Ohgami, Nobutaka; Sugii, Shigeki; Curphey, Thomas; Chang, Catherine C. Y.; Chang, Ta-Yuan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Lipid Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1341-1347</span>CODEN:
                <span class="NLM_cas:coden">JLPRAW</span>;
        ISSN:<span class="NLM_cas:issn">0022-2275</span>.
    
            (<span class="NLM_cas:orgname">Lipid Research, Inc.</span>)
        </div><div class="casAbstract">We report the chem. synthesis of a new photoactivatable cholesterol analog 7,7-azocholestanol (AC) and its linoleate ester (ACL).  We also examd. the biochem. properties of the sterol and its ester by employing several different mutant Chinese hamster ovary (CHO) cell lines with defined abnormalities in cholesterol metab. as tools.  AC mimics cholesterol in supporting the growth of a mutant cell line (M19) that requires cholesterol for growth.  In normal cells, tritiated ACL present in low-d. lipoprotein (LDL) was hydrolyzed and reesterified in a manner similar to tritiated cholesteryl linoleate (CL) in LDL.  Also, in the mutant cell line (AC29) lacking the enzyme acyl-CoA:cholesterol acyltransferase or in the mutant cell line (CT60) defective in the Niemann-Pick type C1 protein, the hydrolysis of ACL in LDL was normal, but the reesterification of the liberated AC was defective.  Therefore, the metab. of ACL in LDL is very similar to that of CL in LDL.  Tritium-labeled AC delivered to intact CHO cells as a cyclodextrin complex was shown to photoaffinity label several discrete polypeptides, including caveolin-1.  These results demonstrate AC as an effective reagent for studying cholesterol-protein interactions involved in intracellular cholesterol trafficking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVO0Op3StP2LVg90H21EOLACvtfcHk0lgADJfqgwgxwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XntFWktb4%253D&md5=17671a1d29ca9eaf699fba7db02a34d0</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1194%2Fjlr.M200015-JLR200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1194%252Fjlr.M200015-JLR200%26sid%3Dliteratum%253Aachs%26aulast%3DCruz%26aufirst%3DJ.%2BC.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DE.%26aulast%3DOhgami%26aufirst%3DN.%26aulast%3DSugii%26aufirst%3DS.%26aulast%3DCurphey%26aufirst%3DT.%26aulast%3DChang%26aufirst%3DC.%2BC.%2BY.%26aulast%3DChang%26aufirst%3DT.-Y.%26atitle%3DSynthesis%2520and%2520Biochemical%2520Properties%2520of%2520a%2520New%2520Photoactivatable%2520Cholesterol%2520Analog%25207%252C7-Azocholestanol%2520and%2520Its%2520Linoleate%2520Ester%2520in%2520Chinese%2520Hamster%2520Ovary%2520Cell%2520Lines%26jtitle%3DJ.%2520Lipid%2520Res.%26date%3D2002%26volume%3D43%26issue%3D8%26spage%3D1341%26epage%3D1347%26doi%3D10.1194%2Fjlr.M200015-JLR200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramdas, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talwar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walke, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borhade, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhayagude, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loriya, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gote, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bommakanti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivaram, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goswami, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nigade, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallurwar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dash, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuldharan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narasimham, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gundu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamboj, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palle, V. P.</span></span> <span> </span><span class="NLM_article-title">Discovery and Characterization of Potent Pan-Genotypic HCV NS5A Inhibitors Containing Novel Tricyclic Central Core Leading to Clinical Candidate</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">10563</span>– <span class="NLM_lpage">10582</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01562</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01562" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFeqsr%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=10563-10582&issue=23&author=V.+Ramdasauthor=R.+Talwarauthor=M.+Banerjeeauthor=A.+A.+Joshiauthor=A.+K.+Dasauthor=D.+S.+Walkeauthor=P.+Borhadeauthor=U.+Dhayagudeauthor=R.+Loriyaauthor=G.+Goteauthor=A.+Bommakantiauthor=A.+Sivaramauthor=G.+Agarwalauthor=A.+Goswamiauthor=P.+Nigadeauthor=M.+Mehtaauthor=V.+Patilauthor=D.+Modiauthor=H.+Kumarauthor=S.+Mallurwarauthor=A.+Dashauthor=F.+Modiauthor=S.+Kuldharanauthor=P.+Srivastavaauthor=M.+Singhauthor=L.+Narasimhamauthor=J.+Gunduauthor=S.+Sharmaauthor=R.+K.+Kambojauthor=V.+P.+Palle&title=Discovery+and+Characterization+of+Potent+Pan-Genotypic+HCV+NS5A+Inhibitors+Containing+Novel+Tricyclic+Central+Core+Leading+to+Clinical+Candidate&doi=10.1021%2Facs.jmedchem.9b01562"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Characterization of Potent Pan-Genotypic HCV NS5A Inhibitors Containing Novel Tricyclic Central Core Leading to Clinical Candidate</span></div><div class="casAuthors">Ramdas, Vidya; Talwar, Rashmi; Banerjee, Moloy; Joshi, Advait Arun; Das, Amit Kumar; Walke, Deepak Sahebrao; Borhade, Prashant; Dhayagude, Usha; Loriya, Rajesh; Gote, Ganesh; Bommakanti, Apparao; Sivaram, Aruna; Agarwal, Gautam; Goswami, Arnab; Nigade, Prashant; Mehta, Maneesh; Patil, Vinod; Modi, Dipak; Kumar, Hemant; Mallurwar, Sadanand; Dash, Amruta; Modi, Falguni; Kuldharan, Sandip; Srivastava, Pratima; Singh, Minakshi; Narasimham, Lakshmi; Gundu, Jayasagar; Sharma, Sharad; Kamboj, Rajender Kumar; Palle, Venkata P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10563-10582</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Identification of a novel class of potent pan-genotypic NS5A inhibitors with good pharmacokinetic profile suitable for potential use in treating HCV infections are disclosed here.  Present series of compds. are with less complex tricyclic central core, identified through a systematic SAR study carried out on biphenyl moiety.  The SAR outcome has confirmed the requirement of near planar and linear conformation of the mol. to achieve the best pan-genotypic activity.  In addn., SAR with substituted imidazoles on improvement of antiviral activity is disclosed.  The newly identified compds. 12, 16, 19-21 have shown desirable pharmacokinetic profile with a favorable uptake of compds. in liver and maintained a significant concn. for up to 8 h in the liver.  In addn., compds. 20 and 21 have shown superior pan-genotypic anti-HCV activity compared to ledipasvir and daclatasvir.  Addnl. characterization and preliminary safety assessment resulted in identification of compd. 20 as a potential clin. candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonkEOeBLBCurVg90H21EOLACvtfcHk0lhvMRyAC4USTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFeqsr%252FK&md5=be4b419bf7d32cd7d52cc414da0255e3</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01562%26sid%3Dliteratum%253Aachs%26aulast%3DRamdas%26aufirst%3DV.%26aulast%3DTalwar%26aufirst%3DR.%26aulast%3DBanerjee%26aufirst%3DM.%26aulast%3DJoshi%26aufirst%3DA.%2BA.%26aulast%3DDas%26aufirst%3DA.%2BK.%26aulast%3DWalke%26aufirst%3DD.%2BS.%26aulast%3DBorhade%26aufirst%3DP.%26aulast%3DDhayagude%26aufirst%3DU.%26aulast%3DLoriya%26aufirst%3DR.%26aulast%3DGote%26aufirst%3DG.%26aulast%3DBommakanti%26aufirst%3DA.%26aulast%3DSivaram%26aufirst%3DA.%26aulast%3DAgarwal%26aufirst%3DG.%26aulast%3DGoswami%26aufirst%3DA.%26aulast%3DNigade%26aufirst%3DP.%26aulast%3DMehta%26aufirst%3DM.%26aulast%3DPatil%26aufirst%3DV.%26aulast%3DModi%26aufirst%3DD.%26aulast%3DKumar%26aufirst%3DH.%26aulast%3DMallurwar%26aufirst%3DS.%26aulast%3DDash%26aufirst%3DA.%26aulast%3DModi%26aufirst%3DF.%26aulast%3DKuldharan%26aufirst%3DS.%26aulast%3DSrivastava%26aufirst%3DP.%26aulast%3DSingh%26aufirst%3DM.%26aulast%3DNarasimham%26aufirst%3DL.%26aulast%3DGundu%26aufirst%3DJ.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DKamboj%26aufirst%3DR.%2BK.%26aulast%3DPalle%26aufirst%3DV.%2BP.%26atitle%3DDiscovery%2520and%2520Characterization%2520of%2520Potent%2520Pan-Genotypic%2520HCV%2520NS5A%2520Inhibitors%2520Containing%2520Novel%2520Tricyclic%2520Central%2520Core%2520Leading%2520to%2520Clinical%2520Candidate%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D23%26spage%3D10563%26epage%3D10582%26doi%3D10.1021%2Facs.jmedchem.9b01562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasgar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danchik, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baljinnyam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheff, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lal-Nag, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunford, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oppermann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasiliou, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeonov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jadhav, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, D. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of Orally Bioavailable, Quinoline-Based Aldehyde Dehydrogenase 1A1 (ALDH1A1) Inhibitors with Potent Cellular Activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">4883</span>– <span class="NLM_lpage">4903</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00270</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00270" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1cXps12msL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4883-4903&issue=11&author=S.-M.+Yangauthor=N.+J.+Martinezauthor=A.+Yasgarauthor=C.+Danchikauthor=C.+Johanssonauthor=Y.+Wangauthor=B.+Baljinnyamauthor=A.+Q.+Wangauthor=X.+Xuauthor=P.+Shahauthor=D.+Cheffauthor=X.+S.+Wangauthor=J.+Rothauthor=M.+Lal-Nagauthor=J.+E.+Dunfordauthor=U.+Oppermannauthor=V.+Vasiliouauthor=A.+Simeonovauthor=A.+Jadhavauthor=D.+J.+Maloney&title=Discovery+of+Orally+Bioavailable%2C+Quinoline-Based+Aldehyde+Dehydrogenase+1A1+%28ALDH1A1%29+Inhibitors+with+Potent+Cellular+Activity&doi=10.1021%2Facs.jmedchem.8b00270"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Orally Bioavailable, Quinoline-Based Aldehyde Dehydrogenase 1A1 (ALDH1A1) Inhibitors with Potent Cellular Activity</span></div><div class="casAuthors">Yang, Shyh-Ming; Martinez, Natalia J.; Yasgar, Adam; Danchik, Carina; Johansson, Catrine; Wang, Yuhong; Baljinnyam, Bolormaa; Wang, Amy Q.; Xu, Xin; Shah, Pranav; Cheff, Dorian; Wang, Xinran S.; Roth, Jacob; Lal-Nag, Madhu; Dunford, James E.; Oppermann, Udo; Vasiliou, Vasilis; Simeonov, Anton; Jadhav, Ajit; Maloney, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4883-4903</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aldehyde dehydrogenases (ALDHs) are responsible for the metab. of aldehydes (exogenous and endogenous) and possess vital physiol. and toxicol. functions in areas such as CNS, inflammation, metabolic disorders, and cancers.  Overexpression of certain ALDHs (e.g., ALDH1A1) is an important biomarker in cancers and cancer stem cells (CSCs) indicating the potential need for the identification and development of small mol. ALDH inhibitors.  Herein, a newly designed series of quinoline-based analogs of ALDH1A1 inhibitors is described.  Extensive medicinal chem. optimization and biol. characterization led to the identification of analogs with significantly improved enzymic and cellular ALDH inhibition.  Selected analogs, e.g., 86 (NCT-505) and 91 (NCT-506), demonstrated target engagement in a cellular thermal shift assay (CETSA), inhibited the formation of 3D spheroid cultures of OV-90 cancer cells, and potentiated the cytotoxicity of paclitaxel in SKOV-3-TR, a paclitaxel resistant ovarian cancer cell line.  Lead compds. also exhibit high specificity over other ALDH isoenzymes and unrelated dehydrogenases.  The in vitro ADME profiles and pharmacokinetic evaluation of selected analogs are also highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMdOrSgvA10rVg90H21EOLACvtfcHk0lhvMRyAC4USTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXps12msL8%253D&md5=6f63e6c9803cb8f0e113fb1f81bebf8a</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00270%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DS.-M.%26aulast%3DMartinez%26aufirst%3DN.%2BJ.%26aulast%3DYasgar%26aufirst%3DA.%26aulast%3DDanchik%26aufirst%3DC.%26aulast%3DJohansson%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DBaljinnyam%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DA.%2BQ.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DShah%26aufirst%3DP.%26aulast%3DCheff%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DX.%2BS.%26aulast%3DRoth%26aufirst%3DJ.%26aulast%3DLal-Nag%26aufirst%3DM.%26aulast%3DDunford%26aufirst%3DJ.%2BE.%26aulast%3DOppermann%26aufirst%3DU.%26aulast%3DVasiliou%26aufirst%3DV.%26aulast%3DSimeonov%26aufirst%3DA.%26aulast%3DJadhav%26aufirst%3DA.%26aulast%3DMaloney%26aufirst%3DD.%2BJ.%26atitle%3DDiscovery%2520of%2520Orally%2520Bioavailable%252C%2520Quinoline-Based%2520Aldehyde%2520Dehydrogenase%25201A1%2520%2528ALDH1A1%2529%2520Inhibitors%2520with%2520Potent%2520Cellular%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D11%26spage%3D4883%26epage%3D4903%26doi%3D10.1021%2Facs.jmedchem.8b00270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naidu, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorenson, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matiskella, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dicker, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terry, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higley, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">The Discovery and Preclinical Evaluation of BMS-707035, a Potent HIV-1 Integrase Strand Transfer Inhibitor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2124</span>– <span class="NLM_lpage">2130</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.05.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2Fj.bmcl.2018.05.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=29779976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpvVKjur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=2124-2130&issue=12&author=B.+N.+Naiduauthor=M.+A.+Walkerauthor=M.+E.+Sorensonauthor=Y.+Uedaauthor=J.+D.+Matiskellaauthor=T.+P.+Connollyauthor=I.+B.+Dickerauthor=Z.+Linauthor=S.+Bolliniauthor=B.+J.+Terryauthor=H.+Higleyauthor=M.+Zhengauthor=D.+D.+Parkerauthor=D.+Wuauthor=S.+Adamsauthor=M.+R.+Krystalauthor=N.+A.+Meanwell&title=The+Discovery+and+Preclinical+Evaluation+of+BMS-707035%2C+a+Potent+HIV-1+Integrase+Strand+Transfer+Inhibitor&doi=10.1016%2Fj.bmcl.2018.05.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery and preclinical evaluation of BMS-707035, a potent HIV-1 integrase strand transfer inhibitor</span></div><div class="casAuthors">Naidu, B. Narasimhulu; Walker, Michael A.; Sorenson, Margaret E.; Ueda, Yasutsugu; Matiskella, John D.; Connolly, Timothy P.; Dicker, Ira B.; Lin, Zeyu; Bollini, Sagarika; Terry, Brian J.; Higley, Helen; Zheng, Ming; Parker, Dawn D.; Wu, Dedong; Adams, Stephen; Krystal, Mark R.; Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2124-2130</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">BMS-707035 is an HIV-1 integrase strand transfer inhibitor (INSTI) discovered by systematic optimization of N-methylpyrimidinone carboxamides guided by structure-activity relationships (SARs) and the single crystal x-ray structure of compd. 10 (I).  It was rationalized that the unexpectedly advantageous profiles of N-methylpyrimidinone carboxamides with a satd. C2-substitutent may be due, in part, to the geometric relationship between the C2-substituent and the pyrimidinone core.  The single crystal x-ray structure of 10 provided support for this reasoning and guided the design of a spirocyclic series 12 which led to discovery of the morpholino-fused pyrimidinone series 13.  Several carboxamides derived from this bicyclic scaffold displayed improved antiviral activity and pharmacokinetic profiles when compared with corresponding spirocyclic analogs.  Based on the excellent antiviral activity, preclin. profiles and acceptable in vitro and in vivo toxicity profiles, 13a (BMS-707035) was selected for advancement into phase I clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBipQIkcGe_rVg90H21EOLACvtfcHk0lhvMRyAC4USTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpvVKjur8%253D&md5=92cf04a143ca99ed7950220c91945e79</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.05.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.05.027%26sid%3Dliteratum%253Aachs%26aulast%3DNaidu%26aufirst%3DB.%2BN.%26aulast%3DWalker%26aufirst%3DM.%2BA.%26aulast%3DSorenson%26aufirst%3DM.%2BE.%26aulast%3DUeda%26aufirst%3DY.%26aulast%3DMatiskella%26aufirst%3DJ.%2BD.%26aulast%3DConnolly%26aufirst%3DT.%2BP.%26aulast%3DDicker%26aufirst%3DI.%2BB.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DBollini%26aufirst%3DS.%26aulast%3DTerry%26aufirst%3DB.%2BJ.%26aulast%3DHigley%26aufirst%3DH.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DParker%26aufirst%3DD.%2BD.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DAdams%26aufirst%3DS.%26aulast%3DKrystal%26aufirst%3DM.%2BR.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DThe%2520Discovery%2520and%2520Preclinical%2520Evaluation%2520of%2520BMS-707035%252C%2520a%2520Potent%2520HIV-1%2520Integrase%2520Strand%2520Transfer%2520Inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26issue%3D12%26spage%3D2124%26epage%3D2130%26doi%3D10.1016%2Fj.bmcl.2018.05.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Velázquez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chelliah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clasby, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neelamkavil, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soriano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatraman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chackalamannil, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, I. W.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of P2-P4 Macrocycles Containing a Unique Spirocyclic Proline: A New Class of HCV NS3/4A Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1173</span>– <span class="NLM_lpage">1178</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00321</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00321" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1yks7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=1173-1178&issue=12&author=F.+Vel%C3%A1zquezauthor=M.+Chelliahauthor=M.+Clasbyauthor=Z.+Guoauthor=J.+Howeauthor=R.+Millerauthor=S.+Neelamkavilauthor=U.+Shahauthor=A.+Sorianoauthor=Y.+Xiaauthor=S.+Venkatramanauthor=S.+Chackalamannilauthor=I.+W.+Davies&title=Design+and+Synthesis+of+P2-P4+Macrocycles+Containing+a+Unique+Spirocyclic+Proline%3A+A+New+Class+of+HCV+NS3%2F4A+Inhibitors&doi=10.1021%2Facsmedchemlett.6b00321"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of P2-P4 macrocycles containing a unique spirocyclic proline: A new class of HCV NS3/4A inhibitors</span></div><div class="casAuthors">Velazquez, Francisco; Chelliah, Mariappan; Clasby, Martin; Guo, Zhuyan; Howe, John; Miller, Randy; Neelamkavil, Santhosh; Shah, Unmesh; Soriano, Aileen; Xia, Yan; Venkatraman, Srikanth; Chackalamannil, Samuel; Davies, Ian W.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1173-1178</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new class of hepatitis C NS3/4A inhibitors was identified by introducing a novel spirocyclic proline-P2 surrogate onto the P2-P4 macrocyclic core of MK-5172 (grazoprevir).  The potency profile of new analogs showed excellent pan-genotypic activity for most compds.  The potency evaluation included the most difficult genotype 3a (EC50 values ≤10 nM) and other key genotype 1b mutants.  Mol. modeling was used to design new target compds. and rationalize our results.  A synthetic approach based on the Julia-Kocienski olefination and macrolactamization to assemble the P2-P4 macrocyclic core contg. the novel spirocyclic proline-P2 moiety is presented as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopIMrKI6Cq2bVg90H21EOLACvtfcHk0lgQdMSxsDuIzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1yks7zK&md5=e988dfb6bd402e437e0291b8458d2e1f</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00321%26sid%3Dliteratum%253Aachs%26aulast%3DVel%25C3%25A1zquez%26aufirst%3DF.%26aulast%3DChelliah%26aufirst%3DM.%26aulast%3DClasby%26aufirst%3DM.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DHowe%26aufirst%3DJ.%26aulast%3DMiller%26aufirst%3DR.%26aulast%3DNeelamkavil%26aufirst%3DS.%26aulast%3DShah%26aufirst%3DU.%26aulast%3DSoriano%26aufirst%3DA.%26aulast%3DXia%26aufirst%3DY.%26aulast%3DVenkatraman%26aufirst%3DS.%26aulast%3DChackalamannil%26aufirst%3DS.%26aulast%3DDavies%26aufirst%3DI.%2BW.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520P2-P4%2520Macrocycles%2520Containing%2520a%2520Unique%2520Spirocyclic%2520Proline%253A%2520A%2520New%2520Class%2520of%2520HCV%2520NS3%252F4A%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26issue%3D12%26spage%3D1173%26epage%3D1178%26doi%3D10.1021%2Facsmedchemlett.6b00321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rudd, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butcher, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romano, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bush, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liverton, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiFilippo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summa, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swestock, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritzen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burlein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMuzio, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gates, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHale, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahlhut, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chase, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soriano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fandozzi, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trainor, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludmerer, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCauley, J. A.</span></span> <span> </span><span class="NLM_article-title">P2-Quinazolinones and Bis-Macrocycles as New Templates for next-Generation Hepatitis C Virus NS3/4a Protease Inhibitors: Discovery of MK-2748 and MK-6325</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">727</span>– <span class="NLM_lpage">735</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201402558</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1002%2Fcmdc.201402558" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=25759009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvVShurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=727-735&issue=4&author=M.+T.+Ruddauthor=J.+W.+Butcherauthor=K.+T.+Nguyenauthor=C.+J.+McIntyreauthor=J.+J.+Romanoauthor=K.+F.+Gilbertauthor=K.+J.+Bushauthor=N.+J.+Livertonauthor=M.+K.+Hollowayauthor=S.+Harperauthor=M.+Ferraraauthor=M.+DiFilippoauthor=V.+Summaauthor=J.+Swestockauthor=J.+Fritzenauthor=S.+S.+Carrollauthor=C.+Burleinauthor=J.+M.+DiMuzioauthor=A.+Gatesauthor=D.+J.+Grahamauthor=Q.+Huangauthor=S.+McClainauthor=C.+McHaleauthor=M.+W.+Stahlhutauthor=S.+Blackauthor=R.+Chaseauthor=A.+Sorianoauthor=C.+M.+Fandozziauthor=A.+Taylorauthor=N.+Trainorauthor=D.+B.+Olsenauthor=P.+J.+Colemanauthor=S.+W.+Ludmererauthor=J.+A.+McCauley&title=P2-Quinazolinones+and+Bis-Macrocycles+as+New+Templates+for+next-Generation+Hepatitis+C+Virus+NS3%2F4a+Protease+Inhibitors%3A+Discovery+of+MK-2748+and+MK-6325&doi=10.1002%2Fcmdc.201402558"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">P2-Quinazolinones and Bis-Macrocycles as New Templates for Next-Generation Hepatitis C Virus NS3/4a Protease Inhibitors: Discovery of MK-2748 and MK-6325</span></div><div class="casAuthors">Rudd, Michael T.; Butcher, John W.; Nguyen, Kevin T.; McIntyre, Charles J.; Romano, Joseph J.; Gilbert, Kevin F.; Bush, Kimberly J.; Liverton, Nigel J.; Holloway, M. Katharine; Harper, Steven; Ferrara, Marco; DiFilippo, Marcello; Summa, Vincenzo; Swestock, John; Fritzen, Jeff; Carroll, Steven S.; Burlein, Christine; DiMuzio, Jillian M.; Gates, Adam; Graham, Donald J.; Huang, Qian; McClain, Stephanie; McHale, Carolyn; Stahlhut, Mark W.; Black, Stuart; Chase, Robert; Soriano, Aileen; Fandozzi, Christine M.; Taylor, Anne; Trainor, Nicole; Olsen, David B.; Coleman, Paul J.; Ludmerer, Steven W.; McCauley, John A.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">727-735</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">With the goal of identifying inhibitors of hepatitis C virus (HCV) NS3/4a protease that are potent against a wide range of genotypes and clin. relevant mutant viruses, several subseries of macrocycles were investigated based on observations made during the discovery of MK-5172.  Quinazolinone-contg. macrocycles were identified as promising leads, and optimization for superior cross-genotype and mutant enzyme potency as well as rat liver and plasma concns. following oral dosing, led to the development of MK-2748 I.  Addnl. investigation of a series of bis-macrocycles contg. a fused 18- and 15-membered ring system were also optimized for the same properties, leading to the discovery of MK-6325 II.  Both compds. display the broad genotype and mutant potency necessary for clin. development as next-generation HCV NS3/4a protease inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4cK2wuPGi1rVg90H21EOLACvtfcHk0lgQdMSxsDuIzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvVShurc%253D&md5=65834635e5b209b0674ec60fe905e2a9</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201402558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201402558%26sid%3Dliteratum%253Aachs%26aulast%3DRudd%26aufirst%3DM.%2BT.%26aulast%3DButcher%26aufirst%3DJ.%2BW.%26aulast%3DNguyen%26aufirst%3DK.%2BT.%26aulast%3DMcIntyre%26aufirst%3DC.%2BJ.%26aulast%3DRomano%26aufirst%3DJ.%2BJ.%26aulast%3DGilbert%26aufirst%3DK.%2BF.%26aulast%3DBush%26aufirst%3DK.%2BJ.%26aulast%3DLiverton%26aufirst%3DN.%2BJ.%26aulast%3DHolloway%26aufirst%3DM.%2BK.%26aulast%3DHarper%26aufirst%3DS.%26aulast%3DFerrara%26aufirst%3DM.%26aulast%3DDiFilippo%26aufirst%3DM.%26aulast%3DSumma%26aufirst%3DV.%26aulast%3DSwestock%26aufirst%3DJ.%26aulast%3DFritzen%26aufirst%3DJ.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26aulast%3DBurlein%26aufirst%3DC.%26aulast%3DDiMuzio%26aufirst%3DJ.%2BM.%26aulast%3DGates%26aufirst%3DA.%26aulast%3DGraham%26aufirst%3DD.%2BJ.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DMcClain%26aufirst%3DS.%26aulast%3DMcHale%26aufirst%3DC.%26aulast%3DStahlhut%26aufirst%3DM.%2BW.%26aulast%3DBlack%26aufirst%3DS.%26aulast%3DChase%26aufirst%3DR.%26aulast%3DSoriano%26aufirst%3DA.%26aulast%3DFandozzi%26aufirst%3DC.%2BM.%26aulast%3DTaylor%26aufirst%3DA.%26aulast%3DTrainor%26aufirst%3DN.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DColeman%26aufirst%3DP.%2BJ.%26aulast%3DLudmerer%26aufirst%3DS.%2BW.%26aulast%3DMcCauley%26aufirst%3DJ.%2BA.%26atitle%3DP2-Quinazolinones%2520and%2520Bis-Macrocycles%2520as%2520New%2520Templates%2520for%2520next-Generation%2520Hepatitis%2520C%2520Virus%2520NS3%252F4a%2520Protease%2520Inhibitors%253A%2520Discovery%2520of%2520MK-2748%2520and%2520MK-6325%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26issue%3D4%26spage%3D727%26epage%3D735%26doi%3D10.1002%2Fcmdc.201402558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chobanian, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pio, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teumelsan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clements, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas-Fowlkes, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felix, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priest, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hampton, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pai, L.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corona, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metzger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasternak, A.</span></span> <span> </span><span class="NLM_article-title">The Design and Synthesis of Novel Spirocyclic Heterocyclic Sulfone ROMK Inhibitors as Diuretics</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1109</span>– <span class="NLM_lpage">1114</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.10.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1016%2Fj.bmcl.2016.10.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=28111141" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVehs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=1109-1114&issue=4&author=H.+R.+Chobanianauthor=Y.+Guoauthor=B.+Pioauthor=H.+Tangauthor=N.+Teumelsanauthor=M.+Clementsauthor=J.+Frieauthor=R.+Fergusonauthor=Z.+Guoauthor=B.+S.+Thomas-Fowlkesauthor=J.+P.+Felixauthor=J.+Liuauthor=M.+Kohlerauthor=B.+Priestauthor=C.+Hamptonauthor=L.-Y.+Paiauthor=A.+Coronaauthor=J.+Metzgerauthor=V.+Tongauthor=E.+M.+Joshiauthor=L.+Xuauthor=K.+Owensauthor=K.+Maloneyauthor=K.+Sullivanauthor=A.+Pasternak&title=The+Design+and+Synthesis+of+Novel+Spirocyclic+Heterocyclic+Sulfone+ROMK+Inhibitors+as+Diuretics&doi=10.1016%2Fj.bmcl.2016.10.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">The design and synthesis of novel spirocyclic heterocyclic sulfone ROMK inhibitors as diuretics</span></div><div class="casAuthors">Chobanian, Harry R.; Guo, Yan; Pio, Barbara; Tang, Haifeng; Teumelsan, Nardos; Clements, Matthew; Frie, Jessica; Ferguson, Ronald; Guo, Zach; Thomas-Fowlkes, Brande S.; Felix, John P.; Liu, Jessica; Kohler, Martin; Priest, Birgit; Hampton, Caryn; Pai, Lee-Yuh; Corona, Aaron; Metzger, Joseph; Tong, Vincent; Joshi, Elizabeth M.; Xu, Ling; Owens, Karen; Maloney, Kevin; Sullivan, Kathleen; Pasternak, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1109-1114</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A spirocyclic class of ROMK inhibitors was developed contg. a structurally diverse heterocyclic sulfone moiety and spirocyclic core starting from lead 1.  These compds. not only displayed exquisite ROMK potency but significantly improved selectivity over hERG.  The lead compds. were found to have favorable pharmacokinetic properties and displayed robust diuretic, natriuretic and blood pressure lowering effects in spontaneously hypertensive rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsxktlvW_zbrVg90H21EOLACvtfcHk0lj-eYPd6g2eNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVehs7g%253D&md5=eb7449c00304bb21e4d1b292c4c4d6d6</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.10.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.10.032%26sid%3Dliteratum%253Aachs%26aulast%3DChobanian%26aufirst%3DH.%2BR.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DPio%26aufirst%3DB.%26aulast%3DTang%26aufirst%3DH.%26aulast%3DTeumelsan%26aufirst%3DN.%26aulast%3DClements%26aufirst%3DM.%26aulast%3DFrie%26aufirst%3DJ.%26aulast%3DFerguson%26aufirst%3DR.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DThomas-Fowlkes%26aufirst%3DB.%2BS.%26aulast%3DFelix%26aufirst%3DJ.%2BP.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DKohler%26aufirst%3DM.%26aulast%3DPriest%26aufirst%3DB.%26aulast%3DHampton%26aufirst%3DC.%26aulast%3DPai%26aufirst%3DL.-Y.%26aulast%3DCorona%26aufirst%3DA.%26aulast%3DMetzger%26aufirst%3DJ.%26aulast%3DTong%26aufirst%3DV.%26aulast%3DJoshi%26aufirst%3DE.%2BM.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DOwens%26aufirst%3DK.%26aulast%3DMaloney%26aufirst%3DK.%26aulast%3DSullivan%26aufirst%3DK.%26aulast%3DPasternak%26aufirst%3DA.%26atitle%3DThe%2520Design%2520and%2520Synthesis%2520of%2520Novel%2520Spirocyclic%2520Heterocyclic%2520Sulfone%2520ROMK%2520Inhibitors%2520as%2520Diuretics%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26issue%3D4%26spage%3D1109%26epage%3D1114%26doi%3D10.1016%2Fj.bmcl.2016.10.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pettus, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booker, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cee, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastwood, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herberich, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanman, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laszlo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipford, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rex, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sastri, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamayo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winston, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurz, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tasker, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.-L.</span></span> <span> </span><span class="NLM_article-title">Discovery and Optimization of Quinazolinone-Pyrrolopyrrolones as Potent and Orally Bioavailable Pan-Pim Kinase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">6407</span>– <span class="NLM_lpage">6430</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00610</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00610" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsF2msbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=6407-6430&issue=13&author=L.+H.+Pettusauthor=K.+L.+Andrewsauthor=S.+K.+Bookerauthor=J.+Chenauthor=V.+J.+Ceeauthor=F.+Chavezauthor=Y.+Chenauthor=H.+Eastwoodauthor=N.+Guerreroauthor=B.+Herberichauthor=D.+Hickmanauthor=B.+A.+Lanmanauthor=J.+Laszloauthor=M.+R.+Leeauthor=J.+R.+Lipfordauthor=B.+Mattsonauthor=C.+Mohrauthor=Y.+Nguyenauthor=M.+H.+Normanauthor=D.+Powersauthor=A.+B.+Reedauthor=K.+Rexauthor=C.+Sastriauthor=N.+Tamayoauthor=P.+Wangauthor=J.+T.+Winstonauthor=B.+Wuauthor=T.+Wuauthor=R.+P.+Wurzauthor=Y.+Xuauthor=Y.+Zhouauthor=A.+S.+Taskerauthor=H.-L.+Wang&title=Discovery+and+Optimization+of+Quinazolinone-Pyrrolopyrrolones+as+Potent+and+Orally+Bioavailable+Pan-Pim+Kinase+Inhibitors&doi=10.1021%2Facs.jmedchem.6b00610"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Optimization of Quinazolinone-pyrrolopyrrolones as Potent and Orally Bioavailable Pan-Pim Kinase Inhibitors</span></div><div class="casAuthors">Pettus, Liping H.; Andrews, Kristin L.; Booker, Shon K.; Chen, Jie; Cee, Victor J.; Chavez, Frank, Jr.; Chen, Yuping; Eastwood, Heather; Guerrero, Nadia; Herberich, Bradley; Hickman, Dean; Lanman, Brian A.; Laszlo, Jimmy, III; Lee, Matthew R.; Lipford, J. Russell; Mattson, Bethany; Mohr, Christopher; Nguyen, Yen; Norman, Mark H.; Powers, David; Reed, Anthony B.; Rex, Karen; Sastri, Christine; Tamayo, Nuria; Wang, Paul; Winston, Jeffrey T.; Wu, Bin; Wu, Tian; Wurz, Ryan P.; Xu, Yang; Zhou, Yihong; Tasker, Andrew S.; Wang, Hui-Ling</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6407-6430</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The high expression of proviral insertion site of Moloney murine leukemia virus kinases (Pim-1, -2, and -3) in cancers, particularly the hematopoietic malignancies, is believed to play a role in promoting cell survival and proliferation while suppressing apoptosis.  The three isoforms of Pim protein appear largely redundant in their oncogenic functions.  Thus, a pan-Pim kinase inhibitor is highly desirable.  However, cell active pan-Pim inhibitors have proven difficult to develop because Pim-2 has a low Km for ATP and therefore requires a very potent inhibitor to effectively block the kinase activity at cellular ATP concns.  Herein, the authors report a series of quinazolinone-pyrrolopyrrolones as potent and selective pan-Pim inhibitors.  In particular, compd. (R)-2-(tert-butylamino)-3-methyl-8-(6-methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4-b]pyrrol-2-yl)quinazolin-4(3H)-one (17) is orally efficacious in a mouse xenograft model (KMS-12 BM) of multiple myeloma, with 93% tumor growth inhibition at 50 mg/kg QD upon oral dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2s5EkmHtIBbVg90H21EOLACvtfcHk0lj-eYPd6g2eNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsF2msbc%253D&md5=0ac3b462493e0abee1a774aa7854c87d</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00610%26sid%3Dliteratum%253Aachs%26aulast%3DPettus%26aufirst%3DL.%2BH.%26aulast%3DAndrews%26aufirst%3DK.%2BL.%26aulast%3DBooker%26aufirst%3DS.%2BK.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DCee%26aufirst%3DV.%2BJ.%26aulast%3DChavez%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DEastwood%26aufirst%3DH.%26aulast%3DGuerrero%26aufirst%3DN.%26aulast%3DHerberich%26aufirst%3DB.%26aulast%3DHickman%26aufirst%3DD.%26aulast%3DLanman%26aufirst%3DB.%2BA.%26aulast%3DLaszlo%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DM.%2BR.%26aulast%3DLipford%26aufirst%3DJ.%2BR.%26aulast%3DMattson%26aufirst%3DB.%26aulast%3DMohr%26aufirst%3DC.%26aulast%3DNguyen%26aufirst%3DY.%26aulast%3DNorman%26aufirst%3DM.%2BH.%26aulast%3DPowers%26aufirst%3DD.%26aulast%3DReed%26aufirst%3DA.%2BB.%26aulast%3DRex%26aufirst%3DK.%26aulast%3DSastri%26aufirst%3DC.%26aulast%3DTamayo%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWinston%26aufirst%3DJ.%2BT.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DWurz%26aufirst%3DR.%2BP.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DTasker%26aufirst%3DA.%2BS.%26aulast%3DWang%26aufirst%3DH.-L.%26atitle%3DDiscovery%2520and%2520Optimization%2520of%2520Quinazolinone-Pyrrolopyrrolones%2520as%2520Potent%2520and%2520Orally%2520Bioavailable%2520Pan-Pim%2520Kinase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D13%26spage%3D6407%26epage%3D6430%26doi%3D10.1021%2Facs.jmedchem.6b00610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dransfield, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasparian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vimolratana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattaropong, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houze, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaminath, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartberger, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correll, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, D. C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, J. C.</span></span> <span> </span><span class="NLM_article-title">Discovery and Optimization of Potent GPR40 Full Agonists Containing Tricyclic Spirocycles</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">551</span>– <span class="NLM_lpage">555</span>, <span class="refDoi"> DOI: 10.1021/ml300427u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300427u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntVOktLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=551-555&issue=6&author=Y.+Wangauthor=J.+J.+Liuauthor=P.+J.+Dransfieldauthor=L.+Zhuauthor=Z.+Wangauthor=X.+Duauthor=X.+Jiaoauthor=Y.+Suauthor=A.-R.+Liauthor=S.+P.+Brownauthor=A.+Kasparianauthor=M.+Vimolratanaauthor=M.+Yuauthor=V.+Pattaropongauthor=J.+B.+Houzeauthor=G.+Swaminathauthor=T.+Tranauthor=K.+Nguyenauthor=Q.+Guoauthor=J.+Zhangauthor=R.+Zhuangauthor=F.+Liauthor=L.+Miaoauthor=M.+D.+Bartbergerauthor=T.+L.+Correllauthor=D.+Chowauthor=S.+Wongauthor=J.+Luoauthor=D.+C.-H.+Linauthor=J.+C.+Medina&title=Discovery+and+Optimization+of+Potent+GPR40+Full+Agonists+Containing+Tricyclic+Spirocycles&doi=10.1021%2Fml300427u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Optimization of Potent GPR40 Full Agonists Containing Tricyclic Spirocycles</span></div><div class="casAuthors">Wang, Yingcai; Liu, Jiwen; Dransfield, Paul J.; Zhu, Liusheng; Wang, Zhongyu; Du, Xiaohui; Jiao, Xianyun; Su, Yongli; Li, An-rong; Brown, Sean P.; Kasparian, Annie; Vimolratana, Marc; Yu, Ming; Pattaropong, Vatee; Houze, Jonathan B.; Swaminath, Gayathri; Tran, Thanhvien; Nguyen, Khanh; Guo, Qi; Zhang, Jane; Zhuang, Run; Li, Frank; Miao, Lynn; Bartberger, Michael D.; Correll, Tiffany L.; Chow, David; Wong, Simon; Luo, Jian; Lin, Daniel C.-H.; Medina, Julio C.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">551-555</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">GPR40 (FFAR1 or FFA1) is a target of high interest being pursued to treat type II diabetes due to its unique mechanism leading to little risk of hypoglycemia.  The authors recently reported the discovery of AM-1638 (I), a potent full agonist of GPR40.  In this report, they present the discovery of GPR40 full agonists contg. conformationally constrained tricyclic spirocycles and their structure-activity relationships leading to more potent agonists such as AM-5262 (II) with improved rat PK profile and general selectivity profile.  AM-5262 enhanced glucose stimulated insulin secretion (mouse and human islets) and improved glucose homeostasis in vivo (OGTT in HF/STZ mice) when compared to AM-1638.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgX9JpdxT4OrVg90H21EOLACvtfcHk0lhqvNT8LBMYaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntVOktLY%253D&md5=7f4681a65e80ba0f45642f63c6a33b22</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1021%2Fml300427u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300427u%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%2BJ.%26aulast%3DDransfield%26aufirst%3DP.%2BJ.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DDu%26aufirst%3DX.%26aulast%3DJiao%26aufirst%3DX.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DA.-R.%26aulast%3DBrown%26aufirst%3DS.%2BP.%26aulast%3DKasparian%26aufirst%3DA.%26aulast%3DVimolratana%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DPattaropong%26aufirst%3DV.%26aulast%3DHouze%26aufirst%3DJ.%2BB.%26aulast%3DSwaminath%26aufirst%3DG.%26aulast%3DTran%26aufirst%3DT.%26aulast%3DNguyen%26aufirst%3DK.%26aulast%3DGuo%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhuang%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DMiao%26aufirst%3DL.%26aulast%3DBartberger%26aufirst%3DM.%2BD.%26aulast%3DCorrell%26aufirst%3DT.%2BL.%26aulast%3DChow%26aufirst%3DD.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DD.%2BC.-H.%26aulast%3DMedina%26aufirst%3DJ.%2BC.%26atitle%3DDiscovery%2520and%2520Optimization%2520of%2520Potent%2520GPR40%2520Full%2520Agonists%2520Containing%2520Tricyclic%2520Spirocycles%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26issue%3D6%26spage%3D551%26epage%3D555%26doi%3D10.1021%2Fml300427u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sherwood, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowley, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paton, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggerstaff, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuenswander, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kivell, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prisinzano, T. E.</span></span> <span> </span><span class="NLM_article-title">Addressing Structural Flexibility at the A-Ring on Salvinorin A: Discovery of a Potent Kappa-Opioid Agonist with Enhanced Metabolic Stability</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">3866</span>– <span class="NLM_lpage">3878</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00148</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00148" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC2sXls1Gls7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=3866-3878&issue=9&author=A.+M.+Sherwoodauthor=R.+S.+Crowleyauthor=K.+F.+Patonauthor=A.+Biggerstaffauthor=B.+Neuenswanderauthor=V.+W.+Dayauthor=B.+M.+Kivellauthor=T.+E.+Prisinzano&title=Addressing+Structural+Flexibility+at+the+A-Ring+on+Salvinorin+A%3A+Discovery+of+a+Potent+Kappa-Opioid+Agonist+with+Enhanced+Metabolic+Stability&doi=10.1021%2Facs.jmedchem.7b00148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Addressing Structural Flexibility at the A-Ring on Salvinorin A: Discovery of a Potent Kappa-Opioid Agonist with Enhanced Metabolic Stability</span></div><div class="casAuthors">Sherwood, Alexander M.; Crowley, Rachel Saylor; Paton, Kelly F.; Biggerstaff, Andrew; Neuenswander, Benjamin; Day, Victor W.; Kivell, Bronwyn M.; Prisinzano, Thomas E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3866-3878</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Previous structure-activity studies on the neoclerodane diterpenoid salvinorin A have demonstrated the importance of the acetoxy functionality on the A-ring in its activity as a kappa opioid receptor agonist.  Few studies have focused on understanding the role of conformation in these interactions.  Herein we describe the synthesis and evaluation of both flexible and conformationally restricted compds. derived from salvinorin A.  One such compd., spirobutyrolactone (I), was synthesized in a single step from salvinorin B and had similar potency and selectivity to salvinorin A (EC50 = 0.6 ± 0.2 nM at κ >10,000 nM at μ and δ).  Microsomal stability studies demonstrated that 14 was more metabolically resistant than salvinorin A.  Evaluation of analgesic and anti-inflammatory properties revealed similar in vivo effects between 14 and salvinorin A.  To our knowledge, this study represents the first example of bioisosteric replacement of an acetate group by a spirobutyrolactone to produce a metabolically resistant deriv.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphQfDVKsiZz7Vg90H21EOLACvtfcHk0lhqvNT8LBMYaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXls1Gls7s%253D&md5=32073a4c5da4fb19e2d9adc0bba34d2d</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00148%26sid%3Dliteratum%253Aachs%26aulast%3DSherwood%26aufirst%3DA.%2BM.%26aulast%3DCrowley%26aufirst%3DR.%2BS.%26aulast%3DPaton%26aufirst%3DK.%2BF.%26aulast%3DBiggerstaff%26aufirst%3DA.%26aulast%3DNeuenswander%26aufirst%3DB.%26aulast%3DDay%26aufirst%3DV.%2BW.%26aulast%3DKivell%26aufirst%3DB.%2BM.%26aulast%3DPrisinzano%26aufirst%3DT.%2BE.%26atitle%3DAddressing%2520Structural%2520Flexibility%2520at%2520the%2520A-Ring%2520on%2520Salvinorin%2520A%253A%2520Discovery%2520of%2520a%2520Potent%2520Kappa-Opioid%2520Agonist%2520with%2520Enhanced%2520Metabolic%2520Stability%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D9%26spage%3D3866%26epage%3D3878%26doi%3D10.1021%2Facs.jmedchem.7b00148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toselli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fredenwall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svensson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weidolf, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, M. A.</span></span> <span> </span><span class="NLM_article-title">Hip To Be Square: Oxetanes as Design Elements To Alter Metabolic Pathways</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">7383</span>– <span class="NLM_lpage">7399</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00030</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00030" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtl2jt7bP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7383-7399&issue=16&author=F.+Toselliauthor=M.+Fredenwallauthor=P.+Svenssonauthor=X.-Q.+Liauthor=A.+Johanssonauthor=L.+Weidolfauthor=M.+A.+Hayes&title=Hip+To+Be+Square%3A+Oxetanes+as+Design+Elements+To+Alter+Metabolic+Pathways&doi=10.1021%2Facs.jmedchem.9b00030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Hip To Be Square: Oxetanes as Design Elements To Alter Metabolic Pathways</span></div><div class="casAuthors">Toselli, Francesca; Fredenwall, Marlene; Svensson, Peder; Li, Xue-Qing; Johansson, Anders; Weidolf, Lars; Hayes, Martin A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7383-7399</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oxetane-contg. ring systems are increasingly used in medicinal chem. programs to modulate druglike properties.  We have shown previously that oxetanes are hydrolyzed to diols by human microsomal epoxide hydrolase (mEH).  Mapping the enzymes that contribute to drug metab. is important since an exaggerated dependence on one specific isoenzyme increases the risk of drug-drug interactions with co-administered drugs.  Herein, we illustrate that mEH-catalyzed hydrolysis is an important metabolic pathway for a set of more structurally diverse oxetanes and the degree of hydrolysis is modulated by minor structural modifications.  A homol. model based on the Bombyx mori EH crystal structure was used to rationalize substrate binding.  This study shows that oxetanes can be used as drug design elements for directing metabolic clearance via mEH, thus potentially decreasing the dependence on cytochromes P 450.  Metab. by mEH should be assessed early in the design process to understand the complete metabolic fate of oxetane-contg. compds., and further study is required to allow accurate pharmacokinetic predictions of its substrates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMLs6g2Qt2aLVg90H21EOLACvtfcHk0lhltpTrafGhbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtl2jt7bP&md5=78a21c62c543e11c5a71f287e9252603</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00030%26sid%3Dliteratum%253Aachs%26aulast%3DToselli%26aufirst%3DF.%26aulast%3DFredenwall%26aufirst%3DM.%26aulast%3DSvensson%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DX.-Q.%26aulast%3DJohansson%26aufirst%3DA.%26aulast%3DWeidolf%26aufirst%3DL.%26aulast%3DHayes%26aufirst%3DM.%2BA.%26atitle%3DHip%2520To%2520Be%2520Square%253A%2520Oxetanes%2520as%2520Design%2520Elements%2520To%2520Alter%2520Metabolic%2520Pathways%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D16%26spage%3D7383%26epage%3D7399%26doi%3D10.1021%2Facs.jmedchem.9b00030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grönberg, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berggren, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castagnoli, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weidolf, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Novel Microsomal Epoxide Hydrolase-Catalyzed Hydration of a Spiro Oxetane</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>44</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1341</span>– <span class="NLM_lpage">1348</span>, <span class="refDoi"> DOI: 10.1124/dmd.116.071142</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1124%2Fdmd.116.071142" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=27256986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhsl2gur3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2016&pages=1341-1348&issue=8&author=X.-Q.+Liauthor=M.+A.+Hayesauthor=G.+Gr%C3%B6nbergauthor=K.+Berggrenauthor=N.+Castagnoliauthor=L.+Weidolf&title=Discovery+of+a+Novel+Microsomal+Epoxide+Hydrolase-Catalyzed+Hydration+of+a+Spiro+Oxetane&doi=10.1124%2Fdmd.116.071142"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a novel microsomal epoxide hydrolase-catalyzed hydration of a spiro oxetane</span></div><div class="casAuthors">Li, Xue-Qing; Hayes, Martin A.; Gronberg, Gunnar; Berggren, Kristina; Castagnoli, Jr. Neal; Weidolf, Lars</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1341-1348</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Oxetane moieties are increasingly being used by the pharmaceutical industry as building blocks in drug candidates because of their pronounced ability to improve physicochem. parameters and metabolic stability of drug candidates.  The enzymes that catalyze the biotransformation of the oxetane moiety are, however, not well studied.  The in vitro metab. of a spiro oxetane-contg. compd. AZD1979 [(3-(4-(2-oxa-6-azaspiro[3.3]heptan-6-ylmethyl) phenoxy)azetidin-1-yl)(5-(4-ethoxyphenyl)-1,3,4-oxadiazol- 2-yl)methanone] was studied and one of its metabolites, M1, attracted our interest because its formation was NAD(P)H independent.  The focus of this work was to elucidate the structure of M1 and to understand the mechanism(s) of its formation.  We established that M1 was formed via hydration and ring opening of the oxetanyl moiety of AZD1979.  Incubations of AZD1979 using various human liver subcellular fractions revealed that the hydration reaction leading to M1 occurred mainly in the microsomal fraction.  The underlying mechanism as a hydration, rather than an oxidn. reaction, was supported by the incorporation of 18O from H218O into M1.  Enzyme kinetics were performed probing the formation of M1 in human liver microsomes.  The formation of M1 was substantially inhibited by progabide, a microsomal epoxide hydrolase inhibitor, but not by trans-4-[4-(1-adamantylcarbamoylamino)cyclohexyloxy]- benzoic acid, a sol. epoxide hydrolase inhibitor.  On the basis of these results, we propose that microsomal epoxide hydrolase catalyzes the formation of M1.  The substrate specificity of microsomal epoxide hydrolase should therefore be expanded to include not only epoxides but also the oxetanyl ring system present in AZD1979.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNrbQCNYH9F7Vg90H21EOLACvtfcHk0liwdluJoQorgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhsl2gur3E&md5=a1a857a6ff437193d8f07b170fb608c8</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1124%2Fdmd.116.071142&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.116.071142%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.-Q.%26aulast%3DHayes%26aufirst%3DM.%2BA.%26aulast%3DGr%25C3%25B6nberg%26aufirst%3DG.%26aulast%3DBerggren%26aufirst%3DK.%26aulast%3DCastagnoli%26aufirst%3DN.%26aulast%3DWeidolf%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520a%2520Novel%2520Microsomal%2520Epoxide%2520Hydrolase-Catalyzed%2520Hydration%2520of%2520a%2520Spiro%2520Oxetane%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2016%26volume%3D44%26issue%3D8%26spage%3D1341%26epage%3D1348%26doi%3D10.1124%2Fdmd.116.071142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grönberg, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bangur, E.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castagnoli, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weidolf, L.</span></span> <span> </span><span class="NLM_article-title">Metabolism of Strained Rings: Glutathione S-Transferase-Catalyzed Formation of a Glutathione-Conjugated Spiro-Azetidine without Prior Bioactivation</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>47</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1247</span>– <span class="NLM_lpage">1256</span>, <span class="refDoi"> DOI: 10.1124/dmd.119.088658</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=10.1124%2Fdmd.119.088658" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=31492694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlCntb3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2019&pages=1247-1256&issue=11&author=X.-Q.+Liauthor=G.+Gr%C3%B6nbergauthor=E.-H.+Bangurauthor=M.+A.+Hayesauthor=N.+Castagnoliauthor=L.+Weidolf&title=Metabolism+of+Strained+Rings%3A+Glutathione+S-Transferase-Catalyzed+Formation+of+a+Glutathione-Conjugated+Spiro-Azetidine+without+Prior+Bioactivation&doi=10.1124%2Fdmd.119.088658"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism of strained rings: glutathione S-transferase-catalyzed formation of a glutathione-conjugated spiro-azetidine without prior bioactivation</span></div><div class="casAuthors">Li, Xue-Qing; Groenberg, Gunnar; Bangur, Eva-Henriette; Hayes, Martin A.; Castagnoli, Neal; Weidolf, Lars</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1247-1256</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">AZD1979 [(3-(4-(2-oxa-6-azaspiro[3.3]heptan-6-ylmethyl)phenoxy)azetidin-1-yl)(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)methanone] is a melanin-concg. hormone receptor 1 antagonist designed for the treatment of obesity.  In this study, metabolite profiles of AZD1979 in human hepatocytes revealed a series of glutathione-related metabolites, including the glutathionyl, cysteinyl, cysteinylglycinyl, and mercapturic acid conjugates.  The formation of these metabolites was not inhibited by coincubation with the cytochrome P 450 (P 450) inhibitor 1-aminobenzotriazole.  In efforts to identify the mechanistic features of this pathway, investigations were performed to characterize the structure of the glutathionyl conjugate M12 of AZD1979 and to identify the enzyme system catalyzing its formation.  Studies with various human liver subcellular fractions established that the formation of M12 was NAD(P)H-independent and proceeded in cytosol and S9 fractions but not in microsomal or mitochondrial fractions.  Metabolite M12 was purified from rat liver S9 incubations and its structure elucidated by NMR.  These results establish that M12 is the product of the GST-catalyzed glutathione attack on the carbon atom a to the nitrogen atom of the strained spiro-azetidinyl moiety to give, after ring opening, the corresponding amino-thioether conjugate product, a direct conjugation pathway that occurs without the prior substrate bioactivation by P 450.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrPA57-Kg_vrVg90H21EOLACvtfcHk0liwdluJoQorgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlCntb3O&md5=0c59a3f2baa40d89a84b8a11843e67c0</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1124%2Fdmd.119.088658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.119.088658%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.-Q.%26aulast%3DGr%25C3%25B6nberg%26aufirst%3DG.%26aulast%3DBangur%26aufirst%3DE.-H.%26aulast%3DHayes%26aufirst%3DM.%2BA.%26aulast%3DCastagnoli%26aufirst%3DN.%26aulast%3DWeidolf%26aufirst%3DL.%26atitle%3DMetabolism%2520of%2520Strained%2520Rings%253A%2520Glutathione%2520S-Transferase-Catalyzed%2520Formation%2520of%2520a%2520Glutathione-Conjugated%2520Spiro-Azetidine%2520without%2520Prior%2520Bioactivation%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2019%26volume%3D47%26issue%3D11%26spage%3D1247%26epage%3D1256%26doi%3D10.1124%2Fdmd.119.088658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5LYQ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5LYQ','PDB','5LYQ'); return false;">PDB: 5LYQ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CLS" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CLS','PDB','5CLS'); return false;">PDB: 5CLS</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5D6E" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5D6E','PDB','5D6E'); return false;">PDB: 5D6E</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01473%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-1%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01473" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                10MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679aa8b2acad3bf8","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
